Clustering O 0 8.446366700809449e-05
of O 0 3.2168604775506537e-06
missense O 0 0.001007133862003684
mutations O 0 0.000455583562143147
in O 0 5.12727501700283e-06
the O 0 8.095111115835607e-05
ataxia B-Disease 1 0.9999517202377319
- I-Disease 1 0.9960902333259583
telangiectasia I-Disease 1 0.9969118237495422
gene O 0 8.172339585144073e-05
in O 0 2.1468106297106715e-06
a O 0 7.74028740124777e-06
sporadic B-Disease 0 0.0012636911123991013
T I-Disease 1 0.9907656908035278
- I-Disease 1 0.5119273066520691
cell I-Disease 0 0.23288510739803314
leukaemia I-Disease 1 0.9879177212715149
. O 0 2.0508179659373127e-05

Ataxia B-Disease 1 0.9997876286506653
- I-Disease 1 0.9988858103752136
telangiectasia I-Disease 1 0.999562680721283
( O 0 0.0010637488448992372
A B-Disease 1 0.9997894167900085
- I-Disease 1 0.9994188547134399
T I-Disease 1 0.9995759129524231
) O 0 3.516175013373868e-07
is O 0 1.3173516322240175e-07
a O 0 6.917020982655231e-07
recessive B-Disease 0 0.0008057999075390399
multi I-Disease 1 0.6486225128173828
- I-Disease 1 0.9965471625328064
system I-Disease 1 0.7288420796394348
disorder I-Disease 1 0.9993311166763306
caused O 0 0.0002250602701678872
by O 0 2.1992374854562513e-07
mutations O 0 4.067137524543796e-06
in O 0 6.319119449926802e-08
the O 0 5.018677740054045e-08
ATM O 0 1.2302983122935984e-05
gene O 0 3.4867305203079013e-06
at O 0 8.151732799888123e-06
11q22 O 0 4.3276671931380406e-05
- O 0 5.053905624663457e-05
q23 O 0 2.3209775463328697e-05
( O 0 4.79549214560393e-07
ref O 0 0.00014185391773935407
. O 0 1.973112375708297e-07
3 O 0 9.392802553520596e-07
) O 0 2.4480090132783516e-07
. O 0 6.097955633777019e-07

The O 0 2.4654602384543978e-05
risk O 0 0.0005768321570940316
of O 0 1.4998806364019401e-05
cancer B-Disease 1 0.9991764426231384
, O 0 1.2017127346553025e-06
especially O 0 4.980804078513756e-06
lymphoid B-Disease 0 0.0018438638653606176
neoplasias I-Disease 0 0.0031862871255725622
, O 0 1.354835148958955e-06
is O 0 8.564896347706963e-07
substantially O 0 4.3320778786437586e-05
elevated O 0 0.006567471195012331
in O 0 7.366070349235088e-06
A B-Disease 1 0.9987190961837769
- I-Disease 1 0.9992038607597351
T I-Disease 1 0.9997833371162415
patients O 0 4.363892730907537e-05
and O 0 4.2008232981061155e-07
has O 0 1.3928188309364486e-06
long O 0 2.3587115265399916e-06
been O 0 8.183116619875364e-07
associated O 0 2.2940150756767252e-06
with O 0 2.217152541561518e-05
chromosomal O 1 0.999702513217926
instability O 1 0.9988238215446472
. O 0 7.606758299516514e-05

By O 0 1.0610991921566892e-05
analysing O 0 0.0006688010762445629
tumour B-Disease 1 0.9994743466377258
DNA O 0 4.138430449529551e-05
from O 0 6.366130378410162e-07
patients O 0 1.7189452137245098e-06
with O 0 1.4376537649241072e-07
sporadic B-Disease 0 0.000282146007521078
T I-Disease 1 0.8436154723167419
- I-Disease 0 0.009993840008974075
cell I-Disease 0 0.0024502300657331944
prolymphocytic I-Disease 0 0.007622324395924807
leukaemia I-Disease 1 0.9862914681434631
( O 0 8.228401384258177e-06
T B-Disease 0 0.06047581136226654
- I-Disease 0 0.0001993967016460374
PLL I-Disease 0 0.0001275759859709069
) O 0 2.236473193306665e-07
, O 0 8.416814978318143e-08
a O 0 3.356901743245544e-07
rare O 0 7.0041783146734815e-06
clonal B-Disease 0 0.00018191142589785159
malignancy I-Disease 0 0.011388810351490974
with O 0 9.857535587798338e-08
similarities O 0 3.8964330428825633e-07
to O 0 6.45530420229079e-08
a O 0 1.0891831152548548e-06
mature B-Disease 0 2.9916331186541356e-05
T I-Disease 0 0.04516374319791794
- I-Disease 0 0.0006474843248724937
cell I-Disease 0 0.00046360454871319234
leukaemia I-Disease 0 0.05420667305588722
seen O 0 1.1011690730811097e-05
in O 0 1.395604272147466e-06
A B-Disease 1 0.9630572199821472
- I-Disease 1 0.9577761888504028
T I-Disease 1 0.9994046688079834
, O 0 8.235934245703902e-08
we O 0 1.0580007092642063e-08
demonstrate O 0 1.3514520169621846e-08
a O 0 3.552326077738144e-08
high O 0 2.687935420908616e-07
frequency O 0 1.8738025175935036e-07
of O 0 2.3111370595074732e-08
ATM O 0 2.4586066501797177e-05
mutations O 0 3.774308424908668e-05
in O 0 5.147421234141802e-06
T B-Disease 1 0.5227267742156982
- I-Disease 0 0.0021067645866423845
PLL I-Disease 0 0.001858562114648521
. O 0 1.6799294826341793e-05

In O 0 2.6353327484684996e-06
marked O 0 2.3696802600170486e-06
contrast O 0 3.0272232720562897e-07
to O 0 1.2093168244575736e-08
the O 0 7.510340793714931e-08
ATM O 0 2.2166936105350032e-05
mutation O 0 1.5320918464567512e-05
pattern O 0 1.4205499610397965e-05
in O 0 2.2741187422070652e-06
A B-Disease 1 0.9965246319770813
- I-Disease 1 0.9968019723892212
T I-Disease 1 0.9997209906578064
, O 0 7.590091399833909e-08
the O 0 1.5489066029772403e-08
most O 0 8.453605815361698e-09
frequent O 0 1.535296405563713e-07
nucleotide O 0 3.3982635727625166e-07
changes O 0 3.2362754609494004e-07
in O 0 6.766958904336207e-08
this O 0 1.0484028933888112e-07
leukaemia B-Disease 0 0.015061602927744389
were O 0 2.0944573861925164e-06
missense O 0 0.0005704181385226548
mutations O 0 0.0005057007074356079
. O 0 8.132399671012536e-06

These O 0 4.538920848062844e-07
clustered O 0 1.020596482703695e-05
in O 0 4.64119949583619e-07
the O 0 1.5821764520751458e-07
region O 0 2.8256226869416423e-07
corresponding O 0 7.725029860239374e-08
to O 0 9.078274132434672e-09
the O 0 3.5002287290808454e-08
kinase O 0 6.384900075318001e-07
domain O 0 9.89307835652653e-08
, O 0 2.4913966001349763e-08
which O 0 9.62740198673373e-09
is O 0 1.3975228974061338e-08
highly O 0 9.199473538501479e-08
conserved O 0 2.990175573813758e-07
in O 0 5.4672515403808575e-08
ATM O 0 5.1237652769486886e-06
- O 0 9.027372470882256e-06
related O 0 1.936399911528497e-07
proteins O 0 5.293425076047242e-08
in O 0 4.4708958313322e-08
mouse O 0 1.0847360272236983e-06
, O 0 2.799336407122155e-08
yeast O 0 4.508081019594101e-07
and O 0 9.886004903592038e-08
Drosophila O 0 3.51964081346523e-06
. O 0 2.043895847236854e-06

The O 0 3.520866357575869e-06
resulting O 0 9.753429367265198e-06
amino O 0 7.759696018183604e-06
- O 0 3.173024015268311e-05
acid O 0 3.6687267765955767e-06
substitutions O 0 5.05750961110607e-07
are O 0 2.1220204260430364e-08
predicted O 0 3.8496352772199316e-07
to O 0 6.344054614970673e-09
interfere O 0 1.7540945407290565e-07
with O 0 2.2335487415148236e-07
ATP O 0 0.0017696747090667486
binding O 0 3.2008892958401702e-06
or O 0 3.689631284942152e-07
substrate O 0 6.002990630804561e-06
recognition O 0 6.076642421248835e-06
. O 0 8.505788173351903e-06

Two O 0 6.343991003632254e-07
of O 0 2.456325205457688e-07
seventeen O 0 7.806137546140235e-06
mutated O 0 0.00010769365326268598
T B-Disease 0 0.012809920124709606
- I-Disease 0 3.621759606176056e-05
PLL I-Disease 0 6.83119724271819e-05
samples O 0 6.943927814972994e-07
had O 0 5.389587158788345e-07
a O 0 3.7611545167237637e-07
previously O 0 6.323945399344666e-06
reported O 0 4.785045894095674e-05
A B-Disease 1 0.9480668306350708
- I-Disease 1 0.9288715124130249
T I-Disease 1 0.99439537525177
allele O 0 0.00010203865531366318
. O 0 1.0390112038294319e-05

In O 0 2.6917728064290714e-06
contrast O 0 4.325943791627651e-06
, O 0 2.1990780396663467e-07
no O 0 3.348214931975235e-07
mutations O 0 2.525915306250681e-06
were O 0 1.3343198190796102e-07
detected O 0 3.674073241199949e-06
in O 0 2.4392553754637447e-08
the O 0 3.0945138007609785e-08
p53 O 0 6.526814217977517e-07
gene O 0 7.733579536761681e-07
, O 0 8.051305400158526e-08
suggesting O 0 4.512446309945517e-07
that O 0 3.618266930516256e-08
this O 0 1.7165208419100964e-06
tumour B-Disease 1 0.9999083280563354
suppressor O 0 0.0003791262279264629
is O 0 6.364904265865334e-07
not O 0 2.4295232492477226e-08
frequently O 0 5.516408805306128e-07
altered O 0 6.1914070101920515e-06
in O 0 5.208943321122206e-07
this O 0 1.1309283536320436e-06
leukaemia B-Disease 1 0.9442723989486694
. O 0 9.325804967375007e-06

Occasional O 0 0.0001738715945975855
missense O 0 0.0007334022666327655
mutations O 0 6.592641875613481e-05
in O 0 2.812846275901393e-07
ATM O 0 9.102514013648033e-06
were O 0 3.3797377341215906e-07
also O 0 1.764557282513124e-07
found O 0 5.477484705807001e-07
in O 0 1.27537430216762e-06
tumour B-Disease 1 0.9997946619987488
DNA O 0 3.946759534301236e-06
from O 0 1.5538252284841292e-07
patients O 0 6.145395445855684e-07
with O 0 1.4506355228149914e-07
B B-Disease 0 0.00025707948952913284
- I-Disease 0 0.0005571452202275395
cell I-Disease 0 0.0006862900918349624
non I-Disease 0 0.000241018773522228
- I-Disease 0 0.27215445041656494
Hodgkins I-Disease 1 0.9976022839546204
lymphomas I-Disease 0 0.4074484705924988
( O 0 1.5128292716326541e-06
B B-Disease 0 6.2426901422441e-05
- I-Disease 0 1.7166032193927094e-05
NHL I-Disease 0 1.590341707924381e-05
) O 0 2.70890261333534e-08
and O 0 2.5725029217937845e-08
a O 0 6.035804744897177e-07
B B-Disease 0 3.621075666160323e-05
- I-Disease 0 5.273377973935567e-05
NHL I-Disease 0 0.00011027059372281656
cell O 0 5.079906259197742e-05
line O 0 4.6872752136550844e-05
. O 0 3.687925527628977e-06

The O 0 1.7276672679145122e-06
evidence O 0 3.2703320584914763e-07
of O 0 2.09066808309899e-08
a O 0 4.026975943816069e-07
significant O 0 7.618177164658846e-07
proportion O 0 9.770742508408148e-07
of O 0 2.8896911885567533e-07
loss O 0 0.001191018964163959
- O 0 1.7107247913372703e-05
of O 0 1.1235800201347956e-07
- O 0 1.0583230505289976e-05
function O 0 4.127764441363979e-07
mutations O 0 9.86044710771239e-07
and O 0 1.0370621694733018e-08
a O 0 6.541270636262198e-08
complete O 0 3.280237024227972e-07
absence O 0 5.813401457999134e-07
of O 0 1.0034025166305582e-08
the O 0 5.499820687759893e-08
normal O 0 4.459611488982773e-07
copy O 0 3.5446245760795136e-07
of O 0 9.702132430788879e-09
ATM O 0 4.0372187868342735e-06
in O 0 1.4032983131073706e-07
the O 0 9.51282856931357e-08
majority O 0 2.2647553521437658e-07
of O 0 1.0031500323748332e-06
mutated O 0 0.0022575350012630224
tumours B-Disease 1 0.999326229095459
establishes O 0 3.064527118112892e-05
somatic O 0 2.2919395632925443e-05
inactivation O 0 0.0016001901822164655
of O 0 8.494340875131456e-08
this O 0 5.036629602273024e-08
gene O 0 6.442751327995211e-07
in O 0 9.625293273529678e-08
the O 0 1.7573628952050058e-07
pathogenesis O 0 0.00010932412260444835
of O 0 4.759843363899563e-07
sporadic B-Disease 0 0.0006855857791379094
T I-Disease 1 0.9285620450973511
- I-Disease 0 0.00031100932392291725
PLL I-Disease 0 9.558985766489059e-05
and O 0 2.8433336751731986e-07
suggests O 0 4.824266284231271e-07
that O 0 1.743303812418162e-08
ATM O 0 2.059912503682426e-06
acts O 0 9.047652156368713e-07
as O 0 1.7884090084407944e-06
a O 0 0.0003901720338035375
tumour B-Disease 1 0.9999287128448486
suppressor O 0 0.00337070575915277
. O 0 1.3354825568967499e-05

As O 0 3.8696480260114186e-06
constitutional O 0 5.774541023129132e-06
DNA O 0 9.487417628406547e-06
was O 0 7.516698133258615e-06
not O 0 1.214638167823523e-08
available O 0 2.428156520295488e-08
, O 0 6.605412750104733e-08
a O 0 1.4958033034417895e-06
putative O 0 0.00010621341789374128
hereditary O 0 0.33141377568244934
predisposition O 0 0.0021660979837179184
to O 0 2.827530352078611e-06
T B-Disease 1 0.7718266248703003
- I-Disease 0 0.00016615995264146477
PLL I-Disease 0 7.429037941619754e-05
will O 0 9.912911025367066e-08
require O 0 9.1754316144943e-08
further O 0 1.8685024372189218e-07
investigation O 0 2.9503394216590095e-06
. O 0 1.8378138122443488e-07
. O 0 1.5380544482468395e-06

Myotonic B-Disease 1 0.9985972046852112
dystrophy I-Disease 1 0.99962317943573
protein O 0 0.00026324234204366803
kinase O 0 0.00017344985099043697
is O 0 4.5014002125753905e-07
involved O 0 6.43683648604565e-08
in O 0 1.8449977545742513e-08
the O 0 1.3174894064604814e-08
modulation O 0 2.0063683336957183e-07
of O 0 1.1067996297242644e-08
the O 0 8.940022411252357e-08
Ca2 O 0 8.12998041510582e-06
+ O 0 2.8331171051831916e-05
homeostasis O 0 0.003074551234021783
in O 0 3.847928383038379e-06
skeletal O 1 0.7655318975448608
muscle O 0 0.3780173361301422
cells O 0 0.00020891953317914158
. O 0 9.348555977339856e-06

Myotonic B-Disease 1 0.999804675579071
dystrophy I-Disease 1 0.9999715089797974
( O 0 0.001069510355591774
DM B-Disease 1 0.9996547698974609
) O 0 1.7559199250172242e-06
, O 0 2.014509163927869e-07
the O 0 2.6305417577532353e-07
most O 0 1.360784040116414e-06
prevalent O 0 0.002034079283475876
muscular B-Disease 1 0.9995183944702148
disorder I-Disease 1 0.999552309513092
in O 0 1.077968227036763e-05
adults O 0 1.748404247337021e-05
, O 0 1.1144934433104936e-06
is O 0 1.736499370963429e-06
caused O 0 1.4518505849991925e-05
by O 0 1.6347370035418862e-07
( O 0 1.4365791400905437e-07
CTG O 0 1.7336569726467133e-05
) O 0 8.07680606840222e-08
n O 0 3.3609296679060208e-06
- O 0 5.589404736383585e-06
repeat O 0 9.197470944855013e-07
expansion O 0 9.337021822375391e-08
in O 0 6.550107567449004e-09
a O 0 9.137791856517197e-09
gene O 0 2.013899624841997e-08
encoding O 0 3.421977368134321e-08
a O 0 3.4643005619727774e-07
protein O 0 1.7387498019161285e-06
kinase O 0 1.2412916476023383e-05
( O 0 5.557945996770286e-07
DM B-Disease 1 0.6120447516441345
protein O 0 2.8228771498106653e-06
kinase O 0 7.534058568126056e-06
; O 0 1.7877137281629984e-07
DMPK O 0 2.7820944524137303e-05
) O 0 3.609912369029189e-08
and O 0 3.0605797007865476e-08
involves O 0 2.81335587715148e-07
changes O 0 1.2033743814754416e-06
in O 0 3.6203005038260017e-07
cytoarchitecture O 0 4.549906589090824e-05
and O 0 2.1941668819636106e-06
ion O 0 0.000767526391427964
homeostasis O 0 0.29033219814300537
. O 0 1.7438731447327882e-05

To O 0 2.0378590193104174e-07
obtain O 0 2.5227947730854794e-07
clues O 0 1.0881593652811716e-06
to O 0 3.4634112466847e-08
the O 0 1.368097883869268e-07
normal O 0 8.339852684002835e-07
biological O 0 4.5782607571709377e-07
role O 0 2.049891349997779e-07
of O 0 4.358947336413621e-08
DMPK O 0 5.233585034147836e-05
in O 0 4.523942607193021e-07
cellular O 0 5.867272921022959e-05
ion O 0 0.0001514018513262272
homeostasis O 0 0.009557873010635376
, O 0 5.595920242740249e-07
we O 0 9.344201146177511e-08
have O 0 1.4447094187630682e-08
compared O 0 2.1664324378889432e-07
the O 0 9.057126248990244e-08
resting O 0 7.025123522907961e-06
[ O 0 4.833425464312313e-07
Ca2 O 0 1.060220597537409e-06
+ O 0 3.2284717690345133e-06
] O 0 1.8957505290018162e-06
i O 0 8.467987413496303e-07
, O 0 6.482446135436248e-09
the O 0 1.2020498374454291e-08
amplitude O 0 1.3647697016949678e-07
and O 0 2.872923055008414e-08
shape O 0 1.7780862435756717e-06
of O 0 1.3925024688887788e-07
depolarization O 0 1.665049967414234e-05
- O 0 4.905138484900817e-05
induced O 0 2.1276118786772713e-05
Ca2 O 0 6.476883299910696e-06
+ O 0 4.94565074404818e-06
transients O 0 1.4494420611299574e-05
, O 0 4.872366332620004e-08
and O 0 9.886774066103499e-09
the O 0 1.5365335670480817e-08
content O 0 7.499976106828399e-08
of O 0 5.2557382446138945e-08
ATP O 0 0.00041158980457112193
- O 0 1.0978243153658696e-05
driven O 0 2.361671249673236e-06
ion O 0 1.143962344940519e-05
pumps O 0 9.398964721185621e-06
in O 0 6.276860062826017e-07
cultured O 0 2.9494387490558438e-05
skeletal O 0 0.005455834791064262
muscle O 0 0.00034888717345893383
cells O 0 3.0761057132622227e-06
of O 0 1.709628492108095e-07
wild O 0 5.356131168809952e-06
- O 0 8.015379717107862e-05
type O 0 2.7892856451217085e-05
and O 0 6.601968038921768e-07
DMPK O 0 0.00025632345932535827
[ O 0 1.4178443962009624e-05
- O 0 8.303732465719804e-05
/ O 0 7.10176391294226e-05
- O 0 0.0003270740562584251
] O 0 2.4651852072565816e-05
knockout O 0 0.0014872814062982798
mice O 0 0.00020678533473983407
. O 0 4.398099918034859e-06

In O 0 1.0955860489048064e-05
vitro O 0 7.9831421317067e-05
- O 0 8.242198964580894e-05
differentiated O 0 2.794035208353307e-05
DMPK O 0 0.0005060227704234421
[ O 0 1.7458050933782943e-05
- O 0 7.770131196593866e-05
/ O 0 4.377822915557772e-05
- O 0 5.776280886493623e-05
] O 0 2.8902886697323993e-06
myotubes O 0 5.9053313634649385e-06
exhibit O 0 5.297015945870953e-07
a O 0 3.4366922818662715e-07
higher O 0 7.109222224244149e-07
resting O 0 1.1341651770635508e-05
[ O 0 6.86976761699043e-07
Ca2 O 0 2.193654154325486e-06
+ O 0 4.184739736956544e-06
] O 0 3.136507302770042e-06
i O 0 1.4354495760926511e-06
than O 0 3.226758238383809e-08
do O 0 8.184085942275487e-08
wild O 0 4.7157539029285545e-07
- O 0 1.813808557926677e-05
type O 0 1.2493078429542948e-05
myotubes O 0 3.8577425584662706e-05
because O 0 9.6105623015319e-08
of O 0 6.08182437744631e-09
an O 0 2.1478287592913148e-08
altered O 0 1.2265695659152698e-06
open O 0 7.261215841936064e-07
probability O 0 2.9511840082818708e-08
of O 0 2.115929653712101e-08
voltage O 0 9.928624422173016e-06
- O 0 1.0160487363464199e-05
dependent O 0 1.0845498081835103e-06
l O 0 2.4744369511608966e-05
- O 0 6.4389396357000805e-06
type O 0 3.2074560749606462e-06
Ca2 O 0 2.1301973447407363e-06
+ O 0 1.962153419299284e-06
and O 0 2.1511542058760824e-07
Na O 0 2.1530666344915517e-05
+ O 0 7.4262788984924555e-06
channels O 0 1.3978520655655302e-05
. O 0 6.797546575398883e-06

The O 0 3.4862448501371546e-06
mutant O 0 4.6011278755031526e-05
myotubes O 0 7.489384734071791e-05
exhibit O 0 3.0193200473149773e-06
smaller O 0 7.31178317892045e-07
and O 0 8.884266833319998e-08
slower O 0 1.1321899364702404e-06
Ca2 O 0 2.9857351364626084e-06
+ O 0 1.88189665095706e-06
responses O 0 1.9317370458793448e-07
upon O 0 1.2346787059414055e-07
triggering O 0 3.8015105019439943e-06
by O 0 6.819070108576852e-08
acetylcholine O 0 1.973164216906298e-05
or O 0 9.355915722153441e-07
high O 0 2.2585127226193435e-05
external O 0 1.495532978879055e-05
K O 0 8.763661026023328e-05
+ O 0 7.169687887653708e-05
. O 0 9.567301276547369e-06

In O 0 1.7390614175383234e-06
addition O 0 3.33180423695012e-07
, O 0 7.56254863176764e-08
we O 0 3.027572503810916e-08
observed O 0 1.210631523917982e-07
that O 0 2.812430954790557e-09
these O 0 4.184407487173303e-09
Ca2 O 0 1.3751212009083247e-06
+ O 0 5.77892615183373e-06
transients O 0 2.1267556803650223e-05
partially O 0 1.0247668797092047e-05
result O 0 1.723158788990986e-07
from O 0 1.289773710055897e-08
an O 0 2.9469469087217703e-09
influx O 0 1.93912867985091e-08
of O 0 4.396326414024543e-09
extracellular O 0 2.3522233050243813e-07
Ca2 O 0 9.77914169197902e-07
+ O 0 6.644166319347278e-07
through O 0 7.964671056015504e-08
the O 0 3.1440012548955565e-07
l O 0 2.5180523152812384e-05
- O 0 1.2087967661500443e-05
type O 0 7.851418558857404e-06
Ca2 O 0 8.287703167297877e-06
+ O 0 9.665777724876534e-06
channel O 0 2.4526538254576735e-05
. O 0 2.9514371817640495e-06

Neither O 0 1.4640037079516333e-05
the O 0 7.045103984637535e-07
content O 0 6.622746013817959e-07
nor O 0 8.626475391793065e-07
the O 0 5.76419125764005e-08
activity O 0 1.2756451894802012e-07
of O 0 5.245683709631521e-08
Na O 0 1.3621443031297531e-05
+ O 0 6.627992661378812e-06
/ O 0 8.793499546300154e-06
K O 0 4.737516974273603e-06
+ O 0 5.931934083491797e-06
ATPase O 0 2.2457101295003667e-05
and O 0 9.889245120575652e-07
sarcoplasmic O 0 0.00014737428864464164
reticulum O 0 6.241011578822508e-05
Ca2 O 0 1.4701248801429756e-05
+ O 0 1.619275462871883e-05
- O 0 1.913304004119709e-05
ATPase O 0 1.025951041810913e-05
are O 0 4.64869494010145e-08
affected O 0 6.663615863544692e-07
by O 0 3.250218583161768e-07
DMPK O 0 0.0016786514315754175
absence O 0 5.909522224101238e-05
. O 0 5.8997761698265094e-06

In O 0 2.782531282718992e-06
conclusion O 0 1.885735855466919e-06
, O 0 1.3380778796090453e-07
our O 0 1.056780831731885e-07
data O 0 4.057008311519894e-07
suggest O 0 2.4544610255361476e-07
that O 0 2.961875722462537e-08
DMPK O 0 2.4695005777175538e-05
is O 0 9.067099426829373e-08
involved O 0 6.912306815820557e-08
in O 0 3.3226015716536494e-08
modulating O 0 1.8462283151166048e-06
the O 0 9.872437800595435e-08
initial O 0 1.325358738313298e-07
events O 0 7.239464139274787e-08
of O 0 5.0200565482327875e-08
excitation O 0 2.6339097530581057e-05
- O 0 0.000700370641425252
contraction O 0 3.573805224732496e-05
coupling O 0 8.993963092507329e-06
in O 0 1.8097766769642476e-06
skeletal O 0 0.14907093346118927
muscle O 0 0.0042165364138782024
. O 0 1.86797660717275e-06
. O 0 4.189715582469944e-06

Constitutional O 0 0.0006804722943343222
RB1 O 0 0.0241075549274683
- O 0 0.00026790215633809566
gene O 0 2.973804294015281e-05
mutations O 0 7.301987352548167e-05
in O 0 1.1167244338139426e-06
patients O 0 6.2380449890042655e-06
with O 0 9.58781924964569e-07
isolated O 0 0.0002790323633234948
unilateral B-Disease 0 0.00042935210512951016
retinoblastoma I-Disease 0 0.2639581263065338
. O 0 1.754756704031024e-05

In O 0 8.113776857499033e-06
most O 0 2.056873881883803e-06
patients O 0 8.162180165527388e-06
with O 0 5.499096005223691e-07
isolated O 0 0.00028811159427277744
unilateral B-Disease 0 0.00019225537835154682
retinoblastoma I-Disease 0 0.03908471763134003
, O 0 1.4823885067016818e-05
tumor B-Disease 0 0.1402668058872223
development O 0 3.4865368547798425e-07
is O 0 8.771974080445943e-08
initiated O 0 4.763776075833448e-07
by O 0 1.8179740379764553e-08
somatic O 0 1.497296125307912e-06
inactivation O 0 8.098671241896227e-05
of O 0 2.232332363405476e-08
both O 0 3.0098732395344996e-08
alleles O 0 3.782845965361048e-07
of O 0 1.482387546047903e-07
the O 0 5.0732946874632034e-06
RB1 O 0 0.006629627663642168
gene O 0 6.474298425018787e-05
. O 0 8.780460120760836e-06

However O 0 1.9206011074857088e-06
, O 0 6.09023089737093e-08
some O 0 5.522080570585786e-09
of O 0 1.387845838252133e-08
these O 0 4.7522775048491894e-08
patients O 0 1.6209064597205725e-06
can O 0 9.679142465301993e-08
transmit O 0 1.980290107894689e-05
retinoblastoma B-Disease 0 0.003240201622247696
predisposition O 0 0.0001580463140271604
to O 0 1.0738445865854374e-07
their O 0 2.7641183919513423e-07
offspring O 0 9.923124707711395e-06
. O 0 3.672307684610132e-06

To O 0 1.4673881310045545e-07
determine O 0 1.844181838350778e-07
the O 0 6.540996366766194e-08
frequency O 0 1.6445895880679018e-06
and O 0 1.2700928664344246e-07
nature O 0 6.119784643487947e-07
of O 0 1.5472744507860625e-07
constitutional O 0 4.675610034610145e-05
RB1 O 0 0.005180179141461849
- O 0 0.00011758616892620921
gene O 0 9.245352885045577e-06
mutations O 0 2.291314558533486e-05
in O 0 6.384857442753855e-07
patients O 0 3.279397105870885e-06
with O 0 1.7059117851658812e-07
isolated O 0 3.175969686708413e-05
unilateral B-Disease 0 1.1012993127224036e-05
retinoblastoma I-Disease 0 0.00026052846806123853
, O 0 1.3072695992377703e-07
we O 0 6.7735058451035e-08
analyzed O 0 4.498928376506228e-07
DNA O 0 1.0535813999013044e-06
from O 0 8.242943749792175e-08
peripheral O 0 1.6936428437475115e-05
blood O 0 0.00011621474550338462
and O 0 1.585174459250993e-06
from O 0 3.57148855982814e-05
tumor B-Disease 1 0.9960796236991882
tissue O 0 0.019516468048095703
. O 0 7.339326202782104e-06

The O 0 2.000261474677245e-06
analysis O 0 2.8393119464453775e-06
of O 0 4.5107913138053846e-06
tumors B-Disease 1 0.9998477697372437
from O 0 1.1984726597802364e-06
54 O 0 2.677014435903402e-06
( O 0 7.88027776366107e-08
71 O 0 1.024936068461102e-06
% O 0 1.4429056172104993e-08
) O 0 9.759910213347212e-09
of O 0 2.0056733163187346e-08
76 O 0 4.137185442232294e-06
informative O 0 4.02090381612652e-06
patients O 0 5.2152303396724164e-05
showed O 0 9.148727258434519e-05
loss O 0 0.00011127723701065406
of O 0 6.410385253730055e-07
constitutional O 0 0.0001439296902390197
heterozygosity O 0 0.0052289837040007114
( O 0 9.924345249601174e-06
LOH O 1 0.9954419136047363
) O 0 1.146170575339056e-06
at O 0 1.2876475921075325e-05
intragenic O 0 0.0003346544981468469
loci O 0 8.28841730253771e-05
. O 0 5.507874448085204e-06

Three O 0 3.3610481295909267e-06
of O 0 9.417073556505784e-07
13 O 0 1.6691994460416026e-05
uninformative O 0 0.00902183074504137
patients O 0 0.0002698905300348997
had O 0 1.1093441571574658e-05
constitutional O 0 4.1050443542189896e-05
deletions O 0 0.00016800012963358313
. O 0 8.026785508263856e-06

For O 0 1.0084861514769727e-06
39 O 0 9.49902278080117e-06
randomly O 0 1.1180446790604037e-06
selected O 0 7.0077530835988e-06
tumors B-Disease 1 0.9998767375946045
, O 0 7.738005933788372e-07
SSCP O 0 0.00021374280913732946
, O 0 4.3701362528736354e-07
hetero O 0 4.314382022130303e-05
- O 0 8.35769151308341e-06
duplex O 0 9.67280357144773e-06
analysis O 0 1.0205541656205241e-07
, O 0 1.8589823014281137e-08
sequencing O 0 1.1409865408040787e-07
, O 0 3.208230836548864e-08
and O 0 3.182116969924209e-08
Southern O 0 3.611482952692313e-07
blot O 0 1.0070099961012602e-05
analysis O 0 6.438703792355227e-08
were O 0 1.1882359984838331e-08
used O 0 3.153393635102475e-08
to O 0 4.2132651145720956e-08
identify O 0 2.245325958938338e-06
mutations O 0 5.9150643210159615e-05
. O 0 2.9045493192825234e-06

Mutations O 0 0.00012325923307798803
were O 0 9.105179401558416e-07
detected O 0 1.7372714864904992e-05
in O 0 1.9054517963468243e-07
21 O 0 9.465315429224574e-07
( O 0 8.854881627939903e-08
91 O 0 7.331802862609038e-07
% O 0 2.4724942093712343e-08
) O 0 2.2257083287513524e-08
of O 0 3.6042266060576367e-07
23 O 0 0.0031128101982176304
tumors B-Disease 1 0.9999545812606812
with O 0 0.00011109244951512665
LOH O 1 0.9993950128555298
. O 0 4.157560397288762e-05

In O 0 5.9616622820612974e-06
6 O 0 3.861018285533646e-06
( O 0 9.763749631019891e-08
38 O 0 4.5887207988926093e-07
% O 0 2.9395327061365606e-08
) O 0 2.8618263314683645e-08
of O 0 1.8540023916102655e-07
16 O 0 0.0008355972822755575
tumors B-Disease 1 0.9999591112136841
without O 0 1.6856667571119033e-05
LOH O 1 0.9951590895652771
, O 0 3.034660949197132e-07
one O 0 1.75078213260349e-07
mutation O 0 2.900319941545604e-06
was O 0 1.966555828403216e-06
detected O 0 4.051118594361469e-06
, O 0 2.4667473397244066e-08
and O 0 1.1267084154553686e-08
in O 0 3.862557207412465e-08
9 O 0 3.3862710324683576e-07
( O 0 1.9027437403451586e-08
56 O 0 1.6826962223603914e-07
% O 0 1.1478356043426174e-08
) O 0 1.335750443587358e-08
of O 0 5.670724689821327e-08
the O 0 3.29094982589595e-05
tumors B-Disease 1 0.9999692440032959
without O 0 2.671552101674024e-05
LOH O 1 0.9947829842567444
, O 0 4.5734034870292817e-07
both O 0 1.097661126436833e-07
mutations O 0 6.199962172104279e-06
were O 0 3.687450487177557e-07
found O 0 1.5398758250739775e-06
. O 0 1.93784580915235e-06

Thus O 0 3.607686721807113e-06
, O 0 9.14054893996763e-08
a O 0 6.023802967547454e-08
total O 0 1.8335505558297882e-08
of O 0 3.619122779241479e-08
45 O 0 3.438177031966916e-07
mutations O 0 2.4309338186867535e-06
were O 0 2.623346517793834e-07
identified O 0 3.811671604125877e-06
in O 0 8.763227015151642e-06
tumors B-Disease 1 0.9998939037322998
of O 0 1.39803410093009e-06
36 O 0 8.564358722651377e-05
patients O 0 0.00010398422455182299
. O 0 5.192855951463571e-06

Thirty O 0 3.485562410787679e-05
- O 0 3.3809916203608736e-05
nine O 0 5.235058893049427e-07
of O 0 2.6260892127538682e-08
the O 0 1.6264547753053193e-07
mutations O 0 4.863068170379847e-06
- O 0 3.085257503698813e-06
including O 0 3.322741193301226e-08
34 O 0 4.26472297476721e-07
small O 0 1.857524267734334e-07
mutations O 0 5.415325631474843e-06
, O 0 5.703723005012762e-08
2 O 0 2.521294106827554e-07
large O 0 4.942812665831298e-07
structural O 0 0.00046737640514038503
alterations O 0 0.00020302431948948652
, O 0 4.811479357158532e-07
and O 0 3.648614779194759e-07
hypermethylation O 0 0.0005074921646155417
in O 0 4.001432444056263e-06
3 O 0 0.00023715045244898647
tumors O 1 0.9999393224716187
- O 0 3.299786840216257e-05
were O 0 7.957352465837175e-08
not O 0 1.9230258274660628e-08
detected O 0 9.461651870878995e-07
in O 0 9.65524193929923e-09
the O 0 4.801898967343732e-08
corresponding O 0 6.452399361478456e-07
peripheral O 0 0.0001767953799571842
blood O 0 0.00030691447318531573
DNA O 0 4.692122820415534e-05
. O 0 4.485896170081105e-06

In O 0 5.626548045256641e-06
6 O 0 3.507959945636685e-06
( O 0 9.965328473526824e-08
17 O 0 3.9116011407713813e-07
% O 0 8.080131230769894e-09
) O 0 4.382905594013664e-09
of O 0 6.912040717566015e-09
the O 0 1.86293689807826e-07
36 O 0 3.089355914198677e-06
patients O 0 1.0200388942394056e-06
, O 0 4.641784201453447e-08
a O 0 4.671190652061341e-07
mutation O 0 3.8044988741603447e-06
was O 0 2.196681180066662e-06
detected O 0 3.0187959509930806e-06
in O 0 3.630323064385266e-08
constitutional O 0 3.2963748708425555e-07
DNA O 0 4.3279598571643874e-07
, O 0 2.541417032375648e-08
and O 0 1.607281596704979e-08
1 O 0 6.353442216777694e-08
of O 0 8.184816380207849e-09
these O 0 1.3375784035929428e-08
mutations O 0 2.76603009297105e-06
is O 0 5.989078744050857e-08
known O 0 9.583800419932231e-08
to O 0 7.431976811744789e-09
be O 0 6.991439249759424e-08
associated O 0 4.4299309820416966e-07
with O 0 4.052886026784108e-07
reduced O 0 4.907987386104651e-05
expressivity O 0 0.005238282959908247
. O 0 1.8278773495694622e-05

The O 0 1.4999760651335237e-06
presence O 0 1.6766521184763405e-06
of O 0 1.8063919071664714e-07
a O 0 1.6495548607053934e-06
constitutional O 0 9.230931937054265e-06
mutation O 0 1.6497815522598103e-05
was O 0 7.924688361526933e-06
not O 0 2.3211564226244263e-08
associated O 0 5.723994078721262e-08
with O 0 7.030457105372534e-09
an O 0 4.7992344320846314e-08
early O 0 1.7735119399731047e-06
age O 0 5.621217042062199e-06
at O 0 2.2399159206543118e-05
treatment O 0 6.906510679982603e-05
. O 0 2.904139364545699e-06

In O 0 6.423520062526222e-06
1 O 0 7.788432412780821e-06
patient O 0 1.647992030484602e-05
, O 0 1.6178287864931917e-07
somatic O 0 5.437883373815566e-06
mosaicism O 0 0.0005379045614972711
was O 0 8.978083315014374e-06
demonstrated O 0 4.1475098555565637e-07
by O 0 3.411374649431309e-08
molecular O 0 1.0531363159316243e-06
analysis O 0 3.9125033879372495e-08
of O 0 1.2737897847614477e-08
DNA O 0 6.506901399916387e-07
and O 0 3.4956315175804775e-08
RNA O 0 2.376492375333328e-06
from O 0 2.8925697392878646e-07
peripheral O 0 0.0003178016049787402
blood O 0 0.0011826143600046635
. O 0 6.787745860492578e-06

In O 0 6.505693363578757e-06
2 O 0 9.964698620024137e-06
patients O 0 3.7229590361675946e-06
without O 0 2.0962868063634232e-07
a O 0 1.6830505273901508e-06
detectable O 0 0.00015978266310412437
mutation O 0 2.168841820093803e-05
in O 0 5.753025220656127e-07
peripheral O 0 0.00030317564960569143
blood O 0 0.00043295574141666293
, O 0 1.368177777294477e-06
mosaicism O 0 0.000236084932112135
was O 0 2.0163624867564067e-05
suggested O 0 1.0833878150151577e-06
because O 0 1.3774375418051932e-07
1 O 0 1.0589661059157152e-07
of O 0 4.155221233759221e-08
the O 0 2.9960463052702835e-06
patients O 0 0.00021611832198686898
showed O 0 0.0032774191349744797
multifocal O 1 0.9995367527008057
tumors B-Disease 1 0.9999932050704956
and O 0 1.4974560826885863e-06
the O 0 1.3766916140411922e-07
other O 0 2.3280421146409935e-08
later O 0 7.271978006428981e-07
developed O 0 2.8919430405949242e-06
bilateral B-Disease 0 8.680099563207477e-05
retinoblastoma I-Disease 0 0.06110421568155289
. O 0 1.8204227671958506e-05

In O 0 1.4127422218734864e-06
conclusion O 0 1.5893554063950432e-06
, O 0 1.853443762911411e-07
our O 0 1.9791033878391318e-07
results O 0 7.242308015520393e-07
emphasize O 0 3.4888086020146147e-07
that O 0 1.589022780024152e-08
the O 0 6.597946367037366e-08
manifestation O 0 4.392215487314388e-06
and O 0 3.4579926477817935e-07
transmissibility O 0 2.21607642743038e-05
of O 0 1.3513572127976659e-07
retinoblastoma B-Disease 0 0.00011281480692559853
depend O 0 3.3440664992667735e-07
on O 0 1.1951831311307615e-06
the O 0 8.822361508009635e-08
nature O 0 2.52238606890387e-07
of O 0 1.2057629561468275e-08
the O 0 7.181331085348575e-08
first O 0 3.0658856076115626e-07
mutation O 0 8.37942707221373e-07
, O 0 7.528580425741893e-09
its O 0 4.524889352097716e-09
time O 0 2.1750997447611553e-08
in O 0 9.787855859144656e-09
development O 0 1.3641264118291474e-08
, O 0 9.742632478548785e-09
and O 0 4.944308962251398e-09
the O 0 5.145319281751881e-09
number O 0 5.033822247924036e-09
and O 0 6.148587416987539e-09
types O 0 4.308714807166325e-08
of O 0 2.555435507645143e-08
cells O 0 7.157372579058574e-07
that O 0 1.8443044424998334e-08
are O 0 1.65993494505301e-08
affected O 0 2.7683233838615706e-07
. O 0 1.672256075835321e-07
. O 0 1.0651907587089227e-06

Hereditary B-Disease 1 0.9996335506439209
deficiency I-Disease 1 0.9997621178627014
of I-Disease 0 1.6013686945370864e-06
the I-Disease 0 2.1940097667538794e-06
fifth I-Disease 0 1.64263037731871e-05
component I-Disease 0 1.449071987735806e-06
of I-Disease 0 5.03607218149682e-08
complement I-Disease 0 1.6567140619372367e-06
in O 0 2.9828747756255325e-06
man O 0 0.0001916025794344023
. O 0 6.209968887560535e-06

I O 0 0.009639863856136799
. O 0 4.774151966557838e-05

Clinical O 0 0.001072430401109159
, O 0 3.74594128516037e-06
immunochemical O 0 0.0004340117739047855
, O 0 1.0936399803540553e-06
and O 0 6.112820756243309e-07
family O 0 7.406581516988808e-06
studies O 0 3.6178196296532406e-06
. O 0 2.802448761940468e-06

The O 0 1.734030320221791e-06
first O 0 1.1095917216152884e-06
recognized O 0 2.120268163707806e-06
human O 0 4.163855919614434e-06
kindred O 0 0.0006344558205455542
with O 0 0.0002111248904839158
hereditary B-Disease 1 0.9999533891677856
deficiency I-Disease 1 0.9998955726623535
of I-Disease 0 5.341748874343466e-07
the I-Disease 0 8.144476169036352e-07
fifth I-Disease 0 2.5215365894837305e-05
component I-Disease 0 2.009599938901374e-06
of I-Disease 0 4.9685031200397134e-08
complement I-Disease 0 1.1794926422226126e-06
( O 0 7.065639806569379e-07
C5 O 0 0.0007417687447741628
) O 0 2.214690368873562e-07
is O 0 4.614815338754852e-07
described O 0 1.5036933291412424e-05
. O 0 3.29946783494961e-06

The O 0 3.4089598557329737e-06
proband O 0 7.793543773004785e-05
, O 0 2.2879883943005552e-07
a O 0 4.054103612816107e-07
20 O 0 5.396345272856706e-07
- O 0 1.2524177691375371e-05
year O 0 1.1744327821361367e-06
- O 0 2.295942795171868e-05
old O 0 3.281811223132536e-05
black O 0 9.074691661226097e-06
female O 0 1.0517018381506205e-05
with O 0 0.00016224355204030871
systemic B-Disease 1 0.999981164932251
lupus I-Disease 1 0.9999352693557739
erythematosus I-Disease 1 0.9999608993530273
since O 0 0.005932772997766733
age O 0 0.00022222916595637798
11 O 0 6.019661668688059e-06
, O 0 4.148827201788663e-07
lacked O 0 2.228746234322898e-05
serum O 0 0.0002840406959876418
hemolytic O 0 0.0840788334608078
complement O 0 2.870414846256608e-06
activity O 0 1.6492151644342812e-06
, O 0 1.0271097039549204e-07
even O 0 2.80229699001211e-07
during O 0 1.2975758181710262e-05
remission O 0 0.00032263054163195193
. O 0 2.6766390419652453e-06

C5 O 0 0.026972895488142967
was O 0 0.00028775003738701344
undetectable O 0 0.00036348836147226393
in O 0 5.093332333672151e-07
her O 0 1.3640296856465284e-06
serum O 0 5.105386208015261e-06
by O 0 2.8791603767786e-08
both O 0 2.208085163601936e-07
immunodiffusion O 0 0.00039307164843194187
and O 0 7.062944860081188e-06
hemolytic O 1 0.9948970675468445
assays O 0 0.0003011315129697323
. O 0 1.1227675713598728e-05

Other O 0 7.122931577896452e-08
complement O 0 6.030861641193042e-07
components O 0 2.1072196432214696e-06
were O 0 2.706734107960074e-07
normal O 0 4.624269877240295e-06
during O 0 7.534180440416094e-06
remission O 0 0.0001438882463844493
of O 0 7.541711966041476e-07
lupus O 1 0.9972276091575623
, O 0 1.0883398999794736e-06
but O 0 6.609086540265707e-07
C1 O 0 0.000327492190990597
, O 0 3.4412670402161893e-07
C4 O 0 0.00018496171105653048
, O 0 6.948963005015685e-07
C2 O 0 9.495137783233076e-05
, O 0 1.747822580000502e-07
and O 0 3.7148902265471406e-07
C3 O 0 0.0030544535256922245
levels O 0 6.082917025196366e-05
fell O 0 0.0014615287072956562
during O 0 1.995250568143092e-05
exacerbations O 0 0.005860391538590193
. O 0 8.306717063533142e-06

A O 0 2.095186209771782e-05
younger O 0 1.6766083717811853e-05
half O 0 3.7748418435512576e-06
- O 0 4.881879431195557e-05
sister O 0 2.357396442675963e-05
, O 0 3.350747874719673e-07
who O 0 5.98091730807937e-07
had O 0 2.0875177142443135e-06
no O 0 4.740725671581458e-06
underlying O 0 0.08764959871768951
disease O 1 0.9988239407539368
, O 0 1.591827867741813e-06
was O 0 8.779302152106538e-05
also O 0 3.166702242651809e-07
found O 0 2.7746855835175666e-07
to O 0 3.7609527936410814e-08
lack O 0 6.460036274802405e-06
immunochemically O 0 0.004759463015943766
detectable O 0 0.00998044665902853
C5 O 0 0.01051158457994461
. O 0 1.393693673890084e-05

By O 0 1.8664395611267537e-05
hemolytic O 1 0.9789060354232788
assay O 0 0.00018549581000115722
, O 0 1.6452046338599757e-06
she O 0 1.1848060239572078e-06
exhibited O 0 2.4400987967965193e-06
1 O 0 7.882470072217984e-07
- O 0 2.699417791518499e-06
2 O 0 1.234135993399832e-07
% O 0 4.292004529560245e-09
of O 0 2.8213227309947797e-09
the O 0 5.960576743291313e-08
normal O 0 1.8147437685911427e-06
serum O 0 6.370354185492033e-06
C5 O 0 1.9567678464227356e-05
level O 0 6.256713049879181e-07
and O 0 3.345871490978425e-08
normal O 0 7.48903289604641e-07
concentrations O 0 7.939702868497989e-07
of O 0 7.891013176219985e-09
other O 0 7.254043143944955e-09
complement O 0 4.738230643397401e-07
components O 0 1.6952168152783997e-05
. O 0 3.318217750347685e-06

C5 O 0 0.013462208211421967
levels O 0 6.06544672336895e-05
of O 0 9.910321807637956e-08
other O 0 4.4207979499333305e-08
family O 0 3.20234732953395e-07
members O 0 1.347490830028164e-08
were O 0 2.6992269752668108e-08
either O 0 6.59514043377385e-08
normal O 0 4.455870339370449e-07
or O 0 3.427824424306891e-08
approximately O 0 2.6736380220881983e-08
half O 0 2.2090371487593075e-07
- O 0 7.652943168068305e-06
normal O 0 9.330485681857681e-07
, O 0 5.40306110963229e-08
consistent O 0 4.880723736278014e-07
with O 0 3.573543096990761e-07
autosomal O 0 0.0022035858128219843
codominant O 0 0.0002802000381052494
inheritance O 0 1.7360891433781944e-05
of O 0 3.116109041911841e-07
the O 0 3.2317309432983166e-06
gene O 0 0.00033385975984856486
determining O 0 0.004811536055058241
C5 B-Disease 1 0.9999110698699951
deficiency I-Disease 1 0.9999686479568481
. O 0 0.00014571423525922

Normal O 0 0.0018690438009798527
hemolytic O 1 0.9874783754348755
titers O 0 0.0017287071095779538
were O 0 9.344323643745156e-07
restored O 0 8.313168109452818e-06
to O 0 8.211511470790356e-08
both O 0 9.883523262033123e-07
homozygous O 0 0.0006116561708040535
C5 B-Disease 1 0.9994970560073853
- I-Disease 1 0.9982978701591492
deficient I-Disease 1 0.9996103644371033
( O 0 2.066453089355491e-05
C5D B-Disease 1 0.9989301562309265
) O 0 2.15067530007218e-06
sera O 0 6.939129525562748e-05
by O 0 5.4992121079067147e-08
addition O 0 8.221682890052762e-08
of O 0 5.079754217263144e-08
highly O 0 5.1671190703928005e-06
purified O 0 2.648720874276478e-05
human O 0 9.309116649092175e-06
C5 O 0 0.004267364740371704
. O 0 1.0546064004302025e-05

In O 0 3.395682824702817e-06
specific O 0 2.4983069124573376e-06
C5 O 0 0.0013090880820527673
titrations O 0 0.00022168317809700966
, O 0 4.5279568894329714e-07
however O 0 2.1307002384673979e-07
, O 0 7.301937898773758e-08
it O 0 8.020726482982354e-08
was O 0 4.642285148293013e-06
noted O 0 1.854748745699908e-07
that O 0 3.6691092386575974e-09
when O 0 2.2626304385653384e-08
limited O 0 1.2354757217281076e-08
amounts O 0 3.521563485264778e-08
of O 0 2.6703560251917224e-08
C5 O 0 2.835552550095599e-05
were O 0 9.705486547773035e-08
assayed O 0 8.740239536564332e-07
in O 0 3.846794527362363e-08
the O 0 4.3338946653648236e-08
presence O 0 2.527162905607838e-07
of O 0 6.937813168406137e-08
low O 0 1.5097670257091522e-05
dilutions O 0 4.299722786527127e-05
of O 0 3.8666709656354215e-07
either O 0 1.3793102880299557e-05
C5D B-Disease 1 0.9993865489959717
serum O 0 0.0001639063993934542
, O 0 1.34554838382428e-07
curving O 0 2.6054351565107936e-06
rather O 0 1.8794112577324995e-07
than O 0 4.076406767694607e-08
linear O 0 7.554517651442438e-07
dose O 0 1.2558886737679131e-05
- O 0 6.996501269895816e-06
response O 0 1.471662471885793e-07
plots O 0 3.2128886573445925e-07
were O 0 9.714579363162557e-08
consistently O 0 7.011363436504325e-07
obtained O 0 1.52000382058759e-07
, O 0 4.162646050076546e-08
suggesting O 0 3.3456359460615204e-07
some O 0 2.8937606089129986e-08
inhibitory O 0 3.0575220080208965e-06
effect O 0 3.718701009347569e-06
. O 0 1.599985694156203e-06

Further O 0 1.2713802561847842e-06
studies O 0 6.708242494823935e-07
suggested O 0 5.58873637146462e-07
that O 0 3.2494618551481835e-08
low O 0 7.8540842878283e-06
dilutions O 0 6.964081694604829e-05
of O 0 2.63470451500325e-06
C5D B-Disease 1 0.9993743300437927
serum O 0 0.00012710897135548294
contain O 0 6.941326091691735e-07
a O 0 5.900468522668234e-07
factor O 0 4.281892529434117e-07
( O 0 6.044565026286364e-08
or O 0 5.270776881616257e-08
factors O 0 7.076079810985902e-08
) O 0 1.2773565316592794e-08
interfering O 0 2.0552529633732775e-07
at O 0 6.80926973473106e-07
some O 0 7.738106155841251e-09
step O 0 9.5266437938335e-07
in O 0 1.2195555143534875e-07
the O 0 4.5981391849636566e-07
hemolytic O 0 0.3003871440887451
assay O 0 8.209527550206985e-06
of O 0 2.864863688500918e-07
C5 O 0 0.0008049760363064706
, O 0 6.319541512311844e-08
rather O 0 2.4412708299337282e-08
than O 0 2.357363193539186e-08
a O 0 3.9048026678756287e-07
true O 0 2.45015121436154e-06
C5 O 0 0.0011355977039784193
inhibitor O 0 4.130536399316043e-05
or O 0 1.8324006987313624e-06
inactivator O 0 0.0003856549155898392
. O 0 5.202194188314024e-06

Of O 0 4.762167918670457e-06
clinical O 0 5.7074048527283594e-05
interest O 0 1.4504712453344837e-06
are O 0 8.633408299374423e-08
( O 0 8.825745112517325e-08
a O 0 4.0199887507696985e-07
) O 0 4.9842594052051936e-08
the O 0 6.304636457343804e-08
documentation O 0 2.5792023734538816e-06
of O 0 4.934329354000511e-06
membranous O 1 0.9981075525283813
glomerulonephritis B-Disease 1 0.9999715089797974
, O 0 0.08490126579999924
vasculitis B-Disease 1 0.9999743700027466
, O 0 0.0011717431480064988
and O 0 0.496754914522171
arthritis B-Disease 1 0.999998927116394
in O 0 2.467371814418584e-06
an O 0 2.0647102871862444e-07
individual O 0 2.5496376565570245e-07
lacking O 0 2.5457562514930032e-05
C5 O 0 0.001397708198055625
( O 0 1.4097689415848436e-07
and O 0 2.353320027737027e-08
its O 0 4.742353354458828e-08
biologic O 0 2.9348157113417983e-06
functions O 0 1.3480941163379612e-07
) O 0 3.262148950966548e-08
, O 0 2.0884042939428582e-08
and O 0 3.352834809788874e-08
( O 0 5.989295459585264e-08
b O 0 5.895782919651538e-07
) O 0 1.3181177038745773e-08
a O 0 1.402070211042883e-07
remarkable O 0 9.364021025248803e-07
propensity O 0 2.3576369130751118e-05
to O 0 2.692519956326578e-06
bacterial B-Disease 1 0.999810516834259
infections I-Disease 1 0.9999454021453857
in O 0 7.155537105063559e-07
the O 0 4.860161197939306e-07
proband O 0 7.97350294305943e-05
, O 0 8.258838590791129e-08
even O 0 8.525017136662427e-08
during O 0 7.304861924239958e-07
periods O 0 7.410421289932856e-07
of O 0 8.299404896661144e-08
low O 0 3.308726445538923e-05
- O 0 1.9376706404727884e-05
dose O 0 2.8823362754337722e-06
or O 0 7.496058174183418e-08
alternate O 0 9.203517379319237e-07
- O 0 6.921008025528863e-05
day O 0 1.416153918398777e-05
corticosteroid O 0 0.001837868127040565
therapy O 0 0.0002788882120512426
. O 0 5.413239250628976e-06

Other O 0 9.012714485834294e-07
observations O 0 7.250390808621887e-06
indicate O 0 1.137225012826093e-06
that O 0 6.674600427913902e-08
the O 0 7.720020676060813e-07
C5D B-Disease 1 0.9988765120506287
state O 0 4.44008605882118e-07
is O 0 4.8160334387148396e-08
compatible O 0 1.1718757519929568e-07
with O 0 3.854190211427522e-08
normal O 0 1.4885940800013486e-06
coagulation O 0 7.109390480763977e-06
function O 0 4.0440946236230957e-07
and O 0 4.168724387909606e-08
the O 0 9.05738488654606e-08
capacity O 0 4.3907141389354365e-07
to O 0 8.521457317556269e-08
mount O 0 2.2961969079915434e-05
a O 0 4.901542706647888e-05
neutrophilic O 0 0.11889241635799408
leukocytosis O 0 0.2862558662891388
during O 0 0.0010047968244180083
pyogenic B-Disease 1 0.9148502945899963
infection I-Disease 1 0.9699175357818604
. O 0 5.856365532963537e-06
. O 0 9.261299965146463e-06

Susceptibility O 0 0.12336142361164093
to O 0 0.0014082520501688123
ankylosing B-Disease 1 0.9999897480010986
spondylitis I-Disease 1 0.9999995231628418
in O 0 0.009137570858001709
twins O 0 0.036936063319444656
: O 0 1.1758410067841396e-07
the O 0 3.104972634559999e-08
role O 0 2.610817375625629e-07
of O 0 5.323618523789264e-08
genes O 0 9.235538982466096e-07
, O 0 3.012389129253279e-07
HLA O 0 2.6806834284798242e-05
, O 0 1.2398693627346802e-07
and O 0 1.7045489641986933e-07
the O 0 1.6051391185101238e-06
environment O 0 3.2783827919047326e-05
. O 0 4.6155905693012755e-06

OBJECTIVE O 0 1.4814274436503183e-05
To O 0 7.636442944658484e-08
determine O 0 1.6038187311551155e-07
the O 0 6.697619170381586e-08
relative O 0 1.0227020084130345e-06
effects O 0 2.1575265236606356e-06
of O 0 1.3390621234066202e-07
genetic O 0 1.1808020644821227e-05
and O 0 3.708391602685879e-07
environmental O 0 7.190148608060554e-06
factors O 0 1.6040022501329076e-06
in O 0 3.44508021044021e-06
susceptibility O 0 0.0028862743638455868
to O 0 0.0009748631273396313
ankylosing B-Disease 1 0.9999974966049194
spondylitis I-Disease 1 0.9999997615814209
( O 0 0.00204362440854311
AS B-Disease 1 0.9986264705657959
) O 0 4.136333245696733e-06
. O 0 6.385238066286547e-06

METHODS O 0 3.669804573291913e-05
Twins O 0 0.00020323968783486634
with O 0 4.2219571128043754e-07
AS B-Disease 0 0.009970481507480145
were O 0 2.877645783883054e-07
identified O 0 5.288258648761257e-07
from O 0 6.170323985088544e-08
the O 0 1.7797322016122052e-07
Royal O 0 0.00024547899374738336
National O 0 0.00035047484561800957
Hospital O 1 0.55168616771698
for O 0 0.0001490185532020405
Rheumatic B-Disease 1 0.9999333620071411
Diseases I-Disease 1 0.9996367692947388
database O 0 0.000721215270459652
. O 0 2.5236966394004412e-05

Clinical O 0 0.00031021542963571846
and O 0 1.1405311397538753e-06
radiographic O 0 9.536233847029507e-05
examinations O 0 8.374214303330518e-06
were O 0 1.8360007913997833e-07
performed O 0 5.949423780293728e-07
to O 0 3.972176543243222e-08
establish O 0 1.395165213580185e-06
diagnoses O 0 0.0004067365371156484
, O 0 1.8829288137567346e-06
and O 0 3.693478720379062e-05
disease O 1 0.9996107220649719
severity O 0 0.029906895011663437
was O 0 9.672650048742071e-05
assessed O 0 8.146884624693485e-07
using O 0 1.941219629486568e-08
a O 0 1.448014899096961e-07
combination O 0 2.856060632439039e-07
of O 0 3.5700953304740324e-08
validated O 0 3.1271167699742364e-06
scoring O 0 1.2546991001727292e-06
systems O 0 0.000178776346729137
. O 0 7.528133210144006e-06

HLA O 0 0.0011470071040093899
typing O 0 5.8916510170092806e-05
for O 0 1.0103218528456637e-06
HLA O 0 0.00019557417545001954
- O 0 5.761164356954396e-05
B27 O 0 2.1560068489634432e-05
, O 0 1.027309963319567e-06
HLA O 0 3.897334318025969e-05
- O 0 1.3878393474442419e-05
B60 O 0 7.932263542898e-06
, O 0 1.7908753591200366e-07
and O 0 4.004064066975843e-07
HLA O 0 0.00015226964023895562
- O 0 0.00019162340322509408
DR1 O 0 0.0018707455601543188
was O 0 4.404576884553535e-06
performed O 0 3.573157982827979e-07
by O 0 2.904670992620595e-08
polymerase O 0 8.802005027064297e-07
chain O 0 1.0657932989488472e-06
reaction O 0 1.2471174670736218e-07
with O 0 2.363440998465194e-08
sequence O 0 3.1401208389070234e-07
- O 0 1.931590986714582e-06
specific O 0 6.360971838148544e-08
primers O 0 1.6573492302995874e-06
, O 0 1.5306926570701762e-07
and O 0 2.508572549686505e-07
zygosity O 0 0.00012673763558268547
was O 0 1.6179865269805305e-05
assessed O 0 5.460682132252259e-06
using O 0 1.6912355249587563e-06
microsatellite O 0 0.0005347012192942202
markers O 0 0.00019459276518318802
. O 0 1.0586773896648083e-05

Genetic O 0 0.00028444716008380055
and O 0 2.7398887141316663e-06
environmental O 0 1.8302281432625023e-06
variance O 0 1.8754758457362186e-07
components O 0 1.8120700815416058e-06
were O 0 3.0992543997854227e-07
assessed O 0 1.1573401934583671e-06
with O 0 3.496698752769589e-08
the O 0 1.0621642587693714e-07
program O 0 3.1277383527594793e-07
Mx O 0 3.984659088018816e-06
, O 0 8.569519316381502e-09
using O 0 9.135630918422066e-09
data O 0 4.31976623360697e-08
from O 0 1.597312326850897e-08
this O 0 2.7425377524537e-09
and O 0 7.721416395156666e-09
previous O 0 1.8353145492255862e-07
studies O 0 9.898419506271239e-08
of O 0 5.991626750301293e-08
twins O 0 0.0001166388246929273
with O 0 1.673766746534966e-06
AS B-Disease 1 0.9468584060668945
. O 0 1.2005548342131078e-05

RESULTS O 0 7.79677793616429e-05
Six O 0 1.6148796930792741e-06
of O 0 3.5102181072943495e-07
8 O 0 1.7201560694957152e-05
monozygotic O 0 0.00021375788492150605
( O 0 1.859370740930899e-06
MZ O 0 0.0055846055038273335
) O 0 6.393448757080478e-07
twin O 0 0.00012851355131715536
pairs O 0 1.0375832971476484e-05
were O 0 7.121516773622716e-06
disease O 0 0.1502843052148819
concordant O 0 3.2685307814972475e-05
, O 0 1.326685179492415e-07
compared O 0 3.307436884369963e-07
with O 0 2.7795817203468687e-08
4 O 0 3.685703120481776e-07
of O 0 3.320156594099899e-08
15 O 0 7.109453008524724e-07
B27 O 0 1.9215067368349992e-05
- O 0 3.258316792198457e-05
positive O 0 1.0722559409259702e-06
dizygotic O 0 5.356601104722358e-05
( O 0 6.828127538938134e-07
DZ O 0 0.00046404951717704535
) O 0 2.137648635880396e-07
twin O 0 3.034919973288197e-05
pairs O 0 7.899100751274091e-07
( O 0 6.90016150883821e-08
27 O 0 4.3936842075709137e-07
% O 0 7.774974442043003e-09
) O 0 5.7963700506036275e-09
and O 0 1.3240265772651583e-08
4 O 0 1.1423779966435177e-07
of O 0 4.7385110946152054e-08
32 O 0 3.36023413183284e-06
DZ O 0 0.0015270834555849433
twin O 0 0.00017333841242361814
pairs O 0 2.8015108455292648e-06
overall O 0 1.6799380091470084e-06
( O 0 9.409068724153258e-08
12 O 0 1.625642198632704e-07
. O 0 2.153867484366856e-08
5 O 0 2.9592510486509127e-07
% O 0 3.9787579453332e-08
) O 0 1.296684501994605e-07
. O 0 5.436139076664404e-07

Nonsignificant O 0 0.002380642108619213
increases O 0 2.0568444597302005e-05
in O 0 1.953009558519625e-07
similarity O 0 3.109240083176701e-07
with O 0 4.80963500137932e-08
regard O 0 3.5850735002895817e-07
to O 0 2.513108086077409e-07
age O 0 3.891618689522147e-05
at O 0 0.0012678304919973016
disease O 1 0.9624292254447937
onset O 0 0.0026277070865035057
and O 0 2.627593005399831e-07
all O 0 5.3950184764062215e-08
of O 0 2.2109657038527075e-07
the O 0 2.6042849640361965e-05
disease O 1 0.9843723773956299
severity O 0 0.0003476166457403451
scores O 0 4.1370594772160985e-06
assessed O 0 5.315569069352932e-06
were O 0 4.7225856292243407e-07
noted O 0 9.206754839397036e-06
in O 0 1.6586000128882006e-05
disease O 1 0.9981080293655396
- O 0 0.24788875877857208
concordant O 0 0.009675953537225723
MZ O 1 0.9017396569252014
twins O 0 0.005872855894267559
compared O 0 3.674468825920485e-05
with O 0 2.921016175605473e-06
concordant O 0 0.017201906070113182
DZ O 1 0.9878808259963989
twins O 0 0.10790493339300156
. O 0 1.644520671106875e-05

HLA O 0 0.00569557398557663
- O 0 0.0002340969949727878
B27 O 0 2.8292593924561515e-05
and O 0 2.518895314551628e-07
B60 O 0 7.079345323290909e-06
were O 0 1.4993666752616264e-07
associated O 0 3.9615198943465657e-07
with O 0 2.2385323461548978e-07
the O 0 4.118968718103133e-05
disease O 1 0.8210044503211975
in O 0 3.430153014960524e-07
probands O 0 4.9196460167877376e-05
, O 0 1.1930576704344276e-07
and O 0 5.497534161236217e-08
the O 0 4.988915520698356e-07
rate O 0 2.205846249125898e-05
of O 0 3.607882206324575e-07
disease O 0 0.07010349631309509
concordance O 0 8.197901479434222e-06
was O 0 6.574231065314962e-06
significantly O 0 2.4588123324065236e-06
increased O 0 4.753383677780221e-07
among O 0 4.20916052235043e-07
DZ O 0 0.002199030015617609
twin O 0 0.00021374810603447258
pairs O 0 2.0033810415043263e-06
in O 0 1.2321061149123125e-07
which O 0 3.135281545496582e-08
the O 0 9.448273630141557e-08
co O 0 4.214937871438451e-05
- O 0 0.00017685251077637076
twin O 0 0.0002820884110406041
was O 0 2.842760977728176e-06
positive O 0 3.664138503722825e-08
for O 0 6.890532144865347e-09
both O 0 8.148511199124187e-08
B27 O 0 1.7487211152911186e-05
and O 0 2.625281467771856e-06
DR1 O 0 0.0348401740193367
. O 0 2.1564261260209605e-05

Additive O 0 1.6281714124488644e-05
genetic O 0 1.6233620044658892e-05
effects O 0 3.939238922612276e-06
were O 0 6.495766058378649e-08
estimated O 0 3.835760509218744e-08
to O 0 2.5842796791408773e-09
contribute O 0 3.742697884945301e-08
97 O 0 3.345473089666484e-07
% O 0 1.0410615480793695e-08
of O 0 5.207062780954175e-09
the O 0 4.4727723746973425e-08
population O 0 3.7491496129860025e-08
variance O 0 8.116570029415016e-07
. O 0 2.8265410492167575e-06

CONCLUSION O 0 5.451790275401436e-05
Susceptibility O 0 8.257081935880706e-05
to O 0 4.5159765704738675e-07
AS B-Disease 0 0.07787278294563293
is O 0 2.5419777216484363e-07
largely O 0 1.562123372877977e-07
genetically O 0 4.5471136900232523e-07
determined O 0 6.98697306233953e-07
, O 0 3.085390432033819e-08
and O 0 3.325638786577656e-08
the O 0 2.343292067052971e-07
environmental O 0 9.597429198038299e-06
trigger O 0 1.402731504640542e-05
for O 0 2.8380998173815897e-07
the O 0 4.820803951588459e-05
disease O 1 0.9973637461662292
is O 0 2.4779078557912726e-06
probably O 0 4.384155090519926e-06
ubiquitous O 0 5.191501622903161e-05
. O 0 8.04830779088661e-06

HLA O 0 0.006840352434664965
- O 0 0.00021799041132908314
B27 O 0 1.961958514584694e-05
accounts O 0 1.684728943018854e-07
for O 0 2.4626714889564028e-08
a O 0 1.5441375467162288e-07
minority O 0 7.581584071658654e-08
of O 0 1.1522666376606594e-08
the O 0 1.9174171939084772e-07
overall O 0 7.035328053461853e-06
genetic O 0 4.6262637624749914e-05
susceptibility O 0 5.877167859580368e-05
to O 0 4.504827586515603e-07
AS B-Disease 1 0.7142946720123291
. O 0 1.1195427759957965e-05

Cell O 0 0.0030826206784695387
cycle O 0 0.0003353312495164573
- O 0 3.496575300232507e-05
dependent O 0 3.0237979444791563e-06
colocalization O 0 3.48836874763947e-05
of O 0 2.2485392037197016e-07
BARD1 O 0 0.0001489071873947978
and O 0 4.1920631588254764e-07
BRCA1 O 0 1.2325473107921425e-05
proteins O 0 1.511155147682075e-07
in O 0 7.436020155182632e-08
discrete O 0 1.9800202153419377e-06
nuclear O 0 8.356764737982303e-05
domains O 0 2.8604446924873628e-05
. O 0 4.197714133624686e-06

Germ O 0 0.011974112130701542
- O 0 0.0010958716738969088
line O 0 7.132964674383402e-05
mutations O 0 1.6183799743885174e-05
of O 0 8.865782064049199e-08
the O 0 2.2933359389298857e-07
BRCA1 O 0 4.1699087887536734e-05
gene O 0 5.120248260936933e-06
predispose O 0 5.3557373576040845e-06
women O 0 1.8408977098260948e-07
to O 0 6.899174564978239e-08
early O 0 2.4517135898349807e-05
- O 0 0.20835767686367035
onset O 1 0.9827454686164856
breast B-Disease 1 0.999455988407135
and I-Disease 1 0.6991257667541504
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999939203262329
by O 0 1.0041924269899027e-06
compromising O 0 4.391910624690354e-05
the O 0 7.385382332358859e-07
genes O 0 5.0376470426272135e-06
presumptive O 0 0.0006996128358878195
function O 0 2.6291322683391627e-06
as O 0 2.1392772850958863e-06
a O 0 4.070649447385222e-05
tumor B-Disease 1 0.8084216117858887
suppressor O 0 0.00047144258860498667
. O 0 4.569481006910792e-06

Although O 0 3.9060046219674405e-06
the O 0 5.439027290776721e-07
biochemical O 0 2.3923554181237705e-05
properties O 0 2.5154724880849244e-06
of O 0 3.1550635526400583e-07
BRCA1 O 0 6.766853766748682e-05
polypeptides O 0 4.047090897074668e-06
are O 0 1.9220138369746564e-08
not O 0 2.2898824170169974e-08
understood O 0 1.8521680544836272e-07
, O 0 1.8483049757378467e-08
their O 0 1.2897490186958294e-08
expression O 0 2.7814414238491736e-07
pattern O 0 2.6197815259365598e-06
and O 0 7.679619784539682e-08
subcellular O 0 4.106685537408339e-06
localization O 0 5.875408078281907e-06
suggest O 0 3.0907773407307104e-07
a O 0 7.88217136005187e-08
role O 0 3.7320913293115154e-07
in O 0 7.184276000771206e-07
cell O 0 0.00042418629163876176
- O 0 0.0005799352657049894
cycle O 0 5.671590770361945e-05
regulation O 0 3.0247723771026358e-05
. O 0 3.4374334063613787e-06

When O 0 3.587166065699421e-05
resting O 0 0.0005509972106665373
cells O 0 1.2207894542370923e-05
are O 0 1.1574832115002209e-07
induced O 0 6.9815641836612485e-06
to O 0 3.8784516931400503e-08
proliferate O 0 2.602554332042928e-06
, O 0 5.2827736851668305e-08
the O 0 5.0100126713914506e-08
steady O 0 2.35328070630203e-06
- O 0 4.445718786882935e-06
state O 0 8.494940573200438e-08
levels O 0 2.8696106824099843e-07
of O 0 2.5598698272233378e-08
BRCA1 O 0 5.54220196136157e-06
increase O 0 1.391451007748401e-07
in O 0 8.031105380723602e-08
late O 0 3.6511701182462275e-06
G1 O 0 1.863579745986499e-05
and O 0 1.9492448544156105e-08
reach O 0 5.553623338983016e-08
a O 0 1.4914218127159984e-07
maximum O 0 2.328355748204558e-07
during O 0 2.654548097780207e-06
S O 0 0.0001546117418911308
phase O 0 4.175862341071479e-05
. O 0 4.586639079207089e-06

Moreover O 0 1.4240917153074406e-05
, O 0 9.497379664935579e-07
in O 0 7.630370646438678e-07
S O 0 0.00011072113557020202
phase O 0 1.5093782167241443e-05
cells O 0 2.9954805995657807e-06
, O 0 1.1219096762715708e-07
BRCA1 O 0 3.3774479106796207e-06
polypeptides O 0 4.898354859506071e-07
are O 0 9.282505430974197e-09
hyperphosphorylated O 0 5.747745490225498e-06
and O 0 8.318898636616723e-08
accumulate O 0 2.214382902820944e-06
into O 0 1.922721963865115e-07
discrete O 0 3.8054058677516878e-06
subnuclear O 0 0.0003613768785726279
foci O 0 0.000274387450190261
termed O 0 0.00026907300343737006
" O 0 1.345356122328667e-05
BRCA1 O 0 0.0006757475202903152
nuclear O 0 0.0013567149871960282
dots O 0 0.001213567447848618
. O 0 2.3620053980266675e-05

" O 0 5.742843495681882e-05
BRCA1 O 0 0.00036240380723029375
associates O 0 8.88456852408126e-05
in O 0 5.276611432236678e-07
vivo O 0 5.462953140522586e-06
with O 0 1.0425920748957651e-07
a O 0 2.195941988247796e-06
structurally O 0 0.0002036121004493907
related O 0 6.62236925563775e-06
protein O 0 2.1484313037944958e-05
termed O 0 0.000275058759143576
BARD1 O 0 0.006250475533306599
. O 0 1.0404410204500891e-05

Here O 0 2.806305474223336e-06
we O 0 1.255195343219384e-07
show O 0 9.087442265354184e-08
that O 0 5.1267652345643455e-09
the O 0 3.2263088201034407e-08
steady O 0 2.6371706098871073e-06
- O 0 4.909868493996328e-06
state O 0 7.404600665950056e-08
levels O 0 4.035707092953089e-07
of O 0 3.1000549682858036e-08
BARD1 O 0 2.3616359612788074e-05
, O 0 5.980813710948496e-08
unlike O 0 9.167035130985823e-08
those O 0 2.0246799792289494e-08
of O 0 6.991599832417705e-08
BRCA1 O 0 2.920924271165859e-05
, O 0 2.72805721124314e-07
remain O 0 4.239087729729363e-07
relatively O 0 6.315100904430437e-07
constant O 0 1.0048274816654157e-06
during O 0 8.726350642973557e-06
cell O 0 0.0003339065588079393
cycle O 0 0.00011756710591726005
progression O 0 0.00044538374640978873
. O 0 4.9359159675077535e-06

However O 0 1.930598955368623e-05
, O 0 2.1886346530664014e-06
immunostaining O 0 0.0003568265528883785
revealed O 0 6.233660678844899e-05
that O 0 4.6333099135154043e-07
BARD1 O 0 0.0002691022527869791
resides O 0 1.2554875866044313e-05
within O 0 6.556372227350948e-07
BRCA1 O 0 4.3533596908673644e-05
nuclear O 0 3.2355706935049966e-05
dots O 0 2.2287633328232914e-05
during O 0 6.927868525963277e-06
S O 0 4.475907553569414e-05
phase O 0 1.6530210587006877e-06
of O 0 3.015170690900959e-08
the O 0 2.3915703195598326e-07
cell O 0 3.6859488318441436e-05
cycle O 0 7.214215202111518e-06
, O 0 4.2197225269546834e-08
but O 0 1.625669376892347e-08
not O 0 8.622526692647625e-09
during O 0 2.662049780610687e-07
the O 0 3.958230649914185e-07
G1 O 0 0.0002641441533342004
phase O 0 2.0361201677587815e-05
. O 0 1.7274711581194424e-06

Nevertheless O 0 4.27665509050712e-05
, O 0 9.840597385846195e-07
BARD1 O 0 5.530302587430924e-05
polypeptides O 0 1.5244952464854578e-06
are O 0 2.1479843681504462e-08
found O 0 3.686416150117111e-08
exclusively O 0 3.618329103005635e-08
in O 0 4.24461781278751e-08
the O 0 2.8620009473456776e-08
nuclear O 0 4.2480886008888774e-07
fractions O 0 3.448803553851576e-08
of O 0 7.307423999236562e-09
both O 0 6.738391533644972e-08
G1 O 0 0.00011636500130407512
- O 0 2.2556456315214746e-05
and O 0 1.0057852932732203e-06
S O 0 0.0004266747273504734
- O 0 8.656342834001407e-05
phase O 0 3.141763590974733e-05
cells O 0 1.4531915439874865e-05
. O 0 1.925402330016368e-06

Therefore O 0 8.010374585865065e-06
, O 0 7.415893605866586e-07
progression O 0 2.486595622031018e-05
to O 0 1.2098674062599457e-07
S O 0 7.552885654149577e-05
phase O 0 3.4659467473829864e-06
is O 0 8.543215557210715e-08
accompanied O 0 1.3455060354772286e-07
by O 0 6.3188281274051405e-09
the O 0 2.9142269042381486e-08
aggregation O 0 1.4714493090650649e-06
of O 0 2.4502560336259194e-07
nuclear O 0 6.159547774586827e-05
BARD1 O 0 6.720743840560317e-05
polypeptides O 0 3.5731786738324445e-06
into O 0 2.106910415022867e-06
BRCA1 O 0 0.0002921480918303132
nuclear O 0 0.0002979297423735261
dots O 0 0.00034470358514226973
. O 0 1.3490562196238898e-05

This O 0 3.3054768664442236e-06
cell O 0 0.00020597322145476937
cycle O 0 5.376779881771654e-05
- O 0 2.5500814444967546e-05
dependent O 0 1.0457233656779863e-06
colocalization O 0 1.8925147742265835e-05
of O 0 2.782855403893336e-07
BARD1 O 0 0.00040766852907836437
and O 0 1.6096519175334834e-06
BRCA1 O 0 5.030863030697219e-05
indicates O 0 8.214846616283467e-07
a O 0 1.2264180782040057e-07
role O 0 3.337254952384683e-07
for O 0 1.1259527354923193e-07
BARD1 O 0 0.0002267742092953995
in O 0 2.9614293453050777e-06
BRCA1 O 0 0.0005525245214812458
- O 0 0.002565884031355381
mediated O 0 0.009582470171153545
tumor B-Disease 1 0.9552456140518188
suppression O 0 0.00015458828420378268
. O 0 6.723282240272965e-06

Ethnic O 0 7.3916926339734346e-06
differences O 0 1.5574567441944964e-05
in O 0 1.5586575727866148e-06
the O 0 1.6641852198517881e-06
HFE O 0 0.0008606159826740623
codon O 0 5.848385626450181e-05
282 O 0 2.678235250641592e-05
( O 0 3.408894826861797e-06
Cys O 0 0.006359311752021313
/ O 0 0.0002949543122667819
Tyr O 0 0.00031246652361005545
) O 0 8.25960796646541e-07
polymorphism O 0 2.389263863733504e-05
. O 0 3.349717417222564e-06

Recent O 0 2.5513196305837482e-05
studies O 0 1.681637058936758e-06
have O 0 2.130878868911168e-07
shown O 0 2.6442119178682333e-06
that O 0 8.897594852896873e-06
hereditary B-Disease 1 0.9999868869781494
hemochromatosis I-Disease 1 0.9999990463256836
( O 0 0.0007915474125184119
HH B-Disease 1 0.9986308217048645
) O 0 1.3388262232183479e-06
is O 0 6.142477673165558e-07
likely O 0 2.466225623720675e-07
to O 0 2.1640097713770956e-08
be O 0 1.6807331348900334e-07
caused O 0 1.1082232731496333e-06
by O 0 3.027572503810916e-08
homozygosity O 0 7.0752007559349295e-06
for O 0 7.473359175946825e-08
a O 0 1.4881114793752204e-06
Cys282Tyr O 0 8.630321826785803e-05
mutation O 0 5.052826963947155e-06
in O 0 1.3587153091521031e-07
the O 0 3.9479613178627915e-07
HFE O 0 0.0003635647881310433
gene O 0 1.3402951481111813e-05
located O 0 1.2856217836088035e-05
4 O 0 1.0789050975290593e-05
. O 0 4.376803190098144e-06

5 O 0 2.331768519070465e-05
Mb O 0 0.00019288553448859602
telomeric O 0 0.00043955325963906944
to O 0 3.379877625775407e-06
HLA O 0 0.0011038969969376922
- O 0 0.00033655326114967465
A O 0 2.466628939146176e-05
. O 0 4.508017354964977e-06

Population O 0 1.0180398248849087e-06
studies O 0 6.032300348124409e-07
of O 0 3.1130550581792704e-08
this O 0 2.7571934069214876e-08
polymorphism O 0 4.7097759647840576e-07
are O 0 5.292927429678684e-09
facilitated O 0 1.220058010176217e-07
by O 0 3.652130686759847e-08
the O 0 7.898907483649964e-08
fact O 0 4.9140101765488e-08
that O 0 9.190526562008472e-09
the O 0 3.420007601562247e-07
Cys282Tyr O 0 0.00022396192071028054
mutation O 0 1.754199547576718e-05
creates O 0 2.020068450292456e-06
a O 0 2.09663176065078e-06
Rsal O 0 0.00010231244959868491
restriction O 0 5.603526915365364e-06
site O 0 3.61946331395302e-05
. O 0 5.476306796481367e-06

We O 0 2.3078346202964894e-06
have O 0 1.874177684157985e-07
studied O 0 1.8014338820648845e-06
the O 0 7.482786372747796e-07
codon O 0 1.4497806660074275e-05
282 O 0 1.1366024409653619e-05
( O 0 1.2794677104466246e-06
Cys O 0 0.00212741456925869
/ O 0 8.262611663667485e-05
Tyr O 0 5.47790368727874e-05
) O 0 6.297329235849247e-08
polymorphism O 0 3.7485926895897137e-07
in O 0 1.948538574936265e-08
different O 0 9.359645503081993e-09
ethnic O 0 1.4831468320153363e-07
groups O 0 5.179499567020684e-07
. O 0 1.5405883004859788e-06

In O 0 2.7904825401492417e-06
agreement O 0 1.3024800864513963e-06
with O 0 8.687787556027615e-08
previous O 0 7.233913947857218e-07
observations O 0 7.105386430339422e-07
the O 0 3.637746885942761e-07
Tyr O 0 2.4602650228189304e-05
allele O 0 1.6003901919248165e-06
appeared O 0 1.4332364344227244e-06
to O 0 1.1967881796692836e-08
be O 0 3.436930384737025e-08
rare O 0 2.789812185710616e-07
or O 0 2.3236775348323135e-07
absent O 0 6.037316779838875e-06
in O 0 3.49908134467114e-07
Asiatic O 0 6.4820928855624516e-06
( O 0 6.114790807032477e-08
Indian O 0 1.194720056219012e-07
, O 0 3.55970541932038e-08
Chinese O 0 3.337006049264346e-08
) O 0 1.3300282830641663e-07
populations O 0 9.617307341613923e-07
. O 0 1.6013290178307216e-06

The O 0 1.7618176570977084e-06
highest O 0 4.682292455981951e-06
allele O 0 1.2317412938500638e-06
frequency O 0 1.4210307881512563e-06
( O 0 9.544542933781486e-08
7 O 0 3.421534700009943e-07
. O 0 1.5174364875747415e-08
5 O 0 8.043446086958284e-08
% O 0 1.0355501345316043e-08
) O 0 1.5054583357709816e-08
was O 0 1.0265999890179955e-06
found O 0 1.536639757659941e-07
in O 0 1.9259425698692212e-07
Swedes O 0 1.2007162695226725e-05
. O 0 1.4593679225072265e-06

Saamis O 0 0.0012713283067569137
( O 0 2.2699671262671473e-06
2 O 0 1.117187821364496e-06
% O 0 7.639531673930833e-08
) O 0 2.679621502466034e-08
and O 0 7.747812702518786e-08
Mordvinians O 0 8.282726412289776e-06
( O 0 6.279553588228737e-08
1 O 0 1.2107955171813956e-07
. O 0 1.1422577550490587e-08
8 O 0 7.420945280500746e-08
% O 0 5.136014280537893e-09
) O 0 8.980898691390848e-09
had O 0 6.307318756171298e-08
significantly O 0 2.2295840551578294e-07
lower O 0 4.4572982460522326e-07
frequencies O 0 2.2084557826929085e-07
of O 0 4.398769348767928e-08
the O 0 4.0503820741832897e-07
Tyr O 0 0.00013035845768172294
allele O 0 3.985452713095583e-05
. O 0 5.52493975192192e-06

Comparisons O 0 2.446693088131724e-06
with O 0 2.6113551143680525e-07
allele O 0 2.4242660856543807e-06
frequencies O 0 2.678768851183122e-06
based O 0 7.58286262225738e-07
on O 0 2.969562956423033e-06
prevalence O 0 4.643248757929541e-05
estimates O 0 1.0869064226426417e-06
of O 0 2.5159519623230153e-07
HH B-Disease 1 0.8632892966270447
showed O 0 7.92674381955294e-06
some O 0 1.5724703317232525e-08
disagreements O 0 1.9055859183936263e-06
with O 0 7.506545074420501e-08
the O 0 2.0492346664013894e-07
RFLP O 0 1.2010941645712592e-05
data O 0 7.372131562988216e-07
, O 0 1.143328489661144e-07
particularly O 0 4.09901815601188e-07
in O 0 6.089290423005878e-07
Finns O 0 3.1748946639709175e-05
. O 0 3.517500090310932e-06

The O 0 1.3852027223038021e-05
newly O 0 0.0001221588609041646
described O 0 7.304424070753157e-05
HFE O 0 0.0015382064739242196
marker O 0 1.0571357961453032e-05
provides O 0 8.266702167247786e-08
a O 0 1.3688065791939152e-07
new O 0 6.795452378582922e-08
approach O 0 3.5701425815659604e-08
to O 0 2.6777093875551827e-09
the O 0 2.2620650241833573e-08
screening O 0 2.7690890647136257e-07
of O 0 4.2701152835888934e-08
HH B-Disease 0 0.0011790908174589276
as O 0 8.399414497262114e-08
well O 0 2.6191363744487717e-08
as O 0 2.9377501320482224e-08
studies O 0 1.7580761735302985e-08
of O 0 3.491898326046794e-09
the O 0 2.632839901650641e-08
relationship O 0 3.196665829818812e-07
between O 0 2.449637008794525e-07
the O 0 1.159706812359218e-06
HFE O 0 0.0007086221012286842
Tyr O 0 0.0001233611546922475
allele O 0 6.354548531817272e-06
and O 0 5.60810178740212e-07
different O 0 3.614343313529389e-06
disorders O 1 0.998816967010498
including O 0 0.006062528118491173
cancer B-Disease 1 0.9996211528778076

Autosomal B-Disease 1 0.9888233542442322
dominant I-Disease 1 0.9927281141281128
neurohypophyseal I-Disease 1 0.9982506632804871
diabetes I-Disease 1 0.9998644590377808
insipidus I-Disease 1 0.9942471981048584
associated O 0 0.00014440917584579438
with O 0 1.1603959819694865e-06
a O 0 6.3688667069072835e-06
missense O 0 0.00012812481145374477
mutation O 0 2.4285318431793712e-05
encoding O 0 8.122602594085038e-06
Gly23 O 0 0.0012867703335359693
- O 0 0.0012292799074202776
- O 0 0.0005040442338213325
> O 0 6.429133645724505e-05
Val O 0 0.0005152641679160297
in O 0 3.011480885106721e-06
neurophysin O 0 0.0007107011042535305
II O 0 0.036821164190769196
. O 0 1.3602127182821278e-05

Autosomal B-Disease 1 0.9917579293251038
dominant I-Disease 1 0.9961782693862915
neurohypophyseal I-Disease 1 0.9991156458854675
diabetes I-Disease 1 0.9999099969863892
insipidus I-Disease 1 0.9947910308837891
( O 0 3.394440864212811e-05
ADNDI B-Disease 0 0.024165643379092216
) O 0 2.9935331440356094e-06
is O 0 1.0635479156917427e-05
an O 0 0.000997162307612598
inherited B-Disease 1 0.9999973773956299
disease I-Disease 1 0.999998927116394
caused O 1 0.9270747303962708
by O 0 4.405152139952406e-05
progressive O 1 0.9978713989257812
degeneration O 1 0.9992603659629822
of O 0 6.652827551079099e-07
the O 0 2.6843385967367794e-06
magnocellular O 0 0.0007535441545769572
neurons O 0 1.1105001249234192e-05
of O 0 8.645338311907835e-08
the O 0 1.1214469850528985e-06
hypothalamus O 0 4.651075505535118e-05
leading O 0 3.5122714052704396e-06
to O 0 3.6049858209707963e-08
decreased O 0 2.142073981303838e-06
ability O 0 8.256932204631084e-08
to O 0 1.0822210683159028e-08
produce O 0 9.279410306817226e-08
the O 0 5.152541007191758e-07
hormone O 0 1.3356595445657149e-05
arginine O 0 5.133684680913575e-06
vasopressin O 0 1.0783435755001847e-05
( O 0 5.295752885103866e-07
AVP O 0 7.866710075177252e-05
) O 0 7.901240337560012e-07
. O 0 2.058956170003512e-06

Affected O 0 4.847241143579595e-05
individuals O 0 3.528785725848138e-07
are O 0 5.87694906073466e-08
not O 0 1.6638598765439383e-07
symptomatic O 0 8.22966467239894e-05
at O 0 7.91994170867838e-05
birth O 0 3.176115205860697e-05
, O 0 1.6753048726059205e-07
but O 0 9.567818892719515e-08
usually O 0 1.0843791642400902e-06
develop O 0 6.398820551112294e-05
diabetes B-Disease 1 0.9953456521034241
insipidus I-Disease 0 0.019171254709362984
at O 0 6.905397458467633e-05
1 O 0 9.214712918037549e-06
- O 0 0.0002214208070654422
6 O 0 2.3095250071492046e-05
yr O 0 0.0005654923734255135
of O 0 3.2918165970841073e-07
age O 0 2.787477569654584e-05
. O 0 4.614912541001104e-06

The O 0 5.848785804118961e-06
genetic O 0 5.5273187172133476e-05
locus O 0 3.6179626476950943e-05
of O 0 7.963742518768413e-07
the O 0 0.0001529477594885975
disease O 1 0.9991554021835327
is O 0 1.5469779555132845e-06
the O 0 1.0992666830134112e-06
AVP O 0 0.0013428841484710574
- O 0 0.000734749308321625
neurophysin O 0 0.000490456644911319
II O 0 0.00378572684712708
( O 0 4.0966574488265906e-07
NPII O 0 2.4925528123276308e-05
) O 0 3.900492373531961e-08
gene O 0 4.238792712385475e-07
, O 0 6.217069881131465e-08
and O 0 2.2868670157549786e-07
mutations O 0 9.10393828235101e-06
that O 0 1.1769796515181952e-07
cause O 0 6.322166882455349e-06
ADNDI B-Disease 0 0.00024467843468301
have O 0 1.1639454555734119e-07
been O 0 2.3047635977491154e-07
found O 0 6.575796618335517e-08
in O 0 6.85009293732719e-09
both O 0 2.600517801099045e-09
the O 0 1.4473791942748448e-08
signal O 0 2.7815499947791977e-07
peptide O 0 2.1718004461490636e-07
of O 0 1.2178348995917077e-08
the O 0 2.070542990395552e-07
prepro O 0 0.0003014254034496844
- O 0 0.00034807887277565897
AVP O 0 0.00043039434240199625
- O 0 0.0001218179240822792
NPII O 0 0.00011022621765732765
precursor O 0 7.631973858224228e-06
and O 0 4.656224348309479e-07
within O 0 2.3612344648427097e-06
NPII O 0 0.0023419621866196394
itself O 0 3.9228096284205094e-05
. O 0 4.250067831890192e-06

An O 0 3.984054728789488e-06
affected O 0 1.0035538252850529e-05
girl O 0 8.313557918881997e-05
who O 0 2.161359873298352e-07
presented O 0 2.061336203951214e-07
at O 0 2.3243699160957476e-06
9 O 0 7.677605253775255e-07
months O 0 2.4684587174306216e-07
of O 0 1.2192386655840437e-08
age O 0 8.415448746745824e-07
and O 0 8.044704458143315e-08
her O 0 1.1025655339835794e-06
similarly O 0 1.949566694747773e-06
affected O 0 6.390108069354028e-07
younger O 0 1.8331121509618242e-06
brother O 0 6.719743851135718e-06
and O 0 9.19684239875096e-08
father O 0 9.336288826489181e-07
were O 0 4.418420829210845e-08
all O 0 3.7234857419576883e-09
found O 0 3.095847844747368e-08
to O 0 4.009717002873003e-09
have O 0 1.3958365130406492e-08
a O 0 1.3651080621457368e-07
novel O 0 1.5935351029838785e-06
missense O 0 4.9018697609426454e-05
mutation O 0 8.20511286292458e-06
( O 0 2.4170742563001113e-07
G1758 O 0 1.503947078163037e-05
- O 0 0.00010023475624620914
- O 0 8.190088556148112e-05
> O 0 8.064849680522457e-06
T O 0 1.7409518477506936e-05
) O 0 4.6044728030381066e-09
encoding O 0 1.7106421168477937e-08
the O 0 3.607916099213071e-08
amino O 0 1.1590837090125206e-07
acid O 0 5.324197331901814e-07
substitution O 0 2.2473322758287395e-07
Gly23 O 0 3.91158064303454e-05
- O 0 0.00018731439195107669
- O 0 0.00019798174616880715
> O 0 5.010495806345716e-05
Val O 0 0.0003829114430118352
within O 0 5.199883162276819e-06
NPII O 0 0.0011409061262384057
. O 0 5.594033609668259e-06

The O 0 9.697539098851848e-06
mutation O 0 0.0002094680385198444
was O 0 2.3282223992282525e-05
confirmed O 0 2.189361339333118e-06
by O 0 8.731344536272445e-08
restriction O 0 1.2978873655811185e-06
endonuclease O 0 7.273688243003562e-05
analysis O 0 6.688836947432719e-06
. O 0 3.4065969884977676e-06

A O 0 6.0216523706912994e-05
T1 O 0 0.002171264262869954
- O 0 1.584167330292985e-05
weighted O 0 1.9023791537620127e-06
magnetic O 0 7.68020470331976e-07
resonance O 0 5.9289586715749465e-06
imaging O 0 2.401343226665631e-05
of O 0 2.3477477384403755e-07
the O 0 7.750880286039319e-06
fathers O 0 0.00013419537572190166
pituitary O 0 0.037793178111314774
gland O 0 0.004823954310268164
demonstrates O 0 1.3067702639091294e-05
an O 0 2.168027094739955e-06
attenuated O 0 0.0015048618661239743
posterior O 0 0.004342373926192522
pituitary O 0 0.027651576325297356
bright O 0 0.0006113577401265502
spot O 0 0.00032001748331822455
. O 0 1.0061728062282782e-05

This O 0 4.920992978441063e-06
mutation O 0 7.20798852853477e-05
may O 0 9.090014145840541e-07
be O 0 9.20803699955286e-09
valuable O 0 1.8738626650360857e-08
for O 0 7.2278436569206406e-09
developing O 0 1.7493401571755385e-07
models O 0 2.3793543277861318e-06
of O 0 1.6329496475009364e-06
dominantly B-Disease 0 0.4279837906360626
inherited I-Disease 1 0.9994495511054993
neurodegeneration I-Disease 1 0.9999526739120483
, O 0 9.041916655405657e-07
as O 0 1.4979490003952378e-07
the O 0 1.0393537053232649e-07
early O 0 1.0442992106618476e-06
age O 0 1.7985859130931203e-06
of O 0 1.4615530119499454e-07
onset O 0 0.012201830744743347
of O 0 4.028634066344239e-06
symptoms O 0 0.23020930588245392
suggests O 0 2.325185732843238e-06
that O 0 5.3129877386481894e-08
this O 0 9.045110260785805e-08
mutation O 0 6.274935913097579e-06
may O 0 4.045841990318877e-07
be O 0 3.788759173062317e-08
particularly O 0 1.9889613156465202e-07
deleterious O 0 1.8124363805327448e-06
to O 0 3.504169754364739e-08
the O 0 1.020327886180894e-06
magnocellular O 0 0.0005834130570292473
neuron O 0 0.00045308933476917446
. O 0 9.317085414295434e-07
. O 0 2.527746573832701e-06

Frequent O 0 0.00047862675273790956
inactivation O 0 0.01346606481820345
of O 0 7.971577360876836e-06
PTEN O 0 0.01926456019282341
/ O 0 0.0015434111701324582
MMAC1 O 0 0.03662773221731186
in O 0 0.0004532570019364357
primary O 1 0.9978824257850647
prostate B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999915361404419
. O 0 0.00011144120071548969

Sporadic B-Disease 1 0.9962678551673889
prostate I-Disease 1 0.9999890327453613
carcinoma I-Disease 1 0.9999992847442627
is O 0 3.651560837170109e-05
the O 0 7.051247621348011e-07
most O 0 3.101075662925723e-07
common O 0 6.955208846193273e-06
male B-Disease 0 0.00010575147462077439
cancer I-Disease 1 0.9693720936775208
in O 0 1.3128979503562732e-07
the O 0 4.389425001249947e-08
Western O 0 2.5005280690493237e-07
world O 0 7.022592285466089e-07
, O 0 4.3902620205926723e-08
yet O 0 2.645626118180644e-08
many O 0 1.2357578293986649e-09
of O 0 2.393074183260069e-09
the O 0 1.6520070644787666e-08
major O 0 4.5214238753032987e-07
genetic O 0 4.1035158915292413e-07
events O 0 3.6585028340141434e-08
involved O 0 1.0894494550939271e-07
in O 0 6.393814544480847e-08
the O 0 1.824794111371375e-07
progression O 0 1.8296057533007115e-05
of O 0 6.536681240731923e-08
this O 0 2.6382596729490615e-07
often O 0 3.187785841873847e-05
fatal O 1 0.9996851682662964
cancer B-Disease 1 0.9997530579566956
remain O 0 3.2544944588153157e-06
to O 0 5.6893917133038485e-08
be O 0 6.602496682717174e-07
elucidated O 0 0.00020908853912260383
. O 0 5.354532731871586e-06

Numerous O 0 3.7326088204281405e-05
cytogenetic O 0 0.005542602855712175
and O 0 5.527032044483349e-06
allelotype O 0 0.00046448304783552885
studies O 0 3.3679789339657873e-06
have O 0 5.654571850755019e-07
reported O 0 7.579784778499743e-06
frequent O 0 1.0789400221256074e-05
loss O 0 0.00036209108657203615
of O 0 7.482486239496211e-07
heterozygosity O 0 0.0015162930358201265
on O 0 6.016921906848438e-05
chromosomal O 0 0.30357375741004944
arm O 0 0.01591077260673046
10q O 0 0.0003042820899281651
in O 0 6.363920692820102e-05
sporadic B-Disease 1 0.9943910241127014
prostate I-Disease 1 0.9999979734420776
cancer I-Disease 1 0.999984860420227
. O 0 8.978852565633133e-05

Deletion O 0 0.0002831103338394314
mapping O 0 3.198110789526254e-05
studies O 0 2.6832685762201436e-06
have O 0 2.1736840949415637e-07
unambiguously O 0 1.3456421584123746e-05
identified O 0 1.5306328577935346e-06
a O 0 5.749827778345207e-07
region O 0 1.1235301826673094e-06
of O 0 1.5188501834018098e-07
chromosome O 0 1.7052145267371088e-05
10q23 O 0 3.2885041036934126e-06
to O 0 2.0819175716724203e-08
be O 0 4.1249304416624e-08
the O 0 5.1488072472238855e-08
minimal O 0 2.0811612557736225e-06
area O 0 3.237786586396396e-06
of O 0 9.354657208859862e-07
loss O 0 0.003394767874851823
. O 0 6.682015282422071e-06

A O 0 6.750567263225093e-05
new O 0 3.809522240771912e-05
tumor B-Disease 0 0.039416324347257614
suppressor O 0 0.0001557436480652541
gene O 0 1.6703907022019848e-05
, O 0 1.8621122990225558e-06
PTEN O 0 0.0005389104480855167
/ O 0 0.00011748416727641597
MMAC1 O 0 0.001252169138751924
, O 0 1.112717654905282e-06
was O 0 2.225120806542691e-05
isolated O 0 1.3089705134916585e-05
recently O 0 1.596442780282814e-05
at O 0 2.3398201847157907e-06
this O 0 2.7197645025012207e-08
region O 0 2.155853167096211e-07
of O 0 3.8017603287698876e-08
chromosome O 0 5.502702606463572e-06
10q23 O 0 3.88885518987081e-06
and O 0 6.394643747853479e-08
found O 0 1.0180656317970715e-07
to O 0 1.0668561145621425e-08
be O 0 5.572871941694757e-08
inactivated O 0 1.8745473653325462e-06
by O 0 2.541005095224591e-08
mutation O 0 2.3548363969894126e-06
in O 0 1.0986912002408644e-06
three O 0 0.001046947087161243
prostate B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9999947547912598
cell O 0 0.4459429681301117
lines O 0 0.0008962891879491508
. O 0 1.6304726159432903e-05

We O 0 1.930926737259142e-05
screened O 0 0.00042515629320405424
80 O 0 0.000761848350521177
prostate B-Disease 1 0.9998181462287903
tumors I-Disease 1 0.9999178647994995
by O 0 5.617908414023987e-07
microsatellite O 0 4.514319516601972e-05
analysis O 0 6.964766612327367e-07
and O 0 1.632923272154585e-07
found O 0 9.510893050901359e-07
chromosome O 0 6.646899237239268e-06
10q23 O 0 2.9885925414419034e-06
to O 0 1.9067982748310897e-08
be O 0 2.3974292773232264e-08
deleted O 0 6.84836436448677e-07
in O 0 2.6351591486672987e-07
23 O 0 2.040215122178779e-06
cases O 0 7.560008725704392e-07
. O 0 1.5550392618024489e-06

We O 0 1.6750474287619e-06
then O 0 2.974668973365624e-07
proceeded O 0 2.7715410055861867e-07
with O 0 1.2104337088203465e-08
sequence O 0 1.5827890820219181e-07
analysis O 0 5.247044398970502e-08
of O 0 1.87520683425646e-08
the O 0 3.212024637377908e-07
entire O 0 1.397577489115065e-05
PTEN O 0 0.001228440087288618
/ O 0 7.812429976183921e-05
MMAC1 O 0 0.0002446821890771389
coding O 0 0.00011801954678958282
region O 0 7.438832199113676e-06
and O 0 3.398464798465284e-07
tested O 0 2.7180119559488958e-06
for O 0 2.0632866082337387e-08
homozygous O 0 9.425933171769429e-07
deletion O 0 8.280887300315953e-07
with O 0 3.4775435864276005e-08
new O 0 5.613323992292862e-07
intragenic O 0 2.9211163564468734e-05
markers O 0 3.7857939787500072e-06
in O 0 6.964209120496889e-08
these O 0 1.5312117795929225e-08
23 O 0 4.1631076896919694e-07
cases O 0 5.108924128194303e-08
with O 0 2.0604673522939265e-07
10q23 O 0 0.0003395292442291975
loss O 0 0.00045161510934121907
of O 0 1.9026023210244603e-06
heterozygosity O 0 0.004686037544161081
. O 0 1.83223146450473e-05

The O 0 6.596033017558511e-07
identification O 0 2.384469155458646e-07
of O 0 5.452983486975427e-08
the O 0 1.809704457400585e-07
second O 0 1.9680824152601417e-06
mutational O 0 3.4592430893098935e-05
event O 0 2.5288509277743287e-06
in O 0 1.843548886881763e-07
10 O 0 1.838162688727607e-07
( O 0 7.839545190790886e-08
43 O 0 3.0709115890203975e-06
% O 0 5.656917778651405e-07
) O 0 6.485747235274175e-06
tumors B-Disease 1 0.9997466206550598
establishes O 0 0.00016314485401380807
PTEN O 0 0.0016219767276197672
/ O 0 5.8244251704309136e-05
MMAC1 O 0 0.00015004770830273628
as O 0 1.953058159642751e-07
a O 0 4.850057848670986e-07
main O 0 2.6894788334175246e-06
inactivation O 0 0.0002558873384259641
target O 0 6.680846809103969e-07
of O 0 2.537886700793024e-07
10q O 0 0.0001204473155667074
loss O 0 0.00043793744407594204
in O 0 3.7791385693708435e-05
sporadic B-Disease 1 0.9961181879043579
prostate I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999963045120239
. O 0 4.828579221793916e-06
. O 0 4.898881797998911e-06

Risk O 0 0.0005620265728794038
reversals O 0 5.83908476983197e-05
in O 0 1.1892628890564083e-06
predictive O 0 2.1996282157488167e-05
testing O 0 0.00012102758773835376
for O 0 0.00021742373064626008
Huntington B-Disease 1 0.9999439716339111
disease I-Disease 1 0.9999806880950928
. O 0 8.813290332909673e-05

The O 0 1.038420009535912e-06
first O 0 6.238808509806404e-07
predictive O 0 9.099407179746777e-06
testing O 0 2.6461153538548388e-05
for O 0 2.3161046556197107e-05
Huntington B-Disease 1 0.9999672174453735
disease I-Disease 1 0.9999816417694092
( O 0 4.2420685986144235e-07
HD B-Disease 0 9.500173473497853e-05
) O 0 1.110430574158272e-07
was O 0 9.929864290825208e-07
based O 0 5.3358579776841e-08
on O 0 8.37235205608522e-08
analysis O 0 8.96370337954977e-08
of O 0 3.9230922510569144e-08
linked O 0 1.5086515304574277e-05
polymorphic O 0 1.4854975233902223e-05
DNA O 0 3.6994547372160014e-06
markers O 0 1.1749525583582e-06
to O 0 1.792006010248315e-08
estimate O 0 9.964168867782064e-08
the O 0 2.6680039511006726e-08
likelihood O 0 3.013449259015033e-07
of O 0 3.026140404926991e-08
inheriting O 0 1.3216847946750931e-05
the O 0 9.545050261294818e-07
mutation O 0 9.490709999226965e-06
for O 0 5.878080742149905e-07
HD B-Disease 0 0.000705474813003093
. O 0 9.564701031195e-06

Limits O 0 1.836407022892672e-06
to O 0 4.8766619187290416e-08
accuracy O 0 3.231427001537668e-07
included O 0 4.604335046565211e-08
recombination O 0 3.6793957747249806e-07
between O 0 3.8600607155103717e-08
the O 0 6.149856801584974e-08
DNA O 0 1.0953810942737618e-06
markers O 0 8.139638794091297e-07
and O 0 4.5679893645456104e-08
the O 0 3.793184930600546e-07
mutation O 0 1.207766581501346e-05
, O 0 1.6131359359405906e-07
pedigree O 0 8.712155249668285e-06
structure O 0 6.883559308334952e-06
, O 0 6.788482664887852e-08
and O 0 1.691964079952868e-08
whether O 0 2.604063098488041e-08
DNA O 0 1.3534646825519303e-07
samples O 0 2.276990684890734e-08
were O 0 7.453795802803143e-09
available O 0 1.3048725655551152e-08
from O 0 4.61132181328594e-08
family O 0 3.2384582482336555e-07
members O 0 7.90296041941474e-08
. O 0 1.5307905414374545e-06

With O 0 1.0944103934207305e-07
direct O 0 1.3927760278420465e-07
tests O 0 3.2645300507283537e-07
for O 0 8.519681848895289e-09
the O 0 4.206431825082291e-08
HD B-Disease 0 4.394541247165762e-05
mutation O 0 2.530636265873909e-06
, O 0 3.521791924754325e-08
we O 0 9.504174336427695e-09
have O 0 3.8910981103867925e-09
assessed O 0 6.190150969587194e-08
the O 0 1.4447039120568661e-08
accuracy O 0 2.044604201500988e-07
of O 0 1.3753629346524576e-08
results O 0 1.0367620717488535e-07
obtained O 0 2.489306538677738e-08
by O 0 5.977561556846922e-09
linkage O 0 5.382324275160499e-07
approaches O 0 2.1597733734779467e-07
when O 0 1.0040059095217657e-07
requested O 0 2.65222457329628e-08
to O 0 5.672344816076702e-09
do O 0 1.3102920526364414e-08
so O 0 7.44832417964858e-09
by O 0 9.198101835750094e-09
the O 0 7.095080434282863e-08
test O 0 6.758928066119552e-07
individuals O 0 1.3838365475749015e-07
. O 0 1.41211182835832e-06

For O 0 3.2017030093811627e-07
six O 0 2.880039744468377e-07
such O 0 2.146853894657852e-08
individuals O 0 1.9177074150888984e-08
, O 0 1.029488814197066e-07
there O 0 2.152619487105767e-07
was O 0 6.2243711909104604e-06
significant O 0 5.0182234190288e-07
disparity O 0 3.378391966180061e-06
between O 0 4.657507872707356e-07
the O 0 1.4003773003423703e-06
tests O 0 9.745061106514186e-06
. O 0 1.3138753729435848e-06

Three O 0 1.2269227909200708e-06
went O 0 2.6749369226308772e-06
from O 0 4.816924459305483e-08
a O 0 7.796836030138365e-07
decreased O 0 2.6854682801058516e-05
risk O 0 1.3929528677181224e-06
to O 0 4.856776314454692e-09
an O 0 2.9417872582371274e-08
increased O 0 3.7802132624165097e-07
risk O 0 1.5781332649567048e-06
, O 0 1.0908566494549632e-08
while O 0 3.262882941612588e-08
in O 0 2.5573321238425706e-08
another O 0 6.188569301457392e-08
three O 0 5.8901239441411235e-08
the O 0 7.545057201241434e-07
risk O 0 2.6786694434122182e-05
was O 0 5.544803570955992e-05
decreased O 0 7.719099085079506e-05
. O 0 3.677529775814037e-06

Knowledge O 0 3.1407873848365853e-06
of O 0 2.712806974614068e-07
the O 0 7.644756010449782e-07
potential O 0 1.1632968153207912e-06
reasons O 0 1.675423106917151e-07
for O 0 7.350563269170607e-09
these O 0 5.133928393519227e-09
changes O 0 2.1640845204728976e-07
in O 0 1.145938455238138e-07
results O 0 5.232478201833146e-07
and O 0 7.188868522689518e-08
impact O 0 3.073338916692592e-07
of O 0 1.7363847248930142e-08
these O 0 3.971403472746715e-08
risk O 0 2.2420713321480434e-06
reversals O 0 2.834982524291263e-06
on O 0 7.117627660591097e-07
both O 0 2.987931964071322e-07
patients O 0 2.4690007194294594e-06
and O 0 5.680131920371423e-08
the O 0 1.6339700437129068e-07
counseling O 0 5.493864705385931e-07
team O 0 6.44026343366022e-08
can O 0 6.587770329247178e-09
assist O 0 2.82176007004864e-08
in O 0 2.3954912720114407e-08
the O 0 1.3358473438529472e-08
development O 0 2.3591622877461305e-08
of O 0 1.9284620123016794e-08
strategies O 0 3.0351847613019345e-07
for O 0 2.871537141402314e-08
the O 0 4.858687816522433e-07
prevention O 0 2.476424560882151e-05
and O 0 1.0490250446082428e-07
, O 0 4.705618650291399e-08
where O 0 5.078204523556451e-08
necessary O 0 1.2444620267615392e-07
, O 0 1.1051145776264093e-07
management O 0 1.2075061022187583e-06
of O 0 4.913147932938955e-08
a O 0 3.481749672573642e-06
risk O 0 1.3059181583230384e-05
reversal O 0 1.9444714780547656e-06
in O 0 3.743804555256247e-08
any O 0 2.78687561916513e-08
predictive O 0 2.4936180125223473e-06
testing O 0 3.992201072833268e-06
program O 0 1.3769267752650194e-06
. O 0 2.036361195223435e-07
. O 0 1.056159703693993e-06

A O 0 3.8045593100832775e-05
novel O 0 1.9400300516281277e-05
common O 0 1.3545583897212055e-05
missense O 0 0.0004335376725066453
mutation O 0 7.861850463086739e-05
G301C O 0 2.7358799343346618e-05
in O 0 2.9165218506932433e-07
the O 0 6.559574217135378e-07
N O 0 0.0001371987455058843
- O 0 0.00011468332377262414
acetylgalactosamine O 0 0.00025792280212044716
- O 0 0.0002147914347006008
6 O 0 2.3716500436421484e-05
- O 0 0.00012693624012172222
sulfate O 0 0.00022797632846049964
sulfatase O 0 0.00039953901432454586
gene O 0 2.0472007236094214e-05
in O 0 4.707697826233925e-06
mucopolysaccharidosis B-Disease 0 0.006687067449092865
IVA I-Disease 0 0.41264045238494873
. O 0 1.3458668036037125e-05

Mucopolysaccharidosis B-Disease 1 0.8486729264259338
IVA I-Disease 1 0.984714686870575
( O 0 0.00036721455398947
MPS B-Disease 1 0.998991072177887
IVA I-Disease 1 0.9998137354850769
) O 0 2.7156022497365484e-06
is O 0 2.065058197331382e-06
an O 0 6.452303296100581e-06
autosomal B-Disease 1 0.9971779584884644
recessive I-Disease 1 0.9987369179725647
lysosomal I-Disease 1 0.9996191263198853
storage I-Disease 1 0.9998346567153931
disorder I-Disease 1 0.9999462366104126
caused O 0 0.11747550964355469
by O 0 5.353858341550222e-06
a O 0 0.00015997688751667738
genetic B-Disease 1 0.9975753426551819
defect I-Disease 1 0.9993516802787781
in O 0 9.536965990264434e-06
N O 0 0.0010522551601752639
- O 0 0.0003883507160935551
acetylgalactosamine O 0 0.0012505280319601297
- O 0 0.0008372203446924686
6 O 0 7.860269397497177e-05
- O 0 0.0011283843778073788
sulfate O 0 0.0018871631473302841
sulfatase O 0 0.002119139302521944
( O 0 1.370663198940747e-06
GALNS O 0 0.0002634685661178082
) O 0 1.0161194268221152e-06
. O 0 2.7820217383123236e-06

In O 0 2.134019950972288e-06
previous O 0 2.5020146949827904e-06
studies O 0 3.319004804325232e-07
, O 0 4.998844715942141e-08
we O 0 2.6099206351659632e-08
have O 0 3.3242484320794574e-09
found O 0 1.1636675623094561e-08
two O 0 9.44169453731547e-09
common O 0 3.206953067547147e-07
mutations O 0 2.9021459795330884e-06
in O 0 1.4172194084949297e-07
Caucasians O 0 9.870759640762117e-07
and O 0 8.941471207890572e-08
Japanese O 0 2.0275203951314325e-06
, O 0 3.470120191195747e-07
respectively O 0 8.850549420458265e-06
. O 0 4.204974175081588e-06

To O 0 8.331401772920799e-07
characterize O 0 1.42916487675393e-05
the O 0 1.0501656788619584e-06
mutational O 0 6.390027556335554e-05
spectrum O 0 5.5083523875509854e-06
in O 0 9.088655872346862e-08
various O 0 2.0308217330011757e-08
ethnic O 0 5.18401606086627e-08
groups O 0 6.493734616697111e-08
, O 0 9.153721691745886e-08
mutations O 0 1.6527609432159807e-06
in O 0 5.457946983256079e-08
the O 0 1.856169689062881e-07
GALNS O 0 5.396145206759684e-05
gene O 0 3.0097698981990106e-06
in O 0 2.0033389773743693e-06
Colombian O 0 0.00011372163862688467
MPS B-Disease 1 0.9765225648880005
IVA I-Disease 1 0.9992352724075317
patients O 0 0.00012986799993086606
were O 0 8.071406227827538e-07
investigated O 0 2.220480928372126e-05
, O 0 1.0919271176135226e-07
and O 0 3.020016947630211e-08
genetic O 0 7.289635277629714e-07
backgrounds O 0 1.5977883549567196e-07
were O 0 8.252932559571491e-08
extensively O 0 1.3059615184829454e-06
analyzed O 0 3.107651025402447e-07
to O 0 1.0308795594937692e-08
identify O 0 8.272159846001159e-08
racial O 0 1.2222963619024085e-07
origin O 0 6.589080214780552e-08
, O 0 4.9576925675864914e-08
based O 0 5.128371682872057e-08
on O 0 1.9854456922985264e-07
mitochondrial O 0 1.8890423234552145e-06
DNA O 0 1.501388510405377e-06
( O 0 4.698489064480782e-08
mtDNA O 0 4.596850260440988e-07
) O 0 1.9132708928282227e-07
lineages O 0 9.715941814647522e-06
. O 0 3.737491169886198e-06

Three O 0 6.238009518710896e-06
novel O 0 2.0099536413908936e-05
missense O 0 0.00026992143830284476
mutations O 0 0.00022343637829180807
never O 0 1.1541774256329518e-05
identified O 0 7.621497388754506e-07
previously O 0 4.830969828617526e-07
in O 0 3.354760380602784e-08
other O 0 8.114371397027753e-09
populations O 0 5.018256388211739e-08
and O 0 2.2495960649848712e-08
found O 0 1.228169139722013e-07
in O 0 3.5557153665877195e-08
16 O 0 1.309073525135318e-07
out O 0 4.29509441346454e-08
of O 0 5.9548959541189106e-08
19 O 0 8.149821042024996e-06
Colombian O 0 3.1402094464283437e-05
MPS B-Disease 1 0.5759130120277405
IVA I-Disease 1 0.9946683049201965
unrelated O 0 1.9618442820501514e-05
alleles O 0 2.053351863651187e-06
account O 0 3.982137286584475e-07
for O 0 3.54042185790604e-07
84 O 0 4.5091528591001406e-05
. O 0 5.987838903820375e-06

2 O 0 4.982585323887179e-06
% O 0 5.817883064196394e-08
of O 0 7.333981866253225e-09
the O 0 7.243939137424604e-08
alleles O 0 6.000707912789949e-07
in O 0 1.4700606243422953e-07
this O 0 1.590090619174589e-07
study O 0 1.3749978506893967e-06
. O 0 1.2310744068599888e-06

The O 0 3.4461515951988986e-06
G301C O 0 4.519523645285517e-05
and O 0 3.530886374392139e-07
S162F O 0 2.609259172459133e-05
mutations O 0 1.2854611668444704e-05
account O 0 2.875163147564308e-07
for O 0 2.8760049985976366e-07
68 O 0 3.402098809601739e-05
. O 0 5.741746463172603e-06

4 O 0 1.5462166629731655e-05
% O 0 4.5609638732457825e-07
and O 0 3.31521164298465e-07
10 O 0 3.03377487398393e-06
. O 0 2.2958074623602442e-06

5 O 0 8.10385427030269e-06
% O 0 1.6788906975762075e-07
of O 0 1.4128161751614243e-07
mutations O 0 1.0040486813522875e-05
, O 0 1.133196150249205e-07
respectively O 0 3.2917569114943035e-07
, O 0 4.277500664784384e-08
whereas O 0 1.1885332895644751e-07
the O 0 6.242724026606083e-08
remaining O 0 2.590485337350401e-07
F69V O 0 8.9374472736381e-05
is O 0 6.459269741299067e-08
limited O 0 1.9153167940544336e-08
to O 0 1.0510615489067732e-08
a O 0 1.7025475074206042e-07
single O 0 9.127915632234362e-07
allele O 0 6.940843377378769e-06
. O 0 2.3555576262879185e-06

The O 0 3.3350163448631065e-06
skewed O 0 5.204290573601611e-05
prevalence O 0 5.238678204477765e-05
of O 0 1.4199753195498488e-07
G301C O 0 9.170589692075737e-06
in O 0 1.7790212325508037e-07
only O 0 8.417730157361802e-08
Colombian O 0 3.707645419126493e-06
patients O 0 1.470303345740831e-06
and O 0 1.0596247079774912e-07
haplotype O 0 1.4395499420061242e-05
analysis O 0 2.498583171473001e-07
by O 0 4.683403886929227e-08
restriction O 0 5.921822321397485e-07
fragment O 0 3.4344518553552916e-06
length O 0 1.247100044565741e-06
polymorphisms O 0 4.384364274301333e-06
in O 0 1.2819955941267835e-07
the O 0 1.1774770314332272e-07
GALNS O 0 8.889694436220452e-05
gene O 0 2.5999693207268137e-06
suggest O 0 4.1222017443942605e-07
that O 0 4.8873513236458166e-08
G301C O 0 1.973457756321295e-06
originated O 0 3.3849602232294274e-07
from O 0 8.336784418361276e-08
a O 0 4.343395119121851e-07
common O 0 2.070024947897764e-06
ancestor O 0 2.2165479094837792e-05
. O 0 1.0918934094661381e-05

Investigation O 0 3.804675361607224e-05
of O 0 1.7701599119845923e-07
the O 0 5.569300469687732e-07
genetic O 0 8.300658919324633e-06
background O 0 2.9136158445908222e-06
by O 0 5.348880449673743e-08
means O 0 1.1614705641704859e-07
of O 0 1.8760225373171124e-08
mtDNA O 0 7.583419687762216e-07
lineages O 0 9.921099035636871e-07
indicate O 0 4.0904345155468036e-07
that O 0 9.062739003695697e-09
all O 0 1.3592202918744078e-08
our O 0 4.392159098642878e-07
patients O 0 1.018506054606405e-06
are O 0 1.192622711698732e-08
probably O 0 3.2336654953724064e-07
of O 0 2.5654516733197852e-08
native O 0 1.2147746701884898e-06
American O 0 1.1032302609237377e-05
descent O 0 0.0003229268186260015

Low O 0 7.956224726513028e-05
frequency O 0 2.7691348805092275e-05
of O 0 1.9778628939093323e-06
BRCA1 O 0 0.0005044657737016678
germline O 0 0.0006424916791729629
mutations O 0 0.00017181299335788935
in O 0 4.03013245886541e-06
45 O 0 3.1322651921072975e-05
German O 1 0.9969461560249329
breast B-Disease 1 0.9999258518218994
/ I-Disease 1 0.9999157190322876
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999949932098389
families O 0 2.060160113614984e-05
. O 0 2.0800320271519013e-05

In O 0 1.3886900660509127e-06
this O 0 1.0383095627730654e-07
study O 0 1.989651821077132e-07
we O 0 1.8129345846773504e-07
investigated O 0 1.0186343388340902e-05
45 O 0 7.584354989376152e-06
German O 1 0.9584951996803284
breast B-Disease 1 0.999895453453064
/ I-Disease 1 0.9998038411140442
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999886751174927
families O 0 6.540166737067921e-07
for O 0 3.611751822063525e-07
germline O 0 0.0001017924805637449
mutations O 0 1.7804783055908047e-05
in O 0 2.7566474614104663e-07
the O 0 1.0643012728905887e-06
BRCA1 O 0 0.00020630932704079896
gene O 0 6.330720498226583e-05
. O 0 7.6187461672816426e-06

We O 0 4.31973103331984e-06
identified O 0 3.0547939786629286e-06
four O 0 5.316637157193327e-07
germline O 0 7.847321103326976e-05
mutations O 0 4.4633889046963304e-05
in O 0 1.3068186035525287e-06
three O 0 1.4862881471344735e-05
breast B-Disease 1 0.9990123510360718
cancer I-Disease 1 0.9876567125320435
families O 0 7.032243587445919e-08
and O 0 1.5422331500758446e-07
in O 0 1.9441174572421005e-06
one O 0 0.0006782272248528898
breast B-Disease 1 0.9999525547027588
- I-Disease 1 0.9999877214431763
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999954700469971
family O 0 8.81751566339517e-06
. O 0 2.5403604553275727e-08
among O 0 5.721786155987729e-09
these O 0 1.8816264102383684e-09
were O 0 3.793806513385789e-08
one O 0 1.9788430449807493e-07
frameshift O 0 0.00010253776417812333
mutation O 0 5.076019078842364e-06
, O 0 7.653692790654532e-08
one O 0 2.029467083275449e-07
nonsense O 0 1.8751925381366163e-05
mutation O 0 8.36659182823496e-06
, O 0 7.214321584569916e-08
one O 0 4.974818779146517e-08
novel O 0 4.765516621318966e-07
splice O 0 1.3303761988936458e-05
site O 0 1.2790535947715398e-05
mutation O 0 8.118235200527124e-06
, O 0 5.125320612364703e-08
and O 0 1.1559333046307074e-07
one O 0 9.158574130196939e-07
missense O 0 0.0004040055791847408
mutation O 0 0.0004177360387984663
. O 0 8.571518264943734e-06

The O 0 1.7469390513724647e-05
missense O 0 0.0006481193122453988
mutation O 0 0.00025976827600970864
was O 0 4.5804379624314606e-05
also O 0 5.48766990959848e-07
found O 0 3.837967312847468e-07
in O 0 3.077506391946372e-07
2 O 0 4.018863819510443e-06
. O 0 2.820436748152133e-06

8 O 0 7.40302220947342e-06
% O 0 6.272192365486262e-08
of O 0 1.4133573422725476e-08
the O 0 7.195892237632506e-08
general O 0 1.0714672527001312e-07
population O 0 2.0824499458171886e-08
, O 0 3.320105790294292e-08
suggesting O 0 2.3950485683599254e-07
that O 0 1.2403797100546399e-08
it O 0 5.194794638896383e-08
is O 0 3.6096716371503135e-07
not O 0 1.2031506457788055e-06
disease O 1 0.5821517705917358
associated O 0 2.473342465236783e-05
. O 0 5.133596459927503e-06

The O 0 7.168321644712705e-06
average O 0 5.09164783579763e-05
age O 0 2.3636885089217685e-05
of O 0 5.341236374079017e-06
disease O 1 0.9985224604606628
onset O 0 0.16614073514938354
in O 0 5.762893238170363e-07
those O 0 4.9461885254231674e-08
families O 0 2.401800998086401e-07
harbouring O 0 0.0005138746928423643
causative O 0 0.00041813607094809413
mutations O 0 0.0001886630052467808
was O 0 2.01731836568797e-05
between O 0 1.402422185492469e-06
32 O 0 2.5019095119205303e-05
. O 0 5.216323188506067e-06

3 O 0 1.7586582544026896e-05
and O 0 2.5324397938675247e-06
37 O 0 2.0009096260764636e-05
. O 0 6.558287623192882e-06

4 O 0 3.7749781768070534e-05
years O 0 5.352776042855112e-06
, O 0 8.891777270036982e-08
whereas O 0 3.3009237654368917e-07
the O 0 3.907470045305672e-07
family O 0 7.023160833341535e-06
harbouring O 0 0.00010967474372591823
the O 0 1.3132315643815673e-06
missense O 0 0.00011309926776448265
mutation O 0 1.2102811524528079e-05
had O 0 3.21630380994975e-07
an O 0 2.5718502882909888e-08
average O 0 1.7099330307246419e-06
age O 0 9.045754723047139e-07
of O 0 1.252500112514099e-07
onset O 0 0.000840898952446878
of O 0 1.0996766377502354e-06
51 O 0 7.154266495490447e-05
. O 0 4.4382713895174675e-06

2 O 0 9.933462570188567e-05
years O 0 4.2137289710808545e-05
. O 0 1.1414852451707702e-05

These O 0 3.779780683998979e-07
findings O 0 1.6895378394110594e-06
show O 0 9.259517241844151e-07
that O 0 1.8667552126316878e-07
BRCA1 O 0 2.8252175980014727e-05
is O 0 3.154630405788339e-07
implicated O 0 6.358573500619968e-06
in O 0 9.806190348626842e-08
a O 0 2.787517132674111e-07
small O 0 4.794038090949471e-07
fraction O 0 3.3034191346814623e-06
of O 0 2.095094350806903e-05
breast B-Disease 1 0.9998868703842163
/ I-Disease 1 0.999923586845398
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999939203262329
families O 0 5.348962304196903e-07
suggesting O 0 2.616086476336932e-06
the O 0 1.882947202602736e-07
involvement O 0 1.1404549695726018e-06
of O 0 1.0259075367002879e-07
another O 0 3.5271341403131373e-06
susceptibility O 0 8.176331903086975e-05
gene O 0 3.871951048495248e-05
( O 0 4.5653082452190574e-06
s O 0 0.001309940591454506
) O 0 1.5001423889771104e-05

Paternal O 0 0.02262554131448269
transmission O 1 0.9921403527259827
of O 1 0.7262519598007202
congenital B-Disease 1 0.9999980926513672
myotonic I-Disease 1 0.999991774559021
dystrophy I-Disease 1 0.9999902248382568
. O 0 0.007485897280275822

We O 0 1.6463645806652494e-05
report O 0 2.7459368538984563e-06
a O 0 2.307348495378392e-06
rare O 0 1.56950864038663e-05
case O 0 2.1659585399902426e-05
of O 0 1.1329285371175501e-05
paternally O 1 0.9906696081161499
transmitted O 1 0.999595582485199
congenital B-Disease 1 0.9999969005584717
myotonic I-Disease 1 0.9999885559082031
dystrophy I-Disease 1 0.9999949932098389
( O 0 0.028829224407672882
DM B-Disease 1 0.9998973608016968
) O 0 1.321957097388804e-05
. O 0 1.2170557056379039e-05

The O 0 5.527954726858297e-06
proband O 0 0.0002963342994917184
is O 0 7.652604381291894e-07
a O 0 8.034335792217462e-07
23 O 0 2.7142352791997837e-06
year O 0 1.3259721072245156e-06
old O 0 0.0007678958354517817
, O 0 3.371975617483258e-05
mentally B-Disease 1 0.9998637437820435
retarded I-Disease 1 0.9981955885887146
male O 0 0.0005070067127235234
who O 0 0.004917780868709087
suffers O 1 0.9994531273841858
severe O 1 0.9997838139533997
muscular B-Disease 1 0.9998903274536133
weakness I-Disease 1 0.9991562366485596
. O 0 0.00021483629825524986

He O 0 3.8901420339243487e-05
presented O 0 1.408877142239362e-05
with O 0 0.00013624767598230392
respiratory O 1 0.999810516834259
and O 0 1.4024184565641917e-05
feeding O 0 0.00019195019558537751
difficulties O 0 0.00041237447294406593
at O 0 0.0006355239311233163
birth O 0 0.0005234741838648915
. O 0 8.471528417430818e-06

His O 0 5.215051714912988e-05
two O 0 2.591478914837353e-05
sibs O 0 0.43760815262794495
suffer O 0 0.009922776371240616
from O 0 4.137025825912133e-05
childhood O 1 0.7024445533752441
onset O 1 0.9988622665405273
DM B-Disease 1 0.9998037219047546
. O 0 0.0002284840156789869

Their O 0 4.864983793595457e-07
late O 0 2.885106368921697e-05
father O 0 5.448031515697949e-06
had O 0 8.36382696434157e-07
the O 0 7.27166664660217e-08
adult O 0 8.041894261623383e-07
type O 0 1.8528267901274376e-05
of O 0 1.9809890545730013e-06
DM B-Disease 1 0.9998213648796082
, O 0 4.869272629548504e-07
with O 0 3.53737107161578e-07
onset O 0 0.0005572896916419268
around O 0 1.785031827239436e-06
30 O 0 1.5822685099919909e-06
years O 0 1.0399470511401887e-06
. O 0 1.2693558346654754e-06

Only O 0 4.389743253341294e-07
six O 0 2.6381465545455285e-07
other O 0 3.2541386474349565e-08
cases O 0 2.1265812222281966e-07
of O 0 1.2395098281103856e-07
paternal O 0 0.0002615556004457176
transmission O 1 0.811836838722229
of O 0 0.0021182934287935495
congenital B-Disease 1 0.9999978542327881
DM I-Disease 1 0.999984860420227
have O 0 4.4094012991990894e-05
been O 0 5.4250500397756696e-05
reported O 0 0.00010014304280048236
recently O 0 9.540699829813093e-05
. O 0 4.178833478363231e-06

We O 0 3.1913427847030107e-06
review O 0 6.174303734951536e-07
the O 0 1.6686526294051873e-07
sex O 0 7.134107704587223e-07
related O 0 1.574924908709363e-06
effects O 0 1.2064968359482009e-05
on O 0 1.9555161998141557e-05
transmission O 0 0.09746440500020981
of O 0 0.0012922161258757114
congenital B-Disease 1 0.9999936819076538
DM I-Disease 1 0.9999576807022095
. O 0 0.0005108952173031867

Decreased O 0 0.0008542201831005514
fertility O 0 0.00032141015981324017
of O 0 3.0215647939257906e-07
males O 0 4.827879251934064e-07
with O 0 2.3681005245634879e-07
adult O 0 4.2222200136166066e-05
onset O 1 0.9813618063926697
DM B-Disease 1 0.9999358654022217
and O 0 5.84653844271088e-06
contraction O 0 4.7112323954934254e-05
of O 0 3.735958387096616e-08
the O 0 1.365009154596919e-07
repeat O 0 1.651910110922472e-06
upon O 0 1.8104950072483916e-07
male O 0 7.868057423365826e-07
transmission O 0 2.7791802494903095e-05
contribute O 0 9.918301202560542e-08
to O 0 1.1919791376158173e-08
the O 0 5.6945484772086274e-08
almost O 0 3.076200698615139e-07
absent O 0 4.399140379973687e-06
occurrence O 0 7.400410140689928e-06
of O 0 1.796626634131826e-07
paternal O 0 0.00027191988192498684
transmission O 1 0.8038792610168457
of O 0 0.002823303919285536
congenital B-Disease 1 0.9999967813491821
DM I-Disease 1 0.9999759197235107
. O 0 0.0007381246541626751

Also O 0 2.092814156640088e-06
the O 0 2.3724678044345637e-07
fathers O 0 3.952410452257027e-07
of O 0 4.057897484699424e-08
the O 0 1.5718413806098397e-06
reported O 0 0.0001278636191273108
congenitally O 0 0.0012662375811487436
affected O 0 2.1820155780005734e-06
children O 0 3.552543716978107e-07
showed O 0 1.6323298268616782e-06
, O 0 4.769294648099276e-08
on O 0 3.1517225806965143e-07
average O 0 1.2494476777646923e-06
, O 0 1.333681183268709e-07
shorter O 0 6.727329491695855e-06
CTG O 0 0.00010376461432315409
repeat O 0 1.4471866052190308e-05
lengths O 0 2.0466874047997408e-05
and O 0 2.9646037091879407e-07
hence O 0 2.144195605069399e-06
less O 0 5.805484306620201e-06
severe O 1 0.5778182744979858
clinical O 0 0.004197691101580858
symptoms O 0 0.039356380701065063
than O 0 1.7245429262402467e-07
the O 0 2.5123267732851673e-07
mothers O 0 2.3671168492001016e-06
of O 0 1.1170434532914442e-07
children O 0 3.6823726077273022e-06
with O 0 0.0036191914696246386
congenital B-Disease 1 0.9999960660934448
DM I-Disease 1 0.9999614953994751
. O 0 0.00036696999450214207

We O 0 7.098517016856931e-06
conclude O 0 7.568921773781767e-06
that O 0 1.1967681246005668e-07
paternal O 0 4.974920375389047e-05
transmission O 0 0.23430469632148743
of O 0 0.0013945577666163445
congenital B-Disease 1 0.9999979734420776
DM I-Disease 1 0.9999933242797852
is O 0 7.391302642645314e-05
rare O 0 1.5668168998672627e-05
and O 0 3.322266479699465e-07
preferentially O 0 3.130446884824778e-06
occurs O 0 1.2811991609851248e-06
with O 0 2.1011423712025135e-07
onset O 0 0.0024639395996928215
of O 0 3.6964784158044495e-06
DM B-Disease 1 0.9994971752166748
past O 0 6.66232108414988e-06
30 O 0 5.849650506206672e-07
years O 0 1.8124039513622847e-07
in O 0 2.778182484064473e-08
the O 0 8.311016586048936e-08
father O 0 5.544532996282214e-06
. O 0 3.9514267768936406e-07
. O 0 1.2193710290375748e-06

The O 0 2.141655932064168e-05
RB1 O 0 0.004384167958050966
gene O 0 7.119306246750057e-05
mutation O 0 6.099076199461706e-05
in O 0 6.927048730176466e-07
a O 0 4.018584604636999e-06
child O 0 3.4116052120225504e-05
with O 0 1.2209781743877102e-05
ectopic B-Disease 1 0.9940066337585449
intracranial I-Disease 1 0.9993212223052979
retinoblastoma I-Disease 1 0.9888911247253418
. O 0 8.421242819167674e-05

The O 0 2.5563320377841592e-05
RB1 O 0 0.0034647928550839424
gene O 0 5.531589704332873e-05
mutation O 0 7.547148561570793e-05
was O 0 2.1582345652859658e-05
investigated O 0 1.3599559679278173e-05
in O 0 2.5515979018564394e-07
a O 0 2.4796831894491334e-06
child O 0 2.154210233129561e-05
with O 0 3.446509936111397e-06
ectopic B-Disease 0 0.4195612668991089
intracranial I-Disease 1 0.9878101348876953
retinoblastoma I-Disease 0 0.00018645692034624517
using O 0 4.831034061680839e-07
DNA O 0 1.2585867352754576e-06
obtained O 0 1.243093379343918e-07
from O 0 2.0394351096797436e-08
both O 0 1.7650446437755818e-08
the O 0 4.957503847435873e-07
pineal B-Disease 0 0.0002964510058518499
and I-Disease 0 3.187560650985688e-05
retinal I-Disease 1 0.8255967497825623
tumours I-Disease 1 0.9998618364334106
of O 0 2.3697955384704983e-06
the O 0 3.619597919168882e-05
patient O 0 0.0047683315351605415
. O 0 1.4481985999736935e-05

A O 0 8.320774941239506e-05
nonsense O 0 0.0003118192544206977
mutation O 0 8.916693332139403e-05
in O 0 1.406732621944684e-06
exon O 0 3.409565761103295e-05
17 O 0 3.883147655869834e-06
( O 0 1.0329348043569553e-07
codon O 0 2.009776380873518e-06
556 O 0 1.2259345112397568e-06
) O 0 2.2418474188157234e-08
of O 0 2.5760133581798073e-08
the O 0 2.816838104990893e-07
RB1 O 0 0.0002550300268922001
gene O 0 3.300997605037992e-06
was O 0 3.5367270356800873e-06
found O 0 6.680114950086136e-08
to O 0 5.38277378225871e-09
be O 0 2.1988300957787033e-08
present O 0 2.6437595224138022e-08
homozygously O 0 5.0451853894628584e-06
in O 0 3.735616260769348e-08
both O 0 2.0127783884049677e-08
the O 0 5.433283263300837e-07
retinal B-Disease 0 7.677563553443179e-05
and I-Disease 0 8.595335998506926e-07
the I-Disease 0 2.4011897039599717e-05
pineal I-Disease 1 0.803395688533783
tumours I-Disease 1 0.9996916055679321
. O 0 8.080873521976173e-05

The O 0 1.1533636552485405e-06
same O 0 1.2699225635515177e-06
mutation O 0 1.1528485629241914e-05
was O 0 1.5822851082702982e-06
present O 0 8.14352318911915e-08
heterozygously O 0 7.972778803377878e-06
in O 0 5.501876998437183e-08
the O 0 2.677445110066401e-08
DNA O 0 4.821777679353545e-07
from O 0 2.4032068779433757e-08
the O 0 2.7517714329405862e-08
constitutional O 0 8.597540954724536e-07
cells O 0 4.3995584064759896e-07
of O 0 2.5048763063750812e-08
the O 0 4.3461960785862175e-07
patient O 0 2.3283089831238613e-05
, O 0 7.773376609065963e-08
proving O 0 2.551549869167502e-06
it O 0 1.6357905252561977e-08
to O 0 8.892264702353714e-09
be O 0 3.914347246336547e-08
of O 0 1.3507026608294836e-07
germline O 0 6.260766531340778e-05
origin O 0 2.5098127025557915e-06
. O 0 3.765547262446489e-06

The O 0 3.627022806540481e-06
initial O 0 5.473581495607505e-06
mutation O 0 1.3317585398908705e-05
was O 0 3.2447353532916168e-06
shown O 0 1.4003543924445694e-07
to O 0 1.507507008113862e-08
have O 0 3.889088873165747e-08
occurred O 0 1.4336725371322245e-06
in O 0 5.136114822335003e-08
the O 0 1.6643090816614858e-07
paternally O 0 5.0717506383080035e-05
derived O 0 5.280827735987259e-06
RB1 O 0 0.0020199324935674667
allele O 0 6.329066673060879e-05
. O 0 7.788737093505915e-06

The O 0 5.021137894800631e-06
mutation O 0 3.763974382309243e-05
is O 0 2.666910745574569e-07
in O 0 4.068003178758772e-08
an O 0 2.2133047394845562e-08
area O 0 1.4825374705651484e-07
of O 0 4.344312465320854e-09
the O 0 1.7697066923005877e-08
gene O 0 9.023897717952423e-08
that O 0 1.8558672376656205e-09
encodes O 0 1.862982479394759e-08
the O 0 4.795272445790033e-08
protein O 0 4.313838246616797e-07
- O 0 3.154186970277806e-06
binding O 0 4.714049453014013e-07
region O 0 5.335929245120496e-07
known O 0 3.48789370718805e-07
as O 0 1.0371951475462993e-07
the O 0 1.8734951368060138e-07
pocket O 0 5.946935198153369e-05
region O 0 4.261007404693373e-07
and O 0 6.243713102094262e-08
has O 0 2.031946024771969e-07
been O 0 1.1825117240960026e-07
detected O 0 1.0604998124108533e-06
in O 0 1.3250826214061817e-08
other O 0 7.138406310502887e-09
cases O 0 1.1101955266212826e-07
of O 0 1.4581560492388235e-07
retinoblastoma B-Disease 0 0.00200071232393384
. O 0 1.6430549294454977e-06
. O 0 5.11013058712706e-06

Low O 0 0.0002856328501366079
levels O 0 1.2414870070642792e-05
of O 0 1.173636192675076e-07
beta O 0 2.9864440875826403e-06
hexosaminidase O 0 1.3838466657034587e-05
A O 0 9.682140671429806e-07
in O 0 2.198121933361108e-07
healthy O 0 1.5207851902232505e-06
individuals O 0 2.6948235642976215e-08
with O 0 1.7266344229938113e-06
apparent O 1 0.5951339602470398
deficiency O 1 0.9994295239448547
of O 0 3.2345226941288274e-07
this O 0 3.8020726833565277e-07
enzyme O 0 1.8722977983998135e-05
. O 0 3.1108672828850104e-06

Appreciable O 0 0.0004369372909422964
beta O 0 9.127239172812551e-05
hexosaminidase O 0 0.00013286697503644973
A O 0 6.8798049142060336e-06
( O 0 3.0220601843211625e-07
hex O 0 9.332638001069427e-06
A O 0 1.2844166121794842e-06
) O 0 6.927314188942546e-08
activity O 0 3.485010893200524e-07
has O 0 2.0099514586036094e-07
been O 0 2.3898556378298963e-07
detected O 0 5.4515448937308975e-06
in O 0 2.8774977067769214e-07
cultured O 0 1.4742762687092181e-05
skin O 0 0.0020798775367438793
fibroblasts O 0 1.980835986614693e-05
and O 0 4.013527723145671e-05
melanoma B-Disease 1 0.9998693466186523
tissue O 0 0.004961980972439051
from O 0 1.2050729765178403e-06
healthy O 0 5.624122877634363e-06
individuals O 0 1.7673286833996826e-08
previously O 0 6.207973910932196e-06
reported O 0 1.422689365426777e-05
as O 0 1.8885596091422485e-06
having O 0 0.0003825763997156173
deficiency B-Disease 1 0.9846991896629333
of I-Disease 0 8.449371335927935e-08
hex I-Disease 0 1.0789050975290593e-05
A I-Disease 0 7.238234047690639e-07
activity O 0 1.2166408680513996e-07
indistinguishable O 0 2.481991998593003e-07
from O 0 3.571123485812677e-08
that O 0 8.588370015161217e-09
of O 0 6.080945524900017e-08
patients O 0 1.2655394129978959e-05
with O 0 0.0003857413830701262
Tay B-Disease 1 0.9999911785125732
- I-Disease 1 0.9999504089355469
Sachs I-Disease 1 0.999954342842102
disease I-Disease 1 0.9996225833892822
( O 0 9.301574209530372e-06
TSD B-Disease 0 0.0046824002638459206
) O 0 6.1781775002600625e-06
. O 0 4.652167717722477e-06

Identification O 0 4.567890300677391e-06
and O 0 5.713804966944735e-07
quantitation O 0 0.00020995951490476727
of O 0 7.87117983236385e-07
hex O 0 7.852552516851574e-05
A O 0 4.312790679250611e-06
, O 0 8.874748402831756e-08
amounting O 0 2.694723946206068e-07
to O 0 3.289722627641822e-08
3 O 0 1.776316594259697e-06
. O 0 8.9985780959978e-07

5 O 0 2.5029072276083753e-05
% O 0 2.386567530265893e-06
- O 0 0.00019285832240711898
6 O 0 2.1682255464838818e-05
. O 0 2.6471411729289684e-06

9 O 0 1.0122110325028189e-05
% O 0 7.088277698130696e-08
of O 0 2.0308721815354147e-08
total O 0 1.0757388224647002e-07
beta O 0 1.5196283129625954e-06
hexosaminidase O 0 1.0025254596257582e-05
activity O 0 4.994756181986304e-07
, O 0 3.425399341949742e-08
has O 0 4.687085564114568e-08
been O 0 3.626924538480125e-08
obtained O 0 8.02028310431524e-08
by O 0 5.734812447144577e-08
cellulose O 0 0.00011775694292737171
acetate O 0 2.3686121494392864e-05
gel O 0 0.00011959094263147563
electrophoresis O 0 3.55095871782396e-05
, O 0 3.735416953531967e-07
DEAE O 0 9.880708967102692e-05
- O 0 2.910686089308001e-05
cellulose O 0 5.178483479539864e-05
ion O 0 3.631505387602374e-05
- O 0 2.3687091015744954e-05
exchange O 0 2.438133378745988e-06
chromatography O 0 9.441650763619691e-05
, O 0 3.2074669320536486e-07
radial O 0 2.65017370111309e-05
immunodiffusion O 0 0.0001326264755334705
, O 0 4.5458088493433024e-07
and O 0 5.555953634939215e-07
radioimmunoassay O 0 0.000533600221388042
. O 0 7.0510527621081565e-06

Previous O 0 6.705616397084668e-05
family O 0 1.754715049173683e-05
studies O 0 1.164908780992846e-06
suggested O 0 6.035314754626597e-07
that O 0 6.730219492823153e-09
these O 0 6.448902301059434e-09
individuals O 0 1.8855722316857282e-08
may O 0 5.111234031573986e-07
be O 0 4.3984506703509396e-08
compound O 0 5.432480065792333e-07
heterozygotes O 0 7.361951475104433e-07
for O 0 1.2990840403404036e-08
the O 0 5.707640582386375e-08
common O 0 6.379598289640853e-07
mutant O 0 7.854317118471954e-06
TSD B-Disease 0 0.0001338115253020078
gene O 0 2.6876427909883205e-06
and O 0 2.2335487415148236e-07
a O 0 1.736552462716645e-06
rare O 0 1.4147608453640714e-05
( O 0 2.8423144726730243e-07
allelic O 0 3.043092874577269e-05
) O 0 6.284819846769096e-07
mutant O 0 2.104469785990659e-05
gene O 0 3.957852823077701e-05
. O 0 5.070808583695907e-06

Thus O 0 6.04631713940762e-06
, O 0 2.2629546947428025e-07
the O 0 1.1318114445657557e-07
postulated O 0 4.679765879700426e-06
rate O 0 1.6027574929466937e-06
mutant O 0 6.045840450497053e-07
gene O 0 5.86211513109447e-07
appears O 0 2.1608961731089948e-07
to O 0 2.4946573695672214e-09
code O 0 1.4839938167199307e-08
for O 0 2.1602928335084925e-09
the O 0 2.8590001477368787e-08
expression O 0 8.042250243533999e-08
of O 0 5.263594005100458e-08
low O 0 1.1388332495698705e-05
amounts O 0 2.9353762442951847e-07
of O 0 7.172761939955308e-08
hex O 0 2.1302692402969114e-05
A O 0 8.824801625451073e-06
. O 0 3.651838824225706e-06

Heterozygotes O 0 0.00011631639790721238
for O 0 4.373446813588089e-07
the O 0 8.888467846190906e-07
rare O 0 1.5739109585410915e-05
mutant O 0 2.4080600269371644e-05
may O 0 1.2516635479187244e-06
be O 0 2.34074057914313e-08
indistinguishable O 0 4.3534473093131965e-07
from O 0 8.791051442358366e-08
heterozygotes O 0 1.7261157836401253e-06
for O 0 5.944637138100006e-08
the O 0 1.0130388545803726e-06
common O 0 1.9865623471559957e-05
TSD B-Disease 0 0.0034230095334351063
mutant O 0 0.00027342044631950557
. O 0 9.001383659779094e-06

However O 0 2.1080520582472673e-06
, O 0 5.997320329242939e-08
direct O 0 3.701225637087191e-08
visualization O 0 2.110027025992167e-06
and O 0 1.849425217415046e-07
quantitation O 0 4.926181281916797e-05
of O 0 1.697816287560272e-07
hex O 0 3.4653712646104395e-05
A O 0 1.0022071137427702e-06
by O 0 3.985274688034224e-08
the O 0 8.974566867436806e-08
methods O 0 6.943358812350198e-07
described O 0 1.6564026736887172e-05
may O 0 3.14016142510809e-06
prevent O 0 1.8857880377254332e-06
false O 0 1.8404025468043983e-06
- O 0 4.299284046282992e-05
positive O 0 1.5837298406040645e-06
prenatal O 0 0.00015561362670268863
diagnosis O 0 0.001434828038327396
of O 0 7.719991117483005e-07
TSD B-Disease 0 0.0021588841918855906
in O 0 4.137375071877614e-06
fetuses O 0 2.8459173336159438e-05
having O 0 6.504370162474515e-07
the O 0 1.7476575919772586e-07
incomplete O 0 2.6966779842041433e-05
hex B-Disease 0 0.000920297869015485
A I-Disease 0 0.001272615510970354
deficiency I-Disease 1 0.9827752709388733
of O 0 5.490722898571221e-08
the O 0 5.774027727056819e-07
type O 0 0.0001449537230655551
described O 0 6.8818653744529e-06
in O 0 1.4139888548925228e-07
the O 0 2.9498008302653034e-07
four O 0 1.0714832114899764e-06
healthy O 0 2.4417620807071216e-05
individuals O 0 1.9497229004628025e-06

The O 0 8.066884038271382e-05
tumor B-Disease 0 0.10562559962272644
suppressor O 0 0.000326067500282079
gene O 0 4.921072468277998e-05
Smad4 O 0 0.00042233351268805563
/ O 0 9.58923264988698e-05
Dpc4 O 0 9.257221245206892e-05
is O 0 2.2372027785877435e-07
required O 0 5.9407152974699784e-08
for O 0 2.7952122394481194e-08
gastrulation O 0 6.8754234234802425e-06
and O 0 1.292098517069462e-07
later O 0 7.554819489996589e-07
for O 0 7.199489004960924e-08
anterior O 0 0.00017570033378433436
development O 0 1.1698691793071703e-07
of O 0 5.0267825457694926e-08
the O 0 7.669372052987455e-07
mouse O 0 7.434302096953616e-05
embryo O 0 4.0496634028386325e-05
. O 0 4.854958660871489e-06

Mutations O 0 0.0009176802122965455
in O 0 4.595483005687129e-06
the O 0 6.6383163357386366e-06
SMAD4 O 0 0.020201796665787697
/ O 0 0.003791291732341051
DPC4 O 0 0.04378513619303703
tumor B-Disease 0 0.07853126525878906
suppressor O 0 5.8435976825421676e-05
gene O 0 2.691305780899711e-06
, O 0 7.362534404364851e-08
a O 0 1.336235158078125e-07
key O 0 1.0889150416915072e-06
signal O 0 2.2404299215850187e-06
transducer O 0 5.19633886142401e-06
in O 0 7.662355017146183e-08
most O 0 1.1191291093837208e-07
TGFbeta O 0 3.689978620968759e-05
- O 0 2.5498698960291222e-05
related O 0 4.277884215753147e-07
pathways O 0 1.5134265822780435e-06
, O 0 2.362481055229182e-08
are O 0 1.9819728080960886e-09
involved O 0 1.983902642166413e-08
in O 0 2.2344663008766474e-08
50 O 0 2.0020982560708944e-07
% O 0 1.381226013563719e-07
of O 0 2.3544480427517556e-06
pancreatic B-Disease 1 0.9998863935470581
cancers I-Disease 1 0.9996769428253174
. O 0 3.4931425034301355e-05

Homozygous O 0 0.0013130189618095756
Smad4 O 0 0.002810161095112562
mutant O 0 0.0011088611790910363
mice O 0 0.002452225424349308
die O 0 0.001382183632813394
before O 0 3.076915390920476e-06
day O 0 5.923437129240483e-06
7 O 0 7.941763215058018e-06
. O 0 2.2815045213064877e-06

5 O 0 2.0530565961962566e-05
of O 0 1.7393202824678156e-06
embryogenesis O 0 0.0005508922040462494
. O 0 4.401940168463625e-05

Mutant O 0 2.4481509171891958e-05
embryos O 0 2.1208445559750544e-06
have O 0 2.593228884961718e-07
reduced O 0 1.4553693290508818e-06
size O 0 5.047375452704728e-06
, O 0 4.3139164063177304e-07
fail O 0 2.5724862098286394e-06
to O 0 5.565117433548039e-08
gastrulate O 0 2.35048482863931e-05
or O 0 2.589112000350724e-07
express O 0 2.0485195761921204e-07
a O 0 3.3240030461456627e-07
mesodermal O 0 2.2511883798870258e-05
marker O 0 2.090049565595109e-05
, O 0 2.127670626350664e-07
and O 0 1.65112581385074e-07
show O 0 9.318318916484714e-06
abnormal O 0 0.00018024182645604014
visceral O 0 9.176407183986157e-05
endoderm O 0 0.0012278568465262651
development O 0 1.616703229956329e-05
. O 0 1.3558455975726247e-05

Growth B-Disease 1 0.9977021813392639
retardation I-Disease 1 0.9994994401931763
of O 0 1.4808856576564722e-06
the O 0 5.837501703354064e-06
Smad4 O 0 0.032217837870121
- O 0 0.014783533290028572
deficient O 0 0.0006859592394903302
embryos O 0 1.0107748948939843e-06
results O 0 5.203690420785279e-07
from O 0 3.54002267499709e-08
reduced O 0 6.523528668367362e-07
cell O 0 6.887197287142044e-06
proliferation O 0 7.222909971460467e-06
rather O 0 5.213515663626822e-08
than O 0 3.9470119617135424e-08
increased O 0 7.818481435606373e-07
apoptosis O 0 4.3831398215843365e-05
. O 0 3.0113776574580697e-06

Aggregation O 0 5.233430056250654e-05
of O 0 2.3788597900420427e-06
mutant O 0 6.944584310986102e-05
Smad4 O 0 0.0009250048897229135
ES O 0 0.0002639608574099839
cells O 0 6.312160166999092e-06
with O 0 3.0485261959256604e-07
wild O 0 1.3695755114895292e-05
- O 0 0.0004458920157048851
type O 0 0.00010593586193863302
tetraploid O 0 0.0003938409499824047
morulae O 0 0.002232295460999012
rescues O 0 0.0003851545334327966
the O 0 1.9768011043197475e-05
gastrulation B-Disease 0 0.024191608652472496
defect I-Disease 0 0.1875143200159073
. O 0 3.268019645474851e-05

These O 0 3.459329036559211e-06
results O 0 8.65150650497526e-06
indicate O 0 2.623096634124522e-06
that O 0 1.3182088309804385e-07
Smad4 O 0 3.075359563808888e-05
is O 0 1.0356512802900397e-07
initially O 0 1.219796246232363e-07
required O 0 9.056051020195355e-09
for O 0 3.0427089736662083e-09
the O 0 9.427083114132984e-09
differentiation O 0 3.742905363424143e-08
of O 0 1.746218991627302e-08
the O 0 5.726505492020806e-08
visceral O 0 3.2290013223246206e-06
endoderm O 0 8.841118687996641e-05
and O 0 2.96295610269226e-07
that O 0 5.700786687157233e-08
the O 0 6.578142688340449e-07
gastrulation B-Disease 0 0.0007576780044473708
defect I-Disease 0 0.0009552366682328284
in O 0 4.6459112468255626e-07
the O 0 6.144709914224222e-07
epiblast O 0 0.00043631563312374055
is O 0 2.9070608320580504e-07
secondary O 0 2.2397161956178024e-06
and O 0 2.7958662940363865e-07
non O 0 1.5053087736305315e-05
- O 0 0.0019448058446869254
cell O 0 0.00016037812747526914
autonomous O 0 9.011029760586098e-06
. O 0 4.027811883133836e-06

Rescued O 0 0.001067963894456625
embryos O 0 0.00017912170733325183
show O 0 0.0003737534279935062
severe O 1 0.9089178442955017
anterior O 0 0.24853843450546265
truncations O 0 0.0008869686862453818
, O 0 1.4704463637826848e-06
indicating O 0 2.4727025902393507e-06
a O 0 4.924847871734528e-07
second O 0 3.7315396639314713e-07
important O 0 9.425198754797748e-08
role O 0 6.852382057331852e-07
for O 0 1.92040744195765e-07
Smad4 O 0 0.0002914753567893058
in O 0 3.6815756629948737e-06
anterior O 0 0.0032596271485090256
patterning O 0 0.000590001989621669
during O 0 3.719294909387827e-05
embryogenesis O 0 0.000453904242021963
. O 0 1.807037006074097e-05

Prevalence O 0 0.0016456461744382977
of O 0 1.951363628904801e-06
p16 O 0 7.587182335555553e-05
and O 0 2.0392462829477154e-06
CDK4 O 0 0.0011613517999649048
germline O 0 0.0011128764599561691
mutations O 0 0.00036721036303788424
in O 0 1.252249421668239e-05
48 O 0 0.001965690404176712
melanoma B-Disease 1 0.9997578263282776
- O 1 0.6830673217773438
prone O 0 0.009393765591084957
families O 0 9.740404038893757e-07
in O 0 1.5646849078621017e-06
France O 0 0.00024975300766527653
. O 0 8.236111170845106e-06

The O 0 6.787710299249738e-05
French O 0 0.013730512000620365
Familial B-Disease 1 0.995819091796875
Melanoma I-Disease 1 0.9996602535247803
Study O 0 4.746094418806024e-05
Group O 0 2.326293906662613e-05
. O 0 9.608061191102024e-06

Germline O 0 0.005865410435944796
mutations O 0 0.000714331166818738
in O 0 9.399469149684592e-07
the O 0 5.37193500349531e-07
p16 O 0 9.282503015128896e-06
and O 0 1.7796762108446273e-07
CDK4 O 0 4.115655247005634e-05
genes O 0 7.148307190618652e-07
have O 0 4.076850146361721e-08
been O 0 2.1537407235427963e-07
reported O 0 4.995113727090938e-07
in O 0 1.035198593513087e-08
a O 0 9.27969452391153e-08
subset O 0 3.5209498605581757e-07
of O 0 9.778732419363223e-07
melanoma B-Disease 1 0.9975054860115051
pedigrees O 0 1.718500061542727e-05
, O 0 1.5785232676535088e-07
but O 0 6.634770244318133e-08
their O 0 6.639745464553926e-08
prevalence O 0 4.5424283598549664e-05
is O 0 2.563180601100612e-07
not O 0 4.5898147504885856e-08
well O 0 2.720579743709095e-07
known O 0 4.259014531271532e-06
. O 0 1.8208928622698295e-06

We O 0 1.2087469940524898e-06
searched O 0 3.2540474421693943e-06
for O 0 3.2089470636265105e-08
such O 0 1.9092117042873724e-07
germline O 0 6.039030631654896e-05
mutations O 0 3.882828968926333e-05
in O 0 2.2769008864997886e-06
48 O 0 5.335810055839829e-05
French O 0 0.24236446619033813
melanoma B-Disease 1 0.9998914003372192
- O 1 0.9159075617790222
prone O 0 0.0033606099896132946
families O 0 4.161106303968154e-08
selected O 0 4.4245684449606415e-08
according O 0 1.7227439030875757e-08
to O 0 1.923490700050934e-09
two O 0 8.8274410003919e-09
major O 0 2.7090504772786517e-07
criteria O 0 4.4264343301847475e-08
families O 0 1.1641621000535451e-09
with O 0 7.612444896665238e-09
at O 0 2.1551265945163323e-06
least O 0 2.193949732998135e-08
three O 0 2.285968037085695e-08
affected O 0 8.272569829159693e-08
members O 0 9.964240987869744e-09
( O 0 3.4288181183228517e-08
n O 0 2.3773288830852835e-06
= O 0 1.5155166011027177e-06
20 O 0 9.68704796378006e-08
) O 0 2.7434743365972736e-09
or O 0 8.079175550790296e-09
families O 0 1.1574886604748258e-09
with O 0 3.943052107047151e-09
two O 0 1.7505541904938582e-08
affected O 0 6.93478270363812e-08
members O 0 4.342953552338713e-09
, O 0 5.4413029637601085e-09
one O 0 3.4290907890976996e-09
of O 0 1.511346936489133e-09
them O 0 2.0052706162232425e-09
affected O 0 3.2248077985741475e-08
before O 0 3.711426543873131e-08
the O 0 1.696436413567426e-08
age O 0 1.577939201524714e-07
of O 0 7.651471456426862e-09
50 O 0 4.969886902017606e-08
( O 0 2.7166640492737315e-08
n O 0 1.6249894088105066e-06
= O 0 1.5576990790577838e-06
28 O 0 2.7962207127529837e-07
) O 0 4.667848330086599e-09
, O 0 5.272071224027286e-09
and O 0 7.295182680167045e-09
one O 0 4.3366316759829715e-08
additional O 0 9.472669404431144e-08
minor O 0 0.00018154441204387695
criterion O 0 0.00011685804929584265
. O 0 4.7964708755898755e-06

Sixteen O 0 9.756266081240028e-06
different O 0 4.097368559996539e-07
p16 O 0 5.309917833073996e-05
germline O 0 0.00010360940359532833
mutations O 0 2.648554254847113e-05
were O 0 2.5013008553287364e-07
found O 0 2.891665076276695e-07
in O 0 8.4904691277643e-08
21 O 0 2.613296032905055e-07
families O 0 9.173083626023981e-09
, O 0 2.998996606606852e-08
while O 0 9.050097560248105e-08
one O 0 2.496234685622767e-07
germline O 0 4.104405888938345e-05
mutation O 0 9.2692698672181e-06
, O 0 1.62730501074293e-07
Arg24His O 0 1.3213923921284731e-05
, O 0 2.8549195008054085e-07
was O 0 1.1800443644460756e-05
detected O 0 1.4311917766463012e-05
in O 0 1.186309290801546e-07
the O 0 6.19069453478005e-07
CDK4 O 0 0.0005264216451905668
gene O 0 5.9923509979853407e-05
. O 0 8.321307177538984e-06

The O 0 5.149136086401995e-07
frequency O 0 1.7700783701002365e-06
of O 0 1.2788609637937043e-07
p16 O 0 1.5843410437810235e-05
gene O 0 7.412976628984325e-06
mutation O 0 7.911594366305508e-06
in O 0 6.328165369495764e-08
our O 0 5.943390135598747e-08
sample O 0 8.134566087392159e-08
( O 0 3.655726743545529e-08
44 O 0 9.868108463706449e-08
% O 0 1.0220010615569208e-08
) O 0 9.837490821951178e-09
is O 0 1.8035821724993184e-08
among O 0 1.8115946076591172e-08
the O 0 1.0978349251899999e-07
highest O 0 2.0900934032397345e-05
rates O 0 2.750520707195392e-06
yet O 0 4.1692382524161076e-07
reported O 0 1.1896473779415828e-06
and O 0 4.106537332404514e-08
the O 0 1.755959004867691e-07
CDK4 O 0 0.00018330466991756111
mutation O 0 5.235356184130069e-06
is O 0 1.1343789907414248e-07
the O 0 4.117620022725532e-08
second O 0 9.404724323758273e-07
mutation O 0 3.4791075904649915e-06
detected O 0 2.502272081983392e-06
in O 0 2.2544799804791182e-08
this O 0 1.8520667666166446e-08
gene O 0 6.371924996528833e-07
worldwide O 0 1.0145788564841496e-06
. O 0 2.3189809326140676e-06

In O 0 4.0598170016892254e-06
summary O 0 4.880434971710201e-06
, O 0 2.52964923674881e-07
our O 0 1.8951998015381832e-07
results O 0 6.028716938999423e-07
show O 0 2.360632578302102e-07
frequent O 0 4.006214737728442e-07
involvement O 0 2.940688830221916e-07
of O 0 1.687394046712143e-08
the O 0 1.462969834165051e-07
p16 O 0 9.411684004589915e-06
gene O 0 4.874392743658973e-06
in O 0 1.9938888726755977e-06
familial B-Disease 1 0.7988643646240234
melanoma I-Disease 1 0.9997549653053284
and O 0 4.676320770613529e-07
confirm O 0 7.273545747921162e-07
the O 0 1.0981993625591713e-07
role O 0 3.454795205470873e-07
of O 0 1.8540601942618196e-08
the O 0 1.1719182424485552e-07
CDK4 O 0 5.672326005878858e-05
gene O 0 1.3826165741193108e-06
as O 0 5.027046654504375e-07
a O 0 2.843662878149189e-05
melanoma B-Disease 1 0.9975946545600891
- O 0 0.00012031118967570364
predisposing O 0 3.345005097799003e-05
gene O 0 7.309925877052592e-06
. O 0 6.006421813253837e-07
. O 0 1.4073929150981712e-06

Progression O 0 0.0022909650579094887
of O 0 3.7728550523752347e-06
somatic O 0 0.0002473104395903647
CTG O 0 0.004316483158618212
repeat O 0 8.102718129521236e-05
length O 0 6.802650204917882e-06
heterogeneity O 0 1.3134058463037945e-05
in O 0 3.228879847938515e-07
the O 0 1.463935859646881e-06
blood O 0 0.00046069969539530575
cells O 0 7.798510341672227e-05
of O 0 3.6922283470630646e-05
myotonic B-Disease 1 0.9999462366104126
dystrophy I-Disease 1 0.9999886751174927
patients O 1 0.9234970808029175
. O 0 5.7404558901907876e-05

The O 0 4.019830157631077e-06
genetic O 0 6.56996708130464e-05
basis O 0 1.1452973922132514e-05
of O 0 0.0002176412963308394
myotonic B-Disease 1 0.9999780654907227
dystrophy I-Disease 1 0.9999932050704956
( O 0 0.0009526190697215497
DM B-Disease 1 0.9998835325241089
) O 0 9.450658353671315e-07
is O 0 2.5482614773864043e-07
the O 0 6.536107122201429e-08
expansion O 0 1.1218620556974201e-06
of O 0 7.161961690371754e-08
an O 0 6.199018116603838e-07
unstable O 0 0.0060047851875424385
CTG O 0 0.00019987544510513544
repeat O 0 8.398080353799742e-06
in O 0 9.456819327624544e-08
the O 0 6.998310198014224e-08
34 O 0 4.905105015495792e-07
UTR O 0 6.991998816374689e-06
of O 0 6.241867112066757e-08
the O 0 1.236426555806247e-06
DM B-Disease 1 0.9346352219581604
protein O 0 3.1205627237795852e-06
kinase O 0 2.9733034807577496e-06
gene O 0 1.7240577108168509e-06
on O 0 1.5835968270039302e-06
chromosome O 0 0.00010030102566815913
19 O 0 1.390788565913681e-05
. O 0 1.458925453334814e-06

One O 0 9.363002959617006e-07
of O 0 5.647905965133759e-08
the O 0 1.1638211816489274e-07
principal O 0 1.3965416201244807e-06
features O 0 7.055687660795229e-07
of O 0 4.5280691551852215e-07
the O 0 2.9943674235255457e-05
DM B-Disease 1 0.9998586177825928
mutation O 0 9.708845755085349e-05
is O 0 2.7147274295202806e-07
an O 0 5.575976302907293e-08
extraordinarily O 0 3.625388126238249e-05
high O 0 1.3840116480423603e-05
level O 0 1.4229469798010541e-06
of O 0 7.268935320325909e-08
somatic O 0 1.1306542546662968e-05
mosaicism O 0 0.0005208743386901915
, O 0 3.068137743866828e-07
due O 0 6.543049266838352e-07
to O 0 8.905860937602483e-09
an O 0 6.528457419108236e-08
extremely O 0 6.909110652486561e-06
high O 0 1.9690553017426282e-05
degree O 0 5.79870572892105e-07
of O 0 8.54769766078789e-08
somatic O 0 8.682303814566694e-06
instability O 0 9.54736697167391e-06
both O 0 1.0480590617589769e-07
within O 0 9.713949822298673e-08
and O 0 5.3346976613966035e-08
between O 0 1.6152141313341417e-07
different O 0 4.615801003637898e-07
tissues O 0 0.00026828734553419054
. O 0 7.487100447178818e-06

This O 0 8.473015441268217e-06
instability O 0 0.0001497896882938221
appears O 0 2.0760764982696855e-06
to O 0 2.2327622417606108e-08
be O 0 2.0858804461454383e-08
biased O 0 7.819474490133871e-08
towards O 0 1.471061406022045e-08
further O 0 1.3392352116170514e-08
expansion O 0 1.2516045444499468e-07
and O 0 1.339023203428269e-08
continuous O 0 1.335447876726903e-07
throughout O 0 2.0921925170114264e-07
the O 0 1.265913738279778e-07
life O 0 1.349079212786819e-07
of O 0 4.1491685642824905e-09
an O 0 1.3249461972009158e-08
individual O 0 1.0455509347195857e-08
, O 0 1.9935979977958596e-08
features O 0 1.2979477048702392e-07
that O 0 2.312861369091479e-08
could O 0 4.792136110154388e-08
be O 0 1.7563435150691475e-08
associated O 0 5.9534539076366855e-08
with O 0 2.4073036897220845e-08
the O 0 5.072890303381428e-07
progressive O 0 0.0002416271308902651
nature O 0 1.942540166055551e-06
of O 0 4.916349212180648e-07
the O 0 0.00020873914763797075
disease O 1 0.9973904490470886
. O 0 9.56527583184652e-06

Although O 0 4.047882612212561e-06
increasing O 0 3.432215407883632e-06
measured O 0 8.128476110869087e-06
allele O 0 6.900464086356806e-06
size O 0 6.9583534241246525e-06
between O 0 2.9691836971323937e-06
patients O 0 5.6322169257327914e-06
clearly O 0 3.3345793326589046e-07
correlates O 0 3.347097390360432e-07
with O 0 3.510679036367037e-08
an O 0 8.203465284850608e-08
increased O 0 1.412720735061157e-06
severity O 0 0.00010318394197383896
of O 0 9.06244508769305e-07
symptoms O 0 0.003595333779230714
and O 0 1.1503939134627217e-07
an O 0 1.1106064334853727e-07
earlier O 0 3.2605928481643787e-06
age O 0 1.7352941767967422e-06
of O 0 7.725751771658906e-08
onset O 0 0.0013137870701029897
, O 0 5.238664968487683e-08
this O 0 5.9800360219242066e-09
correlation O 0 6.0575267468721e-08
is O 0 1.9429235109669207e-08
not O 0 6.3438974073903864e-09
precise O 0 1.0830660812644055e-07
and O 0 4.0251979527283765e-08
measured O 0 1.2956550108356168e-06
allele O 0 8.674273885844741e-07
length O 0 8.185832598428533e-07
cannot O 0 1.1954472256547888e-07
be O 0 4.758007321470359e-09
used O 0 8.152611030709522e-09
as O 0 9.567029835011454e-09
an O 0 1.2859612930071762e-08
accurate O 0 4.604185619427881e-07
predictor O 0 9.59280805545859e-06
of O 0 1.841240049316184e-07
age O 0 1.0682879292289726e-05
of O 0 1.8838754840544425e-06
onset O 1 0.5722019076347351
. O 0 2.9238535717013292e-05

In O 0 1.1774910717576859e-06
order O 0 1.9914591575798113e-07
to O 0 2.2393345844307078e-08
further O 0 3.860038688685563e-08
characterize O 0 2.2694650851917686e-06
the O 0 6.598864388251968e-07
dynamics O 0 0.00011097375681856647
of O 0 9.998862879001535e-06
DM B-Disease 1 0.9989271759986877
CTG O 0 0.0038107542786747217
repeat O 0 0.00013377313734963536
somatic O 0 6.611031130887568e-05
instability O 0 9.566426160745323e-05
, O 0 2.6171144895670295e-07
we O 0 7.561193626770546e-08
have O 0 2.2395695964405604e-08
studied O 0 4.954468977302895e-07
repeat O 0 1.3355005421544774e-06
length O 0 6.535496481774317e-07
changes O 0 2.388452173818223e-07
over O 0 6.382190775866547e-08
time O 0 3.4139139870603685e-07
in O 0 2.625914930831641e-06
111 O 0 0.0008317833999171853
myotonic B-Disease 1 0.9998086094856262
dystrophy I-Disease 1 0.9999532699584961
patients O 0 0.00024027902691159397
with O 0 6.37737798570015e-07
varying O 0 1.1242525033594575e-05
clinical O 0 0.0007175318314693868
severity O 0 0.0029148629400879145
and O 0 2.0758805021614535e-06
CTG O 0 0.0002935146912932396
repeat O 0 8.421940037806053e-06
size O 0 9.486236081102106e-07
over O 0 5.7650815676879574e-08
time O 0 4.898410566056555e-08
intervals O 0 4.2192399973828287e-07
of O 0 3.339820509040692e-08
1 O 0 8.649062692711595e-07
- O 0 2.732216853473801e-05
7 O 0 4.320958851167234e-06
years O 0 1.243633278136258e-06
. O 0 1.2498790056270082e-06

We O 0 3.859453954646597e-06
have O 0 8.316281707720918e-08
found O 0 7.050199712921312e-08
a O 0 3.3716052172394484e-08
direct O 0 3.127004077896345e-08
progression O 0 7.770633601467125e-06
of O 0 1.6586152895570194e-08
the O 0 9.670321787780267e-08
size O 0 1.584225401529693e-06
heterogeneity O 0 3.876391474477714e-06
over O 0 3.167517661495367e-07
time O 0 1.6726453111459705e-07
related O 0 1.2305690688663162e-07
to O 0 2.391017694947095e-08
initial O 0 7.720616963524662e-07
CTG O 0 2.399612458248157e-05
repeat O 0 1.6548981420783093e-06
size O 0 4.65812092897977e-07
and O 0 2.7114044343079513e-08
the O 0 2.280050281910917e-08
time O 0 4.8091948201545165e-08
interval O 0 2.8618052283491124e-07
and O 0 1.613913980236248e-08
always O 0 4.814536325170593e-08
biased O 0 1.3987541080950905e-07
towards O 0 7.745315855345325e-08
further O 0 9.603488848597408e-08
expansion O 0 7.834887583157979e-06
. O 0 2.7387525278754765e-06

Attempts O 0 2.54912242780847e-06
to O 0 8.425553232882521e-08
mathematically O 0 9.86518784884538e-07
model O 0 1.276980924558302e-06
the O 0 2.1690952678454778e-07
dynamics O 0 6.222198135219514e-05
have O 0 1.8535958190568635e-07
proved O 0 1.0628913287291653e-06
only O 0 1.696672669027066e-08
partially O 0 4.997404630557867e-06
successful O 0 5.768094979430316e-07
suggesting O 0 7.372743198175158e-07
that O 0 1.1450062231688207e-08
individual O 0 8.593286082714258e-09
specific O 0 4.049500645919579e-08
genetic O 0 2.144091467926046e-06
and O 0 6.464667876571184e-07
/ O 0 7.420824113069102e-05
or O 0 1.8480143353372114e-06
environmental O 0 6.732406291121151e-06
factors O 0 1.6882833620002202e-07
also O 0 8.649874416732928e-08
play O 0 8.257908490350019e-08
a O 0 1.8476129071132164e-07
role O 0 3.8674974689456576e-07
in O 0 3.690187497795705e-07
somatic O 0 1.711884942778852e-05
mosaicism O 0 0.0008142514270730317
. O 0 1.637903096707305e-06
. O 0 4.97631708640256e-06

Aspartylglucosaminuria B-Disease 1 0.9806617498397827
among O 0 1.2166216038167477e-05
Palestinian O 0 6.869032949907705e-05
Arabs O 0 5.525136293726973e-05
. O 0 2.6283394618076272e-05

Aspartylglucosaminuria B-Disease 1 0.998663067817688
( O 0 0.0006480807205662131
AGU B-Disease 1 0.9984898567199707
) O 0 2.1015280253777746e-06
is O 0 1.1247169595662854e-06
a O 0 8.69113500812091e-06
rare O 0 0.00034796042018570006
disorder B-Disease 1 0.9958908557891846
of I-Disease 0 3.313891738798702e-06
glycoprotein I-Disease 0 0.14042291045188904
metabolism I-Disease 1 0.6576942205429077
caused O 0 0.0005764630623161793
by O 0 1.883999402707559e-06
the O 0 0.00015597014862578362
deficiency B-Disease 1 0.998889148235321
of I-Disease 0 4.5301854356694093e-07
the I-Disease 0 1.0250571904180106e-05
lysosomal I-Disease 0 0.0409916490316391
enzyme I-Disease 0 0.00026732374681159854
aspartylglucosaminidase I-Disease 0 0.00182886712718755
( O 0 2.1536391159315826e-06
AGA O 0 0.00031579163623973727
) O 0 2.5302019821538124e-06
. O 0 4.478202754398808e-06

AGU B-Disease 1 0.9991243481636047
is O 0 0.0002345133834751323
inherited O 0 0.09085090458393097
as O 0 5.715582574339351e-06
an O 0 1.128633175540017e-05
autosomal O 1 0.9791263341903687
recessive O 1 0.8604724407196045
trait O 0 0.002709069289267063
and O 0 3.3474532301625004e-06
occurs O 0 1.3171372756914934e-06
with O 0 3.0250383531438274e-08
a O 0 3.728583521933615e-07
high O 0 3.992669462604681e-06
frequency O 0 1.6945338074947358e-06
in O 0 1.775814126858677e-07
Finland O 0 2.5715837637108052e-06
because O 0 8.266875539675311e-08
of O 0 2.601412241176604e-08
a O 0 2.7868468350789044e-06
founder O 0 4.079233622178435e-05
effect O 0 7.161303528846474e-06
. O 0 2.566436251072446e-06

While O 0 1.0743853636085987e-05
very O 0 1.8749765331449453e-06
few O 0 1.6571659671171801e-06
patients O 0 5.071974101156229e-06
with O 0 2.8104111606808146e-06
AGU B-Disease 1 0.9988868832588196
have O 0 3.402537913643755e-07
been O 0 9.232597903974238e-07
reported O 0 1.9497265384416096e-06
from O 0 1.2745630328936386e-07
non O 0 1.4812967492616735e-06
- O 0 2.4301629309775308e-05
Finnish O 0 2.3204840545076877e-05
origin O 0 2.6177335143984237e-07
, O 0 6.622935302402766e-07
we O 0 8.278382665594108e-06
diagnosed O 1 0.994021475315094
the O 0 1.284814061364159e-05
disorder O 1 0.9913228750228882
in O 0 2.3434981812897604e-06
8 O 0 7.4738459261425305e-06
patients O 0 1.373125314785284e-06
originating O 0 4.0154597513719636e-07
from O 0 1.4876559362164699e-07
3 O 0 5.361034709494561e-07
unrelated O 0 9.540799510432407e-07
families O 0 1.10866098523843e-08
, O 0 7.421125935991313e-09
all O 0 1.6892385268363341e-09
Palestinian O 0 1.650343364190121e-07
Arabs O 0 1.433161003205896e-07
from O 0 1.0855271170839842e-07
the O 0 1.5162220279307803e-07
region O 0 1.4819015632383525e-06
of O 0 2.1668910221706028e-07
Jerusalem O 0 0.0001913613814394921
. O 0 1.2873160812887363e-05

The O 0 6.7275992478244e-05
clinical O 0 0.002721264725551009
diagnosis O 1 0.9837567806243896
of O 0 0.0001276480033993721
AGU B-Disease 1 0.99981290102005
is O 0 3.0839055398246273e-05
often O 0 1.2885843716503587e-06
difficult O 0 2.626836703711888e-06
, O 0 7.603755847185312e-08
in O 0 2.869051485276941e-08
particular O 0 2.491714923280597e-08
early O 0 2.5500145284240716e-07
in O 0 3.837282491758742e-08
the O 0 5.687145687716111e-08
course O 0 1.1982817795797018e-06
of O 0 4.5229935352608663e-08
the O 0 5.391338163462933e-06
disease O 0 0.443450391292572
, O 0 4.275852916180156e-08
and O 0 1.8369108900628817e-08
most O 0 1.4675777926242972e-08
of O 0 2.2250208786545045e-08
the O 0 1.4860808050798369e-06
patients O 0 1.0016319720307365e-05
are O 0 2.759077517566766e-07
diagnosed O 1 0.6274483799934387
after O 0 8.603586252320383e-07
the O 0 8.882759061634715e-08
age O 0 1.1573147276067175e-06
of O 0 8.303791076968992e-08
5 O 0 3.603096502047265e-06
years O 0 3.1037818644108484e-06
. O 0 1.2866994438809343e-06

However O 0 5.201931799092563e-06
, O 0 4.935699280395056e-07
since O 0 9.620774790164432e-07
these O 0 4.5755236044442427e-08
patients O 0 1.9823762613668805e-06
excrete O 0 1.4243767054722412e-06
early O 0 3.987974821484386e-07
large O 0 1.651799834689882e-07
amounts O 0 4.0375013554694306e-07
of O 0 8.685368158012352e-08
aspartylglucosamine O 0 3.898877548635937e-05
in O 0 4.600367162765906e-07
urine O 0 2.795055479509756e-06
, O 0 4.401102415840796e-08
biochemical O 0 1.103820636672026e-06
screening O 0 5.920202283959952e-07
is O 0 4.958241106578498e-08
easy O 0 8.987740329757798e-08
by O 0 1.693475866204608e-07
urine O 0 1.8442171494825743e-05
chromatography O 0 0.0002993111265823245
. O 0 9.694364280221635e-07
. O 0 2.244968527520541e-06

Detection O 0 9.951371612260118e-05
of O 0 6.956594802431937e-07
heterozygous O 0 8.928534043661784e-06
carriers O 0 8.451983376289718e-06
of O 0 7.568680189251609e-07
the O 0 0.0003090814861934632
ataxia B-Disease 1 0.999981164932251
- I-Disease 1 0.9991574287414551
telangiectasia I-Disease 1 0.9989000558853149
( O 0 3.063920303247869e-06
ATM O 0 4.268896736903116e-05
) O 0 3.1676265166424855e-07
gene O 0 1.84777638878586e-06
by O 0 5.752772835876385e-07
G2 O 0 0.000494222913403064
phase O 0 5.119975685374811e-05
chromosomal O 0 0.0015432302607223392
radiosensitivity O 0 0.00042447674786671996
of O 0 2.021174395849812e-06
peripheral O 0 0.14184966683387756
blood O 0 0.4651623070240021
lymphocytes O 0 0.04652053117752075
. O 0 3.368630132172257e-05

In O 0 0.0007975012995302677
ataxia B-Disease 1 0.9998611211776733
- I-Disease 1 0.9989031553268433
telangiectasia I-Disease 1 0.9995300769805908
( O 0 0.00032166094752028584
A B-Disease 1 0.9996815919876099
- I-Disease 1 0.9991083741188049
T I-Disease 1 0.999695897102356
) O 0 1.2873598507212591e-06
patients O 0 2.738775947364047e-06
, O 0 7.301562021666541e-08
mutations O 0 7.345968242589151e-07
in O 0 1.4476332133028791e-08
a O 0 4.429051969623288e-08
single O 0 1.244262648469885e-07
gene O 0 2.558440144184715e-07
, O 0 3.312073104666524e-08
ATM O 0 4.2072165342688095e-06
, O 0 1.3832955403358937e-07
result O 0 5.813357120132423e-07
in O 0 1.504375404692837e-06
an O 0 0.0003805665182881057
autosomal B-Disease 1 0.9999910593032837
recessive I-Disease 1 0.9999790191650391
syndrome I-Disease 1 0.9999996423721313
that O 0 2.3127217900764663e-06
embraces O 0 3.1223430596583057e-06
a O 0 6.096681772760348e-07
variety O 0 2.6757331283988606e-07
of O 0 1.549285570945358e-07
clinical O 0 7.959817594382912e-06
features O 0 3.991310677520232e-06
and O 0 1.5867276488279458e-06
manifests O 0 4.1412255086470395e-05
extreme O 0 6.741612014593557e-05
radiosensitivity O 0 0.0002689314424060285
and O 0 7.027295509942633e-07
a O 0 2.519582949389587e-06
strong O 0 7.032825578789925e-06
pre O 0 0.0010664545698091388
- O 0 0.0006530925165861845
disposition O 0 0.00010464032675372437
to O 0 8.682867701281793e-06
malignancy B-Disease 1 0.857063889503479
. O 0 1.2896754014946055e-05

Heterozygotes O 0 4.2535240936558694e-05
for O 0 1.0896385305159129e-07
the O 0 1.7003051766550925e-07
ATM O 0 1.0162367289012764e-05
gene O 0 2.3452084860764444e-06
have O 0 4.959375843327507e-08
no O 0 9.406969070369087e-08
clinical O 0 1.1721904229489155e-06
expression O 0 2.6678722520045994e-07
of O 0 7.72255361880525e-07
A B-Disease 1 0.99967360496521
- I-Disease 1 0.9992309808731079
T I-Disease 1 0.9998544454574585
but O 0 4.9714312808646355e-06
may O 0 1.4358371117850766e-05
be O 0 2.071077142318245e-05
cancer B-Disease 1 0.9828402996063232
prone O 0 0.00011159986752318218
with O 0 4.8937696561779376e-08
a O 0 8.347721518475737e-07
moderate O 0 6.538990419358015e-06
increase O 0 1.9984737775757822e-07
in O 0 8.761339387319822e-08
in O 0 3.461275355221005e-07
vitro O 0 1.935177897394169e-05
radiosensitivity O 0 0.00023115814838092774
. O 0 3.0416429126489675e-06

We O 0 3.7324082313716644e-06
performed O 0 4.1019725358637515e-06
a O 0 1.110101948142983e-06
blind O 0 1.2514530681073666e-05
chromosomal O 0 8.701090700924397e-05
analysis O 0 1.633937245060224e-06
on O 0 4.6570376071031205e-06
G2 O 0 0.0005732771824114025
- O 0 5.59422405785881e-05
phase O 0 1.3940312783233821e-05
lymphocytes O 0 1.7263992049265653e-05
from O 0 2.290551464056989e-07
7 O 0 3.340771854709601e-06
unrelated O 0 4.9416608817409724e-05
A B-Disease 1 0.9988470077514648
- I-Disease 1 0.9994101524353027
T I-Disease 1 0.9998277425765991
patients O 0 4.24665049649775e-05
, O 0 1.1459570714578149e-07
13 O 0 6.950739361855085e-07
obligate O 0 4.518010882748058e-06
A B-Disease 1 0.9895350337028503
- I-Disease 1 0.9898102283477783
T I-Disease 1 0.9978299736976624
heterozygotes O 0 2.252799276902806e-05
( O 0 1.1421949608347859e-07
parents O 0 1.1533598609503315e-07
of O 0 1.4242060863978168e-08
the O 0 2.510748515760497e-07
patients O 0 1.5521916338911979e-06
) O 0 2.527967524201813e-08
, O 0 1.5414091336651836e-08
and O 0 3.912592916321955e-08
14 O 0 2.808075407756405e-07
normal O 0 2.9903722520430165e-07
controls O 0 6.174945497150475e-07
following O 0 4.837613118979789e-07
X O 0 1.7465408745920286e-05
- O 0 1.4699697885589558e-06
irradiation O 0 2.373415952661162e-07
with O 0 2.2532590904233984e-08
1 O 0 3.1935607580635406e-07
Gy O 0 7.697033652220853e-06
in O 0 3.72506470114331e-08
order O 0 2.453655412182343e-08
to O 0 1.1569993851878735e-08
evaluate O 0 2.0524167609892174e-07
this O 0 1.782498415536793e-08
cytogenetic O 0 9.693267202237621e-06
method O 0 7.593726536470058e-08
as O 0 3.728625586063572e-08
a O 0 6.66255459691456e-08
tool O 0 3.523889233747468e-07
for O 0 1.7654150141765967e-08
detection O 0 1.4167899280437268e-06
of O 0 1.294345679525577e-07
ATM O 0 7.32930566300638e-05
carriers O 0 5.178133142180741e-05
. O 0 8.952663847594522e-06

Both O 0 3.720639506354928e-05
A B-Disease 1 0.9968478083610535
- I-Disease 1 0.996589183807373
T I-Disease 1 0.9980005621910095
homozygotes O 0 0.0003024796023964882
and O 0 6.424915000025067e-07
heterozygotes O 0 1.9009041352546774e-05
showed O 0 4.755909685627557e-06
significantly O 0 1.8729211888057762e-06
increased O 0 5.793377795271226e-07
levels O 0 3.2309942525898805e-06
of O 0 1.3416675983535242e-06
radiation O 1 0.9632948040962219
- O 0 0.04851735010743141
induced O 0 0.004007635172456503
chromatid O 0 0.025624914094805717
damage O 0 0.0005498991813510656
relative O 0 1.0600386985970545e-06
to O 0 2.213743677259572e-08
that O 0 1.9079443802638707e-08
of O 0 7.15416632601773e-08
normal O 0 6.887039489811286e-06
controls O 0 4.8416000936413184e-05
. O 0 8.990190508484375e-06

These O 0 4.5975866669323295e-07
results O 0 2.2922151856619166e-06
show O 0 7.292472332665056e-07
that O 0 1.7506575744619113e-08
the O 0 2.875862321616296e-07
G2 O 0 0.0004369602247606963
- O 0 6.803048017900437e-05
phase O 0 1.389997032674728e-05
chromosomal O 0 0.00018817363888956606
radiosensitivity O 0 4.27488521381747e-05
assay O 0 2.264639533677837e-06
can O 0 2.8289923292845742e-08
be O 0 3.809336401872088e-09
used O 0 6.565404664371499e-09
for O 0 3.4858094188905397e-09
the O 0 3.4432098061643046e-08
detection O 0 2.6626005364960292e-06
of O 0 8.148368237925752e-07
A B-Disease 1 0.9992597699165344
- I-Disease 1 0.9982913136482239
T I-Disease 1 0.998737633228302
heterozygotes O 0 0.0005957794492132962
. O 0 1.3706128811463714e-05

In O 0 2.177180931539624e-06
combination O 0 8.139289093378466e-06
with O 0 6.434542001443333e-07
molecular O 0 4.905376408714801e-05
genetic O 0 2.212169965787325e-05
analyses O 0 1.55084228481428e-06
, O 0 6.961393239635072e-08
this O 0 3.2949472483778663e-08
test O 0 4.0656530586602457e-07
may O 0 1.0205813794073038e-07
be O 0 2.294581191719658e-09
of O 0 1.3034838763914536e-09
value O 0 8.529892348008161e-09
in O 0 2.0628732499972102e-08
studies O 0 3.8017603287698876e-08
of O 0 1.8309469496102793e-08
familial B-Disease 0 9.037298877956346e-05
and I-Disease 0 1.2599305136973271e-06
sporadic I-Disease 0 0.00059770472580567
cancers I-Disease 1 0.966695249080658
aimed O 0 4.991098649043124e-06
at O 0 1.0051217032014392e-05
determination O 0 6.473250095950789e-07
of O 0 2.8843929911204214e-08
the O 0 1.1310756065086025e-07
potential O 0 2.924618627275777e-07
involvement O 0 5.0958198016815e-07
of O 0 1.060249488205045e-07
ATM O 0 0.0008822393137961626
mutations O 0 0.0010354438563808799
in O 0 3.539626413839869e-05
tumor B-Disease 1 0.9965494871139526
risk O 0 0.00011040674871765077
or O 0 6.157944199003396e-07
development O 0 8.625250416116614e-07
. O 0 8.650828249301412e-07
. O 0 3.388365485079703e-06

Ataxia B-Disease 1 0.9998195767402649
- I-Disease 1 0.9974634647369385
telangiectasia I-Disease 1 0.9975560903549194
: O 0 2.1133298560016556e-06
identification O 0 4.994561209059611e-07
and O 0 1.3505494678156538e-07
detection O 0 7.242719675559783e-06
of O 0 3.9111387195589487e-07
founder O 0 0.00010579998343018815
- O 0 0.00010674098302843049
effect O 0 2.2188580715010175e-06
mutations O 0 1.5746682038297877e-06
in O 0 2.4287771793751745e-08
the O 0 2.4478778115621935e-08
ATM O 0 2.147936811525142e-06
gene O 0 8.672950571053661e-07
in O 0 1.8801534906742745e-07
ethnic O 0 3.307569329535909e-07
populations O 0 2.3826105461921543e-06
. O 0 3.1633474009140627e-06

To O 0 8.685749719461455e-08
facilitate O 0 1.7430453169708926e-07
the O 0 2.6802536012837663e-07
evaluation O 0 4.3967398255517764e-07
of O 0 2.715291280708243e-08
ATM O 0 1.131484896177426e-05
heterozygotes O 0 5.5719528972986154e-06
for O 0 5.923528334506045e-08
susceptibility O 0 6.7644041337189265e-06
to O 0 5.8124591362229694e-08
other O 0 7.121851126612455e-07
diseases O 1 0.9962679743766785
, O 0 1.9259279326888645e-07
such O 0 1.826657012315991e-07
as O 0 0.0010628878371790051
breast B-Disease 1 0.9998942613601685
cancer I-Disease 1 0.9992803931236267
, O 0 1.4858353836189053e-07
we O 0 2.9845026006114495e-08
have O 0 7.848728778014902e-09
attempted O 0 6.653817763435654e-08
to O 0 4.701588007804958e-09
define O 0 7.112505073791908e-08
the O 0 3.3421528655708244e-08
most O 0 3.305030560341038e-08
common O 0 4.2462292526579404e-07
mutations O 0 9.956244184650132e-07
and O 0 1.6444495543055382e-08
their O 0 3.1540732692292295e-08
frequencies O 0 4.4178159441798925e-06
in O 0 1.6137519196490757e-05
ataxia B-Disease 1 0.9999054670333862
- I-Disease 1 0.9990195035934448
telangiectasia I-Disease 1 0.9995338916778564
( O 0 0.00011374214227544144
A B-Disease 1 0.9995172023773193
- I-Disease 1 0.9978528022766113
T I-Disease 1 0.9991206526756287
) O 0 4.889785714112804e-07
homozygotes O 0 1.03408037830377e-05
from O 0 7.610240970734594e-08
10 O 0 1.4677408444185858e-07
ethnic O 0 2.1443499065298965e-07
populations O 0 2.214655296484125e-06
. O 0 2.588632924016565e-06

Both O 0 2.464392309775576e-06
genomic O 0 4.4638101826421916e-05
mutations O 0 3.081729664700106e-05
and O 0 9.517874133280202e-08
their O 0 2.024506073894372e-08
effects O 0 1.1423707064750488e-06
on O 0 2.22008694095166e-07
cDNA O 0 4.163774747212301e-07
were O 0 2.113903008194029e-07
characterized O 0 3.177408507326618e-05
. O 0 2.2916447051102296e-06

Protein O 0 7.696717511862516e-05
- O 0 5.2912149840267375e-05
truncation O 0 1.922726005432196e-05
testing O 0 2.9868201636418235e-06
of O 0 1.3924355890537754e-08
the O 0 3.223571809485293e-08
entire O 0 3.995790223143558e-07
ATM O 0 3.860006017930573e-06
cDNA O 0 1.7428487808501814e-06
detected O 0 1.836820774769876e-05
92 O 0 1.703734596958384e-06
( O 0 8.031427256582901e-08
66 O 0 1.0950448086077813e-06
% O 0 2.3229324241924587e-08
) O 0 2.8629511206190728e-08
truncating O 0 5.613721896224888e-06
mutations O 0 5.548780791286845e-06
in O 0 1.0096036362483574e-07
140 O 0 3.468902320946654e-07
mutant O 0 3.1936326649883995e-06
alleles O 0 3.727215016624541e-06
screened O 0 1.846367376856506e-05
. O 0 3.042182243007119e-06

The O 0 4.012246790807694e-06
haplotyping O 0 0.00034964436781592667
of O 0 8.08838990451477e-07
patients O 0 4.7308076318586245e-06
with O 0 1.261370528027328e-07
identical O 0 6.844623567303643e-05
mutations O 0 0.00017187971388921142
indicates O 0 1.1122340310976142e-06
that O 0 8.738870960200984e-09
almost O 0 1.5076738080210816e-08
all O 0 3.05243386122811e-09
of O 0 8.444549948194435e-09
these O 0 4.487570759437176e-09
represent O 0 1.7892871184699288e-08
common O 0 3.253735485486686e-07
ancestry O 0 4.1760341673580115e-07
and O 0 2.4074972770904424e-07
that O 0 3.1785138077111696e-08
very O 0 1.5623751892235305e-07
few O 0 1.5948654663588968e-07
spontaneously O 0 5.22247046319535e-06
recurring O 0 4.758062641485594e-05
ATM O 0 0.0003597001195885241
mutations O 0 0.00011970582272624597
exist O 0 9.826795576373115e-06
. O 0 6.559907888004091e-06

Assays O 0 0.00012004852760583162
requiring O 0 1.388543751090765e-05
minimal O 0 1.02463109215023e-05
amounts O 0 8.92838954769104e-07
of O 0 6.672652119732447e-08
genomic O 0 2.7407040761318058e-06
DNA O 0 1.3014396245125681e-06
were O 0 3.897926248441763e-08
designed O 0 1.346518843092781e-07
to O 0 5.137493985785113e-09
allow O 0 1.4912860279991946e-08
rapid O 0 1.049965362653893e-06
screening O 0 6.452817160607083e-07
for O 0 3.821024918693183e-08
common O 0 7.320972486013488e-07
ethnic O 0 9.390922173224681e-07
mutations O 0 0.00011851642921101302
. O 0 5.6347639656451065e-06

These O 0 1.4019354921401828e-06
rapid O 0 5.0476832257118076e-05
assays O 0 4.3404965254012495e-05
detected O 0 0.00011327066749799997
mutations O 0 1.5816282029845752e-05
in O 0 2.8619035674637416e-07
76 O 0 2.203960548285977e-06
% O 0 6.11626020941003e-08
of O 0 6.813570507802069e-08
Costa O 0 4.217990499455482e-05
Rican O 0 3.358881440362893e-05
patients O 0 4.322034783399431e-06
( O 0 4.3241264791049616e-08
3 O 0 1.2816693129025225e-07
) O 0 1.4496364109106707e-08
, O 0 1.9145314666957347e-08
50 O 0 3.8847595362767606e-08
% O 0 8.87684414863088e-09
of O 0 2.1249933368494567e-08
Norwegian O 0 7.520200597355142e-05
patients O 0 3.922407358913915e-06
( O 0 2.1092045443538154e-08
1 O 0 7.559549430879997e-08
) O 0 9.425716207545065e-09
, O 0 1.6101596500561755e-08
25 O 0 4.7821561821592695e-08
% O 0 9.385316523946585e-09
of O 0 2.391017694947095e-08
Polish O 0 0.0022499242331832647
patients O 0 8.9849709183909e-06
( O 0 3.245899904413818e-08
4 O 0 2.2709451741320663e-07
) O 0 1.0325502231012251e-08
, O 0 9.714075765998587e-09
and O 0 1.7513757555320808e-08
14 O 0 1.7318690481715748e-07
% O 0 9.425896507764264e-09
of O 0 3.692707650770899e-08
Italian O 0 0.00021309388102963567
patients O 0 1.107122534449445e-05
( O 0 3.999941711185784e-08
1 O 0 1.7613713509945228e-07
) O 0 1.249652825663361e-08
, O 0 9.259746747147801e-09
as O 0 1.8161337322908366e-08
well O 0 3.006327631283057e-08
as O 0 9.734183947784913e-08
in O 0 1.556863082896598e-07
patients O 0 6.25738721282687e-07
of O 0 4.1815056306404585e-08
Amish O 0 1.0216121154371649e-05
/ O 0 2.441457036184147e-05
Mennonite O 0 1.342042196483817e-05
and O 0 6.609855063288705e-07
Irish O 0 3.0300241633085534e-05
English O 0 5.994775619910797e-06
backgrounds O 0 1.63081622304162e-05
. O 0 1.262718524230877e-05

Additional O 0 1.4180403695718269e-06
mutations O 0 2.1011052012909204e-05
were O 0 3.7435802369145676e-07
observed O 0 1.1407051943024271e-06
in O 0 1.56744036416967e-07
Japanese O 0 1.4723477761435788e-06
, O 0 1.7320623157957016e-07
Utah O 0 1.2785358194378205e-06
Mormon O 0 1.3834670653523062e-07
, O 0 2.596841319757459e-08
and O 0 2.512052965641942e-08
African O 0 4.958420731782098e-07
American O 0 5.616977887257235e-06
patients O 0 2.572016092017293e-05
. O 0 2.9187217478465755e-06

These O 0 3.4822170391635154e-07
assays O 0 3.4027427773253294e-06
should O 0 6.065631197316179e-08
facilitate O 0 8.430890119370815e-08
screening O 0 2.8040074084856315e-06
for O 0 6.816104587414884e-07
A B-Disease 1 0.9967029690742493
- I-Disease 1 0.9876002073287964
T I-Disease 1 0.9964386224746704
heterozygotes O 0 1.6655898434692062e-05
in O 0 2.420407270165015e-07
the O 0 1.775776752310776e-07
populations O 0 5.919862928749353e-07
studied O 0 3.4134232009819243e-06
. O 0 2.966914678381727e-07
. O 0 1.972358859347878e-06

The O 0 0.0001275389950023964
von B-Disease 1 0.9591454267501831
Hippel I-Disease 1 0.9848930835723877
- I-Disease 1 0.983156144618988
Lindau I-Disease 1 0.967807948589325
tumor I-Disease 1 0.5682525634765625
suppressor O 0 0.0001444297085981816
gene O 0 6.185582151374547e-06
is O 0 2.3315644170907035e-07
required O 0 6.610681424490394e-08
for O 0 6.420675902063522e-08
cell O 0 2.6834712116396986e-05
cycle O 0 1.1769187949539628e-05
exit O 0 9.45464944379637e-06
upon O 0 4.9884861255122814e-06
serum O 0 0.0004224067961331457
withdrawal O 0 0.00013253760698717088
. O 0 8.193985195248388e-06

The O 0 2.378789577051066e-05
inactivation O 0 0.00786388386040926
of O 0 2.7272815259493655e-06
the O 0 3.082114926655777e-05
von B-Disease 1 0.9920346140861511
Hippel I-Disease 1 0.9938522577285767
- I-Disease 1 0.9917963743209839
Lindau I-Disease 1 0.9822116494178772
( I-Disease 0 2.2500895283883438e-05
VHL I-Disease 0 0.25749513506889343
) I-Disease 0 1.0724056664912496e-05
tumor I-Disease 0 0.05023258179426193
suppressor O 0 0.00022093893494457006
gene O 0 3.114153878414072e-05
predisposes O 0 5.7183828175766394e-05
affected O 0 1.5700585436206893e-06
individuals O 0 7.010414293517897e-08
to O 0 6.441835864734458e-08
the O 0 7.491650194424437e-06
human O 0 0.013381009921431541
VHL B-Disease 1 0.9997979998588562
cancer I-Disease 1 0.9999932050704956
syndrome I-Disease 1 0.9999864101409912
and O 0 7.124519470380619e-06
is O 0 1.0111865549333743e-06
associated O 0 2.1221312636043876e-06
with O 0 1.9942351627832977e-06
sporadic B-Disease 0 0.15941385924816132
renal I-Disease 1 0.9999574422836304
cell I-Disease 1 0.9997552037239075
carcinomas I-Disease 1 0.9999822378158569
( O 0 0.0001551606837892905
RCC B-Disease 1 0.997696578502655
) O 0 3.6782380448130425e-06
and O 0 1.1167084267071914e-05
brain B-Disease 1 0.9864556789398193
hemangioblastomas I-Disease 0 0.019816439598798752
. O 0 2.7765890990849584e-05

VHL O 0 0.2975772023200989
- O 0 0.0010462551144883037
negative O 0 2.3111466362024657e-05
786 O 0 0.000158029593876563
- O 0 0.0003785857406910509
0 O 0 1.213411997014191e-05
RCC B-Disease 0 0.021700769662857056
cells O 0 3.3738808724592673e-06
are O 0 8.362010106566231e-08
tumorigenic O 0 2.931662675109692e-05
in O 0 7.676404152334726e-07
nude O 0 0.00024420974659733474
mice O 0 3.202190782758407e-05
which O 0 8.431870668346164e-08
is O 0 8.50046717459918e-08
suppressed O 0 3.11893330717794e-07
by O 0 3.6747486831245624e-08
the O 0 1.6922425061238755e-07
reintroduction O 0 1.00413199106697e-05
of O 0 1.3066977544440306e-06
VHL B-Disease 0 0.04868478327989578
. O 0 1.463654734834563e-05

Remarkably O 0 0.001056353677995503
, O 0 9.424117024536827e-07
this O 0 7.466577045533995e-08
occurs O 0 2.3011266137018538e-07
without O 0 3.603796372431134e-08
affecting O 0 2.662684437382268e-07
the O 0 1.3693902189970686e-07
growth O 0 1.1316749350953614e-06
rate O 0 1.1544926792339538e-06
and O 0 8.292537501120023e-08
cell O 0 8.946859452407807e-06
cycle O 0 4.472944056033157e-06
profile O 0 8.966256928033545e-07
of O 0 1.636820456951682e-08
these O 0 3.034984530358997e-08
cells O 0 1.007327909974265e-06
in O 0 2.340330524930323e-07
culture O 0 4.242972863721661e-06
. O 0 3.490007429718389e-06

The O 0 5.86065061725094e-06
786 O 0 8.110193448374048e-05
- O 0 8.928596071200445e-05
0 O 0 2.037481408478925e-06
cell O 0 1.5117970178835094e-05
line O 0 9.925764970830642e-06
, O 0 1.0588691168322839e-07
like O 0 3.1762630214871024e-07
many O 0 2.634623967878724e-07
cancer B-Disease 1 0.8502282500267029
cells O 0 3.827819909929531e-06
, O 0 1.050488691589635e-07
fails O 0 6.276333124333178e-07
to O 0 1.3145951882620466e-08
exit O 0 1.2037428405164974e-06
the O 0 6.192288992679096e-07
cell O 0 3.422427107580006e-05
cycle O 0 1.0081514119519852e-05
upon O 0 2.386239884799579e-06
serum O 0 0.00015279003127943724
withdrawal O 0 7.342611934291199e-05
. O 0 5.342616532288957e-06

Here O 0 1.5547411749139428e-05
, O 0 3.4406699001010566e-07
it O 0 8.176159838058084e-08
is O 0 4.1036951614614736e-08
shown O 0 4.346908610841638e-08
that O 0 4.785182916577924e-09
reintroduction O 0 2.8439981747396814e-07
of O 0 1.5550876142356174e-08
the O 0 2.4323799152625725e-07
wild O 0 7.08887728251284e-06
- O 0 0.000339392339810729
type O 0 8.185474143829197e-05
VHL B-Disease 0 0.001044012838974595
gene O 0 7.158893367886776e-06
restores O 0 9.096994290302973e-06
the O 0 1.1016504686267581e-07
ability O 0 3.7119013995834393e-07
of O 0 8.53170035952644e-07
VHL O 0 0.305057555437088
- O 0 0.03572407364845276
negative O 0 0.00014349872071761638
RCC B-Disease 1 0.9988596439361572
cancer I-Disease 1 0.8767619132995605
cells O 0 4.3592802967395983e-07
to O 0 8.926421379840122e-09
exit O 0 1.077943124982994e-06
the O 0 2.1016553830577323e-07
cell O 0 1.5541438187938184e-05
cycle O 0 2.9458215067279525e-06
and O 0 7.901092402562426e-08
enter O 0 1.5055464928082074e-06
G0 O 0 0.0003514174895826727
/ O 0 5.287310705170967e-05
quiescence O 0 0.0001272837253054604
in O 0 3.2069576718640747e-06
low O 0 0.00039515530806966126
serum O 0 0.0004280439461581409
. O 0 8.426374733971898e-06

Both O 0 2.0672217942774296e-05
VHL O 0 0.0533326230943203
- O 0 0.00042507241596467793
positive O 0 2.7797702841780847e-06
and O 0 1.4393523315447965e-06
VHL O 0 0.061283089220523834
- O 0 0.001628468162380159
negative O 0 1.0684315384423826e-05
RCC B-Disease 0 0.025737429037690163
cells O 0 2.5180959255521884e-06
exit O 0 1.8570244719740003e-06
the O 0 2.596138983790297e-07
cell O 0 1.7954729628399946e-05
cycle O 0 4.058833383169258e-06
by O 0 7.074257268868678e-08
contact O 0 4.815969532501185e-06
inhibition O 0 3.411953366594389e-05
. O 0 5.571214387600776e-06

The O 0 2.3345277440967038e-05
cyclin O 0 0.0013130151201039553
- O 0 0.00015004986198619008
dependent O 0 1.3737744666286744e-05
kinase O 0 7.765406189719215e-05
inhibitor O 0 4.141304816585034e-05
, O 0 5.432557372841984e-07
p27 O 0 3.288355583208613e-05
, O 0 2.401599203949445e-07
accumulates O 0 4.875369086221326e-06
upon O 0 3.915661750397703e-07
serum O 0 1.2979075108887628e-05
withdrawal O 0 2.390652070971555e-06
, O 0 1.6966628990644494e-08
only O 0 4.488486027298677e-09
in O 0 7.633323306777129e-09
the O 0 3.076927512779548e-08
presence O 0 1.4361627620473882e-07
of O 0 6.81868002061492e-08
VHL B-Disease 0 0.0002558807609602809
, O 0 9.414974755372896e-08
as O 0 4.601797698455812e-08
a O 0 1.84855579732357e-07
result O 0 1.5720272017460957e-07
of O 0 7.951886260570973e-09
the O 0 4.495445793395447e-08
stabilization O 0 1.0009597417592886e-06
of O 0 2.840416613025809e-08
the O 0 2.7601512897490466e-07
protein O 0 5.498637619893998e-06
. O 0 2.4431562906102045e-06

We O 0 2.9614236609631917e-06
propose O 0 2.218104782514274e-06
that O 0 8.127292261406183e-08
the O 0 7.411198339468683e-07
loss O 0 4.264775270712562e-05
of O 0 2.2226713269901666e-07
wild O 0 1.792769762687385e-05
- O 0 0.0017349140252918005
type O 0 0.0002704353246372193
VHL B-Disease 0 0.0013448891695588827
gene O 0 7.459852895408403e-06
results O 0 1.224712150360574e-06
in O 0 3.4119864267267985e-08
a O 0 1.6619155474018044e-07
specific O 0 2.000895733544894e-07
cellular O 0 0.001606566016562283
defect O 0 0.003742416389286518
in O 0 1.1398568631193484e-06
serum O 0 4.659492333303206e-05
- O 0 1.0806134014273994e-05
dependent O 0 1.1911937463082722e-06
growth O 0 9.609743756300304e-07
control O 0 1.158364852926752e-06
, O 0 6.986973488665171e-08
which O 0 1.1132468813457308e-07
may O 0 2.4964781459857477e-06
initiate O 0 2.128756204911042e-05
tumor B-Disease 1 0.6259203553199768
formation O 0 0.0003156562161166221
. O 0 5.993060312903253e-06

This O 0 4.44409533884027e-06
is O 0 2.3726133804302663e-06
corrected O 0 4.216562592773698e-05
by O 0 4.406612674756616e-08
the O 0 8.144175467350578e-08
reintroduction O 0 1.8153115206587245e-06
of O 0 1.2597331533470424e-07
wild O 0 2.3315753423958085e-05
- O 0 0.016629008576273918
type O 0 0.0038672613445669413
VHL B-Disease 0 0.37934330105781555
, O 0 6.686419965262758e-06
implicating O 0 0.002770790131762624
VHL B-Disease 0 0.013746533542871475
as O 0 1.1176972520843265e-06
the O 0 4.196418785795686e-07
first O 0 3.857341653201729e-06
tumor B-Disease 0 0.0010202174307778478
suppressor O 0 3.10309519591101e-06
involved O 0 7.003504975955366e-08
in O 0 1.8117949807106015e-08
the O 0 3.52818609883343e-08
regulation O 0 6.554440687978058e-07
of O 0 6.967982812966511e-08
cell O 0 2.8314694645814598e-05
cycle O 0 4.981350230082171e-06
exit O 0 2.7498360850586323e-06
, O 0 1.0075279277543814e-07
which O 0 2.0226456953764682e-08
is O 0 2.3028162488003545e-08
consistent O 0 7.304333138336006e-08
with O 0 1.7342831171163198e-08
its O 0 8.63190905420197e-08
gatekeeper O 0 8.049943062360398e-06
function O 0 2.0131820122060162e-07
in O 0 2.2117100684226898e-07
the O 0 1.4054198800295126e-06
kidney O 1 0.8508365750312805
. O 0 9.376066714139597e-07
. O 0 2.521472197258845e-06

Piebaldism B-Disease 1 0.9976230263710022
with O 0 0.006992369890213013
deafness B-Disease 1 0.9999793767929077
: O 0 5.165439233678626e-06
molecular O 0 2.306120404682588e-05
evidence O 0 6.883230980747612e-07
for O 0 1.3838260315424122e-07
an O 0 7.68586414778838e-06
expanded O 0 0.010701296851038933
syndrome O 1 0.9998756647109985
. O 0 2.465763463987969e-05

In O 0 2.6437630822329083e-06
a O 0 1.0453334198246012e-06
South O 0 1.622237959963968e-06
African O 0 1.7656122963671805e-06
girl O 0 2.5834397092694417e-05
of O 0 3.408266593396547e-07
Xhosa O 0 0.0001686432515271008
stock O 0 0.00016360597510356456
with O 0 1.1929412721656263e-05
severe O 1 0.8861708045005798
piebaldism B-Disease 0 0.31048980355262756
and O 0 0.00038797620800323784
profound O 1 0.9940529465675354
congenital O 1 0.9999984502792358
sensorineural B-Disease 1 0.9999792575836182
deafness I-Disease 1 0.9999992847442627
we O 0 0.00210807123221457
identified O 0 4.4980937673244625e-05
a O 0 1.6358175116693019e-06
novel O 0 1.4268210861700936e-06
missense O 0 6.885725724714575e-06
substitution O 0 3.353513307047251e-07
at O 0 8.761111303101643e-07
a O 0 1.4883597998505138e-07
highly O 0 5.368360120883153e-07
conserved O 0 8.490888490086945e-07
residue O 0 4.934245225740597e-07
in O 0 1.7339454316811498e-08
the O 0 1.6191400220577634e-08
intracellular O 0 1.2391830068736454e-06
kinase O 0 1.1682174090310582e-06
domain O 0 2.420472071662516e-07
of O 0 4.09160456626978e-08
the O 0 8.919411129681976e-07
KIT O 0 0.0005607475759461522
proto O 0 0.008853152394294739
- O 0 0.0014443525578826666
oncogene O 0 0.0007625463185831904
, O 0 1.502961595178931e-06
R796G O 0 0.00010555430344538763
. O 0 5.467904884426389e-06

Though O 0 2.5364050088683143e-05
auditory B-Disease 0 0.0003713142650667578
anomalies I-Disease 0 0.01144937239587307
have O 0 9.573402621754212e-07
been O 0 1.0719307965700864e-06
observed O 0 1.4502388694381807e-06
in O 0 3.2768008395578363e-07
mice O 0 5.0575854402268305e-06
with O 0 2.0659295785208087e-07
dominant O 0 0.00025405993801541626
white O 0 0.00015872441872488707
spotting O 0 0.0006877338164485991
( O 0 1.9429478470556205e-06
W O 0 0.0027333705220371485
) O 0 7.352669229021558e-08
due O 0 5.962328373243508e-07
to O 0 1.5035979572530778e-07
KIT O 0 0.0011481308611109853
mutations O 0 0.0007824819185771048
, O 0 2.5496485250187106e-05
deafness B-Disease 1 0.9999861717224121
is O 0 5.3685425882576965e-06
not O 0 1.352754850358906e-07
typical O 0 6.2446938500215765e-06
in O 0 1.2812785143978545e-06
human O 0 4.780050403496716e-06
piebaldism B-Disease 0 0.0012363319983705878
. O 0 1.0510400898056105e-05

Thus O 0 5.42470161235542e-06
, O 0 3.3744044003469753e-07
the O 0 4.6485885718539066e-07
occurrence O 0 0.00021358065714593977
of O 0 3.172579454258084e-05
sensorineural B-Disease 1 0.999914288520813
deafness I-Disease 1 0.9999978542327881
in O 0 0.00019155710469931364
this O 0 4.444535989023279e-06
patient O 0 6.454424146795645e-05
extends O 0 1.3346117384571698e-06
considerably O 0 2.365638692936045e-06
the O 0 1.3176959612337669e-07
phenotypic O 0 4.6197565097827464e-06
range O 0 2.6162711037613917e-06
of O 0 3.4483238664506644e-07
piebaldism B-Disease 0 0.0001214009098475799
due O 0 3.6632479805120965e-06
to O 0 1.1568894109359462e-07
KIT O 0 2.668336128408555e-05
gene O 0 4.985808118362911e-06
mutation O 0 5.025439804740017e-06
in O 0 9.069849227216764e-08
humans O 0 1.9648052784759784e-07
and O 0 9.4194653854629e-08
tightens O 0 2.0352310457383282e-05
the O 0 1.3442337376545765e-07
clinical O 0 1.0529615792620461e-06
similarity O 0 2.49737269086836e-07
between O 0 3.413575200283958e-07
piebaldism B-Disease 0 6.744590064045042e-05
and O 0 7.46223420833303e-08
the O 0 3.004905479997433e-08
various O 0 1.2557975992422143e-07
forms O 0 1.2058307220286224e-05
of O 0 0.00033827853621914983
Waardenburg B-Disease 1 0.9997480511665344
syndrome I-Disease 1 0.99996018409729
. O 0 1.9149139916407876e-05
. O 0 1.5483887182199396e-05

Cycloheximide O 0 0.00046414887765422463
facilitates O 0 6.686694177915342e-06
the O 0 3.1583149961988966e-07
identification O 0 5.782591188108199e-07
of O 0 1.82351897137778e-07
aberrant O 0 3.056961941183545e-05
transcripts O 0 1.096924279408995e-05
resulting O 0 3.2582054245722247e-06
from O 0 1.7443089461721684e-07
a O 0 4.4995550751991686e-07
novel O 0 1.5350476587627782e-06
splice O 0 4.106852793483995e-05
- O 0 0.00011670815001707524
site O 0 1.220554349856684e-05
mutation O 0 1.0581566129985731e-05
in O 0 2.85432065538771e-07
COL17A1 O 0 5.994065941195004e-05
in O 0 5.376291483116802e-07
a O 0 5.524281732505187e-06
patient O 0 6.063891123631038e-05
with O 0 9.98038194666151e-06
generalized O 0 0.1665564477443695
atrophic B-Disease 1 0.9997679591178894
benign I-Disease 1 0.9994394183158875
epidermolysis I-Disease 1 0.99357670545578
bullosa I-Disease 1 0.9815857410430908
. O 0 0.00038654712261632085

Patients O 0 0.0017396738985553384
with O 0 7.222010026453063e-05
generalized O 1 0.6966683268547058
atrophic B-Disease 1 0.9998575448989868
benign I-Disease 1 0.9993669390678406
epidermolysis I-Disease 1 0.9922050833702087
bullosa I-Disease 1 0.9013251662254333
often O 0 2.246564872621093e-05
show O 0 1.5266241462086327e-05
decreased O 0 2.062302883132361e-05
expression O 0 2.2302674551610835e-06
of O 0 7.685692366976582e-07
type O 0 0.0018408404430374503
XVII O 0 0.27076393365859985
collagen O 0 0.0007670490304008126
, O 0 4.618971729541954e-07
a O 0 6.042549216545012e-07
transmembrane O 0 1.2289767255424522e-05
hemidesmosomal O 0 9.231381227436941e-06
protein O 0 2.3384922087643645e-07
encoded O 0 7.434715598719777e-08
by O 0 2.2696808343880548e-07
COL17A1 O 0 0.0007928631966933608
. O 0 6.359823146340204e-06

This O 0 1.7163047232315876e-06
report O 0 7.66110474614834e-07
documents O 0 2.780425631954131e-07
a O 0 6.341142011478951e-07
novel O 0 1.4593679225072265e-06
splice O 0 5.747401519329287e-05
- O 0 0.0001108646101783961
site O 0 1.1144657946715597e-05
mutation O 0 5.3416388254845515e-06
in O 0 1.6127637536555994e-07
COL17A1 O 0 2.9186185201979242e-05
in O 0 3.40197630066541e-07
a O 0 4.735773472930305e-06
patient O 0 0.00012070187221979722
with O 0 1.1292866474832408e-05
generalized O 0 0.06464385986328125
atrophic B-Disease 1 0.9998654127120972
benign I-Disease 1 0.9993770718574524
epidermolysis I-Disease 1 0.9930576086044312
bullosa I-Disease 1 0.9470614194869995
, O 0 5.3728040256828535e-06
and O 0 1.881064548570066e-07
applies O 0 1.918692049684978e-07
a O 0 3.0523719374286884e-07
new O 0 2.827924845405505e-07
methodology O 0 2.2857592796299286e-07
to O 0 1.2898671464256495e-08
define O 0 1.7409719532679446e-07
and O 0 5.202003450222037e-08
characterize O 0 6.711326818731322e-07
the O 0 8.862011924293256e-08
resulting O 0 3.673536923542997e-07
mRNA O 0 6.615657071051828e-07
splice O 0 2.2592406821786426e-05
variants O 0 3.20658837154042e-05
. O 0 7.3787118708423804e-06

Mutational O 0 0.0015819293912500143
analysis O 0 9.850073183770292e-06
of O 0 1.624992478355125e-06
COL17A1 O 0 0.0025127266999334097
identified O 0 1.3552999917010311e-05
a O 0 3.950110567529919e-06
maternally O 0 0.00031535059679299593
inherited O 0 0.43713682889938354
G O 0 0.008960741572082043
- O 0 5.993962986394763e-05
to O 0 5.584090558841126e-07
- O 0 0.00018405463197268546
T O 0 0.00018128822557628155
transversion O 0 9.445637260796502e-06
at O 0 1.0152020877285395e-06
the O 0 1.209386368827836e-07
- O 0 2.299804464200861e-06
1 O 0 1.4597003428207245e-07
position O 0 2.1426838259230863e-07
of O 0 3.8995398909946744e-08
exon O 0 3.444548201514408e-05
32 O 0 1.1146411452500615e-05
. O 0 2.890572659453028e-06

This O 0 3.9944603713593096e-07
acceptor O 0 5.805384716950357e-06
splice O 0 0.00010812871187226847
- O 0 0.0002729281550273299
site O 0 2.153360219381284e-05
mutation O 0 8.112089744827244e-06
led O 0 1.9182529342742782e-07
to O 0 8.401654483236598e-09
the O 0 4.40163141490757e-08
formation O 0 2.2398551209334983e-06
of O 0 3.2206465050421684e-08
aberrant O 0 3.170986019540578e-06
transcripts O 0 2.3679544938204344e-06
present O 0 4.1790823956944223e-07
at O 0 1.2394663826853503e-05
extremely O 0 4.31695043516811e-05
low O 0 0.0002653067058417946
levels O 0 6.025150651112199e-05
. O 0 4.315897513151867e-06

Based O 0 3.3855262699944433e-06
on O 0 2.1010632735851686e-06
our O 0 3.3102293173215003e-07
recent O 0 1.8259306671097875e-06
finding O 0 4.6489296323670715e-07
that O 0 1.2239480895459565e-07
cycloheximide O 0 5.0457292672945186e-05
stabilized O 0 9.16170101845637e-05
mutant O 0 7.069488219713094e-06
COL17A1 O 0 2.7157444492331706e-05
transcripts O 0 1.1611996342253406e-06
in O 0 1.0234937519726373e-07
keratinocytes O 0 2.694618615350919e-06
homozygous O 0 1.218050670104276e-06
for O 0 5.6353911759288167e-08
a O 0 2.229234041806194e-06
frameshift O 0 0.000576082500629127
mutation O 0 1.5356743460870348e-05
, O 0 1.0193110711043118e-07
the O 0 5.8157080928822324e-08
effects O 0 4.834025162381295e-07
of O 0 1.8653897981835144e-08
the O 0 8.75594352578446e-08
splice O 0 2.3340622647083364e-05
- O 0 3.548041058820672e-05
site O 0 1.8029978718914208e-06
mutation O 0 6.349789600790245e-07
on O 0 3.9464627121788e-08
splicing O 0 7.04280694208137e-07
of O 0 9.331093053788209e-08
COL17A1 O 0 3.370785998413339e-05
transcripts O 0 1.5563063016088563e-06
were O 0 4.406200915241243e-08
determined O 0 1.1622705642366782e-07
using O 0 7.868787577081093e-08
reverse O 0 4.496081146498909e-06
transcriptase O 0 9.008950655697845e-06
polymerase O 0 3.807282610068796e-06
chain O 0 2.978249995067017e-06
reaction O 0 2.83677650259051e-07
of O 0 5.932265789709845e-09
total O 0 1.9061474176851334e-08
RNA O 0 4.1924548099814274e-07
from O 0 3.058053010818185e-08
keratinocytes O 0 8.466356575809186e-07
incubated O 0 2.865188832856802e-07
for O 0 4.4770910534452923e-08
2 O 0 3.2415807709185174e-06
. O 0 1.7480203950981377e-06

5 O 0 2.2357840862241574e-05
h O 0 2.3271815734915435e-05
in O 0 2.997433057316812e-07
the O 0 7.604031537766787e-08
presence O 0 2.2397603061108384e-07
or O 0 1.5189776547686051e-07
absence O 0 3.644545927272702e-07
of O 0 5.7544692566580125e-08
10 O 0 5.213047984398145e-07
microg O 0 5.607111597782932e-05
cycloheximide O 0 6.852407386759296e-05
per O 0 4.2883921196334995e-06
ml O 0 0.000184659322258085
. O 0 2.7558216970646754e-06

Using O 0 1.1463619102869416e-06
this O 0 1.7316361322627927e-07
approach O 0 8.124129067255126e-07
, O 0 9.310968351883275e-08
an O 0 7.156212689096719e-08
abnormally O 0 4.065625398652628e-05
spliced O 0 1.3581128769146744e-05
transcript O 0 4.301166700315662e-05
was O 0 6.971997208893299e-06
identified O 0 2.231749505199332e-07
that O 0 2.0671024891782963e-09
contains O 0 6.486576609177064e-09
an O 0 4.427757716030101e-09
extra O 0 1.5731334457314006e-08
264 O 0 6.828180687534768e-08
bases O 0 5.15203915085749e-08
upstream O 0 1.3169723445116688e-07
from O 0 3.493138933663431e-08
exon O 0 3.5108648717141477e-06
32 O 0 3.1821963375477935e-07
, O 0 2.492789263897066e-08
resulting O 0 1.4301680550943274e-07
in O 0 8.469071133276884e-08
a O 0 1.5359379403889761e-06
premature O 0 5.782387961517088e-05
termination O 0 1.131204317061929e-05
codon O 0 7.435449333570432e-06
27 O 0 3.3419285045965808e-06
bp O 0 1.2691605661530048e-05
downstream O 0 1.4462348190136254e-06
from O 0 9.046524951372703e-08
the O 0 1.1606621797000116e-07
cryptic O 0 9.649751518736593e-06
splice O 0 5.415859413915314e-05
site O 0 5.3222673159325495e-05
. O 0 4.343231466918951e-06

Three O 0 4.6709769208064245e-07
other O 0 4.04763191852453e-08
splice O 0 1.3948026207799558e-05
variants O 0 2.8937222396052675e-06
, O 0 1.4666410663721763e-07
including O 0 2.5355150867767406e-08
one O 0 4.039988255044591e-08
derived O 0 3.422075423031856e-08
from O 0 3.676648674399985e-08
the O 0 2.0288586810579545e-08
skipping O 0 1.023710069603112e-06
of O 0 1.8894098730015685e-08
exon O 0 2.8288654903008137e-06
32 O 0 5.12715928380203e-07
, O 0 3.508543855446078e-08
were O 0 7.309503757824132e-08
also O 0 5.134014031682455e-07
identified O 0 5.730652446800377e-06
. O 0 1.6479920077472343e-06

These O 0 8.004707297004643e-07
results O 0 5.458224677568069e-06
indicate O 0 1.0488845418876735e-06
the O 0 1.4760620103970723e-07
usefulness O 0 1.922439196277992e-06
of O 0 1.6975150174403097e-07
cycloheximide O 0 0.0004143609548918903
treatment O 0 2.3806027456885204e-05
in O 0 2.5401141101610847e-07
evaluating O 0 6.423958893719828e-07
the O 0 2.877596330108645e-07
abnormal O 0 5.5373625400534365e-06
processing O 0 1.550054093968356e-07
of O 0 1.6983012329774283e-08
mRNA O 0 2.7601512897490466e-07
due O 0 4.919505727229989e-07
to O 0 2.6495245109003918e-08
splice O 0 1.4883322364767082e-05
- O 0 0.00011881968384841457
site O 0 2.785242577374447e-05
mutations O 0 1.612847154319752e-05
, O 0 2.5614431820031314e-07
because O 0 3.255740637087001e-07
( O 0 8.67123262082714e-08
i O 0 8.406079814449186e-07
) O 0 1.3495896844517574e-08
aberrant O 0 4.6195265213100356e-07
splicing O 0 1.050040509653627e-06
often O 0 1.703681249409783e-07
generates O 0 4.981703227713297e-07
a O 0 8.450899713352555e-07
premature O 0 4.0953975258162245e-05
termination O 0 1.0857939741981681e-05
codon O 0 4.621157586370828e-06
, O 0 9.816033497145327e-08
( O 0 5.6307388973664274e-08
ii O 0 3.8261099689407274e-05
) O 0 2.6284544318855296e-08
transcripts O 0 4.579649157676613e-07
with O 0 2.328839912024705e-07
premature O 0 7.747948984615505e-05
termination O 0 3.6437261314858915e-06
codons O 0 1.9915742086595856e-06
can O 0 6.429217336290094e-08
occur O 0 1.892281176196775e-07
at O 0 1.677538080002705e-06
low O 0 2.1722409655922092e-05
or O 0 8.966855489234149e-07
undetectable O 0 0.00019025236542802304
levels O 0 3.193032625858905e-06
due O 0 5.816617658638279e-07
to O 0 3.2488667756069844e-08
nonsense O 0 5.307130322762532e-06
- O 0 1.3429746559268096e-06
mediated O 0 1.242401594936382e-06
mRNA O 0 3.680746942791302e-07
decay O 0 3.392365215404425e-06
, O 0 8.674706464262272e-08
and O 0 5.631995847465987e-08
( O 0 1.0492131252703985e-07
iii O 0 4.12886765843723e-05
) O 0 2.9429660486357534e-08
the O 0 7.027831827599584e-08
levels O 0 3.5269923159830796e-07
of O 0 3.3623814843508626e-09
these O 0 3.221320543644879e-09
transcripts O 0 1.2845693220242538e-07
can O 0 7.501604670778761e-09
be O 0 1.023676876599211e-08
increased O 0 5.159138893873205e-08
by O 0 9.304559256406719e-08
cycloheximide O 0 0.00012877128028776497
. O 0 2.5970898605010007e-06

A O 0 2.59377047768794e-05
deletion O 0 0.00012852397048845887
mutation O 0 3.082635157625191e-05
in O 0 6.999704851295974e-07
COL17A1 O 0 0.00012005356984445825
in O 0 7.030298547761049e-07
five O 0 5.088487000648456e-07
Austrian O 0 0.00027142054750584066
families O 0 5.660976967192255e-07
with O 0 1.663518196437508e-05
generalized O 0 0.32436829805374146
atrophic B-Disease 1 0.9997664093971252
benign I-Disease 1 0.999221682548523
epidermolysis I-Disease 1 0.9951203465461731
bullosa I-Disease 1 0.9778203964233398
represents O 0 3.9990558434510604e-05
propagation O 0 1.3731157196161803e-05
of O 0 2.606215048217564e-07
an O 0 9.105370963879977e-07
ancestral O 0 4.753146640723571e-05
allele O 0 9.163990034721792e-05
. O 0 1.0191706678597257e-05

Patients O 0 0.0010940415086224675
with O 0 4.7844161599641666e-05
generalized O 1 0.5578939318656921
atrophic B-Disease 1 0.9997923970222473
benign I-Disease 1 0.9994770884513855
epidermolysis I-Disease 1 0.9960683584213257
bullosa I-Disease 1 0.9892557859420776
, O 0 5.500021416082745e-06
a O 0 1.964860985026462e-06
usually O 0 9.121388870880764e-07
nonlethal O 0 7.92688751971582e-06
form O 0 2.3817335659259697e-06
of O 0 2.776257588266162e-06
junctional B-Disease 1 0.8625909090042114
epidermolysis I-Disease 1 0.9750493764877319
bullosa I-Disease 1 0.9243912100791931
, O 0 5.45647617400391e-06
have O 0 7.547115501438384e-07
generalized O 0 7.95391752035357e-05
blistering B-Disease 0 0.05657941848039627
, O 0 5.199816223466769e-05
nail B-Disease 1 0.9997078776359558
dystrophy I-Disease 1 0.9995235204696655
, O 0 4.4618776882998645e-05
patchy B-Disease 1 0.9660321474075317
alopecia I-Disease 1 0.9998816251754761
, O 0 2.751348256424535e-05
and O 0 8.815895125735551e-05
dental B-Disease 1 0.9991658926010132
abnormalities I-Disease 1 0.9997115731239319
. O 0 5.1568880735430866e-05

Skin B-Disease 1 0.9715476036071777
fragility I-Disease 0 0.012154852040112019
in O 0 2.3453249013982713e-06
most O 0 4.885068847215734e-07
cases O 0 6.520841679957812e-07
is O 0 6.645826999829296e-08
due O 0 3.5013243859793874e-07
to O 0 1.2495718237914843e-08
mutations O 0 2.9790098210469296e-07
in O 0 7.1838219817266236e-09
the O 0 2.0947394929748953e-08
gene O 0 5.361576995710493e-07
encoding O 0 1.9249489469075343e-06
type O 0 0.000589509611018002
XVII O 0 0.430514931678772
collagen O 0 0.004210806451737881
( O 0 3.438889507378917e-06
COL17A1 O 0 0.0013254716759547591
) O 0 2.1653613657690585e-06
. O 0 2.4495416255376767e-06

Recently O 0 0.00011684065975714475
, O 0 5.976469310553512e-07
we O 0 2.3567567097870779e-07
reported O 0 1.8656887732504401e-06
five O 0 1.9945800033838168e-07
Austrian O 0 9.351847256766632e-05
families O 0 2.8026175868944847e-07
with O 0 4.915734734822763e-06
generalized O 0 0.0395459420979023
atrophic B-Disease 1 0.9997809529304504
benign I-Disease 1 0.9992291927337646
epidermolysis I-Disease 1 0.991424024105072
bullosa I-Disease 1 0.9489999413490295
who O 0 1.4130848285276443e-05
share O 0 1.0462371164976503e-06
the O 0 6.781248202969437e-07
same O 0 4.22715675085783e-06
COL17A1 O 0 0.0091673219576478
mutation O 0 0.0004088949353899807
. O 0 9.520425919617992e-06

Affected O 0 2.072294410027098e-05
individuals O 0 2.889850918563752e-07
in O 0 2.0913407183797972e-07
three O 0 5.732843888495154e-08
families O 0 1.7980795519179082e-08
are O 0 1.075147615381411e-08
homozygous O 0 3.235874146412243e-07
for O 0 2.6230356553469392e-08
4003delTC O 0 4.677503966377117e-06
, O 0 4.555947086259948e-08
whereas O 0 7.857224915142069e-08
those O 0 5.2881850010066955e-09
in O 0 2.9711836546653103e-08
two O 0 3.255063418805548e-08
others O 0 6.730735435667157e-08
are O 0 4.730302549660337e-08
compound O 0 2.17833567148773e-05
heterozygotes O 0 0.00012819898256566375
. O 0 4.9153127292811405e-06

To O 0 4.7317101348198776e-07
determine O 0 1.1595020623644814e-06
if O 0 2.184375631486546e-07
the O 0 9.451139248994878e-08
occurrence O 0 7.196844762802357e-06
of O 0 1.1980036163095065e-07
4003delTC O 0 2.312776086910162e-05
in O 0 9.510252141353703e-08
these O 0 1.4215600252498461e-08
unrelated O 0 3.129933475065627e-06
families O 0 4.8833172172635386e-08
signifies O 0 6.200413622536871e-07
propagation O 0 5.4700200280422e-07
of O 0 1.7927511919424433e-08
an O 0 9.736803008308925e-08
ancestral O 0 1.5598263871652307e-06
allele O 0 3.414930688450113e-06
or O 0 3.816869877937279e-07
a O 0 1.7840072814578889e-06
mutational O 0 0.00015715713379904628
hot O 0 8.412734314333647e-05
spot O 0 9.496549864707049e-06
, O 0 8.236217041712734e-08
haplotypes O 0 1.0705863360271906e-06
were O 0 6.524598461510323e-08
determined O 0 1.2190253073640633e-07
for O 0 1.892944823111975e-08
polymorphisms O 0 2.5297094907728024e-06
both O 0 8.752053304306173e-08
within O 0 5.639164442072797e-07
and O 0 1.2145291066190111e-06
flanking O 0 0.0025638856459409
COL17A1 O 0 0.1460178941488266
. O 0 3.774312062887475e-05

Five O 0 1.258933207282098e-05
intragenic O 0 0.00011387724953237921
polymorphisms O 0 1.2153576790296938e-05
were O 0 1.0100774261445622e-07
chosen O 0 9.794582922495465e-08
based O 0 6.578444100568959e-08
on O 0 2.9574624704764574e-07
their O 0 1.7806269170250744e-07
informativeness O 0 0.0005178097053430974
. O 0 5.3692797337134834e-06

One O 0 8.837391192173527e-07
of O 0 5.3147914513829164e-08
these O 0 2.0375455989096736e-08
, O 0 5.261375335408047e-08
not O 0 2.1511084469238995e-08
previously O 0 2.232242195532308e-06
reported O 0 3.0874857657181565e-06
, O 0 2.489942829697611e-08
was O 0 3.454568513916456e-06
2988 O 0 4.0418490243609995e-06
A O 0 7.025526542747684e-07
or O 0 2.644910352955776e-07
C O 0 1.6823829582790495e-06
that O 0 3.6976461892379575e-09
introduces O 0 8.063260992230425e-08
a O 0 1.1541917643853594e-07
new O 0 1.3455394309858093e-07
restriction O 0 5.837212313508644e-08
site O 0 3.6956004123567254e-07
for O 0 6.694872922707873e-08
Eco0109 O 0 2.2070644263294525e-05
I O 0 6.16238612565212e-05
. O 0 3.241772446926916e-06

All O 0 5.800829967483878e-07
the O 0 1.2174793937447248e-06
4003delTC O 0 3.152310091536492e-05
alleles O 0 3.0365274596988456e-06
showed O 0 2.046519284704118e-06
the O 0 5.9319066991747604e-08
same O 0 7.660162992806363e-08
haplotype O 0 3.3261831049458124e-06
for O 0 1.0726405541561235e-08
these O 0 8.830421727168414e-09
five O 0 2.9841672244401707e-07
polymorphic O 0 2.619526094349567e-05
markers O 0 7.411141996271908e-05
. O 0 6.23272262600949e-06

Fourteen O 0 3.929222657461651e-05
microsatellite O 0 0.0002198919391958043
polymorphisms O 0 2.6224957764497958e-05
were O 0 1.389822443798039e-07
selected O 0 8.129168094228589e-08
based O 0 9.85247936569067e-08
on O 0 1.6854424700341042e-07
their O 0 8.044873567314426e-08
high O 0 3.574081347323954e-05
heterozygosity O 0 1.4144612578093074e-05
and O 0 3.8928963164153174e-08
their O 0 3.234719869738001e-08
location O 0 1.3324192877917085e-06
within O 0 7.843057687750843e-07
10q23 O 0 5.2822611905867234e-05
- O 0 0.00010562982788542286
q25 O 0 8.502206765115261e-05
near O 0 8.32143341540359e-05
COL17A1 O 0 0.0015948464861139655
. O 0 8.943848115450237e-06

Three O 0 2.791762653941987e-06
families O 0 4.350081610482448e-07
shared O 0 2.725435479078442e-06
microsatellite O 0 0.00026493892073631287
polymorphisms O 0 5.652978506986983e-05
covering O 0 2.355513242946472e-05
at O 0 9.218018021783791e-06
most O 0 4.1052106780625763e-07
19 O 0 1.958552729774965e-06
cM O 0 4.270166300557321e-06
, O 0 4.721558966025441e-08
whereas O 0 1.016011310639442e-07
the O 0 6.785467121517286e-08
others O 0 4.5108112800562594e-08
shared O 0 8.0245364131315e-08
smaller O 0 6.034244961483637e-07
regions O 0 5.336661956789612e-07
consistent O 0 1.099503606383223e-06
with O 0 2.3734726539714757e-07
cross O 0 4.721473487734329e-06
- O 0 1.4927771189832129e-05
over O 0 1.3264650533528766e-07
events O 0 6.505636207521093e-08
during O 0 2.8978681143598806e-07
passage O 0 9.352707053267295e-08
of O 0 8.163892672996553e-09
this O 0 1.6496960242307068e-08
mutation O 0 1.618109592982364e-07
through O 0 1.2460874110331588e-08
several O 0 6.690583376212089e-08
generations O 0 1.9482286006677896e-06
. O 0 1.7811614725360414e-06

These O 0 1.7360953279421665e-06
results O 0 1.1420153896324337e-05
indicate O 0 2.2590979824599344e-06
that O 0 1.4846823148673138e-07
4003delTC O 0 3.427332922001369e-05
occurs O 0 5.847307420481229e-07
on O 0 1.0951454498808744e-07
a O 0 1.1222542894984144e-07
single O 0 2.825692604346841e-07
ancestral O 0 3.8073808354965877e-06
allele O 0 7.501773779949872e-06
. O 0 7.361572329500632e-07
. O 0 1.841736889218737e-06

The O 0 1.0009262041421607e-05
haptoglobin O 0 0.0009983000345528126
- O 0 0.00012582597264554352
gene O 0 9.601658348401543e-06
deletion O 0 2.211860009992961e-05
responsible O 0 5.0907133299915586e-06
for O 0 1.0113186590388068e-06
anhaptoglobinemia B-Disease 0 0.0025269142352044582
. O 0 7.69866346672643e-06

We O 0 1.7096820101869525e-06
have O 0 9.0173422506723e-08
found O 0 1.2401791593674716e-07
an O 0 5.589297202845955e-08
allelic O 0 1.3729742022405844e-05
deletion O 0 8.772458386374637e-06
of O 0 1.3349614391700015e-07
the O 0 1.4865371440464514e-06
haptoglobin O 0 8.168663043761626e-05
( O 0 1.9153009134242893e-07
Hp O 0 1.0507386605240754e-06
) O 0 2.8419989916983468e-08
gene O 0 1.2235909707669634e-07
from O 0 2.575738200505384e-08
an O 0 2.5101037692820682e-08
individual O 0 5.369630784457513e-08
with O 0 1.0513241477383417e-06
anhaptoglobinemia B-Disease 0 0.0033795179333537817
. O 0 1.4315548469312489e-05

The O 0 3.3119106319645653e-06
Hp O 0 1.6559288269490935e-05
gene O 0 9.463038622925524e-06
cluster O 0 1.4299555914476514e-05
consists O 0 7.79797346694977e-07
of O 0 9.873360795609187e-08
coding O 0 1.304340003116522e-05
regions O 0 6.123129878687905e-07
of O 0 4.0927751854269445e-08
the O 0 2.2624648465807695e-07
alpha O 0 9.146406227955595e-07
chain O 0 2.0894337922072737e-06
and O 0 7.077064623217666e-08
beta O 0 8.309659733640729e-07
chain O 0 1.2225277714605909e-06
of O 0 1.2961312911841105e-08
the O 0 1.1185636594746029e-07
haptoglobin O 0 1.6744161257520318e-05
gene O 0 6.640302672167309e-07
( O 0 5.1943985113211966e-08
Hp O 0 5.488680585585826e-07
) O 0 7.670511337209973e-09
and O 0 7.482484853937876e-09
of O 0 5.175842421323296e-09
the O 0 7.366411836073894e-08
alpha O 0 3.7067863445372495e-07
chain O 0 4.1890896795848676e-07
and O 0 1.172843600016904e-08
beta O 0 3.5016449828617624e-07
chain O 0 1.243126916961046e-06
of O 0 1.4370966638921345e-08
the O 0 1.9335543299803248e-07
haptoglobin O 0 0.00010411579569336027
- O 0 4.752575478050858e-05
related O 0 1.8474876242180471e-06
gene O 0 1.7083910961446236e-06
( O 0 1.6741039132739388e-07
Hpr O 0 2.0848856365773827e-05
) O 0 8.178359678367997e-08
, O 0 3.799353720523868e-08
in O 0 5.0924047201306166e-08
tandem O 0 5.34324362888583e-06
from O 0 1.2844346031215537e-07
the O 0 5.033085699324147e-07
5 O 0 1.8947511080114054e-06
side O 0 9.371272426506039e-06
. O 0 3.259715867898194e-06

Southern O 0 4.554660335998051e-05
blot O 0 0.00025221871328540146
and O 0 4.561846935757785e-07
PCR O 0 9.619264346838463e-06
analyses O 0 2.1980474684824003e-06
have O 0 8.716950361531417e-08
indicated O 0 3.775630261770857e-07
that O 0 2.809471322251511e-09
the O 0 6.338309876952053e-09
individual O 0 5.7183169310803805e-09
with O 0 8.209225654809416e-08
anhaptoglobinemia B-Disease 0 3.999787804787047e-05
was O 0 5.681362381437793e-06
homozygous O 0 1.851504123351333e-07
for O 0 6.105465022443468e-09
the O 0 3.033925466411347e-08
gene O 0 1.9555258745640458e-07
deletion O 0 5.473693818203174e-07
and O 0 1.6911736011593348e-08
that O 0 2.3960611272855203e-09
the O 0 2.2837804536379736e-08
gene O 0 2.2248177344863507e-07
deletion O 0 1.1204379006812815e-06
was O 0 1.2207044619572116e-06
included O 0 4.77034980406188e-08
at O 0 5.787689474345825e-07
least O 0 2.5802572523048184e-08
from O 0 1.7196645885064754e-08
the O 0 4.80732396113126e-08
promoter O 0 1.9877674276358448e-05
region O 0 5.295859182297136e-07
of O 0 1.4284691651766934e-08
Hp O 0 1.2558219850689056e-06
to O 0 5.113310663773518e-08
Hpr O 0 1.5867044567130506e-05
alpha O 0 1.070793587132357e-06
but O 0 5.792328039433414e-08
not O 0 1.601888932611928e-08
to O 0 5.669145863862468e-08
Hpr O 0 7.431637641275302e-05
beta O 0 6.371271865646122e-06
( O 0 4.1351796653543715e-07
Hpdel O 0 3.734734855243005e-05
) O 0 4.262458048742701e-07
. O 0 1.6676629002176924e-06

In O 0 1.375578904116992e-06
addition O 0 4.3612681110971607e-07
, O 0 1.0922291693304942e-07
we O 0 3.538902149102796e-08
found O 0 6.309978317631249e-08
seven O 0 1.6144959147368354e-08
individuals O 0 1.7615628955525153e-09
with O 0 2.4987587110558707e-08
hypohaptoglobinemia B-Disease 0 1.4150441529636737e-05
in O 0 5.5953236710593046e-08
three O 0 2.0577097359364416e-08
families O 0 7.225872344918116e-09
, O 0 1.4662460579017988e-08
and O 0 9.624243624273277e-09
the O 0 3.41482504495616e-08
genotypes O 0 4.931746957481664e-07
of O 0 1.3056443037839927e-08
six O 0 7.698245241272161e-08
of O 0 8.22180545867468e-09
the O 0 3.1021905044781306e-08
seven O 0 4.790600982573778e-08
individuals O 0 4.625352101328417e-09
were O 0 2.6433360389432892e-08
found O 0 5.507483535893698e-08
to O 0 1.2013164685242828e-08
be O 0 3.615163279846456e-07
Hp2 O 0 0.00018318064394406974
/ O 0 0.0001584754791110754
Hpdel O 0 0.000699988566339016
. O 0 1.0840889444807544e-05

The O 0 3.809850568359252e-06
phenotypes O 0 8.817241177894175e-05
and O 0 8.563279152440373e-07
genotypes O 0 1.5939325749059208e-05
in O 0 1.5673566622353974e-07
one O 0 3.1367171970941854e-08
of O 0 6.423368503760685e-09
these O 0 2.958119971196993e-09
three O 0 2.1232997582387725e-08
families O 0 2.324430603550809e-08
showed O 0 9.07975618247292e-07
the O 0 5.7985179324759883e-08
father O 0 1.2581282362589263e-06
to O 0 3.604153775427221e-08
be O 0 2.079937786447772e-07
hypohaptoglobinemic B-Disease 0 3.5786415537586436e-05
( O 0 1.2516797198713903e-07
Hp2 O 0 1.280271499126684e-05
) O 0 8.520188998772937e-08
and O 0 1.9182384392024687e-07
Hp2 O 0 0.00010147460852749646
/ O 0 4.296440602047369e-05
Hpdel O 0 6.0372170992195606e-05
, O 0 1.1320263126890495e-07
the O 0 8.678297547248803e-08
mother O 0 1.7496882946943515e-06
to O 0 1.5482626736229577e-08
be O 0 5.991638118985065e-08
Hp2 O 0 7.654044566152152e-06
- O 0 4.779571554536233e-06
1 O 0 2.2571309443719656e-07
and O 0 7.575773253165607e-08
Hp1 O 0 2.50995817623334e-05
/ O 0 8.149097993737087e-06
Hp2 O 0 1.7876256606541574e-05
, O 0 7.506115906608102e-08
one O 0 1.1296091173562672e-08
of O 0 4.239364415070668e-09
the O 0 2.3355763545396258e-08
two O 0 2.4600282699793752e-08
children O 0 2.4920096208802534e-08
to O 0 9.524026900464833e-09
be O 0 1.402781748538473e-07
hypohaptoglobinemic B-Disease 0 1.2759468518197536e-05
( O 0 9.89358781566807e-08
Hp2 O 0 8.796166184765752e-06
) O 0 3.9446337751769533e-08
and O 0 8.998443234986553e-08
Hp2 O 0 4.2640229366952553e-05
/ O 0 2.1416926756501198e-05
Hpdel O 0 4.9033893446903676e-05
, O 0 1.148525967664682e-07
and O 0 2.166268586734077e-08
the O 0 3.387087588180293e-08
other O 0 1.9834637043913972e-08
child O 0 5.597148060587642e-07
to O 0 1.4662124847575342e-08
be O 0 7.272569035876586e-08
Hp1 O 0 1.3319795471034013e-05
and O 0 4.931897592541645e-07
Hp1 O 0 0.0001570096064824611
/ O 0 5.477945524035022e-05
Hpdel O 0 0.00014922485570423305
, O 0 4.415876446728362e-07
showing O 0 8.256985211119172e-07
an O 0 1.1002855160313629e-07
anomalous O 0 2.000737913476769e-05
inheritance O 0 1.9616329154814593e-05
of O 0 5.48340665318392e-07
Hp O 0 5.271452391752973e-05
phenotypes O 0 4.335329867899418e-05
in O 0 5.656227699546434e-07
the O 0 5.24523841249902e-07
child O 0 1.2046538358845282e-05
with O 0 2.0110128389205784e-06
Hp1 O 0 0.00414713378995657
. O 0 1.4442582141782623e-05

The O 0 3.6823963455390185e-05
Hp2 O 0 0.0014789607375860214
/ O 0 0.00015384201833512634
Hpdel O 0 0.00012386754679027945
individuals O 0 1.0377868875366403e-07
had O 0 5.398244411480846e-07
an O 0 4.8040973865681735e-08
extremely O 0 5.44349722986226e-06
low O 0 7.499870662286412e-06
level O 0 1.1032418569811853e-06
of O 0 6.197120683282265e-08
Hp O 0 2.2932276806386653e-06
( O 0 1.0110913706284919e-07
mean O 0 5.704930003957998e-07
+ O 0 2.57773444900522e-06
/ O 0 5.592017259914428e-06
- O 0 9.901325938699301e-06
SD O 0 2.724730620684568e-05
= O 0 2.252412059533526e-06
0 O 0 1.8183213512656948e-07
. O 0 4.790189578329773e-08
049 O 0 1.0502745681151282e-05
+ O 0 2.017996393988142e-06
/ O 0 4.575559614750091e-06
- O 0 6.783804565202445e-06
0 O 0 6.146362352410506e-07
. O 0 8.029834219769327e-08
043 O 0 1.4615778127335943e-05
mg O 0 2.1644862499670126e-05
/ O 0 8.037945917749312e-06
ml O 0 1.6966012481134385e-05
; O 0 2.890683390432969e-07
n O 0 3.758034836209845e-06
= O 0 2.547212488934747e-06
6 O 0 3.694761687711434e-07
) O 0 9.065280082154459e-09
, O 0 6.044286848805314e-09
compared O 0 5.321039964201191e-08
with O 0 7.294278958625e-09
the O 0 3.224851141681029e-08
level O 0 2.228674134130415e-07
( O 0 1.6947579339898766e-08
1 O 0 2.8429912646288358e-08
. O 0 7.543198066173318e-09
64 O 0 9.965309288872959e-08
+ O 0 4.809562028640357e-07
/ O 0 1.7903441857924918e-06
- O 0 1.7371188505421742e-06
1 O 0 1.7647643346663244e-07
. O 0 2.9380190724737076e-08
07 O 0 4.453030214790488e-06
mg O 0 9.347334525955375e-06
/ O 0 2.3086272449290846e-06
ml O 0 2.6282800718036015e-06
) O 0 6.302446120542982e-09
obtained O 0 4.6590624691589255e-08
from O 0 5.401185632081251e-08
52 O 0 7.883326702540217e-07
healthy O 0 1.4725386563441134e-06
volunteers O 0 3.565268116290099e-07
having O 0 6.550016564688121e-07
phenotype O 0 9.841293831414077e-06
Hp2 O 0 3.158141043968499e-05
, O 0 1.2790708581178478e-07
whereas O 0 1.4274864668095688e-07
the O 0 1.0197544497714262e-07
serum O 0 2.5917947823472787e-06
Hp O 0 5.236412334852503e-07
level O 0 1.4583923757527373e-07
of O 0 7.54600382180115e-09
an O 0 1.687271833361592e-08
individual O 0 1.2476569999364528e-08
with O 0 3.606856751048326e-07
Hp1 O 0 0.00032328846282325685
/ O 0 0.0001156084836111404
Hpdel O 0 0.00047727071796543896
was O 0 0.00010232035128865391
0 O 0 8.313319085573312e-06
. O 0 2.761525365713169e-06

50 O 0 2.051639421551954e-05
mg O 0 0.00014666953939013183
/ O 0 2.368031709920615e-05
ml O 0 4.120673838770017e-05
, O 0 1.0607450207089641e-07
which O 0 2.4511809471050583e-08
was O 0 5.072145086160162e-07
approximately O 0 8.42765413011648e-09
half O 0 7.565950532750776e-09
the O 0 7.687265934919196e-09
level O 0 7.593552453499797e-08
of O 0 2.1158207630378456e-08
Hp O 0 1.6897248542591115e-06
in O 0 1.9509768378611625e-07
control O 0 8.233975677285343e-06
sera O 0 0.0002096866664942354
from O 0 6.679146480337295e-08
the O 0 1.227543862114544e-07
Hp1 O 0 2.5930905394488946e-05
phenotype O 0 2.912526724685449e-06
( O 0 3.461661179926523e-08
1 O 0 1.0092744417988797e-07
. O 0 1.752906264584908e-08
26 O 0 2.2641418695457105e-07
+ O 0 4.912801045975357e-07
/ O 0 2.0053976186318323e-06
- O 0 1.8430547470416059e-06
0 O 0 1.0443614684163549e-07
. O 0 1.8276288926699635e-08
33 O 0 3.3977389080064313e-07
mg O 0 4.0439158510707784e-06
/ O 0 2.3606219201610656e-06
ml O 0 5.635774414258776e-06
; O 0 8.335702972317449e-08
n O 0 2.7510059226187877e-06
= O 0 1.6420539168393589e-06
9 O 0 4.79154721233499e-07
) O 0 1.557896034398709e-08
, O 0 1.4655134883412302e-08
showing O 0 2.494797115559777e-07
a O 0 4.5188630792836193e-07
gene O 0 7.819003258191515e-06
- O 0 8.947747846832499e-05
dosage O 0 6.912650860613212e-05
effect O 0 6.89893749949988e-06
. O 0 2.2285346403805306e-06

The O 0 1.3738497273152461e-06
other O 0 2.1310944475771976e-07
allele O 0 7.828539310139604e-06
( O 0 4.941342126585369e-07
Hp2 O 0 2.5513489163131453e-05
) O 0 5.254575796698191e-08
of O 0 1.029180207723357e-08
individuals O 0 1.3402829068809297e-08
with O 0 1.7755432679678051e-07
Hp2 O 0 0.0003168840194121003
/ O 0 8.10662895673886e-05
Hpdel O 0 0.00013874933938495815
was O 0 1.1476776307972614e-05
found O 0 8.405777407460846e-08
to O 0 5.717531337268156e-09
have O 0 7.814491276292301e-09
, O 0 1.1643158437379952e-08
in O 0 7.219232323052438e-09
all O 0 2.8705937626938294e-09
exons O 0 6.556872449436923e-07
, O 0 5.893045340599201e-08
no O 0 7.172707228164654e-08
mutation O 0 5.377362981562328e-07
, O 0 1.0401961958450556e-08
by O 0 1.1973132707510104e-08
DNA O 0 1.1270683444308816e-06
sequencing O 0 2.1839143755642e-06
. O 0 1.679164256529475e-06

On O 0 2.4632270196889294e-06
the O 0 7.022043746474083e-08
basis O 0 2.1291070240181398e-08
of O 0 1.0717182696851069e-08
the O 0 5.399764546609731e-08
present O 0 6.031804389294848e-08
study O 0 1.247899064082958e-07
, O 0 1.4727963737470873e-08
the O 0 1.580987252225441e-08
mechanism O 0 2.0997542549139325e-07
of O 0 1.9193539202433385e-08
anhaptoglobinemia B-Disease 0 3.610496787587181e-05
and O 0 7.148518932353909e-08
the O 0 1.3725424707899947e-07
mechanism O 0 2.558406549724168e-06
of O 0 1.7689532683107245e-07
anomalous O 0 2.8140691938460805e-05
inheritance O 0 1.812079608498607e-05
of O 0 7.740057412775059e-07
Hp O 0 4.742515739053488e-05
phenotypes O 0 3.829713023151271e-05
were O 0 8.981722317003005e-07
well O 0 2.4822763862175634e-06
explained O 0 2.372129529248923e-05
. O 0 5.549108664126834e-06

However O 0 5.825539119541645e-06
, O 0 2.5101618916778534e-07
the O 0 9.517057009134078e-08
mechanism O 0 3.363725681992946e-06
of O 0 9.471925750403898e-07
hypohaptoglobinemia B-Disease 0 0.011077038012444973
remains O 0 0.0011396777117624879
unknown O 0 0.0006015457911416888

ATM O 0 0.0033754752948880196
mutations O 0 0.0018386984011158347
and O 0 1.078608966054162e-05
phenotypes O 0 0.0034341898281127214
in O 0 0.0004889975534752011
ataxia B-Disease 1 0.9999722242355347
- I-Disease 1 0.9993221759796143
telangiectasia I-Disease 1 0.999171257019043
families O 0 6.988918812567135e-06
in O 0 1.0174042017752072e-06
the O 0 6.019886313879397e-07
British O 0 1.6760232028900646e-05
Isles O 0 6.37871926301159e-06
: O 0 8.760320469036742e-08
expression O 0 3.0661013283861394e-08
of O 0 8.486547464769956e-09
mutant O 0 5.07675679273234e-07
ATM O 0 3.5422797282080865e-06
and O 0 2.3272191640444362e-07
the O 0 1.3106815686114714e-06
risk O 0 9.209596464643255e-05
of O 0 1.0321995432605036e-05
leukemia B-Disease 1 0.9999350309371948
, O 0 0.20058682560920715
lymphoma B-Disease 1 0.9999997615814209
, O 0 0.0005698549211956561
and O 0 0.009383313357830048
breast B-Disease 1 0.9998975992202759
cancer I-Disease 1 0.9996077418327332
. O 0 3.32864947267808e-05

We O 0 3.920821200154023e-06
report O 0 4.46525461939018e-07
the O 0 4.427776900683966e-08
spectrum O 0 1.1741975640688906e-06
of O 0 8.145138963300269e-08
59 O 0 5.920144758420065e-06
ATM O 0 5.785691973869689e-05
mutations O 0 9.448405035072938e-05
observed O 0 3.235447366023436e-05
in O 0 2.261223562527448e-05
ataxia B-Disease 1 0.9999262094497681
- I-Disease 1 0.9991987347602844
telangiectasia I-Disease 1 0.9996654987335205
( O 0 0.00020541467529255897
A B-Disease 1 0.9997450709342957
- I-Disease 1 0.9993403553962708
T I-Disease 1 0.9997047781944275
) O 0 1.4666845800093142e-06
patients O 0 3.1805780054128263e-06
in O 0 9.396245559400995e-08
the O 0 4.654048950669676e-07
British O 0 1.7888451111502945e-05
Isles O 0 4.270639692549594e-05
. O 0 5.6128546930267476e-06

Of O 0 3.037367378055933e-06
51 O 0 2.5641107640694827e-05
ATM O 0 0.00018779006495606154
mutations O 0 0.0001168196031358093
identified O 0 4.314045327191707e-06
in O 0 1.4070597842419375e-07
families O 0 2.3910542878979868e-08
native O 0 5.346289455587794e-08
to O 0 1.0214398216135123e-08
the O 0 9.116295274225195e-08
British O 0 3.1740237318444997e-06
Isles O 0 2.631630650284933e-06
, O 0 8.627498004898371e-08
11 O 0 2.5753999466360256e-07
were O 0 6.660992113438624e-08
founder O 0 2.400075118202949e-06
mutations O 0 2.603890152386157e-06
, O 0 2.549870359302986e-08
and O 0 2.0102078224226716e-08
2 O 0 7.822458059081328e-08
of O 0 7.6454318431729e-09
these O 0 1.9115137916969616e-08
11 O 0 4.274324112429895e-07
conferred O 0 2.9870052458136342e-06
a O 0 2.416916004222003e-06
milder O 0 6.959580059628934e-05
clinical O 0 1.9421107936068438e-05
phenotype O 0 5.604152192972833e-06
with O 0 3.2496540569582066e-08
respect O 0 1.1307088954026767e-07
to O 0 1.812995122918437e-07
both O 0 4.741639259009389e-06
cerebellar B-Disease 1 0.9802058935165405
degeneration I-Disease 1 0.9969107508659363
and O 0 4.0477125367033295e-06
cellular O 0 0.007156652864068747
features O 0 0.00020724089699797332
. O 0 2.3441696612280793e-05

We O 0 4.6077443585090805e-06
report O 0 9.659792112870491e-07
, O 0 4.096266081887734e-08
in O 0 3.2442969200019434e-08
two O 0 1.9392994943245867e-07
A B-Disease 1 0.9884989857673645
- I-Disease 1 0.9649564623832703
T I-Disease 1 0.9981021285057068
families O 0 4.93674470192218e-08
, O 0 2.7053193463189018e-08
an O 0 4.395842267967964e-08
ATM O 0 2.0523870261968113e-05
mutation O 0 1.1600659490795806e-05
( O 0 2.2515948217005644e-07
7271T O 0 1.2289709047763608e-05
- O 0 2.399308141320944e-05
- O 0 1.7380272765876725e-05
> O 0 3.5013051729038125e-06
G O 0 5.755397523898864e-06
) O 0 1.767321933243693e-08
that O 0 5.681440207183641e-09
may O 0 4.459424118863353e-08
be O 0 5.900870903019495e-09
associated O 0 1.7787726847018348e-08
with O 0 5.224881416410199e-09
an O 0 6.925213114072903e-08
increased O 0 1.579099830451014e-06
risk O 0 2.8275248041609302e-05
of O 0 4.083113708475139e-06
breast B-Disease 1 0.9996856451034546
cancer I-Disease 1 0.9982727766036987
in O 0 2.632855853335059e-07
both O 0 1.7844637056896318e-07
homozygotes O 0 4.838318272959441e-05
and O 0 3.6279320170251594e-07
heterozygotes O 0 1.851533852459397e-05
( O 0 4.2134217892453307e-07
relative O 0 6.698731340293307e-06
risk O 0 1.3903111721447203e-05
12 O 0 6.943371886336536e-07
. O 0 5.102778644072714e-08
7 O 0 1.1491760005810647e-06
; O 0 4.4251979147702514e-07
P O 0 0.00013013824354857206
= O 0 2.894398676289711e-06
. O 0 4.0480333751702346e-08
0025 O 0 1.3894270523451269e-05
) O 0 2.3657321435166523e-08
, O 0 1.0440921904830702e-08
although O 0 3.3894529849476385e-08
there O 0 8.00754662577674e-09
is O 0 2.6998447921755542e-08
a O 0 3.286831713467109e-07
less O 0 2.090697535095387e-06
severe O 0 0.4277542531490326
A B-Disease 1 0.9994114637374878
- I-Disease 1 0.9977746605873108
T I-Disease 1 0.9989230036735535
phenotype O 0 1.767318826750852e-05
in O 0 1.0357974389307856e-07
terms O 0 8.984551413959707e-08
of O 0 1.8820724534407418e-08
the O 0 3.177823089117737e-07
degree O 0 7.088965048751561e-06
of O 0 1.2228844752826262e-05
cerebellar B-Disease 1 0.9985226988792419
degeneration I-Disease 1 0.9996242523193359
. O 0 0.0002643232874106616

This O 0 6.95688004270778e-06
mutation O 0 6.815690721850842e-05
( O 0 6.317486054285837e-07
7271T O 0 2.829850018315483e-05
- O 0 9.784211579244584e-05
- O 0 6.0509457398438826e-05
> O 0 7.453581019944977e-06
G O 0 1.2121732652303763e-05
) O 0 9.832276326449119e-09
also O 0 3.925447966679485e-09
allows O 0 2.1152264384483033e-09
expression O 0 1.1569882829576272e-08
of O 0 3.3749365524471386e-09
full O 0 4.393118402390428e-08
- O 0 9.327745260634401e-07
length O 0 9.973827985731987e-08
ATM O 0 8.32924911264854e-07
protein O 0 1.507082174612151e-07
at O 0 2.7672939495460014e-07
a O 0 4.625945493330619e-08
level O 0 1.1365816021680075e-07
comparable O 0 3.8990685879980447e-07
with O 0 3.728583308770794e-08
that O 0 4.12053466902762e-08
in O 0 2.6930257490676013e-07
unaffected O 0 2.1013174773543142e-05
individuals O 0 3.112304511887487e-07
. O 0 2.64709569819388e-06

In O 0 2.316213567610248e-06
addition O 0 5.263679554445844e-07
, O 0 7.54667013325161e-08
we O 0 1.555680917419977e-08
have O 0 1.7982236144575836e-08
studied O 0 1.1997659612461575e-06
18 O 0 2.6738962333183736e-06
A B-Disease 1 0.95195072889328
- I-Disease 1 0.9968932867050171
T I-Disease 1 0.9996269941329956
patients O 0 1.2512776265793946e-05
, O 0 5.734276697921814e-08
in O 0 2.575492530354495e-08
15 O 0 8.018768937745335e-08
families O 0 1.081100808875135e-08
, O 0 7.951162217523233e-08
who O 0 7.906750738584378e-07
developed O 0 0.00040154665475711226
leukemia B-Disease 1 0.9999111890792847
, O 0 0.002203728538006544
lymphoma B-Disease 1 0.999998927116394
, O 0 1.3092725566821173e-05
preleukemic O 0 0.007906663231551647
T O 0 0.295389860868454
- O 0 0.00042446659062989056
cell O 0 0.00019544086535461247
proliferation O 0 0.0008160694851540029
, O 0 5.168277311895508e-06
or O 0 0.008113979361951351
Hodgkin B-Disease 1 0.9999942779541016
lymphoma I-Disease 1 0.9999997615814209
, O 0 1.0249252227367833e-05
mostly O 0 1.7246284187422134e-06
in O 0 4.0965933294501156e-06
childhood O 0 0.0011825874680653214
. O 0 6.4929072323138826e-06

A O 0 2.0000245058326982e-05
wide O 0 5.350713763618842e-06
variety O 0 1.4447226703850902e-06
of O 0 3.367466945292108e-07
ATM O 0 0.0001382295595249161
mutation O 0 4.1598403186071664e-05
types O 0 2.098504182868055e-06
, O 0 2.4553835942242586e-07
including O 0 3.5366693396099436e-07
missense O 0 0.00011440109665272757
mutations O 0 2.2653550331597216e-05
and O 0 1.6146888981438678e-07
in O 0 3.1360536922875326e-07
- O 0 2.0842056983383372e-05
frame O 0 9.946536920324434e-06
deletions O 0 1.752619027683977e-06
, O 0 7.383925293424909e-08
were O 0 4.025489630521406e-08
seen O 0 1.2127027275710134e-06
in O 0 9.895852315366938e-08
these O 0 1.7639500526911434e-07
patients O 0 1.5196880667645019e-05
. O 0 2.110662990162382e-06

We O 0 1.782170784281334e-06
also O 0 1.2150813688549533e-07
show O 0 1.5387192320304166e-07
that O 0 1.2637902280232538e-08
25 O 0 4.340190074003658e-08
% O 0 3.0070368417511872e-09
of O 0 5.901377164718724e-09
all O 0 1.2553030614981253e-07
A B-Disease 1 0.998816728591919
- I-Disease 1 0.9987614154815674
T I-Disease 1 0.9997585415840149
patients O 0 5.243191026238492e-06
carried O 0 7.733918323538091e-07
in O 0 1.2786586012225598e-07
- O 0 7.38478047423996e-06
frame O 0 9.071585736819543e-06
deletions O 0 7.68750578572508e-06
or O 0 1.2788869980795425e-06
missense O 0 5.131462967256084e-05
mutations O 0 1.3187713193474337e-05
, O 0 4.978805279165499e-08
many O 0 3.2882152556368283e-09
of O 0 7.9856290469138e-09
which O 0 2.4120515362824335e-08
were O 0 5.272657332966446e-08
also O 0 5.7426717603448196e-08
associated O 0 5.211855125253351e-08
with O 0 2.274043708894169e-08
expression O 0 2.969077002035192e-07
of O 0 6.492236082067393e-08
mutant O 0 7.737608029856347e-06
ATM O 0 4.223186624585651e-05
protein O 0 3.154411388095468e-05
. O 0 5.10406198372948e-06

The O 0 7.1456543082604185e-06
DMPK O 0 0.0012504219776019454
gene O 0 7.144169649109244e-05
of O 0 1.7886846762849018e-05
severely O 1 0.9955516457557678
affected O 1 0.6027916073799133
myotonic B-Disease 1 0.9999834299087524
dystrophy I-Disease 1 0.9999960660934448
patients O 1 0.9099256992340088
is O 0 1.7050144379027188e-05
hypermethylated O 0 0.000832954014185816
proximal O 0 0.0002984929597005248
to O 0 4.3708280372811714e-07
the O 0 8.577877110838017e-07
largely O 0 4.9539198698766995e-06
expanded O 0 7.793886652507354e-06
CTG O 0 0.0013361703604459763
repeat O 0 0.0002174378460040316
. O 0 8.975781383924186e-06

Using O 0 4.747259026771644e-06
methylation O 0 5.693021375918761e-05
- O 0 4.0316877857549116e-05
sensitive O 0 1.2520918062364217e-05
restriction O 0 5.73813849769067e-07
enzymes O 0 8.614916282567719e-07
, O 0 9.258620536911621e-08
we O 0 5.658483459569652e-08
characterized O 0 1.4902730072208215e-06
the O 0 1.1175464464940887e-07
methylation O 0 1.0293548484696657e-06
pattern O 0 2.324290107935667e-06
on O 0 3.080113799569517e-07
the O 0 1.827939684062585e-07
5 O 0 3.368565444361593e-07
side O 0 4.877387596025073e-07
of O 0 1.901332424836255e-08
the O 0 3.0432045150519116e-07
CTG O 0 3.4783231967594475e-05
repeat O 0 2.8224385459907353e-06
in O 0 3.3920269260079294e-08
the O 0 4.4863401882366816e-08
DMPK O 0 8.688268280820921e-06
gene O 0 2.1372856906509696e-07
of O 0 2.1535553784701733e-08
normal O 0 6.428849701478612e-07
individuals O 0 1.716810160701243e-08
and O 0 8.491004166444327e-08
of O 0 4.458323132894293e-07
patients O 0 0.00013475226296577603
affected O 0 2.8666954676737078e-05
with O 0 0.00236891838721931
myotonic B-Disease 1 0.9999816417694092
dystrophy I-Disease 1 0.9999880790710449
, O 0 2.5800388812058372e-06
showing O 0 4.048114078614162e-06
expansions O 0 4.3962672862107866e-06
of O 0 1.3592570269338466e-07
the O 0 1.430573547622771e-06
repetitive O 0 0.0015451668296009302
sequence O 0 2.1716194169130176e-05
. O 0 7.181740329542663e-06

The O 0 1.6030999177019112e-06
gene O 0 4.014527803519741e-06
segment O 0 5.874769613001263e-06
analyzed O 0 1.263086119251966e-06
corresponds O 0 1.5783696483140375e-07
to O 0 1.4692863814502743e-08
the O 0 1.1220702589298526e-07
genomic O 0 7.348564849962713e-06
SacI O 0 8.743185753701255e-05
- O 0 1.5296116544050165e-05
HindIII O 0 2.3413795133819804e-05
fragment O 0 3.5772432056546677e-06
carrying O 0 3.67358268249518e-07
exons O 0 8.185987098840997e-06
11 O 0 4.878750587522518e-06
- O 0 6.889907672302797e-05
15 O 0 4.02902969653951e-06
. O 0 2.281291244798922e-06

There O 0 1.4557705299012014e-06
is O 0 3.3973987001445494e-07
constitutive O 0 4.453628662304254e-06
methylation O 0 8.064757821557578e-06
in O 0 3.1879920925348415e-07
intron O 0 5.93171025684569e-05
12 O 0 1.600379391675233e-06
at O 0 7.141377409425331e-07
restriction O 0 1.249629519861628e-07
sites O 0 1.0228868774220246e-07
of O 0 4.8838384003602187e-08
SacII O 0 2.2804151740274392e-05
and O 0 1.7232211746431858e-07
HhaI O 0 3.147452662233263e-05
, O 0 8.699046105675734e-08
localized O 0 2.8046169973094948e-06
1 O 0 7.600035587529419e-07
, O 0 6.70897222221356e-08
159 O 0 5.540883307730837e-07
- O 0 5.1316678764123935e-06
1 O 0 3.161928248118784e-07
, O 0 3.797730840915392e-08
232 O 0 3.520933091749612e-07
bp O 0 3.118040240224218e-06
upstream O 0 3.1210817041937844e-07
of O 0 1.621383560745926e-08
the O 0 2.0283660262521153e-07
CTG O 0 5.751524804509245e-05
repeat O 0 5.641387815558119e-06
, O 0 4.1183739085681736e-08
whereas O 0 8.96165204267163e-08
most O 0 3.592863251355993e-08
, O 0 2.1791068505194744e-08
if O 0 6.755388248791405e-09
not O 0 2.449866309817139e-09
all O 0 1.9800305839368093e-09
, O 0 5.5665054787823465e-09
of O 0 1.7414418795880238e-09
the O 0 7.428844206458507e-09
other O 0 2.9348925512096002e-09
sites O 0 7.317692762853767e-08
of O 0 2.681917266045275e-08
SacII O 0 1.2679870451393072e-05
, O 0 1.0210175815927869e-07
HhaI O 0 1.0377901162428316e-05
, O 0 8.99753374028478e-08
and O 0 7.631099663285568e-08
HpaII O 0 1.861127202573698e-05
in O 0 2.089032449248407e-07
this O 0 2.8914765692888977e-08
region O 0 3.3400888810319884e-07
are O 0 2.613596983280786e-08
unmethylated O 0 4.806498964171624e-06
, O 0 6.328563983970525e-08
in O 0 4.734834035957647e-08
normal O 0 4.350575295575254e-07
individuals O 0 6.180946421352473e-09
and O 0 2.7744015085318097e-08
most O 0 3.3808010613256556e-08
of O 0 6.384102135825742e-08
the O 0 6.2749422795604914e-06
patients O 0 7.809703674865887e-05
. O 0 4.758704108098755e-06

In O 0 1.4050968957235455e-06
a O 0 3.22259495533217e-07
number O 0 4.839505507447939e-08
of O 0 1.184191020797698e-07
young O 0 3.875774382322561e-06
and O 0 5.306401362759061e-06
severely O 1 0.6667844653129578
affected O 0 2.316199788765516e-05
patients O 0 1.3692410902876873e-05
, O 0 7.124045708906124e-08
however O 0 6.611689684632438e-08
, O 0 1.3794693387580992e-08
complete O 0 6.976493693855446e-08
methylation O 0 3.0783371585130226e-07
of O 0 6.6204197679553545e-09
these O 0 3.776952972600611e-09
restriction O 0 5.643834910529222e-08
sites O 0 9.865680539178356e-08
was O 0 4.744190391647862e-06
found O 0 1.3656575958975736e-07
in O 0 3.7831483723493875e-08
the O 0 1.5521412422003777e-07
mutated O 0 1.0400382052466739e-05
allele O 0 1.613074891793076e-05
. O 0 2.6426816930325003e-06

In O 0 1.863778834376717e-06
most O 0 1.2486073330819636e-07
of O 0 3.683724258962684e-08
these O 0 6.873575131294274e-08
patients O 0 2.426371111141634e-06
, O 0 5.87405821761422e-08
the O 0 2.547095618865569e-07
onset O 0 0.0010386380599811673
of O 0 7.828979278201587e-07
the O 0 0.001272558351047337
disease O 1 0.9998955726623535
was O 1 0.9985350370407104
congenital O 1 0.999987006187439
. O 0 0.00018888027989305556

Preliminary O 0 5.8482462918618694e-05
in O 0 4.342535703472095e-06
vivo O 0 0.000150777748785913
footprinting O 0 0.0004857175808865577
data O 0 4.6526332653229474e-07
gave O 0 1.3741546922574344e-07
evidence O 0 3.512058910359883e-08
for O 0 1.1803796162723756e-08
protein O 0 2.941145851309557e-07
- O 0 2.1270020624797326e-06
DNA O 0 4.0017124547375715e-07
contact O 0 1.7679464292541525e-07
in O 0 4.350110316408973e-08
normal O 0 6.362154749695037e-07
genes O 0 5.288177931106475e-07
at O 0 1.0020609124694602e-06
an O 0 7.120907952185007e-08
Sp1 O 0 1.265008540940471e-05
consensus O 0 1.9906995873952837e-07
binding O 0 4.664402126763889e-07
site O 0 1.472978283345583e-06
upstream O 0 7.198348725978576e-07
of O 0 2.5685313431722534e-08
the O 0 2.2150875622628519e-07
CTG O 0 3.992082929471508e-05
repeat O 0 2.682403874132433e-06
and O 0 4.8772758276527384e-08
for O 0 9.344787166298829e-09
a O 0 6.491976023426105e-08
significant O 0 1.3154836153717042e-07
reduction O 0 4.7101087830014876e-07
of O 0 3.826113204041803e-09
this O 0 4.583364798804723e-09
interaction O 0 2.899855111593297e-08
in O 0 7.118259759408829e-08
cells O 0 1.9068859558046825e-07
with O 0 3.44934925067264e-08
a O 0 1.7816694253269816e-06
hypermethylated O 0 0.00017347763059660792
DMPK O 0 0.00032212649239227176
gene O 0 1.1537483260326553e-05
. O 0 6.624274533351127e-07
. O 0 2.132770759999403e-06

The O 0 8.046786388149485e-05
hemochromatosis B-Disease 1 0.9987510442733765
gene O 0 2.678649252629839e-05
product O 0 1.0703616908358526e-06
complexes O 0 3.016902155650314e-06
with O 0 1.86120544753976e-07
the O 0 3.673663115932868e-07
transferrin O 0 2.7534404580364935e-05
receptor O 0 3.488297124931705e-06
and O 0 1.2815250727271632e-07
lowers O 0 4.488293143367628e-06
its O 0 1.8512263721959243e-08
affinity O 0 1.64844180972068e-07
for O 0 2.266526522021195e-08
ligand O 0 2.2811479993833927e-06
binding O 0 6.204635155881988e-06
. O 0 2.305476755282143e-06

We O 0 8.411393537244294e-06
recently O 0 2.787907942547463e-05
reported O 0 1.766956529536401e-06
the O 0 2.3360309242548283e-08
positional O 0 1.1802849257946946e-06
cloning O 0 6.31480588708655e-07
of O 0 2.7295447679875906e-08
a O 0 5.940590313002758e-07
candidate O 0 2.527319793443894e-06
gene O 0 1.0106426088896114e-05
for O 0 4.820146205020137e-05
hereditary B-Disease 1 0.9999933242797852
hemochromatosis I-Disease 1 0.9999995231628418
called O 1 0.9083720445632935
HFE O 1 0.9682896733283997
. O 0 8.633919787826017e-05

The O 0 1.4411640449907281e-06
gene O 0 2.514796051400481e-06
product O 0 5.628215262731828e-07
, O 0 8.522025751744877e-08
a O 0 1.9412220808590064e-07
member O 0 1.212319631349601e-07
of O 0 1.8822591485445628e-08
the O 0 4.958316708325583e-07
major O 0 5.911663538427092e-05
histocompatibility O 0 0.11917657405138016
complex O 0 0.0005216305726207793
class O 0 5.154346945346333e-05
I O 0 0.00021289709548000246
- O 0 1.4555660527548753e-05
like O 0 3.3626756135163305e-07
family O 0 4.1200050304723845e-07
, O 0 7.458876183363827e-08
was O 0 1.9136791706841905e-06
found O 0 2.369950280467492e-08
to O 0 3.3110798547397735e-09
have O 0 1.0724749088808494e-08
a O 0 3.4526706826909503e-07
mutation O 0 5.398803750722436e-06
, O 0 3.571321940398775e-07
Cys O 0 0.00036318576894700527
- O 0 6.628435221500695e-05
282 O 0 1.619239992578514e-05
- O 0 0.00015930726658552885
- O 0 0.00011567620822461322
> O 0 1.0982378626067657e-05
Tyr O 0 2.2662625269731507e-05
( O 0 8.046484367696394e-08
C282Y O 0 2.053782736766152e-06
) O 0 1.7409245600674694e-08
, O 0 1.1942434596790008e-08
in O 0 2.7646448685914038e-08
85 O 0 1.3210001270635985e-07
% O 0 1.4717993934709739e-08
of O 0 7.381095201708376e-08
patient O 0 1.979364787985105e-05
chromosomes O 0 1.442062966816593e-05
. O 0 4.276556865079328e-06

This O 0 4.702873866335722e-06
mutation O 0 0.00010398154699942097
eliminates O 0 1.1170460311404895e-05
the O 0 3.9356686443170474e-07
ability O 0 7.791914526933397e-07
of O 0 1.9940704021337297e-07
HFE O 0 0.00024151794787030667
to O 0 1.861345708675799e-07
associate O 0 1.2872517345385859e-06
with O 0 1.1463291684776777e-06
beta2 O 0 0.004348170943558216
- O 0 0.0023976885713636875
microglobulin O 0 0.00035246831248514354
( O 0 4.6861066493875114e-07
beta2m O 0 2.369777939748019e-05
) O 0 9.713226489793669e-08
and O 0 8.684524033242269e-08
prevents O 0 3.8617217796854675e-06
cell O 0 0.00021266945987008512
- O 0 0.0002042561100097373
surface O 0 8.343259833054617e-05
expression O 0 1.4817156625213102e-05
. O 0 3.0546016205335036e-06

A O 0 3.878388451994397e-05
second O 0 8.602400157542434e-06
mutation O 0 2.2451575205195695e-05
that O 0 9.19238800634048e-08
has O 0 3.2321577236871235e-07
no O 0 8.981724164414118e-08
effect O 0 2.2264308086050733e-07
on O 0 7.375640507234493e-07
beta2m O 0 8.130381320370361e-05
association O 0 5.79407867462578e-07
, O 0 1.0062451138992401e-07
H63D O 0 3.2548385206609964e-05
, O 0 7.989731187763027e-08
was O 0 1.325599100709951e-06
found O 0 3.0896774916300274e-08
in O 0 1.0572441588863057e-08
eight O 0 2.289921852138832e-08
out O 0 1.603224575319473e-08
of O 0 8.208877133597525e-09
nine O 0 4.1051677612813364e-07
patients O 0 6.297798336163396e-07
heterozygous O 0 1.901400139558973e-07
for O 0 1.6449671846885394e-08
the O 0 3.062758366922935e-07
C282Y O 0 3.066693898290396e-05
mutant O 0 3.876355185639113e-05
. O 0 5.487149337568553e-06

In O 0 2.987563675560523e-06
this O 0 3.0889472668604867e-07
report O 0 4.479090023323806e-07
, O 0 1.9952262064748538e-08
we O 0 1.3423014699753821e-08
demonstrate O 0 6.412108888298462e-08
in O 0 6.000398400374252e-08
cultured O 0 2.5536896828270983e-06
293 O 0 4.1080247683566995e-06
cells O 0 3.320449650345836e-06
overexpressing O 0 4.3340645788703114e-05
wild O 0 6.59234410704812e-06
- O 0 5.1825143600581214e-05
type O 0 1.2026794138364494e-05
or O 0 5.55681708647171e-07
mutant O 0 4.915950285067083e-06
HFE O 0 3.727845614776015e-05
proteins O 0 1.8831215697900916e-07
that O 0 1.1297642821261888e-08
both O 0 2.114767738703449e-08
the O 0 1.213631293239814e-07
wild O 0 4.044428806082578e-06
- O 0 0.00016062786744441837
type O 0 2.793134808598552e-05
and O 0 8.906542348086077e-07
H63D O 0 0.0003712717443704605
HFE O 0 0.0003060504677705467
proteins O 0 6.127178266979172e-07
form O 0 4.1817253304543556e-07
stable O 0 8.806557161733508e-06
complexes O 0 3.551998588591232e-06
with O 0 9.423454372381457e-08
the O 0 3.8614680875070917e-07
transferrin O 0 9.064796904567629e-05
receptor O 0 1.3453265637508593e-05
( O 0 7.392886800516862e-07
TfR O 0 0.00022431582328863442
) O 0 6.906375915605167e-07
. O 0 1.5271830307028722e-06

The O 0 9.56881558522582e-06
C282Y O 0 0.00030069606145843863
mutation O 0 0.00015609944239258766
nearly O 0 4.702605110651348e-06
completely O 0 1.3019240213907324e-05
prevents O 0 2.0307538761699107e-06
the O 0 2.9379083343883394e-07
association O 0 5.912488632020541e-07
of O 0 1.9653461080793022e-08
the O 0 1.8377227206656244e-07
mutant O 0 5.444447651825612e-06
HFE O 0 8.418175275437534e-05
protein O 0 6.381862363014079e-07
with O 0 9.290833702380041e-08
the O 0 1.258531483472325e-06
TfR O 0 0.0013677640818059444
. O 0 3.5020166251342744e-06

Studies O 0 1.197993060486624e-05
on O 0 6.703281997033628e-06
cell O 0 0.00019847694784402847
- O 0 8.889829769032076e-05
associated O 0 2.852357965821284e-06
transferrin O 0 1.077666092896834e-05
at O 0 1.98315319721587e-06
37 O 0 1.0505102636670927e-06
degrees O 0 5.62751210964052e-07
C O 0 5.002878879167838e-06
suggest O 0 1.8202506169018307e-07
that O 0 8.057538636307982e-09
the O 0 1.2300282037358556e-07
overexpressed O 0 3.2406718673883006e-05
wild O 0 4.516663011600031e-06
- O 0 5.166354094399139e-05
type O 0 2.59165190072963e-05
HFE O 0 0.00019758494454436004
protein O 0 2.2589708805753617e-06
decreases O 0 1.6901680055525503e-06
the O 0 2.2208148209301726e-08
affinity O 0 1.2328771958891593e-07
of O 0 2.8613733604743175e-08
the O 0 3.579218343929824e-07
TfR O 0 0.00010544464021222666
for O 0 3.5946905541095475e-07
transferrin O 0 0.0003559586184564978
. O 0 6.343207587633515e-06

The O 0 1.1037279364245478e-05
overexpressed O 0 0.0006618598126806319
H63D O 0 0.00044766394421458244
protein O 0 5.79279731027782e-06
does O 0 1.7310945565895963e-07
not O 0 1.5028792432758564e-08
have O 0 7.574021410050591e-09
this O 0 6.1973075560217694e-09
effect O 0 5.0881130420066256e-08
, O 0 5.026310478939422e-09
providing O 0 5.748345355272022e-09
the O 0 7.924209732834697e-09
first O 0 6.9119350243340705e-09
direct O 0 5.564891658593751e-09
evidence O 0 1.66575180315931e-08
for O 0 5.672128100542295e-09
a O 0 1.5161613475811464e-07
functional O 0 7.373228640972229e-07
consequence O 0 1.3495094890458859e-06
of O 0 5.2049308862933685e-08
the O 0 1.2626911711777211e-06
H63D O 0 0.006174586713314056
mutation O 0 0.0002926283923443407
. O 0 4.546529908111552e-06

Addition O 0 4.783990789292147e-06
of O 0 1.3669323379872367e-06
soluble O 0 0.0016359392320737243
wild O 0 0.00012148499808972701
- O 0 0.0027293399907648563
type O 0 0.0006814771913923323
HFE O 0 0.008293194696307182
/ O 0 0.0001720735162962228
beta2m O 0 0.00014517144882120192
heterodimers O 0 7.325532351387665e-05
to O 0 1.520470505056437e-07
cultured O 0 7.852257112972438e-06
cells O 0 2.9266598176036496e-06
also O 0 2.1171736364067328e-07
decreased O 0 1.3814461681249668e-06
the O 0 5.719257600844685e-08
apparent O 0 1.2220323242218e-06
affinity O 0 3.366638736679306e-07
of O 0 2.9341215679323795e-08
the O 0 3.03219309216729e-07
TfR O 0 2.5118642952293158e-05
for O 0 8.314787081076247e-09
its O 0 1.4119777347332274e-08
ligand O 0 3.0747810342290904e-07
under O 0 3.5493536643116386e-07
steady O 0 7.764692782075144e-06
- O 0 3.697351348819211e-05
state O 0 3.2062740729088546e-07
conditions O 0 1.730579128889076e-06
, O 0 1.3176023827554673e-08
both O 0 1.0225313928913238e-08
in O 0 2.7211447317654347e-08
293 O 0 3.5309435020280944e-07
cells O 0 4.014586920675356e-07
and O 0 5.891887866482648e-08
in O 0 8.740290127207118e-07
HeLa O 0 0.000386998028261587
cells O 0 2.8251421099412255e-05
. O 0 4.419299330038484e-06

Furthermore O 0 8.604295544500928e-06
, O 0 5.364895514503587e-07
at O 0 1.4696108792122686e-06
4 O 0 5.949486308054475e-07
degrees O 0 9.714706266095163e-07
C O 0 4.054682449350366e-06
, O 0 5.195558117065957e-08
the O 0 1.1737929384025847e-07
added O 0 1.4581631830878905e-06
soluble O 0 1.245982275577262e-05
complex O 0 5.395869720814517e-06
of O 0 8.092270036286209e-07
HFE O 0 0.0024832922499626875
/ O 0 0.00011599032586673275
beta2m O 0 0.00013476562162395567
inhibited O 0 7.055673904687865e-06
binding O 0 1.7898918258651975e-06
of O 0 1.9423812602781254e-07
transferrin O 0 4.063392407260835e-05
to O 0 5.796825917059323e-07
HeLa O 0 0.0003773315402213484
cell O 0 7.504353561671451e-05
TfR O 0 0.00014989112969487906
in O 0 3.820653944330843e-07
a O 0 7.121524845388194e-07
concentration O 0 9.390837658429518e-05
- O 0 4.288858690415509e-05
dependent O 0 1.9124202026432613e-06
manner O 0 1.0505419595574494e-05
. O 0 4.215011813357705e-06

Scatchard O 0 0.0004044008965138346
plots O 0 1.114557289838558e-05
of O 0 1.1293877122398044e-07
these O 0 2.945908761375904e-08
data O 0 7.693817565268546e-07
indicate O 0 5.952795163466362e-07
that O 0 1.8299310511338263e-08
the O 0 1.1199128380212642e-07
added O 0 3.3162740464831586e-07
heterodimer O 0 1.0410542927274946e-05
substantially O 0 3.5348116398381535e-06
reduced O 0 2.834277950114483e-07
the O 0 2.4561511935417002e-08
affinity O 0 2.4936269937825273e-07
of O 0 1.3192500603054214e-07
TfR O 0 9.575060539646074e-05
for O 0 3.341101830756088e-07
transferrin O 0 0.0003229237627238035
. O 0 5.361154308047844e-06

These O 0 3.9957865283213323e-07
results O 0 1.7758660533218062e-06
establish O 0 2.410111505923851e-07
a O 0 3.7472091207746416e-07
molecular O 0 6.572005986527074e-06
link O 0 5.203226464800537e-06
between O 0 4.198151941636752e-07
HFE O 0 0.0003507337241899222
and O 0 1.9593058198097424e-07
a O 0 1.9786486404882453e-07
key O 0 9.595640904080938e-07
protein O 0 3.0885144042258617e-07
involved O 0 1.3934165110640606e-07
in O 0 1.095187229793737e-07
iron O 0 0.0005169434007257223
transport O 0 2.0458655853872187e-06
, O 0 7.544755931121472e-08
the O 0 1.2956053296875325e-07
TfR O 0 5.956617678748444e-05
, O 0 1.1298411806137665e-07
and O 0 4.7071356590322466e-08
raise O 0 1.796013293642318e-07
the O 0 5.856784213165156e-08
possibility O 0 5.020593221161107e-07
that O 0 2.095714535244042e-08
alterations O 0 3.4181987302872585e-06
in O 0 8.667529272088359e-08
this O 0 2.5024885275115594e-08
regulatory O 0 8.752342637308175e-07
mechanism O 0 1.5595096556353383e-06
may O 0 1.71960635952928e-07
play O 0 2.315796798768588e-08
a O 0 5.699133964753855e-08
role O 0 1.8844239946247399e-07
in O 0 1.0231015323824977e-07
the O 0 1.2778043583239196e-06
pathogenesis O 0 0.012962768785655499
of O 0 0.00013996708730701357
hereditary B-Disease 1 0.9999899864196777
hemochromatosis I-Disease 1 0.999998927116394
. O 0 0.0006136203883215785
. O 0 6.0068377933930606e-05

Genomic O 0 0.00038100016536191106
organization O 0 3.960846697736997e-06
of O 0 1.8461810213921126e-07
the O 0 3.170478066749638e-06
UBE3A O 0 0.0027585155330598354
/ O 0 0.000262128101894632
E6 O 0 0.002114399103447795
- O 0 0.00037839720607735217
AP O 0 5.5260217777686194e-05
gene O 0 6.315736754913814e-06
and O 0 7.824202157280524e-07
related O 0 8.333512596436776e-06
pseudogenes O 0 0.0002528037584852427
. O 0 1.8883394659496844e-05

The O 0 3.3627218272158643e-06
UBE3A O 0 0.0002615384291857481
gene O 0 4.531604190560756e-06
encodes O 0 4.916072384730796e-07
the O 0 4.2720054693745624e-07
E6 O 0 0.0004262820293661207
- O 0 0.00014042896509636194
AP O 0 4.304544199840166e-05
ubiquitin O 0 6.214845143404091e-06
- O 0 1.293384048040025e-05
protein O 0 9.668788152339403e-07
ligase O 0 2.3344512101175496e-06
and O 0 1.1985693504357187e-07
has O 0 2.1637130487306422e-07
recently O 0 1.5517948668275494e-06
been O 0 6.896662085864591e-08
shown O 0 3.1874201056325546e-08
to O 0 9.186144289685672e-09
be O 0 1.5493948524181178e-07
mutated O 0 6.117921293480322e-05
in O 0 0.0002709938562475145
Angelman B-Disease 1 0.9999456405639648
syndrome I-Disease 1 0.9999991655349731
patients O 0 0.10383125394582748
who O 0 1.6780513760750182e-05
lack O 0 1.6234333088505082e-05
15q11 O 0 0.000584466615691781
- O 0 0.0006610043346881866
q13 O 0 5.6089938880177215e-05
deletions O 0 2.0675095584010705e-05
or O 0 4.651160907087615e-06
chromosome O 0 0.00023542500275652856
15 O 0 1.549020998936612e-05
paternal O 0 0.0003024077450390905
uniparental B-Disease 0 0.22474822402000427
disomy I-Disease 0 0.06362085044384003
. O 0 3.6319350328994915e-05

Previous O 0 5.7901455875253305e-05
UBE3A O 0 0.0004044053493998945
cDNA O 0 5.05462503497256e-06
analysis O 0 1.1257545793341706e-06
has O 0 3.3557910228410037e-07
shown O 0 1.4669822689938883e-07
a O 0 3.2234677860287775e-07
coding O 0 1.0236719390377402e-05
region O 0 1.0109753247888875e-06
of O 0 4.346303583702138e-08
approximately O 0 3.71053516801112e-07
2 O 0 3.8058924474171363e-06
. O 0 3.317284608783666e-06

6 O 0 2.4754706828389317e-05
kb O 0 2.621000567160081e-05
and O 0 5.716121904697502e-07
a O 0 3.8008288356650155e-06
3 O 0 7.670815648452844e-06
- O 0 0.0002600746229290962
untranslated O 0 0.00034725392470136285
region O 0 1.09580332718906e-05
( O 0 2.637027023411065e-07
UTR O 0 2.6250580049236305e-05
) O 0 7.164325666053628e-08
of O 0 7.716900540799543e-08
< O 0 4.086818535142811e-06
50 O 0 5.736890216212487e-07
bp O 0 9.102687727136072e-06
, O 0 2.3914372704325615e-08
whereas O 0 7.166197946162356e-08
Northern O 0 2.4572645429543627e-07
analysis O 0 9.52764622752511e-08
has O 0 6.935218976877877e-08
indicated O 0 1.8665522816263547e-07
mRNA O 0 5.6279905180645073e-08
sizes O 0 2.728044137256802e-07
of O 0 4.0043079962970296e-08
5 O 0 1.2433712299753097e-06
- O 0 2.7386180590838194e-05
8 O 0 2.7649987259792397e-06
kb O 0 4.649186666938476e-05
. O 0 3.0134544886095682e-06

We O 0 1.097535232474911e-06
have O 0 3.5322393898695736e-08
analyzed O 0 2.5067743081308436e-07
additional O 0 9.752002760876621e-09
cDNA O 0 1.757310883476748e-07
clones O 0 3.8673570657010714e-07
and O 0 7.131452317565845e-09
provide O 0 5.106748357519564e-09
evidence O 0 1.627633317013988e-08
for O 0 3.141930937644588e-09
an O 0 3.325112274410458e-08
additional O 0 5.532383440254307e-08
0 O 0 2.039594392044819e-06
. O 0 1.3275385981614818e-06

5 O 0 1.2560263712657616e-05
kb O 0 2.2562995582120493e-05
of O 0 8.807168683233613e-07
5 O 0 7.827643457858358e-06
- O 0 3.687010394060053e-05
UTR O 0 5.975654858048074e-05
and O 0 3.9354958403237106e-07
> O 0 1.973470943994471e-06
2 O 0 4.2790270526893437e-07
kb O 0 3.146951939925202e-06
of O 0 3.21023321703251e-07
3 O 0 1.73237276612781e-05
- O 0 0.0007203448913060129
UTR O 0 0.0008203302859328687
. O 0 6.711750756949186e-06

We O 0 1.2989831930099172e-06
have O 0 4.3568611829414294e-08
established O 0 1.3273293575366552e-07
the O 0 4.7474667752567257e-08
genomic O 0 2.615537596284412e-06
organization O 0 2.615889229673485e-07
of O 0 5.2312557841105445e-08
UBE3A O 0 7.650120824109763e-05
and O 0 1.608248254569844e-07
the O 0 2.426698699764529e-07
sequence O 0 8.089709240266529e-07
of O 0 4.7129842073445616e-07
intron O 0 0.0011700690956786275
- O 0 0.0010371182579547167
exon O 0 0.00035006960388273
borders O 0 5.1351977162994444e-05
. O 0 8.269513273262419e-06

We O 0 3.300336402389803e-06
have O 0 1.066408898964255e-07
also O 0 4.630659589111019e-08
mapped O 0 6.248102408790146e-07
two O 0 1.711653752067832e-08
highly O 0 2.819049598201673e-07
homologous O 0 9.18737271149439e-07
processed O 0 2.9107170007591776e-07
pseudogenes O 0 4.581480425258633e-06
, O 0 2.103463998537336e-07
UBE3AP1 O 0 4.0836664993548766e-05
and O 0 1.8052054429062991e-07
UBE3AP2 O 0 3.426303737796843e-05
, O 0 2.050297531752676e-08
to O 0 5.71026204099212e-09
chromosomes O 0 1.4663767444744735e-07
2 O 0 8.382146177154937e-08
and O 0 2.7072653452364648e-08
21 O 0 2.51345085189314e-07
, O 0 1.748585276573067e-08
respectively O 0 1.423017295110185e-07
, O 0 1.751479317135818e-08
and O 0 1.5894563887286495e-08
determined O 0 1.1208723549316346e-07
their O 0 3.053273900377462e-08
genomic O 0 5.091558250569506e-06
organization O 0 1.4672078805233468e-06
. O 0 1.9250167042628163e-06

These O 0 1.103589056583587e-06
results O 0 2.141367531294236e-06
will O 0 2.8899107107349664e-08
form O 0 3.289145311669017e-08
the O 0 1.624730039395672e-08
basis O 0 2.205962879031631e-08
for O 0 1.9124145822502214e-08
studies O 0 7.55448965605865e-08
of O 0 4.8472188041159825e-08
mutation O 0 3.459157596807927e-06
and O 0 2.5871719344650046e-07
imprinting O 0 6.257400673348457e-05
of O 0 3.7096826872584643e-06
UBE3A O 0 0.012768452055752277
. O 0 2.1346600988181308e-05

Mutation O 0 0.0005081887356936932
spectrum O 0 6.948989175725728e-05
and O 0 3.147446932416642e-06
genotype O 0 0.000163150456501171
- O 0 0.0012007297482341528
phenotype O 0 0.0001340580201940611
analyses O 0 3.3600190363358706e-05
in O 0 1.028814040182624e-05
Cowden B-Disease 1 0.9862470626831055
disease I-Disease 1 0.9990611672401428
and O 0 0.0002589502837508917
Bannayan B-Disease 1 0.9985114932060242
- I-Disease 1 0.9998219609260559
Zonana I-Disease 1 0.9993966817855835
syndrome I-Disease 1 0.9999444484710693
, O 0 1.1337175237713382e-05
two O 0 2.2290820197667927e-05
hamartoma B-Disease 1 0.9794129133224487
syndromes I-Disease 1 0.9566506147384644
with O 0 5.152494122739881e-05
germline O 0 0.11146432161331177
PTEN O 0 0.28011035919189453
mutation O 0 0.004732266068458557
. O 0 2.4353830667678267e-05

The O 0 0.00021290703443810344
tumour B-Disease 1 0.9994770884513855
suppressor O 0 0.0019879008177667856
gene O 0 0.00012692849850282073
PTEN O 0 0.0013346390333026648
, O 0 4.795830363946152e-07
which O 0 4.020371591195726e-08
maps O 0 5.823511628477718e-07
to O 0 3.400309367407317e-07
10q23 O 0 0.00010277867841068655
. O 0 5.0340263442194555e-06

3 O 0 5.337824404705316e-06
and O 0 1.4018695537743042e-07
encodes O 0 3.915781121577311e-07
a O 0 4.652890766010387e-07
403 O 0 6.389145141838526e-07
amino O 0 4.2689143242569116e-07
acid O 0 1.7610550457902718e-06
dual O 0 1.530472218291834e-06
specificity O 0 4.195321253064321e-06
phosphatase O 0 0.0006608501425944269
( O 0 4.884127520199399e-07
protein O 0 1.4400457075680606e-06
tyrosine O 0 9.153071914624888e-06
phosphatase O 0 0.00019757986592594534
; O 0 1.9215083568724367e-07
PTPase O 0 9.03613181435503e-06
) O 0 4.5657944980348475e-08
, O 0 3.171495421838699e-08
was O 0 1.9616688859969145e-06
shown O 0 1.0145667062033681e-07
recently O 0 3.4569308127174736e-07
to O 0 2.3126043302568178e-09
play O 0 3.918186308737859e-08
a O 0 1.2618806977116037e-07
broad O 0 8.585979571762437e-07
role O 0 2.564733222243376e-06
in O 0 1.5202616623355425e-06
human O 0 4.4798533053835854e-05
malignancy B-Disease 1 0.9801850318908691
. O 0 1.8897300833486952e-05

Somatic O 0 0.0006906786584295332
PTEN O 0 0.002654634416103363
deletions O 0 8.184451871784404e-05
and O 0 1.0479906222826685e-06
mutations O 0 1.4987867871241178e-05
were O 0 3.0984239174358663e-07
observed O 0 3.48026878782548e-06
in O 0 4.280051086880121e-07
sporadic B-Disease 0 0.00027569991652853787
breast I-Disease 1 0.9932225942611694
, I-Disease 0 2.5425344574614428e-05
brain I-Disease 1 0.9957701563835144
, I-Disease 0 4.4538643123814836e-05
prostate I-Disease 1 0.9998750686645508
and I-Disease 0 0.0005695567815564573
kidney I-Disease 1 0.9999208450317383
cancer I-Disease 1 0.999647855758667
cell O 0 0.0002717151364777237
lines O 0 1.3066793144389521e-05
and O 0 1.874381467814601e-07
in O 0 1.4208123388925742e-07
several O 0 5.780396463705983e-07
primary O 0 0.0002521179849281907
tumours B-Disease 1 0.9996867179870605
such O 0 5.94069751969073e-06
as O 0 0.03748398646712303
endometrial B-Disease 1 0.9998593330383301
carcinomas I-Disease 1 0.9999935626983643
, O 1 0.998916745185852
malignant B-Disease 1 0.9999992847442627
melanoma I-Disease 1 0.9999995231628418
and O 1 0.9992234706878662
thyroid B-Disease 1 0.9999957084655762
tumours I-Disease 1 0.9999916553497314
. O 0 0.0005463603301905096

In O 0 2.8883266622869996e-06
addition O 0 1.788190729712369e-06
, O 0 1.2954313888258184e-06
PTEN O 0 0.0003381276619620621
was O 0 1.8972854377352633e-05
identified O 0 4.6273621023829037e-07
as O 0 8.60160298543633e-08
the O 0 1.7402830110313516e-07
susceptibility O 0 6.923562068550382e-06
gene O 0 1.5239967297020485e-06
for O 0 3.21548498050106e-07
two O 0 2.1856625608052127e-05
hamartoma B-Disease 1 0.9964434504508972
syndromes I-Disease 1 0.9993155002593994
Cowden B-Disease 1 0.9996370077133179
disease I-Disease 1 0.9998787641525269
( O 0 3.1733004561829148e-06
CD B-Disease 0 0.00027475369279272854
; O 0 1.9503384010022273e-06
MIM O 0 0.00026569474721327424
158350 O 0 5.393887113314122e-05
) O 0 2.677374197901372e-07
and O 0 7.581452905469632e-07
Bannayan B-Disease 0 0.003807893255725503
- I-Disease 0 0.018228018656373024
Zonana I-Disease 0 0.034662388265132904
( I-Disease 0 1.864959472186456e-06
BZS I-Disease 0 0.00021378436940722167
) I-Disease 0 5.284547910378024e-07
or I-Disease 0 2.050893954219646e-06
Ruvalcaba I-Disease 0 0.0010931548895314336
- I-Disease 0 0.0035779797472059727
Riley I-Disease 0 0.002136178547516465
- I-Disease 1 0.905396580696106
Smith I-Disease 0 0.13444608449935913
syndrome I-Disease 1 0.9996399879455566
( O 0 1.1018519217032008e-05
MIM O 0 0.0012270408915355802
153480 O 0 0.0004441611818037927
) O 0 2.869492391255335e-06
. O 0 5.7215111155528575e-06

Constitutive O 0 0.00012560634058900177
DNA O 0 3.0458626497420482e-05
from O 0 5.343277393876633e-07
37 O 0 1.4904477438903996e-06
CD B-Disease 0 4.280975645087892e-06
families O 0 9.741613382630021e-08
and O 0 1.6248888812242512e-07
seven O 0 1.001628106678254e-06
BZS B-Disease 0 7.237702084239572e-05
families O 0 1.2169321905730612e-07
was O 0 5.268442691885866e-06
screened O 0 3.27019665746775e-06
for O 0 6.554565743499552e-07
germline O 0 0.0007765297777950764
PTEN O 0 0.0065368423238396645
mutations O 0 0.0011326898820698261
. O 0 1.3755035979556851e-05

PTEN O 0 0.005700647830963135
mutations O 0 0.00019669397443067282
were O 0 5.293566687214479e-07
identified O 0 9.667857057138463e-07
in O 0 1.0090684554597829e-07
30 O 0 1.4875396914248995e-07
of O 0 3.2344544820261945e-08
37 O 0 8.492443726026977e-07
( O 0 6.438740030034751e-08
81 O 0 7.024340789030248e-07
% O 0 1.2326228926440308e-08
) O 0 1.0043120113323312e-08
CD B-Disease 0 3.5975060086457233e-07
families O 0 1.0494989766129947e-08
, O 0 1.3637907692043427e-08
including O 0 6.458567725076136e-08
missense O 0 1.1799915228039026e-05
and O 0 3.7233175476103497e-07
nonsense O 0 3.180243220413104e-05
point O 0 4.111564066988649e-06
mutations O 0 8.661852007207926e-06
, O 0 6.787771411609356e-08
deletions O 0 1.203686679218663e-06
, O 0 1.2571528884564032e-07
insertions O 0 4.266926225682255e-06
, O 0 2.1833197649812064e-07
a O 0 1.2512697367128567e-06
deletion O 0 1.7076474250643514e-05
/ O 0 9.398669135407545e-06
insertion O 0 3.025872274520225e-06
and O 0 4.569662905851146e-07
splice O 0 0.00018325225391890854
site O 0 0.00014089491742197424
mutations O 0 0.0003035701811313629
. O 0 6.025841230439255e-06

These O 0 8.235948030232976e-07
mutations O 0 2.053589378192555e-05
were O 0 2.954527644760674e-07
scattered O 0 6.474231213360326e-07
over O 0 1.55510008426063e-07
the O 0 1.778278289066293e-07
entire O 0 9.609221933715162e-07
length O 0 5.647021907861927e-07
of O 0 5.6157876571205634e-08
PTEN O 0 5.005547791370191e-05
, O 0 4.3536296345791925e-08
with O 0 8.152206909528559e-09
the O 0 2.770615203928628e-08
exception O 0 5.5288808198383776e-08
of O 0 3.3362281826043727e-09
the O 0 3.725355668393604e-08
first O 0 3.041617446797318e-07
, O 0 8.350518498900783e-08
fourth O 0 2.5474334961472778e-06
and O 0 1.2636581914193812e-07
last O 0 3.469789817245328e-06
exons O 0 1.9142347809975035e-05
. O 0 4.334236109571066e-06

A O 0 4.961356535204686e-05
hot O 0 6.311365723377094e-05
spot O 0 7.77399145590607e-06
for O 0 2.555860021402623e-07
PTEN O 0 0.00012646432151086628
mutation O 0 5.17155103807454e-06
in O 0 8.595370815100978e-08
CD B-Disease 0 2.2887900286150398e-06
was O 0 4.499886472331127e-06
identified O 0 3.049698023005476e-07
in O 0 3.797470071731368e-08
exon O 0 2.1232588096609106e-06
5 O 0 2.2593492587930086e-07
that O 0 5.2299760078255986e-09
contains O 0 1.3618697281003733e-08
the O 0 4.349454840735234e-08
PTPase O 0 7.995773557922803e-06
core O 0 1.5267170283550513e-06
motif O 0 9.606912954041036e-07
, O 0 9.600573669388268e-09
with O 0 3.852468122289565e-09
13 O 0 7.102947563453199e-08
of O 0 6.963488896616354e-09
30 O 0 1.0389315718839498e-07
( O 0 1.8124586276258015e-08
43 O 0 1.182865929649779e-07
% O 0 6.450071143859759e-09
) O 0 1.0147327422771468e-08
CD B-Disease 0 1.0569365258561447e-06
mutations O 0 3.193693373759743e-06
identified O 0 4.631772583252314e-07
in O 0 6.633340632333784e-08
this O 0 1.201007648887753e-07
exon O 0 7.104413089109585e-05
. O 0 5.737313131248811e-06

Seven O 0 3.1034207950142445e-06
of O 0 1.7563878884629958e-07
30 O 0 9.159159048977017e-07
( O 0 4.6573742196187595e-08
23 O 0 4.500009822550055e-07
% O 0 9.034882175740222e-09
) O 0 3.16532333677344e-09
were O 0 5.186179041771766e-09
within O 0 1.3134097365252728e-08
the O 0 7.172912575015289e-08
core O 0 2.5658805498096626e-06
motif O 0 3.8002126530045643e-06
, O 0 4.154103905307238e-08
the O 0 3.683822669131587e-08
majority O 0 2.5228182209957595e-08
( O 0 1.8539857649102487e-08
five O 0 1.8181509631176596e-08
of O 0 6.418077624914531e-09
seven O 0 9.096424946619663e-08
) O 0 5.82983217256583e-09
of O 0 5.5685549504858045e-09
which O 0 3.056962682990161e-08
were O 0 1.6242692879586684e-07
missense O 0 2.3857481210143305e-05
mutations O 0 1.9923032596125267e-05
, O 0 1.720132729587931e-07
possibly O 0 1.0229448434984079e-06
pointing O 0 1.1630349945335183e-06
to O 0 1.1417306211569667e-08
the O 0 3.682080418343503e-08
functional O 0 3.308329610263172e-07
significance O 0 5.546751822294027e-07
of O 0 1.0814745365905765e-07
this O 0 2.7024421456189884e-07
region O 0 1.1877307770191692e-05
. O 0 4.477297352423193e-06

Germline O 0 0.01362712774425745
PTEN O 0 0.00671065878123045
mutations O 0 0.00021907975315116346
were O 0 4.5775840362694e-07
identified O 0 5.289090836413379e-07
in O 0 2.7921750245241128e-08
four O 0 3.6696569338801055e-08
of O 0 3.955996064064493e-08
seven O 0 4.322419897562213e-07
( O 0 9.03748755831657e-08
57 O 0 7.678974043301423e-07
% O 0 3.0797284722439144e-08
) O 0 5.143320436218346e-08
BZS B-Disease 0 3.0191991754691117e-05
families O 0 1.8003365198637766e-07
studied O 0 9.068212420970667e-06
. O 0 3.2289119644701714e-06

Interestingly O 0 6.710029992973432e-05
, O 0 7.5591151471599e-07
none O 0 3.2621557011225377e-07
of O 0 1.611674527168816e-08
these O 0 2.8659286499532755e-08
mutations O 0 6.1448890846804716e-06
was O 0 5.055386282037944e-06
observed O 0 6.767125455553469e-07
in O 0 8.460869338478005e-08
the O 0 5.025991640650318e-07
PTPase O 0 0.00020550086628645658
core O 0 9.432670049136505e-05
motif O 0 0.00021570184617303312
. O 0 7.430437563016312e-06

It O 0 6.870639026601566e-06
is O 0 8.965077427092183e-07
also O 0 1.3533976073176746e-07
worthy O 0 1.1382600177967106e-06
of O 0 1.3441722046536597e-07
note O 0 2.0586419395840494e-06
that O 0 1.3126408404673384e-08
a O 0 1.365058750479875e-07
single O 0 1.4194623645380489e-06
nonsense O 0 1.9546938347048126e-05
point O 0 1.934376541612437e-06
mutation O 0 5.848440196132287e-06
, O 0 6.644965111490819e-08
R233X O 0 2.471924517521984e-06
, O 0 9.405265188888734e-08
was O 0 1.1374527275620494e-06
observed O 0 1.274650429650137e-07
in O 0 9.484579344132271e-09
the O 0 1.1635898466977324e-08
germline O 0 2.7215523914492223e-06
DNA O 0 5.604829311778303e-07
from O 0 3.365816070299843e-08
two O 0 1.8128353929114382e-08
unrelated O 0 7.80159609803377e-07
CD B-Disease 0 5.082020834379364e-06
families O 0 3.823211969233853e-08
and O 0 8.10282188012934e-08
one O 0 7.123026080080308e-07
BZS B-Disease 0 0.0004302487359382212
family O 0 1.1359535164956469e-05
. O 0 4.012548743048683e-06

Genotype O 0 0.0005552356597036123
- O 0 0.00017174029198940843
phenotype O 0 2.421293902443722e-05
studies O 0 4.0206020912592066e-07
were O 0 4.9848964067678025e-08
not O 0 9.665209965703525e-09
performed O 0 3.543357252056012e-07
on O 0 1.4628442102093686e-07
this O 0 7.044255845300995e-09
small O 0 7.897747167362468e-08
group O 0 1.1685857259635668e-07
of O 0 8.221761760296431e-08
BZS B-Disease 0 0.0002638476435095072
families O 0 1.6880965176824247e-06
. O 0 6.170104370539775e-06

However O 0 9.822925676417071e-06
, O 0 2.4207038222812116e-06
genotype O 0 7.111407467164099e-05
- O 0 6.511032552225515e-05
phenotype O 0 2.50177599809831e-05
analysis O 0 4.375273761070275e-07
inthe O 0 2.0564208170981146e-05
group O 0 2.4511209062438866e-07
of O 0 2.7422094817097786e-08
CD B-Disease 0 9.181817404169124e-06
families O 0 8.754774682984134e-08
revealed O 0 1.5463348290722934e-06
two O 0 1.9430160591582535e-08
possible O 0 9.37733943828789e-08
associations O 0 6.523428908167261e-08
worthy O 0 3.3029201063072833e-07
of O 0 3.6233430478205264e-08
follow O 0 3.955759098062117e-07
- O 0 1.1756131243600976e-05
up O 0 6.092322450967913e-07
in O 0 1.4953853622046154e-07
independent O 0 4.0202073137152183e-07
analyses O 0 5.48467505723238e-06
. O 0 3.361689550729352e-06

The O 0 1.979478156499681e-06
first O 0 2.8636829938477604e-06
was O 0 9.162049536826089e-06
an O 0 1.4940967218990409e-07
association O 0 2.740197544426337e-07
noted O 0 1.6458277229958185e-07
in O 0 4.033644174228357e-08
the O 0 4.992803681602709e-08
group O 0 5.3303345737276686e-08
of O 0 1.5958597998633195e-08
CD B-Disease 0 7.962019481055904e-06
families O 0 3.8492314047289256e-07
with O 0 0.00014149377238936722
breast B-Disease 1 0.9998098015785217
disease I-Disease 1 0.9992623925209045
. O 0 1.7615320757613517e-05

A O 0 8.432918548351154e-06
correlation O 0 4.434006768860854e-06
was O 0 9.416045941179618e-06
observed O 0 1.0849822729142033e-06
between O 0 9.866451478046656e-08
the O 0 1.4975746864820394e-07
presence O 0 1.7473638536102953e-06
/ O 0 1.2347884876362514e-05
absence O 0 1.3510984899767209e-06
of O 0 5.220212173639993e-08
a O 0 2.7102778403786942e-06
PTEN O 0 0.0002997683477587998
mutation O 0 5.14404973728233e-06
and O 0 3.743790344401532e-08
the O 0 1.2832371965032507e-07
type O 0 5.579535354627296e-05
of O 0 2.1746720904047834e-06
breast O 1 0.9903443455696106
involvement O 0 9.017301636049524e-05
( O 0 5.7987890613731e-06
unaffected O 0 0.0020353381987661123
versus O 0 0.03672824800014496
benign O 1 0.996411144733429
versus O 1 0.9477335810661316
malignant O 1 0.9996806383132935
) O 0 3.8113589653221425e-06
. O 0 5.359993792808382e-06

Specifically O 0 2.6168302156293066e-06
and O 0 1.5484421567180107e-07
more O 0 1.1717144587919393e-08
directly O 0 1.0765906210963294e-07
, O 0 5.247884971026906e-08
an O 0 7.835284776547269e-08
association O 0 1.0246799320157152e-06
was O 0 6.518729151139269e-06
also O 0 4.1471928113878676e-08
observed O 0 4.941436060335036e-08
between O 0 1.0173431874704875e-08
the O 0 1.4133924253201258e-08
presence O 0 7.429739667941249e-08
of O 0 5.3110323250393776e-08
a O 0 1.0226669473922811e-05
PTEN O 0 0.005344115197658539
mutation O 0 0.0016112022567540407
and O 0 0.0008732357528060675
malignant B-Disease 1 0.9999638795852661
breast I-Disease 1 0.999931812286377
disease I-Disease 1 0.999756395816803
. O 0 7.145621930249035e-05

Secondly O 0 0.00029500917298719287
, O 0 2.0800202946702484e-06
there O 0 1.8163838433338242e-07
appeared O 0 1.1134671922263806e-06
to O 0 1.2466104593045202e-08
be O 0 8.418095553963667e-09
an O 0 1.0330939659297655e-08
interdependent O 0 7.931408617878333e-06
association O 0 5.556350970437052e-07
between O 0 3.288982952653896e-07
mutations O 0 5.976428838039283e-06
upstream O 0 7.718444976489991e-07
and O 0 6.069114277806875e-08
within O 0 6.661843343636065e-08
the O 0 2.641222636157181e-07
PTPase O 0 5.361501462175511e-05
core O 0 1.2463446182664484e-05
motif O 0 1.3026146007177886e-05
, O 0 8.427031161772902e-08
the O 0 3.307887652681529e-08
core O 0 1.2888461924376315e-06
motif O 0 2.0648928966693347e-06
containing O 0 7.513606448128485e-08
the O 0 4.371678130610235e-08
majority O 0 5.054885932054276e-08
of O 0 4.4789533859557196e-08
missense O 0 6.390996713889763e-05
mutations O 0 2.1860272681806237e-05
, O 0 9.9563031596972e-08
and O 0 2.5609686815641908e-08
the O 0 9.629295760760215e-08
involvement O 0 5.245553893473698e-07
of O 0 2.0390228172573188e-08
all O 0 5.9382003314567555e-08
major O 0 2.816001870087348e-05
organ O 0 0.3272066116333008
systems O 0 0.03600502759218216
( O 0 2.0195386696286732e-06
central O 0 8.682163752382621e-06
nervous O 0 0.0031766060274094343
system O 0 0.0011507099261507392
, O 0 0.00011704461212502792
thyroid O 1 0.9998424053192139
, O 0 6.807351019233465e-05
breast O 1 0.9987278580665588
, O 0 0.00017170589126180857
skin O 1 0.9994238615036011
and O 0 0.10746525228023529
gastrointestinal O 1 0.9999505281448364
tract O 1 0.9993151426315308
) O 0 1.0440251571708359e-05
. O 0 9.903404134092852e-06

However O 0 2.80105700767308e-06
, O 0 8.8077506177342e-08
these O 0 4.203493997323449e-09
observations O 0 1.7660775597505562e-07
would O 0 2.3503188728568603e-08
need O 0 1.4642059120717477e-08
to O 0 5.716354056772843e-09
be O 0 2.751194116967781e-08
confirmed O 0 4.3471821697949053e-08
by O 0 3.15543169371324e-09
studying O 0 3.488890953917689e-08
a O 0 2.0059410132944322e-08
larger O 0 3.602009712722065e-08
number O 0 2.0981824278010208e-08
of O 0 3.2011040929091905e-08
CD B-Disease 0 8.884375347406603e-06
families O 0 5.460216243591276e-07
. O 0 3.448870756983524e-06

Molecular O 1 0.7220340371131897
defects O 1 0.9989238381385803
leading O 0 0.00015559584426227957
to O 0 2.6890018034464447e-07
human O 0 2.5663089218141977e-06
complement B-Disease 0 5.3540115914074704e-05
component I-Disease 1 0.9128308892250061
C6 I-Disease 1 0.9999819993972778
deficiency I-Disease 1 0.9999866485595703
in O 0 1.0167882464884315e-06
an O 0 3.0452892474386317e-07
African O 0 1.2263601547601866e-06
- O 0 9.47310691117309e-05
American O 0 3.0849721497361315e-06
family O 0 7.679614100197796e-06
. O 0 3.6771439226868097e-06

Complement B-Disease 0 0.0016360599547624588
component I-Disease 1 0.982092022895813
C6 I-Disease 1 0.9999481439590454
deficiency I-Disease 1 0.9999808073043823
( O 0 1.3107392987876665e-05
C6D B-Disease 0 0.002104145707562566
) O 0 1.6843767980390112e-06
was O 0 0.0011466940632089972
diagnosed O 1 0.8539208173751831
in O 0 8.687124619655151e-08
a O 0 4.104071535948606e-07
16 O 0 1.4906765954947332e-06
- O 0 1.5917405107757077e-05
year O 0 8.02168074187648e-07
- O 0 5.664963282470126e-06
old O 0 5.063777280156501e-06
African O 0 2.2071967009651416e-07
- O 0 4.462395736481994e-06
American O 0 6.263620662139147e-07
male O 0 6.382004812621744e-06
with O 0 6.44143219687976e-05
meningococcal B-Disease 1 0.9995179176330566
meningitis I-Disease 1 0.9995075464248657
. O 0 2.8387372367433272e-05

The O 0 1.679285560385324e-05
patients O 0 4.286630064598285e-05
father O 0 9.236999176209792e-06
and O 0 1.392862429838715e-07
two O 0 1.9934542194732785e-07
brothers O 0 2.2980544599704444e-05
also O 0 9.068548934010323e-07
had O 0 1.9948779481637757e-06
C6D B-Disease 0 6.395800301106647e-05
, O 0 7.540440094544465e-08
but O 0 2.794029008157395e-08
gave O 0 7.781341793133834e-08
no O 0 5.308591255470674e-08
history O 0 7.877179655224609e-07
of O 0 1.6283837567243609e-06
meningitis B-Disease 1 0.9995386600494385
or O 0 1.8102323338098358e-06
other O 0 1.4162266097628162e-06
neisserial B-Disease 1 0.9587985277175903
infection I-Disease 1 0.9950048327445984
. O 0 1.5819659893168136e-05

By O 0 3.4194957265754056e-07
using O 0 1.1997201454505557e-06
exon O 0 4.447807805263437e-05
- O 0 8.31419038149761e-06
specific O 0 2.6257092144987837e-07
polymerase O 0 1.2942537978233304e-05
chain O 0 2.4755203412496485e-05
reaction O 0 1.6224730643443763e-06
( O 0 7.237075294597162e-08
PCR O 0 1.6907015378819779e-06
) O 0 5.0250861249878653e-08
/ O 0 7.704824724896753e-07
single O 0 2.9438257342917495e-07
- O 0 2.561175051596365e-06
strand O 0 4.378412654659769e-07
conformation O 0 4.1335829337185714e-07
polymorphism O 0 1.7294560450409335e-07
as O 0 8.416056296312036e-09
a O 0 1.7152784081986283e-08
screening O 0 8.166652776253613e-08
step O 0 5.1525304911592684e-08
and O 0 3.112982094322092e-09
nucleotide O 0 4.259329244860055e-08
sequencing O 0 2.951245825499882e-08
of O 0 5.126638225050328e-09
target O 0 7.978720617529689e-08
exons O 0 6.059635779820383e-07
, O 0 6.272299657439362e-08
we O 0 2.411306354588305e-08
determined O 0 1.0420731655358395e-07
that O 0 3.7792444729234376e-09
the O 0 3.2840176800164045e-08
proband O 0 9.583227438270114e-06
was O 0 8.603815899732581e-07
a O 0 8.138275120472827e-08
compound O 0 5.359603960641834e-07
heterozygote O 0 7.133623967092717e-07
for O 0 2.1156996155013985e-08
two O 0 1.8860437478451786e-07
C6 O 0 0.0040522669441998005
gene O 0 7.519032078562304e-05
mutations O 0 0.00033983495086431503
. O 0 1.1433035069785547e-05

The O 0 2.758588152573793e-06
first O 0 1.3728987369177048e-06
, O 0 2.2772759677991417e-07
1195delC O 0 6.999971901677782e-06
located O 0 7.332991458497418e-07
in O 0 8.978367560530387e-08
exon O 0 7.673874279134907e-06
7 O 0 2.0637451143556973e-06
, O 0 7.498231013869372e-08
is O 0 6.770573435233018e-08
a O 0 1.5077837645094405e-07
novel O 0 4.773366981680738e-07
mutation O 0 1.8909493064711569e-06
, O 0 2.437450952186282e-08
while O 0 2.0660273492012493e-08
the O 0 3.365944323263648e-08
second O 0 3.250001725518814e-07
, O 0 5.9552370146320754e-08
1936delG O 0 2.7632986530079506e-06
in O 0 1.0156760765767103e-07
exon O 0 5.890044576517539e-06
12 O 0 7.536700650234707e-07
, O 0 7.344539909581727e-08
has O 0 1.2367173951588484e-07
been O 0 1.0296243146967754e-07
described O 0 2.471994662300858e-07
before O 0 1.34501846105195e-07
to O 0 3.523639691138669e-08
cause O 0 3.138883130304748e-06
C6D B-Disease 0 2.917722667916678e-05
in O 0 4.1025995045629315e-08
an O 0 3.4422448891291424e-08
unrelated O 0 1.8258069758303463e-06
African O 0 4.32274589456938e-07
- O 0 1.6181778846657835e-05
American O 0 3.345833761159156e-07
individual O 0 4.925012149215036e-07
. O 0 2.160485109925503e-06

Both O 0 1.0325489711249247e-05
mutations O 0 0.000495496264193207
result O 0 2.630460585351102e-05
in O 0 8.68999177328078e-06
premature O 0 0.0006392364739440382
termination O 0 6.15854951320216e-05
codons O 0 3.835768802673556e-05
and O 0 3.2447044304717565e-06
C6 O 0 0.02151833102107048
null O 0 0.00032573851058259606
alleles O 0 7.442878995789215e-05
. O 0 2.003340341616422e-05

Allele O 0 0.00017706156359054148
- O 0 3.761703192139976e-05
specific O 0 6.670781544926285e-07
PCR O 0 1.4608001947635785e-05
indicated O 0 1.220000285684364e-06
that O 0 1.1262400789746607e-08
the O 0 9.077464113715905e-08
probands O 0 1.3609575944428798e-05
two O 0 1.3782994301436702e-07
brothers O 0 1.4670715245301835e-05
also O 0 9.469939072914713e-07
inherited O 0 0.0004117173666600138
the O 0 6.066753712730133e-07
1195delC O 0 2.1934112737653777e-05
mutation O 0 1.7362957578370697e-06
from O 0 2.6387118268189624e-08
their O 0 9.544757872959053e-09
heterozygous O 0 4.208104940062185e-07
mother O 0 1.9411550056247506e-06
and O 0 6.514936501389457e-08
the O 0 2.3217060629576736e-07
1936delG O 0 2.734920235525351e-05
mutation O 0 3.5453417694952805e-06
from O 0 3.983427987463983e-08
their O 0 6.38516155504476e-08
homozygous O 0 8.250024620792829e-06
father O 0 1.3256902093417011e-05
. O 0 4.574524723466311e-07
. O 0 2.504996473362553e-06

PAX6 O 0 0.1444394588470459
mutations O 0 0.026479993015527725
reviewed O 0 0.001107658608816564
. O 0 7.702548464294523e-05

Mutations O 0 0.0008989807683974504
in O 0 3.1424203825736186e-06
PAX6 O 0 0.00041865819366648793
are O 0 1.555613380332943e-07
responsible O 0 1.3880398910259828e-06
for O 0 9.789072663579645e-08
human O 0 7.53777430873015e-06
aniridia B-Disease 1 0.999340832233429
and O 0 1.5404825717268977e-06
have O 0 1.4103552814503928e-07
also O 0 1.4857475605367654e-07
been O 0 1.4550610671903996e-07
found O 0 1.77151775915263e-07
in O 0 1.3971128964840318e-07
patients O 0 1.8320005210625823e-06
with O 0 1.5736293335066875e-06
Peters B-Disease 1 0.9993322491645813
anomaly I-Disease 1 0.9997262358665466
, O 0 9.059689182322472e-05
with O 0 0.16609418392181396
congenital B-Disease 1 0.9999990463256836
cataracts I-Disease 1 0.9999624490737915
, O 0 1.495086689828895e-05
with O 0 9.589552973920945e-06
autosomal B-Disease 1 0.9926550388336182
dominant I-Disease 1 0.7094841003417969
keratitis I-Disease 1 0.9678450226783752
, O 0 3.971161277149804e-06
and O 0 1.158173745352542e-06
with O 0 2.8977960027987137e-05
isolated B-Disease 1 0.9674779772758484
foveal I-Disease 1 0.9997913241386414
hypoplasia I-Disease 1 0.9998513460159302
. O 0 0.00025839588488452137

No O 0 3.1904542083793785e-06
locus O 0 8.847840035741683e-06
other O 0 8.107892313091725e-08
than O 0 1.613820614920769e-07
chromosome O 0 1.2947773029736709e-05
11p13 O 0 4.687841737904819e-06
has O 0 2.4799146558507346e-07
been O 0 2.9887868890909886e-07
implicated O 0 1.5866529793129303e-05
in O 0 1.218857164531073e-06
aniridia B-Disease 1 0.9992592930793762
, O 0 6.817730309194303e-07
and O 0 4.065559835453314e-07
PAX6 O 0 0.0008375957841053605
is O 0 9.388834882884112e-07
clearly O 0 5.237176310401992e-07
the O 0 9.205722761862489e-08
major O 0 3.1404699711856665e-06
, O 0 5.4620709732944306e-08
if O 0 2.6029507438352084e-08
not O 0 5.21883514181809e-09
only O 0 4.808458520244585e-09
, O 0 4.0585632632428315e-08
gene O 0 1.0761692692540237e-06
responsible O 0 6.261294402065687e-06
. O 0 4.2286769712518435e-06

Twenty O 0 1.170571158581879e-05
- O 0 3.350707265781239e-05
eight O 0 9.588916327629704e-07
percent O 0 1.541993469800218e-06
of O 0 7.919226874264496e-08
identified O 0 2.096643584081903e-06
PAX6 O 0 0.00011647534847725183
mutations O 0 1.631049599382095e-05
are O 0 1.4993666752616264e-07
C O 0 0.0002605058834888041
- O 0 0.0007907068356871605
T O 0 0.0003056632122024894
changes O 0 5.480761160470138e-07
at O 0 1.247485556632455e-06
CpG O 0 4.5295564632397145e-06
dinucleotides O 0 8.609877113485709e-06
, O 0 3.9860957201653946e-08
20 O 0 3.065025211412831e-08
% O 0 1.4472875120574713e-09
are O 0 1.29519395208888e-09
splicing O 0 4.3801918536701123e-07
errors O 0 7.3775581768131815e-06
, O 0 1.902268387254935e-08
and O 0 5.744684283826018e-09
more O 0 1.020808215734803e-09
than O 0 1.0904697589353418e-08
30 O 0 8.742676271822347e-08
% O 0 6.84257139837996e-09
are O 0 9.028439329483717e-09
deletion O 0 1.3340569466890884e-06
or O 0 1.7014306763485365e-07
insertion O 0 2.7444548322819173e-06
events O 0 1.839320020735613e-06
. O 0 2.2718904801877216e-06

There O 0 3.930574166588485e-06
is O 0 1.1822428405139362e-06
a O 0 7.920305051811738e-07
noticeably O 0 5.4453521443065256e-05
elevated O 0 0.0004157298826612532
level O 0 1.3262769016364473e-06
of O 0 7.440461047281133e-08
mutation O 0 1.9282854282209883e-06
in O 0 3.273773430123583e-08
the O 0 1.725891429771309e-08
paired O 0 4.214217312892288e-07
domain O 0 1.6850407291713054e-07
compared O 0 5.506905154106789e-07
with O 0 2.162008883033195e-08
the O 0 1.2761708489961165e-07
rest O 0 1.8300713122698653e-07
of O 0 1.8683417479792297e-08
the O 0 3.77130845663487e-07
gene O 0 1.401947702106554e-05
. O 0 3.6070227906748187e-06

Increased O 0 1.8120121239917353e-05
mutation O 0 7.152492617024109e-05
in O 0 3.284065144271153e-07
the O 0 2.6409884412714746e-07
homeodomain O 0 2.179894181608688e-05
is O 0 1.4170396411827824e-07
accounted O 0 1.413444152831289e-07
for O 0 1.4826528449418674e-08
by O 0 6.44440447672423e-08
the O 0 5.479370770444802e-07
hypermutable O 0 0.0001617366069694981
CpG O 0 3.369516707607545e-05
dinucleotide O 0 5.1100643759127706e-05
in O 0 1.467941274313489e-06
codon O 0 1.3519437743525486e-05
240 O 0 4.173206434643362e-06
. O 0 2.5140095658571227e-06

Very O 0 2.473495214871946e-06
nearly O 0 7.064622877805959e-07
all O 0 4.9776279098523446e-08
mutations O 0 7.32774606149178e-06
appear O 0 9.985741371565382e-07
to O 0 1.872391237611737e-07
cause O 0 0.0001449664414394647
loss O 0 6.796389061491936e-05
of O 0 3.00841520584072e-08
function O 0 1.4418029081753048e-07
of O 0 1.9905888493099155e-08
the O 0 7.590598727347242e-08
mutant O 0 7.720639132458018e-07
allele O 0 4.985528789802629e-07
, O 0 2.6982798218000426e-08
and O 0 4.433318157026633e-09
more O 0 1.5392284113957544e-09
than O 0 1.0177973130964801e-08
80 O 0 4.9952422642718375e-08
% O 0 7.910196941907088e-09
of O 0 1.677030603275398e-08
exonic O 0 1.2234887435624842e-05
substitutions O 0 1.4409207551580039e-06
result O 0 1.5135450439629494e-06
in O 0 4.220439393520792e-07
nonsense O 0 3.335019573569298e-05
codons O 0 4.261672802385874e-05
. O 0 5.868995685887057e-06

In O 0 1.475116505389451e-06
a O 0 6.971118864385062e-07
gene O 0 8.038198302529054e-07
with O 0 5.5233897455764236e-08
such O 0 8.198976075846076e-08
extraordinarily O 0 7.978234498295933e-05
high O 0 2.066066736006178e-05
sequence O 0 7.060534130687302e-07
conservation O 0 2.458328651755437e-07
throughout O 0 8.286497887866062e-08
evolution O 0 1.1634083563194508e-07
, O 0 3.183233943104824e-08
there O 0 2.2094409857231767e-08
are O 0 2.1385210047242253e-08
presumed O 0 7.225355147966184e-06
undiscovered O 0 6.618297629756853e-05
missense O 0 4.899477062281221e-05
mutations O 0 1.8299944713362493e-05
, O 0 3.60281333655621e-08
these O 0 1.6014634063310496e-09
are O 0 2.529282561170021e-09
hypothesized O 0 1.1452151937874078e-07
to O 0 5.0257256134500494e-09
exist O 0 4.2566981051095354e-08
in O 0 1.588302325217228e-07
as O 0 1.648443003432476e-06
- O 0 0.00018832208297681063
yet O 0 4.160704520472791e-06
unidentified O 0 5.214748307480477e-05
phenotypes O 0 3.660587390186265e-05
. O 0 5.596305072685936e-07
. O 0 2.1138337160664378e-06

Genetic O 0 0.0006339577957987785
heterogeneity O 0 0.00020076398504897952
and O 0 1.8241310044686543e-06
penetrance O 0 0.0006049642106518149
analysis O 0 1.2881851034762803e-06
of O 0 1.2096967338948161e-07
the O 0 1.1380819842088385e-06
BRCA1 O 0 6.417917757062241e-05
and O 0 5.70631755181239e-07
BRCA2 O 0 0.00012846356548834592
genes O 0 2.2538286430062726e-05
in O 0 4.046220419695601e-05
breast B-Disease 1 0.9994933605194092
cancer I-Disease 1 0.9989820122718811
families O 0 3.483433374640299e-06
. O 0 6.442686299124034e-06

The O 0 0.015708550810813904
Breast B-Disease 1 0.9999536275863647
Cancer I-Disease 1 0.9999185800552368
Linkage O 0 0.003780052065849304
Consortium O 0 0.0010310107609257102
. O 0 3.2817140890983865e-05

The O 0 2.5118097255472094e-06
contribution O 0 3.7681375033571385e-06
of O 0 1.1008036153725698e-06
BRCA1 O 0 0.0003051295061595738
and O 0 6.551268143084599e-06
BRCA2 O 0 0.0011811513686552644
to O 0 9.595113078830764e-05
inherited B-Disease 1 0.9999898672103882
breast I-Disease 1 0.9999949932098389
cancer I-Disease 1 0.9999983310699463
was O 0 0.0016242207493633032
assessed O 0 2.4175340058718575e-06
by O 0 3.561675043783907e-08
linkage O 0 1.8257808278576704e-06
and O 0 1.1599816929219742e-07
mutation O 0 8.085436320470762e-07
analysis O 0 8.594322054022996e-08
in O 0 2.7632953703005114e-08
237 O 0 1.4206118237325427e-07
families O 0 5.9443845401574436e-09
, O 0 3.1683675683069623e-09
each O 0 7.924735312414555e-10
with O 0 5.900623101240399e-09
at O 0 5.628182861983078e-07
least O 0 1.6283662418459244e-08
four O 0 3.5344903892564616e-08
cases O 0 2.0288942437218793e-07
of O 0 2.147891791537404e-06
breast B-Disease 1 0.9995974898338318
cancer I-Disease 1 0.9982140064239502
, O 0 4.159328526043282e-08
collected O 0 7.013357361529415e-08
by O 0 2.7958475357081625e-07
the O 0 0.00028545671375468373
Breast B-Disease 1 0.9999822378158569
Cancer I-Disease 1 0.9999551773071289
Linkage O 0 0.00035519571974873543
Consortium O 0 0.00023941186373122036
. O 0 8.45166141516529e-06

Families O 0 7.248402198456461e-07
were O 0 2.0165562375495938e-07
included O 0 1.1067599103853354e-07
without O 0 6.726834556047834e-08
regard O 0 7.697276060980585e-08
to O 0 1.6125138557754326e-08
the O 0 2.596524950604362e-07
occurrence O 0 7.684653246542439e-05
of O 0 3.873982677760068e-06
ovarian B-Disease 1 0.9995469450950623
or I-Disease 0 9.14935390028404e-06
other I-Disease 0 5.373167823563563e-06
cancers I-Disease 1 0.9984488487243652
. O 0 1.0169871529797092e-05

Overall O 0 0.0007413352723233402
, O 0 8.745844388613477e-05
disease O 1 0.9956573247909546
was O 0 0.00012690911535173655
linked O 0 1.387775773764588e-05
to O 0 3.880789734012069e-08
BRCA1 O 0 4.372347120806808e-06
in O 0 4.85877080791397e-08
an O 0 1.303549179709762e-08
estimated O 0 5.1279119617220204e-08
52 O 0 1.8537267010287906e-07
% O 0 5.974848615863948e-09
of O 0 4.044543366887865e-09
families O 0 1.0646505899103431e-08
, O 0 2.3569180385152322e-08
to O 0 1.8818425928657234e-08
BRCA2 O 0 1.8160318404625286e-06
in O 0 5.084116594389343e-08
32 O 0 1.55124595835332e-07
% O 0 5.705232730690568e-09
of O 0 6.0191029938039264e-09
families O 0 7.248925459890643e-09
, O 0 1.3832844203420791e-08
and O 0 6.593074974858837e-09
to O 0 4.058839930820568e-09
neither O 0 6.801352725460674e-08
gene O 0 9.77073639774062e-08
in O 0 4.691235844234143e-08
16 O 0 1.1170817515449016e-07
% O 0 1.1303051827837862e-08
( O 0 1.502306012923782e-08
95 O 0 1.2296270313072455e-07
% O 0 3.2262413185435435e-08
confidence O 0 1.6513681657670531e-06
interval O 0 3.4995262012671446e-06
[ O 0 4.223187715979293e-06
CI O 0 0.000296869344310835
] O 0 2.8078604827896925e-06
6 O 0 7.980194709489297e-07
% O 0 6.163572408013351e-08
- O 0 4.53063648819807e-06
28 O 0 5.707683499167615e-07
% O 0 1.2516590430777796e-08
) O 0 1.615543077093662e-08
, O 0 3.596250053305994e-08
suggesting O 0 3.9331774814854725e-07
other O 0 1.1465998284165835e-07
predisposition O 0 9.41347680054605e-05
genes O 0 1.0076631042466033e-05
. O 0 4.627544058166677e-06

The O 0 4.470334260986419e-06
majority O 0 1.2887305729236687e-06
( O 0 2.5840748207883735e-07
81 O 0 2.0386009964568075e-06
% O 0 2.0027451697046672e-08
) O 0 1.9307510257249305e-08
of O 0 6.05741092840617e-08
the O 0 0.0002804694522637874
breast B-Disease 1 0.999941349029541
- I-Disease 1 0.9999721050262451
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.999976634979248
families O 0 1.763147707833923e-07
were O 0 1.58109045855781e-07
due O 0 7.608962846461509e-07
to O 0 2.606020821360744e-08
BRCA1 O 0 4.5525348468800075e-06
, O 0 3.9790311490151e-08
with O 0 2.0534008271511084e-08
most O 0 3.8833150028949603e-08
others O 0 5.703897087983023e-08
( O 0 4.6587867785774506e-08
14 O 0 3.5354418059796444e-07
% O 0 1.3063792714262945e-08
) O 0 3.39004770921747e-08
due O 0 6.49699302357476e-07
to O 0 3.507821872972272e-07
BRCA2 O 0 0.00014503902639262378
. O 0 4.3338432078599e-06

Conversely O 0 5.847337160957977e-05
, O 0 3.7113565554136585e-07
the O 0 2.109518817405842e-07
majority O 0 5.738489150530768e-08
of O 0 1.7477518099440204e-08
families O 0 2.6869297897746947e-08
with O 0 6.65577246650173e-08
male B-Disease 0 1.5009562730483594e-06
and I-Disease 0 1.2996597433811985e-06
female I-Disease 0 0.00024031430075410753
breast I-Disease 1 0.9992615580558777
cancer I-Disease 1 0.9864451289176941
were O 0 3.0741827572455804e-07
due O 0 1.2122355883548153e-06
to O 0 9.320651628286214e-08
BRCA2 O 0 1.6556303307879716e-05
( O 0 3.6419055504666176e-07
76 O 0 4.808103767572902e-06
% O 0 1.2095941315237724e-07
) O 0 1.8214385022474744e-07
. O 0 9.873904218693497e-07

The O 0 3.4039310321531957e-06
largest O 0 1.1080859621870331e-05
proportion O 0 1.6913612626012764e-06
( O 0 1.3574408797012438e-07
67 O 0 8.11189636351628e-07
% O 0 1.3133846898938373e-08
) O 0 4.939397779679666e-09
of O 0 1.8111928623554263e-09
families O 0 4.568745382016459e-09
due O 0 1.4705429407513293e-07
to O 0 1.973680996414373e-09
other O 0 3.2345452982696088e-09
genes O 0 1.3114951968873356e-07
was O 0 2.25863914238289e-06
found O 0 8.554074781841337e-08
in O 0 1.1024509305457286e-08
families O 0 1.3373201435129545e-09
with O 0 6.62292087838523e-09
four O 0 3.8263049617626166e-08
or O 0 5.155744986495847e-08
five O 0 5.725522456145882e-08
cases O 0 1.0556365737102169e-07
of O 0 1.7134708230059914e-07
female O 0 0.0011509176110848784
breast B-Disease 1 0.999896764755249
cancer I-Disease 1 0.999198853969574
only O 0 6.489796646746981e-07
. O 0 3.620073357524234e-06

These O 0 4.501370653997583e-07
estimates O 0 1.446056899112591e-06
were O 0 1.6258624668807897e-07
not O 0 4.282798826693579e-08
substantially O 0 2.7435444280854426e-06
affected O 0 2.2584853809348715e-07
either O 0 8.051166844325053e-08
by O 0 5.739890340805687e-08
changing O 0 1.3284453643791494e-06
the O 0 2.892591624004126e-07
assumed O 0 4.201133833703352e-06
penetrance O 0 3.689110235427506e-05
model O 0 1.208075104841555e-06
for O 0 5.269841807375997e-08
BRCA1 O 0 8.789306775724981e-06
or O 0 1.0438536435231072e-07
by O 0 2.2764609752812248e-08
including O 0 7.536183943557262e-08
or O 0 3.785487763252604e-07
excluding O 0 8.039893145905808e-06
BRCA1 O 0 0.00021982926409691572
mutation O 0 3.48673238477204e-05
data O 0 4.382407496450469e-06
. O 0 6.515106178994756e-06

Among O 0 2.10538587452902e-06
those O 0 2.58536886121874e-07
families O 0 2.902462199472211e-07
with O 0 4.3251344322925434e-05
disease O 1 0.9980053305625916
due O 0 1.5352234186138958e-05
to O 0 1.157962330466944e-07
BRCA1 O 0 1.0836144610948395e-05
that O 0 2.2805460631047936e-08
were O 0 3.2803868066366704e-08
tested O 0 2.500835876162455e-07
by O 0 4.268305708876596e-09
one O 0 6.143523023638409e-09
of O 0 2.9167945836405806e-09
the O 0 1.225842449770198e-08
standard O 0 3.394111445231829e-07
screening O 0 1.5885811421867402e-07
methods O 0 8.271275930837874e-08
, O 0 3.630302103374561e-08
mutations O 0 4.4806111532125215e-07
were O 0 3.6482457943520785e-08
detected O 0 1.3379071788222063e-06
in O 0 1.9951349017333087e-08
the O 0 1.726424869730181e-08
coding O 0 1.1087920483987546e-06
sequence O 0 1.308611672357074e-07
or O 0 3.82483804628464e-08
splice O 0 1.7911331724462798e-06
sites O 0 1.6240956313140487e-07
in O 0 3.3188964465580284e-08
an O 0 1.0852824416929252e-08
estimated O 0 5.1849948334847795e-08
63 O 0 2.7578778372117085e-07
% O 0 7.2800458994493056e-09
( O 0 9.10478803461956e-09
95 O 0 1.9375065107851697e-07
% O 0 6.054834500446304e-08
CI O 0 0.00012789851462002844
51 O 0 2.7039009182772133e-06
% O 0 3.0190557254172745e-07
- O 0 1.2780183169525117e-05
77 O 0 3.3661647194094257e-06
% O 0 8.794976480430705e-08
) O 0 2.1453091392231727e-07
. O 0 6.910632350809465e-07

The O 0 3.109452336502727e-06
estimated O 0 1.4014260614203522e-06
sensitivity O 0 1.5365428680524928e-06
was O 0 1.2618628488780814e-06
identical O 0 9.542868184553299e-08
for O 0 2.1242627656903323e-09
direct O 0 9.579008697357949e-09
sequencing O 0 8.651193894593234e-08
and O 0 1.7357887571733954e-08
other O 0 9.19248943631601e-09
techniques O 0 2.7149419565830613e-06
. O 0 2.7319517812429694e-06

The O 0 2.3737451556371525e-05
penetrance O 0 0.0025934732984751463
of O 0 1.9659144072647905e-06
BRCA2 O 0 0.0002608342038001865
was O 0 2.4485221729264595e-05
estimated O 0 1.8685274483232206e-07
by O 0 5.94995732683401e-08
maximizing O 0 1.043853103510628e-06
the O 0 5.129252258484485e-07
LOD O 0 0.00010867408127523959
score O 0 1.1768634067266248e-06
in O 0 4.5406832782646234e-07
BRCA2 O 0 6.912538810865954e-05
- O 0 5.2856121328659356e-05
mutation O 0 4.435808477865066e-06
families O 0 3.015975735820575e-08
, O 0 2.6501464134298658e-08
over O 0 3.5899176964449e-08
all O 0 3.660436220798147e-08
possible O 0 8.332204970429302e-07
penetrance O 0 0.00020500023674685508
functions O 0 6.450457931350684e-06
. O 0 9.507542017672677e-06

The O 0 3.566628492990276e-06
estimated O 0 6.545335054397583e-06
cumulative O 0 2.2597188944928348e-05
risk O 0 0.0001235615200130269
of O 0 6.907271654199576e-06
breast B-Disease 1 0.9996044039726257
cancer I-Disease 1 0.9977549910545349
reached O 0 1.0171132998948451e-05
28 O 0 1.1336160241626203e-06
% O 0 2.0266734068741243e-08
( O 0 1.3532809539640311e-08
95 O 0 2.5353924115734117e-07
% O 0 7.37588763399799e-08
CI O 0 9.247983689419925e-05
9 O 0 7.136972612897807e-07
% O 0 2.4336786808021316e-08
- O 0 1.266547997147427e-06
44 O 0 1.3436519452625362e-07
% O 0 7.947565272559132e-09
) O 0 2.9852640359706584e-09
by O 0 4.549172150092318e-09
age O 0 1.3315462865648442e-07
50 O 0 3.7762710292099655e-08
years O 0 4.670041064969155e-08
and O 0 4.0159953584861796e-08
84 O 0 4.993013362764032e-07
% O 0 1.291201279229881e-08
( O 0 1.414090711193694e-08
95 O 0 1.7956399744889495e-07
% O 0 3.366881884403483e-08
CI O 0 6.642159860348329e-05
43 O 0 6.902873224134964e-07
% O 0 3.382935886975247e-08
- O 0 1.2582722774823196e-06
95 O 0 1.8605204843424872e-07
% O 0 7.34705896121568e-09
) O 0 4.516120810649227e-09
by O 0 2.6165098532260345e-08
age O 0 9.804205092223128e-07
70 O 0 1.1382286402294994e-06
years O 0 1.7248898984689731e-06
. O 0 1.3258039643915254e-06

The O 0 0.0005401817033998668
corresponding O 1 0.9836969971656799
ovarian B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.9999959468841553
risks O 0 0.0727359727025032
were O 0 7.814501259417739e-06
0 O 0 1.5099354641279206e-05
. O 0 4.9153127292811405e-06

4 O 0 1.8115042621502653e-05
% O 0 2.291775018647968e-07
( O 0 7.813942914935978e-08
95 O 0 3.3013330380526895e-07
% O 0 8.959960240417786e-08
CI O 0 9.098910231841728e-05
0 O 0 3.9097511717045563e-07
% O 0 2.418344280386009e-08
- O 0 6.660330882368726e-07
1 O 0 5.351237319928259e-08
% O 0 2.734890092170872e-09
) O 0 1.4297195649604078e-09
by O 0 3.4743594667929756e-09
age O 0 7.634010756873977e-08
50 O 0 3.0298483721935554e-08
years O 0 4.355955240953335e-08
and O 0 1.3773213680678964e-08
27 O 0 1.912698053274653e-07
% O 0 4.78978545714881e-09
( O 0 5.267236424799648e-09
95 O 0 5.965377170014108e-08
% O 0 3.15770307679486e-08
CI O 0 3.344309880048968e-05
0 O 0 2.0061386862835207e-07
% O 0 3.87866627704625e-08
- O 0 8.490774803249224e-07
47 O 0 1.843707053694743e-07
% O 0 7.510623234452396e-09
) O 0 2.8714257638284835e-09
by O 0 9.28868626459689e-09
age O 0 3.9967048337530287e-07
70 O 0 4.861737465944316e-07
years O 0 8.657390253574704e-07
. O 0 9.67087203207484e-07

The O 0 1.5104727026482578e-05
lifetime O 0 0.00039004444261081517
risk O 0 0.0012508244253695011
of O 0 5.6779659644234926e-05
breast B-Disease 1 0.999846339225769
cancer I-Disease 1 0.9995476603507996
appears O 0 8.634092409920413e-06
similar O 0 2.2721496861777268e-07
to O 0 2.5740881426372653e-08
the O 0 4.2176952774752863e-07
risk O 0 6.0800512073910795e-06
in O 0 2.460718917518534e-07
BRCA1 O 0 7.817669029464014e-06
carriers O 0 7.606104190926999e-07
, O 0 7.867691920182551e-08
but O 0 3.2773595393109645e-08
there O 0 2.2840678681745885e-08
was O 0 2.2762380069707433e-07
some O 0 2.4878006321671364e-09
suggestion O 0 1.1532917199019721e-07
of O 0 1.544384353735495e-08
a O 0 1.8875458636102849e-06
lower O 0 0.00013133350876159966
risk O 0 7.67334768170258e-06
in O 0 2.1456078513892862e-07
BRCA2 O 0 1.1835326404252555e-05
carriers O 0 1.5934469956846442e-06
< O 0 2.242293703602627e-06
50 O 0 2.4565406420151703e-07
years O 0 1.7653231054737262e-07
of O 0 7.705457960582862e-08
age O 0 1.2630605851882137e-05
. O 0 3.6392289075593e-06

Eye B-Disease 1 0.8307459354400635
movement I-Disease 0 0.0006209639250300825
abnormalities I-Disease 0 0.3328390419483185
correlate O 0 1.6200401660171337e-05
with O 0 3.2358911994379014e-06
genotype O 0 0.0002969007764477283
in O 0 1.855885966506321e-05
autosomal O 1 0.9879010915756226
dominant O 1 0.9905205965042114
cerebellar B-Disease 1 0.9978721141815186
ataxia I-Disease 1 0.9995718598365784
type I-Disease 1 0.9994899034500122
I I-Disease 1 0.9948117733001709
. O 0 3.8191072235349566e-05

We O 0 9.996670996770263e-06
compared O 0 3.0232038625399582e-05
horizontal O 0 0.0002026906586252153
eye O 0 0.008755575865507126
movements O 0 6.653976743109524e-05
( O 0 7.487775519621209e-07
visually O 0 1.0476534953340888e-05
guided O 0 9.821605090110097e-06
saccades O 0 0.0003161691129207611
, O 0 4.7093541866161104e-07
antisaccades O 0 2.570478682173416e-05
, O 0 8.387600303194631e-08
and O 0 2.5467111086641125e-08
smooth O 0 2.6208360850432655e-06
pursuit O 0 2.9729123980359873e-06
) O 0 8.871465695392544e-08
in O 0 8.148479224701077e-08
control O 0 1.0055446182377636e-06
subjects O 0 1.4511283552565146e-06
( O 0 2.5656385105321533e-07
n O 0 1.3254109035187867e-05
= O 0 7.2359262048848905e-06
14 O 0 5.805605951536563e-07
) O 0 2.321267089655521e-08
and O 0 4.4711690350141e-08
patients O 0 3.809037423252448e-07
with O 0 2.034609636325513e-08
three O 0 1.4106862522567098e-07
forms O 0 2.2887682007421972e-06
of O 0 4.0882223402149975e-06
autosomal O 1 0.9638916254043579
dominant O 1 0.6347028017044067
cerebellar B-Disease 1 0.9829157590866089
ataxias I-Disease 1 0.7212479114532471
type I-Disease 1 0.6683894395828247
I I-Disease 0 0.01607341505587101
spinocerebellar B-Disease 1 0.6512375473976135
ataxias I-Disease 0 0.0012622223002836108
1 I-Disease 0 2.8240808660484618e-06
and I-Disease 0 2.5773312017918215e-07
2 I-Disease 0 8.057032232500205e-07
( O 0 1.4305037154827005e-07
SCA1 B-Disease 0 4.5771455916110426e-05
, O 0 4.4414204580789374e-07
n O 0 8.990585229184944e-06
= O 0 5.624160621664487e-06
11 O 0 6.35083722499985e-07
; O 0 6.691132625746832e-08
SCA2 B-Disease 0 1.8522121536079794e-05
, O 0 1.2802753701635083e-07
n O 0 2.3907430204417324e-06
= O 0 2.0158115603408078e-06
10 O 0 1.0550628815053642e-07
) O 0 3.192950970287711e-08
and O 0 3.562586243788246e-07
SCA3 B-Disease 1 0.979496955871582
/ O 0 0.00038150674663484097
Machado B-Disease 0 0.0008922612760215998
- I-Disease 0 0.015087981708347797
Joseph I-Disease 0 0.0034375630784779787
disease I-Disease 1 0.9936403632164001
( O 0 2.740510808507679e-06
MJD B-Disease 1 0.9955863952636719
) O 0 4.1442837073191185e-07
( O 0 2.5504573386569973e-07
n O 0 1.177734066004632e-05
= O 0 1.1493468264234252e-05
16 O 0 1.7561260392540134e-06
) O 0 3.1017705737212964e-07
. O 0 1.079283492799732e-06

In O 0 1.5868299669818953e-05
SCA1 B-Disease 0 0.0003387542092241347
, O 0 2.746067764292093e-07
saccade O 0 1.2549955499707721e-05
amplitude O 0 2.921751729445532e-06
was O 0 3.6268600069888635e-06
significantly O 0 2.337453906875453e-06
increased O 0 3.381288706805208e-07
, O 0 9.973067705004723e-08
resulting O 0 1.5275369378286996e-06
in O 0 1.250203354175028e-06
hypermetria B-Disease 0 0.00061794527573511
. O 0 9.205288733937778e-06

The O 0 1.2200317769384128e-06
smooth O 0 1.4382243534782901e-05
pursuit O 0 2.876496728276834e-05
gain O 0 1.948109820659738e-05
was O 0 0.00031689368188381195
decreased O 0 0.00012654767488129437
. O 0 4.884090230916627e-06

In O 0 1.8513466784497723e-05
SCA2 B-Disease 0 0.0008649984374642372
, O 0 1.1452592616478796e-06
saccade O 0 2.3771637643221766e-05
velocity O 0 1.0517007467569783e-05
was O 0 1.5044377505546436e-05
markedly O 0 9.71274494077079e-05
decreased O 0 0.00010754197865026072
. O 0 7.620533324370626e-06

The O 0 4.2001324800367e-06
percentage O 0 3.7629768485203385e-05
of O 0 6.148256375126948e-07
errors O 0 0.00039499279228039086
in O 0 1.245718863174261e-06
antisaccades O 0 0.0002881800173781812
was O 0 1.0233693501504604e-05
greatly O 0 6.700225299027807e-07
increased O 0 2.2312940473057097e-07
and O 0 6.989719025796148e-08
was O 0 1.4402461374629638e-06
significantly O 0 2.8041841915182886e-07
correlated O 0 3.671841852792568e-07
with O 0 9.141368195741961e-08
age O 0 2.353358104301151e-05
at O 0 0.0020219578873366117
disease O 1 0.9966385364532471
onset O 1 0.7635781168937683
. O 0 2.3041597160045058e-05

In O 0 2.6107154553756118e-06
addition O 0 4.845074386139459e-07
, O 0 6.630430959830846e-08
a O 0 5.076074316434642e-08
correlation O 0 6.575871935865507e-08
between O 0 5.212938702925385e-08
smooth O 0 9.271039971281425e-07
pursuit O 0 9.914780321196304e-07
gain O 0 2.5359315714013064e-07
and O 0 4.204217773917662e-08
the O 0 3.6161008409862916e-08
number O 0 4.3265441007633854e-08
of O 0 1.8640245968981617e-07
trinucleotide O 0 0.0006705680279992521
repeats O 0 0.00012456532567739487
was O 0 6.575325096491724e-05
found O 0 3.585939566619345e-06
. O 0 2.088537257805001e-06

In O 0 4.0777711546979845e-05
SCA3 B-Disease 1 0.996379554271698
, O 0 8.146525942720473e-06
gaze B-Disease 0 0.0008905746508389711
- I-Disease 0 0.001506454893387854
evoked I-Disease 0 0.00011379409261280671
nystagmus I-Disease 0 0.000728869519662112
was O 0 2.0082812625332735e-05
often O 0 1.263144895347068e-07
present O 0 4.7101892164391757e-08
as O 0 1.9235564252539916e-07
was O 0 3.982360794907436e-06
saccade O 0 9.373114153277129e-06
hypometria O 0 1.9267290554125793e-05
and O 0 1.636427811035901e-07
smooth O 0 6.038197625457542e-06
pursuit O 0 6.110289177740924e-06
gain O 0 4.228410489304224e-06
was O 0 3.1562231015414e-05
markedly O 0 9.492711978964508e-05
decreased O 0 0.00011430534505052492
. O 0 3.278933945694007e-06

Three O 0 5.866718311153818e-06
major O 0 1.0548628779361024e-05
criteria O 0 3.167915110680042e-06
, O 0 1.5399669450744113e-07
saccade O 0 6.541572474816348e-06
amplitude O 0 8.454962880932726e-07
, O 0 7.047779604363313e-08
saccade O 0 2.524923047531047e-06
velocity O 0 5.184243718758808e-07
, O 0 2.79093956834231e-08
and O 0 1.6803284097477444e-08
presence O 0 1.517652918892054e-07
of O 0 1.4892486888129497e-07
gaze B-Disease 0 0.0004807136137969792
- I-Disease 0 0.0004449018742889166
evoked I-Disease 0 7.18733572284691e-05
nystagmus I-Disease 0 0.00010948174895020202
, O 0 7.318082850815699e-08
permitted O 0 4.711618117880789e-08
the O 0 4.7079979026420915e-08
correct O 0 1.0147365401280695e-06
assignment O 0 3.0012859042471973e-07
of O 0 9.365682451800694e-09
90 O 0 4.6308713308462757e-08
% O 0 4.669673980828293e-09
of O 0 4.808477171991399e-09
the O 0 5.190546303879273e-08
SCA1 B-Disease 0 2.2067613826948218e-05
, O 0 3.079604837807892e-08
90 O 0 2.954281441702733e-08
% O 0 4.037898904130088e-09
of O 0 3.1975324610300504e-09
the O 0 3.7341415293212776e-08
SCA2 B-Disease 0 1.2275020708329976e-05
, O 0 2.0691190982802254e-08
and O 0 1.3618750571708915e-08
93 O 0 2.0168255332464469e-07
% O 0 5.830432581177547e-09
of O 0 9.72028502133071e-09
the O 0 2.7199985197512433e-07
patients O 0 9.519994819129352e-07
with O 0 1.2368860780043178e-07
SCA3 B-Disease 1 0.9963098168373108
to O 0 2.6626407745311553e-08
their O 0 3.191781772216018e-08
genetically O 0 2.6795148642122513e-06
confirmed O 0 5.440653694677167e-06
patient O 0 5.559951659961371e-06
group O 0 8.843572629757546e-08
and O 0 5.248696055559776e-08
, O 0 6.796839358003126e-08
therefore O 0 1.4738002107606007e-07
, O 0 1.7610672387036175e-07
may O 0 3.233757865928055e-07
help O 0 1.5298958544462948e-07
orient O 0 6.596515595447272e-05
diagnoses O 0 7.354201807174832e-05
of O 0 2.9478545116035093e-07
SCA1 B-Disease 0 0.0007871541893109679
, O 0 7.012286573626625e-07
SCA2 B-Disease 0 0.0001569235319038853
, O 0 2.6198262048637844e-07
and O 0 4.2526974652901117e-07
SCA3 B-Disease 1 0.9956674575805664
at O 0 8.364094355783891e-06
early O 0 3.5621449114842108e-06
clinical O 0 4.936282948619919e-06
stages O 0 4.769285624206532e-06
of O 0 2.0495336627845973e-07
the O 0 2.9011667720624246e-05
diseases O 1 0.9985306262969971
. O 0 1.329974111285992e-06
. O 0 3.78714457838214e-06

Genetic O 0 6.310504977591336e-05
basis O 0 1.8698623307500384e-06
and O 0 7.965671784404549e-07
molecular O 0 0.0002808895951602608
mechanism O 0 0.0025494240690022707
for O 0 0.003142351983115077
idiopathic B-Disease 1 0.9999898672103882
ventricular I-Disease 1 0.9999051094055176
fibrillation I-Disease 1 0.9999434947967529
. O 0 0.0013476560125127435

Ventricular B-Disease 1 0.9945171475410461
fibrillation I-Disease 1 0.9937331080436707
causes O 0 0.00017007773567456752
more O 0 3.447612684226442e-08
than O 0 6.428629006904885e-08
300 O 0 2.408301043033134e-07
, O 0 5.566476701801548e-08
000 O 0 4.3404386929069005e-07
sudden O 0 1.5862446161918342e-05
deaths O 0 1.3458003422783804e-06
each O 0 2.5520987989580135e-08
year O 0 4.849868560086179e-07
in O 0 1.738008990059825e-07
the O 0 6.796890374971554e-07
USA O 0 3.797371027758345e-05
alone O 0 6.749949989171e-06
. O 0 2.473910399203305e-06

In O 0 8.270035891655425e-07
approximately O 0 4.056365980886767e-07
5 O 0 8.340742851942196e-07
- O 0 3.802315177381388e-06
12 O 0 1.6212575815188757e-07
% O 0 5.564828153836743e-09
of O 0 2.267018128776499e-09
these O 0 6.481172487582398e-09
cases O 0 8.477200452716716e-08
, O 0 2.166351187327109e-08
there O 0 1.3008617294474334e-08
are O 0 8.20252310518299e-09
no O 0 3.7550546494458104e-07
demonstrable O 0 0.0003510814858600497
cardiac O 1 0.7658770084381104
or O 0 8.012980288185645e-06
non O 0 0.0031925877556204796
- O 1 0.9982010126113892
cardiac O 1 0.9979901313781738
causes O 0 2.2664742573397234e-05
to O 0 1.6732730756530145e-08
account O 0 3.3976537139324137e-08
for O 0 4.6092534233821425e-09
the O 0 4.409000453620138e-08
episode O 0 6.298933499238046e-07
, O 0 6.40415223074342e-08
which O 0 2.780652685885343e-08
is O 0 7.819429725941518e-08
therefore O 0 1.8393411949091387e-07
classified O 0 3.249785731895827e-05
as O 0 0.00069140933919698
idiopathic B-Disease 1 0.9999837875366211
ventricular I-Disease 1 0.9998792409896851
fibrillation I-Disease 1 0.9999781847000122
( O 0 0.00044521334348246455
IVF B-Disease 1 0.9980124235153198
) O 0 7.192610610218253e-06
. O 0 6.188886345626088e-06

A O 0 8.5533411038341e-06
distinct O 0 2.4747478164499626e-06
group O 0 1.6351749536624993e-06
of O 0 1.9047610066991183e-06
IVF B-Disease 1 0.999403715133667
patients O 0 0.0002775111061055213
has O 0 1.2071272976754699e-06
been O 0 3.5532553965822444e-07
found O 0 4.068949621682805e-08
to O 0 2.1973363129035306e-09
present O 0 1.8950689906205298e-08
with O 0 5.467261843250526e-08
a O 0 2.968297394545516e-06
characteristic O 0 5.897367009310983e-05
electrocardiographic O 0 0.0018925383919849992
pattern O 0 0.0003548611421138048
. O 0 7.853320312278811e-06

Because O 0 5.980203695798991e-06
of O 0 1.3280993016451248e-07
the O 0 1.025870304260934e-07
small O 0 1.1782319120356988e-07
size O 0 3.758056834612944e-07
of O 0 1.907318392113666e-08
most O 0 4.699904820881784e-08
pedigrees O 0 1.9887556845787913e-06
and O 0 9.725128080617651e-08
the O 0 4.449042592113983e-07
high O 0 0.000273533834842965
incidence O 0 0.0011295074364170432
of O 0 2.1505019276446546e-07
sudden B-Disease 0 0.0003795214870478958
death I-Disease 0 2.380521073064301e-05
, O 0 7.989685002485203e-08
however O 0 5.0515613025936545e-08
, O 0 2.2958213108381642e-08
molecular O 0 2.7051648885390023e-06
genetic O 0 2.8803963232348906e-06
studies O 0 1.8238371524148533e-07
of O 0 4.664851260827163e-08
IVF B-Disease 1 0.9778748154640198
have O 0 1.5487330529140308e-07
not O 0 3.693820715966467e-08
yet O 0 3.4200698451058997e-07
been O 0 4.7594531338290835e-07
done O 0 1.3180269888835028e-06
. O 0 1.8447357206241577e-06

Because O 0 0.0006207555416040123
IVF B-Disease 1 0.9957141280174255
causes O 1 0.6920700669288635
cardiac O 1 0.9982309937477112
rhythm O 1 0.9637248516082764
disturbance O 0 0.19159699976444244
, O 0 1.784609594324138e-06
we O 0 4.032983156321279e-07
investigated O 0 1.018244893202791e-05
whether O 0 7.168808338064991e-07
malfunction O 0 0.0017010446172207594
of O 0 8.766789250103102e-08
ion O 0 1.113037251343485e-05
channels O 0 7.549018391728168e-06
could O 0 9.444006536796223e-06
cause O 0 3.1143408705247566e-05
the O 0 1.1990418897767086e-06
disorder O 0 0.034006912261247635
by O 0 1.0199139666156043e-07
studying O 0 7.210482522168604e-07
mutations O 0 4.683609859057469e-06
in O 0 1.287043858155812e-07
the O 0 6.421202556339267e-07
cardiac O 0 0.0027542924508452415
sodium O 0 1.7273905541514978e-05
channel O 0 3.8968959415797144e-05
gene O 0 3.7223177059786394e-05
SCN5A O 0 0.0009353554924018681
. O 0 7.1626286626269575e-06

We O 0 2.514374045858858e-06
have O 0 1.7672854824013484e-07
now O 0 3.8683862157995463e-07
identified O 0 7.545258426944201e-07
a O 0 6.18666376794863e-07
missense O 0 3.2357620511902496e-05
mutation O 0 7.977859240781981e-06
, O 0 8.361212877616708e-08
a O 0 2.731493395913276e-07
splice O 0 3.635223401943222e-05
- O 0 9.748932643560693e-05
donor O 0 3.0271478408394614e-06
mutation O 0 3.6399474083737005e-06
, O 0 2.943168198044077e-08
and O 0 2.5438271933353462e-08
a O 0 1.1389985274945502e-06
frameshift O 0 0.0001935555919772014
mutation O 0 4.054148575960426e-06
in O 0 1.0969474573130356e-07
the O 0 1.5753920479255612e-07
coding O 0 1.9773027815972455e-05
region O 0 2.9537009140767623e-06
of O 0 1.45172336374344e-07
SCN5A O 0 0.0003247155691497028
in O 0 7.67935489420779e-07
three O 0 1.3909059362049447e-06
IVF B-Disease 1 0.844896137714386
families O 0 9.999740768762422e-07
. O 0 2.6001180231105536e-06

We O 0 5.604770194622688e-07
show O 0 1.4130452541394334e-07
that O 0 8.560142816804728e-09
sodium O 0 9.382867460772104e-08
channels O 0 4.962915056694328e-08
with O 0 2.1537648109415386e-08
the O 0 2.41357298591538e-07
missense O 0 6.129741086624563e-05
mutation O 0 2.657553704921156e-05
recover O 0 3.776109224418178e-06
from O 0 1.1834763569140705e-07
inactivation O 0 3.5737066355068237e-05
more O 0 1.2835720930581829e-08
rapidly O 0 1.134557919613144e-06
than O 0 3.725086017425383e-08
normal O 0 3.3742017535587365e-07
and O 0 2.178483526904529e-08
that O 0 1.228609125547564e-08
the O 0 1.9526818562098924e-07
frameshift O 0 0.0005299962940625846
mutation O 0 2.7072475859313272e-05
causes O 0 2.1335338260541903e-06
the O 0 6.282273545821226e-08
sodium O 0 5.6309261253773e-07
channel O 0 4.6898489358682127e-07
to O 0 1.5021655030977854e-08
be O 0 7.240347343895337e-08
non O 0 9.291699143432197e-07
- O 0 3.150305201415904e-05
functional O 0 1.1377825103409123e-05
. O 0 4.096800239494769e-06

Our O 0 1.6422920452896506e-05
results O 0 8.455619536107406e-06
indicate O 0 2.1147229745110963e-06
that O 0 1.372729627746594e-07
mutations O 0 4.065791472385172e-06
in O 0 7.026578145996609e-07
cardiac O 0 0.0011180221335962415
ion O 0 1.8561939214123413e-05
- O 0 1.234116280102171e-05
channel O 0 1.924287971633021e-06
genes O 0 1.8037253823877109e-07
contribute O 0 5.556791293770402e-08
to O 0 9.179698778893908e-09
the O 0 2.297639980497479e-07
risk O 0 5.412211976363324e-06
of O 0 1.2177645203337306e-07
developing O 0 3.063264739466831e-05
IVF B-Disease 1 0.9953497052192688
. O 0 2.212884055552422e-06
. O 0 2.1146199742361205e-06

Molecular O 0 0.0006114912102930248
heterogeneity O 0 0.00042171074892394245
in O 0 9.642410986998584e-06
mucopolysaccharidosis B-Disease 0 0.003159974468871951
IVA I-Disease 0 0.018640344962477684
in O 0 1.4751066146345693e-06
Australia O 0 4.3498286572685174e-07
and O 0 1.6694961857410817e-07
Northern O 0 2.451156206006999e-06
Ireland O 0 6.940247203601757e-06
: O 0 2.682158424249792e-07
nine O 0 2.9026338665971707e-07
novel O 0 7.028943969089596e-07
mutations O 0 2.146654878742993e-06
including O 0 9.854809945863963e-08
T312S O 0 9.283742656407412e-06
, O 0 6.006742125919118e-08
a O 0 1.5776051043303596e-07
common O 0 3.386080607015174e-07
allele O 0 1.3226807595856371e-06
that O 0 8.21234209524846e-08
confers O 0 6.1363980421447195e-06
a O 0 1.8724440451478586e-05
mild O 0 0.012770256958901882
phenotype O 0 0.0011687740916386247
. O 0 9.30282476474531e-06

Mucopolysaccharidosis B-Disease 1 0.8879452347755432
IVA I-Disease 1 0.9878408312797546
( O 0 0.00041748920921236277
MPS B-Disease 1 0.9986636638641357
IVA I-Disease 1 0.9997969269752502
) O 0 2.743902768997941e-06
is O 0 1.7515731087769382e-06
an O 0 7.501787877117749e-06
autosomal B-Disease 1 0.9973631501197815
recessive I-Disease 1 0.9993165731430054
lysosomal I-Disease 1 0.9997914433479309
storage I-Disease 1 0.9998931884765625
disorder I-Disease 1 0.9999686479568481
caused O 0 0.22047647833824158
by O 0 2.2298781914287247e-06
a O 0 0.00019814338884316385
genetic B-Disease 1 0.9984474778175354
defect I-Disease 1 0.9993699193000793
in O 0 5.1289521252328996e-06
N O 0 0.0006232652813196182
- O 0 0.0004588404844980687
acetylgalactosamine O 0 0.0011674754787236452
- O 0 0.0006137490272521973
6 O 0 7.287879998330027e-05
- O 0 0.0012639216147363186
sulfate O 0 0.002510149497538805
sulfatase O 0 0.002297148806974292
( O 0 1.7357873502987786e-06
GALNS O 0 0.00039207766531035304
) O 0 1.5379224578282447e-06
. O 0 2.350461272726534e-06

Previous O 0 1.4348433069244493e-05
studies O 0 1.3139956536178943e-06
of O 0 2.901698223922722e-07
patients O 0 3.1885258522379445e-06
from O 0 8.605098855696269e-08
a O 0 6.178568128234474e-07
British O 0 2.255260551464744e-05
- O 0 0.00013625832798425108
Irish O 0 7.49289301893441e-06
population O 0 3.754044186621286e-08
showed O 0 4.731177796202246e-07
that O 0 8.682880192623088e-09
the O 0 6.26436147399545e-08
I113F O 0 6.186950486153364e-06
mutation O 0 2.5360916424688185e-06
is O 0 4.1181223764397146e-08
the O 0 1.8162861437076572e-08
most O 0 1.9761078107194407e-08
common O 0 2.607386306863191e-07
single O 0 3.2375210139434785e-06
mutation O 0 4.776383502758108e-05
among O 0 6.343927907437319e-06
MPS B-Disease 1 0.996446430683136
IVA I-Disease 1 0.9998447895050049
patients O 0 0.0009109366801567376
and O 0 1.6850966630954645e-06
produces O 0 1.4740329788764939e-05
a O 0 0.00013338426651898772
severe O 1 0.9452233910560608
clinical O 0 0.004217428155243397
phenotype O 0 0.005977348890155554
. O 0 1.408447224093834e-05

We O 0 7.38766857466544e-06
studied O 0 1.2103111657779664e-05
mutations O 0 1.6942825823207386e-05
in O 0 1.5777888506818272e-07
the O 0 2.072581821721542e-07
GALNS O 0 4.907533366349526e-05
gene O 0 2.1415919491118984e-06
from O 0 3.501698699892586e-07
23 O 0 2.8298395591264125e-06
additional O 0 1.5052263506731833e-06
MPS B-Disease 1 0.9774404764175415
IVA I-Disease 1 0.9995574355125427
patients O 0 0.00018970691598951817
( O 0 1.3632632089866092e-07
15 O 0 1.5468555147890584e-07
from O 0 3.238745094336082e-08
Australia O 0 3.902396983335166e-08
, O 0 2.2947311606458243e-08
8 O 0 9.181209037478766e-08
from O 0 2.040088808996643e-08
Northern O 0 1.7057296020084323e-07
Ireland O 0 3.437665725414263e-07
) O 0 1.8304511684164027e-08
, O 0 8.940069129437234e-09
with O 0 9.984826299103133e-09
various O 0 1.1959762957758358e-07
clinical O 0 8.7567517766729e-05
phenotypes O 0 0.00022179502411745489
( O 0 3.348206519149244e-06
severe O 0 0.02699463628232479
, O 0 3.7719848933193134e-07
16 O 0 1.0530540066611138e-06
cases O 0 1.5691036026055372e-07
; O 0 3.698254857908978e-08
intermediate O 0 3.2709172046452295e-06
, O 0 1.1824441514818318e-07
4 O 0 1.5602860230501392e-06
cases O 0 5.050713411947072e-07
; O 0 3.6315424267741037e-07
mild O 0 0.000244517985265702
, O 0 2.4695748379599536e-07
3 O 0 1.1865802207466913e-06
cases O 0 4.725757491996774e-07
) O 0 2.781109742500121e-07
. O 0 1.0405057082607527e-06

We O 0 2.4115422547765775e-06
found O 0 2.423340674795327e-07
two O 0 2.241368690647505e-08
common O 0 3.6336314224172384e-07
mutations O 0 1.4892133322064183e-06
that O 0 2.53452725473835e-09
together O 0 5.024518134888467e-09
accounted O 0 5.3593169013765873e-08
for O 0 4.474877801641242e-09
32 O 0 5.641166467285075e-08
% O 0 3.0178735066499485e-09
of O 0 4.024574007388537e-09
the O 0 3.325011022070612e-08
44 O 0 2.3856611619521573e-07
unrelated O 0 5.196380357119779e-07
alleles O 0 4.3636310920192045e-07
in O 0 1.282619450648781e-07
these O 0 1.192755121337541e-07
patients O 0 1.4025254131411202e-05
. O 0 1.6472581592097413e-06

One O 0 2.752464979494107e-06
is O 0 5.134410798746103e-07
the O 0 1.3512425312001142e-07
T312S O 0 2.0241148376953788e-05
mutation O 0 7.839588761271443e-06
, O 0 7.769477861074847e-08
a O 0 4.1642351789050736e-07
novel O 0 2.391835550952237e-06
mutation O 0 8.91975923877908e-06
found O 0 2.5544810000610596e-07
exclusively O 0 3.4604633469825785e-07
in O 0 1.3030130503466353e-06
milder O 0 0.0004948305431753397
patients O 0 0.0001142487017204985
. O 0 7.980058398970868e-06

The O 0 8.995926350507943e-07
other O 0 7.117309053228382e-08
is O 0 1.4014258908900956e-07
the O 0 1.548795012240589e-07
previously O 0 2.0800659967790125e-06
described O 0 3.4188835797976935e-06
I113F O 0 6.694197509204969e-06
that O 0 8.90919480411867e-08
produces O 0 2.721350028878078e-06
a O 0 2.0596649846993387e-05
severe O 1 0.5148788690567017
phenotype O 0 0.0018619676120579243
. O 0 1.4554203517036512e-05

The O 0 8.233033440774307e-06
I113F O 0 9.8095100838691e-05
and O 0 1.0960477538901614e-06
T312S O 0 3.130178083665669e-05
mutations O 0 1.177663216367364e-05
accounted O 0 1.2185945479359361e-06
for O 0 3.264040771000509e-08
8 O 0 4.3677113126250333e-07
( O 0 3.233658674162143e-08
18 O 0 1.6367430077934841e-07
% O 0 6.659960583021984e-09
) O 0 4.808037079584437e-09
and O 0 1.526921700190087e-08
6 O 0 2.074042981803359e-07
( O 0 1.6788996859418148e-08
14 O 0 9.295991532098924e-08
% O 0 4.242980189417267e-09
) O 0 3.4662379633232376e-09
of O 0 4.415326770867978e-09
44 O 0 2.849734812571114e-07
unrelated O 0 8.710583188076271e-07
alleles O 0 1.2431909226506832e-06
, O 0 4.737720189496031e-07
respectively O 0 8.007877113413997e-06
. O 0 6.9288462327676825e-06

The O 0 8.051524673646782e-06
relatively O 0 2.2136789993965067e-05
high O 0 7.546810229541734e-05
residual O 0 6.582477362826467e-05
GALNS O 0 0.000453554792329669
activity O 0 1.8541788904258283e-06
seen O 0 1.5745029031677404e-06
when O 0 7.303247429035764e-08
the O 0 3.081050437003796e-08
T312S O 0 2.0129298263782403e-06
mutant O 0 8.650671361465356e-07
cDNA O 0 7.153865340114862e-07
is O 0 2.218814785237555e-07
overexpressed O 0 1.1569921298359986e-05
in O 0 1.7269245233819674e-07
mutant O 0 3.5663904327520868e-06
cells O 0 1.2073091966158245e-06
provides O 0 2.755563599521338e-08
an O 0 4.143492304820029e-08
explanation O 0 1.8650665367658803e-07
for O 0 4.141501364074429e-08
the O 0 8.522649181941233e-07
mild O 0 0.0006875895778648555
phenotype O 0 2.8260419639991596e-05
in O 0 6.834551413703593e-07
patients O 0 1.8505186289985431e-06
with O 0 7.680718283609167e-08
this O 0 3.293204429155594e-07
mutation O 0 5.138592314324342e-05
. O 0 1.7892244841277716e-06

The O 0 2.424267506739852e-07
distribution O 0 1.9528793870904337e-07
and O 0 4.0002621659596116e-08
relative O 0 2.037748316752186e-07
frequencies O 0 5.27478505318868e-07
of O 0 2.6104682859795503e-08
the O 0 1.5660852170640283e-07
I113F O 0 8.645716661703773e-06
and O 0 3.909150905201386e-07
T312S O 0 9.202163710142486e-06
mutations O 0 4.9999694056168664e-06
in O 0 7.240790012019716e-08
Australia O 0 3.48648931947082e-08
corresponded O 0 7.279271585503011e-08
to O 0 4.394105079796873e-09
those O 0 1.2066348809014471e-08
observed O 0 2.535493877076078e-07
in O 0 4.714188861498769e-08
Northern O 0 2.3535854154488334e-07
Ireland O 0 5.051879270467907e-07
and O 0 3.874163567729738e-08
are O 0 1.7887675785033252e-09
unique O 0 6.736307511800987e-09
to O 0 3.6433760453036257e-09
these O 0 3.6404028680436795e-09
two O 0 1.2191410547757187e-08
populations O 0 6.312517797368855e-08
, O 0 1.784005299043656e-08
suggesting O 0 1.1289203172282214e-07
that O 0 6.562538068521917e-09
both O 0 1.9307510257249305e-08
mutations O 0 5.462914600684599e-07
were O 0 5.0101370163702086e-08
probably O 0 1.4354000654748234e-07
introduced O 0 4.43682246498156e-08
to O 0 7.72347963362563e-09
Australia O 0 2.3964691564515306e-08
by O 0 1.515307879174088e-08
Irish O 0 1.7645871821514447e-06
migrants O 0 4.129023523091746e-08
during O 0 2.648583006248373e-07
the O 0 1.414305899061219e-07
19th O 0 5.0452531468181405e-06
century O 0 4.518959030974656e-06
. O 0 3.351292662046035e-06

Haplotype O 0 0.00025152851594612
analysis O 0 1.2509093494372792e-06
using O 0 6.021161311764445e-07
6 O 0 2.0388847588037606e-06
RFLPs O 0 7.51690595279797e-06
provides O 0 5.1421139346530254e-08
additional O 0 2.3251665481893724e-08
data O 0 1.200549490931735e-07
that O 0 2.3822547490226498e-08
the O 0 1.840866161728627e-07
I113F O 0 8.884705493983347e-06
mutation O 0 2.406745124972076e-06
originated O 0 2.2829185297723598e-07
from O 0 1.2636245116937062e-07
a O 0 3.9817385300011665e-07
common O 0 2.217243945779046e-06
ancestor O 0 3.197601472493261e-05
. O 0 1.2884325769846328e-05

The O 0 1.512409539827786e-06
other O 0 1.398918243467051e-07
9 O 0 4.764970981341321e-06
novel O 0 1.7158612308776355e-06
mutations O 0 4.834854735236149e-06
identified O 0 4.423514212703594e-07
in O 0 1.5353265325757093e-08
these O 0 1.0100326797157777e-08
23 O 0 1.0125849030373502e-06
patients O 0 1.7834700827279448e-07
were O 0 7.430516646422802e-09
each O 0 1.2227383550111881e-09
limited O 0 1.2970017948532586e-08
to O 0 5.2411808226793255e-09
a O 0 2.756497394784674e-07
single O 0 2.0030006453453097e-06
family O 0 4.538575922197197e-06
. O 0 2.5372576146764914e-06

These O 0 3.913048658432672e-07
data O 0 3.6629162991630437e-07
provide O 0 4.690027921583351e-08
further O 0 6.101043936723727e-08
evidence O 0 4.677823994825303e-08
for O 0 2.0904765918317025e-08
extensive O 0 3.566261284504435e-06
allelic O 0 0.00022703038121107966
heterogeneity O 0 0.0002182753523811698
in O 0 5.667271398124285e-05
MPS B-Disease 1 0.9825789928436279
IVA I-Disease 1 0.9983797073364258
in O 0 6.287347332545323e-06
British O 0 0.0008216845453716815
- O 0 0.03925786539912224
Irish O 0 0.0010543091921135783
patients O 0 5.449673608382e-06
and O 0 1.8892585273988516e-08
provide O 0 5.967991878463863e-09
evidence O 0 1.525218884523838e-08
for O 0 5.687728510395118e-09
their O 0 1.6012169368195828e-08
transmission O 0 1.1988099686277565e-05
to O 0 3.407719972869927e-08
Australia O 0 4.528742536535901e-08
by O 0 3.861467234855809e-08
British O 0 7.15294982001069e-06
- O 0 9.068297367775813e-05
Irish O 0 8.710194379091263e-06
migrants O 0 4.1330466160616197e-07
. O 0 3.0985034982222714e-07
. O 0 1.2359880656731548e-06

Identification O 0 9.161176421912387e-06
of O 0 2.044229177045054e-06
constitutional O 0 0.00015283493848983198
WT1 O 0 0.010960878804326057
mutations O 0 0.0007253280491568148
, O 0 1.1124801631012815e-06
in O 0 1.0254366316075902e-06
patients O 0 7.488849405490328e-06
with O 0 3.439738975430373e-06
isolated O 0 0.1936199814081192
diffuse B-Disease 1 0.997995138168335
mesangial I-Disease 1 0.9999492168426514
sclerosis I-Disease 1 0.9999923706054688
, O 0 2.9013017410761677e-06
and O 0 1.344559450444649e-07
analysis O 0 2.690605072075414e-07
of O 0 1.2867947418726544e-07
genotype O 0 1.6165289707714692e-05
/ O 0 3.075608765357174e-05
phenotype O 0 6.59248235024279e-06
correlations O 0 6.575633619831933e-07
by O 0 1.9345625545952316e-08
use O 0 1.9269986495373814e-08
of O 0 3.1892504637198726e-08
a O 0 1.3621213383885333e-06
computerized O 0 0.0004975702613592148
mutation O 0 0.00012512077228166163
database O 0 1.5093207366589922e-05
. O 0 6.771826519980095e-06

Constitutional O 0 0.0001749335351632908
mutations O 0 7.524971442762762e-05
of O 0 1.6255539492249227e-07
the O 0 5.036216066400812e-07
WT1 O 0 0.00018153851851820946
gene O 0 3.193836619175272e-06
, O 0 6.260634677346388e-08
encoding O 0 4.146635887991579e-07
a O 0 4.077249741385458e-06
zinc O 0 0.002249006647616625
- O 0 3.842230944428593e-05
finger O 0 1.757310747052543e-05
transcription O 0 1.845638507802505e-06
factor O 0 4.360440186701453e-07
involved O 0 2.542356014600955e-07
in O 0 8.499776527060021e-07
renal O 1 0.9978458881378174
and O 0 2.7119867809233256e-06
gonadal O 0 0.0007386498036794364
development O 0 6.225803872439428e-07
, O 0 8.888131475259797e-08
are O 0 9.728408301157287e-09
found O 0 1.0927750793143787e-07
in O 0 6.571784894049415e-08
most O 0 2.7413449288360425e-07
patients O 0 3.7699237509514205e-06
with O 0 3.10442146655987e-06
Denys B-Disease 1 0.9954577684402466
- I-Disease 1 0.9995001554489136
Drash I-Disease 1 0.9979928731918335
syndrome I-Disease 1 0.9999481439590454
( O 0 3.3879019611049443e-05
DDS B-Disease 1 0.9993042945861816
) O 0 2.110155719492468e-06
, O 0 2.2255485419009347e-06
or O 0 0.00013289396883919835
diffuse B-Disease 1 0.9976810216903687
mesangial I-Disease 1 0.999972939491272
sclerosis I-Disease 1 0.9999951124191284
( O 0 8.467003499390557e-05
DMS B-Disease 1 0.5261615514755249
) O 0 4.580583947699779e-07
associated O 0 1.2117928918087273e-06
with O 0 1.223191361532372e-06
pseudohermaphroditism B-Disease 1 0.9995951056480408
and O 0 3.418239066377282e-05
/ O 0 0.008332452736794949
or O 0 0.0015880336286500096
Wilms B-Disease 1 0.9993219375610352
tumor I-Disease 1 0.9985914826393127
( O 0 1.5895351680228487e-05
WT B-Disease 1 0.9870627522468567
) O 0 2.6674474611354526e-06
. O 0 4.150728727836395e-06

Most O 0 1.5020249520603102e-05
mutations O 0 0.0007365804631263018
in O 0 3.509112502797507e-05
DDS B-Disease 1 0.9998098015785217
patients O 0 0.002275274135172367
lie O 0 3.982302951044403e-05
in O 0 6.455377956626762e-07
exon O 0 1.6243593563558534e-05
8 O 0 9.913807161865407e-07
or O 0 3.4193683973171574e-07
exon O 0 7.268127774295863e-06
9 O 0 1.0543100188442622e-06
, O 0 4.7377788803260046e-08
encoding O 0 1.1953849252677173e-06
zinc O 0 0.0010183778358623385
finger O 0 0.00017992655921261758
2 O 0 6.541588959407818e-07
or O 0 6.050137244528742e-07
zinc O 0 0.00021883485896978527
finger O 0 2.6854067982640117e-05
3 O 0 3.578726648356678e-07
, O 0 3.288630878728327e-08
respectively O 0 2.1679080930425698e-07
, O 0 1.1130850019469563e-08
with O 0 1.7839132837593752e-08
a O 0 1.3261289950605715e-06
hot O 0 2.6683641408453695e-05
spot O 0 4.7992989493650384e-06
( O 0 1.0490910540283949e-07
R394W O 0 1.9197038909624098e-06
) O 0 5.494682753237612e-08
in O 0 1.56314413857217e-07
exon O 0 1.8624854419613257e-05
9 O 0 1.1250311217736453e-05
. O 0 1.760663735694834e-06

We O 0 2.2414599243347766e-06
analyzed O 0 1.6343828974640928e-06
a O 0 1.3599598958080605e-07
series O 0 1.951054997562096e-07
of O 0 7.898786691384885e-08
24 O 0 3.3286742109339684e-06
patients O 0 2.402601012363448e-06
, O 0 9.336790895986269e-08
10 O 0 1.5176166812125302e-07
with O 0 4.576008052481484e-07
isolated B-Disease 0 0.0009333098423667252
DMS I-Disease 0 0.4137217700481415
( O 0 2.1520766040339367e-06
IDMS B-Disease 0 0.0008466269937343895
) O 0 1.6888857601315976e-07
, O 0 6.338928670857058e-08
10 O 0 1.4236525203159545e-07
with O 0 5.975774115540844e-07
DDS B-Disease 1 0.9995673298835754
, O 0 5.243063583293406e-07
and O 0 2.7206678510083293e-07
4 O 0 3.765489736906602e-06
with O 0 3.868444764520973e-06
urogenital B-Disease 1 0.9947528839111328
abnormalities I-Disease 1 0.9996498823165894
and O 0 4.438147516339086e-05
/ O 0 0.010627302341163158
or O 0 0.0004199128015898168
WT B-Disease 1 0.997848629951477
. O 0 3.184601155226119e-05

We O 0 1.6905607481021434e-05
report O 0 1.0088121598528232e-05
WT1 O 0 0.0003381708520464599
heterozygous O 0 1.1518530300236307e-05
mutations O 0 2.2645730496151373e-05
in O 0 5.1195712558183e-07
16 O 0 3.412401156310807e-06
patients O 0 2.05972219191608e-06
, O 0 4.790098628859596e-08
4 O 0 3.3113821018559975e-07
of O 0 5.191080632016565e-08
whom O 0 8.876524475454062e-07
presented O 0 3.7587949464068515e-06
with O 0 8.00436464487575e-06
IDMS B-Disease 1 0.8963426351547241
. O 0 2.1304786059772596e-05

One O 0 2.241874653918785e-06
male O 0 2.111333515131264e-06
and O 0 1.828755671340332e-07
two O 0 4.4635174845097936e-07
female O 0 2.3496981157222763e-05
IDMS B-Disease 0 0.4769752025604248
patients O 0 6.078347360016778e-05
with O 0 3.3509284094179748e-06
WT1 O 0 0.17357777059078217
mutations O 0 0.009648475795984268
underwent O 1 0.7233341932296753
normal O 0 0.0002687040832825005
puberty O 0 0.005641164258122444
. O 0 1.3874291653337423e-05

Two O 0 1.6708081602700986e-05
mutations O 0 0.0004081096558365971
associated O 0 1.0882053175009787e-05
with O 0 5.015787678530614e-07
IDMS B-Disease 0 0.006320356857031584
are O 0 3.765905987052065e-08
different O 0 1.1882223205361697e-08
from O 0 7.563082249362196e-08
those O 0 1.146995742828949e-07
described O 0 2.6118881578440778e-05
in O 0 2.97170063277008e-05
DDS B-Disease 1 0.9997097849845886
patients O 0 0.004787088837474585
. O 0 1.3332148228073493e-05

No O 0 3.8000122003722936e-05
WT1 O 0 0.00229390780441463
mutations O 0 8.499806426698342e-05
were O 0 7.556001264674705e-07
detected O 0 2.138115269190166e-05
in O 0 1.0609696943220115e-07
the O 0 1.6155838977738313e-07
six O 0 5.626701522487565e-07
other O 0 3.2688262763258535e-07
IDMS B-Disease 1 0.5819628238677979
patients O 0 5.421026435215026e-05
, O 0 4.0105800280798576e-07
suggesting O 0 4.141677891311701e-06
genetic O 0 9.529165254207328e-06
heterogeneity O 0 1.5871948562562466e-05
of O 0 1.3098717772663804e-06
this O 0 2.5670393370091915e-05
disease O 1 0.9955787062644958
. O 0 1.5752821127534844e-05

We O 0 2.351170769543387e-05
analyzed O 0 9.649038111092523e-05
genotype O 0 9.82684941845946e-05
/ O 0 8.271961269201711e-05
phenotype O 0 3.432749508647248e-05
correlations O 0 6.777350790798664e-06
, O 0 1.1753498796451822e-07
on O 0 1.4083285293509107e-07
the O 0 3.298657347272638e-08
basis O 0 4.294717470543219e-08
of O 0 2.7081897613356887e-08
the O 0 1.3966067058390763e-07
constitution O 0 2.1729502464040706e-07
of O 0 2.044833635750365e-08
a O 0 6.917430255271029e-07
WT1 O 0 0.00013162512914277613
mutation O 0 6.170316737552639e-06
database O 0 3.7110095263415133e-07
of O 0 8.498716397298267e-08
84 O 0 1.235629588336451e-05
germ O 0 0.0007960681687109172
- O 0 0.00015961562166921794
line O 0 2.734943882387597e-05
mutations O 0 4.489646016736515e-06
, O 0 2.518664210526822e-08
to O 0 2.3602368948161256e-09
compare O 0 6.15340027820821e-08
the O 0 1.1267687227700662e-08
distribution O 0 4.1691933461152075e-08
and O 0 4.0136139745072796e-08
type O 0 3.072997742492589e-06
of O 0 6.518665429666726e-08
mutations O 0 1.0282775292580482e-05
, O 0 6.135094565706822e-08
according O 0 2.300235024677022e-08
to O 0 1.1150016021588272e-08
the O 0 2.3711672270110284e-07
different O 0 8.69947541559668e-07
symptoms O 0 0.007369071710854769
. O 0 4.2107767512789e-06

This O 0 1.023488380269555e-06
demonstrated O 0 3.6631781767937355e-06
( O 0 1.6970359695278603e-07
1 O 0 2.6488052640161186e-07
) O 0 1.8083392561152323e-08
the O 0 3.872959197792625e-08
association O 0 1.3322561187578685e-07
between O 0 8.215820201940005e-08
mutations O 0 1.3967320455776644e-06
in O 0 3.822344041282122e-08
exons O 0 1.0542215704845148e-06
8 O 0 9.417630053576431e-07
and O 0 1.7403527863280033e-07
9 O 0 2.301061385878711e-06
and O 0 4.106056508135225e-07
DMS B-Disease 0 0.003346458077430725
; O 0 1.908286861862507e-07
( O 0 7.194135775989707e-08
2 O 0 3.360832465659769e-07
) O 0 6.293846865901287e-08
among O 0 1.3624574535242573e-07
patients O 0 1.4520614968205336e-06
with O 0 2.1103276992562314e-07
DMS B-Disease 0 0.0014761199709028006
, O 0 4.492908445286048e-08
a O 0 7.237972710072427e-08
higher O 0 1.5985595780421136e-07
frequency O 0 2.86708853991513e-07
of O 0 5.5749023175621915e-08
exon O 0 1.0904408554779366e-05
8 O 0 1.8448554328642786e-06
mutations O 0 2.8027907319483347e-06
among O 0 1.4247662249999848e-07
46 O 0 1.7704143147057039e-06
, O 0 3.871168985369877e-07
XY O 0 0.0002828858559951186
patients O 0 3.0981364034232683e-06
with O 0 9.910207410257499e-08
female O 0 1.8988664578500902e-06
phenotype O 0 2.6164357223024126e-06
than O 0 5.097749422589004e-08
among O 0 6.359492488172691e-08
46 O 0 1.718633939162828e-06
, O 0 4.573612955027784e-07
XY O 0 0.0004269224882591516
patients O 0 3.3704143334034598e-06
with O 0 5.655969559370533e-08
sexual O 0 3.1937801736603433e-07
ambiguity O 0 7.513792752433801e-07
or O 0 6.102906695559795e-07
male O 0 1.562233705953986e-06
phenotype O 0 4.641253781301202e-06
; O 0 4.509434958777092e-08
and O 0 3.8086263032255374e-08
( O 0 3.676108661920807e-08
3 O 0 1.6003443192857958e-07
) O 0 1.012356865004449e-08
statistically O 0 4.2989952930838626e-08
significant O 0 2.6812676523491064e-08
evidence O 0 4.6157040856087406e-08
that O 0 1.001211646922684e-08
mutations O 0 2.7276041691948194e-07
in O 0 2.7817083747549987e-08
exons O 0 9.333334105576796e-07
8 O 0 3.512769808367011e-07
and O 0 3.5094338102226175e-08
9 O 0 3.6133604908172856e-07
preferentially O 0 2.1436159158838564e-07
affect O 0 1.3286387456901139e-07
amino O 0 3.5447389024056974e-08
acids O 0 1.7131627672029026e-08
with O 0 2.409778598888579e-09
different O 0 6.581264866412084e-09
functions O 0 1.7799341378577083e-07
. O 0 3.698297632581671e-07
. O 0 1.6213100479944842e-06

The O 0 2.1170746549614705e-05
185delAG O 0 0.0009759750682860613
BRCA1 O 0 0.0007035512244328856
mutation O 0 3.7394562241388485e-05
originated O 0 1.3641141549669555e-06
before O 0 3.9066242152330233e-07
the O 0 2.6115538176441078e-08
dispersion O 0 1.0291271337337093e-06
of O 0 2.331801773891584e-08
Jews O 0 1.0012597329023265e-07
in O 0 1.0328047750363112e-07
the O 0 9.519870758367688e-08
diaspora O 0 1.9429185726949072e-07
and O 0 1.405540217547241e-07
is O 0 6.795205820253614e-08
not O 0 1.1355648865674084e-08
limited O 0 4.138745168802416e-08
to O 0 1.815890016132471e-07
Ashkenazim O 0 0.00014376798935700208
. O 0 7.354208264587214e-06

The O 0 8.4375587903196e-06
185delAG O 0 0.0005874248454347253
mutation O 0 9.892201342154294e-05
in O 0 1.4044002227819874e-06
BRCA1 O 0 8.972783689387143e-05
is O 0 1.6023402622522553e-06
detected O 0 1.5101355529623106e-05
in O 0 9.924526978011272e-08
Ashkenazi O 0 6.816444056312321e-06
Jews O 0 2.1432356334116776e-07
both O 0 2.3595589482283685e-07
in O 0 7.150903456931701e-06
familial B-Disease 1 0.9921883344650269
breast I-Disease 1 0.9998877048492432
and I-Disease 1 0.9989237189292908
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999974966049194
and O 0 2.9314896892174147e-06
in O 0 4.373530373413814e-07
the O 0 4.729084821519791e-07
general O 0 7.50200740640139e-07
population O 0 3.4206502164124686e-07
. O 0 2.1136320356163196e-06

All O 0 3.873066816595383e-06
tested O 0 8.454941416857764e-05
Ashkenazi O 0 0.00016892055282369256
mutation O 0 2.2899950636201538e-05
carriers O 0 1.7641463045947603e-06
share O 0 1.7294361498443322e-07
the O 0 1.1665258625725983e-07
same O 0 3.084525985741493e-07
allelic O 0 3.7134537706151605e-05
pattern O 0 2.1844247385160998e-05
at O 0 8.562351467844564e-06
the O 0 2.065268972728518e-06
BRCA1 O 0 0.00022723522852174938
locus O 0 0.00016696914099156857
. O 0 8.891080142348073e-06

Our O 0 7.326041213673307e-06
previous O 0 1.046347551891813e-05
study O 0 1.0646504051692318e-06
showed O 0 2.6536874884186545e-06
that O 0 2.9399869205803952e-08
this O 0 8.285343966463188e-08
Ashkenazi O 0 4.7153942432487383e-05
mutation O 0 8.680996870680247e-06
also O 0 1.5549947818271903e-07
occurs O 0 2.9200089102232596e-07
in O 0 3.622589872520621e-08
Iraqi O 0 2.0008708645491424e-07
Jews O 0 9.24393859236261e-08
with O 0 6.296080101719781e-08
a O 0 1.6442886590084527e-06
similar O 0 3.0329647415783256e-06
allelic O 0 0.000392879854189232
pattern O 0 0.0006503669428639114
. O 0 2.8711358027067035e-05

We O 0 1.2694381439359859e-06
extended O 0 5.593961986960494e-07
our O 0 9.753978247317718e-08
analysis O 0 3.3041168023828504e-08
to O 0 3.200607778808262e-09
other O 0 8.03666377890977e-09
non O 0 5.105368927615928e-07
- O 0 7.298119271581527e-06
Ashkenazi O 0 3.5578875667852117e-06
subsets O 0 5.987159852338664e-07
354 O 0 8.763242362874735e-07
of O 0 5.762695920452643e-08
Moroccan O 0 1.090682985704916e-06
origin O 0 7.36923624344854e-08
, O 0 3.753600097411436e-08
200 O 0 9.023054303725075e-08
Yemenites O 0 8.891614015738014e-06
and O 0 6.796502560746376e-08
150 O 0 2.1034379926732072e-07
Iranian O 0 7.963514008224593e-07
Jews O 0 1.6028278650992434e-06
. O 0 2.9440100206556963e-06

Heteroduplex O 0 0.00026362709468230605
analysis O 0 1.2172123433629167e-06
complemented O 0 6.120415037003113e-07
by O 0 1.9828434005830786e-08
direct O 0 2.157699796612178e-08
DNA O 0 4.070335819505999e-07
sequencing O 0 2.3283092787096393e-07
of O 0 4.6814388809934826e-08
abnormally O 0 2.0986737581552006e-05
migrating O 0 5.349482421479479e-07
bands O 0 2.714706397455302e-06
were O 0 1.7674153696134454e-07
employed O 0 4.03019430450513e-06
. O 0 2.067795549010043e-06

Four O 0 2.1531707261601696e-06
of O 0 1.4857617713914806e-07
Moroccan O 0 4.547423031908693e-06
origin O 0 1.394088968709184e-07
( O 0 6.603485758205352e-08
1 O 0 1.5743978565296857e-07
. O 0 9.03483066139188e-09
1 O 0 7.124181422568654e-08
% O 0 7.930651690912782e-09
) O 0 6.586601930536062e-09
and O 0 9.081824181578213e-09
none O 0 4.109804763174907e-08
of O 0 3.277195625983609e-09
the O 0 3.15082040458492e-08
Yemenites O 0 2.164733814424835e-06
or O 0 4.081027782376623e-08
Iranians O 0 7.18467347837759e-08
was O 0 6.56956615330273e-07
a O 0 2.4383095365010377e-07
carrier O 0 2.0873146695521427e-06
of O 0 3.120748104379345e-08
the O 0 6.029032988408289e-07
185delAG O 0 0.0003294048074167222
mutation O 0 0.00015239804633893073
. O 0 7.800236744515132e-06

BRCA1 O 0 0.001732828444801271
allelic O 0 0.00029992929194122553
patterns O 0 2.8954755180166103e-05
were O 0 5.591108447333681e-07
determined O 0 5.794747721665772e-07
for O 0 1.4586560403984095e-08
four O 0 2.3471248056239347e-08
of O 0 3.5733975778384774e-09
these O 0 2.3478488042627532e-09
individuals O 0 1.234130131422262e-09
and O 0 7.169065785461726e-09
for O 0 1.194541798810178e-08
12 O 0 1.342419722050181e-07
additional O 0 6.521599971165415e-08
non O 0 3.99846067011822e-06
- O 0 9.108884114539251e-05
Ashkenazi O 0 0.00016500595666002482
185delAG O 0 0.0001312580134253949
mutation O 0 5.8953712141374126e-05
carriers O 0 1.4075717444939073e-05
who O 0 1.146551949204877e-05
had O 0 0.0014837414491921663
breast B-Disease 1 0.9998440742492676
/ I-Disease 1 0.999842643737793
ovarian I-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999901056289673
. O 0 0.00011610850924625993

Six O 0 2.680006218724884e-05
non O 0 4.008960604551248e-05
- O 0 0.0003433939127717167
Ashkenazi O 0 7.318815914914012e-05
individuals O 0 5.07218338441362e-08
shared O 0 3.664299867978116e-07
the O 0 2.9243508947729424e-07
common O 0 1.813944436435122e-06
Ashkenazi O 0 5.902239718125202e-05
haplotype O 0 5.312748908181675e-05
, O 0 1.5926039509395196e-07
four O 0 9.3821341806688e-08
had O 0 2.1268428440635034e-07
a O 0 1.4381062385382393e-07
closely O 0 6.201294695529214e-07
related O 0 1.763527279763366e-06
pattern O 0 1.0874603503907565e-05
, O 0 1.0853676712940796e-07
and O 0 4.8158586452018426e-08
the O 0 1.3208236282480357e-07
rest O 0 6.357684583235823e-07
( O 0 9.941388867673595e-08
n O 0 4.3086633922939654e-06
= O 0 2.6784828150994144e-06
6 O 0 3.006410906891688e-07
) O 0 9.14127795681452e-09
displayed O 0 3.17020152351688e-07
a O 0 2.7490338538882497e-07
distinct O 0 2.126987965311855e-06
BRCA1 O 0 0.0001836430310504511
allelic O 0 0.0002222571347374469
pattern O 0 0.00023131647321861237
. O 0 1.117958345275838e-05

We O 0 4.862154582951916e-06
conclude O 0 3.361182734806789e-06
that O 0 4.448812873647512e-08
the O 0 3.8325907780745183e-07
185delAG O 0 0.00019445439102128148
BRCA1 O 0 0.0004458111070562154
mutation O 0 4.863864160142839e-05
occurs O 0 4.287682600079279e-07
in O 0 1.8596914230784023e-08
some O 0 7.037729066183829e-09
non O 0 5.949696060270071e-07
- O 0 2.2940037524676882e-05
Ashkenazi O 0 1.5348587112384848e-05
populations O 0 2.121771984775478e-07
at O 0 6.775973133699154e-07
rates O 0 2.704966561850597e-07
comparable O 0 1.2132494475736166e-07
with O 0 2.411863064821773e-08
that O 0 1.4248147550688373e-08
of O 0 9.153686875151834e-08
Ashkenazim O 0 0.0003431880904827267
. O 0 8.514164619555231e-06

The O 0 4.03739159082761e-06
majority O 0 1.429553435627895e-06
of O 0 1.705975307686458e-07
Jewish O 0 4.789815648109652e-06
185delAG O 0 0.00017499977548141032
mutation O 0 2.4874898372218013e-05
carriers O 0 1.573575218571932e-06
have O 0 4.507457163072104e-08
a O 0 2.2103942853846092e-07
common O 0 1.4430495411943411e-06
allelic O 0 4.83859985251911e-05
pattern O 0 5.068878090241924e-05
, O 0 3.738014697773906e-07
supporting O 0 4.922255811834475e-07
the O 0 4.721738946500409e-07
founder O 0 1.0884699804591946e-05
effect O 0 5.123131927575741e-07
notion O 0 4.3772772073680244e-07
, O 0 6.761398196886148e-08
but O 0 2.336449611561875e-08
dating O 0 1.1123040621896507e-06
the O 0 9.672019274375998e-08
mutations O 0 5.54173993805307e-07
origin O 0 1.086251621984502e-08
to O 0 2.809610766263404e-09
an O 0 1.712137098763833e-08
earlier O 0 5.242753218226426e-07
date O 0 2.7278201741864905e-07
than O 0 3.075572152511086e-08
currently O 0 4.523122925093048e-07
estimated O 0 7.73429462697095e-07
. O 0 1.3570283954322804e-06

However O 0 2.6334334961575223e-06
, O 0 8.815935359507421e-08
the O 0 5.348165998952936e-08
different O 0 5.6108202528548645e-08
allelic O 0 1.4265504432842135e-05
pattern O 0 1.538075230200775e-05
at O 0 3.808753717748914e-06
the O 0 4.649200207040849e-07
BRCA1 O 0 1.9668199456646107e-05
locus O 0 3.5552723147702636e-06
even O 0 1.3427884937300405e-07
in O 0 1.4480114884918294e-08
some O 0 3.965815231765646e-09
Jewish O 0 5.641843472403707e-07
mutation O 0 2.2009444364812225e-06
carriers O 0 9.713909321362735e-07
, O 0 9.546691615014424e-08
might O 0 1.665144111484551e-07
suggest O 0 7.716620586961653e-08
that O 0 1.2713673669395575e-08
the O 0 1.0247810422470138e-07
mutation O 0 3.5070465855824295e-06
arose O 0 1.2308441910136025e-06
independently O 0 6.643691108365601e-07
. O 0 6.604309987778834e-07
. O 0 1.6453552689199569e-06

Crystal O 0 0.004383698105812073
structure O 0 0.00025807751808315516
of O 0 2.612306843730039e-06
the O 0 2.4422697606496513e-05
hemochromatosis B-Disease 1 0.9998719692230225
protein O 0 0.00032286590430885553
HFE O 0 0.004039976745843887
and O 0 3.9765203041497443e-07
characterization O 0 1.8620679611558444e-06
of O 0 1.9884410562553967e-08
its O 0 3.836865403172851e-08
interaction O 0 1.1492118545675112e-07
with O 0 3.5642074180941563e-07
transferrin O 0 0.00023361605417449027
receptor O 0 4.077724588569254e-05
. O 0 4.718957370641874e-06

HFE O 0 0.017154455184936523
is O 0 6.570433015440358e-06
an O 0 8.862051572577911e-07
MHC O 0 0.00039321332587860525
- O 0 0.0001496316835982725
related O 0 2.205606733696186e-06
protein O 0 5.743437441196875e-07
that O 0 2.1353701029624972e-08
is O 0 5.3154607826400024e-08
mutated O 0 6.201200335453905e-07
in O 0 8.98641943081202e-08
the O 0 3.871065473504132e-06
iron B-Disease 1 0.9993461966514587
- I-Disease 1 0.9992842078208923
overload I-Disease 1 0.9986465573310852
disease I-Disease 1 0.999921441078186
hereditary B-Disease 1 0.9999915361404419
hemochromatosis I-Disease 1 0.9999988079071045
. O 0 0.011496634222567081

HFE O 0 0.005262389313429594
binds O 0 2.5826931960182264e-05
to O 0 8.607082122580323e-07
transferrin O 0 8.70301591930911e-05
receptor O 0 1.1025950698240194e-05
( O 0 4.0129981471181964e-07
TfR O 0 6.6017011704389e-05
) O 0 5.913334888418831e-08
and O 0 2.735209747584122e-08
reduces O 0 3.857463468648348e-07
its O 0 1.8925188527418868e-08
affinity O 0 1.7615073488741473e-07
for O 0 5.0384933558689227e-08
iron O 0 0.0014744362561032176
- O 0 2.6275500204064883e-05
loaded O 0 1.5904485053397366e-06
transferrin O 0 2.043023232545238e-05
, O 0 3.27437362557248e-07
implicating O 0 7.947479753056541e-05
HFE O 0 0.0013240296393632889
in O 0 6.2245790104498155e-06
iron O 0 0.4325662851333618
metabolism O 0 0.006286910269409418
. O 0 1.0394055607321206e-05

The O 0 1.975811755983159e-05
2 O 0 2.359193422307726e-05
. O 0 6.500142717413837e-06

6 O 0 3.276832649135031e-05
A O 0 6.569342076545581e-06
crystal O 0 0.0007311033550649881
structure O 0 3.242458842578344e-05
of O 0 4.923955430058413e-07
HFE O 0 0.0010650083422660828
reveals O 0 5.4437782637251075e-06
the O 0 1.015918300595331e-07
locations O 0 1.0699942549763364e-06
of O 0 5.382374183682259e-06
hemochromatosis B-Disease 1 0.9999560117721558
mutations O 0 0.00743871321901679
and O 0 2.6098816761077615e-06
a O 0 1.450087711418746e-05
patch O 0 0.16894425451755524
of O 0 7.084977937665826e-07
histidines O 0 0.0003492679097689688
that O 0 1.2263058124517556e-07
could O 0 1.601205497081537e-07
be O 0 4.366161832081161e-08
involved O 0 1.3700800138849445e-07
in O 0 4.5823446725989925e-07
pH O 0 0.00020153459627181292
- O 0 2.694328395591583e-05
dependent O 0 1.5508067008340731e-06
interactions O 0 5.140420853422256e-06
. O 0 4.8141146180569194e-06

We O 0 4.5622396100952756e-06
also O 0 4.323326834310137e-07
demonstrate O 0 6.376752139658493e-07
that O 0 2.386635173934337e-07
soluble O 0 0.0001617378438822925
TfR O 0 0.00026652871747501194
and O 0 3.2453525022901886e-07
HFE O 0 0.00015286682173609734
bind O 0 2.2444803562393645e-06
tightly O 0 4.125570285395952e-06
at O 0 1.9008413119081524e-06
the O 0 1.2899907630981033e-07
basic O 0 8.715593935448851e-07
pH O 0 1.1323117178108077e-05
of O 0 3.03334672935307e-08
the O 0 3.1192161031867727e-07
cell O 0 2.6266230634064414e-05
surface O 0 1.4260540410759859e-05
, O 0 1.139607590516789e-07
but O 0 2.6117033868899853e-08
not O 0 9.631533792742175e-09
at O 0 5.697448841601727e-07
the O 0 2.523261741771421e-07
acidic O 0 3.7064488424221054e-05
pH O 0 2.6115294531336986e-05
of O 0 1.194699592588222e-07
intracellular O 0 4.189479659544304e-05
vesicles O 0 0.0002577966661192477
. O 0 8.332749530381989e-06

TfR O 0 0.04268207773566246
HFE O 0 0.00826932955533266
stoichiometry O 0 0.00019097425683867186
( O 0 2.1508108147827443e-06
2 O 0 2.1400628611445427e-06
1 O 0 6.036725608282723e-07
) O 0 8.43261034333409e-08
differs O 0 9.922612207446946e-07
from O 0 2.9014466917942627e-07
TfR O 0 9.379481343785301e-05
transferrin O 0 3.318728704471141e-05
stoichiometry O 0 1.1007533430529293e-05
( O 0 1.7319928247161442e-07
2 O 0 2.575707185314968e-07
2 O 0 2.280822997136056e-07
) O 0 1.7969824739338947e-08
, O 0 1.2694797213441689e-08
implying O 0 7.181139238809919e-08
a O 0 1.2829479700826596e-08
different O 0 2.403517607163508e-09
mode O 0 1.7020605014295143e-07
of O 0 1.6406836778060097e-08
binding O 0 4.923026040160039e-07
for O 0 8.585000443872559e-08
HFE O 0 8.323758811457083e-05
and O 0 1.8435541448980075e-07
transferrin O 0 1.5504694601986557e-05
to O 0 1.3419769118172553e-07
TfR O 0 6.961379403946921e-05
, O 0 6.57612275745123e-08
consistent O 0 1.5058553515245876e-07
with O 0 1.9422641273081354e-08
our O 0 1.7167454302580154e-07
demonstration O 0 1.0286383940183441e-06
that O 0 9.064107331369087e-08
HFE O 0 6.909375224495307e-05
, O 0 1.544061092317861e-07
transferrin O 0 6.800574738008436e-06
, O 0 1.459767133837886e-07
and O 0 1.6071122388439107e-07
TfR O 0 6.904712790856138e-05
form O 0 1.239136963704368e-06
a O 0 3.1925969778967556e-06
ternary O 0 0.0001561156677780673
complex O 0 0.0006135479197837412
. O 0 1.7104248399846256e-05

Identification O 0 2.061207624137751e-06
of O 0 2.4892383976293786e-07
three O 0 2.63981007719849e-07
novel O 0 3.651075985544594e-06
mutations O 0 7.164685030147666e-06
and O 0 1.0736766142827037e-07
a O 0 2.1203216249432444e-07
high O 0 1.6896765373530798e-06
frequency O 0 7.163956183831033e-07
of O 0 3.186830355161874e-08
the O 0 6.094333571127208e-07
Arg778Leu O 0 0.00013753380335401744
mutation O 0 1.9680152036016807e-05
in O 0 8.320737947542511e-07
Korean O 0 4.16279690398369e-05
patients O 0 2.3846745534683578e-05
with O 0 1.306251942878589e-05
Wilson B-Disease 1 0.6995479464530945
disease I-Disease 1 0.9974461793899536
. O 0 3.3427029848098755e-05

Four O 0 1.9513505321810953e-05
mutations O 0 0.00029820570489391685
- O 0 0.00027452976792119443
- O 0 9.901496378006414e-05
R778L O 0 1.9446126316324808e-05
, O 0 3.1055949989422516e-07
A874V O 0 4.6762593228777405e-06
, O 0 1.2127659942962055e-07
L1083F O 0 1.2124066870455863e-06
, O 0 2.900435625008413e-08
and O 0 6.006754205145626e-08
2304delC O 0 1.1999836715403944e-05
- O 0 3.418379128561355e-05
- O 0 5.763976787420688e-06
in O 0 6.661678497721368e-08
the O 0 1.427939935183531e-07
copper O 0 6.21319777565077e-05
- O 0 2.4033734007389285e-06
transporting O 0 6.145489237496804e-07
enzyme O 0 1.3876283446734305e-06
, O 0 1.7061819335140171e-07
P O 0 3.682287933770567e-05
- O 0 1.0513949746382423e-05
type O 0 7.59428530727746e-06
ATPase O 0 1.3799536645819899e-05
( O 0 1.999484169346033e-07
ATP7B O 0 8.714822797628585e-06
) O 0 2.032150803188415e-08
, O 0 8.340438562015606e-09
were O 0 1.5474745040933158e-08
identified O 0 1.6931561219735158e-07
in O 0 9.216070395723364e-08
Korean O 0 9.129437785304617e-06
Patients O 0 6.711731202813098e-06
with O 0 4.472782165976241e-06
Wilson B-Disease 0 0.3992759883403778
disease I-Disease 1 0.9973369240760803
. O 0 1.2250321560713928e-05

Arg778Leu O 0 0.0017146944301202893
, O 0 7.632495453435695e-07
the O 0 1.286274624590078e-07
most O 0 1.2501826063271437e-07
frequently O 0 2.023079787250026e-06
reported O 0 3.849712356895907e-06
mutation O 0 7.457908282049175e-07
of O 0 8.99274343879597e-09
this O 0 2.7957563375480277e-08
enzyme O 0 4.2390351495669165e-07
, O 0 7.443924232575228e-08
was O 0 4.4093048927607015e-06
found O 0 9.131209566248799e-08
in O 0 2.600390303086897e-08
six O 0 5.5955371891514005e-08
of O 0 2.1853463039178678e-08
eight O 0 1.2048775488437968e-06
unrelated O 0 2.4269853383884765e-05
patients O 0 4.724256996269105e-06
studied O 0 8.178997177310521e-07
, O 0 1.6395668822610787e-08
an O 0 7.487737541111983e-09
allele O 0 1.7240135719021055e-07
frequency O 0 6.1210045032567e-07
of O 0 3.183368164627609e-07
37 O 0 1.3900552403356414e-05
. O 0 2.3212287487694994e-06

5 O 0 8.321624591189902e-06
% O 0 1.5409719367198704e-07
, O 0 5.546594294969509e-08
which O 0 1.3602057258310651e-08
is O 0 2.0259818711565458e-08
considerably O 0 3.1395788369081856e-07
higher O 0 1.0211792300651723e-07
than O 0 3.132542225614543e-09
those O 0 2.6315734036330696e-09
in O 0 8.703921139385784e-09
other O 0 1.086272316541681e-08
Asian O 0 4.3967062879346486e-07
populations O 0 1.4780807759962045e-06
. O 0 2.082062337649404e-06

The O 0 2.8119659418734955e-06
novel O 0 1.7340004205834703e-06
single O 0 5.887517318114988e-07
nucleotide O 0 4.9521013352205046e-06
deletion O 0 8.335778147738893e-06
, O 0 1.5010992626685038e-07
2304delC O 0 8.963300388131756e-06
, O 0 1.790603789686429e-07
was O 0 1.2817910828744061e-05
found O 0 3.5165103895451466e-07
in O 0 2.1306250630459544e-07
one O 0 9.565735581418267e-07
patient O 0 5.530102498596534e-05
. O 0 3.0341507226694375e-06

Since O 0 1.0238632967229933e-05
a O 0 1.4997757489254582e-06
mutation O 0 8.348913070221897e-06
at O 0 1.3056402394795441e-06
cDNA O 0 2.4165012746379944e-06
nucleotide O 0 9.205245078192092e-06
2302 O 0 0.0002572052471805364
( O 0 2.730665187300474e-07
2302insC O 0 9.121092261921149e-06
) O 0 8.443329591045767e-08
had O 0 5.07073309563566e-07
been O 0 1.519040040420805e-07
previously O 0 8.27718452001136e-07
described O 0 6.300861628005805e-07
, O 0 4.240555284695802e-08
this O 0 1.1277490941097312e-08
region O 0 9.6425843310044e-08
of O 0 1.1458473281322767e-08
the O 0 2.2873686589264253e-07
ATP7B O 0 0.00014219546574167907
gene O 0 3.6761762203241233e-06
may O 0 4.91017374315561e-07
be O 0 1.0282819573603774e-07
susceptible O 0 4.917441856377991e-06
to O 0 1.1468950589232918e-07
gene O 0 3.5077369830105454e-05
rearrangements O 0 0.006844078656286001
causing O 1 0.714769184589386
Wilson B-Disease 1 0.9475306272506714
disease I-Disease 1 0.9986775517463684
. O 0 2.735538328124676e-05

Disruption O 0 0.00027992366813123226
of O 0 2.140969996844433e-07
splicing O 0 9.54297047428554e-06
regulated O 0 7.138638466130942e-06
by O 0 9.343773399450583e-08
a O 0 1.5198022538243094e-06
CUG O 0 0.00033983917091973126
- O 0 4.547629214357585e-05
binding O 0 8.284053365059663e-06
protein O 0 1.5301924577215686e-05
in O 0 3.08293238049373e-05
myotonic B-Disease 1 0.9996252059936523
dystrophy I-Disease 1 0.9999333620071411
. O 0 0.00019395851995795965

Myotonic B-Disease 1 0.9997758269309998
dystrophy I-Disease 1 0.9999570846557617
( O 0 0.003376978449523449
DM B-Disease 1 0.9999188184738159
) O 0 8.38825053506298e-06
is O 0 2.7848411718878197e-06
caused O 0 1.319855891779298e-05
by O 0 1.2353275735677016e-07
a O 0 1.2595880889421096e-06
CTG O 0 3.321790063637309e-05
expansion O 0 2.1808402834722074e-06
in O 0 7.756506903433547e-08
the O 0 9.507948561804369e-08
3 O 0 7.270688797689218e-07
untranslated O 0 3.0215725928428583e-05
region O 0 1.4257125258154701e-06
of O 0 2.0811462775327527e-07
the O 0 1.823753882490564e-05
DM B-Disease 1 0.9988784193992615
gene O 0 0.0001605785801075399
. O 0 1.2359807442408055e-05

One O 0 5.778958893642994e-06
model O 0 2.4565419153077528e-05
of O 0 1.314810651820153e-05
DM B-Disease 1 0.9998244643211365
pathogenesis O 0 0.22002020478248596
suggests O 0 9.002044862427283e-06
that O 0 1.208673836572416e-07
RNAs O 0 1.2017208973702509e-05
from O 0 4.324209257333678e-08
the O 0 1.8568206527902476e-08
expanded O 0 1.0185511456484164e-07
allele O 0 1.0231541835992175e-07
create O 0 3.0740064715928384e-08
a O 0 1.571349770301822e-07
gain O 0 3.762937694773427e-07
- O 0 5.038459221395897e-06
of O 0 9.136488188232761e-08
- O 0 1.3273373042466119e-05
function O 0 8.037125098780962e-07
mutation O 0 1.4234274203772657e-06
by O 0 1.3397206899412595e-08
the O 0 2.9023174974440735e-08
inappropriate O 0 4.364471806184156e-07
binding O 0 1.56270004936232e-07
of O 0 8.635611337126647e-09
proteins O 0 3.915340229809772e-08
to O 0 1.9507176318711572e-08
the O 0 3.8080457898104214e-07
CUG O 0 0.0016275381203740835
repeats O 0 0.00019355965196155012
. O 0 1.1236856153118424e-05

Data O 0 1.4387428564077709e-05
presented O 0 4.807260211237008e-06
here O 0 9.440236681257375e-07
indicate O 0 2.1750796008745965e-07
that O 0 1.5093426952716982e-08
the O 0 1.427713840485012e-07
conserved O 0 2.8573974759638077e-06
heterogeneous O 0 2.2458536477643065e-05
nuclear O 0 0.0007445629453286529
ribonucleoprotein O 0 0.0005360959330573678
, O 0 7.387869231934019e-07
CUG O 0 0.00012032106315018609
- O 0 1.3152608516975306e-05
binding O 0 1.709701450636203e-06
protein O 0 1.0285873486282071e-06
( O 0 1.306745929241515e-07
CUG O 0 7.468779949704185e-05
- O 0 5.9053534641861916e-05
BP O 0 4.211475243209861e-05
) O 0 5.522146651060211e-08
, O 0 2.8345176872335287e-08
may O 0 1.0518439808038238e-07
mediate O 0 7.783566502439498e-07
the O 0 2.778649559331825e-07
trans O 0 1.6589368897257373e-05
- O 0 3.588233812479302e-05
dominant O 0 8.976226126833353e-06
effect O 0 7.154970376177516e-07
of O 0 5.825166837780671e-08
the O 0 6.974989901209483e-07
RNA O 0 2.1374446077970788e-05
. O 0 2.033083092101151e-06

CUG O 0 0.031522516161203384
- O 0 0.00466306833550334
BP O 0 0.001495129894465208
was O 0 7.449325039488031e-06
found O 0 3.694616879101886e-08
to O 0 2.11188866394707e-09
bind O 0 4.836441647171341e-08
to O 0 1.4192869102203076e-08
the O 0 3.001223092269356e-07
human O 0 1.959176552190911e-05
cardiac O 1 0.9909035563468933
troponin O 1 0.9811971783638
T O 0 0.04528519883751869
( O 0 3.6265794278733665e-07
cTNT O 0 6.7059545472147875e-06
) O 0 1.0412507123191972e-07
pre O 0 5.307434093992924e-06
- O 0 3.097779199379147e-06
messenger O 0 9.612548410586896e-07
RNA O 0 4.985333816875936e-07
and O 0 5.2731272681683095e-09
regulate O 0 7.056334538901865e-08
its O 0 3.016039329395426e-08
alternative O 0 8.324095688294619e-07
splicing O 0 2.054239303106442e-05
. O 0 2.300354935869109e-06

Splicing O 0 7.583935803268105e-05
of O 0 2.199047685280675e-06
cTNT O 0 0.00031909343670122325
was O 0 0.0002603147295303643
disrupted O 0 0.004920434206724167
in O 0 7.808563532307744e-05
DM B-Disease 1 0.999757707118988
striated O 1 0.9004236459732056
muscle O 0 0.001575410831719637
and O 0 6.736675572938111e-07
in O 0 5.438119501377514e-07
normal O 0 8.657201760797761e-06
cells O 0 1.9385206542210653e-06
expressing O 0 6.191019679135934e-07
transcripts O 0 1.8074033505399711e-06
that O 0 9.978927550946537e-08
contain O 0 3.361525841683033e-06
CUG O 0 0.0021459688432514668
repeats O 0 0.0003142482601106167
. O 0 1.02785779745318e-05

Altered O 0 0.00011770272976718843
expression O 0 5.050027994002448e-06
of O 0 3.9951538610694115e-07
genes O 0 1.1613166861934587e-05
regulated O 0 2.1234198356978595e-05
posttranscriptionally O 0 0.0002074834774248302
by O 0 2.1723815279983683e-06
CUG O 0 0.003554720664396882
- O 0 0.0012860045535489917
BP O 0 0.0003600304771680385
therefore O 0 1.3358533124119276e-06
may O 0 5.89149408369849e-07
contribute O 0 3.238035048980237e-07
to O 0 1.5146423493206385e-06
DM B-Disease 1 0.9994155168533325
pathogenesis O 0 0.026116609573364258
. O 0 2.6183126919931965e-06
. O 0 5.469427833304508e-06

Identification O 0 3.92732954423991e-06
of O 0 3.7322763546399074e-07
a O 0 2.7555299766390817e-06
novel O 0 6.577642579941312e-06
nonsense O 0 7.426600495819002e-05
mutation O 0 8.98172402230557e-06
and O 0 7.81623867851522e-08
a O 0 3.236905001813284e-07
missense O 0 5.779008915851591e-06
substitution O 0 2.9948816404612444e-07
in O 0 1.1117487730416542e-07
the O 0 2.12329027249325e-07
vasopressin O 0 8.293980499729514e-06
- O 0 1.8432252545608208e-05
neurophysin O 0 2.4839651814545505e-05
II O 0 0.00010022539208875969
gene O 0 6.2767162489763e-07
in O 0 7.663451384587461e-08
two O 0 4.546129517279951e-08
Spanish O 0 4.040893600176787e-06
kindreds O 0 7.922487566247582e-05
with O 0 7.5977186497766525e-06
familial B-Disease 1 0.9953569769859314
neurohypophyseal I-Disease 1 0.9987438321113586
diabetes I-Disease 1 0.9997847676277161
insipidus I-Disease 1 0.9928838014602661
. O 0 0.0001471667201258242

Familial B-Disease 1 0.989080011844635
neurohypophyseal I-Disease 1 0.9971291422843933
diabetes I-Disease 1 0.9998787641525269
insipidus I-Disease 1 0.9978975057601929
( O 0 0.0002276971936225891
FNDI B-Disease 1 0.9995357990264893
) O 0 2.2831675323686795e-06
is O 0 1.3141936960892053e-06
an O 0 3.1230158583639422e-06
autosomal B-Disease 1 0.9977070093154907
dominant I-Disease 1 0.9996809959411621
disease I-Disease 1 0.9999626874923706
caused O 1 0.9865719079971313
by O 0 0.0016197377117350698
deficiency O 1 0.9997832179069519
in O 0 6.27770123173832e-06
the O 0 7.48761431168532e-06
antidiuretic O 0 0.002200901508331299
hormone O 0 0.0001240500423591584
arginine O 0 1.9361708837095648e-05
vasopressin O 0 1.0288336852681823e-05
( O 0 1.5341973380600393e-07
AVP O 0 1.0455504707351793e-05
) O 0 1.2155699558036304e-08
encoded O 0 2.1317198672932136e-08
by O 0 4.1501994729742364e-08
the O 0 3.8947982261561265e-07
AVP O 0 0.0004837049054913223
- O 0 0.0002484886790625751
neurophysin O 0 0.00030757233616895974
II O 0 0.008079581893980503
( O 0 2.493789224899956e-06
AVP O 0 0.00024342288088519126
- O 0 6.932382530067116e-05
NPII O 0 8.361659274669364e-05
) O 0 1.3788529429348273e-07
gene O 0 1.8204900698037818e-06
on O 0 3.04942636830674e-06
chromosome O 0 9.786796726984903e-05
20p13 O 0 8.96003475645557e-05
. O 0 4.339935458119726e-06

In O 0 2.630348717502784e-06
this O 0 1.2914307490063948e-07
study O 0 2.321876593214256e-07
, O 0 1.98590157651779e-08
we O 0 1.9836528863947933e-08
analyzed O 0 5.524517021626707e-08
two O 0 9.191682970310922e-09
families O 0 7.792760214897498e-09
with O 0 2.8967317433625794e-08
FNDI B-Disease 0 0.004284735769033432
using O 0 2.909089857894287e-08
direct O 0 2.793794529054594e-08
automated O 0 2.9973209620948182e-06
fluorescent O 0 1.0455773917783517e-05
, O 0 7.909716259746347e-08
solid O 0 8.650515042063489e-07
phase O 0 1.0527749054745072e-06
, O 0 3.410854176877365e-08
single O 0 1.6818586345834774e-07
- O 0 1.4795574543313705e-06
stranded O 0 1.2212593958338402e-07
DNA O 0 6.995574608481547e-08
sequencing O 0 6.960755882801095e-08
of O 0 2.9016364422318475e-08
PCR O 0 4.191186235402711e-06
- O 0 1.5951278328429908e-05
amplified O 0 2.3743474230286665e-05
AVP O 0 0.00027578926528804004
- O 0 9.799113468034193e-05
NPII O 0 0.00028957027825526893
DNA O 0 2.4642473363201134e-05
. O 0 2.235107331216568e-06

In O 0 2.143467781934305e-06
one O 0 3.59273343519817e-07
of O 0 3.368262824210433e-08
the O 0 2.1627805324442306e-07
families O 0 9.116851629187295e-08
, O 0 1.856318334603202e-07
affected O 0 3.5220210747866076e-07
individuals O 0 1.1248725506618484e-08
presented O 0 3.679188864680327e-07
a O 0 6.383560275935452e-07
novel O 0 1.3540239933718112e-06
nonsense O 0 5.687324573955266e-06
mutation O 0 3.4034374039038084e-06
in O 0 1.2118225356516632e-07
exon O 0 2.9988163987582084e-06
3 O 0 1.5783155049575726e-07
of O 0 1.0383050863538301e-08
the O 0 3.2936025462504404e-08
gene O 0 1.9692397756898572e-07
, O 0 1.069961719224466e-08
consisting O 0 3.95220247639827e-08
in O 0 6.881065672814657e-08
a O 0 7.965519444042002e-07
G O 0 2.309069168404676e-05
to O 0 1.1601665050875454e-07
T O 0 0.00012077764404239133
transition O 0 2.699917331483448e-06
at O 0 1.5329671896324726e-06
nucleotide O 0 1.6364166413040948e-06
2101 O 0 4.3921700125792995e-05
, O 0 6.384857442753855e-08
which O 0 1.0930186533641972e-08
produces O 0 5.1640220988247165e-08
a O 0 6.318311562836243e-08
stop O 0 2.939412979685585e-07
signal O 0 1.454009748158569e-06
in O 0 2.0249933641025564e-07
codon O 0 3.7260067529132357e-06
82 O 0 3.6302651551523013e-06
( O 0 3.0479679935524473e-07
Glu O 0 0.00028322695288807154
) O 0 2.855526588518842e-07
of O 0 4.493045651088323e-07
NPII O 0 0.002369942609220743
. O 0 1.3106367987347767e-05

The O 0 4.5057655370328575e-05
premature O 0 0.002319249091669917
termination O 0 6.375948578352109e-05
eliminates O 0 1.3125430086802226e-05
part O 0 6.369846801135282e-07
of O 0 4.139053189078368e-08
the O 0 4.726311999547761e-07
C O 0 4.630615876521915e-05
- O 0 1.1619104043347761e-05
terminal O 0 8.095767043414526e-06
domain O 0 2.8221754178048286e-07
of O 0 4.350832227828505e-08
NPII O 0 5.6598230003146455e-05
, O 0 3.3623255291104215e-08
including O 0 1.0220186474896309e-08
a O 0 9.548658397307008e-08
cysteine O 0 3.450672636517993e-07
residue O 0 1.3574943977801013e-06
in O 0 4.541129072777039e-08
position O 0 4.670281725793757e-07
85 O 0 3.235145982216636e-07
, O 0 3.060667097543046e-08
which O 0 1.1550656431325024e-08
could O 0 1.4608082743450268e-08
be O 0 4.898435879141516e-09
involved O 0 1.9299889686408278e-08
in O 0 1.6896485988127097e-08
the O 0 1.3897602002543863e-07
correct O 0 3.91947560274275e-06
folding O 0 2.946082349808421e-05
of O 0 1.2104433722015528e-07
the O 0 1.6434232747997157e-06
prohormone O 0 0.004961821250617504
. O 0 8.546059689251706e-06

In O 0 2.2161827928357525e-06
the O 0 2.871373681045952e-07
second O 0 2.6087168407684658e-06
family O 0 8.403338256357529e-07
, O 0 3.7822033505108266e-08
a O 0 6.227502069577895e-08
G279A O 0 7.719122550042812e-07
substitution O 0 4.080911253367958e-08
at O 0 4.782265818903397e-07
position O 0 9.332728723165928e-07
- O 0 2.439431227685418e-06
1 O 0 6.006490593790659e-08
of O 0 4.470603887085645e-09
the O 0 2.3027372009210012e-08
signal O 0 7.661491281396593e-07
peptide O 0 6.086527264415054e-07
was O 0 4.0719663729760214e-07
observed O 0 1.1433022706341944e-07
in O 0 1.5398898156604446e-08
all O 0 1.1761096985196673e-08
affected O 0 7.91228785601561e-07
individuals O 0 1.8564068682280777e-07
. O 0 2.607600208648364e-06

This O 0 5.877005150978221e-06
missense O 0 0.0005275623989291489
mutation O 0 0.00015479922876693308
, O 0 5.294232892083528e-07
which O 0 2.0615760831788066e-07
replaces O 0 9.12508912733756e-05
Ala O 0 5.602071905741468e-05
with O 0 6.647385930591554e-07
Thr O 0 0.0007143280818127096
, O 0 3.898120155554352e-07
is O 0 3.106530925833795e-07
frequent O 0 2.665197143869591e-06
among O 0 6.290532382990932e-06
FNDI B-Disease 1 0.9998369216918945
patients O 0 0.0002074016083497554
and O 0 1.982401585109983e-07
is O 0 1.272299243737507e-07
thought O 0 8.152086650170531e-08
to O 0 5.6158704353492794e-09
reduce O 0 1.179799298256512e-07
the O 0 4.84517634902204e-08
efficiency O 0 3.725224928530224e-07
of O 0 1.8660552214555537e-08
cleavage O 0 4.3057511902588885e-06
by O 0 1.3577334811998298e-07
signal O 0 6.1105279201001395e-06
peptidases O 0 3.87765649065841e-05
. O 0 6.250933779483603e-07
. O 0 2.6610750865074806e-06

Genetic O 0 0.0005596989649347961
heterogeneity O 0 0.00029465023544616997
of O 0 1.3150312952348031e-05
Saethre B-Disease 1 0.9893479347229004
- I-Disease 1 0.9989988207817078
Chotzen I-Disease 1 0.9975185394287109
syndrome I-Disease 1 0.9999438524246216
, O 0 2.083067329294863e-06
due O 0 3.2913280847424176e-06
to O 0 6.697005972000625e-08
TWIST O 0 3.0906125175533816e-05
and O 0 3.2323566756531363e-06
FGFR O 0 0.006410642061382532
mutations O 0 0.0005300276097841561
. O 0 8.125724889396224e-06

Thirty O 0 2.3827356926631182e-05
- O 0 6.632734584854916e-05
two O 0 4.355141811629437e-07
unrelated O 0 2.2812197130406275e-05
patients O 0 1.1559270660654875e-06
with O 0 3.476203858099325e-08
features O 0 1.462056502532505e-06
of O 0 3.125894181721378e-06
Saethre B-Disease 1 0.970204770565033
- I-Disease 1 0.9989653825759888
Chotzen I-Disease 1 0.9977678060531616
syndrome I-Disease 1 0.9999047517776489
, O 0 1.5102718862181064e-06
a O 0 2.81521806755336e-06
common O 0 6.932580436114222e-05
autosomal B-Disease 1 0.9942315816879272
dominant I-Disease 1 0.9908393025398254
condition I-Disease 1 0.9964523315429688
of O 0 2.823426439135801e-05
craniosynostosis B-Disease 1 0.9986944794654846
and O 0 0.00063770153792575
limb B-Disease 1 0.9980002045631409
anomalies I-Disease 0 0.13845571875572205
, O 0 3.209128180969856e-07
were O 0 1.283503934246255e-07
screened O 0 6.846451015007915e-07
for O 0 4.146116694414559e-08
mutations O 0 2.5181825549225323e-06
in O 0 1.0447141107761126e-07
TWIST O 0 6.6605298343347386e-06
, O 0 5.059304157839506e-07
FGFR2 O 0 0.00018949306104332209
, O 0 4.797669816980488e-07
and O 0 7.078245403135952e-07
FGFR3 O 0 0.0033450510818511248
. O 0 8.117847755784169e-06

Nine O 0 1.1708714737324044e-05
novel O 0 5.799065547762439e-06
and O 0 6.481935201918532e-07
three O 0 1.057021336237085e-06
recurrent O 0 0.0005650445818901062
TWIST O 0 2.686387779249344e-05
mutations O 0 1.2972504009667318e-05
were O 0 2.1788372350783902e-07
found O 0 3.154474086386472e-07
in O 0 1.2447766550849337e-07
12 O 0 8.396161206292163e-07
families O 0 2.1253222826089768e-07
. O 0 2.118447127941181e-06

Seven O 0 1.7620799326323322e-06
families O 0 8.16117164958996e-08
were O 0 7.82629356876896e-08
found O 0 6.180040657000063e-08
to O 0 6.07190253631984e-09
have O 0 1.728385079502459e-08
the O 0 1.2045980213315488e-07
FGFR3 O 0 6.652085721725598e-05
P250R O 0 1.2290141967241652e-05
mutation O 0 2.926732349806116e-06
, O 0 5.071922259958228e-08
and O 0 2.1956449103299747e-08
one O 0 2.0073112949603455e-08
individual O 0 1.828580842300198e-08
was O 0 6.862820100650424e-06
found O 0 8.670306783642445e-08
to O 0 4.50118342598671e-09
have O 0 9.311142967760588e-09
an O 0 1.1996272064607183e-07
FGFR2 O 0 0.00021536624990403652
VV269 O 0 5.664942000294104e-05
- O 0 7.680639828322455e-05
270 O 0 1.2284459444344975e-05
deletion O 0 5.9473262808751315e-05
. O 0 7.151899353630142e-06

To O 0 3.9984547584026586e-07
date O 0 3.0054500257392647e-06
, O 0 1.0803550054561128e-07
our O 0 2.0018596558202262e-07
detection O 0 9.796581252885517e-06
rate O 0 1.86265049251233e-06
for O 0 1.7809794528034217e-08
TWIST O 0 4.149129836150678e-06
or O 0 7.306464908651833e-07
FGFR O 0 0.00015857753169257194
mutations O 0 1.394850460201269e-05
is O 0 2.6984065470969654e-07
68 O 0 5.652518098031578e-07
% O 0 1.4360717948136426e-08
in O 0 4.560781263762692e-08
our O 0 1.1086376616731286e-06
Saethre B-Disease 0 0.028795331716537476
- I-Disease 1 0.9967049956321716
Chotzen I-Disease 1 0.99533611536026
syndrome I-Disease 1 0.9999326467514038
patients O 0 0.00010785890481201932
, O 0 9.578720039371547e-08
including O 0 6.387816853248296e-08
our O 0 3.280750320300285e-07
five O 0 1.104568355003721e-06
patients O 0 3.3970302411034936e-06
elsewhere O 0 1.888021188278799e-06
reported O 0 2.8047988962498493e-06
with O 0 2.5114070467679994e-07
TWIST O 0 0.0002127891348209232
mutations O 0 0.00035678641870617867
. O 0 1.0146465683646966e-05

More O 0 1.0972320296787075e-07
than O 0 6.89455745828127e-08
35 O 0 1.0364456670686195e-07
different O 0 1.0339770817324734e-08
TWIST O 0 5.366761342884274e-06
mutations O 0 2.0972156562493183e-06
are O 0 1.34702311527235e-08
now O 0 1.378906944182745e-07
known O 0 1.7859295553535048e-07
in O 0 8.429989861724607e-08
the O 0 1.673436571536513e-07
literature O 0 9.576451702741906e-07
. O 0 2.9841778541594977e-06

The O 0 1.8244650163978804e-06
most O 0 1.8440992732848827e-07
common O 0 4.275151752608508e-07
phenotypic O 0 2.8104593639000086e-06
features O 0 2.1222588202363113e-06
, O 0 7.744370833506764e-08
present O 0 3.1406383271814775e-08
in O 0 1.1047389669727181e-08
more O 0 1.1543029865279664e-09
than O 0 3.782453905643024e-09
a O 0 4.623290550398451e-08
third O 0 1.0562206398390117e-07
of O 0 1.0114516335590906e-08
our O 0 2.1134174232884106e-07
patients O 0 5.992844194224745e-07
with O 0 5.213247078472705e-08
TWIST O 0 2.5441839170525782e-05
mutations O 0 1.8182456187787466e-05
, O 0 2.6436217126502015e-07
are O 0 9.31578227891805e-08
coronal B-Disease 0 0.00015417714894283563
synostosis I-Disease 0 0.0003661903028842062
, O 0 1.3241082115200697e-06
brachycephaly B-Disease 0 0.0004242303839419037
, O 0 5.050866093370132e-06
low B-Disease 0 0.010240420699119568
frontal I-Disease 1 0.9978994131088257
hairline I-Disease 1 0.9996435642242432
, O 0 3.639368878793903e-05
facial B-Disease 1 0.9906807541847229
asymmetry I-Disease 0 0.06001737341284752
, O 0 7.370371167780831e-05
ptosis B-Disease 1 0.9909369349479675
, O 0 9.048369065567385e-06
hypertelorism B-Disease 0 0.021161755546927452
, O 0 2.633893018355593e-06
broad B-Disease 0 2.555827632022556e-05
great I-Disease 0 0.00016610859893262386
toes I-Disease 0 0.006414640694856644
, O 0 1.2226221315358998e-06
and O 0 1.6837905150168808e-06
clinodactyly B-Disease 0 0.00138726772274822
. O 0 7.772494427626953e-06

Significant O 0 2.090627640427556e-05
intra O 0 0.0004207887686789036
- O 0 0.00029660819564014673
and O 0 5.709556489819079e-07
interfamilial O 0 9.004240564536303e-05
phenotypic O 0 4.292930680094287e-05
variability O 0 0.00016258905816357583
is O 0 2.3315132580137288e-07
present O 0 8.830392062009196e-08
for O 0 3.5526852570910705e-08
either O 0 6.119796012171719e-07
TWIST O 0 7.823164924047887e-05
mutations O 0 8.381681254832074e-05
or O 0 4.936423920298694e-06
FGFR O 0 0.006868091877549887
mutations O 0 0.000904178770724684
. O 0 8.871938007359859e-06

The O 0 1.727627704894985e-06
overlap O 0 3.775723826038302e-06
in O 0 8.315597597174929e-07
clinical O 0 2.4145708721334813e-06
features O 0 4.774637432092277e-07
and O 0 8.177423183042265e-08
the O 0 6.244867734039872e-08
presence O 0 1.6286557524836098e-07
, O 0 1.712646735541057e-08
in O 0 6.453528822447652e-09
the O 0 2.493977024897731e-09
same O 0 8.395247164116881e-09
genes O 0 2.945319010905223e-08
, O 0 9.1325125239905e-09
of O 0 3.5329856817867267e-09
mutations O 0 1.928004564888397e-07
for O 0 2.46553244487302e-09
more O 0 1.1788670040147053e-09
than O 0 8.004492180191392e-09
one O 0 1.2122350767640455e-07
craniosynostotic B-Disease 0 8.837343193590641e-05
condition I-Disease 0 0.0003875685215461999
- O 0 3.797857743847999e-06
such O 0 3.916169077911036e-08
as O 0 6.141265203041257e-07
Saethre B-Disease 0 8.210286614485085e-05
- I-Disease 0 5.438632069854066e-05
Chotzen I-Disease 0 4.0898084989748895e-05
, I-Disease 0 3.912586237220239e-07
Crouzon I-Disease 0 4.0254060877487063e-05
, I-Disease 0 5.593556693384016e-07
and I-Disease 0 1.2941928844156791e-06
Pfeiffer I-Disease 0 0.4870823621749878
syndromes I-Disease 1 0.7388986349105835
- O 0 7.879925396991894e-05
support O 0 1.3363218442918878e-07
the O 0 2.297079220170417e-07
hypothesis O 0 4.741621069115354e-07
that O 0 1.1858540815978813e-08
TWIST O 0 1.3440392194752349e-06
and O 0 7.907725319000747e-08
FGFRs O 0 3.4915788091893774e-06
are O 0 7.516485212022417e-09
components O 0 8.021950037573333e-08
of O 0 8.352952107770761e-09
the O 0 3.604463216788645e-08
same O 0 3.1210454665142606e-08
molecular O 0 1.1002126711900928e-06
pathway O 0 4.000926594471821e-07
involved O 0 6.509880989824524e-08
in O 0 1.996692056138727e-08
the O 0 4.32846718467772e-08
modulation O 0 3.539976660249522e-06
of O 0 8.261459356617706e-07
craniofacial O 1 0.9957192540168762
and O 0 4.0180580981541425e-05
limb O 1 0.8516805768013
development O 0 1.5531244343947037e-06
in O 0 8.059030847107351e-07
humans O 0 1.4882946288707899e-06
. O 0 7.766690828248102e-07
. O 0 1.6293530507027754e-06

Mutation O 0 0.0004565739072859287
analysis O 0 1.8857121176552027e-05
of O 0 1.979155422304757e-05
UBE3A O 1 0.9419663548469543
in O 0 0.41514936089515686
Angelman B-Disease 1 0.9999775886535645
syndrome I-Disease 1 0.9999991655349731
patients O 1 0.9897240400314331
. O 0 0.00015156116569414735

Angelman B-Disease 1 0.9999719858169556
syndrome I-Disease 1 0.999998927116394
( O 0 0.0004922159714624286
AS B-Disease 1 0.9986206293106079
) O 0 1.7171676063298946e-06
is O 0 1.5968591924320208e-06
caused O 0 1.5448547856067307e-05
by O 0 4.3946354821855493e-07
chromosome O 0 7.302244921447709e-05
15q11 O 0 6.199076597113162e-05
- O 0 4.4047614210285246e-05
q13 O 0 2.066523848043289e-05
deletions O 0 4.924800578010036e-06
of O 0 1.3624223527131107e-07
maternal O 0 1.9941318896599114e-05
origin O 0 5.274428076518234e-07
, O 0 3.0092994052210997e-07
by O 0 4.943292992720671e-07
paternal O 0 0.00028750134515576065
uniparental B-Disease 1 0.7083477973937988
disomy I-Disease 0 0.2291516214609146
( O 0 1.701681139820721e-05
UPD B-Disease 1 0.9931681156158447
) O 0 5.817743726765912e-07
15 O 0 6.327742312350892e-07
, O 0 4.497083949672742e-08
by O 0 2.1080207091017655e-07
imprinting O 0 0.0003563894715625793
defects O 1 0.9287148118019104
, O 0 9.127482769599737e-08
and O 0 5.358437960012452e-08
by O 0 7.509423483043065e-08
mutations O 0 4.4161897676531225e-06
in O 0 2.090439323865212e-07
the O 0 9.361806405649986e-07
UBE3A O 0 0.0008335995371453464
gene O 0 4.654838267015293e-05
. O 0 8.0212676039082e-06

UBE3A O 0 0.0016017724992707372
encodes O 0 8.702166269358713e-06
a O 0 2.8380852654663613e-06
ubiquitin O 0 1.9536091713234782e-05
- O 0 2.2497355530504137e-05
protein O 0 1.691054762886779e-06
ligase O 0 3.6939868550689425e-06
and O 0 1.4962155603370775e-07
shows O 0 5.362075171433389e-06
brain O 0 0.03365391120314598
- O 0 0.00010847396333701909
specific O 0 2.796833996399073e-06
imprinting O 0 0.0005546350148506463
. O 0 1.761898420227226e-05

Here O 0 8.479167263431009e-06
we O 0 7.14348914243601e-07
describe O 0 5.9041099120804574e-06
UBE3A O 0 0.000879871950019151
coding O 0 0.00034833484096452594
- O 0 0.00041887853876687586
region O 0 8.670306669955608e-06
mutations O 0 2.0154358935542405e-05
detected O 0 7.952419764478691e-06
by O 0 8.163538467442777e-08
SSCP O 0 1.6785761545179412e-05
analysis O 0 1.8634129617112194e-07
in O 0 1.212046782939069e-07
13 O 0 1.0063082527267397e-06
AS B-Disease 0 0.0009760587709024549
individuals O 0 2.7608246355725896e-08
or O 0 1.9861559508171922e-07
families O 0 2.223867312522998e-07
. O 0 2.2621031803282676e-06

Two O 0 4.037256985611748e-06
identical O 0 4.5946297177579254e-05
de O 0 0.00010464890510775149
novo O 0 4.680887650465593e-05
5 O 0 3.3664020975265885e-06
- O 0 1.9117102056043223e-05
bp O 0 1.3740102986048441e-05
duplications O 0 6.4561627368675545e-06
in O 0 2.993987493482564e-07
exon O 0 1.2119200619054027e-05
16 O 0 1.0046071565739112e-06
were O 0 3.224851639060944e-07
found O 0 1.9879232695529936e-06
. O 0 1.1839939588753623e-06

Among O 0 9.869911536952714e-07
the O 0 2.5099703293562925e-07
other O 0 5.334585750915721e-08
11 O 0 5.419191779765242e-07
unique O 0 3.9450858935197175e-07
mutations O 0 6.994586328801233e-06
, O 0 6.938606844641981e-08
8 O 0 2.3473513977023686e-07
were O 0 2.2394456067331703e-08
small O 0 3.715988228236711e-08
deletions O 0 1.0965662795570097e-06
or O 0 3.276394693330076e-07
insertions O 0 1.4839600225968752e-05
predicted O 0 1.4828621715423651e-05
to O 0 1.3572415014095895e-07
cause O 0 7.37797290639719e-06
frameshifts O 0 5.12511505803559e-05
, O 0 2.258737339388972e-07
1 O 0 3.586906700547843e-07
was O 0 1.8208459096058505e-06
a O 0 1.8726751704889466e-07
mutation O 0 4.4524168174575607e-07
to O 0 5.703785443955667e-09
a O 0 5.8050247275787115e-08
stop O 0 1.6140006664500106e-07
codon O 0 3.55116839045877e-07
, O 0 2.434755863589544e-08
1 O 0 6.247727668551306e-08
was O 0 3.381369140242896e-07
a O 0 2.0532469591216795e-07
missense O 0 7.537429155490827e-06
mutation O 0 1.7696597751637455e-06
, O 0 2.050066782999238e-08
and O 0 2.929010989305425e-08
1 O 0 3.5176640267309267e-07
was O 0 2.568658055679407e-05
predicted O 0 1.0011352742367308e-06
to O 0 1.737093491271935e-08
cause O 0 5.63055039037863e-07
insertion O 0 2.3789749548086547e-07
of O 0 1.0035861919277522e-08
an O 0 1.3250628683181276e-07
isoleucine O 0 0.00014695667778141797
in O 0 1.1876699801405266e-07
the O 0 1.387155634802184e-07
hect O 0 1.4242858924262691e-05
domain O 0 3.3725834214237693e-07
of O 0 2.789870023889307e-08
the O 0 2.4845923007887905e-07
UBE3A O 0 5.566658001043834e-05
protein O 0 8.128731678880285e-07
, O 0 3.6384335544425994e-08
which O 0 8.118830052694648e-09
functions O 0 3.552868221845529e-08
in O 0 4.162614075653437e-08
E2 O 0 3.6583046494342852e-06
binding O 0 7.208901138255897e-07
and O 0 1.0685773332852477e-07
ubiquitin O 0 1.535416458864347e-06
transfer O 0 2.978428938149591e-06
. O 0 3.937717792723561e-06

Eight O 0 3.876472874253523e-06
of O 0 1.3577023594280035e-07
the O 0 3.0781873761043244e-07
cases O 0 4.3328742549419985e-07
were O 0 1.624699876856539e-07
familial O 0 0.00014722974447067827
, O 0 4.85628788737813e-07
and O 0 1.1545726863460004e-07
five O 0 1.6938538749400323e-07
were O 0 3.820711924618081e-07
sporadic O 0 2.5106333850999363e-05
. O 0 6.240371476451401e-06

In O 0 2.752911314019002e-06
two O 0 6.813505137870379e-07
familial O 0 0.0017662923783063889
cases O 0 5.436421361082466e-06
and O 0 3.373658046257333e-07
one O 0 3.184443073678267e-07
sporadic O 0 1.926431286847219e-05
case O 0 3.0990258892416023e-06
, O 0 2.101455010006248e-07
mosaicism O 0 3.456855483818799e-05
for O 0 2.900608251366066e-07
UBE3A O 0 0.0006901887245476246
mutations O 0 8.974837692221627e-05
was O 0 1.7510337784187868e-05
detected O 0 1.2591493941727094e-05
in O 0 4.4103547480744965e-08
the O 0 9.284774904472215e-08
mother O 0 9.687903457233915e-07
of O 0 1.90865758753489e-08
three O 0 3.7651452089448867e-07
AS B-Disease 0 0.4735463857650757
sons O 0 4.7215860831784084e-05
, O 0 1.850917925594331e-07
in O 0 5.522925761169972e-08
the O 0 7.555584602414456e-08
maternal O 0 7.89244586485438e-06
grandfather O 0 9.991752449423075e-06
of O 0 3.871179288239546e-08
two O 0 8.585130473193203e-08
AS B-Disease 0 0.0006723861442878842
first O 0 3.2132103910953447e-07
cousins O 0 2.6554851046967087e-06
, O 0 8.534420459227476e-08
and O 0 3.4861034947653025e-08
in O 0 4.0352830410483875e-08
the O 0 1.696862739208882e-07
mother O 0 4.656895271182293e-06
of O 0 6.602213886708341e-08
an O 0 1.6034866803238401e-06
AS B-Disease 1 0.9937280416488647
daughter O 0 0.01767798513174057
. O 0 7.990338417585008e-06

The O 0 5.13015265823924e-07
frequencies O 0 1.1874337815243052e-06
with O 0 7.58344995688276e-08
which O 0 9.493994923559512e-08
we O 0 7.203966845281684e-08
detected O 0 3.2824195841385517e-06
mutations O 0 8.332697234436637e-07
were O 0 5.162190319651927e-08
5 O 0 6.51092406656062e-08
( O 0 1.043331732120123e-08
14 O 0 7.176141281206583e-08
% O 0 3.319667429835249e-09
) O 0 1.4224217359526392e-09
of O 0 4.490695815206891e-09
35 O 0 8.517281457898207e-08
in O 0 2.8461164092163926e-08
sporadic O 0 9.306775154982461e-07
cases O 0 8.708940413271193e-08
and O 0 7.32598763875103e-08
8 O 0 3.7826296761522826e-07
( O 0 2.96527300491789e-08
80 O 0 1.0990752485895428e-07
% O 0 8.16437495387845e-09
) O 0 4.224955496567873e-09
of O 0 9.283762203438073e-09
10 O 0 1.1232115326720304e-07
in O 0 1.1313582604088879e-07
familial O 0 0.00010859743633773178
cases O 0 2.093953980875085e-06
. O 0 4.877331321040401e-07
. O 0 3.1096362818061607e-06

The O 0 0.00021971524984110147
hemochromatosis B-Disease 1 0.9980388283729553
845 O 0 0.003274737624451518
G O 0 0.006388096604496241
- O 0 0.00022665878350380808
- O 0 3.4214121114928275e-05
> O 0 2.5711447051435243e-06
A O 0 4.299282636566204e-07
and O 0 9.592321958962202e-08
187 O 0 1.0020791023634956e-06
C O 0 9.674150533101056e-06
- O 0 1.1745250048988964e-05
- O 0 2.3801487259333953e-05
> O 0 1.1920349606953096e-05
G O 0 5.663429692503996e-05
mutations O 0 1.9167995560565032e-05
: O 0 4.7189348606480053e-07
prevalence O 0 1.7220336303580552e-05
in O 0 4.464488370103936e-07
non O 0 1.770772178133484e-05
- O 0 0.0009707309072837234
Caucasian O 0 0.00013365558697842062
populations O 0 9.875685464066919e-06
. O 0 3.5460957406030502e-06

Hemochromatosis B-Disease 1 0.98317551612854
, O 0 0.0001654672814765945
the O 0 0.003044233424589038
inherited B-Disease 1 0.9999908208847046
disorder I-Disease 1 0.9999940395355225
of I-Disease 0 0.00018701242515817285
iron I-Disease 1 0.9990686774253845
metabolism I-Disease 1 0.8877890706062317
, O 0 4.270374120096676e-06
leads O 0 2.3543339921161532e-05
, O 0 1.5869002254476072e-06
if O 0 2.6294933377357665e-06
untreated O 0 0.0034990431740880013
, O 0 2.0686680102244281e-07
to O 0 2.0892098007152526e-07
progressive O 0 0.08081194758415222
iron B-Disease 1 0.9966740608215332
overload I-Disease 0 0.3619788587093353
and O 0 1.2753092960338108e-05
premature B-Disease 0 0.01438696589320898
death I-Disease 0 0.00022842694306746125
. O 0 4.915462795906933e-06

The O 0 0.00012800171680282801
hemochromatosis B-Disease 1 0.9985438585281372
gene O 0 0.0003220279177185148
, O 0 7.3666396929183975e-06
HFE O 0 0.0016740270657464862
, O 0 1.9862934550474165e-06
recently O 0 3.922094765584916e-05
has O 0 6.185088636811997e-07
been O 0 3.5251125041213527e-07
identified O 0 2.6709730605034565e-07
, O 0 1.634000490469134e-08
and O 0 2.0946595569171222e-08
characterization O 0 5.125946813677729e-07
of O 0 1.9625367997377907e-08
this O 0 1.8499557441487013e-08
gene O 0 2.804890470997634e-07
has O 0 1.1557558821095881e-07
shown O 0 5.672369240983244e-08
that O 0 2.547924315976502e-09
it O 0 3.828471317746107e-09
contains O 0 6.955763520721803e-09
two O 0 1.577812192010697e-08
mutations O 0 7.576299481115711e-07
that O 0 1.0314047393933379e-08
result O 0 7.182056549481786e-08
in O 0 3.530851699906634e-08
amino O 0 1.717796749289846e-07
acid O 0 9.766280300027574e-07
substitutions O 0 3.2959439977275906e-07
- O 0 9.65470803748758e-07
cDNA O 0 5.170832650946977e-07
nucleotides O 0 1.4891038517816924e-06
845 O 0 1.0377099897596054e-05
G O 0 4.823337076231837e-05
- O 0 2.70305790763814e-05
- O 0 1.4249405467126053e-05
> O 0 1.6392845054724603e-06
A O 0 3.6142324688626104e-07
( O 0 4.33533315913337e-08
C282Y O 0 9.637129778639064e-07
) O 0 1.527428494796368e-08
and O 0 2.456830472397087e-08
187 O 0 7.813882234586345e-07
C O 0 1.3190328900236636e-05
- O 0 3.326063233544119e-05
- O 0 7.341708987951279e-05
> O 0 1.8470260329195298e-05
G O 0 4.77751309517771e-05
( O 0 4.0632150444253057e-07
H63D O 0 9.441128349862993e-05
) O 0 7.430696200572129e-07
. O 0 1.330283680545108e-06

Although O 0 0.0008986771572381258
hemochromatosis B-Disease 1 0.9997900128364563
is O 0 7.118407211237354e-06
common O 0 4.113610884814989e-06
in O 0 4.759366731832415e-07
Caucasians O 0 3.7087629607412964e-06
, O 0 2.9178821137065825e-07
affecting O 0 3.808524979831418e-06
> O 0 9.527820111543406e-06
= O 0 3.851042038149899e-06
1 O 0 5.00152054883074e-07
/ O 0 2.1901234958932037e-06
300 O 0 7.993465089839447e-08
individuals O 0 3.1461826477396926e-09
of O 0 8.24087997841616e-09
northern O 0 2.2137739108529786e-07
European O 0 5.165874199519749e-07
origin O 0 5.203819242183272e-08
, O 0 5.989466700384583e-08
it O 0 4.3512635272691114e-08
has O 0 4.749595561293063e-08
not O 0 4.186675006678797e-09
been O 0 2.292981271523331e-08
recognized O 0 5.149779624957773e-08
in O 0 3.9267828100264524e-08
other O 0 3.149318317241523e-08
populations O 0 1.054354243024136e-06
. O 0 1.61061461767531e-06

The O 0 2.1665762233169517e-06
present O 0 6.583978802154888e-07
study O 0 2.8712747734971344e-07
used O 0 7.382812583500709e-08
PCR O 0 1.3501260127668502e-06
and O 0 4.014417953612792e-08
restriction O 0 1.5857565927035466e-07
- O 0 2.8666395337495487e-06
enzyme O 0 5.11036660100217e-07
digestion O 0 1.5103469195310026e-06
to O 0 1.4098679557150717e-08
analyze O 0 1.9739347578706656e-07
the O 0 2.4467993853249936e-08
frequency O 0 3.038706495317456e-07
of O 0 2.304802571018172e-08
the O 0 2.220868395852449e-07
845 O 0 1.1768402146117296e-05
G O 0 4.124372935621068e-05
- O 0 1.3429051250568591e-05
- O 0 6.740487151546404e-06
> O 0 9.643739531384199e-07
A O 0 2.2559127899057785e-07
and O 0 6.430296650705714e-08
187 O 0 5.370454232433985e-07
C O 0 6.449190095736412e-06
- O 0 9.961068826669361e-06
- O 0 1.2594771760632284e-05
> O 0 4.7648527470300905e-06
G O 0 1.4139325685391668e-05
mutations O 0 2.443384801154025e-06
in O 0 1.7520481776500674e-07
HLA O 0 7.628269941051258e-06
- O 0 1.304139459534781e-06
typed O 0 5.225522272667149e-07
samples O 0 1.3377498930822185e-07
from O 0 5.194299390609558e-08
non O 0 1.4889548083374393e-06
- O 0 3.534775532898493e-05
Caucasian O 0 1.3619143828691449e-05
populations O 0 3.8911039723643626e-07
, O 0 3.681223859075544e-08
comprising O 0 9.171214543357564e-08
Australian O 0 1.2572071454997058e-06
Aboriginal O 0 3.7492040405595617e-07
, O 0 9.126072342269254e-08
Chinese O 0 8.685616847969868e-08
, O 0 2.6660970320335764e-07
and O 0 9.998797168009332e-07
Pacific O 0 5.7671000831760466e-05
Islanders O 0 4.928634371026419e-05
. O 0 2.5595657007215777e-06

Results O 0 5.625900666927919e-05
showed O 0 9.79922515398357e-06
that O 0 5.386114310113044e-08
the O 0 2.6084779847224127e-07
845 O 0 1.6479574696859345e-05
G O 0 0.00016315450193360448
- O 0 5.083730138721876e-05
- O 0 2.64701375272125e-05
> O 0 2.422638999632909e-06
A O 0 1.1995188060609507e-06
mutation O 0 4.633297521650093e-06
was O 0 1.0738114042396774e-06
present O 0 2.3987144714965325e-08
in O 0 2.4248382857194883e-08
these O 0 4.133993591892704e-09
populations O 0 1.956079032083835e-08
( O 0 5.818879156294088e-09
allele O 0 6.293679177815648e-08
frequency O 0 2.1532518701405934e-07
0 O 0 7.844616334296006e-08
. O 0 7.740069918327208e-09
32 O 0 3.6536633274408814e-08
% O 0 3.2548941319987534e-09
) O 0 6.791562867647372e-09
, O 0 8.220126801461447e-09
and O 0 2.018244948942538e-08
, O 0 2.5871219833106807e-08
furthermore O 0 9.430988967551457e-08
, O 0 4.2401349986675996e-08
it O 0 4.3118060233382494e-08
was O 0 3.626680154411588e-06
always O 0 8.105572391059468e-08
seen O 0 1.7487995762621722e-07
in O 0 1.4053547658932075e-08
conjunction O 0 1.525623929410358e-07
with O 0 1.555380464424161e-07
HLA O 0 5.0762013415805995e-05
haplotypes O 0 6.781792762922123e-06
common O 0 1.568931565998355e-06
in O 0 3.35231732151442e-07
Caucasians O 0 1.8470982467988506e-06
, O 0 1.5667080788261956e-07
suggesting O 0 9.033452101903094e-07
that O 0 9.028563141555423e-08
845 O 0 7.666470992262475e-06
G O 0 8.195814734790474e-05
- O 0 3.827996624750085e-05
- O 0 1.8203689251095057e-05
> O 0 2.016588268816122e-06
A O 0 9.013376711664023e-07
may O 0 2.635131579609151e-07
have O 0 7.941549640122503e-09
been O 0 1.0121598670309595e-08
introduced O 0 1.3922018204937103e-08
into O 0 1.12733831159062e-08
these O 0 9.163220404673211e-09
populations O 0 6.213927861153934e-08
by O 0 1.1832190693894518e-07
Caucasian O 0 2.8363776436890475e-05
admixture O 0 7.166311115724966e-05
. O 0 1.2328541743045207e-05

187 O 0 8.597621490480378e-05
C O 0 0.00010332858073525131
- O 0 4.282875306671485e-05
- O 0 4.1005212551681325e-05
> O 0 8.133803930832073e-06
G O 0 1.7758489775587805e-05
was O 0 7.942505249047827e-07
present O 0 2.4375205853743864e-08
at O 0 8.569327292207163e-08
an O 0 7.044336225447978e-09
allele O 0 9.694976910168407e-08
frequency O 0 3.632144967014028e-07
of O 0 6.26436147399545e-08
2 O 0 2.089760755552561e-06
. O 0 2.0664706426032353e-06

68 O 0 3.663248207885772e-05
% O 0 1.9676892293318815e-07
in O 0 8.34782767356046e-08
the O 0 6.25426110900662e-08
two O 0 6.105257455146784e-08
populations O 0 2.639691558670165e-07
analyzed O 0 1.286782890019822e-06
( O 0 7.904422716364934e-08
Australian O 0 8.947405376602546e-07
Aboriginal O 0 3.310728402539098e-07
and O 0 1.3216779848335136e-07
Chinese O 0 3.2148255968422745e-07
) O 0 4.451351287571015e-07
. O 0 1.6632775441394188e-06

In O 0 2.559070253482787e-06
the O 0 5.928569066782075e-07
Australian O 0 1.8961375189974206e-06
Aboriginal O 0 3.264757424403797e-07
samples O 0 2.3839737650632742e-07
, O 0 5.165026806253081e-08
187 O 0 4.872273393630167e-07
C O 0 7.206466307252413e-06
- O 0 9.042804776981939e-06
- O 0 1.4985081179474946e-05
> O 0 2.6676127617975e-06
G O 0 9.14938937057741e-06
was O 0 8.536632662980992e-07
found O 0 2.2767039808968548e-08
to O 0 2.084900918575272e-09
be O 0 1.5776977946302395e-08
associated O 0 9.894587549297285e-08
with O 0 2.19215152696961e-07
HLA O 0 6.317567022051662e-05
haplotypes O 0 9.926797247317154e-06
common O 0 1.7376407868141541e-06
in O 0 2.7657637247102684e-07
Caucasians O 0 2.1299351828929503e-06
, O 0 1.0809712591708376e-07
suggesting O 0 1.9282546759313846e-07
that O 0 6.271580144101563e-09
it O 0 1.280420214300193e-08
was O 0 4.489349407776899e-07
introduced O 0 1.3210807026098337e-07
by O 0 4.080156301711213e-08
recent O 0 8.79398328379466e-07
admixture O 0 1.744051041896455e-05
. O 0 6.393548574123997e-06

In O 0 1.1152291108373902e-06
the O 0 1.6942220781857031e-07
Chinese O 0 1.2327831200309447e-07
samples O 0 5.545625185732206e-07
analyzed O 0 8.218200377996254e-07
, O 0 7.028516080254121e-08
187 O 0 9.090126695809886e-07
C O 0 8.568805242248345e-06
- O 0 1.3531625882023945e-05
- O 0 1.6707635950297117e-05
> O 0 3.278165422671009e-06
G O 0 1.4290871149569284e-05
was O 0 1.7765300981409382e-06
present O 0 6.502807536890032e-08
in O 0 6.913520422813235e-08
association O 0 8.799875672593771e-08
with O 0 1.9686215324554723e-08
a O 0 1.6419508597209642e-07
wide O 0 6.20371395143593e-07
variety O 0 4.930627710564295e-07
of O 0 2.593807550965721e-07
HLA O 0 7.233472570078447e-05
haplotypes O 0 5.271352620184189e-06
, O 0 2.2586641534871887e-07
showing O 0 7.571423452645831e-07
this O 0 5.045282946980478e-08
mutation O 0 5.388651516113896e-07
to O 0 9.568453585018233e-09
be O 0 4.4575362068144386e-08
widespread O 0 3.028626736067963e-07
and O 0 1.946911964978426e-07
likely O 0 3.530243191107729e-07
to O 0 1.348503886333674e-08
predate O 0 8.553680572731537e-07
the O 0 3.4961384898224424e-08
more O 0 4.965601707596079e-09
genetically O 0 1.7632905269238108e-07
restricted O 0 3.4486987487980514e-07
845 O 0 1.0636767001415137e-05
G O 0 0.00017831515287980437
- O 0 0.00010995727643603459
- O 0 5.3667092288378626e-05
> O 0 6.468019819294568e-06
A O 0 7.40131417842349e-06
mutation O 0 4.6922261390136555e-05
. O 0 2.4263106297439663e-06

Genotype O 0 0.004589200019836426
- O 0 0.0022296993993222713
phenotype O 0 0.0005796747282147408
correlations O 0 0.0004120738885831088
in O 0 9.344369755126536e-05
attenuated B-Disease 1 0.9810658097267151
adenomatous I-Disease 1 0.9998075366020203
polyposis I-Disease 1 0.9994851350784302
coli I-Disease 1 0.999240517616272
. O 0 0.00025798819842748344

Germ O 0 0.02050046995282173
- O 0 0.001571620930917561
line O 0 0.00012427665933500975
mutations O 0 4.087145862285979e-05
of O 0 2.10310304282757e-07
the O 0 4.296693987271283e-06
tumor B-Disease 1 0.5549060702323914
suppressor O 0 0.00012446132313925773
APC O 0 2.7972073439741507e-05
are O 0 2.3134244031552953e-07
implicated O 0 0.0006311164470389485
in O 0 6.896118429722264e-05
attenuated B-Disease 1 0.9934208989143372
adenomatous I-Disease 1 0.9998365640640259
polyposis I-Disease 1 0.9998112320899963
coli I-Disease 1 0.9998204112052917
( O 0 0.000339324091328308
AAPC B-Disease 1 0.998053789138794
) O 0 1.2321619351496338e-06
, O 0 4.2571284097903117e-07
a O 0 4.5728897930530366e-06
variant O 0 0.0028348849155008793
of O 0 0.00032826425740495324
familial B-Disease 1 0.9999027252197266
adenomatous I-Disease 1 0.999687671661377
polyposis I-Disease 1 0.9998853206634521
( O 0 0.001488501438871026
FAP B-Disease 0 0.01406645867973566
) O 0 8.991888535092585e-06
. O 0 1.5056605661811773e-05

AAPC B-Disease 1 0.9921060800552368
is O 0 9.626817700336687e-06
recognized O 0 2.256316292914562e-06
by O 0 1.757872496455093e-07
the O 0 2.5619291932343913e-07
occurrence O 0 1.6124535250128247e-05
of O 0 2.6702497279984527e-07
< O 0 3.806921813520603e-05
100 O 0 2.114285280185868e-06
colonic B-Disease 0 0.0019703186117112637
adenomas I-Disease 0 0.0005465444410219789
and O 0 1.930313544562523e-07
a O 0 2.7669823339238064e-06
later O 0 2.634118209243752e-05
onset O 1 0.8595929741859436
of O 0 0.16666847467422485
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999966621398926
( O 0 3.5249283882876625e-06
age O 0 8.9487029981683e-06
> O 0 8.895651262719184e-06
40 O 0 1.276211492040602e-06
years O 0 1.097438826036523e-06
) O 0 1.8976811588800047e-07
. O 0 1.078782361219055e-06

The O 0 2.6051420718431473e-06
aim O 0 3.866018232656643e-06
of O 0 9.196018169177478e-08
this O 0 8.135435081157993e-08
study O 0 2.0412298340488633e-07
was O 0 8.713590773368196e-07
to O 0 5.24040331129072e-08
assess O 0 3.589717152863159e-06
genotype O 0 3.896353518939577e-05
- O 0 0.00018002097203861922
phenotype O 0 6.503157783299685e-05
correlations O 0 3.816391108557582e-05
in O 0 1.3631371984956786e-05
AAPC B-Disease 1 0.9929172992706299
families O 0 3.281155159129412e-06
. O 0 8.289204743050504e-06

By O 0 1.53281962411711e-06
protein O 0 1.2651556971832179e-05
- O 0 2.6087715014000423e-05
truncation O 0 2.8349577405606396e-05
test O 0 2.427769004498259e-06
( O 0 1.000372122916815e-07
PTT O 0 7.395965440082364e-06
) O 0 4.5894033462445805e-08
assay O 0 6.571370363417373e-07
, O 0 1.8619275010678393e-08
the O 0 2.142763122492397e-08
entire O 0 6.840759851911571e-07
coding O 0 3.782939529628493e-06
region O 0 3.5859557101503015e-07
of O 0 1.3533273168775395e-08
the O 0 1.2850570385580795e-07
APC B-Disease 0 4.126652129343711e-06
gene O 0 7.246073323585733e-07
was O 0 8.660866797072231e-07
screened O 0 4.2346957229710824e-07
in O 0 5.78454439903453e-08
affected O 0 2.147114486206192e-07
individuals O 0 1.6928485280232053e-08
from O 0 4.1032262743101455e-07
11 O 0 1.8838642063201405e-05
AAPC B-Disease 1 0.9888600707054138
kindreds O 0 0.00010230443876935169
, O 0 1.2935386450863007e-07
and O 0 1.8004579160901812e-08
their O 0 2.00799679106467e-08
phenotypic O 0 6.830747679487104e-06
differences O 0 8.848051038512494e-06
were O 0 5.138524102221709e-06
examined O 0 0.0002700593904592097
. O 0 7.99824465502752e-06

Five O 0 7.564981387986336e-06
novel O 0 2.6748919481178746e-05
germ O 0 0.0014225153718143702
- O 0 0.00024476245744153857
line O 0 4.5524891902459785e-05
APC B-Disease 0 3.753673081519082e-05
mutations O 0 9.130439138971269e-06
were O 0 2.9389337896645884e-07
identified O 0 9.354845360576292e-07
in O 0 3.1314422699324496e-07
seven O 0 2.64756522483367e-06
kindreds O 0 0.0005387566634453833
. O 0 1.5246322618622798e-05

Mutations O 0 0.0002433970948914066
were O 0 8.43568159325514e-07
located O 0 7.933435881568585e-07
in O 0 3.2023560692096e-08
three O 0 9.488778651700613e-09
different O 0 2.6925668361599264e-09
regions O 0 7.001501245440522e-08
of O 0 1.1905953556379245e-08
the O 0 1.1714087122527417e-07
APC B-Disease 0 2.9688919767068e-06
gene O 0 4.0714110127737513e-07
( O 0 2.488195960381745e-08
1 O 0 5.389536639199832e-08
) O 0 6.0537472812427495e-09
at O 0 1.8216087482869625e-07
the O 0 2.5709576689791902e-08
5 O 0 9.263866473929738e-08
end O 0 1.230696966558753e-07
spanning O 0 5.519408432519413e-07
exons O 0 1.2817613423976582e-06
4 O 0 2.8507923843790195e-07
and O 0 4.531879582714282e-08
5 O 0 2.3081510391875781e-07
, O 0 3.7850323764132554e-08
( O 0 2.363215578782274e-08
2 O 0 7.058932283143804e-08
) O 0 7.810766256000079e-09
within O 0 2.8237845839385045e-08
exon O 0 2.8506203761935467e-06
9 O 0 1.028707060868328e-06
, O 0 3.0105965720395034e-08
and O 0 1.6912801825696988e-08
( O 0 1.78106773773834e-08
3 O 0 1.1808799627033295e-07
) O 0 9.723103211456419e-09
at O 0 2.9124359457455284e-07
the O 0 8.446196630984559e-08
3 O 0 3.259207517203322e-07
distal O 0 3.1724318887427216e-06
end O 0 5.068489485893224e-07
of O 0 3.000673132191878e-08
the O 0 2.4498353923263494e-07
gene O 0 8.857042303134222e-06
. O 0 3.552520411176374e-06

Variability O 0 0.00017609447240829468
in O 0 8.701267688593362e-07
the O 0 4.6997885760902136e-07
number O 0 1.3456848364512553e-06
of O 0 0.0008953826618380845
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.999966025352478
was O 0 0.005852396134287119
most O 0 3.194931537109369e-07
apparent O 0 6.277635293372441e-06
in O 0 1.5021259969216771e-07
individuals O 0 1.538736071893254e-08
with O 0 1.1679261291419607e-07
mutations O 0 6.331217264232691e-06
in O 0 2.734456927555584e-07
region O 0 6.093926572248165e-07
1 O 0 8.752501230446796e-07
, O 0 1.8238597476738505e-07
and O 0 1.9006745333172148e-06
upper O 1 0.9553475975990295
- O 1 0.9978598952293396
gastrointestinal O 1 0.9960871934890747
manifestations O 0 0.00013282138388603926
were O 0 2.1576065591943916e-06
more O 0 4.3522683768060233e-07
severe O 0 0.02451123669743538
in O 0 6.48822492621548e-07
them O 0 2.847050950549601e-07
. O 0 5.104120191390393e-06

In O 0 1.6101785149658099e-06
individuals O 0 1.2096170109998639e-07
with O 0 3.01344641684409e-07
mutations O 0 2.5783790988498367e-05
in O 0 3.640162447027251e-07
either O 0 6.957457117096055e-07
region O 0 2.4733299142098986e-06
2 O 0 6.73532042583247e-07
or O 0 2.2519706988077814e-07
region O 0 4.945410410073237e-07
3 O 0 1.7682313568911923e-07
, O 0 9.508598353136222e-09
the O 0 2.043812052932026e-08
average O 0 2.711389868181868e-07
number O 0 1.5179518086938515e-08
of O 0 3.729223152504346e-08
adenomas B-Disease 0 8.368806447833776e-05
tended O 0 4.718016555216309e-07
to O 0 1.1907316022075065e-08
be O 0 4.9169255333936235e-08
lower O 0 5.933490001552855e-07
than O 0 8.866217093839168e-09
those O 0 2.639968910145285e-09
in O 0 7.280517522190166e-09
individuals O 0 2.1960040452739804e-09
with O 0 3.3747063810096734e-08
mutations O 0 3.080656142628868e-06
in O 0 6.760534176919464e-08
region O 0 3.8118972156553355e-07
1 O 0 1.5735481895262637e-07
, O 0 2.833441925531588e-08
although O 0 7.909958554819241e-08
age O 0 1.0817360589499003e-06
at O 0 1.869061634351965e-05
diagnosis O 0 0.0071817622520029545
was O 0 4.8100711865117773e-05
similar O 0 2.1517605546250707e-06
. O 0 4.098152658116305e-06

In O 0 1.9889164832420647e-05
all O 0 7.142656613723375e-06
AAPC B-Disease 1 0.9881069660186768
kindreds O 0 0.0005009803571738303
, O 0 9.940646350514726e-07
a O 0 9.854702511802316e-07
predominance O 0 2.5742123398231342e-05
of O 0 8.562433322367724e-06
right O 1 0.9734525084495544
- O 1 0.9995710253715515
sided O 1 0.9995912909507751
colorectal B-Disease 1 0.9999996423721313
adenomas I-Disease 1 0.9999066591262817
and O 0 0.007296385709196329
rectal B-Disease 1 0.9995230436325073
polyp I-Disease 1 0.9963661432266235
sparing O 0 0.0001278084091609344
was O 0 0.00023314230202231556
observed O 0 3.2013300369726494e-05
. O 0 7.36970332582132e-06

No O 0 0.00028531847056001425
desmoid B-Disease 1 0.9577007293701172
tumors I-Disease 1 0.9999468326568604
were O 0 3.5283319448353723e-06
found O 0 1.106876538869983e-06
in O 0 2.1616938283841591e-07
these O 0 1.9507797333062626e-07
kindreds O 0 0.0002285711670992896
. O 0 7.473439836758189e-06

Our O 0 4.073887794220354e-06
data O 0 3.440253976805252e-06
suggest O 0 2.0981658508389955e-06
that O 0 9.42879481158343e-08
, O 0 1.8853891958769964e-07
in O 0 9.280142307943606e-07
AAPC B-Disease 1 0.9850434064865112
families O 0 1.391061061895016e-07
, O 0 4.973528078267009e-08
the O 0 2.142289012851961e-08
location O 0 3.1124500310397707e-07
of O 0 2.8857520817382465e-08
the O 0 9.835034688876476e-07
APC B-Disease 0 0.00023293278354685754
mutation O 0 7.406882650684565e-05
may O 0 2.6036689177999506e-06
partially O 0 1.904068085423205e-05
predict O 0 2.226945525762858e-06
specific O 0 1.4587929797471588e-07
phenotypic O 0 2.3009843062027358e-05
expression O 0 2.8282178391236812e-05
. O 0 1.1584650565055199e-05

This O 0 7.64288245136413e-07
should O 0 1.4868672337797761e-07
help O 0 3.6506957457049793e-08
in O 0 2.760645578803178e-08
the O 0 1.3269643162061584e-08
design O 0 8.710500196684734e-07
of O 0 7.866896822861236e-08
tailored O 0 9.22756953514181e-06
clinical O 0 6.650651630479842e-05
- O 0 0.0001403054193360731
management O 0 5.313450401445152e-06
protocols O 0 3.977502274210565e-06
in O 0 1.896407297863334e-07
this O 0 3.575615181716785e-08
subset O 0 9.648330205891398e-07
of O 0 6.082383947614289e-07
FAP B-Disease 0 0.001789397676475346
patients O 0 4.896562313660979e-05
. O 0 1.0676865258574253e-06
. O 0 2.3041445729177212e-06

Wilms B-Disease 1 0.9700825214385986
' I-Disease 0 0.00512754637748003
tumor I-Disease 0 0.033814143389463425
1 O 0 1.3923207689003902e-06
and O 0 3.2834859098329616e-07
Dax O 0 0.2684585154056549
- O 0 4.745139813167043e-05
1 O 0 6.287152132244955e-07
modulate O 0 4.426613486430142e-06
the O 0 9.867897006188286e-07
orphan O 0 2.220773239969276e-05
nuclear O 0 3.4253072954015806e-05
receptor O 0 8.555250133213121e-06
SF O 0 0.0024209008552134037
- O 0 1.3974934518046211e-05
1 O 0 3.945616526834783e-07
in O 0 6.31371008807946e-08
sex O 0 3.854117096580012e-07
- O 0 3.2721652587497374e-06
specific O 0 1.8754829511635762e-07
gene O 0 3.6083749819226796e-06
expression O 0 7.5905486482952256e-06
. O 0 3.479220140434336e-06

Products O 0 9.94542733678827e-06
of O 0 2.428991820124793e-06
steroidogenic O 0 0.0014720674371346831
factor O 0 1.5346950021921657e-05
1 O 0 5.151192453922704e-06
( O 0 9.998891528084641e-07
SF O 0 0.024102328345179558
- O 0 5.6150896853068843e-05
1 O 0 8.807849667391565e-07
) O 0 1.0460259858291465e-07
and O 0 8.875686035025865e-07
Wilms B-Disease 1 0.9859400987625122
tumor I-Disease 1 0.6451886296272278
1 O 0 1.6718365714041283e-06
( O 0 1.9610818924320483e-07
WT1 O 0 3.036309681192506e-05
) O 0 2.500422624507337e-08
genes O 0 7.933090273581911e-08
are O 0 3.4418883299025538e-09
essential O 0 1.9888316771243808e-08
for O 0 1.5374100215126418e-08
mammalian O 0 3.0367214094439987e-06
gonadogenesis O 0 3.5212004149798304e-05
prior O 0 6.021276135470544e-07
to O 0 6.445744560323874e-08
sexual O 0 1.1481694173198775e-06
differentiation O 0 1.4494904462480918e-05
. O 0 5.43259102414595e-06

In O 0 5.9877647800021805e-06
males O 0 4.434471975400811e-06
, O 0 1.6138204728122219e-06
SF O 0 0.02152581699192524
- O 0 5.043294731876813e-05
1 O 0 5.339915105651016e-07
participates O 0 4.928944576931826e-07
in O 0 4.072769854701619e-08
sexual O 0 2.8674541852069524e-08
development O 0 3.521973468423312e-08
by O 0 2.0730615446495904e-08
regulating O 0 1.8433219111102517e-06
expression O 0 4.094380585684121e-07
of O 0 8.18055951867791e-08
the O 0 1.4199321185515146e-06
polypeptide O 0 0.0001303727476624772
hormone O 0 0.00010251253843307495
Mullerian O 0 0.0012696933699771762
inhibiting O 0 9.820441482588649e-05
substance O 0 0.00020772773132193834
( O 0 2.7075677735410864e-06
MIS O 0 0.00423288531601429
) O 0 1.7919156789503177e-06
. O 0 3.000269543917966e-06

Here O 0 1.0515494068386033e-05
, O 0 3.2153070606000256e-07
we O 0 9.502818443252181e-08
show O 0 4.565098095099529e-07
that O 0 1.5898889671461802e-07
WT1 O 0 0.0002223114133812487
- O 0 6.961604958632961e-05
KTS O 0 0.00035566347651183605
isoforms O 0 1.1529083394634654e-06
associate O 0 1.0742579661382479e-06
and O 0 1.6341196840130578e-07
synergize O 0 4.641195118892938e-05
with O 0 3.371668299223529e-06
SF O 0 0.4894983768463135
- O 0 5.8075980632565916e-05
1 O 0 3.9238483395820367e-07
to O 0 4.838766898274116e-08
promote O 0 9.081115877052071e-07
MIS O 0 0.0019006523070856929
expression O 0 1.789218731573783e-05
. O 0 4.0680915844859555e-06

In O 0 6.943292646610644e-06
contrast O 0 1.716838960419409e-05
, O 0 3.693712187669007e-06
WT1 O 0 0.003010911401361227
missense O 0 0.001553009613417089
mutations O 0 0.0003631459840107709
, O 0 5.90291620028438e-07
associated O 0 1.5249650004989235e-06
with O 0 3.74102484101968e-07
male B-Disease 0 5.227698784437962e-05
pseudohermaphroditism I-Disease 1 0.9980499744415283
in O 0 5.125330062583089e-05
Denys B-Disease 1 0.9889421463012695
- I-Disease 1 0.9987896084785461
Drash I-Disease 1 0.9964967370033264
syndrome I-Disease 1 0.9999023675918579
, O 0 1.9684973722178256e-06
fail O 0 4.656913006328978e-06
to O 0 6.512352257459497e-08
synergize O 0 5.3267707698978484e-05
with O 0 1.0735476280387957e-05
SF O 1 0.9870650768280029
- O 0 0.0015124708879739046
1 O 0 9.68541280599311e-06
. O 0 3.6234928302292246e-06

Additionally O 0 9.884014616545755e-06
, O 0 4.763417109643342e-07
the O 0 1.2599438150573405e-06
X O 0 0.0027801552787423134
- O 0 0.0010343638714402914
linked O 0 0.00021032319637015462
, O 0 4.0896389918998466e-07
candidate O 0 1.5648879525542725e-06
dosage O 0 1.3821702850691509e-05
- O 0 6.535922693728935e-06
sensitive O 0 3.822749022219796e-06
sex O 0 1.179696255348972e-06
- O 0 5.206040896155173e-06
reversal O 0 1.7498384750069818e-06
gene O 0 7.462048756678996e-07
, O 0 1.5574421752262424e-07
Dax O 0 0.01202369760721922
- O 0 5.2784944273298606e-05
1 O 0 1.4545270232702023e-06
, O 0 1.5923698981623602e-07
antagonizes O 0 6.227754965948407e-06
synergy O 0 3.0838896236673463e-06
between O 0 1.5962181123541086e-06
SF O 0 0.011901858262717724
- O 0 2.7011512429453433e-05
1 O 0 3.784336115586484e-07
and O 0 7.717356709235901e-08
WT1 O 0 5.802881423733197e-05
, O 0 8.180044375194484e-08
most O 0 1.5496986804919288e-08
likely O 0 1.3476219251629118e-08
through O 0 1.926490522663471e-09
a O 0 1.0378616188688738e-08
direct O 0 1.1934533361568356e-08
interaction O 0 1.2171943808425567e-07
with O 0 1.2137486464780523e-06
SF O 1 0.9036372303962708
- O 0 0.000593439384829253
1 O 0 9.453477105125785e-06
. O 0 3.291792609161348e-06

We O 0 5.153659458301263e-06
propose O 0 7.423219813063042e-06
that O 0 3.202860341389169e-07
WT1 O 0 0.00013980102085042745
and O 0 2.380532350798603e-06
Dax O 1 0.678420901298523
- O 0 0.00025993131566792727
1 O 0 1.6142914773809025e-06
functionally O 0 3.8754601519030984e-06
oppose O 0 2.3718953912066354e-07
each O 0 1.2982517283433026e-08
other O 0 2.7714131434208866e-08
in O 0 1.6701459060186608e-07
testis O 0 3.555035436875187e-05
development O 0 4.2539545574982185e-07
by O 0 4.944877218804322e-07
modulating O 0 0.00041006383253261447
SF O 1 0.8814771175384521
- O 0 0.00022921762138139457
1 O 0 5.3519083849096205e-06
- O 0 2.8545722670969553e-05
mediated O 0 3.408880002098158e-05
transactivation O 0 0.00012063032045261934
. O 0 1.279938828702143e-06
. O 0 1.7480305132266949e-06

A O 0 3.2482523238286376e-05
mouse O 0 8.130412606988102e-05
model O 0 2.6818188416655175e-05
for O 0 3.0572824471164495e-05
Prader B-Disease 1 0.9998940229415894
- I-Disease 1 0.999874472618103
Willi I-Disease 1 0.9999362230300903
syndrome I-Disease 1 0.9999473094940186
imprinting O 1 0.960885226726532
- O 1 0.696353554725647
centre O 0 0.003828182118013501
mutations O 0 0.0031119228806346655
. O 0 1.3634999049827456e-05

Imprinting O 0 0.0006109855603426695
in O 0 3.0789171887590783e-06
the O 0 2.8175602437841007e-06
15q11 O 0 0.00014378428750205785
- O 0 0.00024791102623566985
q13 O 0 5.690796751878224e-05
region O 0 3.391760401427746e-06
involves O 0 5.965132459095912e-07
an O 0 2.813168009652145e-07
imprinting O 0 8.501127740601078e-05
centre O 0 2.3326248992816545e-05
( O 0 1.583834006169127e-07
IC O 0 9.39580968406517e-06
) O 0 6.722242318346616e-08
, O 0 2.5734156139378683e-08
mapping O 0 2.1471758770985616e-07
in O 0 3.475501131333658e-08
part O 0 3.496198530683614e-08
to O 0 7.631168585930936e-09
the O 0 7.727387441036626e-08
promoter O 0 1.2156241609773133e-05
and O 0 1.757879175556809e-07
first O 0 7.181823775681551e-07
exon O 0 3.329128958284855e-05
of O 0 2.0173076791252242e-06
SNRPN O 0 0.007504782173782587
. O 0 2.0251787645975128e-05

Deletion O 0 0.00022775755496695638
of O 0 7.817384926056548e-07
this O 0 7.704780387030041e-07
IC O 0 0.00014060555258765817
abolishes O 0 0.0001441152417100966
local O 0 1.624100150365848e-06
paternally O 0 6.003951421007514e-05
derived O 0 9.68503059084469e-07
gene O 0 3.523462964949431e-06
expression O 0 2.859180312952958e-06
and O 0 6.598373829547199e-07
results O 0 2.2940936105442233e-05
in O 0 0.00025413776165805757
Prader B-Disease 1 0.9999873638153076
- I-Disease 1 0.9999856948852539
Willi I-Disease 1 0.9999947547912598
syndrome I-Disease 1 0.9999939203262329
( O 0 0.0015502343885600567
PWS B-Disease 1 0.9995371103286743
) O 0 2.3632985175936483e-05
. O 0 1.946111660799943e-05

We O 0 1.5992579847079469e-06
have O 0 7.055916739773238e-08
created O 0 1.3207404947479517e-07
two O 0 7.996530371201516e-08
deletion O 0 1.0127469977305736e-05
mutations O 0 1.9163535398547538e-05
in O 0 4.7077733711375913e-07
mice O 0 7.330611424549716e-06
to O 0 7.948357705345188e-08
understand O 0 3.5954726627096534e-06
PWS B-Disease 1 0.9979863166809082
and O 0 2.593278338736127e-07
the O 0 1.478544504607271e-07
mechanism O 0 1.6384435639338335e-06
of O 0 1.5928621621696948e-07
this O 0 6.174503823785926e-07
IC O 0 0.00026331489789299667
. O 0 9.612423127691727e-06

Mice O 0 0.005333482753485441
harbouring O 0 0.002148951403796673
an O 0 2.6023310510936426e-06
intragenic O 0 0.00033350917510688305
deletion O 0 3.94228809454944e-05
in O 0 1.0141908433070057e-06
Snrpn O 0 8.196753333322704e-05
are O 0 1.3823868982854037e-07
phenotypically O 0 4.2830877646338195e-05
normal O 0 8.17390264273854e-06
, O 0 9.75751390797086e-08
suggesting O 0 4.428072770679137e-07
that O 0 4.133640985060083e-08
mutations O 0 1.229556005455379e-06
of O 0 4.444284229521145e-08
SNRPN O 0 0.00010752310481620952
are O 0 1.599193311108138e-08
not O 0 1.5474125092396207e-08
sufficient O 0 1.1036757996407687e-07
to O 0 1.9005861418008863e-07
induce O 0 3.521848702803254e-05
PWS B-Disease 1 0.996950626373291
. O 0 3.6496840039035305e-05

Mice O 0 0.00010026850213762373
with O 0 2.0458350036278716e-07
a O 0 7.54476900510781e-07
larger O 0 7.699066486566153e-07
deletion O 0 6.047839633538388e-06
involving O 0 9.79840933723608e-07
both O 0 2.484781873590691e-07
Snrpn O 0 0.0001325891789747402
and O 0 4.0306144910573494e-07
the O 0 3.6001943044539075e-06
putative O 0 0.001716138212941587
PWS O 1 0.9980362057685852
- O 0 0.0022174015175551176
IC O 0 8.655541751068085e-05
lack O 0 2.387867425568402e-06
expression O 0 6.218878638719616e-07
of O 0 5.989684126461725e-08
the O 0 5.12291194354475e-07
imprinted O 0 5.033656270825304e-05
genes O 0 4.407879714563023e-06
Zfp127 O 0 7.775542326271534e-05
( O 0 2.686328457457421e-07
mouse O 0 7.615375579916872e-06
homologue O 0 1.1751020792871714e-05
of O 0 3.0945466278353706e-07
ZNF127 O 0 0.0004277510743122548
) O 0 4.6529083874702337e-07
, O 0 3.251331861520157e-07
Ndn O 0 0.0001345676282653585
and O 0 2.0364174702081073e-07
Ipw O 0 7.786242349538952e-05
, O 0 4.0949700519377075e-07
and O 0 1.1274247668779935e-07
manifest O 0 1.6397848412452731e-06
several O 0 2.2975896740717872e-07
phenotypes O 0 4.315674232202582e-05
common O 0 1.1002705832652282e-05
to O 0 9.707902790978551e-06
PWS B-Disease 1 0.9995477795600891
infants O 0 0.2615167796611786
. O 0 3.8436748582171276e-05

These O 0 2.7222432663620566e-07
data O 0 4.2889462292805547e-07
demonstrate O 0 1.6586017181907664e-07
that O 0 8.08310574029747e-09
both O 0 1.1637164121225396e-08
the O 0 3.519777536098445e-08
position O 0 2.892950590194232e-07
of O 0 1.059731502550676e-08
the O 0 1.2590246001309424e-07
IC O 0 1.0081745131174102e-05
and O 0 9.476753604076293e-08
its O 0 5.0345160929055055e-08
role O 0 3.3833143220363127e-07
in O 0 3.633752143628044e-08
the O 0 1.282742356778499e-08
coordinate O 0 1.4875566023420106e-07
expression O 0 2.01288642642794e-07
of O 0 3.324877795307657e-08
genes O 0 2.533180918362632e-07
is O 0 4.780915929814e-08
conserved O 0 2.0313530058047036e-07
between O 0 5.6562281969263495e-08
mouse O 0 2.2908884602657054e-06
and O 0 7.665366297260334e-08
human O 0 1.7330503965240496e-07
, O 0 7.730601225830469e-08
and O 0 7.095202647633414e-08
indicate O 0 2.1767313285181444e-07
that O 0 8.691429798091121e-09
the O 0 4.44830376977734e-08
mouse O 0 2.2727399482391775e-06
is O 0 3.2203882227577196e-08
a O 0 2.976021562517417e-08
suitable O 0 1.294765468173864e-07
model O 0 5.882870368623117e-07
system O 0 1.1515501228132052e-06
in O 0 2.8928006656769867e-08
which O 0 7.473384577849629e-09
to O 0 1.7616030856260068e-09
investigate O 0 3.310109164544883e-08
the O 0 1.6435340199905113e-08
molecular O 0 1.0354345931773423e-06
mechanisms O 0 6.522340640913171e-07
of O 0 3.915250701425066e-08
imprinting O 0 1.2666732800425962e-05
in O 0 1.7681689712389925e-07
this O 0 2.7856001949544407e-08
region O 0 2.392856970345747e-07
of O 0 1.7999118639977496e-08
the O 0 2.506214968889253e-07
genome O 0 3.0732908271602355e-06
. O 0 2.544885830957355e-07
. O 0 9.763142543306458e-07

Mutations O 0 0.00016517801850568503
of O 0 2.0207242812375625e-07
the O 0 4.0853706195775885e-07
ATM O 0 5.065225195721723e-05
gene O 0 1.761699968483299e-05
detected O 0 0.0001317323767580092
in O 0 4.0551462916482706e-06
Japanese O 0 0.001984264934435487
ataxia B-Disease 1 0.9999830722808838
- I-Disease 1 0.9998928308486938
telangiectasia I-Disease 1 0.9999462366104126
patients O 0 0.20754870772361755
: O 0 8.946739740167686e-07
possible O 0 8.800578257250891e-07
preponderance O 0 1.2179543773527257e-05
of O 0 7.178879712910202e-08
the O 0 1.2351556222256477e-07
two O 0 3.218589768039237e-07
founder O 0 4.17064075008966e-05
mutations O 0 3.854617170873098e-05
4612del165 O 0 2.278680221934337e-05
and O 0 9.591221896698698e-07
7883del5 O 0 0.00012949494703207165
. O 0 1.0236368325422518e-05

The O 0 9.11104325496126e-06
ATM O 0 0.00028982714866288006
( O 0 8.37751395010855e-06
A O 1 0.9937679767608643
- O 1 0.9942896366119385
T O 1 0.9992709755897522
, O 0 2.623626755848818e-07
mutated O 0 1.1591505426622462e-06
) O 0 2.431767143207253e-08
gene O 0 4.974676812707912e-07
on O 0 6.109592050052015e-07
human O 0 3.475403445918346e-06
chromosome O 0 9.146267984760925e-05
11q22 O 0 0.0001784551568562165
. O 0 8.205707672459539e-06

3 O 0 1.3640526958624832e-05
has O 0 1.951683771039825e-06
recently O 0 4.107241693418473e-06
been O 0 2.070754305805167e-07
identified O 0 1.184787450370095e-07
as O 0 2.137040766569953e-08
the O 0 2.4915772556255433e-08
gene O 0 3.348099824052042e-07
responsible O 0 3.114614344212896e-07
for O 0 5.442841910507923e-08
the O 0 2.1077905785205076e-06
human O 0 0.000404944468755275
recessive B-Disease 1 0.9987562894821167
disease I-Disease 1 0.9999103546142578
ataxia B-Disease 1 0.9999860525131226
- I-Disease 1 0.9998531341552734
telangiectasia I-Disease 1 0.9998482465744019
( O 0 0.0011099178809672594
A B-Disease 1 0.9998533725738525
- I-Disease 1 0.9996554851531982
T I-Disease 1 0.9998192191123962
) O 0 2.1135313090780983e-06
. O 0 2.6822528980119387e-06

In O 0 1.099926294045872e-06
order O 0 1.1653827414193074e-07
to O 0 9.648872811851561e-09
define O 0 1.9364350123396434e-07
the O 0 1.5247832152454066e-07
types O 0 2.2761410036764573e-06
of O 0 4.254836767358938e-06
disease O 1 0.9987162351608276
- O 0 0.0039044192526489496
causing O 0 6.112269329605624e-05
ATM O 0 4.778907532454468e-05
mutations O 0 2.1665762687916867e-05
in O 0 4.7533609404126764e-07
Japanese O 0 1.9964496459579095e-05
A B-Disease 1 0.9994685053825378
- I-Disease 1 0.9996047616004944
T I-Disease 1 0.9998854398727417
patients O 0 6.890816621307749e-06
as O 0 5.701112471001579e-08
well O 0 2.8215071168347094e-08
as O 0 2.710277335893352e-08
to O 0 4.596637293019512e-09
look O 0 1.1611072636696917e-07
for O 0 1.5429858279958353e-08
possible O 0 2.4002918053156463e-07
mutational O 0 2.45512983383378e-05
hotspots O 0 6.101374310674146e-06
, O 0 1.435743683941837e-07
reverse O 0 2.757020411081612e-06
- O 0 4.218671165290289e-06
transcribed O 0 7.334935503422457e-07
RNA O 0 2.831338576925191e-07
derived O 0 3.2796485527342156e-08
from O 0 1.3272680732256958e-08
ten O 0 1.2321461895226093e-07
patients O 0 2.7719613626686623e-07
belonging O 0 9.51591374587224e-08
to O 0 2.472258486818646e-08
eight O 0 2.583488480922824e-07
unrelated O 0 1.0412151823402382e-05
Japanese O 0 5.234962372924201e-05
A B-Disease 1 0.9989432692527771
- I-Disease 1 0.9983465671539307
T I-Disease 1 0.9994630217552185
families O 0 1.584767801432463e-07
was O 0 1.619024828869442e-06
analyzed O 0 5.592169713963813e-07
for O 0 3.028426931450667e-08
mutations O 0 1.1083141089329729e-06
by O 0 2.7958094506175257e-08
the O 0 6.823142228995493e-08
restriction O 0 6.294213221735845e-07
endonuclease O 0 1.858716677816119e-05
fingerprinting O 0 8.964958396973088e-06
method O 0 5.352424068405526e-06
. O 0 5.6514140851504635e-06

As O 0 3.9774113247403875e-06
has O 0 1.496419713475916e-06
been O 0 7.637898420398415e-07
reported O 0 4.759207854476699e-07
by O 0 2.0032187464380513e-08
others O 0 8.253594074858484e-08
, O 0 1.0154882090773754e-07
mutations O 0 1.320921114711382e-06
that O 0 1.2345286570791814e-08
lead O 0 5.100307589600561e-07
to O 0 5.127080626721181e-08
exon O 0 1.395305480400566e-05
skipping O 0 1.059928945323918e-05
or O 0 5.642461928800913e-07
premature O 0 8.395733857469168e-06
protein O 0 3.0899491321179084e-07
truncation O 0 3.091038934144308e-06
were O 0 1.6045714801293798e-07
also O 0 9.970936787340179e-08
predominant O 0 7.927226874926419e-07
in O 0 1.2525383397132828e-07
our O 0 3.399125887426635e-07
mutants O 0 1.2957691069459543e-05
. O 0 1.543397047498729e-06

Six O 0 6.0069027085774e-07
different O 0 5.3623846696382316e-08
mutations O 0 1.5909598687358084e-06
were O 0 7.347313868422134e-08
identified O 0 2.096630566938984e-07
on O 0 2.399785898887785e-07
12 O 0 1.5687908216932556e-07
of O 0 1.1315887782359368e-08
the O 0 1.2371491209250962e-07
16 O 0 1.4496165476884926e-06
alleles O 0 3.884184934577206e-06
examined O 0 8.033123594941571e-05
. O 0 5.048154889664147e-06

Four O 0 1.2579279200508608e-06
were O 0 2.8184368261463533e-07
deletions O 0 9.393426807946526e-06
involving O 0 7.95458890934242e-06
a O 0 2.4392833438469097e-05
loss O 0 0.0003911406674887985
of O 0 7.717665795325956e-08
a O 0 7.406189297398669e-07
single O 0 2.3765105652273633e-06
exon O 0 2.8983735319343396e-05
exon O 0 1.9070339476456866e-05
7 O 0 1.7452887277613627e-06
, O 0 1.1621874307365943e-07
exon O 0 4.744823399960296e-06
16 O 0 6.429309564737196e-07
, O 0 6.381508654840218e-08
exon O 0 7.0812484409543686e-06
33 O 0 1.7786254602469853e-06
or O 0 4.431004470006883e-07
exon O 0 2.4060787836788222e-05
35 O 0 8.597938176535536e-06
. O 0 3.018479219463188e-06

The O 0 2.3068466816766886e-06
others O 0 5.509868401532003e-07
were O 0 7.323794193325739e-08
minute O 0 4.988106638847967e-07
deletions O 0 3.7241238715068903e-06
, O 0 2.12858594750287e-07
4649delA O 0 6.082005256757839e-06
in O 0 1.8806412072081002e-07
exon O 0 9.05775414139498e-06
33 O 0 1.7287529772147536e-06
and O 0 1.1494223173258433e-07
7883del5 O 0 1.6318024790962227e-05
in O 0 1.730608914840559e-06
exon O 0 0.00012861676805187017
55 O 0 2.4072127416729927e-05
. O 0 4.138550593779655e-06

The O 0 1.6492342183482833e-05
mutations O 0 0.00018557894509285688
4612del165 O 0 3.844612729153596e-05
and O 0 1.6938054159254534e-07
7883del5 O 0 6.122141257947078e-06
were O 0 2.2357671980444138e-07
found O 0 1.189890923569692e-07
in O 0 1.1401376731612345e-08
more O 0 8.578966981254155e-10
than O 0 3.4667535508958736e-09
two O 0 1.0299067376706716e-08
unrelated O 0 5.241268468125782e-07
families O 0 2.320585323900559e-08
; O 0 4.0903401554714947e-08
44 O 0 1.8984304972491373e-07
% O 0 1.0902889258090909e-08
( O 0 1.4197444997421371e-08
7 O 0 9.462430483608841e-08
of O 0 1.4253774160977173e-08
16 O 0 1.1343335160063361e-07
) O 0 2.196896220496569e-09
of O 0 8.673027296346447e-10
the O 0 5.69767433233892e-09
mutant O 0 1.325060452472826e-07
alleles O 0 5.4766964296959486e-08
had O 0 9.380165977290744e-08
one O 0 8.401782380929035e-09
of O 0 8.020661468322032e-09
the O 0 7.841758531412779e-08
two O 0 4.526592647380312e-07
mutations O 0 4.5347289415076375e-05
. O 0 4.232012997817947e-06

The O 0 5.258448709355434e-06
4612del165 O 0 4.182705015409738e-05
mutations O 0 1.6824740669107996e-05
in O 0 6.855114520476491e-08
three O 0 1.0485785573166595e-08
different O 0 1.820593009682625e-09
families O 0 2.3373398772008613e-09
were O 0 7.769519250189205e-09
all O 0 3.3986373715322316e-09
ascribed O 0 5.386412738062063e-08
to O 0 4.171896161864197e-09
the O 0 4.891716187671591e-08
same O 0 4.761818388487882e-07
T O 0 0.00037574954330921173
- O 0 9.85488441074267e-06
- O 0 2.870365506169037e-06
> O 0 2.084683927705555e-07
A O 0 5.544891124031892e-08
substitution O 0 3.50766704571015e-08
at O 0 1.291512177203913e-07
the O 0 4.4410896293811675e-08
splice O 0 4.352170435595326e-06
donor O 0 1.5737717831143527e-06
site O 0 2.120990075127338e-06
in O 0 4.619720641585445e-07
intron O 0 0.00012790728942491114
33 O 0 1.930989310494624e-05
. O 0 3.2549319257668685e-06

Microsatellite O 0 0.0018714508041739464
genotyping O 0 0.0002461178519297391
around O 0 1.0706169177865377e-06
the O 0 1.7921345829563506e-07
ATM O 0 1.678305670793634e-05
locus O 0 1.63186778081581e-05
also O 0 8.509776989740203e-07
indicated O 0 1.5755858839838766e-06
that O 0 8.336860091162634e-09
a O 0 6.891166037803487e-08
common O 0 3.861935624627222e-07
haplotype O 0 2.007496186706703e-05
was O 0 3.9384276533382945e-06
shared O 0 4.443445078550212e-08
by O 0 1.5480974724368934e-08
the O 0 3.0890351609969e-08
mutant O 0 6.564330305991462e-07
alleles O 0 2.1891868584589247e-07
in O 0 8.7716394148174e-08
both O 0 3.7319560419746267e-07
mutations O 0 6.946987559786066e-05
. O 0 4.026744136353955e-06

This O 0 6.572905704160803e-07
suggests O 0 7.370205139523023e-07
that O 0 9.692847413589334e-09
these O 0 5.166778116461046e-09
two O 0 4.621967875095834e-08
founder O 0 1.5603452993673272e-05
mutations O 0 2.0041332390974276e-05
may O 0 4.433849198903772e-07
be O 0 1.8445472704797794e-08
predominant O 0 3.3354635320392845e-07
among O 0 3.314449514846274e-08
Japanese O 0 5.250308277027216e-07
ATM O 0 2.141764161933679e-05
mutant O 0 2.3129943656385876e-05
alleles O 0 1.887244980025571e-05
. O 0 6.617602593905758e-06

W474C O 0 0.0005135030369274318
amino O 0 1.76884132088162e-05
acid O 0 9.750211575010326e-06
substitution O 0 4.46082367488998e-07
affects O 0 7.989926871232456e-07
early O 0 9.206178930298847e-08
processing O 0 6.052121648281172e-08
of O 0 1.3485707661686774e-08
the O 0 3.88798397921164e-08
alpha O 0 1.7711865041292185e-07
- O 0 3.24184810551742e-07
subunit O 0 9.09550550431959e-08
of O 0 4.740364190070068e-08
beta O 0 2.158940560548217e-06
- O 0 4.9725408644007985e-06
hexosaminidase O 0 4.8809192776388954e-06
A O 0 6.142764732430805e-07
and O 0 1.0455732279979202e-07
is O 0 2.976482278427284e-07
associated O 0 1.1332928124829778e-06
with O 0 1.083439542526321e-06
subacute O 1 0.9684305191040039
G B-Disease 0 0.2450752854347229
( I-Disease 0 2.0605709778465098e-06
M2 I-Disease 0 0.0009490361553616822
) I-Disease 0 2.4321022920048563e-06
gangliosidosis I-Disease 0 0.0004943100502714515
. O 0 8.336311111634132e-06

Mutations O 0 0.00033214924042113125
in O 0 1.9221624825149775e-06
the O 0 5.432625016510428e-07
HEXA O 0 0.00010464251681696624
gene O 0 3.5005297149837133e-07
, O 0 1.3401371568022569e-08
encoding O 0 1.6093183674570355e-08
the O 0 6.702538968283989e-08
alpha O 0 3.1019482094052364e-07
- O 0 3.7323334822758625e-07
subunit O 0 1.2246370317825495e-07
of O 0 6.593983670200032e-08
beta O 0 3.3568646813364467e-06
- O 0 1.3734456842939835e-05
hexosaminidase O 0 2.368121931795031e-05
A O 0 1.462042632738303e-06
( O 0 7.129251855531038e-08
Hex O 0 1.7085590116039384e-06
A O 0 5.732805448133149e-07
) O 0 2.209765703753419e-08
, O 0 1.7463122503613704e-08
that O 0 6.029433397003459e-09
abolish O 0 1.0848642659766483e-06
Hex O 0 5.418166892923182e-06
A O 0 2.2634692413703306e-06
enzyme O 0 1.1381557669665199e-05
activity O 0 2.4848630346241407e-05
cause O 0 0.008314964361488819
Tay B-Disease 1 0.9999700784683228
- I-Disease 1 0.9998906850814819
Sachs I-Disease 1 0.9999449253082275
disease I-Disease 1 0.999636173248291
( O 0 2.621590965645737e-06
TSD B-Disease 0 0.000882910389918834
) O 0 5.545286967389984e-07
, O 0 2.996252703724167e-07
the O 0 4.149514097662177e-06
fatal O 1 0.9628503918647766
infantile B-Disease 0 0.1460423320531845
form I-Disease 0 1.1034690942324232e-05
of I-Disease 0 3.5873865726898657e-06
G I-Disease 0 0.0027154358103871346
( I-Disease 0 6.500997073999315e-07
M2 I-Disease 0 0.00016644332208670676
) I-Disease 0 3.8847969108246616e-07
gangliosidosis I-Disease 0 3.391312566236593e-05
, I-Disease 0 5.451308311421599e-07
Type I-Disease 0 2.132496956619434e-05
1 I-Disease 0 8.826054909150116e-06
. O 0 3.4068277727783425e-06

Less O 0 0.0005373565363697708
severe O 1 0.9900312423706055
, O 0 4.656675810110755e-05
subacute O 1 0.9969255328178406
( O 0 0.00010272115468978882
juvenile O 1 0.9948763251304626
- O 1 0.6156094074249268
onset O 1 0.7261104583740234
) O 0 3.447203425821499e-06
and O 0 3.62318278348539e-05
chronic O 1 0.9995817542076111
( O 0 2.382051661697915e-06
adult O 0 4.125203122384846e-05
- O 0 0.006749264430254698
onset O 0 0.002464568242430687
) O 0 9.871138928474466e-08
variants O 0 3.2619564649394306e-07
are O 0 2.340713933790539e-08
characterized O 0 7.787383538016002e-07
by O 0 1.6099631849897378e-08
a O 0 2.2890969830768881e-07
broad O 0 1.3003428875890677e-06
spectrum O 0 8.004227311175782e-06
of O 0 3.082893726968905e-07
clinical O 0 1.7720070900395513e-05
manifestations O 0 1.932935083459597e-05
and O 0 1.7841914257132885e-07
are O 0 3.3601072146893785e-08
associated O 0 5.45113209682313e-07
with O 0 3.145650850910897e-07
residual O 0 4.3073938286397606e-05
levels O 0 6.889640644658357e-06
of O 0 1.269695815153682e-07
Hex O 0 1.3739972018811386e-05
A O 0 2.744488938333234e-06
enzyme O 0 7.814113814674783e-06
activity O 0 2.993516091009951e-06
. O 0 1.225733512910665e-06

We O 0 6.348097485897597e-06
identified O 0 7.637172529939562e-06
a O 0 4.075306151207769e-06
1422 O 0 0.000377161952201277
G O 0 0.0004340570012573153
- O 0 7.802489562891424e-05
- O 0 3.842458318104036e-05
> O 0 6.387430403265171e-06
C O 0 3.106310714429128e-06
( O 0 2.964786638415262e-08
amino O 0 2.076291281127851e-07
acid O 0 7.849417897887179e-07
W474C O 0 7.396794217129354e-07
) O 0 3.6072125286779055e-09
substitution O 0 1.2644557401131351e-08
in O 0 7.294918447087184e-09
the O 0 1.0576737707879147e-08
first O 0 4.5255909242314374e-08
position O 0 1.5469173320070695e-07
of O 0 1.5383045948169638e-08
exon O 0 4.980552148481365e-06
13 O 0 3.7197398228272505e-07
of O 0 4.594027558368907e-08
HEXA O 0 0.00024332120665349066
of O 0 1.0683653783871705e-07
a O 0 1.1159248742842465e-06
non O 0 8.065327165240888e-06
- O 0 7.543551328126341e-05
Jewish O 0 4.44876832261798e-06
proband O 0 0.00021076988196000457
who O 0 2.657481218193425e-06
manifested O 0 1.4233543879527133e-05
a O 0 5.3832818593946286e-06
subacute O 0 0.017845211550593376
variant O 0 0.0010449551045894623
of O 0 1.0256497262162156e-05
G B-Disease 0 0.02001640759408474
( I-Disease 0 2.4202281565521844e-06
M2 I-Disease 0 0.0016746042529121041
) I-Disease 0 3.496747012832202e-06
gangliosidosis I-Disease 0 0.0007020432385616004
. O 0 1.1208632713533007e-05

On O 0 6.175367161631584e-06
the O 0 1.3226253940956667e-06
second O 0 9.862490514933597e-06
maternally O 0 0.00020893407054245472
inherited O 0 0.0024063291493803263
allele O 0 3.148978066747077e-05
, O 0 4.868181804340566e-07
we O 0 2.6002075514952594e-07
identified O 0 5.339207405086199e-07
the O 0 8.592180051891773e-07
common O 0 0.0002562902227509767
infantile O 1 0.9995255470275879
disease O 1 0.9998537302017212
- O 0 0.1319754719734192
causing O 0 0.0009401377756148577
4 O 0 1.576004797243513e-05
- O 0 5.664888158207759e-05
bp O 0 2.703243626456242e-05
insertion O 0 2.5394990643690107e-06
, O 0 2.503456073554844e-07
+ O 0 6.680084425170207e-06
TATC O 0 0.00010688633483368903
1278 O 0 7.754911348456517e-05
, O 0 2.2862258219902287e-07
in O 0 2.117149477953717e-07
exon O 0 3.8878057239344344e-05
11 O 0 7.705656571488362e-06
. O 0 3.0639989745395724e-06

Pulse O 0 0.0009807927999645472
- O 0 7.401431503240019e-05
chase O 0 9.546056389808655e-06
analysis O 0 2.1483454304416227e-07
using O 0 3.080939166011376e-07
proband O 0 6.404754094546661e-05
fibroblasts O 0 4.698866177932359e-06
revealed O 0 5.972121925879037e-06
that O 0 1.511119940289518e-08
the O 0 5.321933116420041e-08
W474C O 0 2.304801682839752e-06
- O 0 1.485528173361672e-06
containing O 0 8.299310394477288e-08
alpha O 0 3.579600615921663e-07
- O 0 4.930759587296052e-07
subunit O 0 1.9024902542241762e-07
precursor O 0 7.633237828486017e-07
was O 0 3.39745355404375e-07
normally O 0 6.652955164554442e-08
synthesized O 0 3.2959064810711425e-07
, O 0 3.3200485916040634e-08
but O 0 1.2362818324618274e-08
not O 0 3.7191136836867145e-09
phosphorylated O 0 9.429442116015707e-08
or O 0 3.018485017491912e-08
secreted O 0 1.1227145790826398e-07
, O 0 1.9347618618326123e-08
and O 0 1.8080459796010473e-08
the O 0 1.0620001944516844e-07
mature O 0 1.2973304137631203e-06
lysosomal O 0 3.380085763637908e-05
alpha O 0 7.577556857540912e-07
- O 0 1.2180345265733195e-06
subunit O 0 7.136366093618562e-07
was O 0 2.255191247968469e-06
not O 0 1.6685315529230138e-07
detected O 0 1.9465089280856773e-05
. O 0 1.2016060964015196e-06

When O 0 4.920706942357356e-06
the O 0 3.165249893299915e-07
W474C O 0 8.407198038185015e-06
- O 0 3.391365453353501e-06
containing O 0 2.6363329652667744e-07
alpha O 0 6.575909310413408e-07
- O 0 9.384815484736464e-07
subunit O 0 5.967311835775035e-07
was O 0 1.3033400136919226e-06
transiently O 0 3.4118088478862774e-06
co O 0 2.959215862574638e-06
- O 0 2.1853124962945003e-06
expressed O 0 1.0203572209377398e-08
with O 0 4.434662859154059e-09
the O 0 3.0946672779919027e-08
beta O 0 1.5325623792250553e-07
- O 0 1.4508208323604777e-07
subunit O 0 2.282108191309362e-08
to O 0 3.265546277830822e-09
produce O 0 2.973995805177765e-08
Hex O 0 3.208612724847626e-06
A O 0 8.940241400523519e-07
( O 0 8.183836541775236e-08
alphabeta O 0 5.873492227692623e-06
) O 0 4.386746610407499e-08
in O 0 1.9185328881121677e-07
COS O 0 0.00013450797996483743
- O 0 1.300004714721581e-05
7 O 0 9.629054602555698e-07
cells O 0 2.943017420875549e-07
, O 0 1.3551509248088678e-08
the O 0 2.687391287281571e-08
mature O 0 2.602254198791343e-07
alpha O 0 1.3618080174637726e-07
- O 0 3.0547249707524315e-07
subunit O 0 5.699525118529891e-08
was O 0 2.236767500107817e-07
present O 0 2.6252228835232927e-08
, O 0 7.997884132748823e-09
but O 0 6.344321068496583e-09
its O 0 1.1243749042932905e-08
level O 0 2.8331967882877507e-07
was O 0 1.0646158443705644e-06
much O 0 5.985492634863476e-08
lower O 0 1.1963086308242055e-06
than O 0 6.77039047047856e-09
that O 0 2.3275037452918923e-09
from O 0 1.017554662752218e-08
normal O 0 2.52362752917179e-07
alpha O 0 1.9173914722614427e-07
- O 0 5.233151796346647e-07
subunit O 0 1.7801718854570936e-07
transfections O 0 3.1677307106292574e-06
, O 0 2.1556511242692977e-08
although O 0 3.505145684812305e-08
higher O 0 8.364674641825331e-08
than O 0 9.4336121136962e-09
in O 0 2.0175598081095814e-08
those O 0 1.5357102256530197e-08
cells O 0 2.0100434028336167e-07
transfected O 0 1.180758886221156e-06
with O 0 1.6556599646833092e-08
an O 0 8.716335742064985e-08
alpha O 0 1.3258052149467403e-06
- O 0 4.410213477967773e-06
subunit O 0 1.5950768101902213e-06
associated O 0 1.8629135638548178e-06
with O 0 3.5621756069303956e-06
infantile O 1 0.8970782160758972
TSD B-Disease 0 0.06592892110347748
. O 0 1.3790183402306866e-05

Furthermore O 0 1.0067814400827046e-05
, O 0 1.389949773056287e-07
the O 0 4.7602064512375364e-08
precursor O 0 9.924694950314006e-07
level O 0 7.103563461896556e-07
of O 0 1.1687078860234124e-08
the O 0 2.5136250414448114e-08
W474C O 0 1.3049568678979995e-06
alpha O 0 2.9424168701552844e-07
- O 0 4.3635395741148386e-07
subunit O 0 1.4373630108366342e-07
was O 0 3.836499899989576e-07
found O 0 2.9671570089817578e-08
to O 0 3.993665398382973e-09
accumulate O 0 3.5992906077808584e-07
in O 0 8.60877147346173e-09
comparison O 0 1.6934492919062905e-08
to O 0 2.6286437471156887e-09
the O 0 1.9778800819381104e-08
normal O 0 2.574162465407426e-07
alpha O 0 3.597712066039094e-07
- O 0 8.888188176570111e-07
subunit O 0 5.845222403877415e-07
precursor O 0 5.984710696793627e-06
levels O 0 1.1562001418496948e-05
. O 0 1.4769168501516106e-06

We O 0 6.080914772610413e-06
conclude O 0 2.444284064040403e-06
that O 0 4.6211301452103726e-08
the O 0 3.1130377919907914e-07
1422 O 0 0.0001739244908094406
G O 0 0.0002976622781716287
- O 0 6.617515464313328e-05
- O 0 3.3271291613345966e-05
> O 0 8.790203537500929e-06
C O 0 1.124919617723208e-05
mutation O 0 4.19934758610907e-06
is O 0 5.940873748500053e-08
the O 0 4.750084414695266e-08
cause O 0 1.4475443776973407e-06
of O 0 9.694070968180313e-08
Hex B-Disease 0 0.00046673641190864146
A I-Disease 0 0.0065527912229299545
enzyme I-Disease 1 0.9994840621948242
deficiency I-Disease 1 0.9999815225601196
in O 0 1.8231239664601162e-06
the O 0 4.2041001506731845e-06
proband O 0 0.0035585162695497274
. O 0 9.339921234641224e-06

The O 0 4.244377123541199e-06
resulting O 0 1.6065379895735532e-05
W474C O 0 3.082264811382629e-05
substitution O 0 1.8706933815337834e-06
clearly O 0 1.1357877838236163e-06
interferes O 0 1.4616662156186067e-06
with O 0 4.2910819786357024e-08
alpha O 0 5.243473424343392e-07
- O 0 3.222960742732539e-07
subunit O 0 1.0725140953127266e-07
processing O 0 1.7989172818033694e-07
, O 0 3.0770333836471764e-08
but O 0 1.911251423791782e-08
because O 0 1.1708676694865972e-08
the O 0 1.2994482823103226e-08
base O 0 1.4142625559543376e-07
substitution O 0 1.1579115266613371e-07
falls O 0 2.9877470296924002e-05
at O 0 2.65830777834708e-07
the O 0 2.6751122206292166e-08
first O 0 5.154299742571311e-08
position O 0 2.003459940169705e-07
of O 0 3.264171510863889e-08
exon O 0 8.808380698610563e-06
13 O 0 8.411885801251628e-07
, O 0 4.174644274712591e-08
aberrant O 0 1.5995310604921542e-06
splicing O 0 3.5419182040641317e-06
may O 0 6.046561225048208e-07
also O 0 3.74079256459936e-08
contribute O 0 2.734881121568833e-08
to O 0 4.986912216509154e-08
Hex B-Disease 0 0.00015330460155382752
A I-Disease 0 0.0005205956986173987
deficiency I-Disease 1 0.9832736253738403
in O 0 2.725077195009362e-07
this O 0 1.0299483932385556e-07
proband O 0 8.454586350126192e-05
. O 0 8.145789252012037e-07
. O 0 1.8450261904945364e-06

Two O 0 4.870935299550183e-06
frequent O 0 0.00018290520529262722
missense O 0 0.006627967115491629
mutations O 0 0.09265079349279404
in O 0 0.0046541644260287285
Pendred B-Disease 1 0.999908447265625
syndrome I-Disease 1 0.9999964237213135
. O 0 0.00047477526823058724

Pendred B-Disease 1 0.9998086094856262
syndrome I-Disease 1 0.9999978542327881
is O 0 0.011699303984642029
an O 0 0.10801760107278824
autosomal B-Disease 1 0.9999918937683105
recessive I-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9999998807907104
characterized O 1 0.9929813146591187
by O 0 0.00010945408575935289
early O 1 0.5913472771644592
childhood O 1 0.999408483505249
deafness B-Disease 1 0.9999983310699463
and O 1 0.9972397089004517
goiter B-Disease 1 0.9999902248382568
. O 0 0.0009068335057236254

A O 0 1.0501824363018386e-05
century O 0 5.689424142474309e-06
after O 0 7.629904530404019e-07
its O 0 3.3631398110856026e-08
recognition O 0 3.326863691199833e-07
as O 0 2.2933586478757206e-06
a O 0 0.0002616384590510279
syndrome O 1 0.9993882179260254
by O 0 6.790722864025156e-07
Vaughan O 0 0.00010376018326496705
Pendred O 0 0.000313995813485235
, O 0 1.4435945558943786e-06
the O 0 8.642913599032909e-06
disease O 0 0.43260079622268677
gene O 0 2.1185715013416484e-05
( O 0 6.481317313955515e-07
PDS O 0 0.00026739455643109977
) O 0 2.1850445364179905e-07
was O 0 1.5691844055254478e-06
mapped O 0 1.9461560896161245e-06
to O 0 1.58095474489528e-07
chromosome O 0 5.0270646170247346e-05
7q22 O 0 0.00012438975682016462
- O 0 0.00033057728433050215
q31 O 0 0.0003285460697952658
. O 0 1.061360217136098e-05

1 O 0 7.828412890376057e-06
and O 0 6.703670010210772e-07
, O 0 6.011808295625087e-07
recently O 0 1.5589101167279296e-05
, O 0 6.698385135450735e-08
found O 0 2.6538844011270157e-08
to O 0 2.2248158870752377e-09
encode O 0 8.54056025900718e-08
a O 0 1.71317799413373e-06
putative O 0 0.00011672763503156602
sulfate O 0 0.0010797858703881502
transporter O 0 0.00263896188698709
. O 0 1.8643228031578474e-05

We O 0 2.759030166998855e-06
performed O 0 3.2486027521372307e-06
mutation O 0 2.2766880647395737e-06
analysis O 0 7.435609461481363e-08
of O 0 1.4745081600153753e-08
the O 0 3.3801180165937694e-07
PDS B-Disease 0 0.0001539215591037646
gene O 0 4.234035259287339e-06
in O 0 6.645940970884112e-07
patients O 0 3.671663307613926e-06
from O 0 1.2615474531685322e-07
14 O 0 7.962580639286898e-07
Pendred B-Disease 0 6.5264921431662515e-06
families O 0 2.2346497985381575e-08
originating O 0 2.488424399871292e-07
from O 0 3.756357713768921e-08
seven O 0 2.0669812528240072e-08
countries O 0 4.208532189409198e-09
and O 0 5.479078879488952e-08
identified O 0 7.455575428139127e-07
all O 0 1.6487310006141342e-07
mutations O 0 4.760123192681931e-05
. O 0 3.6356977943796664e-06

The O 0 4.243211606080877e-06
mutations O 0 3.0641211196780205e-05
include O 0 3.312080139039608e-07
three O 0 1.5468494041215308e-07
single O 0 6.900648372720752e-07
base O 0 1.299133145948872e-06
deletions O 0 1.4204075569068664e-06
, O 0 3.1721789639505005e-08
one O 0 3.297185102724143e-08
splice O 0 6.743933226971421e-06
site O 0 5.236414381215582e-06
mutation O 0 5.654907454299973e-06
and O 0 3.2678568118171825e-07
10 O 0 2.830816583809792e-06
missense O 0 0.00021282563102431595
mutations O 0 0.000343170075211674
. O 0 1.0390567695139907e-05

One O 0 9.32592956814915e-06
missense O 0 0.0005482628475874662
mutation O 0 0.0001321787858614698
( O 0 2.792889404190646e-07
L236P O 0 6.99435895512579e-06
) O 0 9.767848041519755e-08
was O 0 1.62261858349666e-06
found O 0 6.977864330792727e-08
in O 0 1.499557633621862e-08
a O 0 1.2130597326631687e-07
homozygous O 0 4.825402584174299e-07
state O 0 4.58810802683729e-08
in O 0 2.4186485703125982e-08
two O 0 2.5197405051358146e-08
consanguineous O 0 8.718548087927047e-06
families O 0 2.6153822219043832e-08
and O 0 3.8461045903659397e-08
in O 0 3.079898647229129e-08
a O 0 1.722439009199661e-07
heterozygous O 0 1.7397503881966259e-07
state O 0 4.065962855293037e-08
in O 0 1.418767237026941e-08
five O 0 2.528657105926868e-08
additional O 0 4.675549547528135e-08
non O 0 9.683169082563836e-06
- O 0 0.0003200732753612101
consanguineous O 0 0.0003900585579685867
families O 0 2.2852327674627304e-06
. O 0 6.31208195045474e-06

Another O 0 8.33050871733576e-05
missense O 0 0.002564718946814537
mutation O 0 0.00027891190256923437
( O 0 1.1140874676129897e-06
T416P O 0 2.0224073523422703e-05
) O 0 1.0885916168490439e-07
was O 0 4.086117314727744e-06
found O 0 6.261733176415873e-08
in O 0 1.7189364598380052e-08
a O 0 4.5934140047165783e-08
homozygous O 0 2.9285007485668757e-07
state O 0 1.6633007859923055e-08
in O 0 2.3852239294797073e-08
one O 0 2.470712168189948e-08
family O 0 1.4915227097844763e-07
and O 0 3.280236526848057e-08
in O 0 5.7303839895439523e-08
a O 0 2.0122605803862825e-07
heterozygous O 0 2.2848637115657766e-07
state O 0 5.9338077562642866e-08
in O 0 6.77918023939128e-08
four O 0 2.543658297327056e-07
families O 0 3.9011808894429123e-07
. O 0 2.358277242819895e-06

Pendred B-Disease 0 0.010655310936272144
patients O 0 9.444361057830974e-05
in O 0 3.4912213209281617e-07
three O 0 2.1438897590542183e-07
non O 0 3.2802008718135767e-06
- O 0 5.8165434893453494e-05
consanguineous O 0 5.12448932568077e-05
families O 0 5.525254564986426e-08
were O 0 4.3166689778217915e-08
shown O 0 4.213963933352716e-08
to O 0 7.429538317893503e-09
be O 0 3.441476437160418e-08
compound O 0 8.639121347187029e-07
heterozygotes O 0 2.0602506083378103e-06
for O 0 6.685085907065513e-08
L236P O 0 1.3307709195942152e-05
and O 0 1.3625501651404193e-06
T416P O 0 0.00013831857359036803
. O 0 5.266247626423137e-06

In O 0 1.1035480156351696e-06
total O 0 1.447545514565718e-07
, O 0 8.721458044647079e-08
one O 0 3.306796259039402e-08
or O 0 3.0293861641439435e-08
both O 0 6.5059686527035865e-09
of O 0 4.355155347468553e-09
these O 0 6.526973628240285e-09
mutations O 0 4.795976451532624e-07
were O 0 4.240409978706339e-08
found O 0 5.932630386951132e-08
in O 0 1.5989249035897046e-08
nine O 0 3.1295400049202726e-08
of O 0 6.926214268787589e-09
the O 0 1.0695336527533073e-07
14 O 0 7.32904140932078e-07
families O 0 6.984441824897658e-08
analyzed O 0 6.807238605688326e-06
. O 0 1.4108868526818696e-06

The O 0 1.057872395904269e-06
identification O 0 3.732468485395657e-07
of O 0 6.48511928602602e-08
two O 0 3.2885466794141394e-07
frequent O 0 2.2204851120477542e-05
PDS B-Disease 0 0.0019388230284675956
mutations O 0 1.557484756631311e-05
will O 0 4.0121900468648164e-08
facilitate O 0 1.3328777015431115e-07
the O 0 1.388629129905894e-06
molecular O 0 0.001430726028047502
diagnosis O 1 0.8494042754173279
of O 0 0.0010429859394207597
Pendred B-Disease 1 0.9999737739562988
syndrome I-Disease 1 0.9999980926513672
. O 0 0.0004175459616817534

Insertional O 0 0.0025289931800216436
mutation O 0 0.00022097960754763335
by O 0 7.210261969703424e-07
transposable O 0 0.00011503523273859173
element O 0 1.05309691207367e-05
, O 0 1.021038428916654e-06
L1 O 0 2.9808228646288626e-05
, O 0 1.2770853174970398e-07
in O 0 1.3027518264152604e-07
the O 0 1.0907286878136802e-06
DMD B-Disease 1 0.7412826418876648
gene O 0 1.0071943506773096e-05
results O 0 6.259975180000765e-06
in O 0 5.469146344694309e-06
X B-Disease 1 0.9907113909721375
- I-Disease 1 0.9979962706565857
linked I-Disease 1 0.9944461584091187
dilated I-Disease 1 0.9942629933357239
cardiomyopathy I-Disease 1 0.999920129776001
. O 0 0.0001677949185250327

X B-Disease 1 0.9949747323989868
- I-Disease 1 0.9982032775878906
linked I-Disease 1 0.9963162541389465
dilated I-Disease 1 0.9979648590087891
cardiomyopathy I-Disease 1 0.9999696016311646
( O 0 1.8843242287402973e-05
XLDCM B-Disease 0 0.0034591867588460445
) O 0 3.4659890957300377e-07
is O 0 2.8236129878678184e-07
a O 0 1.2539634326458327e-06
clinical O 0 2.752791806415189e-05
phenotype O 0 1.768514084687922e-05
of O 0 2.42088304958088e-07
dystrophinopathy B-Disease 0 0.0035570356994867325
which O 0 1.7375826928400784e-06
is O 0 1.2192222129669972e-06
characterized O 0 1.3522222616302315e-05
by O 0 3.4703882079156756e-07
preferential O 0 3.0433018764597364e-05
myocardial B-Disease 1 0.9984812140464783
involvement I-Disease 0 4.0266506402986124e-05
without O 0 7.434424560415209e-07
any O 0 1.8297851056559011e-07
overt O 0 1.7879683582577854e-05
clinical O 0 0.0009358850074931979
signs O 0 0.016011130064725876
of O 0 0.000803851056843996
skeletal B-Disease 1 0.999988317489624
myopathy I-Disease 1 0.9999990463256836
. O 0 0.002152614062651992

To O 0 4.5158429884395446e-07
date O 0 2.7899236556550022e-06
, O 0 1.1106530450888386e-07
several O 0 1.760815422358064e-07
mutations O 0 1.3409932762442622e-05
in O 0 1.488589873588353e-06
the O 0 3.580447082640603e-05
Duchenne B-Disease 1 0.9992465972900391
muscular I-Disease 1 0.999122679233551
dystrophy I-Disease 1 0.9974415302276611
gene O 0 0.00047617373638786376
, O 0 9.900050827127416e-06
DMD O 1 0.9982393980026245
, O 0 5.123303026266512e-07
have O 0 6.736129876117047e-08
been O 0 5.816323778162769e-07
identified O 0 1.406520709679171e-06
in O 0 3.8460942164419976e-07
patients O 0 8.696480904291093e-07
with O 0 1.4953198501643783e-07
XLDCM B-Disease 0 0.0015295168850570917
, O 0 1.861452290086163e-07
but O 0 3.145026283846164e-08
a O 0 8.548789764972753e-08
pathogenic O 0 1.118501131713856e-06
correlation O 0 1.276857517495955e-07
of O 0 2.1581318065955202e-08
these O 0 6.531720941893582e-08
cardiospecific O 0 0.00023414206225425005
mutations O 0 8.200678712455556e-05
in O 0 2.440611069687293e-06
DMD O 1 0.9962053894996643
with O 0 4.956085604135296e-07
the O 0 2.8568417747010244e-06
XLDCM B-Disease 0 0.011115957982838154
phenotype O 0 0.00014475977513939142
has O 0 1.689982696007064e-06
remained O 0 3.7840472941752523e-06
to O 0 3.5606699810841747e-08
be O 0 4.6168182166184124e-07
elucidated O 0 9.697733185021207e-05
. O 0 3.75575973521336e-06

We O 0 1.213484847539803e-05
report O 0 9.98901782622852e-07
here O 0 3.4597995579588314e-08
the O 0 1.118565329250032e-08
identification O 0 2.3121291548022782e-08
of O 0 1.7047726785790474e-08
a O 0 3.842974365397822e-07
unique O 0 8.400101592087594e-07
de O 0 2.7080095605924726e-05
novo O 0 1.3248471987026278e-05
L1 O 0 1.1242761502217036e-05
insertion O 0 9.747132025950123e-07
in O 0 8.24350934180984e-08
the O 0 1.2296411000534135e-07
muscle O 0 2.969533124996815e-05
exon O 0 1.5467505363631062e-05
1 O 0 1.923772515510791e-06
in O 0 8.313670605275547e-07
DMD O 1 0.9915892481803894
in O 0 6.114190682637854e-07
three O 0 8.823243433653261e-07
XLDCM B-Disease 0 0.0020542715210467577
patients O 0 5.79437255510129e-06
from O 0 1.0867866961916661e-07
two O 0 6.867927027087717e-08
unrelated O 0 7.536308203270892e-06
Japanese O 0 5.442350357043324e-06
families O 0 5.410041694631218e-07
. O 0 5.0141802603320684e-06

The O 0 2.0372169728943845e-06
insertion O 0 9.362196578877047e-06
was O 0 1.245232760993531e-05
a O 0 5.674511385223013e-07
5 O 0 6.827372089901473e-07
- O 0 3.170741365465801e-06
truncated O 0 1.8775424450723222e-06
form O 0 1.404077352162858e-07
of O 0 4.185479340890197e-08
human O 0 4.112828833058302e-07
L1 O 0 6.9340089794422965e-06
inversely O 0 4.133588845434133e-06
integrated O 0 8.322751455125399e-06
in O 0 4.6698366418240767e-07
the O 0 5.595637730948511e-07
5 O 0 1.996912715185317e-06
- O 0 3.786381785175763e-05
untranslated O 0 6.094192940508947e-05
region O 0 3.5537061648938106e-06
in O 0 2.294904817290444e-07
the O 0 2.813905837228958e-07
muscle O 0 1.0878369721467607e-05
exon O 0 5.529821464733686e-06
1 O 0 4.998797180633119e-07
, O 0 3.437448725662762e-08
which O 0 1.5259404406720023e-08
affected O 0 3.757253708158714e-08
the O 0 1.794851911540718e-08
transcription O 0 5.066170274403703e-07
or O 0 1.1734705651633703e-07
the O 0 1.0561904417727419e-07
stability O 0 1.8590160379972076e-06
of O 0 8.537058704405354e-08
the O 0 1.2796324426744832e-06
muscle O 0 5.0063499656971544e-05
form O 0 4.0477101492797374e-07
of O 0 1.390985460147931e-07
dystrophin O 0 2.959528319479432e-05
transcripts O 0 5.746282567997696e-06
but O 0 1.6641963895835943e-07
not O 0 1.123890314147502e-08
that O 0 4.445926737872696e-09
of O 0 3.121926539506603e-08
the O 0 3.3649673696345417e-06
brain O 0 0.10040394961833954
or O 0 3.1125114219321404e-06
Purkinje O 0 0.0005905198049731553
cell O 0 9.588181274011731e-05
form O 0 2.2843653368909145e-06
, O 0 4.415834666815499e-07
probably O 0 2.569683601905126e-06
due O 0 4.115072727017832e-07
to O 0 3.828916739223587e-09
its O 0 1.6517203604848874e-08
unique O 0 9.12694275712056e-08
site O 0 1.4456516055361135e-06
of O 0 7.676574398374214e-08
integration O 0 5.2258733376220334e-06
. O 0 1.0902704161708243e-05

We O 0 5.8355703913548496e-06
speculate O 0 2.097855713145691e-06
that O 0 1.2724541420539026e-08
this O 0 6.568323218658634e-09
insertion O 0 1.5663614760796918e-07
of O 0 1.4027063066635037e-08
an O 0 3.910645318683237e-08
L1 O 0 1.5042397535580676e-05
sequence O 0 1.6256187791441334e-06
in O 0 1.7057537888831575e-06
DMD O 1 0.9942026734352112
is O 0 3.7721645185229136e-07
responsible O 0 3.3861289239212056e-07
for O 0 7.140626312462928e-09
some O 0 2.9755546915311015e-09
of O 0 7.762616327511296e-09
the O 0 4.745058745925235e-08
population O 0 1.1579862402300023e-08
of O 0 3.2065365473954444e-08
Japanese O 0 3.3513499602122465e-06
patients O 0 1.8003210016104276e-06
with O 0 2.870686444111925e-07
XLDCM B-Disease 0 0.001982314046472311
. O 0 9.91691763374547e-07
. O 0 2.6727107069746125e-06

Severe O 1 0.9768505096435547
early O 0 0.03495575860142708
- O 1 0.9979285001754761
onset O 1 0.9991961121559143
obesity B-Disease 1 0.9999823570251465
, O 0 0.029919007793068886
adrenal B-Disease 1 0.99996018409729
insufficiency I-Disease 1 0.9999758005142212
and O 0 0.0010687373578548431
red O 1 0.9775949120521545
hair O 1 0.9987653493881226
pigmentation O 1 0.9619202017784119
caused O 0 0.0024922997690737247
by O 0 4.725951384898508e-06
POMC O 0 0.015604368411004543
mutations O 0 0.00021544388437177986
in O 0 1.4022349432707415e-06
humans O 0 7.676355380681343e-06
. O 0 5.65831714993692e-06

Sequential O 0 2.796300577756483e-05
cleavage O 0 0.00012380471162032336
of O 0 2.2717379977166274e-07
the O 0 2.23493159978716e-07
precursor O 0 5.9974172472720966e-06
protein O 0 3.4201225389551837e-06
pre O 0 0.00013222846610005945
- O 0 0.00029429534333758056
pro O 0 0.0004482656077016145
- O 0 0.0003724235575646162
opiomelanocortin O 0 0.00021394281066022813
( O 0 8.781589144746249e-07
POMC O 0 0.00014779562479816377
) O 0 1.238711035966844e-07
generates O 0 5.330965109351382e-07
the O 0 7.322117880903534e-07
melanocortin O 0 0.0007494913879781961
peptides O 0 2.2202861146070063e-05
adrenocorticotrophin O 0 0.00020809627312701195
( O 0 9.175797117677575e-07
ACTH O 0 5.813859388581477e-05
) O 0 2.7081904363512876e-07
, O 0 6.646910151175689e-07
melanocyte O 0 0.00040407973574474454
- O 0 0.00034878472797572613
stimulating O 0 5.4253603593679145e-05
hormones O 0 2.157849849027116e-05
( O 0 2.421845977096382e-07
MSH O 0 8.669882663525641e-05
) O 0 3.677595472595385e-08
alpha O 0 2.0730681171698961e-07
, O 0 9.32212440574176e-09
beta O 0 4.795692731818235e-08
and O 0 2.3860733389113875e-09
gamma O 0 4.300881784047306e-08
as O 0 5.094150878903747e-09
well O 0 6.386279505221637e-09
as O 0 1.8344355368071774e-08
the O 0 7.852445804701347e-08
opioid O 0 6.654403023276245e-06
- O 0 4.072617230121978e-06
receptor O 0 1.6956023500824813e-06
ligand O 0 7.56241342969588e-06
beta O 0 3.745391950360499e-05
- O 0 0.00016324040188919753
endorphin O 0 0.0015752254985272884
. O 0 5.80407822781126e-06

While O 0 3.9726728573441505e-06
a O 0 1.289898818868096e-06
few O 0 7.322676651710935e-07
cases O 0 1.2799022215403966e-06
of O 0 1.4569204722647555e-06
isolated O 0 0.143448144197464
ACTH B-Disease 1 0.9773533344268799
deficiency I-Disease 1 0.9989114999771118
have O 0 1.1440869229772943e-06
been O 0 5.86114811085281e-06
reported O 0 4.5991138904355466e-05
( O 0 1.4050916661290103e-06
OMIM O 0 0.0018132602563127875
201400 O 0 8.024839189602062e-05
) O 0 2.6730015179055044e-07
, O 0 1.7259745277442562e-07
an O 0 2.4493265300407074e-06
inherited O 1 0.9947733283042908
POMC O 1 0.9873976111412048
defect O 1 0.6685020327568054
has O 0 3.878059033013415e-06
not O 0 1.047683326760307e-07
been O 0 3.651573763363558e-07
described O 0 1.572394580762193e-06
so O 0 2.1659346316482697e-07
far O 0 9.859243164100917e-07
. O 0 1.5469396430489724e-06

Recent O 0 2.022530861722771e-05
studies O 0 9.340920428257959e-07
in O 0 6.982976685776521e-08
animal O 0 3.679244571230811e-07
models O 0 5.751116418650781e-07
elucidated O 0 5.398381290433463e-06
a O 0 2.1615763046156644e-07
central O 0 1.6502615096669615e-07
role O 0 2.8071596602785576e-07
of O 0 1.1012849654434831e-07
alpha O 0 6.7704318098549265e-06
- O 0 6.837114779045805e-05
MSH O 0 0.0002803871175274253
in O 0 5.055522578345517e-08
the O 0 6.47012043941686e-08
regulation O 0 9.063128345587756e-07
of O 0 2.9709285698231724e-08
food O 0 2.842536446223676e-07
intake O 0 1.597338950887206e-06
by O 0 2.9626384900893754e-08
activation O 0 7.879974646129995e-07
of O 0 7.994075446049465e-08
the O 0 1.4526681297866162e-06
brain O 0 0.006910442374646664
melanocortin O 0 0.0012168294051662087
- O 0 9.233646414941177e-05
4 O 0 5.131951638759347e-06
- O 0 1.4359329725266434e-05
receptor O 0 5.102864633954596e-06
( O 0 6.112441042205319e-07
MC4 O 0 0.00042349984869360924
- O 0 6.602488429052755e-05
R O 0 3.5377161111682653e-05
; O 0 7.604742080502547e-08
refs O 0 3.582124918466434e-06
3 O 0 4.399063300297712e-07
- O 0 1.8050020571536152e-06
5 O 0 5.690987237016998e-08
) O 0 4.508555750959431e-09
and O 0 5.720607543224787e-09
the O 0 1.9178171939415734e-08
linkage O 0 2.5860247205855558e-06
of O 0 3.2915906444941356e-07
human O 0 4.157401417614892e-05
obesity B-Disease 1 0.9990752935409546
to O 0 9.493560071405227e-08
chromosome O 0 6.5228273342654575e-06
2 O 0 1.82478189003632e-07
in O 0 2.4058532943627142e-08
close O 0 1.7053457668225747e-07
proximity O 0 2.8886688596685417e-07
to O 0 3.545875060240178e-08
the O 0 2.597671766579879e-07
POMC O 0 9.570961265126243e-05
locus O 0 5.897694336454151e-06
, O 0 1.4835613626473787e-07
led O 0 1.3794355879781506e-07
to O 0 7.514922906182164e-09
the O 0 5.378179324111443e-08
proposal O 0 6.197245738803758e-07
of O 0 2.1747471379285344e-08
an O 0 9.628414687767872e-08
association O 0 7.43665793834225e-07
of O 0 2.984833145092125e-07
POMC O 0 0.002207504352554679
with O 0 1.0246641977573745e-05
human O 0 0.0024949044454842806
obesity B-Disease 1 0.9997912049293518
. O 0 3.224511965527199e-05

The O 0 1.3782142787022167e-06
dual O 0 5.3208232202450745e-06
role O 0 3.1058486911206273e-06
of O 0 4.668367523663619e-07
alpha O 0 2.7492658773553558e-05
- O 0 0.00021327784634195268
MSH O 0 0.0007207553135231137
in O 0 4.894077392236795e-07
regulating O 0 6.232128271221882e-06
food O 0 8.031133802433033e-07
intake O 0 7.101807568687946e-06
and O 0 1.7384235206918675e-07
influencing O 0 2.0524732462945394e-05
hair O 1 0.8821272253990173
pigmentation O 0 0.026236411184072495
predicts O 0 5.83032779104542e-05
that O 0 9.246531362805399e-08
the O 0 1.995249618857997e-07
phenotype O 0 1.4478519915428478e-05
associated O 0 1.0946563406832865e-06
with O 0 3.064598956825648e-07
a O 0 1.592692751728464e-05
defect O 0 0.0031064364593476057
in O 0 7.349632937803108e-07
POMC O 0 0.0003619656490627676
function O 0 1.9292510842205957e-06
would O 0 8.171831495928927e-07
include O 0 1.0800611562444828e-05
obesity B-Disease 1 0.999854564666748
, O 0 1.7217737422470236e-06
alteration O 0 0.0002938075631391257
in O 0 1.2430165043042507e-05
pigmentation O 1 0.5200647711753845
and O 0 0.000677218078635633
ACTH B-Disease 1 0.9885035157203674
deficiency I-Disease 1 0.999159574508667
. O 0 2.2917298338143155e-05

The O 0 4.658761554310331e-06
observation O 0 2.208523619628977e-05
of O 0 1.7653282213814236e-07
these O 0 4.823410790777416e-07
symptoms O 0 0.0021991680841892958
in O 0 2.20601819478361e-07
two O 0 1.687285617890666e-07
probands O 0 6.78010837873444e-05
prompted O 0 1.2779019016306847e-06
us O 0 9.512319820714765e-08
to O 0 6.417269382552604e-09
search O 0 6.966547516640276e-08
for O 0 2.9669022794109878e-08
mutations O 0 2.255466370115755e-06
within O 0 1.1004093636302059e-07
their O 0 2.1717715981139918e-07
POMC O 0 0.0011895517818629742
genes O 0 2.742298056546133e-05
. O 0 1.140024141932372e-05

Patient O 0 0.0011688309023156762
1 O 0 9.553178642818239e-06
was O 0 3.0183240596670657e-05
found O 0 2.3159718409715424e-07
to O 0 7.641218324749843e-09
be O 0 1.7224746073907227e-08
a O 0 7.48975494957449e-08
compound O 0 3.7802672636644274e-07
heterozygote O 0 3.9798248963052174e-07
for O 0 9.162136827001177e-09
two O 0 2.4284391386686366e-08
mutations O 0 1.4841036772850202e-06
in O 0 1.2520642655999836e-07
exon O 0 7.5698376349464525e-06
3 O 0 1.1316361678836984e-06
( O 0 1.4564881212209002e-07
G7013T O 0 7.539175840065582e-06
, O 0 2.084099577359666e-07
C7133delta O 0 1.0205614671576768e-05
) O 0 2.915338903619613e-08
which O 0 9.535478184830026e-09
interfere O 0 3.109138546619761e-08
with O 0 6.702817412218565e-09
appropriate O 0 2.038113144919862e-08
synthesis O 0 3.6441360862227157e-07
of O 0 1.1824193535403538e-07
ACTH O 0 3.3763684768928215e-05
and O 0 8.6458140913237e-07
alpha O 0 3.0262439395301044e-05
- O 0 0.0009916055714711547
MSH O 0 0.009075748734176159
. O 0 6.029209544067271e-06

Patient O 0 0.00042493545333854854
2 O 0 4.152545898250537e-06
was O 0 2.656807282619411e-06
homozygous O 0 3.631376159773936e-07
for O 0 8.663871398084666e-09
a O 0 2.137921768508022e-07
mutation O 0 2.03787385544274e-06
in O 0 1.8667944345907017e-07
exon O 0 1.0861741429835092e-05
2 O 0 1.0896859521380975e-06
( O 0 1.633374893117434e-07
C3804A O 0 5.49016431250493e-06
) O 0 9.992412230985792e-08
which O 0 1.7615208491861267e-07
abolishes O 0 9.851702634477988e-05
POMC O 0 0.0011647341307252645
translation O 0 2.4848512111930177e-05
. O 0 8.143185368680861e-06

These O 0 3.909848089733714e-07
findings O 0 6.385027404576249e-07
represent O 0 2.2080591577378073e-08
the O 0 4.8410655040243e-08
first O 0 8.870500778357382e-08
examples O 0 2.7299412863612815e-07
of O 0 2.042904725385597e-07
a O 0 0.00019041566702071577
genetic B-Disease 1 0.9993168115615845
defect I-Disease 1 0.9996680021286011
within O 0 8.029471700865543e-07
the O 0 1.0434400792291854e-06
POMC O 0 0.0002461279509589076
gene O 0 2.6416687433084007e-06
and O 0 1.7187767298310064e-07
define O 0 2.369788717260235e-06
a O 0 5.45828697795514e-06
new O 0 0.00010636515798978508
monogenic B-Disease 1 0.9947722554206848
endocrine I-Disease 1 0.9993224143981934
disorder I-Disease 1 0.9977890253067017
resulting O 0 4.015196827822365e-05
in O 0 5.9189251260249875e-06
early O 0 0.001551171182654798
- O 1 0.9980023503303528
onset O 1 0.9992042183876038
obesity B-Disease 1 0.9999792575836182
, O 0 0.002327261958271265
adrenal B-Disease 1 0.9999392032623291
insufficiency I-Disease 1 0.9999709129333496
and O 0 0.00043554959120228887
red O 0 0.46117958426475525
hair O 1 0.9864320158958435
pigmentation O 0 0.11440686881542206
. O 0 6.384726020769449e-06
. O 0 8.148965207510628e-06

A O 0 3.838220800389536e-05
European O 0 7.374764390988275e-05
multicenter O 0 0.008068527095019817
study O 0 2.6458628781256266e-05
of O 0 2.9896478736191057e-05
phenylalanine B-Disease 1 0.9997827410697937
hydroxylase I-Disease 1 0.9996834993362427
deficiency I-Disease 1 0.9999946355819702
: O 0 1.2139895261498168e-05
classification O 0 4.845752482651733e-05
of O 0 1.4203165221715608e-07
105 O 0 3.1280592338589486e-06
mutations O 0 5.632222837448353e-06
and O 0 4.601902858780704e-08
a O 0 2.1951429118871602e-07
general O 0 1.9097542747203988e-07
system O 0 1.162819899036549e-06
for O 0 1.2203535959542933e-07
genotype O 0 9.177002539217938e-06
- O 0 2.8088756153010763e-05
based O 0 9.945425745172543e-07
prediction O 0 3.021970042027533e-05
of O 0 1.0037969104814692e-06
metabolic O 1 0.5537567138671875
phenotype O 0 0.0022295392118394375
. O 0 1.0913739970419556e-05

Phenylketonuria B-Disease 1 0.965069591999054
( O 0 9.52809932641685e-05
PKU B-Disease 0 0.06600495427846909
) O 0 8.30910175864119e-06
and O 0 4.497051486396231e-05
mild B-Disease 1 0.9958048462867737
hyperphenylalaninemia I-Disease 1 0.9999579191207886
( O 0 0.0009827230824157596
MHP B-Disease 1 0.999895453453064
) O 0 2.0959139419574058e-06
are O 0 1.4408877859750646e-06
allelic B-Disease 0 0.03285415470600128
disorders I-Disease 1 0.9997033476829529
caused O 0 0.0010063099907711148
by O 0 6.196169692884723e-07
mutations O 0 2.4760465748840943e-05
in O 0 1.3107049312566232e-07
the O 0 1.6242971412339102e-07
gene O 0 4.035363417642657e-06
encoding O 0 1.6289261111523956e-05
phenylalanine O 0 0.004211826249957085
hydroxylase O 0 0.014037520624697208
( O 0 2.88686223939294e-05
PAH O 1 0.9968944787979126
) O 0 5.235480784904212e-06
. O 0 7.211423508124426e-06

Previous O 0 1.136679475166602e-05
studies O 0 6.30342810836737e-07
have O 0 3.1807029898800465e-08
suggested O 0 7.940841584286318e-08
that O 0 4.792316765644955e-09
the O 0 5.563122229546025e-08
highly O 0 7.771715900162235e-06
variable O 0 0.00015368807362392545
metabolic O 1 0.8061503767967224
phenotypes O 0 0.016199778765439987
of O 0 0.0016728226328268647
PAH B-Disease 1 0.9999680519104004
deficiency I-Disease 1 0.9996929168701172
correlate O 0 0.00047877643373794854
with O 0 0.0004962182138115168
PAH O 1 0.9993187189102173
genotypes O 0 0.011658993549644947
. O 0 4.7795641876291484e-05

We O 0 4.109686415176839e-06
identified O 0 4.775657544087153e-06
both O 0 5.709730430680793e-07
causative O 0 0.00024723546812310815
mutations O 0 0.00014686716895084828
in O 0 2.245122459498816e-06
686 O 0 6.896401464473456e-05
patients O 0 1.2573543244798202e-05
from O 0 1.5127383790058957e-07
seven O 0 2.872036191092775e-07
European O 0 3.7160352803766727e-06
centers O 0 8.723754035599995e-06
. O 0 3.772988065975369e-06

On O 0 1.9922883893741528e-06
the O 0 9.894834107626593e-08
basis O 0 4.9063395124449016e-08
of O 0 1.4732430386743545e-08
the O 0 4.030145106526106e-08
phenotypic O 0 2.190156919823494e-06
characteristics O 0 1.2902236221634666e-06
of O 0 1.9537138484793104e-07
297 O 0 1.0602575457596686e-05
functionally O 0 0.00012774966307915747
hemizygous O 0 0.0006395243690349162
patients O 0 1.240711753780488e-05
, O 0 4.801907849127929e-08
105 O 0 1.3095392148443352e-07
of O 0 8.819194263764984e-09
the O 0 9.535572331742515e-08
mutations O 0 1.1014368510586792e-06
were O 0 2.149558220310155e-08
assigned O 0 5.8249224110795694e-08
to O 0 2.748706595667727e-09
one O 0 1.2957061201746e-08
of O 0 4.769856065678368e-09
four O 0 5.7898425609437254e-08
arbitrary O 0 4.6864329306117725e-07
phenotype O 0 1.7839609427028336e-05
categories O 0 4.824961251870263e-06
. O 0 3.4988054267159896e-06

We O 0 9.471544217376504e-06
proposed O 0 4.170484771748306e-06
and O 0 3.4396268233649607e-07
tested O 0 2.28394492296502e-06
a O 0 5.8764786814435865e-08
simple O 0 1.0061587119025717e-07
model O 0 1.9568466314012767e-07
for O 0 7.137630486653279e-09
correlation O 0 1.0121275551000508e-07
between O 0 1.1811648903403693e-07
genotype O 0 3.18629463436082e-06
and O 0 1.2914998137603106e-07
phenotypic O 0 3.135911902063526e-05
outcome O 0 5.3935324103804305e-05
. O 0 8.016198080440518e-06

The O 0 7.3901906034734566e-06
observed O 0 3.868485146085732e-05
phenotype O 0 6.277787178987637e-05
matched O 0 6.378384568961337e-06
the O 0 8.120301799863228e-07
predicted O 0 1.5461724615306593e-05
phenotype O 0 1.1057571100536734e-05
in O 0 2.2993650361513573e-07
79 O 0 1.202093130814319e-06
% O 0 1.068024690908942e-08
of O 0 6.077556680139651e-09
the O 0 8.422660613405242e-08
cases O 0 1.645215803591782e-07
, O 0 3.295600592423398e-08
and O 0 2.317718994504503e-08
in O 0 3.293583716867943e-08
only O 0 1.2069617305598968e-08
5 O 0 8.817634977731359e-08
of O 0 3.592369779426008e-08
184 O 0 1.7245165508938953e-06
patients O 0 2.612847538330243e-06
was O 0 2.0636073259083787e-06
the O 0 4.400632747092459e-08
observed O 0 1.7957565034976142e-07
phenotype O 0 3.6574849104908935e-07
more O 0 1.7877443969638307e-09
than O 0 4.631999672710663e-09
one O 0 2.8308003052757158e-08
category O 0 2.693760450256377e-07
away O 0 2.0188268479159888e-07
from O 0 7.479362551521263e-08
that O 0 5.4745555644331034e-08
expected O 0 1.026068503051647e-06
. O 0 1.2846285244449973e-06

Among O 0 1.2455062687877216e-06
the O 0 6.096548190726025e-07
seven O 0 8.983640782389557e-07
contributing O 0 1.0926006552836043e-06
centers O 0 4.0284550095748273e-07
, O 0 5.8019146820242895e-08
the O 0 6.505636207521093e-08
proportion O 0 4.647391449452698e-07
of O 0 9.063847983270534e-08
patients O 0 6.265095748858585e-07
for O 0 1.3434873658013657e-08
whom O 0 1.5283268339771894e-07
the O 0 2.2003494848377159e-07
observed O 0 1.0269181984767783e-06
phenotype O 0 1.9443955352471676e-06
did O 0 1.2005976657292194e-07
not O 0 1.415793704495627e-08
match O 0 2.547717201650812e-07
the O 0 1.6941834246608778e-07
predicted O 0 3.6417527553567197e-06
phenotype O 0 3.174953008056036e-06
was O 0 1.600660311851243e-06
4 O 0 1.8213394525901094e-07
% O 0 4.511310436328131e-08
- O 0 5.67608731216751e-06
23 O 0 1.1027558457499254e-06
% O 0 5.581445705615806e-08
( O 0 1.2195368981338106e-07
P O 0 2.4440523702651262e-05
< O 0 4.439363692654297e-06
. O 0 8.759501923805146e-08
0001 O 0 4.4856671593151987e-05
) O 0 6.31533580985888e-08
, O 0 2.3200721344096564e-08
suggesting O 0 1.1497775176394498e-07
that O 0 6.657433271328728e-09
differences O 0 6.555146825348857e-08
in O 0 1.3607299287343722e-08
methods O 0 1.617865130754126e-08
used O 0 3.420131022835449e-08
for O 0 4.7083119625312975e-08
mutation O 0 4.6493914851453155e-06
detection O 0 6.040789685357595e-06
or O 0 2.400249059064663e-06
phenotype O 0 9.828995098359883e-05
classification O 0 0.00012263889948371798
may O 0 7.777875339343154e-07
account O 0 2.4891690486583684e-08
for O 0 1.2839736385217293e-08
a O 0 1.2943617377914052e-07
considerable O 0 3.323451664982713e-07
proportion O 0 6.331401323222963e-07
of O 0 3.2899396273933235e-07
genotype O 0 9.03698819456622e-05
- O 0 0.0033953178208321333
phenotype O 0 0.00020634396059904248
inconsistencies O 0 0.0001493877498432994
. O 0 1.7471307728555985e-05

Our O 0 5.647114903695183e-06
data O 0 3.7277200135577004e-06
indicate O 0 1.8835467017197516e-06
that O 0 1.219139136310332e-07
the O 0 4.672354407375678e-06
PAH O 1 0.9982432126998901
- O 0 0.0006224339012987912
mutation O 0 2.1288658899720758e-05
genotype O 0 2.8399183520377846e-06
is O 0 9.716506355061938e-08
the O 0 4.5830528705437246e-08
main O 0 7.492340614589921e-07
determinant O 0 2.7312535166856833e-06
of O 0 2.2705791025146027e-07
metabolic O 0 0.008569132536649704
phenotype O 0 6.602468783967197e-05
in O 0 5.992529850118444e-07
most O 0 1.93330856745888e-06
patients O 0 0.0008557615801692009
with O 0 0.12333837896585464
PAH B-Disease 1 0.9999908208847046
deficiency I-Disease 1 0.9998457431793213
. O 0 2.7347481591277756e-05

In O 0 1.0502036502657575e-06
the O 0 2.0187864890885976e-07
present O 0 2.3680756555677362e-07
study O 0 2.5397895342393895e-07
, O 0 3.2646322978280296e-08
the O 0 1.2886492584129883e-07
classification O 0 1.0171996109420434e-05
of O 0 6.941783112779376e-07
105 O 0 0.0001775494747562334
PAH O 1 0.999160647392273
mutations O 0 0.00011949154577450827
may O 0 3.2401726457464974e-07
allow O 0 1.4557682170845965e-08
the O 0 9.229809450062021e-08
prediction O 0 3.3604135296627646e-06
of O 0 1.894591861173467e-08
the O 0 1.2504710866778623e-07
biochemical O 0 1.1257417099841405e-05
phenotype O 0 5.296245490171714e-06
in O 0 6.614086345280157e-08
> O 0 1.452043420613336e-06
10 O 0 1.0509396020097483e-07
, O 0 2.331979587211208e-08
000 O 0 9.916958276789956e-08
genotypes O 0 1.3506038385457941e-06
, O 0 5.195537866597988e-08
which O 0 3.167444972973499e-08
may O 0 5.8456464557821164e-08
be O 0 4.0028549364024e-09
useful O 0 1.577628516713503e-08
for O 0 1.6498502120043668e-08
the O 0 1.4929828751064633e-07
management O 0 5.401306680141715e-06
of O 0 9.053651410795283e-07
hyperphenylalaninemia B-Disease 1 0.9991008043289185
in O 0 2.0587816834449768e-05
newborns O 0 0.0009644373203627765
. O 0 5.697292181139346e-06

Somatic O 0 0.00046158384066075087
instability O 0 0.00048153818352147937
of O 0 9.340964766124671e-07
the O 0 3.527504304656759e-06
CTG O 0 0.0007901639910414815
repeat O 0 3.559271863196045e-05
in O 0 8.793279562269163e-07
mice O 0 1.0350610864406917e-05
transgenic O 0 5.228774625720689e-06
for O 0 6.856618028905359e-07
the O 0 0.00017682315956335515
myotonic B-Disease 1 0.9999511241912842
dystrophy I-Disease 1 0.999981164932251
region O 0 0.000674865790642798
is O 0 5.680636149918428e-06
age O 0 2.340779701626161e-06
dependent O 0 2.603346160867659e-07
but O 0 3.55467797419351e-08
not O 0 7.158408088514534e-09
correlated O 0 4.3123652204712926e-08
to O 0 3.6924101554092204e-09
the O 0 3.544319682191599e-08
relative O 0 5.571499741563457e-07
intertissue O 0 2.205240525654517e-05
transcription O 0 6.622267846978502e-06
levels O 0 9.976916771847755e-06
and O 0 7.195891384981223e-07
proliferative O 0 0.01789206452667713
capacities O 0 0.0004335628473199904
. O 0 1.6502568541909568e-05

A O 0 7.613324851263314e-05
( O 0 2.5018023279699264e-06
CTG O 0 0.0001383718627039343
) O 0 2.7028906401938e-07
nexpansion O 0 1.1381264812371228e-05
in O 0 2.5912018486451416e-07
the O 0 3.139998057122284e-07
3 O 0 3.7323227388696978e-06
- O 0 9.19226004043594e-05
untranslated O 0 0.00015908502973616123
region O 0 4.832245849684114e-06
( O 0 1.2784501279838878e-07
UTR O 0 9.492647222941741e-06
) O 0 2.1438667729967165e-08
of O 0 1.7177370637000422e-08
the O 0 8.749872790758673e-07
DM O 1 0.9838045239448547
protein O 0 4.0179288589570206e-06
kinase O 0 9.263313586416189e-06
gene O 0 1.264701268155477e-06
( O 0 2.0230979203006427e-07
DMPK O 0 7.035503949737176e-05
) O 0 1.566569096667081e-07
is O 0 2.7404612978898513e-07
responsible O 0 5.845562554895878e-06
for O 0 1.591684304003138e-05
causing O 1 0.9971733093261719
myotonic B-Disease 1 0.9999817609786987
dystrophy I-Disease 1 0.9999911785125732
( O 0 0.0052901338785886765
DM B-Disease 1 0.99983811378479
) O 0 1.4089658179727849e-05
. O 0 1.6361766029149294e-05

Major O 0 0.0009215960162691772
instability O 0 0.00040770642226561904
, O 0 4.968276243744185e-07
with O 0 9.831848046815139e-08
very O 0 1.853070870083684e-07
large O 0 7.30673050952646e-08
expansions O 0 8.947789638114045e-07
between O 0 4.482337345734777e-08
generations O 0 1.8921620892342617e-07
and O 0 8.341922352883557e-08
high O 0 7.113981610018527e-06
levels O 0 1.2230138963786885e-06
of O 0 4.374906126258793e-08
somatic O 0 3.1581091661792016e-06
mosaicism O 0 0.0002064417494693771
, O 0 3.310652516574919e-07
is O 0 3.6683695725514553e-07
observed O 0 2.9841694413335063e-06
in O 0 1.3688030549019459e-06
patients O 0 2.0714169295388274e-05
. O 0 2.7210307962377556e-06

There O 0 3.7474023883987684e-06
is O 0 2.8116448902437696e-07
a O 0 2.647110761699878e-07
good O 0 3.321303552183963e-07
correlation O 0 1.8996384198999294e-07
between O 0 1.8114967303972662e-07
repeat O 0 5.69980784348445e-06
size O 0 1.6154081095010042e-06
( O 0 5.364471533653159e-08
at O 0 5.47729712252476e-07
least O 0 4.4461835102538316e-08
in O 0 1.0279406836843918e-07
leucocytes O 0 9.873199815046974e-06
) O 0 5.95444191731076e-08
, O 0 1.0277779693979028e-07
clinical O 0 5.416193289420335e-06
severity O 0 3.532308983267285e-05
and O 0 5.576975468102319e-07
age O 0 2.4059549105004407e-05
of O 0 3.152051931465394e-06
onset O 1 0.7197450995445251
. O 0 3.13808377541136e-05

The O 0 6.560581823578104e-05
trinucleotide O 0 0.02512429654598236
repeat O 0 0.0004290023061912507
instability O 0 7.385166827589273e-05
mechanisms O 0 1.937057459144853e-05
involved O 0 9.21918672247557e-06
in O 0 8.338297448062804e-06
DM B-Disease 1 0.999798595905304
and O 0 9.193963705911301e-07
other O 0 9.485377177043119e-07
human O 0 0.0009636520408093929
genetic B-Disease 1 0.9999018907546997
diseases I-Disease 1 0.9999948740005493
are O 0 2.776106612145668e-06
unknown O 0 8.592040103394538e-05
. O 0 9.031479748955462e-06

We O 0 6.384628250089008e-06
studied O 0 1.2977713595319074e-05
somatic O 0 2.838014370354358e-05
instability O 0 3.5106953873764724e-05
by O 0 1.5781799334035895e-07
measuring O 0 0.00016903624054975808
the O 0 2.606966063467553e-06
CTG O 0 0.0003435010148677975
repeat O 0 1.1910905413969886e-05
length O 0 2.1388366349128773e-06
at O 0 8.697069802110491e-07
several O 0 4.967157352098184e-08
ages O 0 3.476698680060508e-07
in O 0 4.142852105815109e-08
various O 0 3.486741917413383e-08
tissues O 0 7.427312993968371e-06
of O 0 1.327547067830892e-07
transgenic O 0 7.91009279055288e-06
mice O 0 1.2120842256990727e-05
carrying O 0 1.7223059103343985e-06
a O 0 1.1267105719525716e-06
( O 0 3.727886905835476e-07
CTG O 0 5.352474909159355e-05
) O 0 1.2743758759370394e-07
55expansion O 0 1.3456960914481897e-05
surrounded O 0 4.080894996150164e-06
by O 0 9.610085527356205e-08
45 O 0 2.3665968740260723e-07
kb O 0 2.645339236551081e-06
of O 0 1.2458788489766448e-07
the O 0 3.0760147637920454e-06
human O 0 7.322726014535874e-05
DM B-Disease 1 0.9995953440666199
region O 0 9.600028533895966e-06
, O 0 7.290887538147217e-08
using O 0 1.0260680483042961e-07
small O 0 7.429803758896014e-07
- O 0 8.337613689946011e-05
pool O 0 2.800725633278489e-05
PCR O 0 5.442185283754952e-05
. O 0 3.7918284760962706e-06

These O 0 6.971465040805924e-07
mice O 0 1.4181081496644765e-05
have O 0 4.938929620834642e-08
been O 0 5.419223469971257e-08
shown O 0 3.0783542825929544e-08
to O 0 5.589635421188177e-09
reproduce O 0 1.002599319122055e-07
the O 0 4.932603303586802e-08
intergenerational O 0 2.515417463655467e-06
and O 0 1.8901818066296983e-07
somatic O 0 7.676092536712531e-06
instability O 0 1.3052422218606807e-05
of O 0 1.1122980936306703e-07
the O 0 1.2809766758437036e-06
55 O 0 1.2156821867392864e-05
CTG O 0 0.00015600540791638196
repeat O 0 1.9947445252910256e-05
suggesting O 0 2.844851906047552e-06
that O 0 2.4965149947320242e-08
surrounding O 0 3.227811475881026e-07
sequences O 0 1.556444289008141e-07
and O 0 4.4697362255874395e-08
the O 0 8.749682933739678e-08
chromatin O 0 7.4249333010811824e-06
environment O 0 1.5504591601711581e-06
are O 0 1.9627988123716023e-08
involved O 0 2.2624000450832682e-07
in O 0 8.758104286243906e-07
instability O 0 9.029726061271504e-05
mechanisms O 0 8.097095269476995e-05
. O 0 9.777792911336292e-06

As O 0 3.095059355473495e-06
observed O 0 1.9957151380367577e-06
in O 0 3.2165765162517346e-08
some O 0 5.379078960032757e-09
of O 0 1.2229512513783902e-08
the O 0 2.849270117621927e-07
tissues O 0 0.00013089843560010195
of O 0 4.7784910748305265e-06
DM B-Disease 1 0.9999597072601318
patients O 0 0.000611431198194623
, O 0 6.96448751114076e-07
there O 0 1.437494603351297e-07
is O 0 1.3268649468045624e-07
a O 0 1.485301339698708e-07
tendency O 0 6.349855539156124e-07
for O 0 4.199665681881015e-08
repeat O 0 1.6243882328126347e-06
length O 0 6.483221568487352e-07
and O 0 5.099811062336812e-08
somatic O 0 8.202931098821864e-07
mosaicism O 0 1.4143290172796696e-05
to O 0 1.118032066926844e-08
increase O 0 2.0853674342902195e-08
with O 0 1.6173869354929593e-08
the O 0 2.2191851201114332e-07
age O 0 1.9398150925553637e-06
of O 0 2.3335726240247823e-08
the O 0 7.210799140011659e-07
mouse O 0 5.583932943409309e-05
. O 0 3.3342118967993883e-06

Furthermore O 0 2.9510898457374424e-05
, O 0 6.017532996338559e-07
we O 0 8.640029847128972e-08
observed O 0 1.2656047942982696e-07
no O 0 1.53070942587874e-08
correlation O 0 2.2409668787304327e-08
between O 0 2.5867073816243646e-08
the O 0 1.3166558687771612e-07
somatic O 0 8.65074798639398e-06
mutation O 0 3.0123943361104466e-05
rate O 0 8.543232070223894e-06
and O 0 6.59058173368976e-07
tissue O 0 0.003668887075036764
proliferation O 0 0.004332168493419886
capacity O 0 3.936374923796393e-05
. O 0 9.73215173871722e-06

The O 0 4.761450782098109e-06
somatic O 0 7.44281496736221e-05
mutation O 0 0.00011637121497187763
rates O 0 6.527650384668959e-06
in O 0 6.600878776907848e-08
different O 0 2.167103296812911e-08
tissues O 0 3.16426167046302e-06
were O 0 6.738211055790089e-08
also O 0 4.1559662378176654e-08
not O 0 7.644586297317346e-09
correlated O 0 1.4313224028228433e-07
to O 0 5.381336709575635e-09
the O 0 4.133940478823206e-08
relative O 0 1.3042252930972609e-06
inter O 0 3.335411020088941e-05
- O 0 0.00025130799622274935
tissue O 0 1.6504582163179293e-05
difference O 0 1.4416269777939306e-07
in O 0 1.4108982426819239e-08
transcriptional O 0 3.053056047974678e-07
levels O 0 7.683530611757305e-07
of O 0 1.3119500152924957e-08
the O 0 2.829439971208103e-08
three O 0 8.23133277094712e-08
genes O 0 5.778754257335095e-07
( O 0 1.293126672408107e-07
DMAHP O 0 4.784963675774634e-05
, O 0 2.3954507355483656e-07
DMPK O 0 6.148737884359434e-05
and O 0 4.443814134447166e-07
59 O 0 4.60094679510803e-06
) O 0 5.79849590565118e-08
surrounding O 0 6.474083420471288e-07
the O 0 9.887547776088468e-07
repeat O 0 2.5425440981052816e-05
. O 0 5.428921667771647e-07
. O 0 1.9833028090943117e-06

A O 0 5.990060162730515e-05
novel O 0 4.807723962585442e-05
missense O 0 0.0003870512009598315
mutation O 0 0.00011705789802363142
in O 0 1.6846948938109563e-06
patients O 0 7.123840077838395e-06
from O 0 1.9727529831925494e-07
a O 0 1.625353547751729e-06
retinoblastoma B-Disease 0 0.0008127355249598622
pedigree O 0 0.00012270758452359587
showing O 0 1.089090892492095e-05
only O 0 2.919546773227921e-07
mild O 0 6.37841149000451e-05
expression O 0 1.0843182280950714e-06
of O 0 4.191391553831636e-07
the O 0 5.568299093283713e-05
tumor B-Disease 1 0.993243396282196
phenotype O 0 0.0008572795195505023
. O 0 6.072419637348503e-06

We O 0 1.1258726999585633e-06
have O 0 2.0852558790807052e-08
used O 0 2.4086402206080493e-08
single O 0 1.7802551610657247e-07
strand O 0 1.7129722209574538e-06
conformation O 0 1.567416461512039e-06
polymorphism O 0 4.515718217135145e-07
analysis O 0 4.376383699877806e-08
to O 0 4.422929578140611e-09
study O 0 1.8576141513904076e-08
the O 0 1.3664283038394842e-08
27 O 0 2.9542937340920616e-07
exons O 0 7.375211907856283e-07
of O 0 3.254386626849737e-08
the O 0 3.936224288736412e-07
RB1 O 0 0.00020807860710192472
gene O 0 1.3569765542342793e-06
in O 0 8.110676219530433e-08
individuals O 0 7.655982514620518e-09
from O 0 4.6285226318332207e-08
a O 0 6.73855879540497e-07
family O 0 4.024486770504154e-06
showing O 0 3.19891914841719e-05
mild O 0 0.0003265381674282253
expression O 0 9.614271903046756e-07
of O 0 1.133840328293445e-07
the O 0 4.846464889851632e-06
retinoblastoma B-Disease 0 0.029489383101463318
phenotype O 0 0.0017211188096553087
. O 0 1.2166425221948884e-05

In O 0 2.663829945959151e-06
this O 0 1.5439108835835214e-07
family O 0 1.3918494232711964e-06
affected O 0 4.4699069690068427e-07
individuals O 0 4.66541152377431e-08
developed O 0 2.6958194212056696e-05
unilateral B-Disease 0 0.09320644289255142
tumors I-Disease 1 0.9999933242797852
and O 0 1.219747900904622e-06
, O 0 8.075404167584566e-08
as O 0 8.906781800988028e-08
a O 0 2.563386090059794e-07
result O 0 2.2480183758943895e-07
of O 0 2.351489314378341e-08
linkage O 0 4.161387096246472e-06
analysis O 0 1.0118222917299136e-06
, O 0 2.6500762828618463e-07
unaffected O 0 9.516268619336188e-06
mutation O 0 2.8370220661599888e-06
carriers O 0 1.0497551556909457e-06
were O 0 1.172422372519577e-07
also O 0 1.1666059407389184e-07
identified O 0 6.839493948973541e-07
within O 0 1.4799142888932693e-07
the O 0 1.2952806400789996e-06
pedigree O 0 0.00028123147785663605
. O 0 7.656271009182092e-06

A O 0 1.1656305105134379e-05
single O 0 2.501735480109346e-06
band O 0 4.598451141646365e-06
shift O 0 9.966637435354642e-07
using O 0 2.3387242720218637e-07
SSCP O 0 6.582358764717355e-05
was O 0 4.898596671409905e-06
identified O 0 7.015389655862236e-07
in O 0 1.538774796472353e-07
exon O 0 7.693173756706528e-06
21 O 0 8.28086399451422e-07
which O 0 2.0985305937415433e-08
resulted O 0 2.346955341181456e-07
in O 0 3.986840724223839e-08
a O 0 3.2410628136858577e-07
missense O 0 1.60282233991893e-05
mutation O 0 1.8183089878220926e-06
converting O 0 5.822245157105499e-07
a O 0 3.526370619510999e-06
cys O 0 0.001813042676076293
- O 0 0.00016465799126308411
- O 0 4.162761615589261e-05
> O 0 4.001436536782421e-06
arg O 0 5.639155460812617e-06
at O 0 4.982020982424729e-07
nucleotide O 0 8.301248044517706e-07
position O 0 9.431669241166674e-07
28 O 0 5.485728706844384e-07
in O 0 7.522927347736186e-08
the O 0 4.073811510352243e-07
exon O 0 0.0001455599704058841
. O 0 6.509391823783517e-06

The O 0 8.100107152131386e-06
mutation O 0 0.00010601733083603904
destroyed O 0 3.423948510317132e-05
an O 0 5.012770998291671e-07
NdeI O 0 8.360973879462108e-05
restriction O 0 2.739815727181849e-06
enzyme O 0 1.2424417036527302e-05
site O 0 3.4693191992118955e-05
. O 0 4.673218882089714e-06

Analysis O 0 2.121071020155796e-06
of O 0 1.2300891683025839e-07
all O 0 1.3388093123012368e-07
family O 0 6.045511327101849e-07
members O 0 1.929425863522738e-08
demonstrated O 0 1.8835328319255495e-07
that O 0 1.5684713972063946e-08
the O 0 2.5055075525415305e-07
missense O 0 8.125683962134644e-05
mutation O 0 3.848549022222869e-05
co O 0 2.413050788163673e-05
- O 0 2.4876157112885267e-05
segregated O 0 4.332148819230497e-06
with O 0 1.1861095572385238e-06
patients O 0 3.9030477637425065e-05
with O 0 5.872097608516924e-05
tumors B-Disease 1 0.9999819993972778
or O 0 4.330756837589433e-06
who O 0 1.8370742509432603e-06
, O 0 4.680563847614394e-08
as O 0 6.016936282549068e-08
a O 0 1.9000189865892025e-07
result O 0 1.1639522057294016e-07
of O 0 1.2097874702021727e-08
linkage O 0 1.7155994100903627e-06
analysis O 0 5.273824399409932e-07
had O 0 1.8072033753924188e-06
been O 0 3.3585607184249966e-07
predicted O 0 3.181844476785045e-07
to O 0 3.5866580816446003e-09
carry O 0 5.427271432267844e-08
the O 0 2.9212120011834486e-07
predisposing O 0 0.00014812321751378477
mutation O 0 0.00014945627481210977
. O 0 4.130625256948406e-06

These O 0 2.722988483583322e-07
observations O 0 1.4930469660612289e-06
point O 0 4.7567124283887097e-07
to O 0 1.3933866505055903e-08
another O 0 1.492658299184768e-07
region O 0 1.6963433324690413e-07
of O 0 2.1960723017855344e-08
the O 0 3.0745698609280225e-07
RB1 O 0 0.00012175890879007056
gene O 0 8.769361556915101e-07
where O 0 1.0360227520322951e-07
mutations O 0 5.818415047542658e-07
only O 0 3.737025355832202e-09
modify O 0 5.271460778999426e-08
the O 0 1.4036135809192274e-08
function O 0 4.911320772293948e-08
of O 0 8.280870211763158e-09
the O 0 5.195855123929505e-08
gene O 0 4.788057026416936e-07
and O 0 5.341764008903738e-08
raise O 0 1.397580575712709e-07
important O 0 4.511138484986077e-08
questions O 0 9.702007019996017e-08
for O 0 2.621635175614756e-08
genetic O 0 2.037652166109183e-06
counseling O 0 6.857063112875039e-07
in O 0 4.6083325599965974e-08
families O 0 1.2648802893977518e-08
with O 0 4.223225502641981e-08
these O 0 4.5465718301329616e-08
distinctive O 0 1.5608125977450982e-05
phenotypes O 0 0.00019166854326613247
. O 0 1.290508976126148e-06
. O 0 3.6276833270676434e-06

Maternal B-Disease 0 0.019939228892326355
disomy I-Disease 0 0.2738249599933624
and O 0 0.006722295191138983
Prader B-Disease 1 0.9999847412109375
- I-Disease 1 0.9999779462814331
Willi I-Disease 1 0.9999829530715942
syndrome I-Disease 1 0.9999697208404541
consistent O 0 9.299603698309511e-05
with O 0 5.683870085704257e-07
gamete O 0 3.295359420008026e-05
complementation O 0 0.00015185553638730198
in O 0 4.353974816240225e-07
a O 0 1.1236255659241579e-06
case O 0 1.3874695241611334e-06
of O 0 1.1588472403900596e-07
familial O 0 0.0006678485660813749
translocation O 0 0.00023428632994182408
( O 0 6.060005830477166e-07
3 O 0 8.65912340941577e-07
; O 0 1.1737358107666296e-07
15 O 0 3.4515218771957734e-07
) O 0 2.653560571275193e-08
( O 0 4.208871473565523e-08
p25 O 0 2.6433169750816887e-06
; O 0 6.07920540574014e-08
q11 O 0 2.207985062341322e-06
. O 0 4.5300989626184673e-08
2 O 0 5.45784189398546e-07
) O 0 1.881330007336146e-07
. O 0 1.3601807040686253e-06

Maternal B-Disease 0 0.10492122173309326
uniparental I-Disease 1 0.9345415234565735
disomy I-Disease 1 0.637200117111206
( I-Disease 0 5.011002576793544e-05
UPD I-Disease 1 0.990584671497345
) I-Disease 0 3.609475811572338e-07
for I-Disease 0 8.239280901989332e-08
chromosome I-Disease 0 1.5096676179382484e-05
15 I-Disease 0 6.665999308097525e-07
is O 0 3.261022740730368e-08
responsible O 0 1.1294738300193785e-07
for O 0 5.5423399203391455e-09
an O 0 2.7150685255605822e-08
estimated O 0 3.9424449482794444e-08
30 O 0 6.894268267387815e-08
% O 0 8.49660608537306e-09
of O 0 3.4172618512684494e-08
cases O 0 1.0196421271757572e-06
of O 0 3.89864289900288e-05
Prader B-Disease 1 0.9999911785125732
- I-Disease 1 0.999991774559021
Willi I-Disease 1 0.9999966621398926
syndrome I-Disease 1 0.9999946355819702
( O 0 0.0017956962110474706
PWS B-Disease 1 0.9990449547767639
) O 0 2.595782461867202e-05
. O 0 2.3234535547089763e-05

We O 0 5.4636930144624785e-06
report O 0 1.54080430547765e-06
on O 0 2.5040884565896704e-07
an O 0 5.65323006185281e-08
unusual O 0 9.729095609145588e-07
case O 0 9.894018830891582e-07
of O 0 1.0619029211511588e-07
maternal B-Disease 0 8.483108831569552e-05
disomy I-Disease 0 0.0010479319607838988
15 I-Disease 0 6.099919119151309e-06
in O 0 2.210245611422579e-06
PWS B-Disease 1 0.9985822439193726
that O 0 1.9964851105669368e-07
is O 0 7.738567120441076e-08
most O 0 1.180692521529636e-08
consistent O 0 1.0631290336959864e-07
with O 0 3.059430042640088e-08
adjacent O 0 4.359963895694818e-06
- O 0 2.20605252252426e-05
1 O 0 3.474560799077153e-07
segregation O 0 1.004208684207697e-06
of O 0 1.9418379793023632e-08
a O 0 4.881012500845827e-07
paternal O 0 2.407800275250338e-05
t O 0 0.0003771243500523269
( O 0 1.4597060271626106e-07
3 O 0 3.119081952718261e-07
; O 0 4.0563421066508454e-08
15 O 0 1.315089832587546e-07
) O 0 1.501257607117168e-08
( O 0 3.030119799518616e-08
p25 O 0 2.12193504012248e-06
; O 0 5.3002043642891294e-08
q11 O 0 9.55752966547152e-07
. O 0 1.3879808413719275e-08
2 O 0 4.542341969226982e-08
) O 0 4.408813314427107e-09
with O 0 1.3992245584404372e-08
simultaneous O 0 6.870062065900129e-07
maternal O 0 6.736573413945735e-05
meiotic O 0 0.00023004983086138964
nondisjunction O 0 0.00019425796926952899
for O 0 9.41311384394794e-07
chromosome O 0 0.00012841616990044713
15 O 0 7.2844145506678615e-06
. O 0 3.977615961048286e-06

The O 0 1.4896201719238888e-05
patient O 0 0.000104694721812848
( O 0 7.722435952928208e-07
J O 0 0.00010836478759301826
. O 0 1.091523174068243e-07
B O 0 1.8882174117607065e-06
. O 0 1.0693782748205649e-08
) O 0 4.5766732625907025e-09
, O 0 5.997523810918892e-09
a O 0 9.463098393780456e-08
17 O 0 8.308431347359146e-07
- O 0 7.885268132667989e-06
year O 0 1.2929160675412277e-06
- O 0 1.6382486137445085e-05
old O 0 3.50551308656577e-05
white O 0 3.6208673463988816e-06
male O 0 6.135323360467737e-07
with O 0 7.08096592916263e-07
PWS B-Disease 1 0.9972559809684753
, O 0 6.540927870446467e-07
was O 0 3.892283530149143e-06
found O 0 2.7442240480013425e-08
to O 0 2.015404954036626e-09
have O 0 6.7920549184918855e-09
47 O 0 5.46351905938991e-08
chromosomes O 0 6.916857131500365e-08
with O 0 2.655160358244757e-08
a O 0 8.729027172194037e-07
supernumerary O 0 7.71034465287812e-05
, O 0 3.37899678015674e-07
paternal O 0 3.7662081012967974e-05
der O 0 0.003984353039413691
( O 0 2.632052371609461e-07
15 O 0 3.0730163302905567e-07
) O 0 1.7940989138764962e-08
consisting O 0 5.9306390909341644e-08
of O 0 2.272370025480086e-08
the O 0 4.2515455334068974e-07
short O 0 1.4080268556426745e-05
arm O 0 0.0005634016124531627
and O 0 1.1488020845717983e-07
the O 0 3.4081170952049433e-07
proximal O 0 0.00023236378910951316
long O 0 7.742158049950376e-05
arm O 0 0.00018681747314985842
of O 0 9.067912287719082e-08
chromosome O 0 2.1055739125586115e-05
15 O 0 1.2237758255650988e-06
, O 0 1.1498652696673162e-07
and O 0 3.7385603945949697e-07
distal O 0 0.0032045021653175354
chromosome O 0 0.022312788292765617
arm O 0 0.06640711426734924
3p O 0 0.03850792720913887
. O 0 2.883805427700281e-05

The O 0 1.7792935977922752e-05
t O 0 0.0004571604949887842
( O 0 2.37810596104282e-07
3 O 0 3.081086106249131e-07
; O 0 2.7446269257325184e-08
15 O 0 6.186822787412893e-08
) O 0 7.2108932158698735e-09
was O 0 3.296019315257581e-07
present O 0 1.2354285594540215e-08
in O 0 9.361359687432014e-09
the O 0 1.4362635525344558e-08
balanced O 0 3.0118232530185196e-07
state O 0 5.7564893296557784e-08
in O 0 6.256968987372602e-08
the O 0 4.3678235783772834e-07
patients O 0 4.32193155575078e-06
father O 0 4.310817075747764e-06
and O 0 3.781774466915522e-07
a O 0 9.739272172737401e-06
sister O 0 0.001247813575901091
. O 0 7.949348400870804e-06

Fluorescent O 0 0.00016561579832341522
in O 0 2.0980057797714835e-06
situ O 0 2.090105408569798e-05
hybridization O 0 1.2004435347989784e-06
analysis O 0 2.6471562364349666e-07
demonstrated O 0 4.359563092748431e-07
that O 0 4.0646909837960266e-08
the O 0 8.328867693307984e-07
PWS B-Disease 1 0.9954155683517456
critical O 0 2.48670949076768e-05
region O 0 4.302964043745305e-06
resided O 0 2.752593672994408e-06
on O 0 1.5118961016469257e-07
the O 0 2.745113825142198e-08
derivative O 0 6.759785264875973e-07
chromosome O 0 4.3547402128751855e-06
3 O 0 2.363315303455238e-07
and O 0 2.1234535907410645e-08
that O 0 1.4350341359659069e-08
there O 0 5.6762001321430944e-08
was O 0 2.2379931579052936e-06
no O 0 7.73414043919729e-08
deletion O 0 7.69941891576309e-07
of O 0 4.640217099449728e-08
the O 0 2.8940175980096683e-06
PWS B-Disease 1 0.9982568621635437
region O 0 3.6721571632369887e-06
on O 0 6.74204216011276e-07
the O 0 1.7519344908123458e-07
normal O 0 1.2960381354787387e-06
pair O 0 7.060735924824257e-07
of O 0 4.340148507253616e-08
15s O 0 8.366974725504406e-06
present O 0 6.712338631587045e-07
in O 0 2.012242703131051e-06
J O 0 0.005940303206443787
. O 0 7.572588401671965e-06

B O 0 0.009798295795917511
. O 0 5.842700556968339e-05

Methylation O 0 5.515950033441186e-05
analysis O 0 3.4721733754849993e-06
at O 0 4.91836999572115e-06
exon O 0 1.5021251783764455e-05
alpha O 0 1.2080508895451203e-06
of O 0 4.184952828722999e-08
the O 0 1.9437172227299016e-07
small O 0 1.8753198673948646e-06
nuclear O 0 0.0002249682293040678
ribonucleoprotein O 0 0.0007856565644033253
- O 0 0.00010000389738706872
associated O 0 4.257637556293048e-06
polypeptide O 0 1.042803251039004e-05
N O 0 1.3873564057576004e-05
( O 0 1.484212361901882e-07
SNRPN O 0 2.1556428691837937e-05
) O 0 6.151815767907465e-08
gene O 0 1.0282274160999805e-06
showed O 0 1.1950953648920404e-06
a O 0 2.6438308964316093e-07
pattern O 0 5.053005224908702e-06
characteristic O 0 2.1752009615738643e-06
of O 0 2.8288518194585777e-08
only O 0 2.086823513991476e-08
the O 0 8.31818525171002e-08
maternal O 0 1.4329849364003167e-05
chromosome O 0 3.491650568321347e-05
15 O 0 2.0003913050459232e-06
in O 0 1.0471674158907263e-06
J O 0 0.0020576496608555317
. O 0 7.256374829012202e-06

B O 0 0.006477619055658579
. O 0 3.179397026542574e-05

Maternal B-Disease 0 0.0064910356886684895
disomy I-Disease 0 0.011438589543104172
was O 0 0.00015954348782543093
confirmed O 0 1.500856001257489e-06
by O 0 6.995013990263033e-08
polymerase O 0 4.1076764318859205e-06
chain O 0 8.93496508069802e-06
reaction O 0 6.500686708932335e-07
analysis O 0 1.833304565934668e-07
of O 0 4.9551214686971434e-08
microsatellite O 0 4.471560168894939e-05
repeats O 0 1.8028631529887207e-05
at O 0 2.838721684383927e-06
the O 0 3.627880005296902e-07
gamma O 0 4.941784482070943e-06
- O 0 2.645850327098742e-05
aminobutyric O 0 5.642351970891468e-05
acid O 0 1.0708645277190953e-05
receptor O 0 2.183622655138606e-06
beta3 O 0 2.2048450773581862e-05
subunit O 0 3.2468958579556784e-06
( O 0 7.584409900118771e-07
GABRB3 O 0 0.00013964246318209916
) O 0 7.658796334908402e-07
locus O 0 4.242193608661182e-05
. O 0 5.278435764921596e-06

A O 0 7.786131027387455e-05
niece O 0 0.0008488519815728068
( O 0 1.0157318683923222e-06
B O 0 1.0180021490668878e-05
. O 0 4.728480007543112e-08
B O 0 1.0827412779690349e-06
. O 0 5.5871196558143765e-09
) O 0 2.661131315306875e-09
with O 0 4.2329411087393964e-09
45 O 0 3.881633858782152e-08
chromosomes O 0 5.3695078605642266e-08
and O 0 5.3921866971506915e-09
the O 0 1.0488266255492817e-08
derivative O 0 2.683824220639508e-07
3 O 0 1.6300325000884186e-07
but O 0 2.5584835583458698e-08
without O 0 4.740264714087061e-08
the O 0 1.8948328772694367e-07
der O 0 0.0002910049806814641
( O 0 8.30413995345225e-08
15 O 0 1.0084162482826287e-07
) O 0 1.4421710048395653e-08
demonstrated O 0 1.8616864849718695e-07
a O 0 1.963091449397325e-07
phenotype O 0 1.3518190371542005e-06
consistent O 0 4.287875015052123e-07
with O 0 3.239436807689344e-08
that O 0 7.409135349689677e-08
reported O 0 2.0469838091230486e-06
for O 0 3.068886300638951e-08
haploinsufficiency O 0 1.5496931155212224e-05
of O 0 2.8258705242478754e-07
distal O 0 0.0004688412882387638
3 O 0 7.271593494806439e-05
p O 0 0.0015525305643677711
. O 0 8.31838679005159e-06

Uniparental B-Disease 1 0.9934191107749939
disomy I-Disease 1 0.9940424561500549
associated O 0 0.00010981602099491283
with O 0 2.8286929136811523e-06
unbalanced O 0 0.0005092028295621276
segregation O 0 8.529392653144896e-05
of O 0 9.214837746185367e-07
non O 0 4.129757508053444e-05
- O 0 0.0008020686218515038
Robertsonian O 0 0.0001978926593437791
translocations O 0 0.0001387866650475189
has O 0 2.6527413865551353e-06
been O 0 1.1797446859418415e-06
reported O 0 3.5453044802125078e-06
previously O 0 3.361973313076305e-07
but O 0 6.557635856552224e-08
has O 0 4.5800465642287236e-08
not O 0 3.711863927335912e-09
, O 0 2.464667359092232e-09
to O 0 1.0728630206457979e-09
our O 0 1.183325792908363e-08
knowledge O 0 2.3853692354691702e-08
, O 0 2.5838671646738476e-08
been O 0 9.182014792941118e-08
observed O 0 1.101942572745429e-07
in O 0 4.15446059776059e-08
a O 0 3.204412450941163e-07
case O 0 2.7152759685122874e-06
of O 0 1.96002497432346e-06
PWS B-Disease 1 0.9982303977012634
. O 0 3.381642818567343e-05

Furthermore O 0 4.2031177144963294e-05
, O 0 9.080994232135708e-07
our O 0 4.818064098799368e-07
findings O 0 4.5887296096225327e-07
are O 0 5.798438174053899e-09
best O 0 1.6654061596454994e-07
interpreted O 0 1.2504425228598848e-07
as O 0 1.4650809987415414e-07
true O 0 6.474200517914142e-07
gamete O 0 2.5963716325350106e-05
complementation O 0 0.00015091725799720734
resulting O 0 1.8073937098961323e-05
in O 0 7.710846148256678e-06
maternal B-Disease 0 0.01827196776866913
UPD I-Disease 1 0.9986275434494019
15 I-Disease 0 0.000320664286846295
and O 0 0.00010435731383040547
PWS B-Disease 1 0.996654748916626

Schwartz B-Disease 0 0.22123359143733978
- I-Disease 1 0.9872488379478455
Jampel I-Disease 1 0.9865919947624207
syndrome I-Disease 1 0.9996401071548462
type I-Disease 0 0.0015120778698474169
2 I-Disease 0 8.021773282962386e-06
and O 0 4.43882163381204e-06
Stuve B-Disease 1 0.9211077094078064
- I-Disease 1 0.9989936947822571
Wiedemann I-Disease 1 0.9976065158843994
syndrome I-Disease 1 0.9999189376831055
: O 0 1.0269916401739465e-06
a O 0 8.508729933964787e-07
case O 0 8.174053505172196e-07
for O 0 5.9315219402833463e-08
" O 0 6.885554739710642e-07
lumping O 0 7.28501890989719e-06
" O 0 3.457535058259964e-06
. O 0 2.0813756691495655e-06

Recent O 0 3.146666495013051e-05
studies O 0 3.6748651837115176e-06
demonstrated O 0 2.1328542061382905e-06
the O 0 2.1336099109703355e-07
existence O 0 2.8415013275662204e-07
of O 0 5.9163358656633136e-08
a O 0 6.10649863119761e-07
genetically O 0 1.18316427233367e-06
distinct O 0 3.7496798199754267e-07
, O 0 1.0902996905315376e-07
usually O 0 1.822698294517977e-07
lethal O 0 9.266840379495989e-07
form O 0 1.3376555330069095e-07
of O 0 7.819653546903282e-08
the O 0 8.800092473393306e-06
Schwartz B-Disease 0 0.10064643621444702
- I-Disease 1 0.9965315461158752
Jampel I-Disease 1 0.9867852330207825
syndrome I-Disease 1 0.9996851682662964
( O 0 8.60042291606078e-06
SJS B-Disease 0 0.2152637243270874
) O 0 8.820895800454309e-07
of O 0 9.14599581847142e-07
myotonia B-Disease 1 0.9768165946006775
and O 0 0.00018632611318025738
skeletal B-Disease 1 0.9990069270133972
dysplasia I-Disease 1 0.9998043179512024
, O 0 3.608085762607516e-06
which O 0 4.087669651653414e-07
we O 0 8.155910222740204e-07
called O 0 1.486482324253302e-05
SJS B-Disease 0 0.034091003239154816
type I-Disease 0 0.00019937579054385424
2 I-Disease 0 9.005376341519877e-06
. O 0 4.107762379135238e-06

This O 0 0.00019250887271482497
disorder O 1 0.9989317059516907
is O 0 3.5337734516360797e-06
reminiscent O 0 4.879208790953271e-05
of O 0 5.749241154262563e-07
another O 0 1.4303456737252418e-05
rare O 0 0.0005641283933073282
condition O 0 0.10647746175527573
, O 0 1.4880902199365664e-06
the O 0 8.401164450333454e-06
Stuve B-Disease 1 0.8862319588661194
- I-Disease 1 0.9985914826393127
Wiedemann I-Disease 1 0.9972952008247375
syndrome I-Disease 1 0.9999395608901978
( O 0 4.249463927408215e-06
SWS B-Disease 0 0.019705619663000107
) O 0 1.1808889155418001e-07
, O 0 5.970579053382608e-08
which O 0 3.014463700878878e-08
comprises O 0 1.907344397977795e-07
campomelia B-Disease 0 4.888989496976137e-05
at O 0 1.4830176951363683e-05
birth O 0 2.0871415472356603e-05
with O 0 7.647062375326641e-06
skeletal B-Disease 1 0.9978278279304504
dysplasia I-Disease 1 0.999637246131897
, O 0 1.0006265256379265e-05
contractures B-Disease 0 0.04000858590006828
, O 0 8.855073474478559e-07
and O 0 6.103581995375862e-07
early B-Disease 0 2.8741136702592485e-05
death I-Disease 0 0.00011522680142661557
. O 0 3.1200925150187686e-06

To O 0 7.893739280007139e-07
test O 0 1.5911753052932909e-06
for O 0 5.927314461473543e-08
possible O 0 4.479641120269662e-07
nosologic O 0 6.830982601968572e-05
identity O 0 1.355641643385752e-06
between O 0 1.587579845363507e-06
these O 0 1.8484408883523429e-06
disorders O 1 0.9956355690956116
, O 0 2.5055149421859824e-07
we O 0 6.796334162118001e-08
reviewed O 0 2.174797657517047e-07
the O 0 2.6649118467503286e-08
literature O 0 1.7251640116455746e-08
and O 0 7.735332374636528e-09
obtained O 0 3.341795817846105e-08
a O 0 7.70366526126054e-08
follow O 0 7.499561149870715e-08
- O 0 1.3542048691306263e-06
up O 0 7.869013529671065e-08
of O 0 3.4667866355420074e-09
the O 0 9.928423416738497e-09
only O 0 4.668061936996537e-09
two O 0 2.4136808107755314e-08
surviving O 0 4.152467226958834e-06
patients O 0 1.176336127173272e-06
, O 0 1.229722723650184e-08
one O 0 1.3327221992653904e-08
with O 0 1.4035579454230174e-07
SJS B-Disease 0 0.0014680876629427075
type I-Disease 0 1.0626819857861847e-05
2 I-Disease 0 3.352707267367805e-07
at O 0 1.2536776239358005e-06
age O 0 3.236948202811618e-07
10 O 0 4.3563460394580034e-08
years O 0 3.6976906869767845e-08
and O 0 6.277923070285851e-09
another O 0 5.403720848562443e-08
with O 0 1.8231223464226787e-07
SWS B-Disease 0 0.001097393804229796
at O 0 9.758843589224853e-06
age O 0 5.184548626857577e-06
7 O 0 3.4719512314040912e-06
years O 0 2.48282094617025e-06
. O 0 1.2848785218011471e-06

Patients O 0 0.0009141170885413885
reported O 0 5.5821859859861434e-05
as O 0 7.512238084927958e-07
having O 0 6.671152732451446e-06
either O 0 2.879279236367438e-05
neonatal O 1 0.9984588623046875
SJS B-Disease 1 0.994438886642456
or O 0 5.805477485409938e-05
SWS B-Disease 0 0.01598273031413555
presented O 0 1.7327821524304454e-06
a O 0 7.287689527402108e-07
combination O 0 3.1002762170828646e-06
of O 0 2.956069238280179e-07
a O 0 5.239827078185044e-05
severe O 1 0.7053188681602478
, O 0 1.1836115845653694e-05
prenatal O 1 0.9351846575737
- O 1 0.9988038539886475
onset O 1 0.9985209107398987
neuromuscular B-Disease 1 0.999922513961792
disorder I-Disease 1 0.9999161958694458
( O 0 4.142947727814317e-05
with O 0 0.003039140719920397
congenital B-Disease 1 0.9999972581863403
joint I-Disease 1 0.9986590147018433
contractures I-Disease 1 0.9997871518135071
, O 0 0.07992583513259888
respiratory O 1 0.9998886585235596
and O 0 2.496611159585882e-05
feeding O 0 0.0005002970574423671
difficulties O 0 0.00044136965880170465
, O 0 8.511399869348679e-07
tendency O 0 3.283916157670319e-06
to O 0 2.7021485493605724e-07
hyperthermia B-Disease 0 0.035963576287031174
, O 0 1.0915710646486332e-07
and O 0 5.53375549827706e-08
frequent O 0 2.136072453140514e-06
death O 0 8.24167364044115e-06
in O 0 3.9002546259325754e-07
infancy O 0 1.5556768630631268e-05
) O 0 3.117904157079465e-08
with O 0 2.1143200967799203e-08
a O 0 4.850696200264792e-07
distinct O 0 3.9558108255732805e-06
campomelic B-Disease 0 0.014283988624811172
- I-Disease 1 0.6763746738433838
metaphyseal I-Disease 0 0.46878311038017273
skeletal I-Disease 1 0.9937300682067871
dysplasia I-Disease 1 0.9982218146324158
. O 0 0.00013870275870431215

The O 0 1.3201101864979137e-06
similarity O 0 2.697498075576732e-06
of O 0 4.472264834021189e-07
the O 0 2.7253367989032995e-06
clinical O 0 2.926628803834319e-05
and O 0 7.489568361052079e-07
radiographic O 0 0.0009803950088098645
findings O 0 1.521402009529993e-05
is O 0 1.450328568353143e-07
so O 0 5.6246637569756786e-08
extensive O 0 1.6273203300443129e-06
that O 0 2.2064348570438597e-07
these O 0 5.149985895513964e-07
disorders O 1 0.9825901389122009
appear O 0 1.1242526625210303e-06
to O 0 1.9195042000319518e-08
be O 0 4.646425111332064e-08
a O 0 3.119647260518832e-07
single O 0 1.415570409335487e-06
entity O 0 1.2987878108106088e-05
. O 0 6.751874934707303e-06

The O 0 3.5368752833164763e-06
follow O 0 2.440136086079292e-06
- O 0 1.7425614714738913e-05
up O 0 5.488910801432212e-07
observation O 0 1.4053381391931907e-06
of O 0 1.1893878770763422e-08
an O 0 2.3750818201051516e-08
identical O 0 5.817228156956844e-07
and O 0 5.0200945622691506e-08
unique O 0 3.8990458506305004e-07
pattern O 0 5.961640999885276e-05
of O 0 2.9888403787481366e-06
progressive O 1 0.9976701140403748
bone B-Disease 1 0.9997079968452454
dysplasia I-Disease 1 0.9994947910308838
in O 0 2.5172341793222586e-06
the O 0 7.310702585527906e-07
two O 0 6.037860202923184e-07
patients O 0 3.3318979149044026e-06
( O 0 1.694357187886908e-08
one O 0 1.905449487082933e-08
with O 0 2.0134393707849085e-07
SJS B-Disease 0 0.0244197528809309
type I-Disease 0 6.052699973224662e-05
2 I-Disease 0 1.0548009186095442e-06
, O 0 8.641777071716206e-08
one O 0 6.795063711706462e-08
with O 0 3.5626234762276e-07
SWS B-Disease 0 0.0038628478068858385
) O 0 1.1226503460193271e-07
surviving O 0 2.7635726382868597e-06
beyond O 0 1.8197038116340991e-06
infancy O 0 1.7524973372928798e-05
adds O 0 3.6839705330748984e-07
to O 0 7.214580044490049e-09
the O 0 3.010860538665838e-08
evidence O 0 8.606608048467024e-08
in O 0 3.548899130123573e-08
favor O 0 9.210376816781718e-08
of O 0 8.397108075541837e-08
identity O 0 7.388076937786536e-06
. O 0 6.0640859373961575e-06

The O 0 1.2243746823514812e-05
hypothesis O 0 2.1157833543838933e-05
that O 0 3.9590236156072933e-07
SWS B-Disease 0 0.001403473666869104
and O 0 2.6202887966064736e-06
SJS B-Disease 0 0.04956510663032532
type I-Disease 0 0.0001454126468161121
2 I-Disease 0 1.3904181059842813e-06
are O 0 2.4982822921515435e-08
the O 0 2.425144032258686e-07
same O 0 4.432163677847711e-06
disorder O 1 0.8350502252578735
should O 0 5.886159115675582e-08
be O 0 7.876833407749473e-09
testable O 0 4.1096875236235064e-08
by O 0 1.0306200337595328e-08
molecular O 0 1.2525733836810105e-06
methods O 0 7.574182632197335e-07
. O 0 5.475025091072894e-07
. O 0 2.1470193587447284e-06

A O 0 3.452677992754616e-05
mouse O 0 0.00014299823669716716
model O 0 5.792095180368051e-05
of O 0 5.181150118005462e-05
severe O 1 0.9991388320922852
von B-Disease 1 0.9999922513961792
Willebrand I-Disease 1 0.9999879598617554
disease I-Disease 1 0.9999986886978149
: O 0 0.27155283093452454
defects O 1 0.9997368454933167
in O 0 0.00013523962115868926
hemostasis O 1 0.997261643409729
and O 0 0.002798214089125395
thrombosis B-Disease 1 0.9993446469306946
. O 0 5.992465594317764e-05

von B-Disease 1 0.9544312357902527
Willebrand I-Disease 1 0.9793633222579956
factor I-Disease 0 0.0026195740792900324
( I-Disease 0 7.437862950609997e-05
vWf I-Disease 0 0.04868467152118683
) I-Disease 0 0.0018165705259889364
deficiency I-Disease 1 0.999530553817749
causes O 1 0.9978320002555847
severe O 1 0.9998663663864136
von B-Disease 1 0.999995231628418
Willebrand I-Disease 1 0.9999856948852539
disease I-Disease 1 0.9999982118606567
in O 0 0.0005740484339185059
humans O 0 0.0002500909031368792
. O 0 3.822911094175652e-05

We O 0 1.6709469718989567e-06
generated O 0 2.6306895506422734e-07
a O 0 4.0978531501423276e-07
mouse O 0 3.76521688849607e-06
model O 0 7.934343670967792e-07
for O 0 4.298929923152173e-08
this O 0 1.141746324151427e-07
disease O 0 0.0001677338150329888
by O 0 9.060543426642198e-09
using O 0 9.23872178759666e-08
gene O 0 2.503224550309824e-06
targeting O 0 4.943109161104076e-06
. O 0 3.637480176621466e-06

vWf B-Disease 0 0.03253092244267464
- I-Disease 0 0.25078558921813965
deficient I-Disease 0 0.028591956943273544
mice O 0 0.00011938709212699905
appeared O 0 7.396085038635647e-06
normal O 0 4.632210675481474e-06
at O 0 4.150594122620532e-06
birth O 0 2.115168626914965e-06
; O 0 2.4248105745527937e-08
they O 0 8.82486528297477e-09
were O 0 3.6705458228425414e-08
viable O 0 1.5185243000814808e-06
and O 0 2.246638075575902e-07
fertile O 0 2.8703474526992068e-05
. O 0 5.362652700569015e-06

Neither O 0 0.0005704222712665796
vWf O 0 0.003696105442941189
nor O 0 0.0002774391323328018
vWf O 0 0.0019494523294270039
propolypeptide O 0 0.005183670204132795
( O 0 1.5124054698389955e-05
von B-Disease 0 0.06639789789915085
Willebrand I-Disease 0 0.4587542712688446
antigen O 0 0.0018391467165201902
II O 0 0.01958526112139225
) O 0 2.2251698794661934e-07
were O 0 9.083456831149306e-08
detectable O 0 4.917272690363461e-06
in O 0 7.47812123336189e-08
plasma O 0 2.3500379029428586e-06
, O 0 7.495629006371018e-08
platelets O 0 5.821889772050781e-06
, O 0 9.923675037271096e-08
or O 0 2.6183576551375154e-07
endothelial O 0 1.3715137356484775e-05
cells O 0 1.218299303218373e-06
of O 0 3.127773595679173e-08
the O 0 3.21541762104971e-07
homozygous O 0 1.2250789950485341e-05
mutant O 0 4.766700294567272e-05
mice O 0 9.293866605730727e-05
. O 0 4.082884061062941e-06

The O 0 2.0672809114330448e-05
mutant O 0 0.000779415131546557
mice O 0 0.0025928260292857885
exhibited O 0 0.0023458916693925858
defects O 1 0.9981474876403809
in O 0 4.86421367895673e-06
hemostasis O 0 0.004957213997840881
with O 0 2.0663485429395223e-06
a O 0 2.1326537535060197e-05
highly O 0 0.0003546765074133873
prolonged O 0 0.25699785351753235
bleeding O 1 0.9970701932907104
time O 0 1.3709362747249543e-06
and O 0 5.700753149540105e-07
spontaneous O 0 3.594192457967438e-05
bleeding O 0 0.3770213723182678
events O 0 2.401842209565075e-07
in O 0 5.3959244183943156e-08
approximately O 0 7.539159696534625e-08
10 O 0 9.601181716334395e-08
% O 0 2.055865877537144e-08
of O 0 1.8744566432360443e-07
neonates O 0 0.00015311935567297041
. O 0 5.443601367005613e-06

As O 0 3.176064637955278e-06
in O 0 7.263376460286963e-07
the O 0 1.7273064258915838e-06
human O 0 6.253450555959716e-05
disease O 1 0.803460419178009
, O 0 9.127047917445452e-08
the O 0 8.78838619655653e-08
factor O 0 8.050350288613117e-07
VIII O 0 0.00013242682325653732
level O 0 4.285174782125978e-06
in O 0 1.3299533918598172e-07
these O 0 4.836773825900309e-08
mice O 0 2.801099526550388e-06
was O 0 1.2945125718033523e-06
reduced O 0 2.2063611027078878e-07
strongly O 0 7.276245383991409e-08
as O 0 2.4685313348982163e-08
a O 0 1.2578591679357487e-07
result O 0 1.1347469097700014e-07
of O 0 9.103434450707937e-09
the O 0 1.1716254277871485e-07
lack O 0 5.878641218259872e-07
of O 0 1.238347238086135e-07
protection O 0 3.4898409921879647e-06
provided O 0 6.28745226549654e-07
by O 0 1.2892296581412666e-06
vWf O 0 0.00032162474235519767
. O 0 9.447024240216706e-06

Defective O 1 0.9749250411987305
thrombosis B-Disease 1 0.9935505390167236
in O 0 1.2450688700482715e-05
mutant O 0 0.000131250882986933
mice O 0 0.00014104359433986247
was O 0 1.960599001904484e-05
also O 0 2.0676917245054938e-07
evident O 0 6.024889103173336e-07
in O 0 4.9336570384639344e-08
an O 0 4.49114345713042e-08
in O 0 1.7381069028488128e-07
vivo O 0 1.0858561836357694e-05
model O 0 4.5043348109174985e-06
of O 0 8.943703505792655e-06
vascular B-Disease 1 0.9999027252197266
injury I-Disease 1 0.9995936751365662
. O 0 2.960146412078757e-05

In O 0 1.1889702591361129e-06
this O 0 7.611954089270512e-08
model O 0 1.1457881328169606e-06
, O 0 1.360556609597552e-07
the O 0 2.514699986022606e-07
exteriorized O 0 0.00017548100731801242
mesentery O 0 0.00033930662903003395
was O 0 2.7399741156841628e-05
superfused O 0 3.6590932722901925e-05
with O 0 5.412622385847499e-07
ferric O 0 0.001282139914110303
chloride O 0 6.062422107788734e-05
and O 0 6.342532969938475e-07
the O 0 5.256741815173882e-07
accumulation O 0 4.21926197304856e-05
of O 0 3.645265849172574e-07
fluorescently O 0 0.0008747451356612146
labeled O 0 8.063016866799444e-05
platelets O 0 0.0001131877361331135
was O 0 8.030536264413968e-06
observed O 0 9.415277304469782e-07
by O 0 1.7968956456115848e-07
intravital O 0 7.757249113637954e-05
microscopy O 0 3.9116926927817985e-05
. O 0 8.482053999614436e-06

We O 0 3.81498466595076e-06
conclude O 0 2.1479409042513e-06
that O 0 2.441964674915198e-08
these O 0 3.9315040112342103e-08
mice O 0 2.758161826932337e-06
very O 0 3.0491077041006065e-07
closely O 0 7.087085577950347e-06
mimic O 0 0.002675511408597231
severe O 1 0.9786188006401062
human O 0 0.07503907382488251
von B-Disease 1 0.9999837875366211
Willebrand I-Disease 1 0.9999653100967407
disease I-Disease 1 0.9999977350234985
and O 0 8.14954619272612e-05
will O 0 7.33848310119356e-07
be O 0 1.0598713373610735e-07
very O 0 3.768219869471068e-08
useful O 0 2.9409850554884542e-08
for O 0 1.7547295172448685e-08
investigating O 0 4.2550783518890967e-07
the O 0 6.258269991121779e-08
role O 0 4.004808999980014e-07
of O 0 7.742923457954021e-08
vWf O 0 1.3102669072395656e-05
in O 0 3.205632026492822e-07
normal O 0 4.080502094438998e-06
physiology O 0 3.008931889780797e-05
and O 0 5.478555635818338e-07
in O 0 3.306996632090886e-06
disease O 0 0.2789020538330078
models O 0 7.793551958457101e-06
. O 0 7.387692448901362e-07
. O 0 1.6264420992229134e-06

Oral O 0 0.0010098067577928305
contraceptives O 0 0.0011812903685495257
and O 0 2.919643293353147e-06
the O 0 9.697936548036523e-06
risk O 0 0.0032807120587676764
of O 0 0.0004963208339177072
hereditary B-Disease 1 0.9999868869781494
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999954700469971
. O 0 0.000408717809477821

Hereditary B-Disease 1 0.9993810653686523
Ovarian I-Disease 1 0.9999406337738037
Cancer I-Disease 1 0.9994342923164368
Clinical O 0 0.002689441666007042
Study O 0 2.7097248676000163e-05
Group O 0 1.9508499462972395e-05
. O 0 8.2297983681201e-06

BACKGROUND O 0 0.00013300235150381923
Women O 0 1.4282614984040265e-06
with O 0 4.1820962337624223e-07
mutations O 0 1.8610899132909253e-05
in O 0 9.268744349810731e-08
either O 0 1.3110724239595584e-07
the O 0 5.525770347958314e-07
BRCA1 O 0 1.0638309504429344e-05
or O 0 1.9769416326198552e-07
the O 0 1.8908055210431485e-07
BRCA2 O 0 7.354081844823668e-06
gene O 0 8.478791073684988e-07
have O 0 4.059701197434151e-08
a O 0 5.822761863782944e-07
high O 0 0.00012167790555395186
lifetime O 0 0.00045233225682750344
risk O 0 0.006269210483878851
of O 0 0.006887340918183327
ovarian B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999945163726807
. O 0 0.00013967149425297976

Oral O 0 0.0066329012624919415
contraceptives O 0 0.3646668493747711
protect O 0 0.22771623730659485
against O 1 0.9993481040000916
ovarian B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999963045120239
in O 0 4.869189069722779e-06
general O 0 1.5146106306929141e-06
, O 0 1.6792077417449036e-07
but O 0 1.2567596741064335e-07
it O 0 2.2129373888901682e-08
is O 0 2.2695720858223467e-08
not O 0 8.364941628258293e-09
known O 0 5.7363660488363166e-08
whether O 0 1.4041999563119134e-08
they O 0 1.7821855990973745e-08
also O 0 1.288104840568849e-07
protect O 0 1.1539929118953296e-06
against O 0 4.565830749925226e-06
hereditary B-Disease 0 0.48032131791114807
forms I-Disease 0 0.0013025375083088875
of I-Disease 1 0.7318010330200195
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999945163726807
. O 0 0.00018031471699941903

METHODS O 0 1.042415442498168e-05
We O 0 1.6118285657285014e-06
enrolled O 0 5.408492143033072e-06
207 O 0 7.90219201007858e-06
women O 0 1.2205788380015292e-06
with O 0 8.667345537105575e-05
hereditary B-Disease 1 0.9999876022338867
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999980926513672
and O 0 1.7783337398213916e-06
161 O 0 5.98919939420739e-07
of O 0 1.8997882378357644e-08
their O 0 3.2364599888978773e-08
sisters O 0 2.7649223284242908e-06
as O 0 1.7972143950828467e-07
controls O 0 1.040631786963786e-06
in O 0 1.4299145334462082e-07
a O 0 1.4494340803139494e-06
case O 0 4.882972461928148e-06
- O 0 6.153982394607738e-05
control O 0 9.952524123946205e-06
study O 0 5.581238838203717e-06
. O 0 3.8571356526517775e-06

All O 0 5.188482532503258e-07
the O 0 8.207672976823233e-07
patients O 0 4.956093562213937e-06
carried O 0 6.316618623714021e-07
a O 0 8.197675924748182e-07
pathogenic O 0 2.3397498807753436e-05
mutation O 0 1.1427279787312727e-05
in O 0 1.812001215739656e-07
either O 0 7.596962632305804e-07
BRCA1 O 0 2.275344741065055e-05
( O 0 2.3614836663909955e-07
179 O 0 1.036606363413739e-06
women O 0 1.7719941070026834e-07
) O 0 6.042628797331417e-08
or O 0 2.6470198122297006e-07
BRCA2 O 0 1.969472214113921e-05
( O 0 5.047771196586837e-07
28 O 0 4.402523245516932e-06
women O 0 3.3191028592227667e-07
) O 0 3.731671256446134e-07
. O 0 1.3744263469561702e-06

The O 0 2.14366014006373e-06
control O 0 1.0587176802800968e-05
women O 0 4.4835687162958493e-07
were O 0 2.2503648722249636e-07
enrolled O 0 6.279895501393185e-07
regardless O 0 8.23155232865247e-08
of O 0 8.445209864760272e-09
whether O 0 7.305921911893165e-08
or O 0 1.1972406355198473e-07
not O 0 2.8620227965348022e-08
they O 0 2.9790200528623245e-08
had O 0 3.91977550862066e-07
either O 0 1.1650910209937138e-06
mutation O 0 2.982292789965868e-05
. O 0 3.0415094443014823e-06

Lifetime O 0 0.00024319342628587037
histories O 0 3.2453543099109083e-05
of O 0 6.454035883507458e-07
oral O 0 6.55974363326095e-05
- O 0 2.4220400518970564e-05
contraceptive O 0 2.782722276606364e-06
use O 0 2.4806944054489577e-08
were O 0 2.7254870360593486e-08
obtained O 0 3.144528193388396e-08
by O 0 4.346021853507409e-08
interview O 0 3.987585841969121e-06
or O 0 5.0770808002198464e-08
by O 0 1.7213643843660975e-08
written O 0 3.49337874183675e-08
questionnaire O 0 1.0544794548650316e-07
and O 0 7.752406716576843e-09
were O 0 4.161518774026263e-08
compared O 0 4.069877661549981e-07
between O 0 1.7346938818718627e-07
patients O 0 2.761775704129832e-06
and O 0 7.828084847005812e-08
control O 0 2.325953118997859e-06
women O 0 9.630527131321287e-08
, O 0 3.587036090380025e-08
after O 0 2.937849217232724e-07
adjustment O 0 6.499539608739724e-07
for O 0 1.2252346692775973e-08
year O 0 1.0570771991069705e-07
of O 0 2.1850086184826978e-08
birth O 0 3.4342456274316646e-06
and O 0 3.7824275977982325e-07
parity O 0 9.344699356006458e-05
. O 0 6.025956281519029e-06

RESULTS O 0 9.003639570437372e-05
The O 0 2.4054095320025226e-06
adjusted O 0 0.00017748803657013923
odds O 0 0.0010156560456380248
ratio O 0 0.0002883677079807967
for O 0 0.004780298564583063
ovarian B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.999995231628418
associated O 0 2.281844172102865e-05
with O 0 1.8231241938337917e-07
any O 0 3.08994856368372e-08
past O 0 2.0674018230693036e-07
use O 0 3.2710897102106173e-08
of O 0 9.247184351579563e-08
oral O 0 2.329479502805043e-05
contraceptives O 0 0.0005071338964626193
was O 0 0.00016024101932998747
0 O 0 4.286519470042549e-06
. O 0 1.645066504352144e-06

5 O 0 7.07140998201794e-06
( O 0 2.0438555736745911e-07
95 O 0 8.154292459039425e-07
percent O 0 1.3622629921883345e-06
confidence O 0 1.0073067642224487e-06
interval O 0 8.30414592201123e-07
, O 0 3.095930622976084e-08
0 O 0 3.9602159773721723e-08
. O 0 2.5796653702059302e-09
3 O 0 1.4787469027055522e-08
to O 0 2.5677220349962226e-09
0 O 0 9.002683754033569e-08
. O 0 2.1392226656757884e-08
8 O 0 3.1928541943671007e-07
) O 0 8.754824420975638e-08
. O 0 5.215783289713727e-07

The O 0 2.2110945792519487e-05
risk O 0 9.044531179824844e-05
decreased O 0 6.464294528996106e-06
with O 0 7.618214681315294e-08
increasing O 0 3.6222343169356463e-07
duration O 0 9.051017855199461e-07
of O 0 1.2143371641570866e-08
use O 0 5.99878475782134e-08
( O 0 1.7669013629983965e-07
P O 0 1.6309842976625077e-05
for O 0 5.132902813897999e-08
trend O 0 1.725801439533825e-06
, O 0 6.37647232792915e-08
< O 0 5.592090133177408e-07
0 O 0 4.3212246225721174e-08
. O 0 6.121358087085582e-09
001 O 0 3.636928340711165e-07
) O 0 3.6661849112107348e-09
; O 0 1.053139908613332e-09
use O 0 2.4866240178056387e-09
for O 0 3.772330892104492e-09
six O 0 2.572208401829812e-08
or O 0 1.3553086652962065e-08
more O 0 4.717919388497194e-09
years O 0 1.364452089092083e-07
was O 0 6.78514254559559e-07
associated O 0 3.1311877535245e-08
with O 0 9.248414478690847e-09
a O 0 3.776220864892821e-07
60 O 0 7.844404876777844e-07
percent O 0 1.9645294742076658e-06
reduction O 0 2.96703228741535e-06
in O 0 7.205972565316188e-07
risk O 0 3.708202712005004e-05
. O 0 2.1070811726531247e-06

Oral O 0 0.0007321400917135179
- O 0 0.00026787351816892624
contraceptive O 0 8.950787014327943e-05
use O 0 3.751085387193598e-06
protected O 0 0.019976085051894188
against O 1 0.9875161647796631
ovarian B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999847412109375
both O 0 1.6995787177620514e-07
for O 0 6.74694362601258e-08
carriers O 0 1.1648465942926123e-06
of O 0 6.442696331987463e-08
the O 0 1.129296720137063e-06
BRCA1 O 0 0.00020299605967011303
mutation O 0 3.5426182876108214e-05
( O 0 2.3175228136551596e-07
odds O 0 1.9581268134061247e-05
ratio O 0 1.3132339518051594e-06
, O 0 5.892292520570663e-08
0 O 0 3.045712659854871e-08
. O 0 2.7809272662437934e-09
5 O 0 1.949921646371422e-08
; O 0 5.3006159461688185e-09
95 O 0 5.2773355463386906e-08
percent O 0 1.1078855521873265e-07
confidence O 0 1.880165996226424e-07
interval O 0 1.1543171751782211e-07
, O 0 1.1120154574939534e-08
0 O 0 1.2976748564597074e-08
. O 0 1.7936361285109115e-09
3 O 0 8.29022539505786e-09
to O 0 1.035365904122898e-09
0 O 0 1.7777280092445835e-08
. O 0 4.439139722478558e-09
9 O 0 4.021115529440067e-08
) O 0 1.2158104523152247e-09
and O 0 1.9499577508241828e-09
for O 0 4.8540163000154735e-09
carriers O 0 1.2443754826563236e-07
of O 0 1.429856588686107e-08
the O 0 2.528942388835276e-07
BRCA2 O 0 3.603706500143744e-05
mutation O 0 6.030360054865014e-06
( O 0 8.342781399051091e-08
odds O 0 3.7085083022248e-06
ratio O 0 3.281670046817453e-07
, O 0 3.5162276645905877e-08
0 O 0 3.462347564209267e-08
. O 0 4.874241898988885e-09
4 O 0 3.3961377710056695e-08
; O 0 8.68239968809803e-09
95 O 0 1.5475576731205365e-07
percent O 0 3.24417982255909e-07
confidence O 0 1.199723129730046e-07
interval O 0 1.0103337189093509e-07
, O 0 1.2297157070406683e-08
0 O 0 1.7093473303475548e-08
. O 0 3.15972559228328e-09
2 O 0 1.2117064684957768e-08
to O 0 2.8111384331452882e-09
1 O 0 4.896084604411044e-08
. O 0 1.1313168180038247e-08
1 O 0 2.6657053808776254e-07
) O 0 9.679494183956194e-08
. O 0 4.947759748574754e-07

CONCLUSIONS O 0 0.000206176788196899
Oral O 0 0.0003875666589010507
- O 0 0.00012732562026940286
contraceptive O 0 2.7360783860785887e-05
use O 0 8.864402047947806e-07
may O 0 2.575753796918434e-06
reduce O 0 2.3663380943617085e-06
the O 0 2.3452778350474546e-06
risk O 0 0.0004775080014951527
of O 0 0.0006998942699283361
ovarian B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999960660934448
in O 0 2.6342672754253726e-06
women O 0 2.1346011180867208e-07
with O 0 2.123790352470678e-07
pathogenic O 0 3.785133230849169e-05
mutations O 0 1.964160219358746e-05
in O 0 3.693659209602629e-07
the O 0 1.803174995984591e-06
BRCA1 O 0 0.00026453303871676326
or O 0 1.2187677384645212e-05
BRCA2 O 0 0.0014015283668413758
gene O 0 0.0008869669982232153

A O 0 3.2670533983036876e-05
Japanese O 0 2.1802041374030523e-05
family O 0 1.0459663826623e-05
with O 0 7.422653197863838e-06
adrenoleukodystrophy B-Disease 1 0.9998878240585327
with O 0 7.938317594380351e-07
a O 0 1.8043172076431802e-06
codon O 0 1.528340180811938e-05
291 O 0 3.903498964064056e-06
deletion O 0 5.14939483764465e-06
: O 0 1.1532235077993391e-07
a O 0 4.372328987756191e-07
clinical O 0 2.879267412936315e-06
, O 0 9.046128468526149e-08
biochemical O 0 1.283111942029791e-05
, O 0 4.7349334408863797e-07
pathological O 0 0.00030811416218057275
, O 0 3.004682582741225e-07
and O 0 1.0844071312021697e-06
genetic O 0 0.00025615195045247674
report O 0 3.268817818025127e-05
. O 0 6.206168563949177e-06

We O 0 1.7348873370792717e-05
report O 0 3.1357176339952275e-06
a O 0 2.083528443108662e-06
Japanese O 0 1.5967487343004905e-05
family O 0 3.770650437218137e-05
with O 0 0.0003196628240402788
adrenoleukodystrophy B-Disease 1 0.9999616146087646
( O 0 0.00020020559895783663
ALD B-Disease 1 0.9998058676719666
) O 0 1.548573465015579e-07
with O 0 7.046099881335977e-08
a O 0 3.83423582661635e-07
three O 0 1.272173193456183e-07
base O 0 1.9191363662685035e-06
pair O 0 1.5995600506357732e-06
deletion O 0 7.1517220021632966e-06
( O 0 1.0618786205895958e-07
delGAG O 0 9.64318314800039e-06
291 O 0 1.4244811836761073e-06
) O 0 8.878304669224235e-08
in O 0 2.9146784186195873e-07
the O 0 8.153226190188434e-06
ALD B-Disease 1 0.9988256096839905
gene O 0 0.00018982688197866082
. O 0 7.464136615453754e-06

A O 0 1.3787144780508243e-05
variety O 0 3.3977489692915697e-06
of O 0 2.385024231443822e-07
phenotypes O 0 2.5216806534444913e-05
were O 0 4.6324265667863074e-07
observed O 0 1.9630292626970913e-06
within O 0 1.8798935741415335e-07
this O 0 6.563691812289107e-08
family O 0 5.191241598367924e-06
. O 0 5.104403044242645e-06

While O 0 6.642976586590521e-06
the O 0 2.646318080223864e-06
proband O 0 0.00035558195668272674
( O 0 1.605420834493998e-06
patient O 0 1.8766362700262107e-05
1 O 0 4.05617271326264e-07
) O 0 5.125154700635903e-08
was O 0 2.3588531803397927e-06
classified O 0 6.264630201258115e-07
as O 0 6.40830677411941e-08
having O 0 1.2280918326723622e-07
a O 0 1.4128498548870994e-07
rare O 0 9.739958386489889e-07
intermediate O 0 2.3964589672686998e-06
type O 0 7.3716223596420605e-06
of O 0 2.0970425396171777e-07
adult O 0 3.034601832041517e-05
cerebral O 1 0.9199079871177673
and O 0 1.764669650583528e-05
cerebello O 1 0.8872920274734497
- O 1 0.9925980567932129
brain O 1 0.9697176218032837
stem O 0 1.669648554525338e-05
forms O 0 1.1139366051793331e-06
, O 0 1.739027055691622e-07
his O 0 1.4479129504252342e-06
younger O 0 7.984389412740711e-06
brother O 0 3.6856887163594365e-05
( O 0 3.704814162119874e-07
patient O 0 6.838464742031647e-06
2 O 0 3.290821553036949e-07
) O 0 2.553759159695801e-08
and O 0 8.450031430129457e-08
nephew O 0 0.00013891840353608131
( O 0 6.293523142630875e-07
patient O 0 1.2744145351462066e-05
3 O 0 8.203635388781549e-07
) O 0 1.273360226150544e-07
had O 0 2.2684091618430102e-06
a O 0 2.4085973564069718e-05
childhood O 0 0.15064190328121185
ALD B-Disease 1 0.9998036026954651
type O 0 0.28868934512138367
. O 0 2.3543789211544208e-05

Another O 0 1.9702800273080356e-05
nephew O 0 0.0014722973573952913
( O 0 1.9901824543921975e-06
patient O 0 2.9449725843733177e-05
4 O 0 9.97008896774787e-07
) O 0 4.004460762985218e-08
of O 0 7.535651747048178e-08
patient O 0 5.708254320779815e-05
1 O 0 2.1686475975002395e-06
was O 0 2.3865628463681787e-05
classified O 0 2.291356167916092e-06
as O 0 3.088732398737193e-07
having O 0 4.32589246202042e-07
an O 0 3.622027406890993e-07
adolescent O 0 0.00010186482541030273
form O 0 9.01725343283033e-06
. O 0 6.336465958156623e-06

The O 0 4.119311142858351e-06
tau O 0 4.3153122533112764e-05
level O 0 1.0818064765771851e-05
in O 0 9.282293262913299e-07
the O 0 3.433158326515695e-06
cerebrospinal O 0 0.02539849281311035
fluid O 0 0.004059233702719212
( O 0 5.552168204303598e-06
CSF O 0 0.028258515521883965
) O 0 2.8429025178411393e-07
in O 0 3.2275099215439695e-07
patient O 0 6.192470209498424e-06
1 O 0 7.614392529831093e-07
was O 0 3.876069968100637e-06
as O 0 7.98276929003805e-08
high O 0 1.5507149555560318e-06
as O 0 2.831691325866359e-08
that O 0 8.305355514437451e-09
of O 0 8.43486276380645e-08
patients O 0 1.7118376490543596e-05
with O 0 0.00014392242883332074
Alzheimers B-Disease 1 0.9999129772186279
disease I-Disease 1 0.9996285438537598
( O 0 1.5796330217199284e-06
AD B-Disease 0 1.2499847798608243e-05
) O 0 7.532144650213013e-07
. O 0 1.6174290067283437e-06

His O 0 0.00014625629410147667
brain O 0 0.02060592733323574
magnetic O 0 3.487470530671999e-05
resonance O 0 7.350990199483931e-05
image O 0 0.00011606622865656391
( O 0 1.7115580703830346e-06
MRI O 0 0.0007495992467738688
) O 0 6.792924978071824e-07
showed O 0 4.9351900088367984e-05
abnormalities B-Disease 0 0.1915980577468872
in I-Disease 0 2.573912070147344e-07
the I-Disease 0 6.884234835524694e-07
bilateral I-Disease 0 0.00010778488649521023
cerebellar I-Disease 0 0.4311400055885315
hemispheres I-Disease 0 0.0008898713858798146
and O 0 2.0550722183543257e-05
brain O 1 0.9925991296768188
stem O 0 8.249889651779085e-05
, O 0 2.3586682118548197e-07
but O 0 1.1125357701757821e-07
not O 0 2.905352403104189e-08
in O 0 7.63446266205392e-08
the O 0 1.6180446209546062e-06
cerebral O 0 0.08091109991073608
white O 0 1.3817196304444224e-05
matter O 0 1.055170173458464e-06
, O 0 1.1021675305755707e-07
where O 0 1.4961072736241476e-07
marked O 0 3.4699619391176384e-06
reductions O 0 8.295633961097337e-06
of O 0 4.9720391359642235e-08
the O 0 1.374771045448142e-06
cerebral O 0 0.2357889711856842
blood O 0 5.0029422709485516e-05
flow O 0 1.9828487438644515e-06
and O 0 2.2067757754484774e-07
oxygen O 0 5.141450401424663e-06
metabolism O 0 1.6618219888187014e-05
were O 0 8.443796417623162e-08
clearly O 0 2.544893220601807e-07
demonstrated O 0 2.742901017427357e-07
by O 0 3.267398085426976e-08
positron O 0 3.3228261600015685e-05
emission O 0 2.700048753467854e-05
tomography O 0 5.576003604801372e-05
( O 0 1.1772339121307596e-06
PET O 0 7.266942702699453e-05
) O 0 1.3137839687260566e-06
. O 0 2.5769086278160103e-06

In O 0 1.654585503274575e-05
patients O 0 1.3924235645390581e-05
2 O 0 8.656077739033208e-07
and O 0 1.7248785866286198e-07
3 O 0 1.0438878916829708e-06
, O 0 7.347664165990864e-08
the O 0 3.4851768759835977e-07
autopsy O 0 0.0008096000528894365
findings O 0 5.792383490188513e-06
showed O 0 7.941132207633927e-05
massive O 0 0.004141112323850393
demyelination B-Disease 1 0.9998138546943665
of I-Disease 0 7.4776312430913094e-06
the I-Disease 0 0.00011460473615443334
cerebral I-Disease 1 0.9970545768737793
white I-Disease 0 3.578330506570637e-05
matter I-Disease 0 7.804140977896168e-07
with O 0 1.426940627879958e-07
sparing O 0 7.338951490964973e-07
of O 0 1.0446004949926646e-07
the O 0 1.34810215968173e-06
U O 0 6.218015914782882e-05
- O 0 6.0316695453366265e-05
fibers O 0 2.907506541305338e-06
, O 0 1.477506383906757e-08
compatible O 0 4.307991829932689e-08
with O 0 5.394957014459578e-08
the O 0 3.6658587987403735e-07
findings O 0 3.6446401736611733e-06
of O 0 1.915020902742981e-06
childhood O 0 0.48276811838150024
ALD B-Disease 1 0.9997910857200623
. O 0 6.562483758898452e-05

Oleic O 0 0.00781303457915783
and O 0 1.7072354239644483e-05
erucic O 0 0.003744045738130808
acids O 0 1.7942131307790987e-05
( O 0 2.9756137109870906e-07
Lorenzos O 0 9.570660040481016e-06
Oil O 0 7.29760017748049e-07
) O 0 8.592138556196005e-09
were O 0 1.3230017081866663e-08
administered O 0 5.96327183188805e-08
to O 0 1.139259442339835e-08
patients O 0 2.606675195693242e-07
1 O 0 4.5274472171286106e-08
and O 0 3.609271814752901e-08
4 O 0 2.183297027613662e-07
, O 0 1.0617871026852299e-08
but O 0 7.687999570293869e-09
sufficient O 0 3.595289754798614e-08
effectiveness O 0 3.403034440907504e-07
was O 0 2.424233798592468e-06
not O 0 6.89589967350912e-08
obtained O 0 4.916836928714474e-07
. O 0 1.1229089977859985e-06

The O 0 7.891166205808986e-06
findings O 0 1.0546928933763411e-05
in O 0 4.651790561638336e-07
this O 0 8.505413973125542e-08
family O 0 6.636250304836722e-07
suggest O 0 3.779434791795211e-07
that O 0 3.7832492694178654e-08
delGAG291 O 0 9.164793482341338e-06
is O 0 1.3200001092172897e-07
part O 0 8.108340665557989e-08
of O 0 2.97802031923311e-08
the O 0 1.2758074490193394e-06
cause O 0 1.1149547390232328e-05
of O 0 3.5197513170714956e-07
Japanese O 0 0.00019207030709367245
ALD B-Disease 1 0.9992579817771912
with O 0 7.435360203089658e-07
phenotypic O 0 0.00012105931818950921
variations O 0 0.0001620277325855568
. O 0 1.6595635315752588e-05

Moreover O 0 2.4657918402226642e-05
, O 0 5.158617568667978e-07
although O 0 1.32500986183004e-07
the O 0 3.8534771817921865e-08
scale O 0 2.281674369442044e-06
of O 0 4.0843371351684254e-08
the O 0 2.663194891283638e-07
study O 0 3.82880244842454e-07
is O 0 4.176356682705773e-08
limited O 0 5.2861807375848e-08
, O 0 3.2616821243891536e-08
there O 0 2.3071292432064183e-08
is O 0 2.3446997232667854e-08
a O 0 1.1976540292835125e-07
possibility O 0 2.3645733904231747e-07
that O 0 2.6661675534001006e-08
PET O 0 4.6116174416965805e-06
can O 0 1.3821022548654582e-07
detect O 0 1.881792013591621e-05
an O 0 1.436678076061071e-06
insidious B-Disease 0 0.009841982275247574
lesion I-Disease 1 0.9672092795372009
which O 0 3.7376261730059923e-07
is O 0 3.294885004834214e-07
undetectable O 0 2.1575679056695662e-05
by O 0 8.868572365372529e-08
computed O 0 5.009954747947631e-06
tomogram O 0 2.899227911257185e-05
( O 0 4.88624266381521e-07
CT O 0 0.0002158510178560391
) O 0 6.153787523999199e-08
or O 0 1.161450597919611e-07
MRI O 0 1.47292294059298e-05
analysis O 0 1.1829900614657163e-07
, O 0 2.052664704876861e-08
and O 0 7.92674992311504e-09
that O 0 2.8090643144906835e-09
the O 0 2.4869432735386e-08
higher O 0 3.309677367724362e-07
level O 0 3.22691562359978e-07
of O 0 2.895196082874918e-08
tau O 0 2.1856019429833395e-06
reflects O 0 2.5396491309948033e-07
the O 0 4.2406686162621554e-08
process O 0 1.4309431151104945e-07
of O 0 5.295025857776636e-07
neuronal B-Disease 0 0.0005465593421831727
degeneration I-Disease 1 0.9966168999671936
in O 0 0.0002937470271717757
ALD B-Disease 1 0.9994803071022034
. O 0 0.00017688034859020263

Lorenzos O 0 0.0007665312732569873
Oil O 0 1.3249709809315391e-05
should O 0 2.2698930024489528e-07
be O 0 2.0751027562937452e-08
given O 0 1.401970717296308e-08
in O 0 2.682515898300153e-08
the O 0 6.260419382897453e-08
early O 0 1.0571211532806046e-06
stage O 0 1.362280727335019e-05
. O 0 2.9549983082688414e-07
. O 0 1.0711540880947723e-06

Nonsense O 0 0.0008540830458514392
mutation O 0 7.969329453771934e-05
in O 0 7.728211812718655e-07
exon O 0 1.7308950191363692e-05
4 O 0 7.568680189251609e-07
of O 0 4.8102403837901875e-08
human O 0 3.390375127310108e-07
complement O 0 1.0706557986850385e-06
C9 O 0 0.00027222363860346377
gene O 0 9.002852493722457e-06
is O 0 5.095163828627847e-07
the O 0 5.426794587037875e-07
major O 0 5.274701106827706e-05
cause O 0 1.763182444847189e-05
of O 0 2.713438504997612e-07
Japanese O 0 0.00010469701373949647
complement B-Disease 0 0.0016585165867581964
C9 I-Disease 1 0.9966159462928772
deficiency I-Disease 1 0.9990906715393066
. O 0 2.872165532608051e-05

Deficiency B-Disease 1 0.9979285001754761
of I-Disease 0 1.8670433519218932e-06
the I-Disease 0 2.4434825718344655e-06
ninth I-Disease 0 0.00012395238445606083
component I-Disease 0 4.947023171553155e-06
of I-Disease 0 7.254945444401528e-08
human I-Disease 0 5.532309046429873e-07
complement I-Disease 0 1.0711061122492538e-06
( O 0 2.58174225109542e-07
C9 O 0 0.00014369806740432978
) O 0 9.07332733390831e-08
is O 0 3.5887605775997145e-08
the O 0 3.371470214119654e-08
most O 0 2.66247127456154e-07
common O 0 3.2667794584995136e-05
complement B-Disease 1 0.9961944818496704
deficiency I-Disease 1 0.9999904632568359
in O 0 3.6821900266659213e-06
Japan O 0 5.363414857129101e-06
but O 0 1.9951983176724752e-07
is O 0 7.966874449039096e-08
rare O 0 4.127126658204361e-07
in O 0 4.7066151864783023e-08
other O 0 1.2999390897050489e-08
countries O 0 5.069436781468539e-08
. O 0 1.917095005410374e-06

We O 0 1.5395161199194263e-06
studied O 0 1.5385913911813986e-06
the O 0 1.3149079336471914e-07
molecular O 0 8.065750080277212e-06
basis O 0 6.470879725384293e-07
of O 0 2.555458422648371e-06
C9 B-Disease 1 0.99592125415802
deficiency I-Disease 1 0.9995373487472534
in O 0 6.967755439291068e-07
four O 0 5.309715902512835e-07
Japanese O 0 2.917511301347986e-05
C9 B-Disease 0 0.3023413121700287
- I-Disease 1 0.6223354935646057
deficient I-Disease 0 0.14968061447143555
patients O 0 0.00016554743342567235
who O 0 1.2827069440390915e-05
had O 0 0.00025342710432596505
suffered O 1 0.9988095760345459
from O 0 0.0035568021703511477
meningococcal B-Disease 1 0.9998772144317627
meningitis I-Disease 1 0.9998732805252075
. O 0 8.036855433601886e-05

Direct O 0 4.535195614607801e-07
sequencing O 0 2.7150611003889935e-06
of O 0 2.1218974666226131e-07
amplified O 0 3.28714850184042e-05
C9 O 0 0.00011054400965804234
cDNA O 0 1.6044107269408414e-06
and O 0 2.453932381740742e-07
DNA O 0 3.3425342280679615e-06
revealed O 0 3.4953366139234276e-06
a O 0 4.4317144443084544e-07
nonsense O 0 6.973180461500306e-06
substitution O 0 3.3724836612236686e-07
( O 0 1.475485049695635e-07
CGA O 0 1.4728527276020031e-05
- O 0 5.310585402185097e-05
- O 0 4.079661448486149e-05
> O 0 7.2090101639332715e-06
TGA O 0 1.3829851923219394e-05
) O 0 7.228908316392335e-08
at O 0 3.3408977628823777e-07
codon O 0 7.281103080458706e-07
95 O 0 1.5040482992390025e-07
in O 0 3.5651343210929554e-08
exon O 0 1.3596334156318335e-06
4 O 0 1.8296768189429713e-07
in O 0 1.8670840873369343e-08
the O 0 1.1822028511687677e-07
four O 0 1.8656852489584708e-06
C9 B-Disease 0 0.009664459154009819
- I-Disease 0 0.014877570793032646
deficient I-Disease 0 0.0020708406809717417
individuals O 0 1.110718244490272e-06
. O 0 3.2950779313978273e-06

An O 0 1.148466139966331e-06
allele O 0 1.539616278023459e-05
- O 0 1.837377749325242e-05
specific O 0 7.733336246928957e-07
polymerase O 0 1.6853966371854767e-05
chain O 0 2.9385144443949685e-05
reaction O 0 2.626971763675101e-06
system O 0 2.036968453467125e-06
designed O 0 5.40070118404401e-07
to O 0 2.555420763883376e-08
detect O 0 1.5322043509513605e-06
exclusively O 0 4.2799328525688907e-08
only O 0 9.132268274925082e-09
one O 0 7.409076019371241e-09
of O 0 4.197941549932693e-09
the O 0 5.6442981843929374e-08
normal O 0 4.712435952569649e-07
and O 0 2.4471168202921945e-08
mutant O 0 4.79499817629403e-07
alleles O 0 3.5556587363316794e-07
indicated O 0 7.804497954566614e-07
that O 0 4.766300243375099e-09
all O 0 4.015686894121018e-09
the O 0 3.9643651916776435e-08
four O 0 1.3837600931765337e-07
patients O 0 1.9224175673571153e-07
were O 0 8.023430808634657e-09
homozygous O 0 5.058117125145145e-08
for O 0 2.6124791219217514e-09
the O 0 4.345308823872074e-08
mutation O 0 8.344697448592342e-07
in O 0 4.836940092900477e-08
exon O 0 2.1411651687230915e-06
4 O 0 2.8957907716176123e-07
and O 0 3.396597492155706e-08
that O 0 1.0465764255229715e-08
the O 0 5.036629602273024e-08
parents O 0 1.350277614164952e-07
of O 0 9.162106096027856e-08
patient O 0 1.3008666428504512e-05
2 O 0 9.851179356701323e-07
were O 0 4.6374429985007737e-07
heterozygous O 0 9.721141395857558e-06
. O 0 2.653697492860374e-06

The O 0 3.0071905712247826e-06
common O 0 7.640902367711533e-06
mutation O 0 2.158214192604646e-05
at O 0 1.7399806893081404e-06
codon O 0 3.916568402928533e-06
95 O 0 4.339453596458043e-07
in O 0 1.1457384374580215e-07
exon O 0 4.581533175951336e-06
4 O 0 7.577881433462608e-07
might O 0 1.23913636684847e-07
be O 0 1.6217363452142308e-08
responsible O 0 4.815932186374994e-08
for O 0 2.077550220747071e-08
most O 0 3.3478923455732e-07
Japanese O 0 0.0002075442171189934
C9 B-Disease 1 0.9925214648246765
deficiency I-Disease 1 0.9987539052963257
. O 0 2.4064718218141934e-06
. O 0 4.501740932028042e-06

BRCA1 O 0 0.00030142767354846
required O 0 1.0623095931805437e-06
for O 0 1.0486069612625215e-07
transcription O 0 2.428017796773929e-05
- O 0 0.0005455380887724459
coupled O 0 0.00010569309233687818
repair O 0 0.016197558492422104
of O 0 2.2110486952442443e-06
oxidative O 0 0.06319421529769897
DNA O 0 0.005957139655947685
damage O 0 0.2658642828464508
. O 0 1.0705551176215522e-05

The O 0 0.0003127434174530208
breast B-Disease 1 0.9977935552597046
and I-Disease 1 0.7772182822227478
ovarian I-Disease 1 0.999997615814209
cancer I-Disease 1 0.9999854564666748
susceptibility O 0 0.0027785140555351973
gene O 0 4.285163231543265e-05
BRCA1 O 0 0.00012322384282015264
encodes O 0 2.673572680578218e-06
a O 0 6.46298849460436e-06
zinc O 0 0.0017261919565498829
finger O 0 0.00012887557386420667
protein O 0 1.6984848798529129e-06
of O 0 6.394863305558829e-08
unknown O 0 5.559034889301984e-06
function O 0 7.890940651122946e-06
. O 0 3.837718395516276e-06

Association O 0 1.3737246263190173e-05
of O 0 9.47010434515505e-08
the O 0 3.195223996499408e-07
BRCA1 O 0 1.4476297110377345e-05
protein O 0 3.2536985372644267e-07
with O 0 3.771959100618005e-08
the O 0 1.33741949071009e-07
DNA O 0 6.53503775538411e-06
repair O 0 0.00024298459175042808
protein O 0 2.9196739887993317e-06
Rad51 O 0 5.8159890613751486e-05
and O 0 5.084794807430626e-08
changes O 0 1.2445939034932962e-07
in O 0 1.4652199453735193e-08
the O 0 8.709950094498708e-09
phosphorylation O 0 2.1375544889679077e-08
and O 0 1.7438924970747394e-08
cellular O 0 2.4826647404552205e-06
localization O 0 7.792568794684485e-07
of O 0 1.8293377479494666e-08
the O 0 3.503908985180715e-08
protein O 0 3.030724542441021e-07
after O 0 5.706285151063639e-07
exposure O 0 1.2869436432083603e-06
to O 0 2.6897346572241077e-08
DNA O 0 5.777592832600931e-06
- O 0 5.1719140174100175e-05
damaging O 0 1.5067422282299958e-05
agents O 0 1.420271900087755e-07
are O 0 3.3243878760913503e-09
consistent O 0 8.43922336457581e-08
with O 0 5.999766905517845e-09
a O 0 7.134706692113468e-08
role O 0 3.4689654171415896e-07
for O 0 1.1332133453834103e-07
BRCA1 O 0 2.9427492336253636e-05
in O 0 5.586269367086061e-07
DNA O 0 2.8435410058591515e-05
repair O 0 0.020208017900586128
. O 0 1.3364584447117522e-05

Here O 0 7.828039088053629e-06
, O 0 4.7262398084058077e-07
it O 0 4.064520453539444e-08
is O 0 4.6368548112241115e-08
shown O 0 9.119078470121167e-08
that O 0 2.4936834819300202e-08
mouse O 0 1.206122942676302e-05
embryonic O 0 3.004636528203264e-05
stem O 0 3.4971890272572637e-05
cells O 0 2.1949532310827635e-05
deficient B-Disease 0 0.00016450561815872788
in I-Disease 0 2.9918783184257336e-07
BRCA1 I-Disease 0 1.1668017577903811e-05
are O 0 4.0854359895092784e-08
defective O 0 3.246490450692363e-05
in O 0 1.192818785966665e-07
the O 0 2.9691156200328805e-08
ability O 0 2.7969829119456335e-08
to O 0 6.6152070488101344e-09
carry O 0 4.0832702552506817e-08
out O 0 4.061242364628015e-08
transcription O 0 3.4869665341830114e-06
- O 0 2.614410186652094e-05
coupled O 0 1.0019176443165634e-05
repair O 0 0.00048473841161467135
of O 0 4.1264496530857286e-07
oxidative O 0 0.0012658751802518964
DNA O 0 0.0005196658312343061
damage O 0 0.014022509567439556
, O 0 1.9556655672658962e-07
and O 0 8.59806021935583e-08
are O 0 4.666533115482707e-08
hypersensitive O 0 0.00013082953228149563
to O 0 7.94324705566396e-07
ionizing O 0 0.00268283998593688
radiation O 0 0.004501477349549532
and O 0 3.2601371913187904e-07
hydrogen O 0 9.513437362329569e-06
peroxide O 0 0.0008251552353613079
. O 0 7.685380296607036e-06

These O 0 9.497379664935579e-07
results O 0 1.05819090094883e-05
suggest O 0 1.742358449519088e-06
that O 0 1.422840796294622e-07
BRCA1 O 0 2.228459379693959e-05
participates O 0 1.2058616221111151e-06
, O 0 3.9782268146382194e-08
directly O 0 7.585388317465913e-08
or O 0 2.5395036118425196e-07
indirectly O 0 7.330697826546384e-07
, O 0 1.2560096251945652e-07
in O 0 1.100457609481964e-07
transcription O 0 1.208305729960557e-05
- O 0 0.00027162395417690277
coupled O 0 4.304297544877045e-05
repair O 0 0.004462906625121832
of O 0 1.6585541970925988e-06
oxidative O 0 0.004690380766987801
DNA O 0 0.0013119239592924714
damage O 0 0.005343038123100996
. O 0 6.724717422912363e-07
. O 0 1.7861897276816308e-06

Truncation O 0 0.001109502511098981
mutations O 0 0.0008656859863549471
in O 0 2.1163609744689893e-06
the O 0 1.3387266335485037e-06
transactivation O 0 0.0003107544034719467
region O 0 1.3868099813407753e-05
of O 0 1.266236381525232e-06
PAX6 O 0 0.0015524544287472963
result O 0 1.2888614037365187e-05
in O 0 2.0833713278989308e-06
dominant O 0 0.00046278597437776625
- O 0 0.0012718356447294354
negative O 0 2.2804846594226547e-05
mutants O 0 5.4079264373285696e-05
. O 0 5.8058271861227695e-06

PAX6 O 0 0.005173170939087868
is O 0 3.2911366361076944e-06
a O 0 4.2122323407056683e-07
transcription O 0 2.3226107259688433e-06
factor O 0 2.3624343725714425e-07
with O 0 3.8057503815025484e-08
two O 0 1.4096802658514207e-07
DNA O 0 3.4010104172921274e-06
- O 0 5.646802492265124e-06
binding O 0 9.308373023486638e-07
domains O 0 1.6717376638553105e-06
( O 0 1.5619579585290921e-07
paired O 0 2.323049102415098e-06
box O 0 5.790986051579239e-06
and O 0 1.1297000668264445e-07
homeobox O 0 4.93995639772038e-06
) O 0 4.998902269903738e-08
and O 0 3.670902515295893e-08
a O 0 3.7168112498875416e-07
proline O 0 1.3088356354273856e-05
- O 0 2.503759242244996e-05
serine O 0 8.033654012251645e-06
- O 0 2.742410470091272e-05
threonine O 0 2.0933248379151337e-05
( O 0 7.115856419659394e-07
PST O 0 0.00010522949014557526
) O 0 3.79701390329501e-07
- O 0 1.418892770743696e-05
rich O 0 2.680649913600064e-06
transactivation O 0 9.298867371398956e-05
domain O 0 1.779230842657853e-05
. O 0 4.0072068259178195e-06

PAX6 O 0 0.04163626581430435
regulates O 0 0.0019148780265823007
eye O 0 0.007988696917891502
development O 0 2.761933728834265e-06
in O 0 6.927795084266108e-07
animals O 0 3.1443610737369454e-07
ranging O 0 2.0371703612909187e-06
from O 0 1.9214827773339493e-07
jellyfish O 0 6.865536192890431e-07
to O 0 5.127430036111491e-09
Drosophila O 0 1.2278412953037332e-07
to O 0 2.8985997602148927e-08
humans O 0 1.5236973922583275e-06
. O 0 1.7091260815504938e-06

Heterozygous O 0 0.0001428484683856368
mutations O 0 9.263112588087097e-05
in O 0 4.033614118270634e-07
the O 0 3.0400428840948734e-07
human O 0 1.8663988612388493e-06
PAX6 O 0 0.00031990063143894076
gene O 0 6.351919182634447e-06
result O 0 8.165124540937541e-07
in O 0 6.954996223385024e-08
various O 0 7.972240467779557e-08
phenotypes O 0 4.428335159900598e-05
, O 0 7.412074864987517e-07
including O 0 4.626392183126882e-06
aniridia B-Disease 1 0.9998457431793213
, O 0 0.00023714818235021085
Peters B-Disease 1 0.9995211362838745
anomaly I-Disease 1 0.999708354473114
, O 0 2.1958536308375187e-05
autosomal B-Disease 1 0.8650795221328735
dominant I-Disease 0 0.18693086504936218
keratitis I-Disease 1 0.9519398212432861
, O 0 1.3606850188807584e-05
and O 0 3.8111753383418545e-05
familial B-Disease 1 0.9982414245605469
foveal I-Disease 1 0.9989687204360962
dysplasia I-Disease 1 0.9997565150260925
. O 0 0.00022368768986780196

It O 0 1.932547320393496e-06
is O 0 3.3754730566215585e-07
believed O 0 1.8619581965140242e-07
that O 0 1.1775596497898277e-08
the O 0 6.553171516543443e-08
mutated O 0 2.1836895029991865e-06
allele O 0 1.4887390307194437e-06
of O 0 1.1273613864659637e-07
PAX6 O 0 0.00018875136447604746
produces O 0 3.324470526422374e-06
an O 0 2.2678372602058516e-07
inactive O 0 1.0742593985924032e-05
protein O 0 2.466089881636435e-06
and O 0 1.791157160369039e-06
aniridia B-Disease 1 0.99969482421875
is O 0 1.9067247194470838e-05
caused O 0 6.798696267651394e-05
due O 0 4.777042249770602e-06
to O 0 3.5583960311669216e-07
genetic O 0 0.0001129645315813832
haploinsufficiency O 0 0.0025456328876316547
. O 0 2.2568096028408036e-05

However O 0 2.9413492939056596e-06
, O 0 1.4942663995043404e-07
several O 0 8.33071212014147e-08
truncation O 0 2.109454908350017e-05
mutations O 0 3.2397940231021494e-05
have O 0 1.4394481695489958e-07
been O 0 1.5796270247392385e-07
found O 0 4.4024375256412895e-08
to O 0 4.667883857223387e-09
occur O 0 4.3075644384771294e-08
in O 0 1.2225594758774605e-08
the O 0 7.387770750710843e-08
C O 0 1.4300075235951226e-05
- O 0 7.8358216342167e-06
terminal O 0 6.333433702820912e-06
half O 0 1.0381887705079862e-07
of O 0 3.729956077336283e-08
PAX6 O 0 6.635423051193357e-05
in O 0 1.029101554195222e-06
patients O 0 3.1835456866247114e-06
with O 0 5.5852893865449e-07
Aniridia B-Disease 1 0.990649402141571
resulting O 0 2.6301781872462016e-06
in O 0 2.667673868472775e-07
mutant O 0 8.751616746849322e-07
proteins O 0 7.040873128971725e-08
that O 0 3.696447592460572e-09
retain O 0 2.9330079698297595e-08
the O 0 4.56999380560319e-08
DNA O 0 1.0482744983164594e-06
- O 0 1.140857534664974e-06
binding O 0 1.9013148744306818e-07
domains O 0 2.988524556712946e-07
but O 0 4.8320895729148106e-08
have O 0 3.0018352248362135e-08
lost O 0 6.624641173402779e-07
most O 0 1.3273110610612093e-08
of O 0 1.383743608585064e-08
the O 0 2.206295874884745e-07
transactivation O 0 5.2555504225892946e-05
domain O 0 9.856604265223723e-06
. O 0 3.5563982692110585e-06

It O 0 4.5874094212194905e-06
is O 0 4.0078080587591103e-07
not O 0 2.4692987210528372e-08
clear O 0 1.1249523623746427e-07
whether O 0 1.0141638639993289e-08
such O 0 1.5453419877076158e-08
mutants O 0 1.3288711215864168e-06
really O 0 5.352636094357877e-07
behave O 0 5.37396431354864e-07
as O 0 4.303557261664537e-07
loss O 0 1.3891143680666573e-05
- O 0 3.042013986487291e-06
of O 0 6.906797977990209e-08
- O 0 4.470666681299917e-06
function O 0 2.5172457185362873e-07
mutants O 0 1.5998452909116168e-06
as O 0 2.348298693277684e-07
predicted O 0 2.832304744515568e-06
by O 0 4.1943982864722784e-07
haploinsufficiency O 0 0.0002394278417341411
. O 0 4.727759005618282e-06

Contrary O 0 1.0105462024512235e-05
to O 0 9.117199795127817e-08
this O 0 2.678670973921271e-08
theory O 0 1.2602595234056935e-07
, O 0 3.748863619534859e-08
our O 0 5.0644306526237415e-08
data O 0 1.358412191621028e-07
showed O 0 2.8525218453978596e-07
that O 0 2.5318069862834136e-09
these O 0 2.51385401384141e-09
mutants O 0 1.829863549573929e-07
are O 0 1.013150807693819e-08
dominant O 0 4.224629719828954e-06
- O 0 1.1261067811574321e-05
negative O 0 2.0171044923245063e-07
in O 0 6.265412366701639e-08
transient O 0 1.037615106724843e-06
transfection O 0 4.745113074022811e-06
assays O 0 8.55969460644701e-07
when O 0 1.7098290072681266e-07
they O 0 9.026837943792998e-09
are O 0 5.470221609016335e-09
coexpressed O 0 3.871545231959317e-06
with O 0 3.4250604130647844e-07
wild O 0 2.5085897505050525e-05
- O 0 0.001767286448739469
type O 0 0.000378915254259482
PAX6 O 0 0.006081244442611933
. O 0 1.7663027392700315e-05

We O 0 3.1139215934672393e-06
found O 0 8.054067279772426e-07
that O 0 2.4196360470796208e-08
the O 0 2.047043068387211e-07
dominant O 0 7.803494372637942e-05
- O 0 0.00035948483855463564
negative O 0 2.4530083919671597e-06
effects O 0 4.434557013155427e-06
result O 0 2.0863784300217958e-07
from O 0 7.3974266712184544e-09
the O 0 8.080994540193842e-09
enhanced O 0 4.0222667507805454e-07
DNA O 0 7.465301337106212e-07
binding O 0 2.884561638438754e-07
ability O 0 1.2044624497775658e-07
of O 0 3.2163370633497834e-08
these O 0 1.067253379005706e-07
mutants O 0 1.5615838492522016e-05
. O 0 2.444764277242939e-06

Kinetic O 0 2.894763383665122e-05
studies O 0 9.030300134327263e-07
of O 0 4.085420357569092e-08
binding O 0 8.663988637636066e-07
and O 0 2.3412012239987234e-07
dissociation O 0 9.988684723793995e-06
revealed O 0 2.1332143660401925e-06
that O 0 2.4296240574983585e-09
various O 0 6.578064759565905e-09
truncation O 0 2.0832681002502795e-06
mutants O 0 8.874509944689635e-07
have O 0 3.368307588402786e-08
3 O 0 2.522268118809734e-07
- O 0 4.298931798984995e-06
5 O 0 4.0371546106143796e-07
- O 0 1.8036960227618692e-06
fold O 0 2.995841441588709e-07
higher O 0 3.9241996319105965e-08
affinity O 0 1.1040607539314351e-08
to O 0 7.624414433138327e-10
various O 0 4.229737005090328e-09
DNA O 0 2.627202206895163e-07
- O 0 4.5560645389741694e-07
binding O 0 6.684690845304431e-08
sites O 0 4.642447848368647e-08
when O 0 7.456016959395129e-08
compared O 0 1.2260544224318437e-07
with O 0 1.6586437112664498e-08
the O 0 1.9531903205916024e-07
wild O 0 9.254297765437514e-06
- O 0 0.0005219163140282035
type O 0 0.0003121791814919561
PAX6 O 0 0.0038731275126338005
. O 0 1.9990062355645932e-05

These O 0 4.155995156907011e-07
results O 0 8.776657978160074e-07
provide O 0 4.551925414375546e-08
a O 0 1.106875942014085e-07
new O 0 1.318687878892888e-07
insight O 0 8.361132586287567e-08
into O 0 1.8446948857331336e-08
the O 0 2.401218424097351e-08
role O 0 2.436208319522848e-07
of O 0 1.1458303106337553e-07
mutant O 0 2.6165798772126436e-05
PAX6 O 0 0.0010539181530475616
in O 0 9.04377975530224e-06
causing O 0 0.002677209209650755
aniridia B-Disease 1 0.9991003274917603
. O 0 4.5583387873193715e-06
. O 0 6.324018158920808e-06

Reversal O 0 0.014228329993784428
of O 0 0.0010779907461255789
severe O 1 0.9995777010917664
hypertrophic B-Disease 1 0.9999290704727173
cardiomyopathy I-Disease 1 0.9999923706054688
and O 0 0.00011930833716178313
excellent O 0 0.00015205795352812856
neuropsychologic O 0 0.0014156170655041933
outcome O 0 1.4100802218308672e-05
in O 0 9.207002449329593e-07
very B-Disease 0 3.824805844487855e-06
- I-Disease 0 0.00038394256262108684
long I-Disease 0 2.5753368390724063e-05
- I-Disease 0 9.995298751164228e-05
chain I-Disease 0 4.6556324377888814e-05
acyl I-Disease 0 8.623016583442222e-06
- I-Disease 0 3.6376404750626534e-05
coenzyme I-Disease 0 1.2168768989795353e-05
A I-Disease 0 8.066914597293362e-05
dehydrogenase I-Disease 0 0.01988828182220459
deficiency I-Disease 1 0.9980459213256836
. O 0 1.8361042748438194e-05

Very B-Disease 0 5.517102181329392e-05
- I-Disease 0 0.0007432256825268269
long I-Disease 0 4.9176196625921875e-05
- I-Disease 0 0.00010814542474690825
chain I-Disease 0 4.248436744092032e-05
acyl I-Disease 0 1.026215250021778e-05
- I-Disease 0 1.059896658262005e-05
coenzyme I-Disease 0 1.686197833805636e-06
A I-Disease 0 2.4324456262547756e-06
dehydrogenase I-Disease 0 4.8201371100731194e-05
( I-Disease 0 3.143901039948105e-06
VLCAD I-Disease 0 0.029691463336348534
) I-Disease 0 2.8428146833903156e-05
deficiency I-Disease 1 0.9972598552703857
is O 0 2.6142581646126928e-06
a O 0 3.719191954587586e-05
disorder O 1 0.9776309132575989
of O 0 6.138969865787658e-07
fatty O 0 5.832774331793189e-05
acid O 0 8.618354513600934e-06
beta O 0 6.298224093370663e-07
oxidation O 0 6.21082392626704e-07
that O 0 3.0242595983054343e-08
reportedly O 0 3.235363692510873e-06
has O 0 2.4663103204147774e-07
high O 0 1.5094373338797595e-05
rates O 0 5.274063369142823e-06
of O 0 4.3833551899297163e-07
morbidity O 0 0.11716090887784958
and O 0 6.313376161415363e-06
mortality O 0 0.005924946162849665
. O 0 7.05640013620723e-06

We O 0 1.921018792927498e-06
describe O 0 7.215015784822754e-07
the O 0 1.982161421665296e-07
outcome O 0 3.074112271406193e-07
of O 0 2.8222123304999513e-08
a O 0 1.000249767457717e-06
5 O 0 2.045537939920905e-06
- O 0 3.837993790511973e-05
year O 0 2.3141028577811085e-06
- O 0 5.556385440286249e-05
old O 0 0.0002880920947063714
girl O 0 0.00023276005231309682
with O 0 4.47866550530307e-05
VLCAD B-Disease 1 0.9998626708984375
deficiency I-Disease 1 0.9999796152114868
who O 0 4.5530036913987715e-06
was O 0 3.660531319837901e-06
first O 0 1.4057064845474088e-07
seen O 0 7.281631724254112e-07
at O 0 1.3501917237590533e-06
5 O 0 1.6906712119180156e-07
months O 0 1.943682121918755e-07
of O 0 3.6118269264306946e-08
age O 0 1.4095639016886707e-05
with O 0 9.800366387935355e-05
severe O 1 0.99962317943573
hypertrophic B-Disease 1 0.9999638795852661
cardiomyopathy I-Disease 1 0.9999986886978149
, O 1 0.9798091650009155
hepatomegaly B-Disease 1 0.9999932050704956
, O 1 0.9051264524459839
encephalopathy B-Disease 1 0.9999113082885742
, O 0 2.580435830168426e-05
and O 0 2.2974671082920395e-05
hypotonia B-Disease 1 0.8016411066055298
. O 0 3.6675195588031784e-05

Biochemical O 0 0.009062946774065495
studies O 0 0.0009820145787671208
indicated O 1 0.9419243931770325
VLCAD B-Disease 1 0.9999773502349854
deficiency I-Disease 1 0.9999978542327881
caused O 0 0.00857697892934084
by O 0 6.59456759422028e-07
a O 0 6.430225766962394e-06
stable O 0 0.0003607275430113077
yet O 0 6.023049081704812e-06
inactive O 0 2.6063939003506675e-05
enzyme O 0 1.3940897588327061e-05
. O 0 2.560276243457338e-06

Molecular O 0 0.0003513658884912729
genetic O 0 5.769427662016824e-05
analysis O 0 2.3008221887721447e-06
of O 0 2.859819119294116e-07
her O 0 1.9166644051438197e-05
VLCAD O 0 0.004766666330397129
gene O 0 2.9499591619241983e-05
revealed O 0 3.1601928640156984e-05
a O 0 3.237456212445977e-06
T1372C O 0 3.124577415292151e-05
( O 0 5.099723807688861e-07
F458L O 0 1.3880590813641902e-05
) O 0 5.159415081834595e-07
missense O 0 7.957474736031145e-05
mutation O 0 2.663358645804692e-05
and O 0 7.231279255393019e-07
a O 0 1.8794104107655585e-05
1668 O 0 0.008390652015805244
ACAG O 0 0.002383297076448798
1669 O 0 0.0007491408032365143
splice O 0 0.0006679965881630778
site O 0 0.000325753033393994
mutation O 0 0.0006520671886391938
. O 0 1.2522195902420208e-05

After O 0 4.0933948184829205e-05
initial O 0 1.015389079839224e-05
treatment O 0 9.221922482538503e-06
with O 0 3.06296868757272e-07
intravenous O 0 1.9497376342769712e-05
glucose O 0 5.0194103096146137e-05
and O 0 3.69215172213444e-07
carnitine O 0 0.00011022117541870102
, O 0 2.8149904096608225e-07
the O 0 5.338438882063201e-07
patient O 0 1.4040229871170595e-05
has O 0 3.023008616764855e-07
thrived O 0 2.586431719464599e-06
on O 0 5.188813929635216e-07
a O 0 1.6947406038525514e-06
low O 0 0.00011004769476130605
- O 0 9.9598677479662e-05
fat O 0 1.3420908544503618e-05
diet O 0 1.1388019629521295e-06
supplemented O 0 6.175515920858743e-08
with O 0 2.6587077428530392e-08
medium O 0 2.181986701543792e-06
- O 0 2.8702488634735346e-05
chain O 0 1.2837595022574533e-05
triglyceride O 0 1.882897959148977e-05
oil O 0 3.537637894623913e-06
and O 0 3.460671393895609e-07
carnitine O 0 8.270194666692987e-05
and O 0 4.352492339876335e-07
avoidance O 0 9.229580609826371e-05
of O 0 1.2479566748879733e-06
fasting O 0 5.880015669390559e-05
. O 0 7.106604243745096e-06

Her O 0 0.00123314349912107
ventricular O 1 0.9513415098190308
hypertrophy O 0 0.322542279958725
resolved O 0 5.5748016166035086e-05
significantly O 0 9.043158570420928e-06
over O 0 2.348045455846659e-07
1 O 0 6.699975756419008e-07
year O 0 3.0870950240569073e-07
, O 0 2.6056630630932887e-08
and O 0 9.89609816315351e-08
cognitively O 0 7.70424521761015e-05
, O 0 2.2116468301192072e-07
she O 0 1.0413365316708223e-06
is O 0 2.417938205212522e-08
in O 0 2.6745409442696655e-08
the O 0 5.274155867596164e-08
superior O 0 6.011573077557841e-06
range O 0 8.781966016613296e-07
for O 0 1.3963722267362755e-07
age O 0 5.438568223326001e-06
. O 0 2.338055764994351e-06

Clinical O 0 0.0005147400079295039
recognition O 0 8.225003693951294e-05
of O 0 0.008536401204764843
VLCAD B-Disease 1 0.9999939203262329
deficiency I-Disease 1 0.9999984502792358
is O 0 1.855992195487488e-05
important O 0 7.878877568145981e-07
because O 0 1.080465722225199e-06
it O 0 3.947350535327132e-08
is O 0 2.9407328128172594e-08
one O 0 1.0580450293673493e-08
of O 0 1.0398450100979062e-08
the O 0 1.700626199863109e-07
few O 0 1.908408421513741e-06
directly O 0 3.1420422601513565e-05
treatable O 1 0.9997934699058533
causes O 0 0.010795092210173607
of O 0 3.553296846803278e-05
cardiomyopathy B-Disease 1 0.9999865293502808
in O 0 1.7346061213174835e-05
children O 0 2.6015691219072323e-06
. O 0 7.023322723398451e-07
. O 0 2.917152187364991e-06

Cloning O 0 1.6336180124199018e-05
of O 0 2.1906217284595186e-07
a O 0 1.0995696584359393e-06
novel O 0 1.0646281225490384e-06
member O 0 1.0959561791423766e-07
of O 0 2.951532884765129e-08
the O 0 4.450897108654317e-07
low O 0 8.847224671626464e-05
- O 0 3.989677134086378e-05
density O 0 3.6283513509260956e-06
lipoprotein O 0 0.003799069207161665
receptor O 0 4.715911563835107e-05
family O 0 2.0921013856423087e-05
. O 0 5.610853349935496e-06

A O 0 4.831204478250584e-06
gene O 0 1.829155053201248e-06
encoding O 0 1.020083686853468e-06
a O 0 1.7530654758957098e-06
novel O 0 3.2728487440181198e-06
transmembrane O 0 7.693144652876072e-06
protein O 0 1.470526285629603e-06
was O 0 1.0868018307519378e-06
identified O 0 8.89895375166816e-08
by O 0 8.042184695966625e-09
DNA O 0 3.1133942002270487e-07
sequence O 0 1.6045638062678336e-07
analysis O 0 7.537693136328016e-08
within O 0 6.512054540053214e-08
the O 0 6.670005632258835e-07
insulin B-Disease 0 0.0015288266586139798
- I-Disease 0 0.10983587801456451
dependent I-Disease 0 0.00335872289724648
diabetes I-Disease 1 0.9999761581420898
mellitus I-Disease 1 0.9998949766159058
( O 0 3.147365714539774e-05
IDDM B-Disease 0 0.0063362992368638515
) O 0 1.7374270555592375e-06
locus O 0 3.281063254689798e-05
IDDM4 O 0 0.00034032808616757393
on O 0 1.0863937859539874e-05
chromosome O 0 0.0003196811012458056
11q13 O 0 0.0003562358324415982
. O 0 8.942057320382446e-06

Based O 0 1.9094989056611666e-06
on O 0 8.596688303441624e-07
its O 0 4.871706664744124e-07
chromosomal O 0 0.00034049456007778645
position O 0 7.04616559232818e-06
, O 0 8.086918512617558e-08
this O 0 1.3293151468474207e-08
gene O 0 2.0514988818831625e-07
is O 0 4.9266610346876405e-08
a O 0 8.812943974589871e-08
candidate O 0 1.1641852637467309e-07
for O 0 2.3898824252910345e-08
conferring O 0 1.2399676961649675e-05
susceptibility O 0 0.00016591422900091857
to O 0 6.727348591084592e-06
diabetes B-Disease 1 0.9988176226615906
. O 0 1.782523759175092e-05

The O 0 2.2528051886183675e-06
gene O 0 1.2169187357358169e-05
, O 0 5.867070171916566e-07
termed O 0 3.55043048330117e-05
low O 0 7.235404336825013e-05
- O 0 2.023150045715738e-05
density O 0 1.6094385273390799e-06
lipoprotein O 0 0.0003489979717414826
receptor O 0 4.107731456315378e-06
related O 0 9.523273547529243e-07
protein O 0 7.567214765913377e-07
5 O 0 3.8243430822149094e-07
( O 0 4.96617253986642e-08
LRP5 O 0 1.2501278433774132e-05
) O 0 2.3333321053087275e-08
, O 0 5.041951744999551e-09
encodes O 0 2.7025651050394117e-08
a O 0 7.738817942026799e-08
protein O 0 1.3664549669556436e-07
of O 0 2.323366743439692e-08
1615 O 0 1.0199903044849634e-05
amino O 0 2.3327008591422782e-07
acids O 0 6.520219386629833e-08
that O 0 8.383193583760828e-10
contains O 0 3.1036799796879677e-09
conserved O 0 1.6315162554292328e-07
modules O 0 9.156585889513735e-08
which O 0 1.2962623863188583e-08
are O 0 2.118573538822943e-09
characteristic O 0 1.335635033683502e-07
of O 0 1.979276298413879e-08
the O 0 5.081004701423808e-07
low O 0 0.00010800382733577862
- O 0 7.390591053990647e-05
density O 0 3.696051862789318e-06
lipoprotein O 0 0.007840191014111042
( O 0 2.428380412311526e-06
LDL O 0 0.001347693963907659
) O 0 5.929671829107974e-07
receptor O 0 6.288439180934802e-06
family O 0 5.033776687923819e-06
. O 0 4.0687045839149505e-06

These O 0 4.293730739846069e-07
modules O 0 1.2401666253936128e-06
include O 0 2.0864062832970376e-07
a O 0 4.348069921888964e-07
putative O 0 3.1004803986434126e-06
signal O 0 1.0378832939750282e-06
peptide O 0 3.1909760878079396e-07
for O 0 3.091467970506301e-09
protein O 0 3.0305940867947356e-08
export O 0 3.5201200176970815e-08
, O 0 2.9468079532080083e-08
four O 0 1.4475619991571875e-07
epidermal O 0 2.696207411645446e-05
growth O 0 3.648573510872666e-06
factor O 0 1.188375222227478e-06
( O 0 1.5620190652043675e-07
EGF O 0 2.3199221686809324e-05
) O 0 1.1129750987493026e-07
repeats O 0 2.8288438898016466e-06
with O 0 1.6435534178071975e-07
associated O 0 1.9574622456275392e-06
spacer O 0 1.9338607671670616e-05
domains O 0 6.5387284848839045e-06
, O 0 4.3286573259138095e-07
three O 0 1.2222200211908785e-06
LDL O 0 0.008198259398341179
- O 0 0.00010695342643884942
receptor O 0 3.777113988689962e-06
( O 0 1.880275419807731e-07
LDLR O 0 1.9316819816594943e-05
) O 0 7.086384812282631e-08
repeats O 0 1.1071573453591554e-06
, O 0 3.0189632127530786e-08
a O 0 8.189848443862502e-08
single O 0 2.9123219746907125e-07
transmembrane O 0 1.8456455563864438e-06
spanning O 0 1.5210637229756685e-06
domain O 0 6.142717552393151e-07
, O 0 7.594653084197489e-08
and O 0 2.5106304590849504e-08
a O 0 5.221218088991009e-07
cytoplasmic O 0 1.072343275154708e-05
domain O 0 1.1797788829426281e-05
. O 0 5.8143382375419606e-06

The O 0 2.565364525253244e-07
encoded O 0 5.474398108162859e-07
protein O 0 1.7506647509435425e-06
has O 0 2.3312308883305377e-07
a O 0 1.058352268046292e-07
unique O 0 1.295876046469857e-07
organization O 0 2.1265122995828278e-07
of O 0 6.719153589074267e-08
EGF O 0 6.935484270798042e-05
and O 0 5.885013365514169e-07
LDLR O 0 0.0003282279649283737
repeats O 0 1.7299211322097108e-05
; O 0 1.0555540796985952e-07
therefore O 0 1.0464651012398463e-07
, O 0 1.4286113980688242e-07
LRP5 O 0 0.000148681880091317
likely O 0 6.976692361604364e-07
represents O 0 9.898495534343965e-08
a O 0 1.731393410864257e-07
new O 0 3.220407620574406e-07
category O 0 2.203714757342823e-06
of O 0 7.905267551677753e-08
the O 0 2.0791871975234244e-06
LDLR O 0 0.0026791042182594538
family O 0 2.0284280253690667e-05
. O 0 4.334674031269969e-06

Both O 0 3.748596327568521e-06
human O 0 4.277021616871934e-06
and O 0 1.1840809293062193e-06
mouse O 0 7.162977271946147e-05
LRP5 O 0 0.0004771035455632955
cDNAs O 0 6.0100694099674e-05
have O 0 1.8124850953427085e-07
been O 0 3.2504479463568714e-07
isolated O 0 6.595756190108659e-07
and O 0 7.417771730189315e-09
the O 0 8.25355872535738e-09
encoded O 0 2.4977580892482365e-08
mature O 0 3.6753658605448436e-07
proteins O 0 1.8914001032044325e-08
are O 0 5.666440205942536e-09
95 O 0 3.705131490505664e-08
% O 0 4.677732423630232e-09
identical O 0 2.742901017427357e-07
, O 0 5.470276320806988e-08
indicating O 0 4.6917099894017156e-07
a O 0 6.713011089232168e-07
high O 0 9.39023811952211e-06
degree O 0 6.043165399205463e-07
of O 0 9.294183200836414e-08
evolutionary O 0 3.6708299830934266e-06
conservation O 0 2.124224920407869e-06
. O 0 3.197083628947439e-07
. O 0 1.341871097793046e-06

The O 0 5.733549642172875e-06
APC B-Disease 0 6.604743248317391e-05
variants O 0 7.161269877542509e-06
I1307K O 0 3.6344019463285804e-05
and O 0 4.032402500797616e-07
E1317Q O 0 1.994253761949949e-05
are O 0 2.1333332256290305e-07
associated O 0 0.0005427968571893871
with O 1 0.9991324543952942
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.292117905104533e-05
but O 0 7.617123287673166e-07
not O 0 6.010397868294604e-08
always O 0 1.6378517386783642e-07
with O 0 6.873221281011865e-08
a O 0 2.9977668418723624e-06
family O 0 8.669214366818778e-06
history O 0 1.629267899261322e-05
. O 0 8.01486021373421e-06

Classical O 1 0.5612531900405884
familial B-Disease 1 0.9998658895492554
adenomatous I-Disease 1 0.9994348883628845
polyposis I-Disease 1 0.9999161958694458
( O 0 0.00017984081932809204
FAP B-Disease 0 0.0014475142816081643
) O 0 8.22254321519722e-07
is O 0 6.793766829105152e-07
a O 0 6.730428594892146e-06
high O 0 0.04409954696893692
- O 1 0.9922544956207275
penetrance O 1 0.969093918800354
autosomal B-Disease 1 0.9983731508255005
dominant I-Disease 1 0.9984092116355896
disease I-Disease 1 0.9995337724685669
that O 0 4.155947408435168e-07
predisposes O 0 9.220795618603006e-06
to O 0 3.691926053761563e-08
hundreds O 0 2.2174843650191178e-07
or O 0 4.3502018343133386e-07
thousands O 0 3.0970552415965358e-06
of O 0 0.0006071854731999338
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999724626541138
and I-Disease 1 0.9927346706390381
carcinoma I-Disease 1 0.9999997615814209
and O 0 2.6111210900126025e-05
that O 0 2.5775918288672983e-07
results O 0 9.287854254580452e-07
from O 0 1.1039221448072567e-07
truncating O 0 1.6535064787603915e-05
mutations O 0 9.211576070811134e-06
in O 0 1.6958483683993109e-07
the O 0 3.8007169678166974e-07
APC B-Disease 0 5.0483613449614495e-05
gene O 0 2.1089479560032487e-05
. O 0 4.638151949620806e-06

A O 0 9.470938675804064e-05
variant O 0 0.0012837491231039166
of O 0 1.50707264765515e-05
FAP B-Disease 0 0.06074156612157822
is O 0 0.00029762089252471924
attenuated B-Disease 1 0.9239927530288696
adenomatous I-Disease 1 0.9993141889572144
polyposis I-Disease 1 0.9986520409584045
coli I-Disease 1 0.9990365505218506
, O 0 9.158276043308433e-06
which O 0 5.970727556814381e-07
results O 0 2.307760041730944e-06
from O 0 5.734997898798611e-07
germ O 0 0.00034598170896060765
- O 0 8.294489089166746e-05
line O 0 1.115607847168576e-05
mutations O 0 2.2033827917766757e-06
in O 0 3.592822039877319e-08
the O 0 3.569257955859939e-08
5 O 0 1.3689304978470318e-07
and O 0 1.818081507565239e-08
3 O 0 9.643007103932177e-08
regions O 0 5.0020304342979216e-08
of O 0 1.6125078161621786e-08
the O 0 3.3912738217622973e-07
APC B-Disease 0 4.8523237637709826e-05
gene O 0 1.9644938220153563e-05
. O 0 3.2935447507043136e-06

Attenuated B-Disease 1 0.9733635783195496
adenomatous I-Disease 1 0.9991577863693237
polyposis I-Disease 1 0.9992032647132874
coli I-Disease 1 0.9995331764221191
patients O 0 0.011301684193313122
have O 0 1.617694351807586e-06
" O 0 7.869574801588897e-06
multiple O 0 0.0008240131428465247
" O 1 0.9858076572418213
colorectal B-Disease 1 0.9999996423721313
adenomas I-Disease 1 0.9997932314872742
( O 0 9.68142899182567e-07
typically O 0 3.3331517101942154e-07
fewer O 0 5.964569282923549e-08
than O 0 1.936922089385007e-08
100 O 0 9.491568420116892e-08
) O 0 2.077898919594645e-08
without O 0 4.2860431648250596e-08
the O 0 1.8400990597911004e-07
florid O 0 0.00019455660367384553
phenotype O 0 2.3020731532596983e-05
of O 0 5.263061666482827e-07
classical O 0 0.00015571679978165776
FAP B-Disease 0 0.0026218174025416374
. O 0 1.8627393728820607e-05

Another O 0 1.0312499398423824e-05
group O 0 1.7537042822368676e-06
of O 0 1.8419531500057928e-07
patients O 0 3.111849537162925e-06
with O 0 1.328949252865641e-07
multiple O 0 2.6410452846903354e-05
adenomas B-Disease 0 0.23282679915428162
has O 0 2.7210569442104315e-06
no O 0 4.1898965719155967e-07
mutations O 0 2.2761712443752913e-06
in O 0 5.2568012165465916e-08
the O 0 6.859038848006094e-08
APC B-Disease 0 3.945193839172134e-06
gene O 0 7.970876936269633e-07
, O 0 4.1515530568858594e-08
and O 0 2.05725836366355e-08
their O 0 5.268053016038721e-08
phenotype O 0 1.6407939256168902e-05
probably O 0 1.8629099258760107e-06
results O 0 2.6397947294753976e-07
from O 0 1.817148920224554e-08
variation O 0 2.5350755095132627e-07
at O 0 1.3647857031173771e-06
a O 0 3.212487342807435e-07
locus O 0 2.4765965918049915e-06
, O 0 5.491351018349633e-08
or O 0 7.467004081718187e-08
loci O 0 7.11988889179338e-07
, O 0 9.117373878098078e-08
elsewhere O 0 4.4016988454131933e-07
in O 0 9.493579256059093e-08
the O 0 4.2077033413079334e-07
genome O 0 1.1401916708564386e-05
. O 0 1.9476674424367957e-06

Recently O 0 0.00033770661684684455
, O 0 1.0434231398903648e-06
however O 0 2.4092565809041844e-07
, O 0 8.081459412778713e-08
a O 0 6.640315177719458e-07
missense O 0 4.9051293899537995e-05
variant O 0 7.69983817008324e-05
of O 0 6.503142344627122e-07
APC B-Disease 0 9.052720270119607e-05
( O 0 3.947054096897773e-07
I1307K O 0 1.2053006685164291e-05
) O 0 1.5895402327714692e-07
was O 0 2.9573257052106783e-06
described O 0 5.168722623238864e-07
that O 0 1.496897183983492e-08
confers O 0 3.905249741364969e-07
an O 0 1.1442752878565443e-07
increased O 0 5.022239747631829e-06
risk O 0 0.00194124027621001
of O 0 0.12970267236232758
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.802582098927815e-06
including O 0 1.047452997227083e-06
multiple O 0 8.877665095496923e-05
adenomas B-Disease 0 0.3193188011646271
, O 0 2.1854125407116953e-06
in O 0 2.4304886210302357e-06
Ashkenazim O 0 0.001283913035877049
. O 0 2.5740160708664916e-05

We O 0 3.0952453471400077e-06
have O 0 1.1125909082920771e-07
studied O 0 5.242013116912858e-07
a O 0 1.3055191061539517e-07
set O 0 1.6569022420753754e-07
of O 0 1.2332699839134875e-07
164 O 0 1.7184474927489646e-05
patients O 0 1.1754426850529853e-05
with O 0 7.753097634122241e-06
multiple O 1 0.9950467348098755
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999181032180786
and I-Disease 0 0.0016105197137221694
/ I-Disease 1 0.9457690119743347
or I-Disease 0 0.30336976051330566
carcinoma I-Disease 1 0.999998927116394
and O 0 2.5022220143000595e-05
analyzed O 0 8.440956298727542e-05
codons O 0 5.543280713027343e-05
1263 O 0 0.0007738342974334955
- O 0 0.0003072839754167944
1377 O 0 0.00029627553885802627
( O 0 1.4874191265334957e-06
exon O 0 5.638925722450949e-05
15G O 0 4.578193329507485e-05
) O 0 4.3702776508780516e-08
of O 0 1.795988779917934e-08
the O 0 1.4598855102576636e-07
APC B-Disease 0 5.048131242801901e-06
gene O 0 1.0793555702548474e-06
for O 0 1.6235598820912855e-07
germ O 0 0.0004636924422811717
- O 0 9.967308142222464e-05
line O 0 2.5086996174650267e-05
variants O 0 1.8633681975188665e-05
. O 0 7.675755114178173e-06

Three O 0 7.754273610771634e-06
patients O 0 8.15008479548851e-06
with O 0 1.236440283491902e-07
the O 0 1.98027208853091e-07
I1307K O 0 4.795610948349349e-06
allele O 0 9.003462650980509e-07
were O 0 1.647907197366294e-07
detected O 0 6.679396392428316e-06
, O 0 2.6951886056281182e-08
each O 0 6.210596481537323e-09
of O 0 9.341992068812033e-08
Ashkenazi O 0 0.00010623793787090108
descent O 0 3.345314325997606e-05
. O 0 3.7597162645397475e-06

Four O 0 1.532790338387713e-05
patients O 0 2.001207394641824e-05
had O 0 1.5352525224443525e-06
a O 0 2.352219325985061e-06
germ O 0 0.0032722651958465576
- O 0 0.00042510777711868286
line O 0 3.514852505759336e-05
E1317Q O 0 4.730329601443373e-05
missense O 0 5.985070310998708e-05
variant O 0 6.723288970533758e-05
of O 0 2.894987289892015e-07
APC O 0 2.451575710438192e-05
that O 0 1.0238569814191578e-07
was O 0 2.6435891413711943e-06
not O 0 4.79387063379022e-09
present O 0 1.0524938254263816e-08
in O 0 1.7275315400411273e-08
controls O 0 3.5539940768103406e-07
; O 0 1.4667802972212485e-08
one O 0 1.0010646533942236e-08
of O 0 3.130815828811251e-09
these O 0 5.08419129019444e-09
individuals O 0 4.186994306820679e-09
had O 0 8.836305909198927e-08
an O 0 1.9955345820221737e-08
unusually O 0 1.4190427464200184e-06
large O 0 7.637346044475635e-08
number O 0 5.415338577563489e-08
of O 0 4.111608973289549e-07
metaplastic B-Disease 0 0.016467813402414322
polyps I-Disease 0 0.012289881706237793
of I-Disease 0 1.18104210855563e-07
the I-Disease 0 2.406983639957616e-06
colorectum I-Disease 0 0.0020622676238417625
. O 0 1.394873015669873e-05

There O 0 2.191726252931403e-06
is O 0 1.9008417950772127e-07
increasing O 0 1.9378575188966352e-07
evidence O 0 8.854510014089101e-08
that O 0 1.0857462484636926e-08
there O 0 3.0694835118083574e-08
exist O 0 1.1679038891543314e-07
germ O 0 5.325196252670139e-05
- O 0 9.458518434257712e-06
line O 0 1.3435292203212157e-06
variants O 0 2.054188854572203e-07
of O 0 1.8270119639396398e-08
the O 0 1.3171681700896443e-07
APC B-Disease 0 4.385183729027631e-06
gene O 0 4.2624827756299055e-07
that O 0 8.115129901398177e-09
predispose O 0 1.3175426261113898e-07
to O 0 3.969599315922778e-09
the O 0 2.2598701576725944e-08
development O 0 1.209326399020938e-07
of O 0 2.88765750156017e-06
multiple O 1 0.9980486631393433
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999901056289673
and I-Disease 1 0.9985139966011047
carcinoma I-Disease 1 0.9999997615814209
, O 0 6.42319573671557e-05
but O 0 8.88829049472406e-07
without O 0 1.5744217307656072e-07
the O 0 3.12207589558966e-07
florid O 0 0.0001826964144129306
phenotype O 0 6.383313575497596e-06
of O 0 1.0574925823902959e-07
classical O 0 2.1741372620454058e-05
FAP B-Disease 0 8.57991399243474e-05
, O 0 1.3466126347339014e-07
and O 0 8.637739767891617e-08
possibly O 0 6.508925025627832e-07
with O 0 1.4760762212517875e-07
importance O 0 3.560528057278134e-05
for O 1 0.7971082925796509
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
risk O 0 0.013670079410076141
in O 0 4.829311706089356e-07
the O 0 2.8833980536546733e-07
general O 0 3.255070168961538e-07
population O 0 4.02421527212482e-08
. O 0 1.7259218054732628e-07
. O 0 1.3998859458297375e-06

Genomic O 0 0.00026009665452875197
structure O 0 0.00010866516822716221
of O 0 1.7168858903460205e-06
the O 0 6.651013245573267e-05
human O 1 0.8209149241447449
congenital B-Disease 1 0.9999985694885254
chloride I-Disease 1 0.999950647354126
diarrhea I-Disease 1 0.9999983310699463
( O 0 0.0001468939008191228
CLD B-Disease 1 0.7255610227584839
) O 0 6.2659423747390974e-06
gene O 0 7.138332875911146e-05
. O 0 1.2213368790980894e-05

Congenital B-Disease 1 0.9999849796295166
chloride I-Disease 1 0.9997135996818542
diarrhea I-Disease 1 0.9999948740005493
( O 0 0.0004975394112989306
CLD B-Disease 1 0.9786093235015869
) O 0 7.096810804796405e-06
is O 0 3.320060386613477e-06
caused O 0 9.768873496796004e-06
by O 0 1.2578580310673715e-07
mutations O 0 2.963751740026055e-06
in O 0 3.890728805799881e-08
a O 0 1.0385274151758495e-07
gene O 0 3.5388015362514125e-07
which O 0 6.664715357374007e-08
encodes O 0 7.803129165040446e-07
an O 0 3.4119032079615863e-06
intestinal O 1 0.9985966086387634
anion O 0 0.0035453811287879944
transporter O 0 0.016427576541900635
. O 0 1.3722988114750478e-05

We O 0 6.793204192945268e-06
report O 0 1.1861977782245958e-06
here O 0 9.815060053597335e-08
the O 0 1.5211776727142023e-08
complete O 0 2.3065312859671394e-07
genomic O 0 1.4530048701999476e-06
organization O 0 2.269957803946454e-07
of O 0 2.209339911019015e-08
the O 0 3.8834414795019256e-07
human O 0 3.6211781662132125e-06
CLD B-Disease 0 0.0012682127999141812
gene O 0 3.5533471418602858e-06
which O 0 1.5470502034986566e-07
spans O 0 5.310168035066454e-06
approximately O 0 2.937174201633752e-07
39kb O 0 5.1192047976655886e-05
, O 0 1.8591335049222835e-07
and O 0 1.2479156907829747e-07
comprises O 0 7.29252803921554e-07
21 O 0 5.266232619760558e-06
exons O 0 3.9715094317216426e-05
. O 0 4.714328952104552e-06

All O 0 4.205756340525113e-06
exon O 0 0.0004295918042771518
/ O 0 4.970908412360586e-05
intron O 0 8.597728447057307e-05
boundaries O 0 8.302633887069533e-07
conform O 0 4.0560516936238855e-06
to O 0 1.0290235508136902e-07
the O 0 7.537131523349672e-07
GT O 0 0.0002855887287296355
/ O 0 0.0007120936643332243
AG O 1 0.9906755685806274
rule O 0 7.226020534290001e-05
. O 0 8.734491530049127e-06

An O 0 6.45753914341185e-07
analysis O 0 7.450066732417326e-07
of O 0 1.1605393268609987e-07
the O 0 3.954423846153077e-07
putative O 0 3.8016471080482006e-05
promoter O 0 0.00011716844892362133
region O 0 1.1944276820941013e-06
sequence O 0 5.440957124847046e-07
shows O 0 5.30460908976238e-07
a O 0 1.3554581528296694e-06
putative O 0 3.2967422157526016e-05
TATA O 0 0.001110968878492713
box O 0 1.8767599613056518e-05
and O 0 2.203345701445869e-07
predicts O 0 2.0952766135451384e-06
multiple O 0 3.971305773120548e-07
transcription O 0 3.4948534448631108e-06
factor O 0 1.0414249800305697e-06
binding O 0 2.225013759016292e-06
sites O 0 3.6516855743684573e-06
. O 0 2.8908591502840864e-06

The O 0 3.222064833607874e-06
genomic O 0 2.162311830034014e-05
structure O 0 3.533505150699057e-05
was O 0 3.639645456132712e-06
determined O 0 1.1847693315303331e-07
using O 0 2.887690087050032e-08
DNA O 0 2.3049746289416362e-07
from O 0 6.571957200662837e-09
several O 0 3.9893035541638255e-09
sources O 0 1.8834441561921267e-08
including O 0 1.4958555283328678e-08
multiple O 0 5.150280344423663e-07
large O 0 4.624887424142798e-06
- O 0 0.0005507803289219737
insert O 0 3.373230356373824e-05
libaries O 0 4.0717168303672224e-05
and O 0 1.3171909074571886e-07
genomic O 0 7.746601113467477e-06
DNA O 0 7.874349648773205e-06
from O 0 1.0566553783064592e-06
Finnish O 0 0.003395496867597103
CLD B-Disease 1 0.7037407159805298
patients O 0 9.148718527285382e-05
and O 0 9.153474707090936e-07
controls O 0 0.00010413732525194064
. O 0 8.111950592137873e-06

Exon O 0 0.0005729122785851359
- O 0 3.531056427164003e-05
specific O 0 3.7015581710875267e-07
primers O 0 4.950642505718861e-06
developed O 0 2.0121563011343824e-06
in O 0 1.9261061368069932e-07
this O 0 2.3833864659650317e-08
study O 0 4.9170854055091695e-08
will O 0 5.422850168912419e-09
facilitate O 0 1.1091415075270561e-07
mutation O 0 3.39250118486234e-06
screening O 0 6.63803575662314e-07
studies O 0 1.6021111548525369e-07
of O 0 7.38520711252022e-08
patients O 0 3.858555373881245e-06
with O 0 6.057342147869349e-07
the O 0 0.00031490836408920586
disease O 1 0.999085545539856
. O 0 1.4760586964257527e-05

Genomic O 0 5.58227147848811e-05
sequencing O 0 5.926301582803717e-06
of O 0 1.0404551176179666e-06
a O 0 1.6935749954427592e-05
BAC O 0 0.0015104442136362195
clone O 0 0.0009800504194572568
H O 1 0.9970303773880005
_ O 0 1.0785483027575538e-05
RG364P16 O 0 2.22728012886364e-05
revealed O 0 2.896140813390957e-06
the O 0 3.5866872138967665e-08
presence O 0 8.537058704405354e-08
of O 0 1.577246422357348e-08
another O 0 1.2826670570120768e-07
, O 0 2.7573300087624375e-08
highly O 0 1.9488660996103135e-07
homologous O 0 1.163346723842551e-06
gene O 0 9.343851274934423e-07
3 O 0 2.1433031349715748e-07
of O 0 1.7921699679845915e-08
the O 0 2.82664672113242e-07
CLD B-Disease 0 0.0003249822184443474
gene O 0 1.2875512993559823e-06
, O 0 3.575853568804632e-08
with O 0 1.4826103011955638e-08
a O 0 1.578947745883852e-07
similar O 0 1.6492404597556742e-07
genomic O 0 1.5101351209523273e-06
structure O 0 5.024381152907154e-06
, O 0 2.35222785249789e-07
recently O 0 4.879448624706129e-06
identified O 0 1.2463557368391776e-06
as O 0 1.3475815876518027e-06
the O 0 8.737001189729199e-05
Pendred B-Disease 1 0.9998983144760132
syndrome I-Disease 1 0.9999958276748657
gene O 0 0.00037821184378117323
( O 0 5.123613846080843e-06
PDS B-Disease 0 0.002617425750941038
) O 0 6.066453011044359e-07
. O 0 5.890123020435567e-07
. O 0 3.2561554235144285e-06

The O 0 1.3357322131923866e-05
APCI1307K O 0 0.0009569942485541105
allele O 0 0.00013514629972632974
and O 0 6.943590415176004e-05
cancer B-Disease 1 0.9991227984428406
risk O 0 0.00013078727351967245
in O 0 1.2816789762837288e-07
a O 0 3.951894314013771e-07
community O 0 2.8054628842255624e-07
- O 0 1.5999999959603883e-05
based O 0 1.7880768155009719e-07
study O 0 8.235101489617591e-08
of O 0 5.8231009347764484e-08
Ashkenazi O 0 4.3389241909608245e-05
Jews O 0 3.375799224158982e-06
. O 0 7.053728950268123e-06

Mutations O 0 0.0010426483349874616
in O 0 7.282837486854987e-06
APC O 0 0.0002154592948500067
are O 0 1.2114473975088913e-06
classically O 0 0.059759292751550674
associated O 0 0.00024287504493258893
with O 0 0.0012709007132798433
familial B-Disease 1 0.9999585151672363
adenomatous I-Disease 1 0.9997954964637756
polyposis I-Disease 1 0.9999321699142456
( O 0 0.00020776181190740317
FAP B-Disease 0 0.0010264355223625898
) O 0 6.307643616310088e-07
, O 0 3.5160644529241836e-07
a O 0 7.16047043169965e-06
highly O 0 0.0024065629113465548
penetrant O 1 0.9919508695602417
autosomal B-Disease 1 0.9999728202819824
dominant I-Disease 1 0.9998050332069397
disorder I-Disease 1 0.9999973773956299
characterized O 1 0.9751083850860596
by O 0 0.00015163488569669425
multiple O 1 0.9909555315971375
intestinal O 1 0.9999839067459106
polyps B-Disease 1 0.9984511137008667
and O 0 4.485476893023588e-06
, O 0 3.7243756878524437e-07
without O 0 5.904785780330712e-07
surgical O 0 0.0005608951905742288
intervention O 0 3.1171514365269104e-06
, O 0 8.437341136868781e-08
the O 0 2.5735732833709335e-07
development O 0 5.351357231120346e-06
of O 0 0.14591196179389954
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 7.439330511260778e-05
CRC B-Disease 0 0.003685358678922057
) O 0 2.3710592813586118e-06
. O 0 4.100897058378905e-06

APC B-Disease 0 0.0022637664806097746
is O 0 2.1591384211205877e-05
a O 0 9.95217778836377e-05
tumour O 1 0.9997932314872742
- O 0 0.00022957238252274692
suppressor O 0 4.104097024537623e-05
gene O 0 3.5349194149603136e-06
, O 0 2.0241748188709607e-07
and O 0 2.740905813425343e-07
somatic O 0 4.38498827861622e-05
loss O 0 0.008431894704699516
occurs O 0 5.380483707995154e-05
in O 0 5.361905641620979e-05
tumours B-Disease 1 0.9998326301574707
. O 0 5.604727630270645e-05

The O 0 1.7491611288278364e-05
germline O 0 0.0016061278292909265
T O 0 0.013917847536504269
- O 0 3.174171069986187e-05
to O 0 2.4897562411752006e-07
- O 0 1.0537578418734483e-05
A O 0 1.7508166365587385e-06
transversion O 0 1.0303064300387632e-05
responsible O 0 5.741674726778001e-07
for O 0 2.539328569639565e-08
the O 0 1.2430730578216753e-07
APC O 0 4.921007075608941e-06
I1307K O 0 3.6928527151758317e-06
allele O 0 5.26897792951786e-07
converts O 0 2.3525485914888122e-07
the O 0 1.1055467297182986e-07
wild O 0 1.6217692291320418e-06
- O 0 1.114201222662814e-05
type O 0 3.2694701985747088e-06
sequence O 0 5.532288014364894e-07
to O 0 7.052916828342859e-08
a O 0 7.153740625653882e-06
homopolymer O 0 0.016656219959259033
tract O 0 0.4818909168243408
( O 0 1.3132740832588752e-06
A8 O 0 0.0023517266381531954
) O 0 1.9594423861235555e-07
that O 0 5.832615812551012e-08
is O 0 3.6582730444933986e-07
genetically O 0 6.092559488024563e-06
unstable O 0 0.015798188745975494
and O 0 2.530479378037853e-06
prone O 0 0.001121225068345666
to O 0 3.6346605725157133e-07
somatic O 0 7.551036105724052e-05
mutation O 0 0.00026752258418127894
. O 0 7.074782843119465e-06

The O 0 3.9373499021166936e-06
I1307K O 0 3.3805754355853423e-05
allele O 0 1.0520147952775005e-05
was O 0 1.9657622033264488e-05
found O 0 8.784210194789921e-07
in O 0 4.720181436823623e-07
6 O 0 1.7440444935346022e-05
. O 0 3.426210923862527e-06

1 O 0 8.390907169086859e-06
% O 0 2.33204261235187e-07
of O 0 2.399769982730504e-07
unselected O 0 0.0007669802289456129
Ashkenazi O 0 0.00031046956428326666
Jews O 0 2.142016910511302e-06
and O 0 1.1250741636104067e-06
higher O 0 6.574877261300571e-06
proportions O 0 3.1429142836714163e-05
of O 0 1.0253754112454772e-07
Ashkenazim O 0 2.7539366783457808e-05
with O 0 6.136405659162847e-07
family O 0 8.143776540237013e-06
or O 0 6.887275389999559e-07
personal O 0 3.682618626044132e-06
histories O 0 1.316004909313051e-05
of O 0 1.0542336212893133e-06
CRC B-Disease 0 0.00136140629183501
( O 0 1.0107073649123777e-06
ref O 0 0.0007799269515089691
. O 0 3.8074355757089506e-07
2 O 0 1.3472410955728265e-06
) O 0 3.2100251701194793e-07
. O 0 1.4223840025806567e-06

To O 0 7.8744307074885e-07
evaluate O 0 4.012430508737452e-06
the O 0 2.2463551374585222e-07
role O 0 1.131782937591197e-06
of O 0 5.416133035396342e-07
I1307K O 0 7.684368029003963e-05
in O 0 1.5213396181934513e-05
cancer B-Disease 1 0.9006163477897644
, O 0 2.2299347790522006e-07
we O 0 3.1479376616516674e-07
genotyped O 0 3.78107069991529e-05
5 O 0 1.1525071386131458e-06
, O 0 2.2980650271620107e-07
081 O 0 9.04159969650209e-05
Ashkenazi O 0 5.246422369964421e-05
volunteers O 0 1.6248886822722852e-06
in O 0 1.0457248578177314e-07
a O 0 7.558812171737372e-07
community O 0 1.1583770174183883e-06
survey O 0 1.2324368981353473e-05
. O 0 2.529943685658509e-06

Risk O 0 0.000753146770875901
of O 0 6.302811925706919e-06
developing O 0 0.042288973927497864
colorectal B-Disease 1 0.9999979734420776
, I-Disease 0 0.0001688493648543954
breast I-Disease 1 0.9345329403877258
and I-Disease 0 8.344991897502041e-07
other I-Disease 0 3.076235941534833e-07
cancers I-Disease 1 0.7603582143783569
were O 0 2.0950557200194453e-07
compared O 0 1.2981757890884182e-06
between O 0 5.452930622595886e-07
genotyped O 0 4.147121944697574e-05
I1307K O 0 8.291853191622067e-06
carriers O 0 8.276166454379563e-07
and O 0 5.666486657673886e-08
non O 0 6.056770303075609e-07
- O 0 4.127183728996897e-06
carriers O 0 2.293716647727706e-07
and O 0 9.218088514728606e-09
their O 0 9.099615283503226e-09
first O 0 3.0066516387705633e-07
- O 0 2.2064205040805973e-05
degree O 0 1.1794061265391065e-06
relatives O 0 2.8934298370586475e-06
. O 0 2.1497710349649424e-06

Sperm O 0 4.203105345368385e-05
DNA O 0 2.2421216272050515e-05
analysis O 0 1.3627658290715772e-06
in O 0 8.448699873042642e-07
a O 0 1.9199900634703226e-05
Friedreich B-Disease 1 0.9356700778007507
ataxia I-Disease 1 0.9967541098594666
premutation O 1 0.6030832529067993
carrier O 0 0.0009956633439287543
suggests O 0 2.406285830147681e-06
both O 0 1.5755257720684313e-07
meiotic O 0 2.325739296793472e-05
and O 0 1.977018939669506e-07
mitotic O 0 1.566013270348776e-05
expansion O 0 5.525830601982307e-06
in O 0 2.9338315243876423e-07
the O 0 5.76204115532164e-07
FRDA B-Disease 0 0.0004967277054674923
gene O 0 4.677461038227193e-05
. O 0 8.796099791652523e-06

Friedreich B-Disease 1 0.9815056920051575
ataxia I-Disease 1 0.9978060126304626
is O 0 0.0007598160882480443
usually O 0 4.277071275282651e-05
caused O 0 2.4679184207343496e-05
by O 0 5.439002137563875e-08
an O 0 1.0145821249807341e-07
expansion O 0 2.1495231976587093e-06
of O 0 8.717466215557579e-08
a O 0 5.536227035918273e-06
GAA O 0 0.000283498753560707
trinucleotide O 0 0.00033208270906470716
repeat O 0 9.327645784651395e-06
in O 0 4.171111243067571e-07
intron O 0 2.1256404579617083e-05
1 O 0 4.675469256198994e-07
of O 0 4.286370014483509e-08
the O 0 4.1069924350267684e-07
FRDA B-Disease 0 0.0007342417375184596
gene O 0 4.491702566156164e-05
. O 0 8.619406798970886e-06

Occasionally O 0 6.336150545394048e-05
, O 0 4.0149387814381043e-07
a O 0 1.9522238403624215e-07
fully O 0 7.123284149201936e-07
expanded O 0 5.333578769750602e-07
allele O 0 1.6684265347066685e-06
has O 0 4.785651412930747e-07
been O 0 1.4783499580062198e-07
found O 0 3.5508698204012035e-08
to O 0 8.85033557551651e-09
arise O 0 1.1936450050598069e-07
from O 0 1.4094028166766748e-08
a O 0 7.707986782179432e-08
premutation O 0 4.145633283769712e-06
of O 0 1.6077660092150836e-08
100 O 0 1.837980505570158e-07
or O 0 2.542120682846871e-07
less O 0 1.642379743316269e-06
triplet O 0 0.0016995957121253014
repeats O 0 0.0003616303438320756
. O 0 1.0163782462768722e-05

We O 0 6.365988156176172e-06
have O 0 2.627179753744713e-07
examined O 0 2.1144264792383183e-06
the O 0 6.242009931156645e-08
sperm O 0 6.21255935584486e-07
DNA O 0 1.1584222647798015e-06
of O 0 8.143740615196293e-08
a O 0 4.10628581448691e-06
premutation O 0 0.0013297112891450524
carrier O 0 0.0007848753593862057
. O 0 1.2149173016950954e-05

This O 0 7.724158876953879e-07
mans O 0 2.388675966358278e-05
leucocyte O 0 7.353592081926763e-05
DNA O 0 4.371730028651655e-06
showed O 0 1.3815067632094724e-06
one O 0 4.286590993274331e-08
normal O 0 2.2154402756768832e-07
allele O 0 1.2688363426605065e-07
and O 0 1.0824563467792814e-08
one O 0 9.906670150883201e-09
allele O 0 1.5427805521994742e-07
of O 0 1.6631547694601068e-08
approximately O 0 9.001602307989742e-08
100 O 0 5.841656047778088e-07
repeats O 0 2.952407521661371e-05
. O 0 4.384096428111661e-06

His O 0 3.3613557661738014e-06
sperm O 0 2.751305146375671e-06
showed O 0 1.6715574702175218e-06
an O 0 2.260413189958399e-08
expanded O 0 4.123027679270308e-07
allele O 0 1.147478656093881e-06
in O 0 1.5101812778084422e-07
a O 0 3.5852684732162743e-07
tight O 0 6.839012712589465e-06
range O 0 5.535316631721798e-07
centering O 0 9.265736480301712e-07
on O 0 4.281684198303992e-07
a O 0 2.641678520376445e-07
size O 0 9.972208090403e-07
of O 0 9.526773681045597e-08
approximately O 0 4.731403180358029e-07
320 O 0 9.929874067893252e-06
trinucleotide O 0 0.0007975039770826697
repeats O 0 0.00020928298181388527
. O 0 6.517361725855153e-06

His O 0 4.8099886043928564e-05
affected O 0 6.805643351981416e-05
son O 0 0.0023758881725370884
has O 0 4.591163815348409e-06
repeat O 0 8.730660738365259e-06
sizes O 0 5.186149792280048e-06
of O 0 2.8479797720137867e-07
1040 O 0 0.0001364907220704481
and O 0 9.471726798437885e-07
540 O 0 1.730257827148307e-05
. O 0 5.201231942919549e-06

These O 0 5.989604687783867e-07
data O 0 8.895676728570834e-07
suggest O 0 4.156625266205083e-07
that O 0 2.9377501320482224e-08
expansion O 0 3.911582382443157e-07
occurs O 0 1.2705969254511729e-07
in O 0 1.0675869077658717e-08
two O 0 1.100213697924346e-08
stages O 0 7.013925369392382e-07
, O 0 1.7948586616967077e-08
the O 0 1.552669104398774e-08
first O 0 9.449283311369072e-08
during O 0 1.8757458519758075e-07
meiosis O 0 7.590799668832915e-07
followed O 0 1.3610730320579023e-07
by O 0 1.9637612425071893e-08
a O 0 1.818775814399487e-07
second O 0 1.3272398291519494e-06
mitotic O 0 4.072955562151037e-05
expansion O 0 3.888473293045536e-05
. O 0 7.265445674420334e-06

We O 0 1.910498895085766e-06
also O 0 1.0915793779986416e-07
show O 0 1.0800479799399909e-07
that O 0 5.166235883535819e-09
in O 0 1.538055371952396e-08
all O 0 1.555329975921893e-09
informative O 0 1.504092779214261e-07
carrier O 0 4.0824947973305825e-06
father O 0 4.6549499188586196e-07
to O 0 1.4506653656098933e-08
affected O 0 2.2465565052698366e-07
child O 0 7.566724775642797e-07
transmissions O 0 2.7601247438724386e-06
, O 0 4.1034525111172115e-08
with O 0 1.5392791041790588e-08
the O 0 5.9285920173124396e-08
notable O 0 1.8072155683057645e-07
exception O 0 1.771463615796165e-07
of O 0 2.2369397001398283e-08
the O 0 3.6288454907662526e-07
premutation O 0 0.00010416642908239737
carrier O 0 2.1482897864189e-05
, O 0 5.0325194678180196e-08
the O 0 3.5098221218277104e-08
expansion O 0 1.3718910167881404e-06
size O 0 4.3881204874196555e-06
decreases O 0 1.2546568541438319e-05
. O 0 5.861779754923191e-07
. O 0 1.548629711578542e-06

The O 0 8.624093425169121e-06
R496H O 0 0.00015083470498211682
mutation O 0 6.159694748930633e-05
of O 0 4.941746851727657e-07
arylsulfatase O 0 0.0007837028242647648
A O 0 6.847078475402668e-05
does O 0 7.598414413223509e-06
not O 0 9.13247640710324e-06
cause O 0 0.008121289312839508
metachromatic B-Disease 1 0.9986722469329834
leukodystrophy I-Disease 1 0.9992662072181702
. O 0 0.00017901003593578935

Deficiency B-Disease 1 0.998248815536499
of I-Disease 0 1.2170219633844681e-05
arylsulfatase I-Disease 0 0.008738123811781406
A I-Disease 0 0.00017452736210543662
( O 0 2.7803828288597288e-06
ARSA O 0 0.004412653855979443
) O 0 1.4921686215529917e-06
enzyme O 0 2.481145565980114e-05
activity O 0 5.7343666412634775e-05
causes O 0 0.01652413234114647
metachromatic B-Disease 1 0.9995885491371155
leukodystrophy I-Disease 1 0.9998724460601807
( O 0 0.0008984986343421042
MLD B-Disease 1 0.9988062381744385
) O 0 1.0721449143602513e-05
. O 0 1.1117451322206762e-05

A O 0 1.0865202057175338e-05
number O 0 5.421528044280421e-07
of O 0 8.225248961934994e-07
ARSA O 0 0.004372795578092337
gene O 0 4.633941352949478e-05
mutations O 0 0.0001083244860637933
responsible O 0 1.5594943761243485e-05
for O 0 3.5188556921639247e-06
MLD B-Disease 1 0.9992651343345642
have O 0 2.4049163585004862e-06
been O 0 3.5988277886644937e-06
identified O 0 8.555642125429586e-06
. O 0 2.0277677776903147e-06

Recently O 0 0.00016501634672749788
, O 0 4.909236963612784e-07
the O 0 3.6263580227569037e-07
R496H O 0 2.8856071367044933e-05
mutation O 0 7.798205842846073e-06
of O 0 1.715944932811908e-07
ARSA O 0 0.006931222975254059
was O 0 1.5122295735636726e-05
proposed O 0 3.680329143662675e-07
to O 0 2.8392520334818983e-08
be O 0 9.835149228365481e-08
a O 0 2.1142168407095596e-06
cause O 0 3.1382784072775394e-05
of O 0 1.8198842326455633e-06
MLD B-Disease 1 0.9982092380523682
( O 0 2.997189540110412e-06
Draghia O 0 0.00018135686696041375
et O 0 0.0001584647543495521
al O 0 1.9536053514457308e-05
. O 0 2.7823725190501136e-07
, O 0 3.8030083260309766e-07
1997 O 0 4.798150257556699e-06
) O 0 3.836375697119365e-07
. O 0 1.1522367913130438e-06

We O 0 3.4925176350952825e-06
have O 0 1.8656250233561877e-07
investigated O 0 3.2500684028491378e-06
the O 0 1.5561384714146698e-07
R496H O 0 9.631739885662682e-06
mutation O 0 3.822508460871177e-06
and O 0 4.922246432670363e-08
found O 0 1.091156818233685e-07
this O 0 1.446738906452083e-08
mutation O 0 4.201532419756404e-07
at O 0 1.5549932186331716e-07
a O 0 4.7007119974296074e-08
relatively O 0 1.626437722279661e-07
high O 0 6.609962497350352e-07
frequency O 0 1.3584147495748766e-07
in O 0 1.3541897381230683e-08
an O 0 3.3115914455095208e-09
African O 0 1.7079882397297297e-08
American O 0 2.7573774374900495e-08
population O 0 8.269679163674937e-09
( O 0 4.443996104441794e-08
f O 0 3.505334461806342e-06
= O 0 7.78419064317859e-07
0 O 0 5.2890850810172196e-08
. O 0 1.6710851369339252e-08
09 O 0 1.4662202829640592e-06
, O 0 5.410548453710362e-08
n O 0 1.8788140323522384e-06
= O 0 3.3674907626846107e-06
61 O 0 2.3276484171219636e-06
subjects O 0 1.6757154526203522e-06
) O 0 6.165354307086091e-07
. O 0 1.4988448810981936e-06

The O 0 1.629690632398706e-05
ARSA O 0 0.0021342188119888306
enzyme O 0 1.8419057596474886e-05
activity O 0 2.285790742462268e-06
in O 0 7.617516928348778e-08
subjects O 0 3.240126318360126e-07
with O 0 1.0208033529579552e-07
and O 0 1.58651587867098e-07
without O 0 1.1951189549108676e-07
the O 0 1.2478098199153465e-07
R496H O 0 9.656214388087392e-06
mutation O 0 7.986842319951393e-06
was O 0 2.6827672172657913e-06
determined O 0 2.4130736164806876e-07
and O 0 2.22235705393814e-08
found O 0 8.962472719531434e-08
to O 0 1.307189290145061e-08
be O 0 2.2207072447599785e-07
normal O 0 5.961486294836504e-06
. O 0 1.5390287444461137e-06

It O 0 3.224216470698593e-06
is O 0 7.543762308159785e-07
therefore O 0 3.2701731811357604e-07
concluded O 0 1.33334981455846e-06
that O 0 1.6124555912711003e-08
the O 0 1.1546233480430601e-07
R496H O 0 1.4971481505199336e-05
mutation O 0 7.098360583768226e-06
of O 0 3.0740304168830335e-07
ARSA O 0 0.0032339105382561684
does O 0 6.467578828051046e-07
not O 0 4.8210512915147774e-08
negatively O 0 2.3659855230562243e-07
influence O 0 1.2951902306213015e-07
the O 0 5.467981267770483e-08
activity O 0 3.054841499761096e-07
of O 0 1.022763953528738e-07
ARSA O 0 0.002167612547054887
and O 0 8.232437380684132e-07
is O 0 4.195862572942133e-07
not O 0 1.2248939640358003e-07
a O 0 7.874274160712957e-06
cause O 0 0.00021559822198469192
of O 0 2.466520709276665e-05
MLD B-Disease 1 0.9978871941566467

Down O 0 0.0021652954164892435
- O 0 0.000206944125238806
regulation O 0 1.33753455884289e-05
of O 0 7.730430411356792e-07
transmembrane O 0 0.00032680260483175516
carbonic O 0 0.001973931910470128
anhydrases O 0 0.002743060700595379
in O 0 8.670295937918127e-05
renal B-Disease 1 0.9998939037322998
cell I-Disease 1 0.9997907280921936
carcinoma I-Disease 1 0.9999990463256836
cell O 0 0.4869704246520996
lines O 0 0.00018481908773537725
by O 0 1.2508712643466424e-06
wild O 0 5.584852988249622e-05
- O 0 0.010933526791632175
type O 0 0.004199954215437174
von B-Disease 1 0.9765081405639648
Hippel I-Disease 1 0.9727732539176941
- I-Disease 0 0.44093966484069824
Lindau I-Disease 0 0.30527809262275696
transgenes O 0 0.005669953767210245
. O 0 4.526774137048051e-05

To O 0 1.8495198901291587e-06
discover O 0 1.3060314813628793e-05
genes O 0 6.3932070588634815e-06
involved O 0 4.165758582530543e-06
in O 0 7.090506642271066e-06
von B-Disease 1 0.9634033441543579
Hippel I-Disease 1 0.9902689456939697
- I-Disease 1 0.9890131950378418
Lindau I-Disease 1 0.9104650616645813
( O 0 1.2523497389338445e-05
VHL B-Disease 0 0.005763869266957045
) O 0 1.7255940747418208e-06
- O 0 2.7894186132471077e-05
mediated O 0 5.657416477333754e-05
carcinogenesis O 0 0.0028235805220901966
, O 0 5.715287443308625e-07
we O 0 6.412060429283883e-07
used O 0 2.6683414034778252e-05
renal B-Disease 1 0.9999004602432251
cell I-Disease 1 0.9997429251670837
carcinoma I-Disease 1 0.9999986886978149
cell O 0 0.15713556110858917
lines O 0 0.0002508938196115196
stably O 0 0.00041175467777065933
transfected O 0 0.0002177868300350383
with O 0 3.1012314138934016e-06
wild O 0 6.15597891737707e-05
- O 0 0.007933174259960651
type O 0 0.005590118933469057
VHL O 1 0.8378709554672241
- O 0 0.0019880051258951426
expressing O 0 1.929054815263953e-05
transgenes O 0 0.0004762552271131426
. O 0 1.1067552804888692e-05

Large O 0 1.513891857030103e-05
- O 0 2.4649336410220712e-05
scale O 0 5.281648554955609e-06
RNA O 0 3.394433178982581e-06
differential O 0 2.014725623666891e-06
display O 0 6.834682153566973e-07
technology O 0 7.674618132114119e-07
applied O 0 1.2263853932381608e-07
to O 0 1.380127301331413e-08
these O 0 1.8396809409182424e-08
cell O 0 4.955020813213196e-06
lines O 0 3.447920107646496e-06
identified O 0 4.100937474049715e-07
several O 0 4.017803334477321e-08
differentially O 0 1.7563352230354212e-06
expressed O 0 9.565246017473328e-08
genes O 0 1.9730408951090794e-07
, O 0 3.4950186744708844e-08
including O 0 1.5880532444612072e-08
an O 0 2.2516357489621441e-07
alpha O 0 6.420042154786643e-06
carbonic O 0 0.00013154758198652416
anhydrase O 0 0.00016450828115921468
gene O 0 9.718424735183362e-06
, O 0 1.3163223684387049e-06
termed O 0 0.0001636927481740713
CA12 O 0 0.0070016165263950825
. O 0 1.6871012121555395e-05

The O 0 1.1586973869270878e-06
deduced O 0 3.3690100735839223e-06
protein O 0 1.3739178257310414e-06
sequence O 0 8.15392695585615e-07
was O 0 2.2571362023882102e-06
classified O 0 5.822944899591675e-07
as O 0 6.140889752259682e-08
a O 0 5.581380833064031e-07
one O 0 6.548111741722096e-07
- O 0 9.473431418882683e-05
pass O 0 1.1599884601309896e-05
transmembrane O 0 0.0002384691615588963
CA O 0 1.818210876081139e-05
possessing O 0 3.508889108161384e-07
an O 0 1.179920801064327e-07
apparently O 0 1.1380733440091717e-06
intact O 0 1.0397289997854386e-06
catalytic O 0 2.1601431399176363e-06
domain O 0 3.4745639254651906e-07
in O 0 6.261709017962858e-08
the O 0 2.805222152346687e-07
extracellular O 0 2.2911484848009422e-05
CA O 0 0.0006479238509200513
module O 0 0.0001611848419997841
. O 0 5.193083779886365e-06

Reintroduced O 0 0.00024817095254547894
wild O 0 0.0002273351710755378
- O 0 0.005776685196906328
type O 0 0.0007507759728468955
VHL B-Disease 0 0.009406499564647675
strongly O 0 4.126656222069869e-06
inhibited O 0 2.0519109966699034e-06
the O 0 8.616824942464518e-08
overexpression O 0 1.1065567377954721e-06
of O 0 2.2016878986619304e-08
the O 0 1.2798176385331317e-07
CA12 O 0 7.980333612067625e-05
gene O 0 2.380711748628528e-06
in O 0 4.310285248720902e-07
the O 0 2.1548369204538176e-06
parental O 0 0.0005223939078859985
renal B-Disease 1 0.9999067783355713
cell I-Disease 1 0.9998016953468323
carcinoma I-Disease 1 0.9999991655349731
cell O 1 0.9960052371025085
lines O 0 0.013288385234773159
. O 0 5.2755051001440734e-05

Similar O 0 1.5802033885847777e-05
results O 0 5.609317668131553e-06
were O 0 8.515137039921683e-08
obtained O 0 1.6102893596325885e-07
with O 0 2.2882981909333466e-07
CA9 O 0 0.0006278228829614818
, O 0 1.5448785006810795e-07
encoding O 0 4.3619252210191917e-07
another O 0 4.8242618504446e-06
transmembrane O 0 0.0003021031734533608
CA O 0 6.810961349401623e-05
with O 0 1.7709332666981936e-07
an O 0 2.905126450514217e-07
intact O 0 3.140293119940907e-05
catalytic O 0 6.420996214728802e-05
domain O 0 1.5973047993611544e-05
. O 0 6.554686024173861e-06

Although O 0 1.5235825685522286e-06
both O 0 1.746406184111038e-07
domains O 0 1.328401026512438e-06
of O 0 4.551152699150407e-08
the O 0 6.005677164466761e-07
VHL B-Disease 0 0.00048490799963474274
protein O 0 1.2087008371963748e-06
contribute O 0 1.0753756640724532e-07
to O 0 1.246548642086509e-08
regulation O 0 6.040935431883554e-07
of O 0 8.867760925568291e-08
CA12 O 0 0.00020881518139503896
expression O 0 1.5356245057773776e-06
, O 0 1.5800414132627338e-07
the O 0 7.037449734070833e-08
elongin O 0 1.004311070573749e-05
binding O 0 9.770659517016611e-07
domain O 0 9.414254122930288e-07
alone O 0 1.1115596407762496e-06
could O 0 2.0390915267398668e-07
effectively O 0 3.925363671442028e-06
regulate O 0 2.0337836758699268e-05
CA9 O 0 0.0022659688256680965
expression O 0 4.081070073880255e-05
. O 0 1.6379455701098777e-05

We O 0 1.3954545465821866e-05
mapped O 0 0.0001346161589026451
CA12 O 0 0.000904470041859895
and O 0 2.1135354018042563e-06
CA9 O 0 0.0012199804186820984
loci O 0 1.96843557205284e-05
to O 0 5.870484756087535e-07
chromosome O 0 7.720291614532471e-05
bands O 0 3.630584251368418e-05
15q22 O 0 7.429767720168456e-05
and O 0 3.4253976082254667e-06
17q21 O 0 0.000257604056969285
. O 0 8.466036888421513e-06

2 O 0 2.5649129383964464e-05
respectively O 0 9.261741070076823e-06
, O 0 9.000749514598283e-07
regions O 0 1.9658093606267357e-06
prone O 0 0.00018154701683670282
to O 0 4.1109103676717496e-08
amplification O 0 3.4666409192141145e-06
in O 0 1.9334677858751093e-07
some O 0 1.4732970043951354e-07
human O 0 2.7373491320759058e-05
cancers B-Disease 1 0.9955635070800781
. O 0 1.0636605111358222e-05

Additional O 0 8.918798926060845e-07
experiments O 0 3.727687953869463e-06
are O 0 1.690296436152039e-08
needed O 0 3.349217081449751e-08
to O 0 3.3839475666042063e-09
define O 0 5.557586391091718e-08
the O 0 2.49245175609758e-08
role O 0 4.877574042438937e-07
of O 0 3.36929161903754e-07
CA O 0 0.0002100100100506097
IX O 0 0.0003272636968176812
and O 0 2.3086163309926633e-06
CA O 0 6.377694080583751e-05
XII O 0 0.00010921731882262975
enzymes O 0 8.412447414229973e-07
in O 0 4.855028024053354e-08
the O 0 6.081513248545889e-08
regulation O 0 7.629395781805215e-07
of O 0 9.042781812240719e-08
pH O 0 3.1056595616973937e-05
in O 0 7.610052676909618e-08
the O 0 7.460299400463555e-08
extracellular O 0 1.6787271306384355e-06
microenvironment O 0 2.6287503715138882e-05
and O 0 8.319216249219608e-08
its O 0 1.0423018181882071e-07
potential O 0 2.136158173016156e-06
impact O 0 1.3201693036535289e-05
on O 0 0.0002643509942572564
cancer B-Disease 1 0.9963248372077942
cell O 0 0.002159633906558156
growth O 0 3.1682284316048026e-05
. O 0 3.18474531013635e-06

A O 0 3.20468006975716e-06
gene O 0 1.2188280607006163e-06
encoding O 0 5.260191642264544e-07
a O 0 6.908444447617512e-07
transmembrane O 0 6.8295225901238155e-06
protein O 0 6.690787586194347e-07
is O 0 8.877695023556953e-08
mutated O 0 2.902461346820928e-06
in O 0 7.294906936294865e-07
patients O 0 2.226214019174222e-05
with O 0 0.00018146773800253868
diabetes B-Disease 1 0.9999904632568359
mellitus I-Disease 1 0.9999833106994629
and O 1 0.9044647812843323
optic B-Disease 1 0.9999884366989136
atrophy I-Disease 1 0.9998656511306763
( O 0 0.1199735477566719
Wolfram B-Disease 1 0.9997413754463196
syndrome I-Disease 1 0.9999971389770508
) O 0 3.6306260881247e-05
. O 0 1.823333150241524e-05

Wolfram B-Disease 1 0.9993686079978943
syndrome I-Disease 1 0.9999960660934448
( O 0 0.0004539066576398909
WFS B-Disease 1 0.8175946474075317
; O 0 2.5361558073200285e-05
OMIM O 0 0.08728401362895966
222300 O 0 0.000625280779786408
) O 0 6.159682470752159e-07
is O 0 8.203197694456321e-07
an O 0 8.678594895172864e-06
autosomal B-Disease 1 0.9990335702896118
recessive I-Disease 1 0.999722421169281
neurodegenerative I-Disease 1 0.999980092048645
disorder I-Disease 1 0.9998212456703186
defined O 0 0.00011165340401930735
by O 0 5.423191396403126e-06
young O 0 5.945715747657232e-05
- O 0 0.010732432827353477
onset O 0 0.07574427127838135
non O 0 0.0003338289097882807
- O 0 0.029790177941322327
immune O 0 0.06502141803503036
insulin B-Disease 0 0.021443787962198257
- I-Disease 0 0.06924095749855042
dependent I-Disease 0 0.0045289285480976105
diabetes I-Disease 1 0.9999730587005615
mellitus I-Disease 1 0.9999558925628662
and O 0 0.010580413043498993
progressive O 1 0.999326229095459
optic B-Disease 1 0.9999744892120361
atrophy I-Disease 1 0.9992258548736572
. O 0 0.0001271162327611819

Linkage O 0 0.00011176631232956424
to O 0 7.674603352825216e-07
markers O 0 2.794394822558388e-05
on O 0 1.0857640518224798e-05
chromosome O 0 0.00022426490613725036
4p O 0 0.006324910558760166
was O 0 4.3560467020142823e-05
confirmed O 0 2.1982486941851676e-06
in O 0 9.245825793868789e-08
five O 0 1.9242591520196584e-07
families O 0 3.295617148069141e-07
. O 0 4.206285666441545e-06

On O 0 2.6575421543384437e-06
the O 0 1.6547608083783416e-07
basis O 0 2.6265408337167173e-07
of O 0 2.656508399923041e-07
meiotic O 0 0.000773075851611793
recombinants O 0 0.020904390141367912
and O 0 0.00035002792719751596
disease O 1 0.9992497563362122
- O 0 0.007026089821010828
associated O 0 1.0402921361674089e-05
haplotypes O 0 2.1006682800361887e-05
, O 0 2.944039181329572e-07
the O 0 4.740571739603183e-07
WFS B-Disease 0 0.00022371755039785057
gene O 0 3.0898538625478977e-06
was O 0 2.6624077236192534e-06
localized O 0 1.888321776277735e-06
to O 0 4.614876658592948e-08
a O 0 1.4634822491643718e-06
BAC O 0 7.367834041360766e-05
/ O 0 8.926142072596122e-06
P1 O 0 3.835048482869752e-05
contig O 0 8.824632459436543e-06
of O 0 2.4111223240197432e-08
less O 0 8.285897479254345e-08
than O 0 7.257118284087483e-08
250 O 0 4.918435934087029e-07
kb O 0 4.7099027142394334e-05
. O 0 5.737153969676001e-06

Mutations O 0 0.0008470098837278783
in O 0 2.474882421665825e-06
a O 0 2.515122332624742e-06
novel O 0 4.952460130880354e-06
gene O 0 9.763293746800628e-06
( O 0 5.036773700339836e-07
WFS1 O 0 2.3028196665109135e-05
) O 0 1.7750243941350163e-08
encoding O 0 1.2568435181492532e-07
a O 0 4.564188316180662e-07
putative O 0 4.809571237274213e-06
transmembrane O 0 3.48723256138328e-06
protein O 0 4.1932625549634395e-07
were O 0 5.3537895894351095e-08
found O 0 9.467882478020329e-08
in O 0 2.3446819596983914e-08
all O 0 1.8455573069786624e-08
affected O 0 1.851643531836089e-07
individuals O 0 1.0991818122363384e-08
in O 0 1.0963911023509354e-07
six O 0 6.931099392204487e-07
WFS B-Disease 0 0.00019239088578615338
families O 0 8.662289729954864e-08
, O 0 4.306939871412396e-08
and O 0 2.7043183692398998e-08
these O 0 1.563367035828378e-08
mutations O 0 1.2919201708427863e-06
were O 0 9.192106631417118e-08
associated O 0 4.546424463569565e-07
with O 0 7.64454455293162e-07
the O 0 0.0002439944801153615
disease O 1 0.9979822635650635
phenotype O 0 0.0021224822849035263
. O 0 9.9089684226783e-06

WFS1 O 0 0.0034617618657648563
appears O 0 1.0562852367002051e-05
to O 0 7.796094081413685e-08
function O 0 6.188616907820688e-07
in O 0 4.1304895148641663e-07
survival O 0 1.406804130965611e-05
of O 0 2.238660528064429e-07
islet O 0 0.00014108528557699174
beta O 0 1.9374230760149658e-05
- O 0 2.85791938949842e-05
cells O 0 1.4209115306584863e-06
and O 0 1.5703221833973657e-07
neurons O 0 2.334442115170532e-06
. O 0 1.8301550142041378e-07
. O 0 1.4398796110981493e-06

Stable O 0 3.117906453553587e-05
interaction O 0 3.184588877047645e-07
between O 0 1.1557723667010578e-07
the O 0 9.528082500764867e-08
products O 0 2.3311842767270718e-07
of O 0 6.784483730370994e-08
the O 0 7.988479069354071e-07
BRCA1 O 0 9.923407924361527e-05
and O 0 2.9298603294591885e-06
BRCA2 O 0 0.0007926856633275747
tumor B-Disease 0 0.005576655734330416
suppressor O 0 2.6736270228866488e-05
genes O 0 1.5839323168620467e-06
in O 0 2.2213936290427228e-07
mitotic O 0 2.3309770767809823e-05
and O 0 1.8603462876853882e-06
meiotic O 0 0.003197641810402274
cells O 0 0.00023886877170298249
. O 0 1.0172529982810374e-05

BRCA1 O 0 0.0017574363155290484
and O 0 3.3934168186533498e-06
BRCA2 O 0 4.92222752654925e-05
account O 0 2.401720564648713e-07
for O 0 4.998015512569509e-08
most O 0 8.168600373892332e-08
cases O 0 2.578324540536414e-07
of O 0 1.2529660864402103e-07
familial O 0 0.002477383939549327
, O 0 4.526658358372515e-06
early O 0 8.094053919194266e-05
onset O 1 0.8631629943847656
breast B-Disease 1 0.9929584264755249
and I-Disease 0 5.53987811144907e-05
/ I-Disease 1 0.9447289109230042
or I-Disease 1 0.9976213574409485
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999915361404419
and O 0 1.6664483837303123e-07
encode O 0 7.349528630129498e-08
products O 0 2.0744920448123594e-07
that O 0 5.363885779985367e-09
each O 0 6.296918542147978e-09
interact O 0 8.893066194559651e-08
with O 0 6.38029803212703e-07
hRAD51 O 0 0.0003104035567957908
. O 0 8.79979143064702e-06

Results O 0 1.1060039469157346e-05
presented O 0 1.2499696140366723e-06
here O 0 2.6256194018969836e-07
show O 0 5.293995855026878e-07
that O 0 7.677130753336314e-08
BRCA1 O 0 7.575962172268191e-06
and O 0 1.8580080052288395e-07
BRCA2 O 0 8.641571184853092e-06
coexist O 0 1.3810641803502222e-06
in O 0 9.213082563519492e-08
a O 0 3.18555464673409e-07
biochemical O 0 1.0159140401810873e-05
complex O 0 6.0416482483560685e-06
and O 0 4.4306281665740244e-07
colocalize O 0 9.359198884340003e-05
in O 0 7.242763899739657e-07
subnuclear O 0 6.880380533402786e-05
foci O 0 1.0915415259660222e-05
in O 0 1.532992115471643e-07
somatic O 0 1.2081719660272938e-06
cells O 0 1.7732564856487443e-06
and O 0 4.217638860382067e-08
on O 0 1.0143925521788333e-07
the O 0 4.7432944683123424e-08
axial O 0 4.27445058903686e-07
elements O 0 1.808394927138579e-07
of O 0 1.4228001532501366e-07
developing O 0 1.3380998098000418e-05
synaptonemal O 0 0.003018326824530959
complexes O 0 0.0007008780376054347
. O 0 3.317453229101375e-05

Like O 0 9.514715929981321e-05
BRCA1 O 0 0.0011908799642696977
and O 0 9.960859642887954e-06
RAD51 O 0 0.016659656539559364
, O 0 4.648464710044209e-06
BRCA2 O 0 6.93396941642277e-05
relocates O 0 1.0031873898697086e-05
to O 0 2.9317226335479063e-07
PCNA O 0 0.00021629332331940532
+ O 0 7.744687536614947e-06
replication O 0 2.9654086119990097e-06
sites O 0 6.463682211688138e-07
following O 0 5.23156984399975e-07
exposure O 0 1.5779371096869e-05
of O 0 2.132621403916346e-07
S O 0 0.00016442796913906932
phase O 0 1.2291021448618267e-05
cells O 0 2.536696229071822e-06
to O 0 1.5524861396443157e-07
hydroxyurea O 0 0.00010549402941251174
or O 0 6.084627784730401e-06
UV O 0 0.0015490773366764188
irradiation O 0 6.203594239195809e-05
. O 0 6.088447207730496e-06

Thus O 0 2.3672548195463605e-05
, O 0 1.9226574750064174e-06
BRCA1 O 0 4.0281254769070074e-05
and O 0 2.3814060057247843e-07
BRCA2 O 0 1.1758867003663909e-05
participate O 0 8.10623745906014e-08
, O 0 1.9274837725902216e-08
together O 0 1.3661285436228354e-08
, O 0 2.6221051996344613e-08
in O 0 2.0051071913940177e-08
a O 0 2.420481450826628e-07
pathway O 0 9.347728564534918e-07
( O 0 9.602152317711443e-08
s O 0 6.4027194639493246e-06
) O 0 3.509862267492281e-08
associated O 0 1.0228907854070712e-07
with O 0 1.589398657131369e-08
the O 0 3.668243309107311e-08
activation O 0 3.672146533517662e-07
of O 0 7.026692827594161e-08
double O 0 1.797894037736114e-05
- O 0 7.758403080515563e-05
strand O 0 1.7233214748557657e-05
break O 0 8.983915904536843e-06
repair O 0 0.0013655467191711068
and O 0 5.184016345083364e-07
/ O 0 1.5034954230941366e-05
or O 0 7.616600328219647e-07
homologous O 0 2.558473170211073e-05
recombination O 0 4.409300527186133e-05
. O 0 4.9368291001883335e-06

Dysfunction O 0 0.22863426804542542
of O 0 9.06161574221187e-07
this O 0 2.942012713447184e-07
pathway O 0 8.584460374549963e-06
may O 0 1.8907004459833843e-06
be O 0 2.9130431400403722e-08
a O 0 9.951101986871436e-08
general O 0 9.799141764688102e-08
phenomenon O 0 1.394799369336397e-06
in O 0 4.26215720494838e-08
the O 0 7.337833096698887e-08
majority O 0 5.933309665806519e-08
of O 0 2.4032345891100704e-08
cases O 0 6.735166380167357e-07
of O 0 8.541315423826745e-07
hereditary B-Disease 1 0.9991451501846313
breast I-Disease 1 0.9995556473731995
and I-Disease 0 0.0004804838099516928
/ I-Disease 1 0.9956961870193481
or I-Disease 1 0.9983579516410828
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999949932098389
. O 0 1.480143782828236e-05
. O 0 5.387097644415917e-06

A O 0 4.688035187427886e-05
novel O 0 2.1121464669704437e-05
Arg362Ser O 0 0.00017708115046843886
mutation O 0 3.9208756788866594e-05
in O 0 3.2858602594387776e-07
the O 0 4.4556836087394913e-07
sterol O 0 0.00032843078952282667
27 O 0 6.60095174680464e-05
- O 0 9.764815331436694e-05
hydroxylase O 0 7.394864223897457e-05
gene O 0 4.233534582454013e-06
( O 0 3.3994274417636916e-07
CYP27 O 0 5.466658330988139e-05
) O 0 5.983084605531985e-08
: O 0 2.1310247788619563e-08
its O 0 1.75082117692682e-08
effects O 0 3.8483284470203216e-07
on O 0 1.6019386350762943e-07
pre O 0 1.3602766557596624e-06
- O 0 4.828791020372591e-07
mRNA O 0 5.712193384965758e-08
splicing O 0 8.210734563363076e-07
and O 0 1.1087057316672144e-07
enzyme O 0 2.4826692879287293e-06
activity O 0 1.7166697716675117e-06
. O 0 1.1000972790498054e-06

A O 0 2.574688733147923e-05
novel O 0 7.451008059433661e-06
C O 0 9.019748176797293e-06
to O 0 3.0582398835576896e-08
A O 0 8.62840067838988e-07
mutation O 0 8.54515235459985e-07
in O 0 4.639164075115332e-08
the O 0 9.187918692532548e-08
sterol O 0 0.0001383884809911251
27 O 0 2.3712813344900496e-05
- O 0 6.451895023928955e-05
hydroxylase O 0 4.999156226404011e-05
gene O 0 2.413597030681558e-06
( O 0 1.8411874691537378e-07
CYP27 O 0 5.366627738112584e-05
) O 0 1.2720033737423364e-07
was O 0 1.8889145394496154e-06
identified O 0 1.862084246795348e-07
by O 0 1.475329636235756e-08
sequencing O 0 4.4853993586002616e-07
amplified O 0 3.910637587978272e-06
CYP27 O 0 3.075532367802225e-05
gene O 0 9.808984486880945e-07
products O 0 2.416018674011866e-07
from O 0 1.874685295888412e-07
a O 0 1.7147897324321093e-06
patient O 0 6.789858889533207e-05
with O 0 1.606323530722875e-05
cerebrotendinous B-Disease 1 0.9993308782577515
xanthomatosis I-Disease 1 0.9989109039306641
( O 0 3.059411028516479e-05
CTX B-Disease 0 0.05264490470290184
) O 0 1.0362126886320766e-05
. O 0 7.161474513850408e-06

The O 0 1.2295242413529195e-05
mutation O 0 7.510676368838176e-05
changed O 0 7.173108770075487e-06
the O 0 2.2086770457008242e-07
adrenodoxin O 0 1.8246499166707508e-05
cofactor O 0 1.072438976734702e-06
binding O 0 1.7054935597116128e-06
residue O 0 4.3331033339200076e-06
362Arg O 0 2.3078033336787485e-05
to O 0 2.706558746012888e-07
362Ser O 0 0.00014254516281653196
( O 0 1.5777270618855255e-06
CGT O 0 0.0019044253276661038
362Arg O 0 0.00017764804942999035
to O 0 1.169760366792616e-06
AGT O 0 0.002228202298283577
362Ser O 0 0.00013154229964129627
) O 0 1.733589130026303e-07
, O 0 6.502857274881535e-08
and O 0 1.1236936359182437e-07
was O 0 2.4372000552830286e-05
responsible O 0 5.454810889204964e-06
for O 0 3.1354575185105205e-06
deficiency O 1 0.9886626601219177
in O 0 1.426403173354629e-07
the O 0 2.903724976022204e-07
sterol O 0 0.00014683787594549358
27 O 0 2.113278787874151e-05
- O 0 1.7396425391780213e-05
hydroxylase O 0 1.3805394701194018e-05
activity O 0 2.4106356022457476e-07
, O 0 1.2399989479661144e-08
as O 0 2.1757179169412666e-08
confirmed O 0 6.490180481932839e-08
by O 0 3.4505320822830754e-09
expression O 0 1.902558643962493e-08
of O 0 6.025765664219307e-09
mutant O 0 2.229596702818526e-07
cDNA O 0 2.788811741538666e-07
into O 0 8.510385214322014e-07
COS O 0 0.0005280380137264729
- O 0 7.742394518572837e-05
1 O 0 6.180404852784704e-06
cells O 0 1.5096158676897176e-05
. O 0 2.293072157044662e-06

Quantitative O 0 1.8954335246235132e-05
analysis O 0 2.9712400646531023e-06
showed O 0 5.303857506078202e-06
that O 0 1.8062536355500924e-08
the O 0 1.7220639136894533e-08
expression O 0 4.350533444608118e-08
of O 0 1.6059546581459472e-08
CYP27 O 0 1.2200795026728883e-05
gene O 0 2.091458384256839e-07
mRNA O 0 1.2644972002817667e-07
in O 0 6.617619874305092e-08
the O 0 7.74413351223302e-08
patient O 0 5.762476575910114e-06
represented O 0 9.864642152024317e-07
52 O 0 1.5241771507135127e-05
. O 0 2.886748916353099e-06

5 O 0 4.863749836658826e-06
% O 0 7.265040125048472e-08
of O 0 1.8893954845111693e-08
the O 0 1.465850942850011e-07
normal O 0 7.0264841269818135e-06
level O 0 2.388753455306869e-05
. O 0 4.093083134648623e-06

As O 0 1.8974399154103594e-06
the O 0 8.778298479228397e-07
mutation O 0 1.654590232647024e-05
occurred O 0 7.666720193810761e-06
at O 0 5.357978238862415e-07
the O 0 4.149851307033714e-08
penultimate O 0 4.050948518852238e-06
nucleotide O 0 6.508744831990043e-07
of O 0 3.314303853585443e-08
exon O 0 9.34151466935873e-06
6 O 0 3.0314524792629527e-06
( O 0 6.598902757559699e-08
- O 0 1.4886211374687264e-06
2 O 0 1.2350402300853602e-07
position O 0 2.438407307181478e-07
of O 0 8.49592893814588e-08
exon O 0 1.382350910716923e-05
6 O 0 3.721354687513667e-06
- O 0 8.550510756322183e-06
intron O 0 2.8046573788742535e-05
6 O 0 8.862795652930799e-07
splice O 0 6.049979674571659e-06
site O 0 1.5725941011623945e-06
) O 0 1.543368277623358e-08
of O 0 2.7039868122358257e-09
the O 0 2.189631231885869e-08
gene O 0 4.284522958641901e-07
, O 0 4.2448686343732334e-08
we O 0 1.6021944659883047e-08
hypothesized O 0 1.8663725143142074e-07
that O 0 6.952181941244362e-09
the O 0 1.825817577127964e-07
mutation O 0 8.790371794020757e-06
may O 0 5.614437554868346e-07
partially O 0 1.8542494899520534e-06
affect O 0 5.756730914185937e-08
the O 0 1.4780531465419244e-08
normal O 0 9.080771690150868e-08
splicing O 0 4.414104068928282e-07
efficiency O 0 1.0786548045871314e-06
in O 0 2.665410647750832e-07
exon O 0 1.091131525754463e-05
6 O 0 1.5015632470749551e-06
and O 0 1.080301359479563e-07
cause O 0 5.158372005098499e-07
alternative O 0 2.214006116219025e-07
splicing O 0 2.3308782601816347e-06
elsewhere O 0 5.898667723158724e-07
, O 0 3.95089863047815e-08
which O 0 2.523299436063553e-08
resulted O 0 5.10706286149798e-07
in O 0 1.6709998362784972e-07
decreased O 0 2.8240458505024435e-06
transcript O 0 6.087791007303167e-06
in O 0 2.935740042175894e-07
the O 0 2.0193904219922842e-06
patient O 0 0.00012307061115279794
. O 0 5.4642296163365245e-06

Transfection O 0 0.001124803558923304
of O 0 2.3541740574728465e-06
constructed O 0 0.00010157983342651278
minigenes O 0 0.00044048423296771944
, O 0 3.107165014171187e-07
with O 0 1.0763442048755678e-07
or O 0 2.7440651706456265e-07
without O 0 1.0725489119067788e-07
the O 0 1.51349013322033e-07
mutation O 0 1.6326397371813073e-06
, O 0 5.3501047148074576e-08
into O 0 2.1326640364804916e-07
COS O 0 0.00022681010887026787
- O 0 1.4321392882266082e-05
1 O 0 6.40830080556043e-07
cells O 0 5.066005996923195e-07
confirmed O 0 2.452360092775052e-07
that O 0 2.5917876733672074e-09
the O 0 1.567445728767325e-08
mutant O 0 8.526365036232164e-07
minigene O 0 1.532277383375913e-05
was O 0 2.2009717213222757e-06
responsible O 0 1.5209839432372974e-07
for O 0 4.3238279623381e-09
a O 0 1.0072167100361185e-07
mRNA O 0 1.744056277175332e-07
species O 0 1.6598146856949825e-08
alternatively O 0 1.8172396210047737e-07
spliced O 0 1.4736358480149647e-06
at O 0 3.2177410957956454e-06
an O 0 3.0704092068845057e-07
activated O 0 6.275285704759881e-05
cryptic O 0 5.015787337470101e-06
5 O 0 2.9066589490867045e-07
splice O 0 1.5544610505457968e-05
site O 0 7.386245215457166e-06
88 O 0 1.735618525344762e-06
bp O 0 4.2388105612189975e-06
upstream O 0 4.1439790265940246e-07
from O 0 2.3495122292160886e-08
the O 0 2.3286194306137986e-08
3 O 0 1.2270042759610078e-07
end O 0 2.050894494232125e-07
of O 0 6.826135745541251e-08
exon O 0 2.9360049666138366e-05
6 O 0 1.5605715816491283e-05
. O 0 2.8299637051532045e-06

Our O 0 3.2714631288399687e-06
data O 0 1.6004893268473097e-06
suggest O 0 6.569647439391701e-07
that O 0 6.810488617503552e-09
the O 0 3.73441935153096e-08
C O 0 1.0811213542183395e-06
to O 0 6.612242753334385e-09
A O 0 3.989648291735648e-07
mutation O 0 8.291578978969483e-07
at O 0 3.887639934418985e-07
the O 0 5.00044698981128e-08
penultimate O 0 2.7645610316540115e-06
nucleotide O 0 2.8081262826162856e-07
of O 0 2.0689137514295908e-08
exon O 0 3.611149395510438e-06
6 O 0 4.2341667949585826e-07
of O 0 1.0617121404266072e-08
the O 0 1.3505454887763335e-07
CYP27 O 0 5.437687650555745e-05
gene O 0 9.573110446581268e-07
not O 0 4.38243112910186e-08
only O 0 5.35753841290898e-08
causes O 0 9.802824934013188e-06
the O 0 1.4193041351973079e-05
deficiency B-Disease 1 0.939264178276062
in I-Disease 0 1.2891777600998466e-07
the I-Disease 0 2.2932924537144572e-07
sterol I-Disease 0 0.0001835157599998638
27 I-Disease 0 2.9568087484221905e-05
- I-Disease 0 4.7710942453704774e-05
hydroxylase I-Disease 0 2.411362402199302e-05
activity I-Disease 0 3.923437077446579e-07
, O 0 7.213179031850814e-08
but O 0 6.669637286904617e-08
also O 0 1.0953542783909143e-07
partially O 0 7.1839731390355155e-06
leads O 0 1.883615396991445e-07
to O 0 5.036127070923158e-09
alternative O 0 1.0995869104135636e-07
pre O 0 1.552954017824959e-06
- O 0 4.840612746193074e-07
mRNA O 0 4.3122913240267735e-08
splicing O 0 2.9435562964863493e-07
of O 0 3.499921774618997e-08
the O 0 3.841380191715871e-07
gene O 0 1.2199573575344402e-05
. O 0 3.391475729586091e-06

To O 0 1.925287023141209e-07
our O 0 2.7484782094688853e-07
knowledge O 0 3.3774369967431994e-07
, O 0 1.332967940470553e-07
this O 0 2.2254834419754843e-08
is O 0 5.110034706490296e-08
the O 0 4.698918942835917e-08
first O 0 4.7653117007939727e-07
report O 0 1.6565198279749893e-07
regarding O 0 7.335621887705202e-08
effects O 0 7.760219773444987e-07
on O 0 3.776667654165067e-07
pre O 0 1.7013170463542338e-06
- O 0 2.0108412002173282e-07
mRNA O 0 1.689745232624773e-08
splicing O 0 1.6309297734551365e-07
of O 0 1.3983387781024703e-08
a O 0 1.6061912333498185e-07
mutation O 0 1.0037931588158244e-06
at O 0 2.1696929763947992e-07
the O 0 6.484352610414135e-08
- O 0 3.08686435346317e-06
2 O 0 1.3073717752831726e-07
position O 0 1.6153650506112172e-07
of O 0 1.2625108958275177e-08
a O 0 3.024842669674399e-07
5 O 0 4.2280333900635014e-07
splice O 0 1.6607144061708823e-05
site O 0 1.8962000467581674e-05
. O 0 3.388514187463443e-06

ATM O 0 0.004406444728374481
germline O 0 0.0050186109729111195
mutations O 0 0.0010874817380681634
in O 0 1.2056122614012565e-05
classical O 0 0.03422648087143898
ataxia B-Disease 1 0.9999806880950928
- I-Disease 1 0.9998863935470581
telangiectasia I-Disease 1 0.9999233484268188
patients O 0 0.2614195644855499
in O 0 2.9598907076433534e-06
the O 0 2.479867589499918e-06
Dutch O 0 9.539863094687462e-05
population O 0 9.77638137555914e-07
. O 0 4.5907700041425414e-06

Germline O 0 0.0020966820884495974
mutations O 0 0.00017474066407885402
in O 0 2.662082749793626e-07
the O 0 4.469506365012421e-08
ATM O 0 7.871706657169852e-06
gene O 0 1.1297382798147737e-06
are O 0 3.888325394996173e-08
responsible O 0 8.014622494556534e-07
for O 0 9.534496712149121e-07
the O 0 0.013216638006269932
autosomal B-Disease 1 0.9999936819076538
recessive I-Disease 1 0.9999992847442627
disorder I-Disease 1 1.0
ataxia B-Disease 1 0.9999985694885254
- I-Disease 1 0.999932050704956
telangiectasia I-Disease 1 0.9998941421508789
( O 0 0.006695152260363102
A B-Disease 1 0.9999064207077026
- I-Disease 1 0.9996793270111084
T I-Disease 1 0.9997109770774841
) O 0 4.409918801684398e-06
. O 0 5.59971840630169e-06

In O 0 2.95798577099049e-06
our O 0 1.3596178405350656e-06
study O 0 4.699734574842296e-07
, O 0 5.307841988155815e-08
we O 0 2.510338248384869e-08
have O 0 5.331897590110657e-09
determined O 0 4.357575633662236e-08
the O 0 1.5016528465139345e-08
ATM O 0 3.028340415767161e-06
mutation O 0 2.3954651169333374e-06
spectrum O 0 2.7334631340636406e-06
in O 0 1.5034846967409976e-07
19 O 0 1.391500404679391e-06
classical O 0 1.836347655626014e-05
A B-Disease 1 0.9992026686668396
- I-Disease 1 0.9995177984237671
T I-Disease 1 0.9998666048049927
patients O 0 1.9085549865849316e-05
, O 0 2.588696368377441e-08
including O 0 1.3287473343837064e-08
some O 0 1.077798295057164e-08
immigrant O 0 2.0926036370383372e-07
populations O 0 6.716244627114065e-08
, O 0 1.0984503973077153e-08
as O 0 2.1544263262285313e-08
well O 0 3.140237225807141e-08
as O 0 5.97878369035243e-08
12 O 0 7.930473344686106e-08
of O 0 1.9070419909894554e-08
Dutch O 0 2.788284973576083e-06
ethnic O 0 2.1035805275460007e-07
origin O 0 1.3366931170821772e-06
. O 0 3.7846825762244407e-06

Both O 0 1.1654032050500973e-06
the O 0 4.54838470886898e-07
protein O 0 1.7085263834815123e-06
truncation O 0 1.730393159959931e-05
test O 0 2.4908561044867383e-06
( O 0 1.8265143353346502e-07
PTT O 0 1.621969204279594e-05
) O 0 4.3858513265604415e-08
and O 0 1.7518335226895942e-08
the O 0 5.820768578246316e-08
restriction O 0 4.937705284646654e-07
endonuclease O 0 1.2202192010590807e-05
fingerprinting O 0 5.209269147599116e-06
( O 0 3.522249585330428e-07
REF O 0 5.220928505877964e-05
) O 0 1.0991482390920737e-08
method O 0 1.0186925969435379e-08
were O 0 6.966146326448097e-09
used O 0 1.3420224043159124e-08
and O 0 1.0801979755115099e-08
compared O 0 9.137289680438698e-08
for O 0 2.0909303177774063e-09
their O 0 5.6245959001444135e-09
detection O 0 7.985044589986501e-07
efficiency O 0 6.172867301756924e-07
, O 0 2.069434756890587e-08
identifying O 0 1.7231094773251243e-07
76 O 0 7.129870027711149e-07
% O 0 8.386332517318351e-09
and O 0 1.3699957612800517e-08
60 O 0 4.665482933319254e-08
% O 0 7.019122172380321e-09
of O 0 6.952924902492441e-09
the O 0 2.5639701561885886e-07
mutations O 0 1.1260627616138663e-05
, O 0 1.7175084110476746e-07
respectively O 0 2.6963355139741907e-06
. O 0 2.189653741879738e-06

Most O 0 4.434615675563691e-06
patients O 0 5.0014427870337386e-06
were O 0 9.960653102325523e-08
found O 0 1.659973634104972e-07
to O 0 1.1647600217656873e-08
be O 0 1.7094083659685566e-07
compound O 0 5.299433723848779e-06
heterozygote O 0 2.7046828108723275e-05
. O 0 1.2700642173513188e-06

Seventeen O 0 2.4174591089831665e-05
mutations O 0 3.19737009704113e-05
were O 0 1.5393239038985485e-07
distinct O 0 3.030715731711098e-07
, O 0 4.7273442049799996e-08
of O 0 1.338448640808565e-08
which O 0 3.782542279395784e-08
10 O 0 1.2158348283719533e-07
were O 0 5.887113374569708e-08
not O 0 4.9557165482383425e-08
reported O 0 5.329451596480794e-06
previously O 0 2.5211620595655404e-06
. O 0 1.1440497473813593e-06

Mutations O 0 0.0009042834280990064
are O 0 5.112574967824912e-07
small O 0 1.4117159707893734e-06
deletions O 0 2.252855119877495e-05
or O 0 2.8464014576456975e-06
point O 0 1.11908802864491e-05
mutations O 0 5.219574086368084e-05
frequently O 0 5.677083663613303e-06
affecting O 0 9.104527634917758e-06
splice O 0 0.0002755866153165698
sites O 0 4.5628854422830045e-05
. O 0 1.098915709007997e-05

Moreover O 0 6.167736137285829e-05
, O 0 1.4868518292132649e-06
a O 0 4.799431735591497e-06
16 O 0 1.0321748959540855e-05
. O 0 3.054834678550833e-06

7 O 0 8.934395737014711e-05
- O 0 6.17111218161881e-05
kb O 0 4.108447319595143e-05
genomic O 0 9.244894499715883e-06
deletion O 0 6.075025794416433e-06
of O 0 5.514126755201687e-08
the O 0 1.203966348839458e-07
3 O 0 2.654851982697437e-07
end O 0 1.9858850919263205e-07
of O 0 5.4521698267251395e-09
the O 0 2.5763968736214338e-08
gene O 0 2.3529300108293683e-07
, O 0 2.195569592799984e-08
most O 0 1.0544429329684135e-08
likely O 0 5.7899640637515404e-08
a O 0 6.477480241073863e-08
result O 0 7.744562680045419e-08
of O 0 6.048992418072885e-09
recombination O 0 6.270362007398944e-08
between O 0 1.2450706243782861e-08
two O 0 2.080976813090274e-08
LINE O 0 4.657517365558306e-06
elements O 0 2.1691550955438288e-07
, O 0 2.788644337670121e-07
was O 0 2.3115368094295263e-05
identified O 0 4.771792646351969e-06
. O 0 2.559887889219681e-06

The O 0 2.0334593955340097e-06
most O 0 4.808644575859944e-07
frequently O 0 1.4057321777727338e-06
found O 0 7.68013080687524e-07
mutation O 0 4.056070793012623e-06
, O 0 8.853361777028113e-08
identified O 0 2.8233355919837777e-07
in O 0 6.495319837540592e-08
three O 0 1.1206522287920961e-07
unrelated O 0 4.5760702960251365e-06
Turkish O 0 3.084405398112722e-05
A B-Disease 1 0.9990485310554504
- I-Disease 1 0.9974157810211182
T I-Disease 1 0.9994832277297974
individuals O 0 8.753388414106666e-08
, O 0 1.4941964820991416e-07
was O 0 1.1563302905415185e-05
previously O 0 5.419016133600962e-07
described O 0 1.4623589095208445e-07
to O 0 7.0740386881595896e-09
be O 0 1.8155379422069018e-08
a O 0 2.465656621097878e-07
Turkish O 0 9.804909495869651e-06
A B-Disease 1 0.9977964162826538
- I-Disease 1 0.9980917572975159
T I-Disease 1 0.9996035695075989
founder O 0 0.0004899215418845415
mutation O 0 0.0002358622004976496
. O 0 6.497707090602489e-06

The O 0 1.896638423204422e-06
presence O 0 2.2601409455091925e-06
of O 0 2.488051791260659e-07
a O 0 3.7203647025307873e-06
founder O 0 3.731793549377471e-05
mutation O 0 1.0888717952184379e-05
among O 0 8.102636428475307e-08
relatively O 0 2.350185184241127e-07
small O 0 2.848082303330557e-08
ethnic O 0 1.1005621303183943e-08
population O 0 3.658012559526469e-09
groups O 0 4.92679941288543e-09
in O 0 2.1198601984906418e-08
Western O 0 1.8862687056753202e-07
Europe O 0 2.454754167047213e-06
could O 0 2.767814066828578e-07
indicate O 0 1.856688527368533e-07
a O 0 1.5207083947643696e-07
high O 0 2.462475322317914e-06
carrier O 0 1.6776085658420925e-06
frequency O 0 4.694117592407565e-07
in O 0 7.075363583908256e-08
such O 0 8.421086050702797e-08
communities O 0 1.2064781458320795e-06
. O 0 3.520755399222253e-06

In O 0 2.779805799946189e-05
patients O 0 1.9257684471085668e-05
of O 0 1.3206246762820228e-07
Dutch O 0 1.182641335617518e-05
ethnic O 0 1.001851899218309e-07
origin O 0 1.4211214249826298e-07
, O 0 1.5100344796792342e-07
however O 0 1.2202512778003438e-07
, O 0 4.420275345751179e-08
no O 0 8.112083804689973e-08
significant O 0 1.3094030748561636e-07
founder O 0 5.579834123636829e-06
effect O 0 6.291962790783145e-07
could O 0 1.1970900004598661e-07
be O 0 1.6210798037263885e-07
identified O 0 2.4736791601753794e-06
. O 0 1.655572077652323e-06

The O 0 3.3996971069427673e-06
observed O 0 1.3847325135429855e-05
genetic O 0 8.99181941349525e-06
heterogeneity O 0 5.5263999456656165e-06
including O 0 1.047757223204826e-07
the O 0 1.621269944962478e-07
relative O 0 1.8162709238822572e-06
high O 0 4.831306068808772e-05
percentage O 0 1.0531011866987683e-06
of O 0 4.778618745149288e-08
splice O 0 2.969626621052157e-05
- O 0 0.00010987215500790626
site O 0 1.4936131265130825e-05
mutations O 0 1.269309450435685e-05
had O 0 8.902822514755826e-07
no O 0 6.549522879595315e-08
reflection O 0 7.876931249484187e-07
on O 0 1.2064022030244814e-06
the O 0 1.7224438124685548e-06
phenotype O 0 0.00015664324746467173
. O 0 6.185104211908765e-06

All O 0 5.037397386331577e-06
patients O 0 3.023673707502894e-05
manifested O 0 1.3568713256972842e-05
classical O 0 0.0001503547973698005
A B-Disease 1 0.9979526996612549
- I-Disease 1 0.9594793319702148
T I-Disease 1 0.9979475140571594
and O 0 3.101977767983044e-07
increased O 0 1.0989742804667912e-06
cellular O 0 6.011720688547939e-05
radioresistant O 0 0.00010808397200889885
DNA O 0 1.870637970569078e-05
synthesis O 0 3.728770025190897e-05
. O 0 1.0066912182082888e-05

Determination O 0 1.1181865374965128e-05
of O 0 2.1481959322500188e-07
the O 0 3.7976985822751885e-07
genomic O 0 6.586788913409691e-06
structure O 0 6.347897851810558e-06
of O 0 8.430970410699956e-08
the O 0 2.89205104309076e-07
COL4A4 O 0 3.8065045373514295e-05
gene O 0 1.2347545634838752e-06
and O 0 8.70591776447327e-08
of O 0 2.714970719353005e-07
novel O 0 0.00012178992619737983
mutations O 0 0.015717312693595886
causing O 1 0.5667741894721985
autosomal B-Disease 1 0.9995172023773193
recessive I-Disease 1 0.9998950958251953
Alport I-Disease 1 0.9999809265136719
syndrome I-Disease 1 0.9999902248382568
. O 0 0.000979887438006699

Autosomal B-Disease 1 0.9981110095977783
recessive I-Disease 1 0.9998103976249695
Alport I-Disease 1 0.9999697208404541
syndrome I-Disease 1 0.9999935626983643
is O 0 0.0016841415781527758
a O 0 0.0017763770883902907
progressive O 1 0.9973596930503845
hematuric B-Disease 1 0.9982572197914124
glomerulonephritis I-Disease 1 0.9998782873153687
characterized O 0 0.27228355407714844
by O 0 2.6916934075416066e-05
glomerular B-Disease 1 0.9927896857261658
basement I-Disease 1 0.9905667901039124
membrane I-Disease 0 0.3191002905368805
abnormalities I-Disease 1 0.9991729855537415
and O 0 1.0282735729560954e-06
associated O 0 3.4265246995346388e-06
with O 0 3.5495497741067084e-07
mutations O 0 2.9703716791118495e-05
in O 0 2.3810039806448913e-07
either O 0 3.0060581934776565e-07
the O 0 3.6649987578130094e-07
COL4A3 O 0 0.00023462990066036582
or O 0 3.7839643596271344e-07
the O 0 1.6464385055314779e-07
COL4A4 O 0 4.898074985248968e-05
gene O 0 8.347586799573037e-07
, O 0 2.2207172989396895e-08
which O 0 4.686028010070231e-09
encode O 0 1.26246275655717e-08
the O 0 1.3557034606037632e-07
alpha3 O 0 2.8112794097978622e-05
and O 0 5.22005791481206e-07
alpha4 O 0 0.00034349216730333865
type O 0 0.0009778458625078201
IV O 1 0.8115168213844299
collagen O 0 0.005076230503618717
chains O 0 0.0003602539945859462
, O 0 2.206136741733644e-06
respectively O 0 9.009208042698447e-06
. O 0 2.6796581096277805e-06

To O 0 5.574210604208929e-07
date O 0 2.918332256740541e-06
, O 0 2.708092381453753e-07
mutation O 0 2.3635864181414945e-06
screening O 0 5.523705226551101e-07
in O 0 4.4630400708456364e-08
the O 0 1.2867857002163419e-08
two O 0 4.1275825424236245e-08
genes O 0 4.7463444730055926e-07
has O 0 4.7341472964035347e-07
been O 0 3.690155949698237e-07
hampered O 0 1.5246278962877113e-05
by O 0 7.061854745415985e-08
the O 0 8.051826938526574e-08
lack O 0 4.20155657820942e-07
of O 0 8.775688797868497e-08
genomic O 0 6.9609086494892836e-06
structure O 0 1.1480105058581103e-05
information O 0 1.960193230843288e-06
. O 0 6.36944969301112e-06

We O 0 7.509962415497284e-06
report O 0 1.1619906672422076e-06
here O 0 7.202785212712115e-08
the O 0 1.6012229764328367e-08
complete O 0 1.1945138567170943e-07
characterization O 0 4.40940027601755e-07
of O 0 2.2982703740126453e-08
the O 0 9.224863362078395e-08
48 O 0 5.152211315362365e-07
exons O 0 1.0087871942232596e-06
of O 0 2.527904818805382e-08
the O 0 4.148245693613717e-07
COL4A4 O 0 6.597962055820972e-05
gene O 0 1.3008341284148628e-06
, O 0 4.8822364817624475e-08
a O 0 5.355219556690827e-08
comprehensive O 0 2.1438263786421885e-07
gene O 0 3.0914642934476433e-07
screen O 0 8.952133612183388e-07
, O 0 4.93191656403269e-08
and O 0 1.1298827651273768e-08
the O 0 1.8108380572812166e-08
subsequent O 0 1.5378066109406063e-07
detection O 0 6.438507398343063e-07
of O 0 2.8673392549194432e-08
10 O 0 2.051293535032528e-07
novel O 0 8.267646762760705e-07
mutations O 0 4.095812073501293e-06
in O 0 3.9293604459089693e-07
eight O 0 1.1929948414035607e-05
patients O 0 0.0011191964149475098
diagnosed O 1 0.9988160133361816
with O 0 0.00035110206226818264
autosomal B-Disease 1 0.9996457099914551
recessive I-Disease 1 0.9998986721038818
Alport I-Disease 1 0.9999619722366333
syndrome I-Disease 1 0.9999829530715942
. O 0 0.0009290612651966512

Furthermore O 0 1.8284597899764776e-05
, O 0 9.70727910498681e-07
we O 0 2.258474580685288e-07
identified O 0 4.0522945710108615e-07
a O 0 1.2811254634925717e-07
glycine O 0 5.577124397859734e-07
to O 0 1.168587537847543e-08
alanine O 0 1.0755229595815763e-06
substitution O 0 7.677027724639629e-08
in O 0 8.80638992839522e-08
the O 0 1.6749470432841917e-07
collagenous O 0 0.00011341904610162601
domain O 0 1.0635229727995466e-06
that O 0 8.752236624331999e-08
is O 0 1.4861711861158255e-07
apparently O 0 6.620358590225806e-07
silent O 0 3.259324330429081e-06
in O 0 3.22696749321949e-08
the O 0 2.7192559315381004e-08
heterozygous O 0 1.4444565010762744e-07
carriers O 0 5.230048714111035e-07
, O 0 9.941881273789477e-08
in O 0 2.1761874791081937e-07
11 O 0 2.6279942630935693e-06
. O 0 1.9657024949992774e-06

5 O 0 2.7355940801498946e-06
% O 0 4.651408502809318e-08
of O 0 1.0217476642537804e-08
all O 0 1.551893369367008e-08
control O 0 5.755840675192303e-07
individuals O 0 9.550912949407575e-09
, O 0 3.762789901884389e-08
and O 0 3.050351793376649e-08
in O 0 3.654520597251576e-08
one O 0 3.637850554127908e-08
control O 0 2.876482199098973e-07
individual O 0 1.8583723004894637e-08
homozygous O 0 3.114011519755877e-07
for O 0 6.554881970544102e-09
this O 0 1.70064797799796e-08
glycine O 0 2.5167155399685726e-06
substitution O 0 1.1785786000473308e-06
. O 0 3.2820937576616416e-06

There O 0 2.409907665423816e-06
has O 0 9.210893381350616e-07
been O 0 2.2932179888357496e-07
no O 0 4.001636000339204e-08
previous O 0 1.4046692342617462e-07
finding O 0 5.234749167470909e-08
of O 0 6.139306396590882e-09
a O 0 8.152055386290158e-08
glycine O 0 4.886438205176091e-07
substitution O 0 5.91814135475488e-08
that O 0 9.842596071507614e-09
is O 0 1.899161539142824e-08
not O 0 5.761582766439233e-09
associated O 0 2.762878992257356e-08
with O 0 1.026241847057463e-08
any O 0 4.592117619495184e-08
obvious O 0 2.3261925434781006e-06
phenotype O 0 1.1642761819530278e-05
in O 0 3.8120572298794286e-07
homozygous O 0 5.318845069268718e-06
individuals O 0 1.4375261514487647e-07
. O 0 2.932001279987162e-06

Founder O 0 0.0005211097304709256
BRCA1 O 0 0.000853870646096766
and O 0 4.874615569860907e-06
BRCA2 O 0 0.0002832194440998137
mutations O 0 7.837090379325673e-05
in O 0 1.695232072052022e-06
French O 0 0.0008059077663347125
Canadian O 0 0.16081871092319489
breast B-Disease 1 0.999797523021698
and I-Disease 1 0.9971107244491577
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999963045120239
families O 0 2.3910710297059268e-05
. O 0 1.0147152352146804e-05

We O 0 1.4467120763583807e-06
have O 0 7.056846129671612e-08
identified O 0 1.7589826484254445e-07
four O 0 3.6600106056994264e-08
mutations O 0 6.214521022229746e-07
in O 0 1.7460356716014758e-08
each O 0 5.416967763238745e-09
of O 0 3.4146427907444377e-08
the O 0 1.6935879102675244e-05
breast B-Disease 1 0.9993316531181335
cancer I-Disease 1 0.9984288811683655
- O 0 0.0002596526755951345
susceptibility O 0 2.7560437956708483e-05
genes O 0 1.2223727026139386e-06
, O 0 2.257019104945357e-07
BRCA1 O 0 1.096496453101281e-05
and O 0 5.390543265093584e-07
BRCA2 O 0 2.2286187231657095e-05
, O 0 1.8015336422649852e-07
in O 0 3.874496883327083e-07
French O 0 0.000262102868873626
Canadian O 0 0.010799583047628403
breast B-Disease 1 0.9996104836463928
cancer I-Disease 1 0.9997159838676453
and O 0 0.0031397882848978043
breast B-Disease 1 0.9999442100524902
/ I-Disease 1 0.9998862743377686
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999920129776001
families O 0 6.538372872455511e-06
from O 0 1.0641942026268225e-05
Quebec O 0 0.007572293747216463
. O 0 9.702109309728257e-06

To O 0 1.3226695045887027e-06
identify O 0 5.187386705074459e-06
founder O 0 4.4855558371637017e-05
effects O 0 2.1225754608167335e-05
, O 0 4.0949859680949885e-07
we O 0 1.856688527368533e-07
examined O 0 4.808287030755309e-06
independently O 0 4.403181321777083e-07
ascertained O 0 9.07419052964542e-06
French O 0 6.401731661753729e-05
Canadian O 0 0.000572155462577939
cancer B-Disease 0 0.40427476167678833
families O 0 2.6360556404370072e-08
for O 0 5.803450164876267e-09
the O 0 1.078497557926994e-08
distribution O 0 4.0073945939411715e-08
of O 0 1.502317381607554e-08
these O 0 4.7255319657324435e-08
eight O 0 1.8946299178423942e-06
mutations O 0 5.542625513044186e-05
. O 0 3.285961838628282e-06

Mutations O 0 0.00010398065205663443
were O 0 4.781353482030681e-07
found O 0 2.4675338750057563e-07
in O 0 7.05745151208248e-08
41 O 0 8.179582096090598e-07
of O 0 6.053841872244448e-08
97 O 0 4.04882075599744e-06
families O 0 5.239154461378348e-07
. O 0 3.3261703720199876e-06

Six O 0 3.2522852961847093e-06
of O 0 1.3689920308479486e-07
eight O 0 6.845575626357459e-07
mutations O 0 5.372327905206475e-06
were O 0 1.3131021603385307e-07
observed O 0 1.0998592188116163e-06
at O 0 3.3028113648470026e-06
least O 0 4.957352643941704e-07
twice O 0 1.3854457392881159e-05
. O 0 2.259453367514652e-06

The O 0 1.6940013665589504e-05
BRCA1 O 0 0.0007876820745877922
C4446T O 0 0.00024297302297782153
mutation O 0 7.562306564068422e-05
was O 0 4.750410880660638e-06
the O 0 3.876979803862923e-08
most O 0 3.191234299038115e-08
common O 0 5.572339318860031e-07
mutation O 0 4.315650130592985e-06
found O 0 3.863851247842831e-07
, O 0 4.247322493711181e-08
followed O 0 1.7948866570804967e-07
by O 0 1.020787792072042e-07
the O 0 1.2263179769433918e-06
BRCA2 O 0 0.00045010531903244555
8765delAG O 0 0.0011588720371946692
mutation O 0 0.0004375610442366451
. O 0 1.252373567695031e-05

Together O 0 1.6129711184476037e-06
, O 0 1.7356339299112733e-07
these O 0 2.8305464638833655e-08
mutations O 0 1.648403781473462e-06
were O 0 7.354590536579053e-08
found O 0 1.154892004251451e-07
in O 0 4.4986794733858915e-08
28 O 0 2.477909788467514e-07
of O 0 1.7878816649385953e-08
41 O 0 4.890997615802917e-07
families O 0 1.2058941400994172e-08
identified O 0 8.240459692387958e-08
to O 0 5.278702364108767e-09
have O 0 2.9270227130950843e-08
a O 0 1.1989950507995673e-06
mutation O 0 1.8334183550905436e-05
. O 0 2.0317593225627206e-06

The O 0 2.3116544980439357e-06
odds O 0 4.861596244154498e-05
of O 0 1.0984737741637218e-07
detection O 0 2.4801327072054846e-06
of O 0 2.301692170192382e-08
any O 0 2.4193592906840422e-08
of O 0 1.7036088095778723e-08
the O 0 1.0389791782472457e-07
four O 0 7.889358926149725e-07
BRCA1 O 0 7.461212953785434e-05
mutations O 0 3.4633525501703843e-05
was O 0 4.7638102842029184e-05
18 O 0 3.616526100813644e-06
. O 0 1.2262747759450576e-06

7x O 0 0.002848642645403743
greater O 0 2.0868549199803965e-06
if O 0 5.000651981390547e-07
one O 0 6.32824992408132e-08
or O 0 4.6150525179200486e-08
more O 0 3.8699539572917274e-08
cases O 0 2.3566383333673002e-06
of O 0 0.00019432857516221702
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999967813491821
were O 0 2.3684649477218045e-06
also O 0 2.3021539163892157e-07
present O 0 9.49174960851451e-08
in O 0 1.0889861812302115e-07
the O 0 4.7244776624211227e-07
family O 0 7.161071607697522e-06
. O 0 2.818143229887937e-06

The O 0 4.2636556827346794e-06
odds O 0 8.581903239246458e-05
of O 0 1.18588395991992e-07
detection O 0 5.559480541705852e-06
of O 0 5.994118623675604e-08
any O 0 3.6007939741011796e-08
of O 0 1.4006450221870637e-08
the O 0 2.535443286433292e-07
four O 0 8.944393812271301e-07
BRCA2 O 0 5.8058154536411166e-05
mutations O 0 4.015866943518631e-05
was O 0 2.848116673703771e-05
5 O 0 4.2690667214628775e-06
. O 0 2.3979839625098975e-06

3x O 0 0.00038135878276079893
greater O 0 1.6031825680329348e-06
if O 0 2.7287831017019926e-07
there O 0 2.1724297027958528e-08
were O 0 1.8833292259046175e-08
at O 0 1.7606609503673099e-07
least O 0 1.0050516863202574e-08
five O 0 4.8656055184892466e-08
cases O 0 1.8826474956767925e-07
of O 0 1.435508465874591e-06
breast B-Disease 1 0.9993933439254761
cancer I-Disease 1 0.9973961114883423
in O 0 3.6962174476684595e-07
the O 0 8.511611326866841e-07
family O 0 1.451847765565617e-05
. O 0 6.62463662592927e-06

Interestingly O 0 2.8849963200627826e-05
, O 0 1.9165798903486575e-07
the O 0 7.73602906178894e-08
presence O 0 3.4382392755105684e-07
of O 0 2.977561166517262e-07
a O 0 0.00027791751199401915
breast B-Disease 1 0.9989132881164551
cancer I-Disease 1 0.9948009252548218
case O 0 1.72014574673085e-06
< O 0 3.787061359616928e-06
36 O 0 2.9852375860173197e-07
years O 0 8.679903373831621e-08
of O 0 7.274604474361013e-09
age O 0 7.837801376808784e-07
was O 0 8.520300980308093e-07
strongly O 0 4.1339802692164085e-08
predictive O 0 7.359095377523772e-08
of O 0 3.714385021780231e-09
the O 0 1.5906026717971145e-08
presence O 0 2.878666016670195e-08
of O 0 3.8278722414020194e-09
any O 0 6.537427044150945e-09
of O 0 8.495309344880297e-09
the O 0 1.6628779064831178e-07
eight O 0 8.764762924329261e-07
mutations O 0 1.2811337910534348e-05
screened O 0 1.5137821719690692e-05
. O 0 2.5002063921419904e-06

Carriers O 0 2.519258123356849e-05
of O 0 8.142716012571327e-08
the O 0 2.2259806087276957e-07
same O 0 2.743044831277075e-07
mutation O 0 2.5798174192459555e-06
, O 0 2.2383481734777888e-08
from O 0 1.0141058659485225e-08
different O 0 4.502394013172761e-09
families O 0 1.36506068670883e-08
, O 0 1.4708873230517838e-08
shared O 0 2.6752552173547883e-08
similar O 0 1.3236963525287138e-07
haplotypes O 0 2.3666721062909346e-06
, O 0 5.8133796443371466e-08
indicating O 0 2.639643810198322e-07
that O 0 4.0124712441524935e-09
the O 0 1.5088330584944742e-08
mutant O 0 2.494245450179733e-07
alleles O 0 1.1626341489545666e-07
were O 0 6.285569753572418e-08
likely O 0 2.7085306442131696e-08
to O 0 3.1925415644451505e-09
be O 0 9.820318780384696e-09
identical O 0 8.446679800044876e-08
by O 0 2.6583224510545733e-08
descent O 0 1.743853346169999e-07
for O 0 2.4040046397999504e-08
a O 0 3.684708644868806e-07
mutation O 0 2.86694034912216e-06
in O 0 1.3134402365722053e-07
the O 0 2.2546137756762619e-07
founder O 0 7.184000423876569e-06
population O 0 2.532823657475092e-07
. O 0 1.283064989365812e-06

The O 0 9.556016493661446e-07
identification O 0 5.579017852141988e-07
of O 0 1.9613698043485783e-07
common O 0 7.835635187802836e-06
BRCA1 O 0 0.00024369618040509522
and O 0 1.9827825781248976e-06
BRCA2 O 0 0.00010867387027246878
mutations O 0 1.1581204489630181e-05
will O 0 9.474494788719312e-08
facilitate O 0 3.828287447049661e-07
carrier O 0 1.2988522030354943e-05
detection O 0 5.891662567591993e-06
in O 0 7.162480528677406e-07
French O 0 0.0003149546100758016
Canadian O 0 0.012059617787599564
breast B-Disease 1 0.9993345141410828
cancer I-Disease 1 0.9996210336685181
and O 0 0.0036402507685124874
breast B-Disease 1 0.9999687671661377
/ I-Disease 1 0.999950647354126
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999949932098389
families O 0 3.8808040699223056e-05
. O 0 1.694424827292096e-05

Are O 0 4.615740181179717e-06
Dp71 O 0 0.00042508900514803827
and O 0 4.4968533075007144e-06
Dp140 O 0 0.0006246128468774259
brain O 0 0.013877102173864841
dystrophin O 0 0.00026251323288306594
isoforms O 0 5.279936431179522e-06
related O 0 2.3783288725098828e-06
to O 0 9.508136713520798e-07
cognitive B-Disease 0 0.006120643112808466
impairment I-Disease 1 0.9954279661178589
in O 0 0.007980162277817726
Duchenne B-Disease 1 0.999967098236084
muscular I-Disease 1 0.9999212026596069
dystrophy I-Disease 1 0.9998117089271545
? O 0 0.05542610213160515

Molecular O 0 0.00016910539125092328
study O 0 2.108011813106714e-06
and O 0 2.0516634435807646e-07
neuropsychological O 0 1.5021882973087486e-05
analysis O 0 2.3826326867038006e-07
were O 0 6.310747835414077e-08
performed O 0 7.188785389189434e-07
concurrently O 0 5.944392569290358e-07
on O 0 2.8886599920951994e-06
49 O 0 2.7496642360347323e-05
patients O 0 2.908360693254508e-05
with O 0 0.00010129777365364134
Duchenne B-Disease 1 0.9999014139175415
muscular I-Disease 1 0.9999208450317383
dystrophy I-Disease 1 0.9998102784156799
( O 0 0.00010714532982092351
DMD B-Disease 1 0.9987818598747253
) O 0 5.717849944630871e-07
in O 0 7.854003314378133e-08
order O 0 3.0921949445428254e-08
to O 0 3.614126997675271e-09
find O 0 3.443919283085961e-08
a O 0 8.212044377842176e-08
molecular O 0 1.725011657072173e-06
explanation O 0 1.7843038335740857e-07
for O 0 3.394900716102711e-08
the O 0 5.437580057332525e-07
cognitive B-Disease 0 0.00010546133853495121
impairment I-Disease 0 0.0003087731311097741
observed O 0 7.714023013249971e-06
in O 0 8.625661394034978e-07
most O 0 1.821820842451416e-05
DMD B-Disease 1 0.9993047714233398
patients O 0 0.0023723950143903494
. O 0 1.1853364412672818e-05

Complete O 0 7.068598279147409e-06
analysis O 0 6.960855216675554e-07
of O 0 6.371899985424534e-08
the O 0 2.6502203809286584e-07
dystrophin O 0 2.5761326469364576e-05
gene O 0 2.84595375887875e-06
was O 0 3.7340887502068654e-06
performed O 0 2.9860319727958995e-07
to O 0 1.0002648487272836e-08
define O 0 1.5621725424352917e-07
the O 0 1.1852983305971065e-07
localization O 0 2.103084170812508e-06
of O 0 6.198941804314018e-08
deletions O 0 4.786682893609395e-06
and O 0 2.8323944434305304e-07
duplications O 0 1.1123230251541827e-05
in O 0 2.308622129021387e-07
relation O 0 3.639381134235009e-07
to O 0 5.565138749830112e-08
the O 0 2.858425602880743e-07
different O 0 1.1506521104820422e-06
DMD B-Disease 1 0.9971309900283813
promoters O 0 0.0007596980431117117
. O 0 1.3713515727431513e-05

Qualitative O 0 1.7089898392441683e-05
analysis O 0 1.3447687479128945e-06
of O 0 1.0731545785347407e-07
the O 0 4.121376662169496e-07
Dp71 O 0 3.736469443538226e-05
transcript O 0 9.168630640488118e-06
and O 0 1.4194283437518607e-07
testing O 0 3.314089553896338e-07
for O 0 6.028455956652579e-09
the O 0 6.2619336382852e-09
specific O 0 5.4143858285726765e-09
first O 0 5.1582432547547796e-08
exon O 0 9.03278021269216e-07
of O 0 1.6393636670386513e-08
Dp140 O 0 2.504060375940753e-06
were O 0 1.3136069298980146e-07
also O 0 8.633934811541621e-08
carried O 0 8.271147748928342e-07
out O 0 4.1360789282407495e-07
. O 0 1.2253208296897355e-06

Neuropsychological O 0 0.0026456560008227825
analysis O 0 1.9636976503534243e-05
assessed O 0 1.2432571566023398e-05
verbal O 0 1.0421708793728612e-05
and O 0 5.212411906541092e-07
visuospatial O 0 0.000148519771755673
intelligence O 0 1.9331229850649834e-05
, O 0 4.6667958031321177e-07
verbal O 0 4.528536919679027e-06
memory O 0 0.00046963593922555447
, O 0 5.602798864856595e-07
and O 0 2.1532723337713833e-07
reading O 0 6.743026460753754e-06
skills O 0 3.051523344765883e-05
. O 0 1.014875033433782e-05

Comparison O 0 1.2343410162429791e-05
of O 0 4.075816661952558e-07
molecular O 0 3.660629226942547e-05
and O 0 1.0161077170778299e-06
psychometric O 0 0.00040020665619522333
findings O 0 7.986285709193908e-06
demonstrated O 0 3.047937980227289e-06
that O 0 2.4127141173835298e-08
deletions O 0 9.927439350576606e-07
and O 0 4.342343018493011e-08
duplications O 0 1.3314260058905347e-06
that O 0 3.4619649369460603e-08
were O 0 3.9626115722057875e-08
localized O 0 5.577477168117184e-06
in O 0 1.6283233605918213e-07
the O 0 1.0447639198218894e-07
distal O 0 1.4620155525335576e-05
part O 0 5.656589223690389e-07
of O 0 4.0419770641619834e-08
the O 0 1.5297207767162035e-07
gene O 0 1.2078804729753756e-06
seemed O 0 9.149040920419793e-07
to O 0 8.215330637995066e-09
be O 0 3.027029649160795e-08
preferentially O 0 3.4646242852431897e-07
associated O 0 5.425971494332771e-07
with O 0 1.1886528454851941e-06
cognitive B-Disease 0 0.0022749104537069798
impairment I-Disease 0 0.4052320420742035
. O 0 2.685652725631371e-05

Two O 0 3.4860190680774394e-06
altered O 0 4.739197174785659e-05
Dp71 O 0 5.896850416320376e-05
transcripts O 0 3.2222676509263692e-06
and O 0 4.949095355755162e-08
two O 0 2.5992001440044987e-08
deleted O 0 4.5392326342152955e-07
Dp140 O 0 1.3638449445352308e-06
DNA O 0 1.9447593047061673e-07
sequences O 0 4.01161628360569e-08
were O 0 1.6567403449130325e-08
found O 0 5.475954978351183e-08
in O 0 3.564842288028558e-08
four O 0 6.695447041238367e-07
patients O 0 1.2657422303163912e-05
with O 0 5.433769183582626e-05
severe O 1 0.9996542930603027
cerebral B-Disease 1 0.9998682737350464
dysfunction I-Disease 1 0.9988080263137817
. O 0 0.00010826614015968516

These O 0 1.0303457429472473e-06
findings O 0 3.295737997177639e-06
suggest O 0 2.7971327654086053e-07
that O 0 3.513658475284842e-09
some O 0 1.408719474405018e-09
sequences O 0 6.727167800590905e-08
located O 0 2.5107601686613634e-07
in O 0 3.344205978805803e-08
the O 0 3.845840623739605e-08
distal O 0 4.70699751531356e-06
part O 0 1.9025355868507177e-07
of O 0 2.7192820439836396e-08
the O 0 4.589333357785108e-08
gene O 0 4.6119200192151766e-07
and O 0 1.3436006440770143e-07
, O 0 4.7463892371979455e-08
in O 0 4.85849263043292e-08
particular O 0 1.4181449792260992e-08
, O 0 3.2553675310964536e-08
some O 0 2.7900348698040034e-08
DMD B-Disease 0 0.015506057068705559
isoforms O 0 7.443597382916778e-07
expressed O 0 4.620998197424342e-07
in O 0 4.5493086986425624e-07
the O 0 4.701613761426415e-06
brain O 1 0.774273693561554
may O 0 2.3501722807850456e-06
be O 0 4.418681953666237e-08
related O 0 1.7533987772822002e-07
to O 0 5.338280928413042e-08
the O 0 2.840105253198999e-06
cognitive B-Disease 0 0.0013496753526851535
impairment I-Disease 0 0.06290560960769653
associated O 0 6.457496056100354e-05
with O 0 3.944702257285826e-05
DMD B-Disease 1 0.9996621608734131
. O 0 6.875069630041253e-06
. O 0 5.161411081644474e-06

I1307K O 0 0.000868113711476326
APC O 0 0.00022784747125115246
and O 0 1.991015778912697e-06
hMLH1 O 0 0.00021551334066316485
mutations O 0 4.851708217756823e-05
in O 0 4.559180979413213e-07
a O 0 1.1979412875007256e-06
non O 0 5.615676400338998e-06
- O 0 3.808320252574049e-05
Jewish O 0 2.5304575501650106e-06
family O 0 2.5192225621140096e-06
with O 0 3.410605131648481e-06
hereditary B-Disease 1 0.9987800717353821
non I-Disease 1 0.9981130361557007
- I-Disease 1 0.9999512434005737
polyposis I-Disease 1 0.9999599456787109
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
. O 0 0.0003505715576466173

We O 0 5.816174052597489e-06
describe O 0 6.435047453123843e-06
a O 0 6.52998505756841e-06
French O 0 0.00027974412660114467
Canadian O 0 0.0019823177717626095
hereditary B-Disease 1 0.9986457228660583
non I-Disease 1 0.9985425472259521
- I-Disease 1 0.9999576807022095
polyposis I-Disease 1 0.9999586343765259
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
( O 0 0.0002214854466728866
HNPCC B-Disease 1 0.9643099904060364
) O 0 7.738965450698743e-07
kindred O 0 4.212732528685592e-05
which O 0 1.4521387470267655e-07
carries O 0 1.3300224281920237e-06
a O 0 1.637431410017598e-06
novel O 0 1.0350058801122941e-05
truncating O 0 0.00019113527378067374
mutation O 0 0.0001396412553731352
in O 0 2.5388478661625413e-06
hMLH1 O 0 0.0005727998213842511
. O 0 1.2631316167244222e-05

Interestingly O 0 6.2827646615915e-05
, O 0 7.734965947747696e-07
the O 0 2.9196078799031966e-07
I1307K O 0 2.8326958272373304e-05
APC O 0 3.073846528423019e-05
polymorphism O 0 7.91102138464339e-06
, O 0 1.2126895398978377e-07
associated O 0 1.602357144747657e-07
with O 0 3.9360735115678835e-08
an O 0 4.1237589698539523e-07
increased O 0 1.8632244973559864e-05
risk O 0 0.006187328137457371
of O 0 0.10501901060342789
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
, O 0 1.7759321053745225e-05
is O 0 1.0439565585329547e-06
also O 0 2.4729661163291894e-07
present O 0 1.723056897162678e-07
in O 0 2.7990941475763975e-07
this O 0 1.2256276704647462e-07
family O 0 4.744027137348894e-06
. O 0 3.5711927921511233e-06

The O 0 4.178506969765294e-06
I1307K O 0 7.972544699441642e-05
polymorphism O 0 1.3228298485046253e-05
has O 0 5.459794465423329e-07
previously O 0 3.0703387210451183e-07
only O 0 1.179688613461849e-08
been O 0 7.970415794034125e-08
identified O 0 7.951890523827387e-08
in O 0 2.0884122875486355e-08
individuals O 0 8.034978016269179e-09
of O 0 1.4525653568853159e-07
self O 0 0.00014435825869441032
- O 0 0.02006494253873825
reported O 0 7.084070239216089e-05
Ashkenazi O 0 4.9818660045275465e-05
Jewish O 0 4.93155903313891e-06
origins O 0 1.4951679986552335e-05
. O 0 5.260038960841484e-06

In O 0 1.7386918216288905e-06
addition O 0 7.786715059410199e-07
, O 0 1.5215293558412668e-07
in O 0 9.138910428418967e-08
this O 0 3.57064706690835e-08
family O 0 7.419246230710996e-07
, O 0 1.0582311915641185e-07
there O 0 5.382242918017255e-08
appears O 0 3.183383228133607e-07
to O 0 5.667867064573784e-09
be O 0 1.8922769129403605e-08
no O 0 1.1036606295533602e-08
relationship O 0 6.838998700686716e-08
between O 0 4.971489175886745e-08
the O 0 9.288866920087457e-08
I1307K O 0 2.6819973300007405e-06
polymorphism O 0 8.24821825062827e-07
and O 0 4.469216463576231e-08
the O 0 5.412591974618408e-08
presence O 0 6.590927341676434e-07
or O 0 6.489264592346444e-07
absence O 0 1.2880749636678956e-05
of O 0 8.315356353705283e-06
cancer B-Disease 1 0.9975329637527466
. O 0 2.252184231110732e-06
. O 0 3.874572939821519e-06

Identification O 0 6.085271706979256e-06
of O 0 2.882534886339272e-07
a O 0 1.371790290249919e-06
novel O 0 2.125363835148164e-06
mutation O 0 5.031501586927334e-06
of O 0 3.90157843810357e-08
the O 0 1.412412018453324e-07
CPO O 0 1.0426620065118186e-05
gene O 0 1.454779521736782e-06
in O 0 1.643290232777872e-07
a O 0 1.783553102541191e-06
Japanese O 0 5.1244747737655416e-05
hereditary B-Disease 1 0.9209515452384949
coproporphyria I-Disease 0 0.13484136760234833
family O 0 0.00022309472842607647
. O 0 1.8699103748076595e-05

Hereditary B-Disease 1 0.9933885335922241
coproporphyria I-Disease 1 0.8324001431465149
( O 0 4.181022086413577e-05
HCP B-Disease 1 0.556190013885498
) O 0 1.0460574912940501e-06
is O 0 7.138802970985125e-07
an O 0 2.3137451989896363e-06
autosomal B-Disease 1 0.9972652196884155
dominant I-Disease 1 0.9994184970855713
disease I-Disease 1 0.9998599290847778
characterized O 0 0.002872313605621457
by O 0 8.447341315331869e-06
a O 0 0.0019855648279190063
deficiency B-Disease 1 0.9982089996337891
of I-Disease 0 8.509711619808513e-07
coproporphyrinogen I-Disease 0 0.0009531230316497386
oxidase I-Disease 0 3.357824607519433e-05
( O 0 5.581088089456898e-07
CPO O 0 1.91851122508524e-05
) O 0 1.4859459440685896e-07
caused O 0 9.366808058075549e-07
by O 0 2.7803558566574793e-08
a O 0 4.250726419741113e-07
mutation O 0 3.136716713925125e-06
in O 0 8.382082228308718e-08
the O 0 3.2420953743894643e-07
CPO O 0 2.4006791136343963e-05
gene O 0 1.3131328159943223e-05
. O 0 2.5762649329408305e-06

Only O 0 2.1926375666225795e-06
11 O 0 2.8247516183910193e-06
mutations O 0 3.52901815858786e-06
of O 0 1.8866872508738197e-08
the O 0 8.435731047029549e-08
gene O 0 6.343851737256045e-07
have O 0 6.21158235958319e-08
been O 0 7.532849508606887e-07
reported O 0 6.0578258853638545e-06
in O 0 2.539273964430322e-06
HCP B-Disease 1 0.9568828344345093
patients O 0 0.0004486507677938789
. O 0 6.165822469483828e-06

We O 0 6.9570196501445025e-06
report O 0 1.3879247262593708e-06
another O 0 3.209477199561661e-07
mutation O 0 3.651560291473288e-06
in O 0 1.032828436109412e-07
a O 0 7.355978937084728e-07
Japanese O 0 7.304636710614432e-06
family O 0 1.2672991942963563e-05
. O 0 4.910940788249718e-06

Polymerase O 0 0.00017666022176854312
chain O 0 0.0001791645772755146
reaction O 0 2.221633076260332e-05
- O 0 1.608734964975156e-05
single O 0 1.2280700047995197e-06
strand O 0 4.194861048745224e-06
conformational O 0 9.691627838037675e-07
polymorphism O 0 4.24385262931537e-07
and O 0 1.145716232997529e-08
direct O 0 2.5637984180093554e-08
sequence O 0 2.7089240006716864e-07
analyses O 0 3.982691794135462e-07
demonstrated O 0 2.3109195979031938e-07
a O 0 2.1464266808379762e-07
C O 0 2.25110852625221e-06
to O 0 2.946088528688051e-08
T O 0 3.0889730169292307e-06
substitution O 0 2.2996472281988645e-08
in O 0 1.998528453839299e-08
exon O 0 6.757059054507408e-07
1 O 0 5.892708543342451e-08
of O 0 4.386409457879381e-09
the O 0 3.502385581555245e-08
CPO O 0 1.899188760035031e-06
gene O 0 1.9721774435765838e-07
at O 0 4.034687322018726e-07
nucleotide O 0 5.45259808859555e-07
position O 0 5.929061330789409e-07
85 O 0 7.102215136001178e-07
, O 0 5.227036936616969e-08
which O 0 4.239132067596074e-08
lies O 0 3.457758452896087e-07
in O 0 5.6406928905516907e-08
the O 0 1.6175201267287775e-07
putative O 0 4.415675903146621e-06
presequence O 0 5.705763214791659e-06
for O 0 1.7632679316648137e-08
targeting O 0 1.7069859836738033e-07
to O 0 9.03236951899089e-08
mitochondria O 0 1.6912430510274135e-05
. O 0 3.3542723940627184e-06

This O 0 2.1101800484757405e-06
mutation O 0 3.5746812500292435e-05
changes O 0 1.1596735021157656e-06
the O 0 1.4184188046328927e-07
codon O 0 1.5119421732379124e-06
for O 0 1.4614213839081458e-08
glutamine O 0 4.6497410721713095e-07
to O 0 1.4781039503475313e-08
a O 0 3.0302246045721404e-07
termination O 0 4.3414588617451955e-06
codon O 0 3.2543639463256113e-06
at O 0 1.5616647033311892e-06
amino O 0 1.471004566155898e-06
acid O 0 9.621623576094862e-06
position O 0 3.2154280233953614e-06
29 O 0 1.3800549822917674e-05
. O 0 1.6517760741407983e-06

MaeI O 0 0.0009394407388754189
restriction O 0 5.967458491795696e-06
analysis O 0 4.6455923552457534e-07
showed O 0 7.607605994053301e-07
two O 0 1.4725464403397837e-08
other O 0 8.665078432557038e-09
carriers O 0 4.4317985725683684e-07
in O 0 1.6697987348379684e-07
the O 0 5.262480158307881e-07
family O 0 6.373344149324112e-06
. O 0 4.642980456992518e-06

The O 0 4.4662283471552655e-05
C O 0 0.007193447556346655
- O 0 0.05970116704702377
T O 0 0.022320622578263283
mutation O 0 2.2419460947276093e-05
is O 0 1.6409660474892007e-07
located O 0 2.627335220495297e-07
within O 0 7.150564584890162e-08
a O 0 9.387268846694496e-07
recently O 0 3.6295659811003134e-06
proposed O 0 7.307816645152343e-07
putative O 0 1.7738112774168258e-06
alternative O 0 5.036043830841663e-07
translation O 0 3.7405681041491334e-07
initiation O 0 2.1468597424245672e-06
codon O 0 9.500917258264963e-06
( O 0 4.603334105013346e-07
TIC O 0 8.848456491250545e-05
- O 0 9.017562661028933e-06
1 O 0 2.450384499752545e-07
) O 0 1.745116762208454e-08
, O 0 1.0946667572397928e-08
supporting O 0 1.1029035817955446e-07
that O 0 4.151442567490449e-08
TIC O 0 0.0001355572312604636
- O 0 1.2119686289224774e-05
1 O 0 2.669282253009442e-07
is O 0 5.733674868224625e-08
the O 0 7.868668205901486e-08
real O 0 7.690201186960621e-07
TIC O 0 2.611629133753013e-05
rather O 0 9.366024755763647e-08
than O 0 1.89021065466477e-07
TIC O 0 0.000154822992044501
- O 0 1.4824323443463072e-05
2 O 0 1.0754347385955043e-06
. O 0 1.810634699950242e-07
. O 0 9.252429435946397e-07

Human B-Disease 0 5.991368379909545e-05
complement I-Disease 0 0.00021212427236605436
factor I-Disease 0 0.06820297241210938
H I-Disease 1 0.9999512434005737
deficiency I-Disease 1 0.9997770190238953
associated O 0 0.06973885744810104
with O 1 0.6220152378082275
hemolytic B-Disease 1 0.9999852180480957
uremic I-Disease 1 0.9999951124191284
syndrome I-Disease 1 0.9999914169311523
. O 0 0.0011565390741452575

This O 0 9.247004300050321e-07
study O 0 4.0991898231368395e-07
reports O 0 1.876338160400337e-07
on O 0 3.16215448492585e-07
six O 0 4.960643877893745e-07
cases O 0 6.700135486426007e-07
of O 0 2.8412378014763817e-06
deficiency B-Disease 1 0.9992948770523071
in I-Disease 0 1.2492314738210553e-07
the I-Disease 0 5.843829598006778e-08
human I-Disease 0 8.941522366967547e-08
complement I-Disease 0 2.384273898314859e-07
regulatory I-Disease 0 5.636924015561817e-06
protein I-Disease 0 3.2468403787788702e-06
Factor I-Disease 0 4.591233846440446e-06
H I-Disease 1 0.9565606117248535
( O 0 8.549309313821141e-07
FH O 0 6.945206405362114e-05
) O 0 3.1882709805586273e-08
in O 0 1.4576687412670708e-08
the O 0 1.4085482114012393e-08
context O 0 9.809239998048724e-08
of O 0 2.999906882905634e-07
an O 0 0.0009643743396736681
acute B-Disease 1 0.9999150037765503
renal I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999980926513672
. O 0 0.001302613876760006

Five O 0 1.4830792451903108e-06
of O 0 8.128594686240831e-08
the O 0 2.9712015248151147e-07
cases O 0 1.6479545195124956e-07
were O 0 6.421974063641755e-08
observed O 0 6.460052190959686e-07
in O 0 1.5236146566621755e-07
children O 0 3.750140820102388e-07
presenting O 0 3.099605964962393e-05
with O 0 0.008605454117059708
idiopathic O 1 0.9999641180038452
hemolytic B-Disease 1 0.9999978542327881
uremic I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999977350234985
( O 0 0.003702931571751833
HUS B-Disease 1 0.9996013045310974
) O 0 2.3219361537485383e-05
. O 0 2.1881545762880705e-05

Two O 0 3.670819239687262e-07
of O 0 6.886435954811532e-08
the O 0 2.3167559959347273e-07
children O 0 6.125366667220078e-07
exhibited O 0 6.117331940913573e-05
a O 0 0.00019507056276779622
homozygous O 0 0.018028218299150467
deficiency O 1 0.9986037611961365
characterized O 0 6.632975419051945e-05
by O 0 1.2825104533931153e-07
the O 0 2.3886161670816364e-07
absence O 0 1.1247501561229e-06
of O 0 2.3420669847951103e-08
the O 0 1.5205894499104033e-07
150 O 0 3.8782081901445054e-07
- O 0 8.219193659897428e-06
kD O 0 1.061142666003434e-05
form O 0 1.5590055113534618e-07
of O 0 8.345853075297782e-08
Factor O 0 2.5883416583383223e-06
H O 1 0.9375530481338501
and O 0 1.44073084129559e-07
the O 0 1.223739189981643e-07
presence O 0 2.3782352798207285e-07
, O 0 3.81914517788573e-08
upon O 0 3.4302964024846005e-08
immunoblotting O 0 7.137399734347127e-06
, O 0 4.0421543445745556e-08
of O 0 9.257450805932876e-09
the O 0 1.1964782231643767e-07
42 O 0 2.8829740585933905e-06
- O 0 1.3426490113488398e-05
kD O 0 5.097774192108773e-05
Factor O 0 3.292150722700171e-06
H O 0 0.01690433919429779
- O 0 6.82849395161611e-06
like O 0 1.3522144115540868e-07
protein O 0 3.196312263753498e-07
1 O 0 2.5357090294164664e-07
( O 0 6.074731118133059e-08
FHL O 0 2.3683793187956326e-05
- O 0 2.8198828658787534e-06
1 O 0 1.145873937957731e-07
) O 0 9.853320825925493e-09
and O 0 1.391909787429313e-08
other O 0 4.0622804675649604e-08
FH O 0 0.00016461451014038175
- O 0 3.8134658097987995e-05
related O 0 2.364549118283321e-06
protein O 0 3.645248398242984e-06
( O 0 4.846913839173794e-07
FHR O 0 8.227255602832884e-05
) O 0 4.832826903111709e-07
bands O 0 1.7901353203342296e-05
. O 0 3.836356881947722e-06

Southern O 0 3.310288593638688e-05
blot O 0 0.00019964193052146584
and O 0 2.1743950640029652e-07
PCR O 0 2.1339344584703213e-06
analysis O 0 1.0411871187443467e-07
of O 0 1.645419089868483e-08
DNA O 0 5.076965408079559e-07
of O 0 2.9597185147167693e-08
one O 0 3.766887175515876e-07
patient O 0 2.3670065274927765e-05
with O 0 4.755065674544312e-06
homozygous O 0 0.0097995949909091
deficiency O 1 0.998336672782898
ruled O 0 1.813016388041433e-05
out O 0 5.0453213162882093e-08
the O 0 2.9295863512857068e-08
presence O 0 9.384604027218302e-08
of O 0 7.472358731774875e-09
a O 0 1.2507645408277313e-07
large O 0 1.2071244270828174e-07
deletion O 0 1.5183709365373943e-06
of O 0 2.495710305083776e-08
the O 0 2.1957795581784012e-07
FH O 0 7.441281923092902e-05
gene O 0 1.831920144468313e-06
as O 0 4.1099428926827386e-07
the O 0 1.8705845832300838e-06
underlying O 0 0.00039298206684179604
defect O 0 0.007016537711024284
for O 0 3.470398723948165e-06
the O 0 0.0014833550667390227
deficiency O 1 0.9993346333503723
. O 0 2.241114452772308e-05

The O 0 6.942974550838699e-07
other O 0 5.5852364511110864e-08
four O 0 8.61559286136071e-08
children O 0 1.229019801485265e-07
presented O 0 8.85764961822133e-07
with O 0 3.648444817372365e-06
heterozygous O 0 0.00033470106427557766
deficiency O 1 0.9754109382629395
and O 0 1.299106742180811e-07
exhibited O 0 4.556000476441113e-06
a O 0 5.095727146908757e-07
normal O 0 4.136850293434691e-06
immunoblotting O 0 2.306696660525631e-05
pattern O 0 2.325336481590057e-06
of O 0 1.0929769089784713e-08
proteins O 0 3.669285675300671e-08
of O 0 4.279181808897192e-08
the O 0 1.5024743333924562e-06
FH O 0 0.002621588297188282
family O 0 1.869061634351965e-05
. O 0 4.688494755100692e-06

Factor B-Disease 0 0.2953138053417206
H I-Disease 1 0.9999480247497559
deficiency I-Disease 1 0.9997281432151794
is O 0 5.277423952065874e-06
the O 0 1.2348899645076017e-06
only O 0 4.562009507935727e-06
complement B-Disease 1 0.9960951209068298
deficiency I-Disease 1 0.9999815225601196
associated O 0 0.0003621458017732948
with O 0 0.00011852705938508734
HUS B-Disease 1 0.9992189407348633
. O 0 8.242041803896427e-05

These O 0 5.645966325573681e-07
observations O 0 4.227104454912478e-06
suggest O 0 8.2548831414897e-07
a O 0 2.2307345659555722e-07
role O 0 5.060742296336684e-07
for O 0 2.4946592702690396e-07
FH O 0 0.00013585873239208013
and O 0 4.703734646227531e-07
/ O 0 2.16901971725747e-05
or O 0 1.3283415682963096e-06
FH O 0 0.0001043653828673996
receptors O 0 3.333982931508217e-06
in O 0 2.544298638440523e-07
the O 0 1.215511701957439e-06
pathogenesis O 0 0.005999340210109949
of O 0 2.4083585230982862e-05
idiopathic O 1 0.9994940757751465
HUS B-Disease 1 0.999805748462677
. O 0 4.678460391005501e-05
. O 0 1.3195802239351906e-05

Further O 0 1.2623263501154725e-06
evidence O 0 3.837601241230004e-07
for O 0 3.742412602036893e-08
a O 0 1.1156695336467237e-06
major O 0 2.7352436518413015e-05
ancient O 0 0.00014544508303515613
mutation O 0 0.09810375422239304
underlying O 1 0.9251884818077087
myotonic B-Disease 1 0.9998723268508911
dystrophy I-Disease 1 0.9998971223831177
from O 0 7.299239769054111e-06
linkage O 0 0.00011903401900781319
disequilibrium O 0 0.00040315918158739805
studies O 0 2.96554730994103e-06
in O 0 2.224442141596228e-07
the O 0 2.2025749046861165e-07
Japanese O 0 4.009867552667856e-06
population O 0 5.122477659824654e-07
. O 0 3.6262065350456396e-06

The O 0 0.018666794523596764
myotonic B-Disease 1 0.9998394250869751
dystrophy I-Disease 1 0.9999781847000122
( O 0 0.0020577700342983007
DM B-Disease 1 0.9998005032539368
) O 0 7.076550900819711e-06
mutation O 0 0.00011795877799158916
is O 0 1.5007930187493912e-06
an O 0 9.916869885273627e-07
unstable O 0 0.008381341584026814
( O 0 6.488614872068865e-07
CTG O 0 4.013344005215913e-05
) O 0 2.3756422251608456e-07
n O 0 2.914388232966303e-06
repeat O 0 1.8174578144680709e-06
, O 0 2.4498675088580057e-08
present O 0 2.7485926423764795e-08
at O 0 4.757324916226935e-07
a O 0 4.006477638540673e-08
copy O 0 1.3309900737112912e-07
number O 0 6.359125670485355e-09
of O 0 7.923711464741245e-09
5 O 0 3.1388393040288065e-07
- O 0 3.921015832020203e-06
37 O 0 3.3003382782226254e-07
repeats O 0 3.894218991717935e-07
on O 0 3.6819962190293154e-08
normal O 0 1.286742019601661e-07
chromosomes O 0 1.0986812526425638e-07
but O 0 1.2906792967726233e-08
amplified O 0 2.2839159896648198e-07
to O 0 1.0216697710063727e-08
50 O 0 7.614655572751872e-08
- O 0 7.070668175401806e-07
3000 O 0 4.335896051088639e-07
copies O 0 3.4498600598453777e-07
on O 0 8.23901700641727e-06
DM B-Disease 1 0.991292417049408
chromosomes O 0 5.088793477625586e-05
. O 0 7.380373062915169e-06

Previous O 0 6.796803791075945e-05
findings O 0 1.640307527850382e-05
in O 0 1.0120317028849968e-06
Caucasian O 0 2.0868112187599763e-05
populations O 0 8.982887607089651e-07
of O 0 4.667556936510664e-07
a O 0 0.00024155707797035575
DM B-Disease 1 0.999873161315918
founder O 0 0.0004730476066470146
chromosome O 0 9.882782615022734e-05
raise O 0 2.0118204702157527e-06
a O 0 2.2948457001348288e-07
question O 0 9.948710300022867e-08
about O 0 1.1256902965328663e-08
the O 0 2.6575213141200038e-08
molecular O 0 1.1215902304684278e-06
events O 0 1.0407443795656945e-07
involved O 0 1.1361979801449706e-07
in O 0 1.0759378454849866e-07
the O 0 1.6171314598523168e-07
expansion O 0 1.4833020031801425e-05
mutation O 0 0.00010854379797820002
. O 0 4.354603333922569e-06

To O 0 1.0756255051092012e-06
investigate O 0 4.58940485259518e-06
whether O 0 5.332805699254095e-07
a O 0 1.4679901596537093e-06
founder O 0 1.251308640348725e-05
chromosome O 0 1.9478888134472072e-05
for O 0 2.7700900773197645e-07
the O 0 1.3514565580408089e-05
DM B-Disease 1 0.9994683861732483
mutation O 0 8.14153827377595e-05
exists O 0 5.123131927575741e-07
in O 0 7.816880298605611e-08
the O 0 6.94896371555842e-08
Japanese O 0 8.438722716164193e-07
population O 0 3.264420556092773e-08
, O 0 4.003712206213095e-08
we O 0 4.4576552227226784e-08
genotyped O 0 3.2528405427001417e-06
families O 0 1.787956804832902e-08
using O 0 1.7115273465151404e-07
polymorphic O 0 1.0577367902442347e-05
markers O 0 8.40475331642665e-06
near O 0 1.5324527339544147e-05
the O 0 4.2080688444912084e-07
( O 0 2.6963436994265066e-07
CTG O 0 3.606532482081093e-05
) O 0 1.435089416190749e-07
n O 0 5.243441137281479e-06
repeat O 0 6.55161784379743e-06
region O 0 1.423985509063641e-06
and O 0 3.021051782070572e-07
constructed O 0 5.953120125923306e-05
haplotypes O 0 0.00018040722352452576
. O 0 1.0588792065391317e-05

Six O 0 8.446903621006641e-07
different O 0 6.791876216993842e-08
haplotypes O 0 3.489331675154972e-06
were O 0 1.9744658175113727e-07
found O 0 4.605714138961048e-07
and O 0 6.119212798694207e-07
DM B-Disease 1 0.9986417889595032
alleles O 0 7.517687208746793e-06
were O 0 7.979402880664566e-07
always O 0 1.9194878859707387e-06
haplotype O 0 5.756720929639414e-05
A O 0 2.3417211195919663e-05
. O 0 5.779058483312838e-06

To O 0 2.2213448858110496e-07
find O 0 2.776853591512918e-07
an O 0 3.9254199890592645e-08
origin O 0 5.913763345688494e-08
of O 0 5.6162910766488494e-08
the O 0 3.909333941010118e-07
( O 0 2.730456856170349e-07
CTG O 0 3.5573586501413956e-05
) O 0 1.8083466102325474e-07
n O 0 4.305085894884542e-06
repeat O 0 7.246236691571539e-06
mutation O 0 2.6655427518562647e-06
and O 0 2.196633630546785e-08
to O 0 1.0437775976868124e-08
investigate O 0 1.2012276329187443e-07
the O 0 2.8017456799034335e-08
mechanism O 0 3.237831265323621e-07
of O 0 8.055955902364076e-09
the O 0 5.591525464865299e-08
expansion O 0 7.934313543955795e-07
mutation O 0 1.6157208619915764e-06
in O 0 4.6595332037213666e-08
the O 0 4.225973171401165e-08
Japanese O 0 5.38645281267236e-07
population O 0 7.919918942889126e-09
we O 0 1.7264477847334092e-08
have O 0 7.637648735681069e-09
studied O 0 1.9633198178325983e-07
90 O 0 2.2098673468917696e-07
Japanese O 0 4.174467903794721e-06
DM B-Disease 1 0.9943475127220154
families O 0 7.064078033636179e-08
comprising O 0 2.4278725163640047e-07
190 O 0 4.3343084143998567e-07
affected O 0 4.07834789939443e-07
and O 0 1.6229562049829838e-07
130 O 0 9.687561259852373e-07
unaffected O 0 2.525295531086158e-05
members O 0 4.985442956240149e-07
. O 0 2.6092645839526085e-06

The O 0 7.088113306963351e-06
results O 0 1.1408463251427747e-05
suggest O 0 9.250646826330922e-07
that O 0 2.790045350309356e-08
a O 0 2.806447696457326e-07
few O 0 9.940459477775221e-08
common O 0 3.836412076907436e-07
ancestral O 0 4.588371666613966e-06
mutations O 0 1.596019501448609e-05
in O 0 1.5544446796411648e-07
both O 0 8.006573182228749e-08
Caucasian O 0 1.4048628145246767e-05
and O 0 2.8474963187363755e-07
Japanese O 0 2.0204652173561044e-06
populations O 0 2.0824744240144355e-07
have O 0 2.2681957645431794e-08
originated O 0 6.524785334249827e-08
by O 0 1.254859682831011e-08
expansion O 0 1.301971792599943e-07
of O 0 1.0355619473045863e-08
an O 0 3.075079746395204e-08
ancestral O 0 1.5761960412419285e-06
n O 0 9.927943210641388e-06
= O 0 2.8943572942807805e-06
5 O 0 1.7682127406715153e-07
repeat O 0 5.869521828572033e-07
to O 0 3.547532401171338e-08
n O 0 4.053104930790141e-06
= O 0 4.372097464511171e-06
19 O 0 9.982989013224142e-07
- O 0 2.905017481680261e-06
37 O 0 4.2533869759608933e-07
copies O 0 2.5620443011575844e-07
. O 0 1.0187410452999757e-06

These O 0 1.4655532254437276e-07
data O 0 5.602900046142167e-07
support O 0 2.0914025355978083e-07
multistep O 0 8.324521331815049e-06
models O 0 2.9019686280662427e-06
of O 0 2.3077569721863256e-07
triplet O 0 0.0006639364291913807
repeat O 0 1.3006620065425523e-05
expansion O 0 1.4417853435588768e-06
that O 0 2.0194306671328377e-08
have O 0 9.491239794101602e-09
been O 0 1.0646530057556447e-07
proposed O 0 1.5910767103832768e-07
for O 0 4.9957186831761646e-08
both O 0 2.462005795678124e-06
DM B-Disease 1 0.9997119307518005
and O 0 1.3047356333117932e-05
Friedreichs B-Disease 0 0.034679561853408813
ataxia I-Disease 1 0.9792441725730896
. O 0 1.0399568964203354e-05
. O 0 9.57316024141619e-06

The O 0 3.2350365017919103e-06
molecular O 0 7.03040641383268e-05
basis O 0 1.1595581781875808e-05
of O 0 0.0004955699550919235
C6 B-Disease 1 0.9999861717224121
deficiency I-Disease 1 0.999993085861206
in O 0 4.272960723028518e-06
the O 0 7.321489192690933e-07
western O 0 6.506189492938574e-06
Cape O 0 2.8469463359215297e-05
, O 0 3.335530323056446e-07
South O 0 1.4154231848806376e-06
Africa O 0 2.544750259403372e-06
. O 0 4.151207576796878e-06

Deficiency B-Disease 1 0.9981525540351868
of I-Disease 0 8.326151714754815e-07
the I-Disease 0 1.4965139598643873e-06
sixth I-Disease 0 9.3109963927418e-05
component I-Disease 0 4.574010745272972e-06
of I-Disease 0 1.2776200719599728e-07
human I-Disease 0 8.582296118220256e-07
complement I-Disease 0 1.4487927728623617e-06
( O 0 7.038764806566178e-07
C6 O 0 0.001180399558506906
) O 0 1.2395571502565872e-07
has O 0 2.3547482896901784e-07
been O 0 1.8933714329705253e-07
reported O 0 7.796627414791146e-07
in O 0 1.2129620863277069e-08
a O 0 3.152840122311318e-08
number O 0 9.37819510937743e-09
of O 0 6.103590077799481e-09
families O 0 1.0117603643777784e-08
from O 0 3.3457567383265996e-08
the O 0 6.068802349545876e-08
western O 0 1.033218040902284e-06
Cape O 0 9.918147952703293e-06
, O 0 2.4452373281746986e-07
South O 0 9.325130463366804e-07
Africa O 0 1.958967231985298e-06
. O 0 2.7499568204802927e-06

Meningococcal B-Disease 1 0.996185839176178
disease I-Disease 1 0.9997188448905945
is O 0 0.00021635954908560961
endemic O 0 0.00043364925659261644
in O 0 3.698015405007027e-07
the O 0 5.708456569664122e-07
Cape O 0 3.7411177800095174e-06
and O 0 3.984559882042049e-08
almost O 0 3.536742809728821e-08
all O 0 1.5981383327812182e-08
pedigrees O 0 3.956241016567219e-06
of O 0 1.0946793054245063e-06
total O 0 0.00037882092874497175
C6 B-Disease 1 0.9999511241912842
deficiency I-Disease 1 0.999984860420227
( O 0 6.49821549814078e-06
C6Q0 O 0 0.0010713607771322131
) O 0 1.949606058815334e-07
have O 0 6.017533138447106e-08
been O 0 3.699648800647992e-07
ascertained O 0 4.304839421820361e-06
because O 0 1.2211374951220932e-06
of O 0 3.1346742161986185e-06
recurrent O 1 0.9989743232727051
disease O 1 0.9996198415756226
. O 0 3.864182508550584e-05

We O 0 2.607274382171454e-06
have O 0 7.231555798625777e-08
sequenced O 0 1.9419214822846698e-06
the O 0 8.265377715588329e-08
expressed O 0 8.876661894419158e-08
exons O 0 9.559753380017355e-07
of O 0 5.320654139495673e-08
the O 0 3.951807343582914e-07
C6 O 0 0.00022253069619182497
gene O 0 6.231185238902981e-07
from O 0 4.608815729056914e-08
selected O 0 4.017113752752266e-08
cases O 0 3.687914329475461e-08
and O 0 2.1250176729381565e-08
have O 0 2.2770516139303254e-08
found O 0 1.0148588813763126e-07
three O 0 1.326484095898195e-07
molecular O 0 0.00023164221784099936
defects O 1 0.9848100543022156
leading O 0 0.00010015307634603232
to O 0 4.4543153876475117e-07
total O 0 1.776882345438935e-05
deficiency O 1 0.9981579184532166
879delG O 0 0.0003287233703304082
, O 0 4.503762056629057e-07
which O 0 8.2936139733647e-08
is O 0 7.538167778875504e-08
the O 0 1.9925248295749043e-07
common O 0 4.1583675738365855e-06
defect O 0 0.0011958213290199637
in O 0 2.7949144509875623e-07
the O 0 6.695377123833168e-07
Cape O 0 8.811606676317751e-06
and O 0 2.026917798048089e-07
hitherto O 0 8.2837132140412e-06
unreported O 0 2.5274669042119058e-06
, O 0 9.799946099064982e-08
and O 0 7.679854263642483e-08
1195delC O 0 1.6391735698562115e-05
and O 0 1.8878758112350624e-07
1936delG O 0 1.1279757927695755e-05
, O 0 4.764493866105113e-08
which O 0 1.552870543264362e-08
have O 0 1.2895523759937078e-08
been O 0 1.3703228773920273e-07
previously O 0 5.074400064586371e-07
reported O 0 9.389461865794146e-07
in O 0 6.256814089056206e-08
African O 0 4.897527787761646e-07
- O 0 4.143034675507806e-05
Americans O 0 7.231927270368033e-07
. O 0 1.9933070234401384e-06

We O 0 2.7996679818897974e-06
also O 0 1.7203508662078093e-07
show O 0 2.697925651773403e-07
that O 0 1.5894956462148002e-08
the O 0 1.6545557457448012e-07
879delG O 0 4.244540832587518e-05
and O 0 3.578423729777569e-06
1195delC O 0 0.00810300000011921
defects O 1 0.9917038679122925
are O 0 1.988301221444999e-07
associated O 0 2.578592557256343e-06
with O 0 1.0997857771144481e-06
characteristic O 0 0.004070329014211893
C6 O 1 0.994983434677124
/ O 0 0.008913321420550346
C7 O 0 0.16104353964328766
region O 0 1.8500231817597523e-05
DNA O 0 1.6899288311833516e-05
marker O 0 1.7348129404126666e-05
haplotypes O 0 7.029499556665542e-06
, O 0 1.316983713195441e-07
although O 0 9.129781375349921e-08
small O 0 9.24018479508959e-08
variations O 0 1.0223733397651813e-06
were O 0 5.913029781368095e-07
observed O 0 7.55905330152018e-06
. O 0 1.6607002635282697e-06

The O 0 2.6762489142129198e-05
1936delG O 0 0.0027031705249100924
defect O 0 0.010757213458418846
was O 0 2.679308454389684e-05
observed O 0 1.7470772490923991e-06
only O 0 5.362845101331004e-08
once O 0 8.372597335437604e-07
in O 0 1.0786912696403306e-07
the O 0 3.272903370543645e-07
Cape O 0 5.871665962331463e-06
, O 0 8.883707636186955e-08
but O 0 2.7922283152292948e-08
its O 0 5.70815252842749e-08
associated O 0 9.910942253554822e-07
haplotype O 0 1.9319140847073868e-05
could O 0 4.5849154162169725e-07
be O 0 1.1797790477885428e-07
deduced O 0 2.7766998300648993e-06
. O 0 1.3653180985784275e-06

The O 0 1.8363264189247275e-06
data O 0 8.248147196354694e-07
from O 0 1.0469502598198233e-07
the O 0 6.575395161689812e-08
haplotypes O 0 2.6371328658569837e-06
indicate O 0 3.868002522722236e-07
that O 0 7.153112768776282e-09
these O 0 4.6398254127666405e-09
three O 0 1.2061521204032033e-07
molecular O 0 0.00020136671082582325
defects O 0 0.4292573630809784
account O 0 1.3876292825898418e-07
for O 0 5.7525820551518336e-08
the O 0 5.077767582406523e-06
defects O 1 0.9572137594223022
in O 0 1.183615196964638e-07
all O 0 1.6457644136380623e-08
the O 0 3.195754345597379e-07
38 O 0 3.507936298774439e-06
unrelated O 0 5.0098783503926825e-06
C6Q0 O 0 6.369331094902009e-05
individuals O 0 2.960610423485832e-08
we O 0 5.504196209926704e-08
have O 0 2.9365738285491716e-08
studied O 0 8.305215146720002e-07
from O 0 1.3074465243789746e-07
the O 0 1.0720381169448956e-06
Cape O 0 5.799120117444545e-05
. O 0 3.1960057640390005e-06

We O 0 3.139544787700288e-06
have O 0 1.8724554706750496e-07
also O 0 2.1660252969013527e-07
observed O 0 5.430003966466757e-07
the O 0 2.4431440692751494e-07
879delG O 0 7.217912934720516e-05
defect O 0 0.00012285802222322673
in O 0 2.3063994092353823e-07
two O 0 1.8515723922973848e-06
Dutch O 0 0.2726265788078308
C6 B-Disease 1 0.9998905658721924
- I-Disease 1 0.9991413354873657
deficient I-Disease 1 0.9995747208595276
kindreds O 0 0.0008429056615568697
, O 0 7.209341106317879e-07
but O 0 1.8291639491962997e-07
the O 0 5.895574872738507e-07
879delG O 0 0.00032614273368380964
defect O 0 0.0005090652266517282
in O 0 5.776781790700625e-07
the O 0 8.514485330124444e-07
Cape O 0 1.8676166291697882e-05
probably O 0 1.275391468880116e-06
did O 0 6.19251281364086e-08
not O 0 4.152699517590008e-09
come O 0 8.926540395748361e-09
from O 0 9.54630596794459e-09
The O 0 3.8643850786002076e-08
Netherlands O 0 1.7670525949142757e-06
. O 0 2.6510039674576547e-07
. O 0 1.4717651311002555e-06

Complement B-Disease 1 0.833401620388031
C7 I-Disease 1 0.9999642372131348
deficiency I-Disease 1 0.9999914169311523
: O 0 5.319088359101443e-06
seven O 0 1.0520602700125892e-06
further O 0 9.437886774321669e-07
molecular O 0 0.007238147780299187
defects O 1 0.997428834438324
and O 0 6.451980425481452e-07
their O 0 4.696441351370595e-07
associated O 0 3.166558235534467e-05
marker O 0 0.00017138465773314238
haplotypes O 0 0.00018614284635987133
. O 0 7.810045644873753e-06

Seven O 0 3.4314559798076516e-06
further O 0 9.835897571974783e-07
molecular O 0 4.706369509221986e-05
bases O 0 4.326140333432704e-05
of O 0 0.0006836645770817995
C7 B-Disease 1 0.9999924898147583
deficiency I-Disease 1 0.9999966621398926
are O 0 9.448609489481896e-06
described O 0 0.00035487028071656823
. O 0 1.51277199620381e-05

All O 0 2.226131385896224e-07
these O 0 1.672425185006432e-07
new O 0 4.8957385843095835e-06
molecular O 0 0.0009778267703950405
defects O 0 0.3503357768058777
involve O 0 1.804416910999862e-06
single O 0 7.113642368494766e-06
- O 0 1.646144846745301e-05
nucleotide O 0 1.695390551503806e-06
events O 0 1.481290894389531e-07
, O 0 3.606065490657784e-08
deletions O 0 4.0489300090484903e-07
and O 0 1.8915155663989935e-08
substitutions O 0 3.866449844736053e-07
, O 0 2.003050703081044e-08
some O 0 2.5512700840835123e-09
of O 0 1.0785016435477246e-08
which O 0 2.929301423648667e-08
alter O 0 1.7125704516729456e-06
splice O 0 5.786602741864044e-06
sites O 0 9.443901376471331e-07
, O 0 1.0692051688465654e-07
and O 0 9.765426511876285e-08
others O 0 4.605230969900731e-07
codons O 0 1.973901999008376e-05
. O 0 3.870175532938447e-06

They O 0 7.181755563578918e-07
are O 0 2.5226883693107993e-08
distributed O 0 4.373262996182348e-08
along O 0 1.9773375470322208e-07
the O 0 4.497697148053703e-07
C7 O 0 0.0003617310430854559
gene O 0 2.8328745429462288e-06
, O 0 8.420315111834498e-08
but O 0 3.0023620922747796e-08
predominantly O 0 4.91228568932911e-08
towards O 0 7.612520391830913e-08
the O 0 2.456700087805075e-07
3 O 0 1.498717665526783e-06
end O 0 5.97999769524904e-06
. O 0 2.5955000637623016e-06

All O 0 3.482714987512736e-07
were O 0 3.3796797538343526e-07
found O 0 4.210316717490059e-07
in O 0 8.949268703872804e-08
compound O 0 5.103701823827578e-06
heterozygous O 0 3.4390272958262358e-06
individuals O 0 2.3531387682851346e-07
. O 0 3.1320205380325206e-06

The O 0 0.00011167118645971641
C6 O 1 0.9413794875144958
/ O 0 0.004585836082696915
C7 O 0 0.12667928636074066
marker O 0 0.00018910174549091607
haplotypes O 0 0.00010391106479801238
associated O 0 1.2471889021981042e-05
with O 0 1.900707161439641e-06
most O 0 4.070854629389942e-05
C7 B-Disease 1 0.9989219903945923
defects I-Disease 1 0.9997047781944275
are O 0 1.1595574278544518e-06
tabulated O 0 0.00018120856839232147
. O 0 1.1607456826823181e-06
. O 0 3.177258349751355e-06

A O 0 2.4270550056826323e-05
genome O 0 2.5313378500868566e-05
- O 0 7.615165031893412e-06
wide O 0 7.911133366178547e-07
search O 0 2.559167455729039e-07
for O 0 1.874830246606507e-07
chromosomal O 0 0.0008197528077289462
loci O 0 4.655707743950188e-05
linked O 0 0.000433470297139138
to O 0 1.7944809087566682e-06
mental O 0 0.3096385896205902
health O 0 0.000280687992926687
wellness O 0 5.0421644118614495e-05
in O 0 8.237180963988067e-07
relatives O 0 1.8427630266160122e-06
at O 0 0.00011975194502156228
high O 0 0.0011220863088965416
risk O 0 0.00023705344938207418
for O 0 8.109490408969577e-06
bipolar B-Disease 1 0.9998512268066406
affective I-Disease 1 0.9994217157363892
disorder I-Disease 1 0.9997389912605286
among O 0 1.1485658433230128e-06
the O 0 1.9796482320089126e-06
Old O 0 0.0004090235161129385
Order O 0 1.743455413816264e-06
Amish O 0 2.376619704591576e-05
. O 0 6.596954335691407e-06

Bipolar B-Disease 1 0.9997161030769348
affective I-Disease 1 0.9993614554405212
disorder I-Disease 1 0.9998276233673096
( O 0 0.0016845745267346501
BPAD B-Disease 1 0.9997698664665222
; O 0 0.01407795399427414
manic B-Disease 1 0.9999337196350098
- I-Disease 1 0.9999361038208008
depressive I-Disease 1 0.999971866607666
illness I-Disease 1 0.999699592590332
) O 0 1.2357122614048421e-06
is O 0 7.860820119276468e-07
characterized O 0 3.1466458949580556e-06
by O 0 9.829279434825366e-08
episodes O 0 1.0963165095745353e-06
of O 0 6.316287226582062e-07
mania B-Disease 0 0.010842897929251194
and O 0 2.31520652960171e-06
/ O 0 0.00032288930378854275
or O 0 6.667870366072748e-06
hypomania B-Disease 0 0.013324709609150887
interspersed O 0 5.293178401188925e-05
with O 0 2.497340119589353e-06
periods O 0 6.817731627961621e-05
of O 0 1.2568316378747113e-05
depression B-Disease 1 0.8759006261825562
. O 0 2.0027804566780105e-05

Compelling O 0 2.2776221157982945e-05
evidence O 0 2.549613782321103e-06
supports O 0 1.9377405351406196e-06
a O 0 4.481516668874974e-07
significant O 0 7.93228593920503e-07
genetic O 0 6.995172952883877e-06
component O 0 4.021248969365843e-06
in O 0 2.3063927301336662e-07
the O 0 7.09165760781616e-07
susceptibility O 0 2.224214949819725e-05
to O 0 4.733289529212925e-07
develop O 0 0.00013746510376222432
BPAD B-Disease 1 0.9991349577903748
. O 0 3.0716339097125456e-05

To O 0 3.314971195322869e-07
date O 0 4.990574780094903e-06
, O 0 1.8354616315718886e-07
however O 0 8.550078689495422e-08
, O 0 3.563441808296375e-08
linkage O 0 1.3054323062533513e-06
studies O 0 1.2596946419307642e-07
have O 0 1.004289007511261e-08
attempted O 0 8.867338152640514e-08
only O 0 4.094764083362179e-09
to O 0 1.0940572892081946e-08
identify O 0 3.224537579171738e-07
chromosomal O 0 0.00022488094691652805
loci O 0 5.810186394228367e-06
that O 0 4.0902475006987515e-07
cause O 0 5.09582332597347e-06
or O 0 2.2253523468407366e-07
increase O 0 3.484578883217182e-07
the O 0 8.040391321628704e-07
risk O 0 2.4439683329546824e-05
of O 0 5.419553303909197e-07
developing O 0 0.0003321784024592489
BPAD B-Disease 1 0.9995546936988831
. O 0 4.5398515794659033e-05

To O 0 8.671858608977345e-07
determine O 0 1.952856564457761e-06
whether O 0 3.632668210684642e-07
there O 0 1.5091288219082344e-07
could O 0 2.5253103785871645e-07
be O 0 6.04311267693447e-08
protective O 0 3.209126816727803e-06
alleles O 0 2.8720882028210326e-07
that O 0 3.201928322482672e-08
prevent O 0 3.793080338709842e-07
or O 0 1.6888793652469758e-07
reduce O 0 1.4053368886379758e-06
the O 0 5.287860176395043e-07
risk O 0 3.749533107111347e-06
of O 0 4.449839963172053e-08
developing O 0 1.6137641068780795e-05
BPAD B-Disease 1 0.9997530579566956
, O 0 1.3509989571502956e-07
similar O 0 7.430391946172676e-08
to O 0 1.8782712274401092e-08
what O 0 5.674100478358923e-08
is O 0 9.665970424066472e-08
observed O 0 4.900494445791992e-07
in O 0 1.1728596405191638e-07
other O 0 1.7572701835888438e-06
genetic B-Disease 1 0.9995130300521851
disorders I-Disease 1 0.9999903440475464
, O 0 4.834744231629884e-06
we O 0 2.0818877146666637e-06
used O 0 1.7118605683208443e-05
mental O 1 0.6348053216934204
health O 0 0.0017415339825674891
wellness O 0 0.0003918915754184127
( O 0 4.232709045481897e-07
absence O 0 5.134727416589158e-06
of O 0 3.5872830039807013e-07
any O 0 6.569026299985126e-05
psychiatric B-Disease 1 0.9995064735412598
disorder I-Disease 1 0.9995133876800537
) O 0 1.3789674824238318e-07
as O 0 2.467072590661701e-07
the O 0 4.0255974909086945e-07
phenotype O 0 6.6303819039603695e-06
in O 0 1.3490934236415342e-07
our O 0 1.8822920822003653e-07
genome O 0 2.401469373580767e-06
- O 0 4.6672994358232245e-06
wide O 0 6.559511689374631e-07
linkage O 0 6.122509603301296e-06
scan O 0 1.2752291695505846e-05
of O 0 2.6666201691227798e-08
several O 0 3.328043618466836e-08
large O 0 7.104789574441384e-07
multigeneration O 0 5.560393037740141e-05
Old O 0 1.6095298633445054e-05
Order O 0 1.3987819613703323e-07
Amish O 0 2.128998858097475e-06
pedigrees O 0 5.678361503669294e-06
exhibiting O 0 2.2226342935027787e-06
an O 0 2.3657055692183349e-07
extremely O 0 0.00010275476961396635
high O 0 0.0033340805675834417
incidence O 1 0.5482514500617981
of O 0 1.3832951481163036e-05
BPAD B-Disease 1 0.9996894598007202
. O 0 4.3274485506117344e-05

We O 0 3.332005917400238e-06
have O 0 1.1745476768965091e-07
found O 0 1.6822436066377122e-07
strong O 0 5.796019308945688e-08
evidence O 0 2.5041117623914033e-08
for O 0 7.2866304101637525e-09
a O 0 4.0405515733255015e-07
locus O 0 6.666344233963173e-06
on O 0 2.6649049686966464e-06
chromosome O 0 4.756202542921528e-05
4p O 0 0.00131608999799937
at O 0 1.0107197340403218e-05
D4S2949 O 0 1.1470780009403825e-05
( O 0 1.1860468163149562e-07
maximum O 0 4.919562002214661e-07
GENEHUNTER O 0 0.00011358151095919311
- O 0 1.4841904885543045e-05
PLUS O 0 2.5681745228212094e-06
nonparametric O 0 5.802660780318547e-06
linkage O 0 3.7200206861598417e-06
score O 0 1.197113306261599e-06
= O 0 1.5263531167875044e-06
4 O 0 3.035859208466718e-07
. O 0 4.134618691864489e-08
05 O 0 5.80478626943659e-06
, O 0 1.4953995730593306e-07
P O 0 1.0103072781930678e-05
= O 0 5.050111440141336e-07
5 O 0 6.019553211444872e-08
. O 0 7.332373375135148e-09
22 O 0 8.54277573125728e-08
x O 0 6.643754772994725e-07
10 O 0 5.12234983318649e-08
( O 0 2.184083491840738e-08
- O 0 1.6975407106656348e-06
4 O 0 1.916071710184042e-07
) O 0 1.3216824967798857e-08
; O 0 2.5905288580929664e-08
SIBPAL O 0 6.107160515966825e-06
Pempirical O 0 2.6727718704933068e-06
value O 0 1.492891783527739e-07
< O 0 1.8070155647365027e-06
3 O 0 2.8000476959277876e-07
x O 0 1.8815215980794164e-06
10 O 0 1.4779382695451204e-07
( O 0 4.672090625490455e-08
- O 0 2.499898982932791e-06
5 O 0 2.0056795335676725e-07
) O 0 6.4415752731861176e-09
) O 0 4.455604329933749e-09
and O 0 9.337214557092466e-09
suggestive O 0 5.906042019887536e-07
evidence O 0 3.783270940971306e-08
for O 0 7.320844375158231e-09
a O 0 2.189725591961178e-07
locus O 0 4.286535840947181e-06
on O 0 8.312494173878804e-06
chromosome O 0 0.0004614313947968185
4q O 0 0.01764492690563202
at O 0 1.6672585843480192e-05
D4S397 O 0 1.619842259970028e-05
( O 0 1.5763403382607066e-07
maximum O 0 9.239969358532107e-07
GENEHUNTER O 0 0.00011121879651909694
- O 0 1.2579586837091483e-05
PLUS O 0 1.2543592902147793e-06
nonparametric O 0 1.7990113292398746e-06
linkage O 0 3.2387624742113985e-06
score O 0 8.677658343003714e-07
= O 0 1.1992946156169637e-06
3 O 0 1.5488924987039354e-07
. O 0 2.2014738476627826e-08
29 O 0 7.324744046854903e-07
, O 0 4.7378239997897253e-08
P O 0 7.1312351792585105e-06
= O 0 3.6007463677378837e-07
2 O 0 6.005733865777074e-08
. O 0 1.0293980778897094e-08
57 O 0 2.1293087115736853e-07
x O 0 1.121805325965397e-06
10 O 0 8.644018834047529e-08
( O 0 4.3200955701649946e-08
- O 0 1.4668693211206119e-06
3 O 0 1.5653102991564083e-07
) O 0 9.659663291472498e-09
; O 0 1.4362252720445667e-08
SIBPAL O 0 3.600530590119888e-06
Pempirical O 0 1.7523267388241948e-06
value O 0 3.720974461884907e-08
< O 0 6.405556973732018e-07
1 O 0 1.1721284209897931e-07
x O 0 1.7802800584831857e-06
10 O 0 1.1841932945344524e-07
( O 0 2.7362325738522486e-08
- O 0 1.6352466900571017e-06
3 O 0 1.5509500883581495e-07
) O 0 9.731378369792765e-09
) O 0 6.346306147264613e-09
that O 0 3.5931357889040783e-09
are O 0 1.1487161444279081e-08
linked O 0 1.487641111452831e-05
to O 0 1.7784049077818054e-06
mental O 0 0.30606546998023987
health O 0 0.002104127546772361
wellness O 0 0.0046848407946527
. O 0 1.8386062947683968e-05

These O 0 7.27469000594283e-07
findings O 0 2.1461985397763783e-06
are O 0 2.465289128394943e-08
consistent O 0 6.221743547030201e-07
with O 0 7.934254853125822e-08
the O 0 3.112387503279024e-07
hypothesis O 0 7.033866609162942e-07
that O 0 5.9335327762255474e-09
certain O 0 7.662833922950085e-09
alleles O 0 2.602179449695541e-07
could O 0 1.7795811402265826e-07
prevent O 0 4.1963548369494674e-07
or O 0 1.1159296775531402e-07
modify O 0 1.2047213431287673e-06
the O 0 2.9638491128025635e-07
clinical O 0 1.3355818737181835e-05
manifestations O 0 1.881286152638495e-05
of O 0 9.058418868335139e-07
BPAD B-Disease 1 0.9998310804367065
and O 0 2.5353492674184963e-06
perhaps O 0 3.819913672487019e-06
other O 0 9.356522809866874e-07
related O 0 0.0014814881142228842
affective B-Disease 1 0.9990621209144592
disorders I-Disease 1 0.9999040365219116
. O 0 0.00025170992012135684

Segregation O 0 0.010466423816978931
distortion O 1 0.5952507257461548
in O 0 0.009859432466328144
myotonic B-Disease 1 0.9997997879981995
dystrophy I-Disease 1 0.9999357461929321
. O 0 0.0006720321835018694

Myotonic B-Disease 1 0.9997777342796326
dystrophy I-Disease 1 0.9999692440032959
( O 0 0.006518248934298754
DM B-Disease 1 0.9998742341995239
) O 0 6.227357516763732e-06
is O 0 2.4279358967760345e-06
an O 0 3.1656863939133473e-06
autosomal B-Disease 1 0.9961163997650146
dominant I-Disease 1 0.9984064698219299
disease I-Disease 1 0.9998631477355957
which O 0 2.088507471853518e-06
, O 0 2.760219786068774e-07
in O 0 1.0317926779634945e-07
the O 0 2.26865267904941e-07
typical O 0 4.111720954824705e-06
pedigree O 0 1.1454470040916931e-05
, O 0 4.172630241328079e-08
shows O 0 7.542956836914527e-08
a O 0 7.434446303022924e-08
three O 0 1.3602607396023814e-07
generation O 0 8.603294190834276e-06
anticipation O 0 3.606037353165448e-05
cascade O 0 0.0011607961496338248
. O 0 6.6285233515372965e-06

This O 0 4.304424692236353e-06
results O 0 2.6163730581174605e-05
in O 0 2.4521812520106323e-05
infertility B-Disease 1 0.9972826242446899
and O 1 0.8717304468154907
congenital B-Disease 1 0.9999997615814209
myotonic I-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999974966049194
( O 0 2.0314346329541877e-05
CDM B-Disease 0 0.00011586253822315484
) O 0 6.841413124902829e-08
with O 0 8.474872714714365e-08
the O 0 4.150588210904971e-07
disappearance O 0 2.715115260798484e-05
of O 0 5.209557002672227e-06
DM B-Disease 1 0.99982750415802
in O 0 2.3318698367802426e-06
that O 0 4.006134588507848e-07
pedigree O 0 0.00013962651428300887
. O 0 6.29101850790903e-06

The O 0 8.605375114711933e-07
concept O 0 1.503414523540414e-06
of O 0 3.4028849427159e-07
segregation O 0 3.0472861908492632e-05
distortion O 0 0.00015875560347922146
, O 0 2.5692889948913944e-07
where O 0 9.580254811680788e-08
there O 0 1.2645087643647912e-08
is O 0 1.2299339324783887e-08
preferential O 0 7.550456615490475e-08
transmission O 0 1.0945958820229862e-05
of O 0 8.182054145322581e-09
the O 0 2.5264972336458413e-08
larger O 0 1.5627685456820473e-07
allele O 0 1.4736906450707465e-06
at O 0 3.3961102872126503e-06
the O 0 2.5374777123943204e-06
DM B-Disease 1 0.9976142644882202
locus O 0 2.774842141661793e-05
, O 0 4.513832436714438e-07
has O 0 2.309619588913847e-07
been O 0 1.6050152851221355e-07
put O 0 1.0089625845921546e-07
forward O 0 6.882417125098073e-08
to O 0 1.9993978028765014e-08
explain O 0 3.334114921926812e-07
partially O 0 6.042080258339411e-06
the O 0 4.763735148571868e-07
maintenance O 0 0.0001566671417094767
of O 0 2.572405492173857e-06
DM B-Disease 1 0.9996341466903687
in O 0 9.093569133256096e-07
the O 0 6.324304422378191e-07
population O 0 3.3254838172069867e-07
. O 0 1.9598642211349215e-06

In O 0 2.865048827516148e-06
a O 0 2.9080695185257355e-06
survey O 0 4.261878984834766e-06
of O 0 6.04427782491257e-07
DM B-Disease 1 0.9993232488632202
in O 0 1.2214043181302259e-06
Northern O 0 2.5242343326681294e-06
Ireland O 0 5.196100573812146e-06
, O 0 4.080775681813975e-07
59 O 0 4.706364961748477e-06
pedigrees O 0 1.1145933967782184e-05
were O 0 9.791459660846158e-07
ascertained O 0 6.512479740194976e-05
. O 0 3.895704139722511e-06

Sibships O 0 0.0007794477860443294
where O 0 1.1355386959621683e-06
the O 0 2.2451087033914519e-07
status O 0 2.5388257540726045e-07
of O 0 1.36942626127734e-08
all O 0 8.783136884460419e-09
the O 0 4.3499362334387115e-08
members O 0 1.4738670728320358e-08
had O 0 2.3834938644995418e-07
been O 0 7.591134476570005e-08
identified O 0 7.95673003040065e-08
were O 0 2.2184609704822833e-08
examined O 0 3.4481661259633256e-07
to O 0 3.6513763124190746e-09
determine O 0 4.7876685727032964e-08
the O 0 5.669491898174783e-08
transmission O 0 1.745986628520768e-05
of O 0 1.6498492527716735e-07
the O 0 3.330573008497595e-06
DM B-Disease 1 0.9991998076438904
expansion O 0 8.587276170146652e-06
from O 0 2.865180590561067e-07
affected O 0 3.3351867045894323e-07
parents O 0 4.451987578590888e-08
to O 0 6.06079497700307e-09
their O 0 3.601480713655292e-08
offspring O 0 4.527716555458028e-06
. O 0 2.622866304591298e-06

Where O 0 1.777716533979401e-06
the O 0 5.468982067213801e-07
transmitting O 0 0.00015166206867434084
parent O 0 5.6679251429159194e-05
was O 0 2.326052162970882e-05
male O 0 1.325238940808049e-06
, O 0 4.959390480507864e-07
58 O 0 9.034530194185209e-06
. O 0 2.7054486508859554e-06

3 O 0 5.109984158480074e-06
% O 0 6.175445577127903e-08
of O 0 8.329660516892545e-09
the O 0 8.73137722123829e-08
offspring O 0 6.890244890200847e-07
were O 0 1.2055495801632787e-07
affected O 0 3.1028653779685555e-07
, O 0 4.102583872622745e-08
and O 0 3.058718078818856e-08
in O 0 5.0400696949282064e-08
the O 0 8.702762954726495e-08
case O 0 2.06639057864777e-07
of O 0 1.0578190767773776e-08
a O 0 3.578064706744044e-07
female O 0 1.6226525758611388e-06
transmitting O 0 0.00010930285498034209
parent O 0 2.1366457076510414e-05
, O 0 8.360429433196259e-07
68 O 0 1.875730959000066e-05
. O 0 2.4063663204287877e-06

7 O 0 3.1541498174192384e-05
% O 0 6.898858373460826e-07
were O 0 1.3315820979187265e-06
affected O 0 6.1770520005666185e-06
. O 0 5.936631168879103e-06

Studies O 0 6.575585757673252e-06
on O 0 1.0186031431658193e-06
meiotic O 0 4.725965118268505e-05
drive O 0 9.285389751312323e-06
in O 0 2.210662842117017e-06
DM B-Disease 1 0.9976746439933777
have O 0 4.6428642264118025e-08
shown O 0 6.191154255930087e-08
increased O 0 1.0653720750042339e-07
transmission O 0 4.113305294595193e-06
of O 0 7.867764217905915e-09
the O 0 1.067796606690763e-08
larger O 0 6.709355915290871e-08
allele O 0 4.89255626234808e-07
at O 0 1.4312844314190443e-06
the O 0 1.7148877304862253e-06
DM B-Disease 1 0.9937684535980225
locus O 0 3.915133129339665e-05
in O 0 3.2302980343956733e-06
non O 0 0.0001286641345359385
- O 0 0.3262065052986145
DM O 1 0.9976990818977356
heterozygotes O 0 7.932126027299091e-05
for O 0 1.0337237199564697e-06
CTGn O 0 0.0011848299764096737
. O 0 1.6182071703951806e-05

This O 0 7.224888918244687e-07
study O 0 3.076042389693612e-07
provides O 0 6.322446921558367e-08
further O 0 4.194782121658136e-08
evidence O 0 1.020408220142599e-07
that O 0 6.316167144859719e-08
the O 0 3.581475993996719e-06
DM B-Disease 1 0.9995317459106445
expansion O 0 1.2839369446737692e-05
tends O 0 1.8344132968195481e-06
to O 0 4.0652569310850595e-08
be O 0 2.3690152772815054e-07
transmitted O 0 1.099800556403352e-05
preferentially O 0 4.676281605497934e-06
. O 0 1.6134249563037883e-06

Diagnosis O 1 0.9781644344329834
of O 0 0.0006875696126371622
hemochromatosis B-Disease 1 0.999891996383667
. O 0 0.000629484944511205

If O 0 0.0007036867318674922
untreated O 1 0.9106869697570801
, O 0 0.0001382133486913517
hemochromatosis B-Disease 1 0.9999394416809082
can O 0 0.0006548294913955033
cause O 1 0.7369225025177002
serious O 1 0.9962034821510315
illness O 1 0.9984742999076843
and O 0 1.2091689995941124e-06
early B-Disease 0 3.5386241506785154e-05
death I-Disease 0 4.970609370502643e-05
, O 0 1.3873065540792595e-07
but O 0 2.3380216873647441e-07
the O 0 7.092190571711399e-06
disease O 1 0.865152895450592
is O 0 5.763827743976435e-07
still O 0 6.773659606551519e-07
substantially O 0 2.6892483219853602e-05
under O 0 5.8293990150559694e-05
- O 1 0.987054169178009
diagnosed O 1 0.995258629322052
. O 0 1.0461239071446471e-05

The O 0 4.742900728160748e-06
cornerstone O 0 0.00011903265112778172
of O 0 4.2216794327032403e-07
screening O 0 4.260517471266212e-06
and O 0 3.2412421546723635e-07
case O 0 1.5420846466440707e-06
detection O 0 1.1583434570638929e-05
is O 0 1.6053276397087757e-07
the O 0 5.322522156347986e-08
measurement O 0 2.1524872408917872e-06
of O 0 1.5597430547131808e-07
serum O 0 1.2851461178797763e-05
transferrin O 0 8.723503924557008e-06
saturation O 0 5.603949375654338e-06
and O 0 1.374857276914554e-07
the O 0 4.481662188027258e-07
serum O 0 4.6823966840747744e-05
ferritin O 0 0.00018094232655130327
level O 0 2.6779134714161046e-05
. O 0 5.598586085397983e-06

Once O 0 0.00013541034422814846
the O 0 1.0068025403597858e-05
diagnosis O 0 0.02380596660077572
is O 0 1.8153981500290683e-06
suspected O 0 1.5157208508753683e-05
, O 0 2.5396053615622805e-07
physicians O 0 4.976019454261404e-07
must O 0 6.313155864745568e-08
use O 0 2.948864050722477e-07
serum O 0 8.5065359598957e-05
ferritin O 0 0.00022869824897497892
levels O 0 1.7186786863021553e-05
and O 0 1.1481605497465353e-06
hepatic O 1 0.7380819916725159
iron O 0 0.18463005125522614
stores O 0 1.5215747225738596e-05
on O 0 8.823398093227297e-05
liver O 1 0.990082323551178
biopsy O 0 0.011758443899452686
specimens O 0 1.8116019191438681e-06
to O 0 5.8081703002699214e-08
assess O 0 4.638735845219344e-06
patients O 0 1.6460410279250937e-06
for O 0 1.270199057046284e-08
the O 0 1.1149808187838062e-07
presence O 0 1.0307193178960006e-06
of O 0 1.0386734174971934e-06
iron B-Disease 1 0.9889971017837524
overload I-Disease 0 0.30073657631874084
. O 0 1.1993451153102797e-05

Liver O 1 0.9983903169631958
biopsy O 1 0.982286274433136
is O 0 2.2581632492801873e-06
also O 0 4.606785708460848e-08
used O 0 1.4577577367447248e-08
to O 0 3.2168445684988e-09
establish O 0 2.3357724643346955e-08
the O 0 4.027071653922576e-08
presence O 0 2.5961983851630066e-07
or O 0 2.9479079444172385e-07
absence O 0 1.845809265432763e-06
of O 0 4.2986840753655997e-07
cirrhosis B-Disease 1 0.9993784427642822
, O 0 8.163045208675612e-07
which O 0 1.9331837108893524e-07
can O 0 6.783395747333998e-07
affect O 0 6.6485858951637056e-06
prognosis O 0 0.024598749354481697
and O 0 2.7913499707210576e-06
management O 0 0.00016054489242378622
. O 0 1.175277884613024e-05

A O 0 1.4070992619963363e-05
DNA O 0 3.1112889701034874e-05
- O 0 2.1086101696710102e-05
based O 0 2.617358916268131e-07
test O 0 1.9540847517873772e-07
for O 0 4.970225564449038e-09
the O 0 4.696768485246139e-08
HFE O 0 2.7989261070615612e-05
gene O 0 5.602761348200147e-07
is O 0 3.690580996362769e-08
commercially O 0 6.347300995912519e-08
available O 0 1.8238470289588804e-08
, O 0 1.6724818863167457e-08
but O 0 3.919238267258152e-09
its O 0 7.480443819929405e-09
place O 0 4.83046740384907e-08
in O 0 8.226483316775557e-08
the O 0 3.32047989104467e-07
diagnosis O 0 0.001175304059870541
of O 0 3.91863432014361e-06
hemochromatosis B-Disease 1 0.999980092048645
is O 0 2.780367503874004e-05
still O 0 3.662521748992731e-06
being O 0 3.0424405395024223e-06
evaluated O 0 8.594035534770228e-06
. O 0 2.2015763079252793e-06

Currently O 0 9.122205483436119e-06
, O 0 1.9698315156801982e-07
the O 0 2.7526954937684422e-08
most O 0 1.1214599915376766e-08
useful O 0 2.9139879842432492e-08
role O 0 9.59094990093945e-08
for O 0 1.3162310352754503e-08
this O 0 1.9854091704019083e-08
test O 0 2.3949252181409975e-07
is O 0 2.3876452814874938e-08
in O 0 9.972035641681032e-09
the O 0 3.272974424817221e-08
detection O 0 2.534928398745251e-06
of O 0 7.263944894475571e-07
hemochromatosis B-Disease 1 0.9999151229858398
in O 0 1.7054837826435687e-06
the O 0 3.1446668913304165e-07
family O 0 6.508453225251287e-07
members O 0 3.2113838699388e-08
of O 0 7.386348244153851e-08
patients O 0 1.3935695051259245e-06
with O 0 1.1023482926475481e-07
a O 0 4.336013716965681e-06
proven O 0 5.1469985919538885e-05
case O 0 2.2186738988239085e-06
of O 0 2.927129685303953e-07
the O 0 0.00011009449372068048
disease O 1 0.9978342652320862
. O 0 1.0169386769121047e-05

It O 0 1.6691951714165043e-06
is O 0 5.74185492041579e-07
crucial O 0 3.219693326173001e-06
to O 0 7.252935574797448e-06
diagnose O 1 0.9986326098442078
hemochromatosis B-Disease 1 0.9999728202819824
before O 1 0.5655243992805481
hepatic B-Disease 1 0.9995868802070618
cirrhosis I-Disease 1 0.9998469352722168
develops O 0 0.032436903566122055
because O 0 5.314005466061644e-05
phlebotomy O 0 0.05317632108926773
therapy O 0 0.0034126541577279568
can O 0 2.198361835326068e-05
avert O 1 0.9725560545921326
serious O 1 0.999840497970581
chronic O 1 0.9999969005584717
disease O 1 0.999964714050293
and O 0 3.7909280763415154e-06
can O 0 4.331671732415998e-07
even O 0 4.030253251130489e-07
lead O 0 7.129067398636835e-07
to O 0 4.405579190347453e-08
normal O 0 3.0372948458534665e-06
life O 0 1.4479916217169375e-06
expectancy O 0 7.679702321183868e-06
. O 0 1.615020011058732e-07
. O 0 7.733594316050585e-07

Prevalence O 0 0.001019326620735228
of O 0 5.931668738412554e-07
the O 0 1.0569295909590437e-06
I1307K O 0 4.504227399593219e-05
APC B-Disease 0 1.8784105122904293e-05
gene O 0 2.3498582777392585e-06
variant O 0 1.5695175534347072e-05
in O 0 1.2022142925616208e-07
Israeli O 0 1.1211583341719233e-06
Jews O 0 1.1531772514672411e-07
of O 0 1.3701289880430068e-08
differing O 0 1.6237581235145626e-07
ethnic O 0 1.1145130685008553e-07
origin O 0 6.138665185062564e-07
and O 0 6.211538675415795e-06
risk O 0 0.06507422775030136
for O 1 0.9477716088294983
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
. O 0 0.00017987340106628835

BACKGROUND O 0 9.66682200669311e-05
& O 0 6.289153679972515e-05
AIMS O 0 1.107011667045299e-05
Israeli O 0 3.2321038361260435e-06
Jews O 0 2.8870357482446707e-07
of O 0 4.457417190906199e-08
European O 0 3.2905529678828316e-06
birth O 0 4.379438905743882e-05
, O 0 4.915120825899066e-07
i O 0 5.72205090065836e-06
. O 0 2.3660930992264184e-08
e O 0 4.859920181843336e-07
. O 0 1.599077492642209e-08
, O 0 2.3075429567143146e-08
Ashkenazim O 0 1.8183316115027992e-06
, O 0 4.4731990556101664e-08
have O 0 6.387085704773199e-08
the O 0 1.1947537132073194e-05
highest O 1 0.9990008473396301
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
incidence O 1 0.9247368574142456
of O 0 8.544844831703813e-08
any O 0 7.176100069727909e-08
Israeli O 0 6.674067208223278e-06
ethnic O 0 8.842010288390156e-07
group O 0 7.549716428911779e-06
. O 0 3.3871442610688973e-06

The O 0 1.350116690446157e-05
I1307K O 0 0.00022128572163637727
APC B-Disease 0 0.00012357471860013902
gene O 0 2.5581852241884917e-05
variant O 0 0.00027257425244897604
was O 0 5.7017969083972275e-05
found O 0 2.7855314783664653e-06
in O 0 7.193435749286436e-07
6 O 0 1.965642331924755e-05
. O 0 4.0448726394970436e-06

1 O 0 3.2300056318490533e-06
% O 0 3.8874429009183586e-08
of O 0 7.3662116406580935e-09
American O 0 4.6036234380153473e-08
Jews O 0 1.2078741917775915e-07
, O 0 8.302413334604353e-08
28 O 0 3.266180499394977e-07
% O 0 1.1619553319519582e-08
of O 0 6.074916569787092e-08
their O 0 1.7436568668927066e-05
familial O 1 0.9998973608016968
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
cases O 0 0.00015820463886484504
, O 0 1.209644096888951e-06
but O 0 1.2190206177820073e-07
not O 0 3.7673142827543415e-08
in O 0 9.225672670254426e-08
non O 0 3.670266323752003e-06
- O 0 9.890776709653437e-05
Jews O 0 3.909459337592125e-06
. O 0 3.886037575284718e-06

We O 0 1.0091739568451885e-05
assessed O 0 1.4190240108291619e-05
the O 0 1.3459914498525904e-06
I1307K O 0 8.571229409426451e-05
prevalence O 0 3.9137816202128306e-05
in O 0 9.368007169996417e-08
Israeli O 0 1.2568451666084002e-06
Jews O 0 8.706798126922877e-08
of O 0 2.303084123411736e-08
differing O 0 1.4496481526293792e-07
ethnic O 0 1.3182742009121284e-07
origin O 0 5.996789127493685e-07
and O 0 4.8646452341927215e-06
risk O 0 0.09406734257936478
for O 1 0.8172298073768616
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
. O 0 0.00024085289624053985

METHODS O 0 1.6792360838735476e-05
DNA O 0 1.1468362572486512e-05
samples O 0 9.908258107316215e-07
from O 0 1.2454226805402868e-07
500 O 0 4.3364047996874433e-07
unrelated O 0 8.409856491198298e-07
Jews O 0 1.4192929143064248e-07
of O 0 3.797078917955332e-08
European O 0 2.4893363388400758e-06
or O 0 1.3844637578586116e-06
non O 0 6.437969204853289e-06
- O 0 3.315422873129137e-05
European O 0 4.7379731427099614e-07
origin O 0 7.539620128227398e-08
, O 0 5.2460439547985516e-08
with O 0 3.184339192330299e-08
or O 0 1.1334511640370692e-07
without O 0 4.5330722286962555e-08
a O 0 2.234079232721342e-07
personal O 0 1.297298240388045e-06
and O 0 8.189893492271949e-07
/ O 0 3.549902612576261e-05
or O 0 8.261246762231167e-07
family O 0 1.6213703020184767e-06
history O 0 9.087006560548616e-07
of O 0 3.052517456580972e-07
neoplasia B-Disease 0 0.005449375603348017
, O 0 2.449172029628244e-07
were O 0 1.4728728103818867e-07
examined O 0 1.763969635248941e-06
for O 0 2.2807984834116724e-08
the O 0 8.608102319840327e-08
I1307K O 0 3.704577693497413e-06
variant O 0 2.913776825153036e-06
by O 0 2.2541703614820108e-08
the O 0 7.376591071306393e-08
allele O 0 1.6854855857673101e-06
- O 0 5.373623935156502e-06
specific O 0 2.6526754481892567e-07
oligonucleotide O 0 4.6550467232009396e-05
( O 0 1.9945659914810676e-06
ASO O 0 0.007420715410262346
) O 0 3.4408932947371795e-07
method O 0 3.870755335810827e-06
. O 0 3.668275439849822e-06

RESULTS O 0 4.614111821865663e-05
In O 0 6.450048886108561e-07
persons O 0 2.3037614482745994e-07
at O 0 2.050520561169833e-05
average O 0 0.0001205387816298753
risk O 0 0.001864848891273141
for O 0 0.06323055922985077
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
, O 0 3.985263447248144e-06
I1307K O 0 2.7946134650846943e-05
was O 0 1.9236869775340892e-05
found O 0 8.988928357211989e-07
in O 0 3.818799427790509e-07
5 O 0 2.117033318427275e-06
. O 0 2.1547978121816413e-06

0 O 0 5.4378988352254964e-06
% O 0 7.902493592837345e-08
of O 0 1.0822024165690891e-08
120 O 0 9.021832880762304e-08
European O 0 3.5921169683206244e-07
and O 0 2.9957098490740464e-07
1 O 0 6.35861033515539e-06
. O 0 2.3641050574951805e-06

6 O 0 1.3165760719857644e-05
% O 0 1.0719516296830989e-07
of O 0 5.886372633767678e-08
188 O 0 8.51549145863828e-07
non O 0 2.0954403225914575e-06
- O 0 9.925150152412243e-06
European O 0 8.693089625921857e-07
Jews O 0 8.179714541256544e-07
( O 0 6.248084787330299e-07
P O 0 0.00010348961950512603
= O 0 4.887472186965169e-06
0 O 0 6.069960249988071e-07
. O 0 6.201744184863855e-08
08 O 0 3.4839183626900194e-06
) O 0 3.5214972626818053e-07
. O 0 1.042575718201988e-06

It O 0 5.5063774198060855e-06
occurred O 0 3.823837323579937e-05
in O 0 1.262971750293218e-06
15 O 0 4.513239673542557e-06
. O 0 1.590717033650435e-06

4 O 0 7.31112504581688e-06
% O 0 1.0291883967283866e-07
of O 0 4.847579404554381e-08
52 O 0 2.3832899387343787e-06
Ashkenazi O 0 2.269874676130712e-05
Israelis O 0 3.515796834108187e-06
with O 0 8.245643584814388e-06
familial O 1 0.9949994087219238
cancer B-Disease 1 0.9993987083435059
( O 0 2.3229761154652806e-06
P O 0 0.0002451216278132051
= O 0 8.622070708952378e-06
0 O 0 4.019478865302517e-07
. O 0 4.092915872888625e-08
02 O 0 2.259974962726119e-06
) O 0 1.5211863768627154e-08
and O 0 1.8967902803979086e-08
was O 0 7.204544090200216e-07
not O 0 1.5394347130381902e-08
detected O 0 8.310404950861994e-07
in O 0 2.201549342828457e-08
51 O 0 3.652743885140808e-07
non O 0 3.3327575010844157e-07
- O 0 2.059091684714076e-06
European O 0 2.745748304278095e-07
Jews O 0 2.472761195804196e-07
at O 0 2.5419039957341738e-05
increased O 0 0.00015274924226105213
cancer B-Disease 1 0.9988092184066772
risk O 0 0.0005475577781908214
. O 0 6.112970368121751e-06

Colorectal B-Disease 1 0.997462272644043
neoplasia I-Disease 1 0.9858929514884949
occurred O 0 0.0015592729905620217
personally O 0 4.115031333640218e-05
or O 0 4.7267715785892506e-07
in O 0 7.564857185116125e-08
the O 0 5.347258280608003e-08
families O 0 1.5976779010884457e-08
of O 0 1.3546806343356366e-08
13 O 0 2.0443877701836755e-07
of O 0 1.955635298145353e-08
20 O 0 4.5590073227685934e-07
Ashkenazi O 0 8.905259164748713e-06
I1307K O 0 4.432738478499232e-06
carriers O 0 1.24344705909607e-06
, O 0 6.012840714220147e-08
8 O 0 1.8254571898523864e-07
of O 0 1.6001360236828077e-08
whom O 0 5.059887939751206e-07
also O 0 2.348265013552009e-07
had O 0 3.880698216107703e-07
a O 0 1.2926457770845445e-07
personal O 0 8.217008939936932e-07
or O 0 1.4780173387407558e-06
family O 0 2.5100518996623578e-06
history O 0 2.419526708763442e-06
of O 0 1.8998589439434e-06
noncolonic O 0 0.2454589605331421
neoplasia B-Disease 1 0.9834728240966797
. O 0 2.4775819838396274e-05

CONCLUSIONS O 0 6.401848077075556e-05
The O 0 4.001401975983754e-06
I1307K O 0 0.00024688118719495833
APC O 0 0.00020384481467772275
variant O 0 0.0002099399280268699
may O 0 1.1505073871376226e-06
represent O 0 1.1473130001604659e-07
a O 0 6.772471579097328e-07
susceptibility O 0 2.0998309992137365e-05
gene O 0 1.243151564267464e-05
for O 0 1.1032819202227984e-05
colorectal B-Disease 1 0.9999943971633911
, I-Disease 0 8.639870543447614e-07
or I-Disease 0 4.889002411800902e-07
other I-Disease 0 1.874767576737213e-07
, I-Disease 0 4.3319259930285625e-06
cancers I-Disease 1 0.9405521750450134
in O 0 3.308058467155206e-07
Ashkenazi O 0 3.0853527277940884e-05
Jews O 0 8.58989437801938e-07
, O 0 2.5592456154299725e-07
and O 0 1.7698899057450035e-07
partially O 0 4.064586391905323e-05
explains O 0 2.2161998458614107e-06
the O 0 4.295839630685805e-07
higher O 0 3.953213308705017e-05
incidence O 1 0.6772224307060242
of O 0 0.04833688214421272
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
in O 0 2.2245892523642397e-06
European O 0 6.125453182903584e-06
Israelis O 0 1.8760672901407816e-05
. O 0 5.90929766985937e-06

Systematic O 0 1.4486695363302715e-05
analysis O 0 3.494529892122955e-06
of O 0 1.3034978110226803e-06
coproporphyrinogen O 0 0.002007916336879134
oxidase O 0 0.0006515631102956831
gene O 0 0.0011651746463030577
defects O 1 0.9966450333595276
in O 0 1.1831658412120305e-05
hereditary B-Disease 1 0.9873487949371338
coproporphyria I-Disease 0 0.16596175730228424
and O 0 5.207348658586852e-05
mutation O 0 0.0013050615089014173
update O 0 0.0005058855167590082
. O 0 1.285138750972692e-05

Hereditary B-Disease 1 0.9957700371742249
coproporphyria I-Disease 1 0.9565862417221069
( O 0 0.00011092159547843039
HC B-Disease 1 0.9990156888961792
) O 0 4.103134870092617e-06
is O 0 6.9661155066569336e-06
an O 0 3.399316483410075e-05
acute O 1 0.9984574317932129
hepatic B-Disease 1 0.9996697902679443
porphyria I-Disease 1 0.9991984963417053
with O 0 0.0012101872125640512
autosomal O 1 0.9983175992965698
dominant O 1 0.963725745677948
inheritance O 1 0.6768463850021362
caused O 0 0.036063630133867264
by O 0 5.9095568758493755e-06
deficient B-Disease 0 0.012416228652000427
activity I-Disease 0 4.387593435239978e-06
of I-Disease 0 6.313246103673009e-07
coproporphyrinogen I-Disease 0 0.0009246154804714024
III I-Disease 0 0.10601813346147537
oxidase I-Disease 0 6.678642239421606e-05
( O 0 1.6707207350918907e-06
CPO O 0 6.156542076496407e-05
) O 0 1.1270565209997585e-06
. O 0 1.813041535569937e-06

Clinical O 0 0.0010751760564744473
manifestations O 0 0.00038698292337358
of O 0 4.184767931292299e-06
the O 0 0.0003473125398159027
disease O 1 0.9992707371711731
are O 0 5.836299123984645e-07
characterized O 0 0.00013763441529590636
by O 0 3.4349693578406004e-06
acute O 1 0.9943239688873291
attacks O 0 0.0016827174695208669
of O 0 0.0002276296727359295
neurological B-Disease 1 0.9999788999557495
dysfunction I-Disease 1 0.9990361928939819
often O 0 2.8849579393863678e-05
precipitated O 0 0.00039114439277909696
by O 0 5.236516926743207e-07
drugs O 0 3.961134098062757e-06
, O 0 2.7511848088579427e-07
fasting O 0 3.872291017614771e-06
, O 0 4.837867209062097e-07
cyclical O 0 0.0012739815283566713
hormonal O 0 0.001956317573785782
changes O 0 1.8261087461723946e-05
, O 0 3.3376509236404672e-06
or O 0 0.0012891736114397645
infectious B-Disease 1 0.9994912147521973
diseases I-Disease 1 0.9995750784873962
. O 0 3.1319188565248623e-05

Skin O 1 0.9951731562614441
photosensitivity O 1 0.9937130808830261
may O 0 0.00031268762541003525
also O 0 2.1025907699367963e-06
be O 0 3.7436697652992734e-07
present O 0 1.504260694673576e-06
. O 0 2.4707460397621617e-06

The O 0 1.812989694371936e-06
seven O 0 7.501120080632973e-07
exons O 0 6.871209279779578e-06
, O 0 1.9179164212346222e-07
the O 0 2.701762014112319e-07
exon O 0 2.7058898922405206e-05
/ O 0 1.4258648661780171e-05
intron O 0 1.930372673086822e-05
boundaries O 0 5.339197173270804e-07
and O 0 4.281729104604892e-08
part O 0 8.471430135159608e-08
of O 0 3.3436958091215274e-08
3 O 0 4.65063720866965e-07
noncoding O 0 5.511830750037916e-06
sequence O 0 1.9542039808584377e-07
of O 0 1.3731584758147619e-08
the O 0 9.706577941415162e-08
CPO O 0 2.38907705352176e-06
gene O 0 2.0284279855786735e-07
were O 0 2.2669242483175367e-08
systematically O 0 2.3975465524017636e-07
analyzed O 0 2.1214988521478517e-07
by O 0 2.331041315528637e-08
an O 0 1.595273175780676e-07
exon O 0 2.3575583327328786e-05
- O 0 3.5154022043570876e-05
by O 0 7.996543445187854e-07
- O 0 0.00021275220206007361
exon O 0 0.00025028170784935355
denaturing O 0 0.0011569693451747298
gradient O 0 0.0002794708707369864
gel O 0 0.00032615300733596087
electrophoresis O 0 9.941981988959014e-05
( O 0 6.137845502962591e-07
DGGE O 0 5.541304562939331e-05
) O 0 4.7160956029301815e-08
strategy O 0 2.387868960340711e-07
followed O 0 6.464582469334346e-08
by O 0 3.4189879816182156e-09
direct O 0 1.1683021661212933e-08
sequencing O 0 2.1346174605696433e-07
in O 0 1.435981999975411e-07
seven O 0 4.3939439819951076e-07
unrelated O 0 1.521258400316583e-05
heterozygous O 0 5.480297113535926e-05
HC B-Disease 1 0.9911319613456726
patients O 0 8.366492693312466e-05
from O 0 5.607727189271827e-07
France O 0 2.002276414714288e-05
, O 0 4.0879777429836395e-07
Holland O 0 2.23035804083338e-05
, O 0 7.650656357327534e-07
and O 0 1.7008577515298384e-06
Czech O 0 0.03159252554178238
Republic O 0 0.00011998489208053797
. O 0 1.654861625866033e-05

Seven O 0 6.298059361142805e-06
novel O 0 4.991793502995279e-06
mutations O 0 1.056907967722509e-05
and O 0 4.179448254149065e-08
two O 0 4.3280543593482435e-08
new O 0 5.028048803978891e-07
polymorphisms O 0 1.6781088561401702e-05
were O 0 1.0441209497003001e-06
detected O 0 0.00013966564438305795
. O 0 2.828325932568987e-06

Among O 0 1.2916121931993985e-06
these O 0 2.0879329554190917e-07
mutations O 0 7.528147307311883e-06
two O 0 1.389165333876008e-07
are O 0 1.1311727377005809e-07
missense O 0 1.991727731365245e-05
( O 0 1.6022990223518718e-07
G197W O 0 6.857533207949018e-06
, O 0 1.1291356116771567e-07
W427R O 0 2.008848923651385e-06
) O 0 3.086426403342557e-08
, O 0 2.1646949122100523e-08
two O 0 2.3785363012507332e-08
are O 0 2.8962896081452527e-08
nonsense O 0 5.15263718625647e-06
( O 0 1.884044706912391e-07
Q306X O 0 5.064641754870536e-06
, O 0 9.119982280481054e-08
Q385X O 0 2.4974924599519e-06
) O 0 2.6809505726532734e-08
, O 0 1.4176203322335823e-08
two O 0 1.544239935924452e-08
are O 0 6.4359628737520325e-09
small O 0 1.266029698854254e-07
deletions O 0 3.1952988592820475e-06
( O 0 1.3721380298648e-07
662de14bp O 0 6.343111181195127e-06
; O 0 2.1625866963859153e-07
1168del3bp O 0 2.9174389055697247e-05
removing O 0 3.980378551204922e-06
a O 0 5.633155524265021e-07
glycine O 0 4.3672212086676154e-06
at O 0 2.4988526092784014e-06
position O 0 4.792173058376648e-07
390 O 0 2.9425177672237623e-07
) O 0 1.6247827971938023e-08
, O 0 1.1215113282503353e-08
and O 0 1.7473183788752067e-08
one O 0 3.487679833824586e-08
is O 0 3.3969023149893474e-08
a O 0 2.0345753171113756e-07
splicing O 0 8.455143870378379e-06
mutation O 0 1.2273334505152889e-05
( O 0 2.7677745606524695e-07
IVS1 O 0 0.00010425427171867341
- O 0 5.147710180608556e-05
15c O 0 6.62777092657052e-05
- O 0 3.3562653698027134e-05
- O 0 2.3477405193261802e-05
> O 0 7.171425295382505e-06
g O 0 5.4477559388033114e-06
) O 0 2.1913189485189832e-08
which O 0 1.0821653795289876e-08
creates O 0 6.249765505117466e-08
a O 0 3.6838649464243645e-08
new O 0 1.3939958876107994e-07
acceptor O 0 6.478974796664261e-07
splice O 0 3.475279299891554e-05
site O 0 5.640448216581717e-05
. O 0 4.914591045235284e-06

The O 0 7.18216460882104e-06
pathological O 0 0.00025039291358552873
significance O 0 4.483244993025437e-06
of O 0 1.9802342876573675e-07
the O 0 7.439268756570527e-07
point O 0 4.001096840511309e-06
mutations O 0 1.6147525457199663e-05
G197W O 0 7.520870894950349e-06
, O 0 1.5116914653390268e-07
W427R O 0 2.9703448944928823e-06
, O 0 5.3770307317790866e-08
and O 0 2.5325087804617397e-08
the O 0 8.719994326611413e-08
in O 0 4.393487245124561e-07
- O 0 2.2575004550162703e-05
frame O 0 1.699665153864771e-05
deletion O 0 6.196977665240411e-06
390delGly O 0 5.868587322765961e-06
were O 0 7.056428330542985e-08
assessed O 0 1.694902493909467e-07
by O 0 4.533225794745022e-09
their O 0 3.647255608640876e-09
respective O 0 9.215525409445036e-08
expression O 0 9.502473119482602e-08
in O 0 2.751787420152141e-08
a O 0 1.008793262258223e-07
prokaryotic O 0 4.322791085087374e-07
system O 0 1.0136068340216298e-06
using O 0 2.8058536827302305e-07
site O 0 1.3051650057605002e-05
- O 0 1.5053734387038276e-05
directed O 0 1.3866784911442664e-06
mutagenesis O 0 4.591458855429664e-05
. O 0 2.3609281925018877e-06

These O 0 2.44881744038139e-06
mutations O 0 0.00015920020814519376
resulted O 0 5.577365755016217e-06
in O 0 4.5659820102628146e-07
the O 0 6.458222969740746e-07
absence O 0 1.6157208619915764e-06
or O 0 2.4904281303861353e-07
a O 0 4.942595523971249e-07
dramatic O 0 7.85989141149912e-06
decrease O 0 4.605284175340785e-06
of O 0 3.012434888205462e-07
CPO O 0 9.242464875569567e-05
activity O 0 6.6850743678514846e-06
. O 0 1.9456103927950608e-06

The O 0 6.641486720582179e-07
two O 0 1.5631530914106406e-07
polymorphisms O 0 6.621648935833946e-06
were O 0 8.340379054061486e-08
localized O 0 4.718709988082992e-06
in O 0 1.984338382499118e-07
noncoding O 0 1.0092519005411305e-05
part O 0 7.771048871063613e-08
of O 0 6.358882753687567e-09
the O 0 3.846765039838829e-08
gene O 0 2.147190230061824e-07
1 O 0 1.1082659767680525e-07
) O 0 1.2016968753414403e-08
a O 0 1.980655355282579e-07
C O 0 8.629004696558695e-06
/ O 0 5.001504632673459e-06
G O 0 8.383380190934986e-06
polymorphism O 0 1.5135940429900074e-06
in O 0 6.606458669011772e-08
the O 0 2.3770539314682537e-07
promotor O 0 0.00019046525994781405
region O 0 4.018243544123834e-06
, O 0 1.989329376783644e-07
142 O 0 1.5898147012194386e-06
bp O 0 1.262135810975451e-05
upstream O 0 6.682485036435537e-07
from O 0 1.7174814459508525e-08
the O 0 8.399587692053956e-09
transcriptional O 0 3.381291833193245e-07
initiation O 0 8.310531711686053e-07
site O 0 2.4575908810220426e-06
( O 0 1.924622523574726e-07
- O 0 6.575999577762559e-06
142C O 0 1.6679616237524897e-05
/ O 0 1.540414996270556e-05
G O 0 1.4666267816210166e-05
) O 0 4.4930196452241944e-08
, O 0 2.6248272888551583e-08
and O 0 2.782477892537827e-08
2 O 0 1.4741291920472577e-07
) O 0 2.139920418642305e-08
a O 0 2.4736786485846096e-07
6 O 0 5.932188287260942e-07
bp O 0 4.3584172999544535e-06
deletion O 0 9.196506880471134e-07
polymorphism O 0 5.833705927216215e-07
in O 0 3.725604713622488e-08
the O 0 5.9589861933773136e-08
3 O 0 4.124978545405611e-07
noncoding O 0 5.3603876040142495e-06
part O 0 1.0563173447053487e-07
of O 0 1.8038161186950674e-08
the O 0 8.333382339742457e-08
CPO O 0 8.761914614296984e-06
gene O 0 9.086347745324019e-07
, O 0 1.1624612739069562e-07
574 O 0 3.538228384059039e-06
bp O 0 8.930441254051402e-06
downstream O 0 6.817820690230292e-07
of O 0 1.9254114747013773e-08
the O 0 1.2345644506694953e-07
last O 0 6.905124791956041e-07
base O 0 3.1783656595507637e-07
of O 0 1.1254906340241178e-08
the O 0 1.647124889814222e-07
normal O 0 2.7521973606781103e-06
termination O 0 7.939544957480393e-06
codon O 0 4.0554868974140845e-06
( O 0 1.5548182830116275e-07
+ O 0 2.9134712349332403e-06
574 O 0 1.5794908904354088e-05
delATTCTT O 0 5.026796497986652e-05
) O 0 1.1553033800737467e-06
. O 0 2.1026810372859472e-06

Five O 0 1.382771552016493e-05
intragenic O 0 0.0003470800002105534
dimorphisms O 0 0.00042452767957001925
are O 0 2.557050038376474e-07
now O 0 5.874359771951276e-07
well O 0 1.0373396008844793e-07
characterized O 0 2.488742893547169e-06
and O 0 1.0768863489829528e-07
the O 0 2.9972812853884534e-07
high O 0 1.4897991604811978e-05
degree O 0 4.0565441850048956e-07
of O 0 1.4197478037658584e-07
allelic O 0 4.3420615838840604e-05
heterogeneity O 0 7.305853068828583e-05
in O 0 9.224041605193634e-06
HC B-Disease 1 0.9978836178779602
is O 0 2.257114601889043e-06
demonstrated O 0 6.972794608373079e-07
with O 0 2.53915430903362e-08
seven O 0 4.898634742289687e-08
new O 0 2.631097828498241e-08
different O 0 6.747249869931693e-09
mutations O 0 2.1358064827836643e-07
making O 0 2.5647814538842795e-08
a O 0 6.473898395142896e-08
total O 0 1.7148039432868245e-08
of O 0 3.73560915534199e-08
nineteen O 0 4.147970685153268e-06
CPO O 0 7.147426367737353e-05
gene B-Disease 0 7.761349115753546e-05
defects I-Disease 1 0.9825878739356995
reported O 0 2.636563658597879e-05
so O 0 3.3169919788633706e-07
far O 0 8.156275725923479e-07
. O 0 2.797397087306308e-07
. O 0 1.7452987322030822e-06

Coincidence O 0 6.761320400983095e-05
of O 0 4.4655442366092757e-07
two O 0 5.796870254926034e-07
novel O 0 4.429590717336396e-06
arylsulfatase O 0 2.767437217698898e-05
A O 0 1.4833721024842816e-06
alleles O 0 1.1948230849156971e-06
and O 0 6.509458785330935e-07
mutation O 0 2.2791671653976664e-05
459 O 0 8.708690984349232e-06
+ O 0 1.0979048965964466e-05
1G O 0 0.0002558919950388372
> O 0 8.257527042587753e-06
A O 0 8.721638096176321e-07
within O 0 1.2831246465339063e-07
a O 0 7.805771247149096e-07
family O 0 3.950555310439086e-06
with O 0 1.4402227861864958e-05
metachromatic B-Disease 1 0.9991157650947571
leukodystrophy I-Disease 1 0.9986442923545837
: O 0 1.0674523309717188e-06
molecular O 0 3.8516000131494366e-06
basis O 0 2.30826771030479e-07
of O 0 1.9618768476448167e-07
phenotypic O 0 8.481799159199e-05
heterogeneity O 0 0.000570440199226141
. O 0 2.495245098543819e-05

In O 0 3.3367630294378614e-06
a O 0 1.6801751598904957e-06
family O 0 6.666297736046545e-07
with O 0 5.043521866809897e-08
three O 0 1.5197051084214763e-07
siblings O 0 2.265021748826257e-06
, O 0 7.653036249166689e-08
one O 0 1.0951704609851731e-07
developed O 0 2.16436433220224e-06
classical O 0 9.830335329752415e-05
late O 0 0.010271484963595867
infantile O 1 0.9960660338401794
metachromatic B-Disease 1 0.9992425441741943
leukodystrophy I-Disease 1 0.9997015595436096
( O 0 9.03499749256298e-05
MLD B-Disease 1 0.9976263642311096
) O 0 2.2261897356656846e-06
, O 0 1.1259113534833887e-06
fatal O 0 0.009751001372933388
at O 0 1.748494105413556e-05
age O 0 4.718192485597683e-06
5 O 0 5.118077979204827e-07
years O 0 1.7082790293443395e-07
, O 0 4.0961879221868e-08
with O 0 4.574302181481471e-07
deficient O 0 0.0027249944396317005
arylsulfatase O 0 0.00016108833369798958
A O 0 8.42640656628646e-06
( O 0 3.261297081280645e-07
ARSA O 0 0.00015467424236703664
) O 0 6.414347808458842e-08
activity O 0 3.833449682133505e-07
and O 0 1.6129330049352575e-07
increased O 0 1.9360559235792607e-06
galactosylsulfatide O 0 0.0004831957339774817
( O 0 8.605354196333792e-06
GS O 1 0.9946805834770203
) O 0 2.1289056348905433e-06
excretion O 0 7.139926310628653e-05
. O 0 4.981454821972875e-06

The O 0 6.768494245079637e-07
two O 0 1.336105128757481e-07
other O 0 4.308714807166325e-08
siblings O 0 5.493615844898159e-06
, O 0 3.52553627180896e-07
apparently O 0 2.8197832762089092e-06
healthy O 0 1.8981529592565494e-06
at O 0 2.968501121358713e-06
12 O 0 2.453838590099622e-07
( O 0 2.0644124631985505e-08
1 O 0 1.8521133426929737e-07
/ O 0 6.810802801737736e-07
2 O 0 8.334097145734631e-08
) O 0 9.044262228030675e-09
and O 0 1.1821549961155142e-08
15 O 0 8.62767919329599e-08
years O 0 6.17907431887943e-08
, O 0 1.3852091917954112e-08
respectively O 0 1.1620311823890006e-07
, O 0 1.517751968549419e-08
and O 0 1.0350762025268523e-08
their O 0 1.2173495100853415e-08
father O 0 3.7549295939243166e-06
, O 0 2.702416281863407e-07
apparently O 0 1.7471304545324529e-06
healthy O 0 7.521320526393538e-07
as O 0 6.251779893773346e-08
well O 0 1.1602859473214266e-07
, O 0 1.027184168833628e-07
presented O 0 2.7759108434111113e-06
ARSA O 0 0.0014170852955430746
and O 0 3.465549980319338e-06
GS O 1 0.9356408715248108
values O 0 1.0626237099131686e-06
within O 0 3.0970235798122303e-07
the O 0 3.1285048862628173e-07
range O 0 6.930108611413743e-06
of O 0 6.067013146093814e-06
MLD B-Disease 1 0.9991254210472107
patients O 0 0.0016100798966363072
. O 0 1.1401165465940721e-05

Mutation O 0 0.0002810175938066095
screening O 0 1.7100219338317402e-05
and O 0 3.570722526546888e-07
sequence O 0 1.959008386620553e-06
analysis O 0 8.019760571187362e-07
disclosed O 0 1.1235301826673094e-05
the O 0 8.849546162537081e-08
involvement O 0 4.4643093133345246e-07
of O 0 2.5502982836655974e-08
three O 0 9.253058408376091e-08
different O 0 2.4346451255041757e-07
ARSA O 0 0.0027521203737705946
mutations O 0 1.70096245710738e-05
being O 0 2.4789497388155723e-07
the O 0 4.863573366264973e-08
molecular O 0 1.2121175814172602e-06
basis O 0 7.736427676263702e-08
of O 0 1.650911656270182e-07
intrafamilial O 0 0.00017176535038743168
phenotypic O 0 0.00016049161786213517
heterogeneity O 0 0.0009002159349620342
. O 0 2.5345116227981634e-05

The O 0 3.1992945878300816e-05
late O 0 0.0025478398893028498
infantile O 1 0.9904835224151611
patient O 0 0.0795690044760704
inherited O 1 0.7624725103378296
from O 0 4.523305506154429e-06
his O 0 8.873233127815183e-06
mother O 0 1.2082435205229558e-05
the O 0 1.7952392283859808e-07
frequent O 0 2.301509312019334e-06
0 O 0 2.2997539872449124e-06
- O 0 3.0348041036631912e-05
type O 0 2.12240956898313e-05
mutation O 0 1.739750223350711e-05
459 O 0 6.454383310483536e-06
+ O 0 6.4449600358784664e-06
1G O 0 4.8122186854016036e-05
> O 0 3.420569555601105e-06
A O 0 1.140898802987067e-06
, O 0 6.772046390324249e-08
and O 0 3.094914902135315e-08
from O 0 5.038474171215057e-08
his O 0 7.244200901368458e-07
father O 0 9.085584679269232e-06
a O 0 8.858291380420269e-07
novel O 0 1.0382001391917584e-06
, O 0 1.0467884692388907e-07
single O 0 4.325616203004756e-07
basepair O 0 2.29338911594823e-05
microdeletion O 0 1.3097146620566491e-05
of O 0 6.23865403781565e-08
guanine O 0 2.462949851178564e-06
at O 0 1.515094595561095e-06
nucleotide O 0 1.398360836901702e-06
7 O 0 9.774443014975986e-07
in O 0 2.1431149832551455e-07
exon O 0 1.9875398720614612e-05
1 O 0 2.110924697262817e-06
( O 0 4.981251890967542e-07
7delG O 0 6.9171488576103e-05
) O 0 9.65784010986681e-07
. O 0 2.049091335720732e-06

The O 0 2.3811794562789146e-06
two O 0 2.0067463992745616e-06
clinically O 0 0.000226322328671813
unaffected O 0 8.811559382593259e-05
siblings O 0 1.8064269170281477e-05
carried O 0 2.75974844043958e-06
the O 0 6.475145255535608e-07
maternal O 0 6.651749572483823e-05
mutation O 0 3.190790448570624e-05
459 O 0 9.545510692987591e-06
+ O 0 9.632392902858555e-06
1G O 0 0.00012700125807896256
> O 0 6.143107839307049e-06
A O 0 7.972527100719162e-07
and O 0 3.878118803868347e-08
, O 0 2.5621606170034283e-08
on O 0 4.233193351410591e-08
their O 0 5.424412030663461e-09
paternal O 0 1.1227547247472103e-06
allele O 0 8.748570508032572e-07
, O 0 3.5603978432163785e-08
a O 0 7.98618131625517e-08
novel O 0 1.8372338672634214e-07
cytosine O 0 3.8224578702283907e-07
to O 0 1.3178185653828223e-08
thymidine O 0 3.068493697355734e-06
transition O 0 2.8445181214920012e-06
at O 0 2.0276690975151723e-06
nucleotide O 0 6.980033049330814e-06
2435 O 0 8.773645095061511e-05
in O 0 3.1415734724760114e-07
exon O 0 1.4507128980767448e-05
8 O 0 1.2116854577470804e-06
, O 0 3.373979140519623e-08
resulting O 0 1.7203706192958634e-07
in O 0 2.383290897967072e-08
substitution O 0 8.26909953843824e-08
of O 0 6.307944033778767e-08
alanine O 0 1.2012740626232699e-05
464 O 0 3.536824806360528e-06
by O 0 2.7676398417497694e-07
valine O 0 0.00021897262195125222
( O 0 1.1401417623346788e-06
A464V O 0 4.70192389911972e-05
) O 0 1.0144192401639884e-06
. O 0 2.3838945253373822e-06

The O 0 3.8079326714068884e-06
fathers O 0 1.3772453712590504e-05
genotype O 0 6.008287891745567e-05
thus O 0 1.2037511623930186e-05
was O 0 9.37200675252825e-05
7delG O 0 0.0007687784964218736
/ O 0 0.0005419666995294392
A464V O 0 0.0006676309858448803
. O 0 2.012790719163604e-05

Mutation O 0 0.0011794210877269506
A464V O 0 0.00021336530335247517
was O 0 2.079004843835719e-05
not O 0 1.9056790279137203e-07
found O 0 5.149760227141087e-07
in O 0 5.183630946703488e-07
18 O 0 6.701089660055004e-06
unrelated O 0 0.00036562589230015874
MLD B-Disease 1 0.9994660019874573
patients O 0 0.00010757663403637707
and O 0 6.982177183090243e-07
50 O 0 1.7253011037610122e-06
controls O 0 2.4647573809488676e-05
. O 0 5.92981223235256e-06

A464V O 0 0.0005686552613042295
, O 0 2.1781527266284684e-06
although O 0 1.3998004533277708e-06
clearly O 0 4.892961896985071e-06
modifying O 0 4.984826227882877e-05
ARSA O 0 0.021387290209531784
and O 0 3.770355397136882e-05
GS O 1 0.9991262555122375
levels O 0 0.00039782378007657826
, O 0 1.042422582031577e-06
apparently O 0 5.9496783251233865e-06
bears O 0 3.829934485111153e-06
little O 0 5.804902798445255e-07
significance O 0 8.463530321023427e-07
for O 0 1.6966896509984508e-07
clinical O 0 2.4296159608638845e-05
manifestation O 0 0.00011636476847343147
of O 0 5.826383585372241e-06
MLD B-Disease 1 0.9996635913848877
, O 0 3.049595079573919e-06
mimicking O 0 4.999875818612054e-05
the O 0 2.185585344705032e-06
frequent O 0 9.014446550281718e-05
ARSA O 0 0.02691798470914364
pseudodeficiency O 0 0.0019074585288763046
allele O 0 0.0002464672434143722
. O 0 2.1842810383532196e-05

Our O 0 7.308608928724425e-06
results O 0 2.9057932806608733e-06
demonstrate O 0 7.946641744638328e-07
that O 0 4.1607250977904187e-08
in O 0 1.2124120019052498e-07
certain O 0 2.9828669312337297e-07
genetic O 0 0.00026644079480320215
conditions O 0 0.004948565270751715
MLD B-Disease 1 0.9991063475608826
- O 0 0.008105219341814518
like O 0 3.367075987625867e-05
ARSA O 0 0.013994870707392693
and O 0 1.4793577975069638e-05
GS O 1 0.98341965675354
values O 0 4.4076301719542244e-07
need O 0 6.067691060707148e-08
not O 0 1.0043043729979217e-08
be O 0 1.5669913366878063e-08
paralleled O 0 1.1075154588979785e-06
by O 0 4.4537887333717663e-07
clinical O 0 0.00046877964632585645
disease O 1 0.9379759430885315
, O 0 6.825459308856807e-08
a O 0 2.1188016319229064e-07
finding O 0 1.9960452846135013e-07
with O 0 4.872013619205973e-07
serious O 0 0.000890167779289186
diagnostic O 0 0.0006312771583907306
and O 0 7.156306310207583e-06
prognostic O 0 0.016843611374497414
implications O 0 0.0011435323394834995
. O 0 2.293929355801083e-05

Moreover O 0 6.909875810379162e-05
, O 0 1.3039629038757994e-06
further O 0 1.5613817367921001e-06
ARSA O 0 0.002556384075433016
alleles O 0 1.084523228200851e-05
functionally O 0 3.593651854316704e-05
similar O 0 5.264020614959009e-07
to O 0 8.835648657168349e-08
A464V O 0 1.3263554137665778e-05
might O 0 4.975170213583624e-07
exist O 0 9.324065786131541e-08
which O 0 1.2647958236300383e-08
, O 0 5.240790468263867e-09
together O 0 7.618879749315965e-09
with O 0 6.561388943282509e-08
0 O 0 2.08517417377152e-06
- O 0 8.671503746882081e-05
type O 0 6.177012255648151e-05
mutations O 0 5.980916466796771e-05
, O 0 6.484278287643974e-07
may O 0 5.114328359923093e-06
cause O 0 3.936498978873715e-05
pathological O 0 0.0029479796066880226
ARSA O 0 0.44692015647888184
and O 0 3.687372736749239e-05
GS O 1 0.9992062449455261
levels O 0 3.4247059375047684e-05
, O 0 1.053990885679923e-07
but O 0 3.4754084055066414e-08
not O 0 5.6248566693284374e-08
clinical O 0 4.771660314872861e-06
outbreak O 0 0.00012502024765126407
of O 0 1.4070128884213773e-07
the O 0 8.062947017606348e-05
disease O 1 0.9965000152587891
. O 0 1.2486328841987415e-06
. O 0 3.4954200600623153e-06

Human O 0 0.033387478440999985
MLH1 O 1 0.9931529760360718
deficiency O 1 0.9989181756973267
predisposes O 0 0.017174575477838516
to O 0 3.663132883957587e-05
hematological B-Disease 1 0.9970297813415527
malignancy I-Disease 1 0.9992701411247253
and O 0 0.00017882289830595255
neurofibromatosis B-Disease 1 0.9994633793830872
type I-Disease 1 0.7860047221183777
1 I-Disease 0 0.0002671272959560156
. O 0 1.2415272976795677e-05

Heterozygous O 0 0.00026270729722455144
germ O 0 0.002980203600600362
- O 0 0.000266872753854841
line O 0 3.5217042750446126e-05
mutations O 0 2.0075880456715822e-05
in O 0 2.2906343133399787e-07
the O 0 4.802435000783589e-07
DNA O 0 3.185573223163374e-05
mismatch O 0 0.0043657803907990456
repair O 0 0.005492357071489096
genes O 0 1.3965594916953705e-05
lead O 0 3.596850001486018e-05
to O 0 4.071479906997411e-06
hereditary B-Disease 1 0.9997122883796692
nonpolyposis I-Disease 1 0.9999244213104248
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
. O 0 0.0003296771610621363

The O 0 0.000240426161326468
disease O 1 0.9934358596801758
susceptibility O 0 0.0002112668298650533
of O 0 3.906210679360811e-07
individuals O 0 4.931164312438341e-07
who O 0 5.4373699640564155e-06
constitutionally O 0 3.153476063744165e-05
lack O 0 7.322020110223093e-07
both O 0 2.352754933099277e-07
wild O 0 7.990179256012198e-06
- O 0 0.0002596172853372991
type O 0 3.300809839856811e-05
alleles O 0 3.886111699102912e-06
is O 0 1.3901660622650525e-06
unknown O 0 1.0473379006725736e-05
. O 0 3.345116965647321e-06

We O 0 2.732081838985323e-06
have O 0 1.8866212769808044e-07
identified O 0 4.7151016246971267e-07
three O 0 5.424394444730751e-08
offspring O 0 6.465136834776786e-07
in O 0 3.8622118836428854e-07
a O 0 9.407571633346379e-05
hereditary B-Disease 1 0.9997454285621643
nonpolyposis I-Disease 1 0.9999172687530518
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
family O 0 0.003470905125141144
who O 0 8.332956349477172e-05
developed O 0 0.000657362921629101
hematological B-Disease 1 0.9970460534095764
malignancy I-Disease 1 0.9972015619277954
at O 0 2.8016660508001223e-05
a O 0 5.130553972776397e-07
very O 0 1.6645964251438272e-07
early O 0 5.501372584149067e-07
age O 0 3.8522836121046566e-07
, O 0 1.1243256103909971e-08
and O 0 8.025298647851287e-09
at O 0 2.710386581838975e-07
least O 0 4.174363521514124e-09
two O 0 2.6049706836062114e-09
of O 0 1.8283357050563609e-09
them O 0 4.092117311671473e-09
displayed O 0 1.9132994566462003e-06
signs O 0 1.5230278222588822e-05
of O 0 1.5281897276508971e-06
neurofibromatosis B-Disease 1 0.9960021376609802
type I-Disease 0 0.009328163228929043
1 I-Disease 0 2.8711332561215386e-05
( O 0 2.8727095013891812e-06
NF1 B-Disease 0 0.0008136410033330321
) O 0 1.7839849988376955e-06
. O 0 3.862741777993506e-06

DNA O 0 2.005110218306072e-05
sequence O 0 2.0928619051119313e-06
analysis O 0 2.665791782874294e-07
and O 0 6.229569038396221e-08
allele O 0 1.1467315061963745e-06
- O 0 1.7663433027337305e-06
specific O 0 3.414792715261683e-08
amplification O 0 1.527353447272617e-06
in O 0 8.830762965317263e-08
two O 0 6.380766848224084e-08
siblings O 0 5.170086296857335e-06
revealed O 0 6.4912173911579885e-06
a O 0 2.3750922082399484e-06
homozygous O 0 2.061712984868791e-05
MLH1 O 0 0.0017745204968377948
mutation O 0 8.631119999336079e-05
( O 0 7.942202273625298e-07
C676T O 0 6.151740672066808e-05
- O 0 0.00025964449741877615
- O 0 0.0001584492129040882
> O 0 2.0503171981545165e-05
Arg226Stop O 0 8.16230894997716e-05
) O 0 9.68220433605893e-07
. O 0 1.7407938912583631e-06

Thus O 0 1.0163869774260093e-05
, O 0 7.403703534691886e-07
a O 0 1.907269393086608e-06
homozygous O 0 2.7139012672705576e-05
germ O 0 0.0031124050728976727
- O 0 0.0009539374732412398
line O 0 0.0002111566864186898
MLH1 O 0 0.008576147258281708
mutation O 0 0.00019662252452690154
and O 0 3.269847411502269e-06
consequent O 0 0.027679387480020523
mismatch O 1 0.9994215965270996
repair O 1 0.9998905658721924
deficiency O 1 0.9998949766159058
results O 0 0.00019139680080115795
in O 0 2.410840806987835e-06
a O 0 1.3656586816068739e-05
mutator O 0 0.03232845291495323
phenotype O 0 0.0010033489670604467
characterized O 0 0.0003172201104462147
by O 0 1.4105173249845393e-05
leukemia B-Disease 1 0.9998018145561218
and O 0 0.00011173073289683089
/ O 1 0.9837706089019775
or O 1 0.9633341431617737
lymphoma B-Disease 1 0.9999997615814209
associated O 0 0.0003460126754362136
with O 0 1.9851495380862616e-05
neurofibromatosis B-Disease 1 0.9995182752609253
type I-Disease 0 0.09890726208686829
1 I-Disease 0 2.9602933864225633e-05
. O 0 1.113314283429645e-06
. O 0 2.8470230972743593e-06

Missense O 0 0.0032662691082805395
mutations O 0 0.0004115825577173382
in O 0 5.017586772737559e-07
the O 0 7.038550364768525e-08
most O 0 5.4539405880404956e-08
ancient O 0 3.8241461197685567e-07
residues O 0 5.940641472079733e-07
of O 0 3.8378679789730086e-08
the O 0 4.3716076447708474e-07
PAX6 O 0 0.00025465775979682803
paired O 0 9.698223948362283e-06
domain O 0 2.2261174308368936e-06
underlie O 0 3.121634654235095e-05
a O 0 2.242383516204427e-06
spectrum O 0 5.593215973931365e-05
of O 0 5.320925083651673e-06
human O 0 0.4802156984806061
congenital B-Disease 1 0.999997615814209
eye I-Disease 1 0.9998829364776611
malformations I-Disease 1 0.9998588562011719
. O 0 0.0008276914013549685

Mutations O 0 0.0003524706407915801
of O 0 8.290488153761544e-07
the O 0 3.2310374535882147e-06
human O 0 2.2788259229855612e-05
PAX6 O 0 0.017584212124347687
gene O 0 0.001354800770059228
underlie O 1 0.883022129535675
aniridia B-Disease 1 0.9999219179153442
( O 0 0.00824696384370327
congenital B-Disease 1 0.9999904632568359
absence I-Disease 0 0.0006848657503724098
of I-Disease 0 7.267970545399294e-07
the I-Disease 0 1.0805959391291253e-05
iris I-Disease 0 0.031599223613739014
) O 0 3.6924581081621e-07
, O 0 1.124484754200239e-07
a O 0 1.4851767673462746e-06
rare O 0 0.00011198245920240879
dominant O 1 0.8145688772201538
malformation B-Disease 1 0.9998946189880371
of I-Disease 0 2.7139324174640933e-06
the I-Disease 0 4.11247274314519e-05
eye I-Disease 1 0.925406813621521
. O 0 3.0092936867731623e-05

The O 0 5.507953119376907e-06
spectrum O 0 7.631985499756411e-05
of O 0 4.946858098264784e-06
PAX6 O 0 0.01820506900548935
mutations O 0 0.005979947745800018
in O 0 6.980463513173163e-05
aniridia B-Disease 1 0.9995763897895813
patients O 0 0.0003728889278136194
is O 0 4.3180773445783416e-07
highly O 0 9.432532692699169e-07
biased O 0 1.1175650342920562e-06
, O 0 3.4721882258281767e-08
with O 0 2.531373688441363e-08
92 O 0 1.0618123269523494e-06
% O 0 7.85702614081174e-09
of O 0 6.047746303750046e-09
all O 0 2.6676071129827506e-08
reported O 0 7.04963349562604e-06
mutations O 0 5.504303317138692e-06
leading O 0 3.878292318404419e-06
to O 0 6.341880265381405e-08
premature O 0 1.9562567104003392e-05
truncation O 0 4.2281485548301134e-06
of O 0 3.342713839060707e-08
the O 0 1.6742842490202747e-07
protein O 0 1.1060673159590806e-06
( O 0 9.080736873556816e-08
nonsense O 0 1.983323500098777e-06
, O 0 2.6149631793259687e-08
splicing O 0 7.944444746499357e-07
, O 0 4.570821943161718e-08
insertions O 0 8.549187668904779e-07
and O 0 4.6493507710465565e-08
deletions O 0 9.647179695093655e-07
) O 0 2.2762481677318647e-08
and O 0 2.078909666636264e-08
just O 0 1.6321402540597774e-07
2 O 0 1.365240933637324e-07
% O 0 8.067565282487976e-09
leading O 0 1.0678418504994625e-07
to O 0 1.988075926107058e-09
substitution O 0 1.1737946614687189e-08
of O 0 8.786169125585275e-09
one O 0 5.181880879945311e-08
amino O 0 2.1459106847032672e-07
acid O 0 9.708400057206745e-07
by O 0 2.5961531591178755e-08
another O 0 2.4853270019775664e-07
( O 0 3.3861064707707555e-07
missense O 0 3.959959576604888e-05
) O 0 6.592989620912704e-07
. O 0 2.3480013169319136e-06

The O 0 4.415920102474047e-06
extraordinary O 0 3.817604920186568e-06
conservation O 0 1.3089352250972297e-06
of O 0 4.909513506845542e-08
the O 0 2.052093890370088e-07
PAX6 O 0 9.629302803659812e-05
protein O 0 1.8168113911087858e-06
at O 0 7.719991117483005e-07
the O 0 1.1134655863997978e-07
amino O 0 3.096810985425691e-07
acid O 0 2.7205353489989648e-06
level O 0 9.310574569099117e-07
amongst O 0 9.307103141509288e-07
vertebrates O 0 2.4231236238847487e-05
predicts O 0 2.1504194592125714e-05
that O 0 1.809704457400585e-07
pathological O 0 0.0001818770688259974
missense O 0 0.00030109676299616694
mutations O 0 0.0001534935727249831
should O 0 5.273175247566542e-07
in O 0 1.4617955912399339e-07
fact O 0 1.8496967868486536e-07
be O 0 8.4051684723363e-08
common O 0 2.1301678998497664e-07
even O 0 2.489705934749509e-07
though O 0 9.581862769891814e-08
they O 0 7.702471549464462e-09
are O 0 4.090845440174462e-09
hardly O 0 5.794266826342209e-07
ever O 0 9.729402563607437e-07
seen O 0 4.014558726339601e-06
in O 0 2.683493903532508e-06
aniridia B-Disease 1 0.9979276657104492
patients O 0 0.00023492786567658186
. O 0 7.14447514837957e-06

This O 0 1.3871255077901878e-06
indicates O 0 1.9652284208859783e-06
that O 0 3.482920263309097e-08
there O 0 3.7773730809931294e-08
is O 0 5.8325046126128655e-08
a O 0 4.3787841264020244e-07
heavy O 0 7.747786730760708e-05
ascertainment O 0 0.0001888536207843572
bias O 0 7.141103196772747e-06
in O 0 9.139154855120069e-08
the O 0 4.909325923563301e-08
selection O 0 1.2565966756028502e-07
of O 0 1.1604209504412211e-07
patients O 0 1.7300758372584824e-06
for O 0 8.77097079410305e-08
PAX6 O 0 0.0003570917760953307
mutation O 0 6.876302450109506e-06
analysis O 0 1.1308879521720883e-07
and O 0 4.191998925762164e-08
that O 0 2.0604234762799933e-08
the O 0 5.310581627782085e-07
missing O 0 2.1454072339111008e-05
PAX6 O 0 0.001711999881081283
missense O 0 0.001048385282047093
mutations O 0 0.0005331584834493697
frequently O 0 2.9952871045679785e-05
may O 0 9.586562555341516e-06
underlie O 0 0.0002971703070215881
phenotypes O 0 0.00023536257504019886
distinct O 0 9.233961463905871e-06
from O 0 2.127173684129957e-05
textbook O 0 0.020580653101205826
aniridia B-Disease 1 0.9984700083732605
. O 0 5.242965926299803e-05

Here O 0 4.8455362957611214e-06
we O 0 3.6917538182024145e-07
present O 0 2.7637494781629357e-07
four O 0 4.0054047190096753e-07
novel O 0 5.748622697865358e-06
PAX6 O 0 0.0006037255516275764
missense O 0 0.0003003012388944626
mutations O 0 8.225341298384592e-05
, O 0 2.5087138055823743e-07
two O 0 7.787504330281081e-08
in O 0 4.6512536755471956e-07
association O 0 9.474238709117344e-07
with O 0 1.22200788155169e-06
atypical O 0 0.0025315822567790747
phenotypes O 0 0.0015603209612891078
ectopia B-Disease 0 0.004796430002897978
pupillae I-Disease 0 0.0023014522157609463
( O 0 9.49024467900017e-07
displaced B-Disease 0 9.419399589205568e-07
pupils I-Disease 0 1.805153601708298e-06
) O 0 9.968309768737527e-07
and O 0 5.399522342486307e-05
congenital B-Disease 1 0.9999725818634033
nystagmus I-Disease 0 0.038130342960357666
( O 0 7.622108455507259e-07
searching B-Disease 0 2.5817914774961537e-06
gaze I-Disease 0 9.883825441647787e-06
) O 0 8.39152036746782e-08
, O 0 1.981361386071967e-08
and O 0 1.3353046668385105e-08
two O 0 3.073033383316215e-08
in O 0 8.168429133093014e-08
association O 0 1.0720007281861399e-07
with O 0 2.7288317383522553e-08
more O 0 6.976307531658676e-08
recognizable O 0 0.0009284185362048447
aniridia B-Disease 1 0.997497022151947
phenotypes O 0 0.0032678700517863035
. O 0 1.5061531485116575e-05

Strikingly O 0 9.024113387567922e-05
, O 0 6.788909558963496e-07
all O 0 5.607546071928482e-08
four O 0 3.545003437466221e-07
mutations O 0 4.004505626653554e-06
are O 0 2.140092014712991e-08
located O 0 5.257834345684387e-07
within O 0 1.800142541696914e-07
the O 0 2.3038229812755162e-07
PAX6 O 0 5.46240626135841e-05
paired O 0 2.1700916477129795e-06
domain O 0 5.962363047729013e-07
and O 0 8.931721851013208e-08
affect O 0 2.0490647045789956e-07
amino O 0 1.089761170192105e-07
acids O 0 5.654157320122977e-08
which O 0 2.551036493159131e-09
are O 0 7.824270675804712e-10
highly O 0 4.628752137136871e-08
conserved O 0 1.1570516278425202e-07
in O 0 1.3029476164660991e-08
all O 0 6.038547883946421e-09
known O 0 1.8370340626461257e-07
paired O 0 1.0868203617064864e-06
domain O 0 6.919825636941823e-07
proteins O 0 8.93148921932152e-07
. O 0 1.175535317088361e-06

Our O 0 8.141391845128965e-06
results O 0 6.580352874152595e-06
support O 0 2.0407647127740347e-07
the O 0 2.3655454128856945e-07
hypothesis O 0 5.785205985375796e-07
that O 0 6.74562894431574e-09
the O 0 2.7370258948167248e-08
under O 0 1.4239215317957132e-07
- O 0 8.841842031870328e-07
representation O 0 6.736913604754591e-08
of O 0 3.4318088637519395e-07
missense O 0 0.0006271734600886703
mutations O 0 0.000650339643470943
is O 0 3.429620619499474e-06
caused O 0 1.989675365621224e-05
by O 0 6.523858360196755e-07
ascertainment O 0 0.0007360713789239526
bias O 0 2.053628304565791e-05
and O 0 2.8275150043555186e-07
suggest O 0 5.93937272697076e-07
that O 0 2.9138767843051028e-08
a O 0 3.7476846159734123e-07
substantial O 0 1.211149424307223e-06
burden O 0 1.907184923766181e-05
of O 0 1.8848727449949365e-06
PAX6 B-Disease 1 0.7859475016593933
- I-Disease 1 0.9883958101272583
related I-Disease 0 0.009150411002337933
disease I-Disease 1 0.9994601607322693
remains O 0 4.854911458096467e-05
to O 0 6.077257808101422e-08
be O 0 3.2689573004063277e-07
uncovered O 0 3.1766634492669255e-05
. O 0 3.888081039349345e-07
. O 0 1.7152673308373778e-06

The O 0 3.3255169000767637e-06
chromosomal O 0 0.0003399509296286851
order O 0 4.4687223521577835e-07
of O 0 8.748448721007662e-08
genes O 0 3.70350403500197e-06
controlling O 0 8.316173625644296e-05
the O 0 1.371642497360881e-06
major O 0 0.00014169304631650448
histocompatibility O 1 0.8908936977386475
complex O 0 0.00043944205390289426
, O 0 2.4848911834851606e-06
properdin O 0 8.615709521109238e-05
factor O 0 5.566769232245861e-06
B O 0 4.2425297579029575e-05
, O 0 6.952012086003378e-07
and O 0 6.29652822681237e-06
deficiency B-Disease 1 0.9562732577323914
of I-Disease 0 3.350009336600124e-08
the I-Disease 0 1.4222223398974165e-07
second I-Disease 0 1.1917595656996127e-06
component I-Disease 0 1.3741380371357081e-06
of I-Disease 0 7.057828099732433e-08
complement I-Disease 0 4.061307663505431e-06
. O 0 4.7538460421492346e-06

The O 0 1.2766886356985196e-06
relationship O 0 2.2145854927657638e-06
of O 0 4.4385068065366795e-08
the O 0 1.1090167362226566e-07
genes O 0 4.365787162896595e-07
coding O 0 5.887421593797626e-06
for O 0 1.0420175300396295e-07
HLA O 0 7.393080977635691e-06
to O 0 1.0547264395199818e-08
those O 0 1.3345128557773478e-08
coding O 0 2.666791033334448e-06
for O 0 1.2264882798262988e-07
properdin O 0 3.404523158678785e-05
Factor O 0 1.5637809838153771e-06
B O 0 1.0969137292704545e-05
allotypes O 0 3.184932211297564e-05
and O 0 6.193228045958676e-07
for O 0 1.7697221892376547e-06
deficiency B-Disease 1 0.914290726184845
of I-Disease 0 2.121526776477367e-08
the I-Disease 0 8.713576704622028e-08
second I-Disease 0 4.1905440184564213e-07
component I-Disease 0 4.079549853486242e-07
of I-Disease 0 2.5328853681116925e-08
complement I-Disease 0 4.445093964022817e-07
( O 0 1.875178980981218e-07
C2 O 0 2.683873026398942e-05
) O 0 3.9266254248104815e-08
was O 0 2.8422846298781224e-07
studied O 0 2.6279337816959014e-07
in O 0 2.1542865269452705e-08
families O 0 1.078106759422326e-08
of O 0 1.0974162023558165e-07
patients O 0 4.14859750890173e-05
with O 0 4.931934745400213e-05
connective O 1 0.9997192025184631
tissue O 1 0.9998486042022705
disorders O 1 0.9999063014984131
. O 0 8.891661855159327e-05

Patients O 0 0.00015865269233472645
were O 0 4.7237659828169853e-07
selected O 0 1.1142324751745036e-07
because O 0 5.642930744897967e-08
they O 0 7.178260652551671e-09
were O 0 1.3015070798871875e-08
heterozygous O 0 1.2381087799440138e-07
or O 0 2.580336797564087e-07
homozygous O 0 2.377839518885594e-05
for O 0 8.855817577568814e-05
C2 B-Disease 1 0.9999129772186279
deficiency I-Disease 1 0.9999703168869019
. O 0 6.78704964229837e-05

12 O 0 1.0815000678121578e-05
families O 0 1.544278944720645e-07
with O 0 1.3754133476595598e-07
15 O 0 1.073939415618952e-06
matings O 0 3.2499563531018794e-05
informative O 0 3.9516115066362545e-05
for O 0 0.00022230208560358733
C2 B-Disease 1 0.9999282360076904
deficiency I-Disease 1 0.999977707862854
were O 0 1.566489845572505e-05
found O 0 2.5754645321285352e-05
. O 0 7.10863787389826e-06

Of O 0 3.52476035914151e-06
57 O 0 6.222886895557167e-06
informative O 0 2.2004323909641244e-06
meioses O 0 4.2190928070340306e-05
, O 0 5.635724775743256e-08
two O 0 5.8476956610320485e-09
crossovers O 0 3.2999383847709396e-07
were O 0 8.03069184485139e-08
noted O 0 4.7443307948924485e-07
between O 0 1.2283347814445733e-06
the O 0 0.00026721900212578475
C2 B-Disease 1 0.9996974468231201
deficiency I-Disease 1 0.999711811542511
gene O 0 3.358580897838692e-06
and O 0 9.028907754782267e-08
the O 0 4.117075036447204e-07
HLA O 0 7.229892798932269e-05
- O 0 4.0421204175800085e-05
B O 0 4.019063453597482e-06
gene O 0 2.790003748032177e-07
, O 0 1.3455850655930135e-08
with O 0 5.356044052717834e-09
a O 0 5.022412707944568e-08
recombinant O 0 1.8307520122107235e-07
fraction O 0 2.429445089546789e-07
of O 0 1.1545495937070882e-07
0 O 0 4.117355729249539e-06
. O 0 2.5224703676940408e-06

035 O 0 0.09370137006044388
. O 0 0.00013289636990521103

A O 0 2.4701130314497277e-05
lod O 0 0.00019588581926655024
score O 0 9.010720987134846e-07
of O 0 1.091862529278842e-07
13 O 0 1.1510484227983397e-06
was O 0 5.662261628458509e-07
calculated O 0 6.853990441868518e-08
for O 0 3.6455745089369884e-08
linkage O 0 2.703333848330658e-05
between O 0 0.0006079997401684523
C2 B-Disease 1 0.9999227523803711
deficiency I-Disease 1 0.999950647354126
and O 0 4.356131739768898e-06
HLA O 0 0.00016701627464499325
- O 0 5.9127349231857806e-05
B O 0 5.72222052142024e-06
at O 0 2.2548675815414754e-07
a O 0 5.595985186346297e-08
maximum O 0 3.500789702570728e-08
likelihood O 0 5.668853830798071e-08
value O 0 6.942230790230042e-09
of O 0 1.6866983365559918e-09
the O 0 1.1514844189264295e-08
recombinant O 0 1.5387396956612065e-07
fraction O 0 1.0782572701373283e-07
of O 0 7.644458577260593e-08
0 O 0 2.4982546165119857e-06
. O 0 1.7264731013710843e-06

04 O 0 0.02024591900408268
. O 0 0.00011312278365949169

18 O 0 9.914147995004896e-06
families O 0 1.3133600873516116e-07
with O 0 1.60198126764044e-07
21 O 0 4.559698538741941e-07
informative O 0 1.5265845831891056e-07
matings O 0 3.0156106731737964e-06
for O 0 4.562460631518661e-08
both O 0 1.0489950597047937e-07
properdin O 0 2.2947453544475138e-05
Factor O 0 2.24603491005837e-06
B O 0 8.595331564720254e-06
allotype O 0 1.6964719179668464e-05
and O 0 3.6029308603247046e-07
HLA O 0 7.475335587514564e-05
- O 0 8.517428796039894e-05
B O 0 1.6636005966574885e-05
were O 0 4.7022004423524777e-07
found O 0 1.3074356957076816e-06
. O 0 1.4587905070584384e-06

Of O 0 2.936736109404592e-06
72 O 0 7.673002983210608e-06
informative O 0 3.016761183971539e-06
meioses O 0 6.049941657693125e-05
, O 0 1.116534349421272e-07
three O 0 5.9209867231402313e-08
recombinants O 0 1.2711930139630567e-05
were O 0 1.3344345006771619e-07
found O 0 1.2077566680090968e-07
, O 0 6.5442384844516255e-09
giving O 0 6.640135552515858e-09
a O 0 3.6258249735965364e-08
recombinant O 0 1.7878996061426733e-07
fraction O 0 1.7508338601146534e-07
of O 0 1.1247400522051976e-07
0 O 0 3.1525030408374732e-06
. O 0 1.6650790257699555e-06

042 O 0 0.0168114323168993
. O 0 7.757796993246302e-05

A O 0 1.8732853277469985e-05
lod O 0 0.000251042190939188
score O 0 1.2570250191856758e-06
of O 0 8.272411378129618e-08
16 O 0 7.945308766466042e-07
between O 0 5.769563813373679e-07
HLA O 0 5.70380907447543e-05
- O 0 2.7045767637901008e-05
B O 0 3.0724495445610955e-06
and O 0 6.989359491171854e-08
Factor O 0 3.846735978640936e-07
B O 0 2.1326243313524174e-06
allotypes O 0 4.441430064616725e-06
was O 0 6.335870352813799e-07
calculated O 0 5.855600093696012e-08
at O 0 1.075340847478401e-07
a O 0 3.4232115808663366e-08
maximum O 0 3.64072434422269e-08
likelihood O 0 5.57382833221709e-08
value O 0 5.375571543453361e-09
of O 0 4.1524383931346165e-09
the O 0 1.518032810565728e-08
recombinant O 0 2.132554186573543e-07
fraction O 0 1.5660388896776567e-07
of O 0 9.401480838278076e-08
0 O 0 1.969032609849819e-06
. O 0 1.826879952204763e-06

04 O 0 0.015501268208026886
. O 0 8.602468005847186e-05

A O 0 3.743594788829796e-06
crossover O 0 2.3130303361540427e-06
was O 0 3.006487986567663e-06
shown O 0 7.816671399041297e-08
to O 0 7.188810879910079e-09
have O 0 4.934463948558232e-09
occurred O 0 5.72917109309401e-08
between O 0 6.6083090111135334e-09
genes O 0 3.761541123026291e-08
for O 0 1.1458473281322767e-08
Factor O 0 2.906046177031385e-07
B O 0 2.1505543372768443e-06
and O 0 2.1057400090285228e-07
HLA O 0 0.00010296966502210125
- O 0 0.00039084244053810835
D O 0 0.0005029967287555337
, O 0 5.14820825969764e-08
in O 0 3.4269678650389324e-08
which O 0 2.8086111569791683e-07
HLA O 0 4.024128065793775e-05
- O 0 0.00013448244135361165
D O 0 0.00022009517124388367
segregared O 0 8.11272366263438e-06
with O 0 1.3510711482922488e-07
HLA O 0 3.4386146580800414e-05
- O 0 1.083278675650945e-05
A O 0 1.0987174619003781e-06
and O 0 5.950864760961849e-07
B O 0 4.741638622363098e-05
. O 0 1.368836933579587e-06

These O 0 1.104931811823917e-06
studies O 0 4.4518267827697855e-07
suggest O 0 1.903896986732434e-07
that O 0 3.618886301737234e-09
the O 0 1.3969258638724114e-08
genes O 0 1.0162612795738823e-07
for O 0 5.570916172814577e-08
Factor O 0 2.6437201086082496e-06
B O 0 0.0007507623522542417
and O 0 0.0015614167787134647
C2 B-Disease 1 0.9999818801879883
deficiency I-Disease 1 0.9999841451644897
are O 0 4.3622993217695694e-08
located O 0 1.9858738653510954e-07
outside O 0 1.7251878148272226e-07
those O 0 2.454839709287171e-08
for O 0 6.270936125929438e-08
HLA O 0 1.495741253165761e-05
, O 0 5.119966672850751e-08
that O 0 5.94415805466042e-09
the O 0 3.1056593741141114e-08
order O 0 4.308862600055363e-08
of O 0 4.3267093019494496e-08
genese O 0 3.181183637934737e-05
is O 0 5.94876553350332e-07
HLA O 0 1.3078174561087508e-05
- O 0 5.051232164987596e-06
A O 0 8.649244023217761e-07
, O 0 1.4743835663466598e-07
- O 0 6.837304226792185e-06
B O 0 7.17731700206059e-06
, O 0 2.3638293100702867e-07
- O 0 3.1845465855440125e-05
D O 0 0.00011368065315764397
, O 0 1.0733490540815183e-07
Factor O 0 9.362449304717302e-07
B O 0 2.3758628231007606e-05
allotype O 0 0.0008559829439036548
, O 0 0.00026238159625791013
C2 B-Disease 1 0.9998258948326111
deficiency I-Disease 1 0.9999655485153198
, O 0 1.6992336782095663e-07
that O 0 6.6331735659730384e-09
the O 0 4.508815720782877e-08
genes O 0 7.723024850747606e-07
coding O 0 6.4638297772035e-05
for O 0 6.371287599904463e-05
C2 B-Disease 1 0.999885082244873
deficiency I-Disease 1 0.9999575614929199
and O 0 1.1356447657817625e-06
Factor O 0 1.3419811466519604e-06
B O 0 5.165089078218443e-06
allotypes O 0 4.934475327900145e-06
are O 0 6.747945313634318e-09
approximately O 0 3.614238863747232e-08
3 O 0 2.7933580781791534e-07
- O 0 4.8885212891036645e-06
- O 0 4.557104603009066e-06
5 O 0 1.5778309148117842e-07
centimorgans O 0 1.2170532954769442e-06
from O 0 1.553054218561556e-08
the O 0 7.774266208571134e-08
HLA O 0 7.78437879489502e-06
- O 0 3.513058572934824e-06
A O 0 6.340972049656557e-07
and O 0 2.598662831587717e-07
HLA O 0 2.836853855114896e-05
- O 0 1.6299378330586478e-05
B O 0 3.9080914575606585e-06
loci O 0 5.74190380575601e-07
, O 0 3.74559050442258e-08
and O 0 1.2849143971038757e-08
that O 0 1.0105761560907922e-08
the O 0 8.870602385968596e-08
apparent O 0 3.986833235103404e-06
lack O 0 4.157485307132447e-07
of O 0 4.89527245406407e-08
recombinants O 0 1.258265820069937e-05
between O 0 1.8330092643736862e-07
the O 0 3.791290055232821e-07
Factor O 0 2.702658321140916e-06
B O 0 1.8319798982702196e-05
gene O 0 1.7406280676368624e-05
and O 0 0.00023934204364195466
C2 B-Disease 1 0.9999138116836548
deficiency I-Disease 1 0.999942421913147
gene O 0 1.1498467756609898e-05
suggests O 0 4.7495322519353067e-07
that O 0 3.868689812946968e-09
these O 0 1.9882693269579477e-09
two O 0 1.7234999205584245e-08
genes O 0 2.581513172117411e-07
lie O 0 1.0985257858919795e-06
in O 0 2.895483319775849e-08
close O 0 2.1227252489097737e-07
proximity O 0 2.0097714070743677e-07
to O 0 4.3782367953326684e-08
one O 0 1.9240462734160246e-07
another O 0 1.408625507792749e-06
. O 0 2.1867613213544246e-06

Distribution O 0 1.0099489372805692e-05
of O 0 1.1670726962620392e-06
emerin O 0 0.0004264234157744795
and O 0 2.78492848337919e-06
lamins O 0 0.0009301688987761736
in O 0 1.8359744444751414e-06
the O 0 2.5393587748112623e-06
heart O 0 0.0067415847443044186
and O 0 3.8355926790245576e-07
implications O 0 9.128575584327336e-06
for O 0 1.3189737728680484e-06
Emery B-Disease 0 0.400162935256958
- I-Disease 1 0.9987595081329346
Dreifuss I-Disease 1 0.9981825351715088
muscular I-Disease 1 0.999147891998291
dystrophy I-Disease 1 0.9988371729850769
. O 0 0.00011413305037422106

Emerin O 0 0.0016425482463091612
is O 0 1.9704036731127417e-06
a O 0 9.695389735497884e-07
nuclear O 0 1.3946137187303975e-05
membrane O 0 3.776436869884492e-06
protein O 0 1.0489054602658143e-06
which O 0 1.0082045776016457e-07
is O 0 6.866381596637439e-08
missing O 0 3.429371417951188e-07
or O 0 1.960550690682794e-07
defective O 0 0.00013950552965980023
in O 0 5.1322845138201956e-06
Emery B-Disease 0 0.23075076937675476
- I-Disease 1 0.9986841082572937
Dreifuss I-Disease 1 0.9990726709365845
muscular I-Disease 1 0.9998286962509155
dystrophy I-Disease 1 0.9998199343681335
( O 0 0.00018399374675936997
EDMD B-Disease 1 0.9993994235992432
) O 0 1.076910939445952e-05
. O 0 5.968329787719995e-06

It O 0 1.584445953994873e-06
is O 0 1.8755187625174585e-07
one O 0 4.3180605757697776e-08
member O 0 4.4244085728450955e-08
of O 0 1.2954490813399389e-08
a O 0 1.0185847258981084e-06
family O 0 3.94913149648346e-06
of O 0 6.377615591190988e-07
lamina O 0 0.020022748038172722
- O 0 0.000421303091570735
associated O 0 1.1761902669604751e-06
proteins O 0 3.712075056228059e-07
which O 0 6.487915982233972e-08
includes O 0 3.0630212677351665e-07
LAP1 O 0 0.00012009730562567711
, O 0 3.2693031926100957e-07
LAP2 O 0 0.00011646623170236126
and O 0 1.8770947463053744e-06
lamin O 0 0.0006377887330017984
B O 0 0.0003503530751913786
receptor O 0 5.5926295317476615e-05
( O 0 2.8628146537812427e-06
LBR O 0 0.008263555355370045
) O 0 2.480468310750439e-06
. O 0 5.084163603896741e-06

A O 0 3.060233939322643e-05
panel O 0 1.7567375834914856e-05
of O 0 1.8291569858774892e-07
16 O 0 2.4338587536476552e-06
monoclonal O 0 3.2626580832584295e-06
antibodies O 0 1.6709630017430754e-06
( O 0 1.4237788548143726e-07
mAbs O 0 5.135966603120323e-06
) O 0 6.094612103879626e-08
has O 0 1.0632872715632402e-07
been O 0 6.674918040516786e-08
mapped O 0 3.680887346035888e-07
to O 0 5.929493784861961e-09
six O 0 2.566802592696149e-08
specific O 0 1.4599113917768136e-08
sites O 0 1.0957764118302293e-07
throughout O 0 6.110103356604668e-08
the O 0 6.424694021234245e-08
emerin O 0 8.239158887590747e-06
molecule O 0 9.050025369106152e-07
using O 0 3.2467798405377835e-07
phage O 0 4.493209416978061e-06
- O 0 3.8093639886938035e-06
displayed O 0 7.894522013884853e-07
peptide O 0 4.214997204599058e-07
libraries O 0 6.355514869937906e-08
and O 0 2.560026146625205e-08
has O 0 5.4902201895856706e-08
been O 0 2.273584165379816e-08
used O 0 1.139055161303304e-08
to O 0 1.8109901134266693e-08
localize O 0 6.261204816837562e-06
emerin O 0 3.083240881096572e-05
in O 0 4.198800809263048e-07
human O 0 2.4418518478341866e-06
and O 0 3.2096195354824886e-06
rabbit O 0 0.005369328428059816
heart O 1 0.9613456726074219
. O 0 2.459709139657207e-05

Several O 0 5.993631930323318e-06
mAbs O 0 8.377301855944097e-05
against O 0 1.332083797933592e-06
different O 0 2.909795853156538e-07
emerin O 0 0.00019851629622280598
epitopes O 0 7.165245187934488e-05
did O 0 9.68443032434152e-07
not O 0 4.219739224708974e-08
recognize O 0 5.434656600300514e-07
intercalated O 0 8.388627065869514e-06
discs O 0 9.066215170605574e-06
in O 0 3.805119490607467e-07
the O 0 3.2009381811803905e-06
heart O 0 0.3453875482082367
, O 0 1.1876133498844865e-07
though O 0 7.427387771485883e-08
they O 0 8.21997048205958e-09
recognized O 0 1.3548878996516578e-07
cardiomyocyte O 0 7.347590781137114e-06
nuclei O 0 1.1627000731095904e-06
strongly O 0 4.064947631832183e-07
, O 0 2.009655730716986e-08
both O 0 2.2963774881645804e-08
at O 0 4.814977728528902e-06
the O 0 2.717524978379515e-07
rim O 0 6.726219453412341e-06
and O 0 9.117582777662392e-08
in O 0 2.1134293604063714e-07
intranuclear O 0 1.7168586055049673e-05
spots O 0 2.447012775519397e-06
or O 0 2.981624049880338e-07
channels O 0 7.075632765918272e-06
. O 0 4.785318196809385e-06

A O 0 8.77746133483015e-05
polyclonal O 0 0.00047643817379139364
rabbit O 0 0.0003213449090253562
antiserum O 0 0.00038505063275806606
against O 0 1.1213207471882924e-05
emerin O 0 0.00021844191360287368
did O 0 8.497061685375229e-07
recognize O 0 4.402967022087978e-07
both O 0 7.982997374256229e-08
nuclear O 0 2.0699597371276468e-05
membrane O 0 2.372049948462518e-06
and O 0 9.152132207645991e-08
intercalated O 0 4.798420377483126e-06
discs O 0 5.258158125798218e-06
but O 0 7.42842232170915e-08
, O 0 1.9010713003808632e-08
after O 0 7.716371186461402e-08
affinity O 0 1.0854691367967462e-07
purification O 0 1.895891500680591e-06
against O 0 2.3730221698770038e-07
a O 0 2.3078010258359427e-07
pure O 0 1.3489097909769043e-06
- O 0 3.377869143150747e-05
emerin O 0 3.075010681641288e-05
band O 0 2.256129164379672e-06
on O 0 2.343926581716005e-07
a O 0 2.3326029463532905e-07
western O 0 7.983513796716579e-07
blot O 0 7.351376552833244e-05
, O 0 1.7232804339073482e-07
it O 0 5.2236380554404604e-08
stained O 0 7.252446812344715e-05
only O 0 3.802695758281516e-08
the O 0 2.522104409763415e-07
nuclear O 0 3.9291851862799376e-05
membrane O 0 3.3781783713493496e-05
. O 0 2.648451527420548e-06

These O 0 3.4770533829941996e-07
results O 0 1.9724191133718705e-06
would O 0 6.965258592117607e-08
not O 0 1.7988925904433017e-08
be O 0 1.95565004190712e-08
expected O 0 8.214143321083611e-08
if O 0 3.800150594202023e-08
immunostaining O 0 4.722824542113813e-06
at O 0 1.18586524422426e-06
intercalated O 0 2.601938831503503e-06
discs O 0 1.4737257743036025e-06
were O 0 4.721108481930969e-08
due O 0 1.3014889077567204e-07
to O 0 3.3631961660063325e-09
a O 0 4.3056751053427433e-08
product O 0 3.903781831127162e-08
of O 0 5.684453352472474e-09
the O 0 6.02961875983965e-08
emerin O 0 1.236504249391146e-05
gene O 0 1.1516281119838823e-06
and O 0 1.272461958023996e-07
, O 0 6.876918945408761e-08
therefore O 0 4.417005428081211e-08
, O 0 9.387625787837806e-09
cast O 0 3.169922990764462e-08
some O 0 4.326962788070432e-09
doubt O 0 5.786442613953113e-08
upon O 0 4.5354678235298707e-08
the O 0 1.5811326647963142e-07
hypothesis O 0 5.459812655317364e-06
that O 0 1.0251716275888612e-06
cardiac B-Disease 1 0.9927033185958862
defects I-Disease 1 0.9992749094963074
in O 0 4.268424891051836e-05
EDMD B-Disease 1 0.9998157620429993
are O 0 1.3209312328399392e-06
caused O 0 4.2127969209104776e-05
by O 0 1.3890115724279894e-07
absence O 0 3.4779329780576518e-06
of O 0 2.1623515067403787e-07
emerin O 0 0.0011037855874747038
from O 0 1.9363790215720655e-06
intercalated O 0 0.00031935027800500393
discs O 0 0.0004644252476282418
. O 0 1.431123473594198e-05

Although O 0 1.7667358406470157e-05
emerin O 0 0.00035052545717917383
was O 0 1.1617465133895166e-05
abundant O 0 5.475442321767332e-07
in O 0 7.376520727575553e-08
the O 0 9.294129910131232e-08
membranes O 0 7.788670700392686e-06
of O 0 1.3447017011003481e-07
cardiomyocyte O 0 4.112296664970927e-05
nuclei O 0 5.9126291489519645e-06
, O 0 2.154330189796383e-07
it O 0 4.644272522114079e-08
was O 0 3.982314865424996e-06
absent O 0 7.680893077122164e-07
from O 0 1.933625526362448e-08
many O 0 3.134689663397694e-08
non O 0 3.305073278170312e-06
- O 0 0.00017498910892754793
myocyte O 0 0.0003077920700889081
cells O 0 6.507039870484732e-06
in O 0 4.952697736371192e-07
the O 0 3.7202903513389174e-06
heart O 0 0.10750407725572586
. O 0 5.588770363829099e-06

This O 0 3.3660447229522106e-07
distribution O 0 3.276954032571666e-07
of O 0 2.605551685519458e-07
emerin O 0 0.0003529481473378837
was O 0 1.2122461157559883e-05
similar O 0 6.075472924749192e-08
to O 0 1.462045950972879e-08
that O 0 1.3619970040679164e-08
of O 0 4.706345890781449e-08
lamin O 0 1.8535480194259435e-05
A O 0 3.6382780308485962e-06
, O 0 9.47496445746765e-08
a O 0 1.444446837695068e-07
candidate O 0 2.5375572931807255e-07
gene O 0 1.753867024945066e-07
for O 0 2.7871520202893407e-08
an O 0 2.4689720135029347e-07
autosomal O 0 0.004599575884640217
form O 0 2.428305015200749e-05
of O 0 2.6256888304487802e-05
EDMD B-Disease 1 0.9997041821479797
. O 0 6.259119254536927e-05

In O 0 9.02987812878564e-06
contrast O 0 3.343302523717284e-05
, O 0 8.51654385769507e-06
lamin O 0 0.0038405584637075663
B1 O 0 0.11551539599895477
was O 0 9.121627226704732e-05
absent O 0 7.049364739941666e-06
from O 0 1.0571638853207332e-07
cardiomyocyte O 0 1.202809016831452e-05
nuclei O 0 2.1014921003370546e-06
, O 0 7.576380056661947e-08
showing O 0 1.4927223901395337e-06
that O 0 1.6032895189255214e-07
lamin O 0 0.00043380243005231023
B1 O 0 0.004715862218290567
is O 0 1.5546343945516128e-07
not O 0 7.388176292977278e-09
essential O 0 1.6847153005983273e-08
for O 0 1.3466840975695504e-08
localization O 0 9.484743372922821e-07
of O 0 3.529990166839525e-08
emerin O 0 2.1629139155265875e-05
to O 0 1.0930189375812915e-07
the O 0 2.1692596874345327e-06
nuclear O 0 0.0033438652753829956
lamina O 0 0.007286434527486563
. O 0 9.929713087331038e-06

Lamin O 0 0.3370991349220276
B1 O 1 0.9328166246414185
is O 0 7.869560249673668e-06
also O 0 7.399835340038408e-07
almost O 0 6.335435500659514e-07
completely O 0 1.0446944543218706e-05
absent O 0 2.9904522307333536e-05
from O 0 3.883081262756605e-06
skeletal O 0 0.2681976556777954
muscle O 0 0.010746177285909653
nuclei O 0 0.00021997789735905826
. O 0 1.1680653187795542e-05

In O 0 5.58718093088828e-05
EDMD B-Disease 1 0.9974004030227661
, O 0 4.036330665257992e-07
the O 0 4.7796213209494454e-08
additional O 0 6.077200254139825e-08
absence O 0 1.6842901686686673e-06
of O 0 5.37739879291621e-07
lamin O 0 0.0038416676688939333
B1 O 0 0.2582102417945862
from O 0 1.2794024769391399e-05
heart O 1 0.6875424981117249
and O 0 3.5868390568793984e-06
skeletal O 1 0.9782772660255432
muscle O 0 0.005951976869255304
nuclei O 0 5.7423723774263635e-05
which O 0 1.1235215424676426e-06
already O 0 2.9915238428657176e-06
lack O 0 2.840173010554281e-06
emerin O 0 0.00031945991213433444
may O 0 8.20643663246301e-07
offer O 0 3.336789689001307e-08
an O 0 1.8935441659095886e-08
alternative O 0 1.826132773885547e-07
explanation O 0 1.8185312455898384e-07
of O 0 1.8343760288530575e-08
why O 0 2.818329107867612e-07
these O 0 4.3636141811020934e-08
tissues O 0 7.459412245225394e-06
are O 0 3.0585841415131654e-08
particularly O 0 6.541289394590422e-07
affected O 0 1.9065693095399183e-06
. O 0 5.760882118011068e-07
. O 0 2.1770063085568836e-06

Genetic O 0 0.0001780772872734815
mapping O 0 2.11398619285319e-05
of O 0 6.851245188954636e-07
the O 0 1.4554480912920553e-05
copper B-Disease 0 0.27038130164146423
toxicosis I-Disease 0 0.05958329141139984
locus O 0 5.708058233722113e-05
in O 0 1.7362410744681256e-06
Bedlington O 0 0.00015570566756650805
terriers O 0 6.0532198403961957e-05
to O 0 1.776073190740135e-07
dog O 0 3.5446799302008e-05
chromosome O 0 1.7935102732735686e-05
10 O 0 7.36929166578193e-07
, O 0 4.795510122335145e-08
in O 0 3.7556127097104763e-08
a O 0 7.451992587448331e-07
region O 0 1.3968585790280486e-06
syntenic O 0 1.624635115149431e-05
to O 0 4.966797462202521e-08
human O 0 2.1171706521272426e-06
chromosome O 0 5.930189217906445e-05
region O 0 1.828759559430182e-05
2p13 O 0 0.0001392948324792087
- O 0 0.0003382527793291956
p16 O 0 0.00016702551511116326
. O 0 6.9834550231462345e-06

Abnormal O 1 0.9884887337684631
hepatic B-Disease 1 0.9990864992141724
copper I-Disease 1 0.9980306029319763
accumulation I-Disease 0 0.027673818171024323
is O 0 4.29796455136966e-06
recognized O 0 2.746562586253276e-06
as O 0 4.266340056346962e-06
an O 0 0.0005088133038952947
inherited B-Disease 1 0.9999933242797852
disorder I-Disease 1 0.9999961853027344
in O 0 0.0001359996385872364
man O 0 0.000871323689352721
, O 0 9.434422736376291e-07
mouse O 0 1.9568575226003304e-05
, O 0 9.15945577162347e-07
rat O 0 0.00022380970767699182
and O 0 1.4094358675720287e-06
dog O 0 0.00046474678674712777
. O 0 9.442898772249464e-06

The O 0 2.6894997063209303e-05
major O 0 0.0005661975010298193
cause O 0 0.0004618362872861326
of O 0 6.992845101194689e-06
hepatic B-Disease 1 0.9995629191398621
copper I-Disease 1 0.9988362193107605
accumulation I-Disease 0 0.008534709922969341
in O 0 3.4659931316127768e-06
man O 0 0.00012445646279957145
is O 0 6.893203021718364e-07
a O 0 1.29320585529058e-06
dysfunctional O 0 0.0007266231696121395
ATP7B O 0 0.000677587348036468
gene O 0 3.2276562706101686e-05
, O 0 6.112573828431778e-06
causing O 0 0.012179747223854065
Wilson B-Disease 1 0.6456925868988037
disease I-Disease 1 0.9992278814315796
( O 0 7.301196092157625e-06
WD B-Disease 0 0.26679179072380066
) O 0 2.9250218176457565e-06
. O 0 7.123445357137825e-06

Mutations O 0 0.0005776860634796321
in O 0 1.632139969842683e-06
the O 0 6.140058417258842e-07
ATP7B O 0 0.0001369184028590098
genes O 0 1.5623364788552863e-06
have O 0 7.377590094392872e-08
also O 0 4.9819401937156726e-08
been O 0 9.862237249080863e-08
demonstrated O 0 3.6256108160159783e-07
in O 0 2.281586688468451e-07
mouse O 0 1.3746460354013834e-05
and O 0 1.6604627717242693e-06
rat O 0 0.002806710312142968
. O 0 5.522279934666585e-06

The O 0 5.7246111282438505e-06
ATP7B O 0 0.000492068356834352
gene O 0 2.2415548301069066e-05
has O 0 1.964214561667177e-06
been O 0 4.047702475418191e-07
excluded O 0 3.411863360724965e-07
in O 0 2.0854589166674486e-08
the O 0 4.425573152389006e-08
much O 0 4.139670011227281e-07
rarer O 0 8.849317237036303e-05
human O 0 4.8559715651208535e-05
copper B-Disease 1 0.9943374991416931
overload I-Disease 1 0.9954763054847717
disease O 1 0.9979189038276672
non B-Disease 0 0.0001515812473371625
- I-Disease 0 0.00487313698977232
Indian I-Disease 0 1.1115108463854995e-05
childhood I-Disease 0 0.04032708704471588
cirrhosis I-Disease 1 0.9993104934692383
, O 0 3.1471199690713547e-06
indicating O 0 2.325386776647065e-05
genetic O 0 9.435404354007915e-05
heterogeneity O 0 0.0002990262000821531
. O 0 2.87191887764493e-05

By O 0 3.398351964278845e-06
investigating O 0 4.461512071429752e-05
the O 0 2.958166305688792e-06
common O 0 0.00017866659618448466
autosomal O 1 0.9967184662818909
recessive O 1 0.9985572695732117
copper B-Disease 1 0.9993417859077454
toxicosis I-Disease 1 0.9955698847770691
( O 0 1.114051428885432e-05
CT B-Disease 0 0.0035440202336758375
) O 0 1.4301721762421948e-07
in O 0 1.6867384999841306e-07
Bedlington O 0 4.724117388832383e-05
terriers O 0 3.54814255842939e-05
, O 0 1.5166270372901636e-07
we O 0 5.3515744724563774e-08
have O 0 1.200237775833557e-08
identified O 0 5.782404244314421e-08
a O 0 7.33874259140066e-08
new O 0 3.0683833074363065e-07
locus O 0 5.855075869476423e-06
involved O 0 2.7100554689241108e-06
in O 0 8.870998135535046e-05
progressive O 1 0.9998258948326111
liver B-Disease 1 0.9999992847442627
disease I-Disease 1 0.999996542930603
. O 0 0.0002450456959195435

We O 0 9.194022823066916e-06
examined O 0 1.3658696843776852e-05
whether O 0 3.9979553889679664e-07
the O 0 1.0921912689809687e-06
WD B-Disease 0 0.002339879749342799
gene O 0 2.2676158550893888e-05
ATP7B O 0 0.0008394867181777954
was O 0 2.0740280888276175e-05
also O 0 2.3542700944290118e-07
causative O 0 4.259241904946975e-06
for O 0 6.500066973558205e-08
CT B-Disease 0 0.0003484914486762136
by O 0 7.17343198175513e-08
investigating O 0 1.7596465795577387e-06
the O 0 6.280033062466828e-07
chromosomal O 0 0.0014314346481114626
co O 0 0.00011122399155283347
- O 0 2.624156877573114e-05
localization O 0 4.686393822339596e-06
of O 0 1.559054396693682e-07
ATP7B O 0 0.0001274219248443842
and O 0 2.951708495402272e-07
C04107 O 0 4.552960035653086e-06
, O 0 2.4687713207072193e-08
using O 0 2.8217922221074332e-08
fluorescence O 0 6.848005114079569e-07
in O 0 2.069782993885383e-07
situ O 0 1.629940925340634e-05
hybridization O 0 2.661922735569533e-06
( O 0 2.527418700992712e-07
FISH O 0 3.057093408642686e-06
) O 0 4.4334981907923066e-07
. O 0 1.1994181932095671e-06

C04107 O 0 0.0009566534426994622
is O 0 2.359298605369986e-06
an O 0 2.5979863949032733e-07
anonymous O 0 3.2486211694049416e-06
microsatellite O 0 8.048359450185671e-05
marker O 0 2.1230431229923852e-05
closely O 0 3.9607334656466264e-06
linked O 0 4.54451292171143e-05
to O 0 6.588539349650091e-07
CT B-Disease 0 0.11078990995883942
. O 0 8.606913979747333e-06

However O 0 2.3422080630552955e-05
, O 0 3.993107384303585e-06
BAC O 0 0.00024363046395592391
clones O 0 1.239834091393277e-05
containing O 0 2.73928526439704e-06
ATP7B O 0 0.000289157876977697
and O 0 7.273025630638585e-07
C04107 O 0 1.2165891348558944e-05
mapped O 0 2.968778517242754e-06
to O 0 1.7051954515068246e-08
the O 0 1.8585041061669472e-07
canine O 0 0.00015572881966363639
chromosome O 0 6.174397276481614e-05
regions O 0 1.994505055336049e-06
CFA22q11 O 0 4.420339610078372e-05
and O 0 4.718052366570191e-07
CFA10q26 O 0 5.1871775212930515e-05
, O 0 2.2185291470577795e-07
respectively O 0 8.834256277623354e-07
, O 0 8.18521002088346e-08
demonstrating O 0 3.8286563608380675e-07
that O 0 7.286494962954748e-08
WD B-Disease 0 0.00025293274666182697
cannot O 0 2.3086133182914637e-07
be O 0 2.7594978746492416e-08
homologous O 0 4.1992649357780465e-07
to O 0 1.3820877597936487e-07
CT B-Disease 0 0.0035065212287008762
. O 0 3.5896246117772534e-06

The O 0 1.50445639519603e-05
copper O 0 0.0009990452090278268
transport O 0 1.2080925444024615e-05
genes O 0 6.407294677046593e-06
CTR1 O 0 0.00018682549125514925
and O 0 3.94720842677998e-07
CTR2 O 0 0.00015978464216459543
were O 0 3.452904309142468e-07
also O 0 6.332911084427906e-08
excluded O 0 1.3871411397303746e-07
as O 0 4.9964235415700387e-08
candidate O 0 1.1263544763551181e-07
genes O 0 3.5838972678448044e-08
for O 0 2.5022355742976288e-08
CT B-Disease 0 0.0003551655972842127
since O 0 4.306965024625242e-07
they O 0 6.1363323311525164e-09
both O 0 8.884466495828747e-09
mapped O 0 1.2279717793717282e-06
to O 0 8.29948447744755e-08
canine O 0 0.0001631474879104644
chromosome O 0 0.00014058304077479988
region O 0 2.4776671125437133e-05
CFA11q22 O 0 0.001304488629102707
. O 0 1.8548880689195357e-05

2 O 0 8.635377162136137e-05
- O 0 0.000931987538933754
22 O 0 3.0824528948869556e-05
. O 0 6.17300020167022e-06

5 O 0 0.00021843711147084832
. O 0 3.075746644753963e-05

A O 0 1.2920168956043199e-05
transcribed O 0 1.506480657553766e-05
sequence O 0 2.817251015585498e-06
identified O 0 1.1461837630122318e-06
from O 0 7.24776754168488e-08
the O 0 1.536469653729e-07
C04107 O 0 1.1313229151710402e-05
- O 0 1.6400446838815697e-05
containing O 0 1.9568312836781843e-06
BAC O 0 5.8897021517623216e-05
was O 0 4.047403763252078e-06
found O 0 8.769865900148943e-08
to O 0 3.202604625940353e-09
be O 0 7.960293757491854e-09
homologous O 0 8.08364859494759e-08
to O 0 5.801922942083593e-09
a O 0 1.320987479402902e-07
gene O 0 5.102783688926138e-07
expressed O 0 1.325613965263983e-07
from O 0 1.345600963986726e-07
human O 0 7.213453727672459e-07
chromosome O 0 2.780800059554167e-05
2p13 O 0 4.044465094921179e-05
- O 0 4.598035229719244e-05
p16 O 0 1.2840863746532705e-05
, O 0 2.313177276391798e-07
a O 0 5.307832680045976e-07
region O 0 8.251844860751589e-07
devoid O 0 1.0813007520482643e-06
of O 0 4.027470978940073e-08
any O 0 8.860034483859636e-08
positional O 0 1.3752662198385224e-05
candidate O 0 1.4678426850878168e-05
genes O 0 2.096613206958864e-05
. O 0 6.218176622496685e-06

Molecular O 0 3.557809759513475e-05
analysis O 0 1.0367516551923472e-06
of O 0 5.401082603384566e-08
the O 0 1.466736136990221e-07
APC B-Disease 0 7.093806743796449e-06
gene O 0 1.0938611012534238e-06
in O 0 1.2263292603620357e-07
205 O 0 5.530652629204269e-07
families O 0 5.84271475645437e-08
: O 0 1.0212532686182385e-07
extended O 0 7.492283202736871e-07
genotype O 0 1.695347782515455e-05
- O 0 4.587886724038981e-05
phenotype O 0 1.3869104805053212e-05
correlations O 0 4.495541361393407e-06
in O 0 2.409380499557301e-07
FAP B-Disease 0 1.2611913007276598e-05
and O 0 4.153414678853551e-08
evidence O 0 8.995971967351579e-08
for O 0 1.8866082029944664e-08
the O 0 4.887006710418973e-08
role O 0 3.8451810269179987e-07
of O 0 1.8310191762793693e-07
APC B-Disease 0 2.0683533875853755e-05
amino O 0 2.3842608243285213e-06
acid O 0 2.789078098430764e-05
changes O 0 3.306197322672233e-05
in O 0 0.01011334452778101
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999957084655762
predisposition O 1 0.9920550584793091
. O 0 0.00010080133506562561

BACKGROUND O 0 0.0003500482998788357
/ O 0 0.0001289142674067989
AIMS O 0 8.364492714463267e-06
The O 0 9.695796734376927e-07
development O 0 1.2339421118667815e-05
of O 0 0.09041674435138702
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
and O 0 1.663985131017398e-06
a O 0 2.215781478298595e-06
variable O 0 4.085782165930141e-06
range O 0 1.973100097529823e-06
of O 0 6.137623245194845e-07
extracolonic O 0 0.004977669101208448
manifestations O 0 0.005485722795128822
in O 0 0.001043578376993537
familial B-Disease 1 0.9999402761459351
adenomatous I-Disease 1 0.9997567534446716
polyposis I-Disease 1 0.9999321699142456
( O 0 0.0001392751873936504
FAP B-Disease 0 0.0010886489180848002
) O 0 7.921385076770093e-07
is O 0 2.348180032640812e-07
the O 0 1.0467505262568011e-07
result O 0 6.535765351145528e-07
of O 0 7.796732859333133e-08
the O 0 1.1062961675634142e-06
dominant O 0 0.0006822801078669727
inheritance O 0 0.0044830613769590855
of O 0 0.0009421270806342363
adenomatous B-Disease 1 0.9998693466186523
polyposis I-Disease 1 0.9991983771324158
coli I-Disease 1 0.9990512728691101
( O 0 3.821493010036647e-05
APC B-Disease 0 0.00037995987804606557
) O 0 1.9704318674484966e-06
gene O 0 6.035732076270506e-05
mutations O 0 0.0004332418320700526
. O 0 6.524302079924382e-06

In O 0 2.974727294713375e-06
this O 0 1.1709362723877348e-07
study O 0 1.2131175708418596e-07
, O 0 1.063901500231168e-08
direct O 0 2.2071075633789405e-08
mutation O 0 9.857880058916635e-07
analysis O 0 5.324766050307517e-08
of O 0 6.197946156305534e-09
the O 0 6.909064609317284e-08
APC B-Disease 0 2.4536095679650316e-06
gene O 0 8.161464961631282e-07
was O 0 1.315775080001913e-06
performed O 0 4.027390900773753e-07
to O 0 1.8995237383023778e-08
determine O 0 2.7207690322939015e-07
genotype O 0 5.480287654791027e-06
- O 0 1.4152911717246752e-05
phenotype O 0 5.200507985136937e-06
correlations O 0 8.233913604271947e-07
for O 0 4.740282477655455e-08
nine O 0 8.716258435015334e-07
extracolonic O 0 8.425732085015625e-05
manifestations O 0 1.681190769886598e-05
and O 0 1.6011611592148256e-07
to O 0 6.162937182807582e-08
investigate O 0 1.8215181398772984e-06
the O 0 1.490570070927788e-06
incidence O 0 0.0006178845651447773
of O 0 5.963278226772672e-07
APC B-Disease 0 0.00012805995356757194
mutations O 0 5.296111703501083e-05
in O 0 5.225270342634758e-06
non O 0 0.02117144875228405
- O 1 0.9996523857116699
FAP O 1 0.9983752965927124
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999874830245972
. O 0 0.00023024226538836956

METHODS O 0 1.553788206365425e-05
The O 0 1.708818103907106e-06
APC B-Disease 0 3.1557869078824297e-05
gene O 0 7.648243808944244e-06
was O 0 4.729995907837292e-06
analysed O 0 1.186994495583349e-06
in O 0 1.3335871074104944e-07
190 O 0 5.978493504699145e-07
unrelated O 0 1.1667694707284681e-05
FAP B-Disease 0 4.3546428059926257e-05
and O 0 1.147749003393983e-06
15 O 0 2.2769119823351502e-05
non O 0 0.00535967480391264
- O 1 0.999504566192627
FAP O 1 0.9983615279197693
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999905824661255
patients O 0 0.00041786511428654194
using O 0 3.954467956646113e-06
denaturing O 0 0.0009446438052691519
gradient O 0 0.0001391848927596584
gel O 0 0.00010411717812530696
electrophoresis O 0 1.690792851150036e-05
, O 0 5.553432558258464e-08
the O 0 2.1006689721048133e-08
protein O 0 1.401476623641429e-07
truncation O 0 1.2812650993510033e-06
test O 0 2.5554118110449053e-07
, O 0 1.629145884862737e-08
and O 0 5.803317382202522e-09
direct O 0 4.7242611600495366e-08
sequencing O 0 4.824004463443998e-06
. O 0 4.287067440600367e-06

RESULTS O 0 0.00012063376925652847
Chain O 0 3.339682734804228e-05
terminating O 0 6.0370462051650975e-06
signals O 0 2.342264679100481e-06
were O 0 4.857621860310246e-08
only O 0 1.5744900494496505e-08
identified O 0 2.8075774594071845e-07
in O 0 1.779523444156439e-07
patients O 0 5.324903327164066e-07
belonging O 0 3.679272992940241e-07
to O 0 4.9901952792197335e-08
the O 0 1.390425950376084e-06
FAP B-Disease 0 5.7234239648096263e-05
group O 0 1.029704321808822e-06
( O 0 2.870530124710058e-07
105 O 0 4.062074822286377e-06
patients O 0 1.0212653251073789e-05
) O 0 5.15391207045468e-07
. O 0 1.307142724726873e-06

Amino O 0 3.3400934626115486e-05
acid O 0 2.3300126485992223e-05
changes O 0 5.601270345323428e-07
were O 0 7.493898834809443e-08
identified O 0 2.65210644556646e-07
in O 0 4.4554365530302675e-08
four O 0 2.3705793239514605e-07
patients O 0 8.732857281756878e-07
, O 0 1.1011899836432804e-08
three O 0 1.3008196297903396e-08
of O 0 1.2964279427762904e-08
whom O 0 1.7141704233836208e-07
belonged O 0 1.2050752502545947e-06
to O 0 1.4107798484985778e-08
the O 0 2.2815561351308133e-07
non O 0 8.481997610942926e-06
- O 0 0.0007589671877212822
FAP O 0 0.00021251763973850757
group O 0 2.245774339826312e-05
of O 0 0.0012205997481942177
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
patients O 0 0.4219273626804352
. O 0 2.154843241441995e-05

Genotype O 0 0.002166659804061055
- O 0 0.0010853519197553396
phenotype O 0 0.0002052087220363319
correlations O 0 2.517485700082034e-05
identified O 0 5.9353628785174806e-06
significant O 0 7.057881248329068e-07
differences O 0 3.960793947044294e-06
in O 0 5.29011970229476e-07
the O 0 3.067532077238866e-07
nature O 0 7.512338129345153e-07
of O 0 8.403517171018393e-08
certain O 0 4.0157735270440753e-07
extracolonic O 0 0.0005156250554136932
manifestations O 0 0.00014021260722074658
in O 0 7.265785370691447e-06
FAP B-Disease 0 0.0006648951093666255
patients O 0 6.36359663985786e-06
belonging O 0 4.2903781150016584e-07
to O 0 5.788286117081043e-08
three O 0 7.478654993064993e-07
mutation O 0 7.423144415952265e-05
subgroups O 0 4.5893833885202184e-05
. O 0 6.996214324317407e-06

CONCLUSIONS O 0 8.20536442915909e-05
Extended O 0 1.2520153177320026e-05
genotype O 0 6.348004535539076e-05
- O 0 5.9229263570159674e-05
phenotype O 0 1.0946199836325832e-05
correlations O 0 2.2313799945550272e-06
made O 0 2.9548010616053944e-07
in O 0 1.1831502888526302e-07
this O 0 4.1849684606631854e-08
study O 0 8.901873371769398e-08
may O 0 1.1394055121627389e-07
have O 0 7.0837598009632075e-09
the O 0 8.735337786447417e-09
potential O 0 2.7967054450073192e-08
to O 0 6.0742193497276276e-09
determine O 0 3.240969448370379e-08
the O 0 1.583350162093211e-08
most O 0 8.414900776188006e-09
appropriate O 0 2.966149814653818e-08
surveillance O 0 1.0219113164566807e-06
and O 0 1.613991571502993e-07
prophylactic O 0 2.3705757485004142e-05
treatment O 0 1.808450724638533e-05
regimens O 0 1.0835866305569652e-05
for O 0 4.7297969985038435e-08
those O 0 6.013494413537046e-08
patients O 0 1.8795452660924639e-06
with O 0 5.057215162196371e-07
mutations O 0 9.217091428581625e-05
associated O 0 8.935527148423716e-06
with O 0 2.8017832391924458e-06
life O 0 0.00023709800734650344
threatening O 0 0.040993768721818924
conditions O 0 0.0031520624179393053
. O 0 1.6986086848191917e-05

This O 0 2.1888979517825646e-06
study O 0 5.837367780259228e-07
also O 0 4.269773157261625e-08
provided O 0 4.098086847648119e-08
evidence O 0 4.158511401897158e-08
for O 0 2.0554464796873617e-08
the O 0 4.3870477384189144e-07
pathological O 0 9.14218690013513e-05
nature O 0 1.3077873290967545e-06
of O 0 7.155503567446431e-08
amino O 0 7.629832339262066e-07
acid O 0 5.456392500491347e-06
changes O 0 6.919509019098768e-07
in O 0 1.0918146386984517e-07
APC O 0 6.412246420950396e-06
associated O 0 3.056773607568175e-07
with O 0 6.110359862532277e-08
both O 0 6.699694949929835e-07
FAP B-Disease 0 0.00010949990974040702
and O 0 3.711714043674874e-06
non O 0 0.019702278077602386
- O 1 0.9995490908622742
FAP O 1 0.998330295085907
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999953508377075
patients O 0 0.016655439510941505
. O 0 2.432877181490767e-06
. O 0 4.5232281991047785e-06

Inherited B-Disease 1 0.9996123909950256
colorectal I-Disease 1 0.9999953508377075
polyposis I-Disease 1 0.9996076226234436
and O 1 0.9327300190925598
cancer B-Disease 1 0.9998960494995117
risk O 0 0.005009181797504425
of O 0 7.52002904391702e-07
the O 0 8.674061064084526e-06
APC O 0 0.00045111143845133483
I1307K O 0 0.00024863917496986687
polymorphism O 0 0.00014630358782596886
. O 0 8.594372047809884e-06

Germ O 0 0.023883402347564697
- O 0 0.0011053560301661491
line O 0 6.717495125485584e-05
and O 0 5.216753606873681e-07
somatic O 0 1.6369898730772547e-05
truncating O 0 0.00011696194997057319
mutations O 0 5.098907422507182e-05
of O 0 7.652540290337129e-08
the O 0 4.743683348351624e-07
APC B-Disease 0 8.59860210766783e-06
gene O 0 8.749730682211521e-07
are O 0 3.4391142378353834e-08
thought O 0 3.8047349448788736e-07
to O 0 3.9025616160870413e-07
initiate O 0 0.00209208857268095
colorectal B-Disease 1 0.999994158744812
tumor I-Disease 1 0.9993067979812622
formation O 0 0.03958168998360634
in O 0 0.0010792665416374803
familial B-Disease 1 0.999883770942688
adenomatous I-Disease 1 0.9998892545700073
polyposis I-Disease 1 0.9999891519546509
syndrome I-Disease 1 0.9999812841415405
and O 0 0.002781292889267206
sporadic O 1 0.9940641522407532
colorectal O 1 0.999994158744812
carcinogenesis O 1 0.9982329607009888
, O 0 4.3077016016468406e-05
respectively O 0 0.00010609297169139609
. O 0 9.653516826801933e-06

Recently O 0 0.00020635656255763024
, O 0 1.1743946970455e-06
an O 0 5.815969075229077e-07
isoleucine O 0 0.0009087814833037555
- O 0 0.00025221798568964005
- O 0 5.7358050980838016e-05
> O 0 1.0000570000556763e-05
lysine O 0 1.527362474007532e-05
polymorphism O 0 6.810680133639835e-06
at O 0 3.417788093429408e-06
codon O 0 1.2797942872566637e-05
1307 O 0 5.1046918088104576e-05
( O 0 2.4391047759309004e-07
I1307K O 0 4.300043201510562e-06
) O 0 4.872831027569191e-08
of O 0 2.0673676104365768e-08
the O 0 1.4404918147192802e-07
APC B-Disease 0 3.9547890082758386e-06
gene O 0 8.029226705730252e-07
has O 0 9.28419083834342e-08
been O 0 7.961253345456498e-08
identified O 0 8.774216553320002e-08
in O 0 2.5568638761797047e-08
6 O 0 3.2468602739754715e-07
% O 0 1.4420967531236784e-08
- O 0 1.5521679870289518e-06
7 O 0 2.2985889813753602e-07
% O 0 6.932267204717846e-09
of O 0 9.367753683875435e-09
the O 0 2.0477617113101587e-07
Ashkenazi O 0 3.9558006392326206e-05
Jewish O 0 1.5938118167468929e-06
population O 0 4.647746436603484e-07
. O 0 2.638866362758563e-06

To O 0 1.1268158459643018e-06
assess O 0 1.4126294445304666e-05
the O 0 1.5324395690186066e-06
risk O 0 9.172872523777187e-06
of O 0 3.387048863601194e-08
this O 0 4.432652289665384e-08
common O 0 2.081746742987889e-06
APC B-Disease 0 5.8352216001367196e-05
allelic O 0 0.00010225966980215162
variant O 0 0.003340140450745821
in O 0 0.0005896191578358412
colorectal O 1 0.9999886751174927
carcinogenesis O 1 0.9892995357513428
, O 0 2.0065397166035837e-06
we O 0 7.635073728806674e-08
have O 0 1.9099614334550097e-08
analyzed O 0 1.6105596500892716e-07
a O 0 1.5977030898284283e-07
large O 0 5.253148174233502e-07
cohort O 0 6.122048489487497e-06
of O 0 1.1068591021512475e-07
unselected O 0 0.0004050903953611851
Ashkenazi O 0 0.00016443454660475254
Jewish O 0 7.415097115881508e-06
subjects O 0 1.6988549759844318e-05
with O 0 2.3463975594495423e-05
adenomatous B-Disease 1 0.9902732968330383
polyps I-Disease 1 0.8732372522354126
and O 0 6.758278232155135e-06
. O 0 1.4314865438791458e-05
or O 1 0.9941621422767639
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
, I-Disease 0 1.170048221865727e-06
for O 0 9.744569240410783e-08
the O 0 1.3353552503758692e-06
APC O 0 9.47098305914551e-05
I1307K O 0 9.009325003717095e-05
polymorphism O 0 9.138516907114536e-05
. O 0 6.599647349503357e-06

The O 0 1.1483367416076362e-05
APC O 0 0.00010205354919889942
I1307K O 0 4.030757918371819e-05
allele O 0 1.3519669664674439e-05
was O 0 1.3168623809178825e-05
identified O 0 8.493868790537817e-07
in O 0 9.746576523639305e-08
48 O 0 3.641547721144889e-07
( O 0 1.9508181736682673e-08
10 O 0 2.7390260726178894e-08
. O 0 4.399530961762821e-09
1 O 0 4.4077982153112316e-08
% O 0 5.81046100123217e-09
) O 0 5.8536877567405554e-09
of O 0 3.110289270580324e-08
476 O 0 1.6675687220413238e-05
patients O 0 2.0351224520709366e-05
. O 0 1.6093206340883626e-06

Compared O 0 9.88050851447042e-06
with O 0 8.938675222225356e-08
the O 0 1.2695795703621116e-07
frequency O 0 6.672626682302507e-07
in O 0 2.6862380764214322e-08
two O 0 8.370272475133334e-09
separate O 0 3.7899013705100515e-08
population O 0 2.1347146272887585e-08
control O 0 2.61805553236627e-07
groups O 0 1.8626522546583146e-08
, O 0 2.5946578219304683e-08
the O 0 7.065276719231406e-08
APC O 0 7.679921509406995e-06
I1307K O 0 5.2604950724344235e-06
allele O 0 1.3473824083121144e-06
is O 0 1.6674466962740553e-07
associated O 0 1.3496287465386558e-07
with O 0 1.3950886668112616e-08
an O 0 5.925302559717238e-08
estimated O 0 3.9378690530611493e-07
relative O 0 1.5030818758532405e-06
risk O 0 6.761063104931964e-06
of O 0 8.379252847134921e-08
1 O 0 5.243490704742726e-06
. O 0 2.792095529002836e-06

5 O 0 9.844425221672282e-05
- O 0 0.00041615040390752256
1 O 0 1.1290293514321093e-05
. O 0 2.8133392788731726e-06

7 O 0 0.0004238637338858098
for O 0 7.882517820689827e-05
colorectal B-Disease 1 0.999968409538269
neoplasia I-Disease 1 0.9767271280288696
( O 0 1.8305476032765e-06
both O 0 1.98238376469817e-06
P O 0 0.012328213080763817
= O 0 6.245471013244241e-05
. O 0 7.359627716141404e-07
01 O 0 0.00010350916272727773
) O 0 5.517155727829959e-07
. O 0 1.4403891555048176e-06

Furthermore O 0 2.616246092657093e-05
, O 0 1.2826527608922333e-06
compared O 0 2.459994448145153e-06
with O 0 7.488904429919785e-07
noncarriers O 0 0.0003884060715790838
, O 0 9.988093552237842e-07
APC O 0 1.3342018974071834e-05
I1307K O 0 9.45004285313189e-06
carriers O 0 2.0255063191143563e-06
had O 0 3.115773381523468e-07
increased O 0 1.1525560950076397e-07
numbers O 0 1.2158881190771353e-07
of O 0 4.817724175154581e-07
adenomas B-Disease 0 0.1697217971086502
and O 0 0.0036832811310887337
colorectal B-Disease 1 0.999997615814209
cancers I-Disease 1 0.9995777010917664
per O 0 1.4980723790358752e-05
patient O 0 0.00016663767746649683
( O 0 1.2831702633775421e-06
P O 0 0.000710546039044857
= O 0 7.442501100740628e-06
. O 0 6.542568087297695e-08
03 O 0 2.633704752952326e-06
) O 0 9.595758854175074e-09
, O 0 6.558646070686791e-09
as O 0 9.300439529624782e-09
well O 0 1.592378495729463e-08
as O 0 2.6035069211616246e-08
a O 0 1.8006747382059984e-07
younger O 0 1.1612572734520654e-06
age O 0 4.623158929462079e-06
at O 0 3.8260259316302836e-05
diagnosis O 0 0.005970501806586981
. O 0 3.8929592847125605e-06

We O 0 3.782506610150449e-06
conclude O 0 4.316004378779326e-06
that O 0 1.0213486945076511e-07
the O 0 3.877749747971393e-07
APC O 0 3.967678276239894e-05
I1307K O 0 2.8942333301529288e-05
variant O 0 7.872039714129642e-05
leads O 0 5.261463229544461e-06
to O 0 3.488918309813016e-07
increased O 0 4.582019028021023e-05
adenoma B-Disease 1 0.9996916055679321
formation O 0 0.0002474736829753965
and O 0 1.6184891649118072e-07
directly O 0 9.591334304559496e-08
contributes O 0 1.5785201412654715e-07
to O 0 5.913332046247888e-09
3 O 0 3.0291582220343116e-07
% O 0 6.181031153573713e-08
- O 0 1.4556593441739096e-06
4 O 0 1.577731580937325e-07
% O 0 8.907168336236282e-09
of O 0 1.3071593585323171e-08
all O 0 3.314092680284375e-07
Ashkenazi O 0 0.18667198717594147
Jewish O 1 0.9968274235725403
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999910593032837
. O 0 0.00015548222290817648

The O 0 2.320100065844599e-06
estimated O 0 1.7580714484211057e-06
relative O 0 6.334230874927016e-06
risk O 0 2.034635326708667e-05
for O 0 2.1064148825189477e-07
carriers O 0 6.802014468121342e-06
may O 0 1.2045444464092725e-06
justify O 0 5.296116682984575e-07
specific O 0 7.36426244429822e-08
clinical O 0 9.501166005065897e-07
screening O 0 2.8348969749458774e-07
for O 0 6.5590088915712386e-09
the O 0 2.287084654994942e-08
360 O 0 1.0991193022391599e-07
, O 0 1.7241180927385358e-08
000 O 0 3.702976769659472e-08
Americans O 0 1.105476687968121e-08
expected O 0 5.059255769879201e-08
to O 0 1.1206902073013225e-08
harbor O 0 2.017865654124762e-06
this O 0 7.130745327543764e-09
allele O 0 6.061328861051152e-08
, O 0 1.0614265910646736e-08
and O 0 1.101158453309381e-08
genetic O 0 3.881523582549562e-07
testing O 0 4.6813318022032036e-07
in O 0 2.1589757537299192e-08
the O 0 1.4114419855104643e-08
setting O 0 2.399660274932103e-07
of O 0 5.169856009956675e-08
long O 0 1.0496636605239473e-05
- O 0 9.87411622190848e-05
term O 0 6.06468756814138e-06
- O 0 8.347829862032086e-06
outcome O 0 7.833154427316913e-07
studies O 0 1.950870824884987e-07
may O 0 1.874730202189312e-07
impact O 0 1.7398543832314317e-06
significantly O 0 9.203907393384725e-05
on O 1 0.9902563095092773
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999959468841553
prevention O 0 0.06782623380422592
in O 0 1.0203590363744297e-06
this O 0 1.8253233236009692e-07
population O 0 3.8194878015929135e-07
. O 0 2.5405263386346633e-06

Localization O 0 0.0001245281455339864
of O 0 1.0213393579761032e-06
human O 0 3.7888244150963146e-06
BRCA1 O 0 5.8808458561543375e-05
and O 0 4.815831289306516e-07
its O 0 7.362056635429326e-07
loss O 0 0.00019374889961909503
in O 0 1.171475105365971e-06
high O 0 0.00021453091176226735
- O 0 0.00021683455270249397
grade O 0 0.00017596891848370433
, O 0 1.247445084118226e-06
non B-Disease 0 0.00027394670178182423
- I-Disease 1 0.9932604432106018
inherited I-Disease 1 0.999164342880249
breast I-Disease 1 0.9996592998504639
carcinomas I-Disease 1 0.9998807907104492
. O 0 0.0001201572158606723

Although O 0 1.2645156175494776e-06
the O 0 2.6646912942851486e-07
link O 0 3.934129381377716e-06
between O 0 1.228050223289756e-06
the O 0 1.5580761100864038e-05
BRCA1 O 0 0.023672819137573242
tumour B-Disease 1 0.9997697472572327
- O 0 0.00023480360687244684
suppressor O 0 7.07828949089162e-05
gene O 0 1.7049736925400794e-05
and O 0 5.048126240581041e-06
hereditary B-Disease 1 0.9991975426673889
breast I-Disease 1 0.9999309778213501
and I-Disease 1 0.9993250370025635
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999997615814209
is O 0 6.600616870855447e-06
established O 0 8.56928352277464e-07
, O 0 5.093045629678272e-08
the O 0 3.901734757505437e-08
role O 0 4.5334397213991906e-07
, O 0 8.485110924993933e-08
if O 0 2.8709839838825246e-08
any O 0 7.515610356279012e-09
, O 0 2.5442059126135064e-08
of O 0 5.069049890948918e-08
BRCA1 O 0 1.8917098714155145e-05
in O 0 1.3391428410614026e-06
non B-Disease 0 7.499883940909058e-05
- I-Disease 1 0.891619086265564
familial I-Disease 1 0.9962137341499329
cancers I-Disease 1 0.9997852444648743
is O 0 8.517542482877616e-06
unclear O 0 9.656342626840342e-06
. O 0 2.961237214549328e-06

BRCA1 O 0 0.005611578933894634
mutations O 0 0.00026500181411392987
are O 0 3.26117259419334e-07
rare O 0 4.798886948265135e-06
in O 0 2.417517862340901e-06
sporadic B-Disease 0 0.0018960119923576713
cancers I-Disease 1 0.9992893934249878
, O 0 1.6980862937998609e-06
but O 0 7.893822271398676e-07
loss O 0 3.496501813060604e-05
of O 0 1.8403306967229582e-07
BRCA1 O 0 6.677928467979655e-05
resulting O 0 1.95114762391313e-06
from O 0 2.402357495157048e-07
reduced O 0 1.6553321984247304e-06
expression O 0 5.214072871240205e-07
or O 0 2.542503807489993e-07
incorrect O 0 3.1800107080925955e-06
subcellular O 0 1.0378901606600266e-05
localization O 0 1.9477754904073663e-05
is O 0 1.8648707111879048e-07
postulated O 0 1.1499741958687082e-06
to O 0 1.7881237823758056e-08
be O 0 1.97589677952692e-08
important O 0 6.620548731461895e-08
in O 0 4.087229399374337e-07
non B-Disease 0 3.3571872336324304e-05
- I-Disease 0 0.2703632414340973
familial I-Disease 1 0.9912447333335876
breast I-Disease 1 0.9997459053993225
and I-Disease 1 0.9856627583503723
ovarian I-Disease 1 0.999998927116394
cancers I-Disease 1 0.9999939203262329
. O 0 0.00010303067392669618

Epigenetic O 0 0.01566966436803341
loss O 0 0.14107035100460052
, O 0 1.9464253000478493e-06
however O 0 8.571564080739336e-07
, O 0 2.678689554613811e-07
has O 0 3.098778620369558e-07
not O 0 1.6713975981019757e-08
received O 0 7.457354200823829e-08
general O 0 6.327188373234094e-08
acceptance O 0 3.505851964291651e-07
due O 0 1.986107918128255e-06
to O 0 2.8105393568012005e-08
controversy O 0 5.267460778668465e-07
regarding O 0 8.817214336431789e-08
the O 0 7.31917211282962e-08
subcellular O 0 2.1053194814157905e-06
localization O 0 3.666141992653138e-06
of O 0 1.0517838688883785e-07
BRCA1 O 0 1.8406150047667325e-05
proteins O 0 4.120366270399245e-07
, O 0 5.760794863363117e-08
reports O 0 1.28018996292667e-07
of O 0 1.202352528650863e-08
which O 0 4.963842670235863e-08
have O 0 2.0101541764461217e-08
ranged O 0 1.5509205013586325e-06
from O 0 3.896150246873731e-08
exclusively O 0 9.194089045649889e-08
nuclear O 0 8.76731428434141e-06
, O 0 2.0617168416947607e-08
to O 0 1.2548381889132543e-08
conditionally O 0 3.2495538562216097e-06
nuclear O 0 8.009755219973158e-06
, O 0 2.9316041150195815e-08
to O 0 9.386730503990748e-09
the O 0 2.808948522670107e-07
ER O 0 0.00016387389041483402
/ O 0 1.6752259398344904e-05
golgi O 0 0.0001085123440134339
, O 0 7.009798963508729e-08
to O 0 1.0445821096993768e-08
cytoplasmic O 0 1.5926539163046982e-06
invaginations O 0 7.0338387558877e-06
into O 0 1.2532194659797824e-07
the O 0 2.629714117574622e-07
nucleus O 0 8.852068276610225e-06
. O 0 2.5478391307842685e-06

In O 0 2.123329750247649e-06
an O 0 1.2694245299371687e-07
attempt O 0 7.234003760459018e-07
to O 0 3.4514023639076186e-08
resolve O 0 1.368068296869751e-06
this O 0 6.868765467515914e-08
issue O 0 3.0886499757798447e-07
, O 0 4.715798596066634e-08
we O 0 4.316702373330372e-08
have O 0 3.96831403293163e-08
comprehensively O 0 1.7854737961897627e-05
characterized O 0 3.576120070647448e-05
19 O 0 1.300106305279769e-05
anti O 0 0.0002456021320540458
- O 0 0.00106285500805825
BRCA1 O 0 0.0003645643300842494
antibodies O 0 2.8553233278216794e-05
. O 0 4.4656353566097096e-06

These O 0 7.087742233125027e-07
reagents O 0 9.238769052899443e-06
detect O 0 2.7212512577534653e-05
a O 0 1.5549059071418014e-06
220 O 0 9.300085253016732e-07
- O 0 1.2229485946591012e-05
kD O 0 2.6303701815777458e-05
protein O 0 5.826000233355444e-07
localized O 0 2.287554934810032e-06
in O 0 9.160428504628726e-08
discrete O 0 3.7411140851872915e-07
nuclear O 0 1.6273408618872054e-05
foci O 0 5.779995262855664e-06
in O 0 8.122179195879653e-08
all O 0 3.528091951920942e-08
epithelial O 0 7.005130464676768e-05
cell O 0 5.322479773894884e-05
lines O 0 7.687776815146208e-06
, O 0 5.141280468023979e-08
including O 0 2.1036560937659488e-08
those O 0 2.775004936950154e-08
derived O 0 3.6741465692102793e-07
from O 0 7.052720320643857e-06
breast B-Disease 1 0.9933786392211914
malignancies I-Disease 0 0.4104313254356384
. O 0 1.3839351595379412e-05

Immunohistochemical O 0 0.003670881735160947
staining O 0 0.0007551914313808084
of O 0 4.515478394750971e-06
human O 0 0.0001578857481945306
breast O 1 0.9821658730506897
specimens O 0 5.1458402595017105e-05
also O 0 3.833863047475461e-06
revealed O 0 0.00011704472126439214
BRCA1 O 0 0.0004973146715201437
nuclear O 0 0.0004450824053492397
foci O 0 0.00032615457894280553
in O 0 3.235836265957914e-05
benign O 1 0.9965930581092834
breast O 1 0.9988551139831543
, O 0 3.2415064197266474e-05
invasive B-Disease 1 0.992316484451294
lobular I-Disease 1 0.9994877576828003
cancers I-Disease 1 0.9997724890708923
and O 0 7.643258868483827e-05
low B-Disease 1 0.9348744750022888
- I-Disease 1 0.9953328967094421
grade I-Disease 1 0.9742059707641602
ductal I-Disease 1 0.9990946054458618
carcinomas I-Disease 1 0.9999022483825684
. O 0 0.00014570118219126016

Conversely O 0 9.996118751587346e-05
, O 0 2.0039465198351536e-06
BRCA1 O 0 5.868593871127814e-05
expression O 0 3.887876118824352e-06
was O 0 2.761368523351848e-05
reduced O 0 2.7940134259551996e-06
or O 0 3.698960711062682e-07
undetectable O 0 1.986702591239009e-05
in O 0 4.477945481085044e-08
the O 0 3.3958979628323505e-08
majority O 0 3.119581393207227e-08
of O 0 4.53827162516518e-08
high O 0 0.00040424137841910124
- O 0 0.0019887355156242847
grade O 0 0.002193479100242257
, O 0 2.5550087229930796e-05
ductal B-Disease 1 0.9974527955055237
carcinomas I-Disease 1 0.9999575614929199
, O 0 1.9335077467985684e-06
suggesting O 0 1.9110564153379528e-06
that O 0 4.972684308768294e-08
absence O 0 9.050474432115152e-07
of O 0 1.4232141154479905e-07
BRCA1 O 0 4.1202216380042955e-05
may O 0 3.0994701205599995e-07
contribute O 0 2.7331500618288374e-08
to O 0 8.865185918693896e-09
the O 0 1.0772931346991754e-07
pathogenesis O 0 3.04932109429501e-05
of O 0 1.9837360198948772e-08
a O 0 3.698607997648651e-07
significant O 0 7.779285056130902e-07
percentage O 0 9.0231887952541e-06
of O 0 1.0605948546071886e-06
sporadic B-Disease 0 0.018828805536031723
breast I-Disease 1 0.9994093179702759
cancers I-Disease 1 0.9993051290512085
. O 0 3.3420494673919166e-06
. O 0 5.045676061854465e-06

